<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8" />
<script src="data:application/x-javascript;base64,(function() {
  // If window.HTMLWidgets is already defined, then use it; otherwise create a
  // new object. This allows preceding code to set options that affect the
  // initialization process (though none currently exist).
  window.HTMLWidgets = window.HTMLWidgets || {};

  // See if we're running in a viewer pane. If not, we're in a web browser.
  var viewerMode = window.HTMLWidgets.viewerMode =
      /\bviewer_pane=1\b/.test(window.location);

  // See if we're running in Shiny mode. If not, it's a static document.
  // Note that static widgets can appear in both Shiny and static modes, but
  // obviously, Shiny widgets can only appear in Shiny apps/documents.
  var shinyMode = window.HTMLWidgets.shinyMode =
      typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings;

  // We can't count on jQuery being available, so we implement our own
  // version if necessary.
  function querySelectorAll(scope, selector) {
    if (typeof(jQuery) !== "undefined" && scope instanceof jQuery) {
      return scope.find(selector);
    }
    if (scope.querySelectorAll) {
      return scope.querySelectorAll(selector);
    }
  }

  function asArray(value) {
    if (value === null)
      return [];
    if ($.isArray(value))
      return value;
    return [value];
  }

  // Implement jQuery's extend
  function extend(target /*, ... */) {
    if (arguments.length == 1) {
      return target;
    }
    for (var i = 1; i < arguments.length; i++) {
      var source = arguments[i];
      for (var prop in source) {
        if (source.hasOwnProperty(prop)) {
          target[prop] = source[prop];
        }
      }
    }
    return target;
  }

  // IE8 doesn't support Array.forEach.
  function forEach(values, callback, thisArg) {
    if (values.forEach) {
      values.forEach(callback, thisArg);
    } else {
      for (var i = 0; i < values.length; i++) {
        callback.call(thisArg, values[i], i, values);
      }
    }
  }

  // Replaces the specified method with the return value of funcSource.
  //
  // Note that funcSource should not BE the new method, it should be a function
  // that RETURNS the new method. funcSource receives a single argument that is
  // the overridden method, it can be called from the new method. The overridden
  // method can be called like a regular function, it has the target permanently
  // bound to it so "this" will work correctly.
  function overrideMethod(target, methodName, funcSource) {
    var superFunc = target[methodName] || function() {};
    var superFuncBound = function() {
      return superFunc.apply(target, arguments);
    };
    target[methodName] = funcSource(superFuncBound);
  }

  // Add a method to delegator that, when invoked, calls
  // delegatee.methodName. If there is no such method on
  // the delegatee, but there was one on delegator before
  // delegateMethod was called, then the original version
  // is invoked instead.
  // For example:
  //
  // var a = {
  //   method1: function() { console.log('a1'); }
  //   method2: function() { console.log('a2'); }
  // };
  // var b = {
  //   method1: function() { console.log('b1'); }
  // };
  // delegateMethod(a, b, "method1");
  // delegateMethod(a, b, "method2");
  // a.method1();
  // a.method2();
  //
  // The output would be "b1", "a2".
  function delegateMethod(delegator, delegatee, methodName) {
    var inherited = delegator[methodName];
    delegator[methodName] = function() {
      var target = delegatee;
      var method = delegatee[methodName];

      // The method doesn't exist on the delegatee. Instead,
      // call the method on the delegator, if it exists.
      if (!method) {
        target = delegator;
        method = inherited;
      }

      if (method) {
        return method.apply(target, arguments);
      }
    };
  }

  // Implement a vague facsimilie of jQuery's data method
  function elementData(el, name, value) {
    if (arguments.length == 2) {
      return el["htmlwidget_data_" + name];
    } else if (arguments.length == 3) {
      el["htmlwidget_data_" + name] = value;
      return el;
    } else {
      throw new Error("Wrong number of arguments for elementData: " +
        arguments.length);
    }
  }

  // http://stackoverflow.com/questions/3446170/escape-string-for-use-in-javascript-regex
  function escapeRegExp(str) {
    return str.replace(/[\-\[\]\/\{\}\(\)\*\+\?\.\\\^\$\|]/g, "\\$&");
  }

  function hasClass(el, className) {
    var re = new RegExp("\\b" + escapeRegExp(className) + "\\b");
    return re.test(el.className);
  }

  // elements - array (or array-like object) of HTML elements
  // className - class name to test for
  // include - if true, only return elements with given className;
  //   if false, only return elements *without* given className
  function filterByClass(elements, className, include) {
    var results = [];
    for (var i = 0; i < elements.length; i++) {
      if (hasClass(elements[i], className) == include)
        results.push(elements[i]);
    }
    return results;
  }

  function on(obj, eventName, func) {
    if (obj.addEventListener) {
      obj.addEventListener(eventName, func, false);
    } else if (obj.attachEvent) {
      obj.attachEvent(eventName, func);
    }
  }

  function off(obj, eventName, func) {
    if (obj.removeEventListener)
      obj.removeEventListener(eventName, func, false);
    else if (obj.detachEvent) {
      obj.detachEvent(eventName, func);
    }
  }

  // Translate array of values to top/right/bottom/left, as usual with
  // the "padding" CSS property
  // https://developer.mozilla.org/en-US/docs/Web/CSS/padding
  function unpackPadding(value) {
    if (typeof(value) === "number")
      value = [value];
    if (value.length === 1) {
      return {top: value[0], right: value[0], bottom: value[0], left: value[0]};
    }
    if (value.length === 2) {
      return {top: value[0], right: value[1], bottom: value[0], left: value[1]};
    }
    if (value.length === 3) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[1]};
    }
    if (value.length === 4) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[3]};
    }
  }

  // Convert an unpacked padding object to a CSS value
  function paddingToCss(paddingObj) {
    return paddingObj.top + "px " + paddingObj.right + "px " + paddingObj.bottom + "px " + paddingObj.left + "px";
  }

  // Makes a number suitable for CSS
  function px(x) {
    if (typeof(x) === "number")
      return x + "px";
    else
      return x;
  }

  // Retrieves runtime widget sizing information for an element.
  // The return value is either null, or an object with fill, padding,
  // defaultWidth, defaultHeight fields.
  function sizingPolicy(el) {
    var sizingEl = document.querySelector("script[data-for='" + el.id + "'][type='application/htmlwidget-sizing']");
    if (!sizingEl)
      return null;
    var sp = JSON.parse(sizingEl.textContent || sizingEl.text || "{}");
    if (viewerMode) {
      return sp.viewer;
    } else {
      return sp.browser;
    }
  }

  // @param tasks Array of strings (or falsy value, in which case no-op).
  //   Each element must be a valid JavaScript expression that yields a
  //   function. Or, can be an array of objects with "code" and "data"
  //   properties; in this case, the "code" property should be a string
  //   of JS that's an expr that yields a function, and "data" should be
  //   an object that will be added as an additional argument when that
  //   function is called.
  // @param target The object that will be "this" for each function
  //   execution.
  // @param args Array of arguments to be passed to the functions. (The
  //   same arguments will be passed to all functions.)
  function evalAndRun(tasks, target, args) {
    if (tasks) {
      forEach(tasks, function(task) {
        var theseArgs = args;
        if (typeof(task) === "object") {
          theseArgs = theseArgs.concat([task.data]);
          task = task.code;
        }
        var taskFunc = eval("(" + task + ")");
        if (typeof(taskFunc) !== "function") {
          throw new Error("Task must be a function! Source:\n" + task);
        }
        taskFunc.apply(target, theseArgs);
      });
    }
  }

  function initSizing(el) {
    var sizing = sizingPolicy(el);
    if (!sizing)
      return;

    var cel = document.getElementById("htmlwidget_container");
    if (!cel)
      return;

    if (typeof(sizing.padding) !== "undefined") {
      document.body.style.margin = "0";
      document.body.style.padding = paddingToCss(unpackPadding(sizing.padding));
    }

    if (sizing.fill) {
      document.body.style.overflow = "hidden";
      document.body.style.width = "100%";
      document.body.style.height = "100%";
      document.documentElement.style.width = "100%";
      document.documentElement.style.height = "100%";
      if (cel) {
        cel.style.position = "absolute";
        var pad = unpackPadding(sizing.padding);
        cel.style.top = pad.top + "px";
        cel.style.right = pad.right + "px";
        cel.style.bottom = pad.bottom + "px";
        cel.style.left = pad.left + "px";
        el.style.width = "100%";
        el.style.height = "100%";
      }

      return {
        getWidth: function() { return cel.offsetWidth; },
        getHeight: function() { return cel.offsetHeight; }
      };

    } else {
      el.style.width = px(sizing.width);
      el.style.height = px(sizing.height);

      return {
        getWidth: function() { return el.offsetWidth; },
        getHeight: function() { return el.offsetHeight; }
      };
    }
  }

  // Default implementations for methods
  var defaults = {
    find: function(scope) {
      return querySelectorAll(scope, "." + this.name);
    },
    renderError: function(el, err) {
      var $el = $(el);

      this.clearError(el);

      // Add all these error classes, as Shiny does
      var errClass = "shiny-output-error";
      if (err.type !== null) {
        // use the classes of the error condition as CSS class names
        errClass = errClass + " " + $.map(asArray(err.type), function(type) {
          return errClass + "-" + type;
        }).join(" ");
      }
      errClass = errClass + " htmlwidgets-error";

      // Is el inline or block? If inline or inline-block, just display:none it
      // and add an inline error.
      var display = $el.css("display");
      $el.data("restore-display-mode", display);

      if (display === "inline" || display === "inline-block") {
        $el.hide();
        if (err.message !== "") {
          var errorSpan = $("<span>").addClass(errClass);
          errorSpan.text(err.message);
          $el.after(errorSpan);
        }
      } else if (display === "block") {
        // If block, add an error just after the el, set visibility:none on the
        // el, and position the error to be on top of the el.
        // Mark it with a unique ID and CSS class so we can remove it later.
        $el.css("visibility", "hidden");
        if (err.message !== "") {
          var errorDiv = $("<div>").addClass(errClass).css("position", "absolute")
            .css("top", el.offsetTop)
            .css("left", el.offsetLeft)
            // setting width can push out the page size, forcing otherwise
            // unnecessary scrollbars to appear and making it impossible for
            // the element to shrink; so use max-width instead
            .css("maxWidth", el.offsetWidth)
            .css("height", el.offsetHeight);
          errorDiv.text(err.message);
          $el.after(errorDiv);

          // Really dumb way to keep the size/position of the error in sync with
          // the parent element as the window is resized or whatever.
          var intId = setInterval(function() {
            if (!errorDiv[0].parentElement) {
              clearInterval(intId);
              return;
            }
            errorDiv
              .css("top", el.offsetTop)
              .css("left", el.offsetLeft)
              .css("maxWidth", el.offsetWidth)
              .css("height", el.offsetHeight);
          }, 500);
        }
      }
    },
    clearError: function(el) {
      var $el = $(el);
      var display = $el.data("restore-display-mode");
      $el.data("restore-display-mode", null);

      if (display === "inline" || display === "inline-block") {
        if (display)
          $el.css("display", display);
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      } else if (display === "block"){
        $el.css("visibility", "inherit");
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      }
    },
    sizing: {}
  };

  // Called by widget bindings to register a new type of widget. The definition
  // object can contain the following properties:
  // - name (required) - A string indicating the binding name, which will be
  //   used by default as the CSS classname to look for.
  // - initialize (optional) - A function(el) that will be called once per
  //   widget element; if a value is returned, it will be passed as the third
  //   value to renderValue.
  // - renderValue (required) - A function(el, data, initValue) that will be
  //   called with data. Static contexts will cause this to be called once per
  //   element; Shiny apps will cause this to be called multiple times per
  //   element, as the data changes.
  window.HTMLWidgets.widget = function(definition) {
    if (!definition.name) {
      throw new Error("Widget must have a name");
    }
    if (!definition.type) {
      throw new Error("Widget must have a type");
    }
    // Currently we only support output widgets
    if (definition.type !== "output") {
      throw new Error("Unrecognized widget type '" + definition.type + "'");
    }
    // TODO: Verify that .name is a valid CSS classname

    // Support new-style instance-bound definitions. Old-style class-bound
    // definitions have one widget "object" per widget per type/class of
    // widget; the renderValue and resize methods on such widget objects
    // take el and instance arguments, because the widget object can't
    // store them. New-style instance-bound definitions have one widget
    // object per widget instance; the definition that's passed in doesn't
    // provide renderValue or resize methods at all, just the single method
    //   factory(el, width, height)
    // which returns an object that has renderValue(x) and resize(w, h).
    // This enables a far more natural programming style for the widget
    // author, who can store per-instance state using either OO-style
    // instance fields or functional-style closure variables (I guess this
    // is in contrast to what can only be called C-style pseudo-OO which is
    // what we required before).
    if (definition.factory) {
      definition = createLegacyDefinitionAdapter(definition);
    }

    if (!definition.renderValue) {
      throw new Error("Widget must have a renderValue function");
    }

    // For static rendering (non-Shiny), use a simple widget registration
    // scheme. We also use this scheme for Shiny apps/documents that also
    // contain static widgets.
    window.HTMLWidgets.widgets = window.HTMLWidgets.widgets || [];
    // Merge defaults into the definition; don't mutate the original definition.
    var staticBinding = extend({}, defaults, definition);
    overrideMethod(staticBinding, "find", function(superfunc) {
      return function(scope) {
        var results = superfunc(scope);
        // Filter out Shiny outputs, we only want the static kind
        return filterByClass(results, "html-widget-output", false);
      };
    });
    window.HTMLWidgets.widgets.push(staticBinding);

    if (shinyMode) {
      // Shiny is running. Register the definition with an output binding.
      // The definition itself will not be the output binding, instead
      // we will make an output binding object that delegates to the
      // definition. This is because we foolishly used the same method
      // name (renderValue) for htmlwidgets definition and Shiny bindings
      // but they actually have quite different semantics (the Shiny
      // bindings receive data that includes lots of metadata that it
      // strips off before calling htmlwidgets renderValue). We can't
      // just ignore the difference because in some widgets it's helpful
      // to call this.renderValue() from inside of resize(), and if
      // we're not delegating, then that call will go to the Shiny
      // version instead of the htmlwidgets version.

      // Merge defaults with definition, without mutating either.
      var bindingDef = extend({}, defaults, definition);

      // This object will be our actual Shiny binding.
      var shinyBinding = new Shiny.OutputBinding();

      // With a few exceptions, we'll want to simply use the bindingDef's
      // version of methods if they are available, otherwise fall back to
      // Shiny's defaults. NOTE: If Shiny's output bindings gain additional
      // methods in the future, and we want them to be overrideable by
      // HTMLWidget binding definitions, then we'll need to add them to this
      // list.
      delegateMethod(shinyBinding, bindingDef, "getId");
      delegateMethod(shinyBinding, bindingDef, "onValueChange");
      delegateMethod(shinyBinding, bindingDef, "onValueError");
      delegateMethod(shinyBinding, bindingDef, "renderError");
      delegateMethod(shinyBinding, bindingDef, "clearError");
      delegateMethod(shinyBinding, bindingDef, "showProgress");

      // The find, renderValue, and resize are handled differently, because we
      // want to actually decorate the behavior of the bindingDef methods.

      shinyBinding.find = function(scope) {
        var results = bindingDef.find(scope);

        // Only return elements that are Shiny outputs, not static ones
        var dynamicResults = results.filter(".html-widget-output");

        // It's possible that whatever caused Shiny to think there might be
        // new dynamic outputs, also caused there to be new static outputs.
        // Since there might be lots of different htmlwidgets bindings, we
        // schedule execution for later--no need to staticRender multiple
        // times.
        if (results.length !== dynamicResults.length)
          scheduleStaticRender();

        return dynamicResults;
      };

      // Wrap renderValue to handle initialization, which unfortunately isn't
      // supported natively by Shiny at the time of this writing.

      shinyBinding.renderValue = function(el, data) {
        Shiny.renderDependencies(data.deps);
        // Resolve strings marked as javascript literals to objects
        if (!(data.evals instanceof Array)) data.evals = [data.evals];
        for (var i = 0; data.evals && i < data.evals.length; i++) {
          window.HTMLWidgets.evaluateStringMember(data.x, data.evals[i]);
        }
        if (!bindingDef.renderOnNullValue) {
          if (data.x === null) {
            el.style.visibility = "hidden";
            return;
          } else {
            el.style.visibility = "inherit";
          }
        }
        if (!elementData(el, "initialized")) {
          initSizing(el);

          elementData(el, "initialized", true);
          if (bindingDef.initialize) {
            var result = bindingDef.initialize(el, el.offsetWidth,
              el.offsetHeight);
            elementData(el, "init_result", result);
          }
        }
        bindingDef.renderValue(el, data.x, elementData(el, "init_result"));
        evalAndRun(data.jsHooks.render, elementData(el, "init_result"), [el, data.x]);
      };

      // Only override resize if bindingDef implements it
      if (bindingDef.resize) {
        shinyBinding.resize = function(el, width, height) {
          // Shiny can call resize before initialize/renderValue have been
          // called, which doesn't make sense for widgets.
          if (elementData(el, "initialized")) {
            bindingDef.resize(el, width, height, elementData(el, "init_result"));
          }
        };
      }

      Shiny.outputBindings.register(shinyBinding, bindingDef.name);
    }
  };

  var scheduleStaticRenderTimerId = null;
  function scheduleStaticRender() {
    if (!scheduleStaticRenderTimerId) {
      scheduleStaticRenderTimerId = setTimeout(function() {
        scheduleStaticRenderTimerId = null;
        window.HTMLWidgets.staticRender();
      }, 1);
    }
  }

  // Render static widgets after the document finishes loading
  // Statically render all elements that are of this widget's class
  window.HTMLWidgets.staticRender = function() {
    var bindings = window.HTMLWidgets.widgets || [];
    forEach(bindings, function(binding) {
      var matches = binding.find(document.documentElement);
      forEach(matches, function(el) {
        var sizeObj = initSizing(el, binding);

        if (hasClass(el, "html-widget-static-bound"))
          return;
        el.className = el.className + " html-widget-static-bound";

        var initResult;
        if (binding.initialize) {
          initResult = binding.initialize(el,
            sizeObj ? sizeObj.getWidth() : el.offsetWidth,
            sizeObj ? sizeObj.getHeight() : el.offsetHeight
          );
          elementData(el, "init_result", initResult);
        }

        if (binding.resize) {
          var lastSize = {};
          var resizeHandler = function(e) {
            var size = {
              w: sizeObj ? sizeObj.getWidth() : el.offsetWidth,
              h: sizeObj ? sizeObj.getHeight() : el.offsetHeight
            };
            if (size.w === 0 && size.h === 0)
              return;
            if (size.w === lastSize.w && size.h === lastSize.h)
              return;
            lastSize = size;
            binding.resize(el, size.w, size.h, initResult);
          };

          on(window, "resize", resizeHandler);

          // This is needed for cases where we're running in a Shiny
          // app, but the widget itself is not a Shiny output, but
          // rather a simple static widget. One example of this is
          // an rmarkdown document that has runtime:shiny and widget
          // that isn't in a render function. Shiny only knows to
          // call resize handlers for Shiny outputs, not for static
          // widgets, so we do it ourselves.
          if (window.jQuery) {
            window.jQuery(document).on(
              "shown.htmlwidgets shown.bs.tab.htmlwidgets shown.bs.collapse.htmlwidgets",
              resizeHandler
            );
            window.jQuery(document).on(
              "hidden.htmlwidgets hidden.bs.tab.htmlwidgets hidden.bs.collapse.htmlwidgets",
              resizeHandler
            );
          }

          // This is needed for the specific case of ioslides, which
          // flips slides between display:none and display:block.
          // Ideally we would not have to have ioslide-specific code
          // here, but rather have ioslides raise a generic event,
          // but the rmarkdown package just went to CRAN so the
          // window to getting that fixed may be long.
          if (window.addEventListener) {
            // It's OK to limit this to window.addEventListener
            // browsers because ioslides itself only supports
            // such browsers.
            on(document, "slideenter", resizeHandler);
            on(document, "slideleave", resizeHandler);
          }
        }

        var scriptData = document.querySelector("script[data-for='" + el.id + "'][type='application/json']");
        if (scriptData) {
          var data = JSON.parse(scriptData.textContent || scriptData.text);
          // Resolve strings marked as javascript literals to objects
          if (!(data.evals instanceof Array)) data.evals = [data.evals];
          for (var k = 0; data.evals && k < data.evals.length; k++) {
            window.HTMLWidgets.evaluateStringMember(data.x, data.evals[k]);
          }
          binding.renderValue(el, data.x, initResult);
          evalAndRun(data.jsHooks.render, initResult, [el, data.x]);
        }
      });
    });

    invokePostRenderHandlers();
  }

  // Wait until after the document has loaded to render the widgets.
  if (document.addEventListener) {
    document.addEventListener("DOMContentLoaded", function() {
      document.removeEventListener("DOMContentLoaded", arguments.callee, false);
      window.HTMLWidgets.staticRender();
    }, false);
  } else if (document.attachEvent) {
    document.attachEvent("onreadystatechange", function() {
      if (document.readyState === "complete") {
        document.detachEvent("onreadystatechange", arguments.callee);
        window.HTMLWidgets.staticRender();
      }
    });
  }


  window.HTMLWidgets.getAttachmentUrl = function(depname, key) {
    // If no key, default to the first item
    if (typeof(key) === "undefined")
      key = 1;

    var link = document.getElementById(depname + "-" + key + "-attachment");
    if (!link) {
      throw new Error("Attachment " + depname + "/" + key + " not found in document");
    }
    return link.getAttribute("href");
  };

  window.HTMLWidgets.dataframeToD3 = function(df) {
    var names = [];
    var length;
    for (var name in df) {
        if (df.hasOwnProperty(name))
            names.push(name);
        if (typeof(df[name]) !== "object" || typeof(df[name].length) === "undefined") {
            throw new Error("All fields must be arrays");
        } else if (typeof(length) !== "undefined" && length !== df[name].length) {
            throw new Error("All fields must be arrays of the same length");
        }
        length = df[name].length;
    }
    var results = [];
    var item;
    for (var row = 0; row < length; row++) {
        item = {};
        for (var col = 0; col < names.length; col++) {
            item[names[col]] = df[names[col]][row];
        }
        results.push(item);
    }
    return results;
  };

  window.HTMLWidgets.transposeArray2D = function(array) {
      if (array.length === 0) return array;
      var newArray = array[0].map(function(col, i) {
          return array.map(function(row) {
              return row[i]
          })
      });
      return newArray;
  };
  // Split value at splitChar, but allow splitChar to be escaped
  // using escapeChar. Any other characters escaped by escapeChar
  // will be included as usual (including escapeChar itself).
  function splitWithEscape(value, splitChar, escapeChar) {
    var results = [];
    var escapeMode = false;
    var currentResult = "";
    for (var pos = 0; pos < value.length; pos++) {
      if (!escapeMode) {
        if (value[pos] === splitChar) {
          results.push(currentResult);
          currentResult = "";
        } else if (value[pos] === escapeChar) {
          escapeMode = true;
        } else {
          currentResult += value[pos];
        }
      } else {
        currentResult += value[pos];
        escapeMode = false;
      }
    }
    if (currentResult !== "") {
      results.push(currentResult);
    }
    return results;
  }
  // Function authored by Yihui/JJ Allaire
  window.HTMLWidgets.evaluateStringMember = function(o, member) {
    var parts = splitWithEscape(member, '.', '\\');
    for (var i = 0, l = parts.length; i < l; i++) {
      var part = parts[i];
      // part may be a character or 'numeric' member name
      if (o !== null && typeof o === "object" && part in o) {
        if (i == (l - 1)) { // if we are at the end of the line then evalulate
          if (typeof o[part] === "string")
            o[part] = eval("(" + o[part] + ")");
        } else { // otherwise continue to next embedded object
          o = o[part];
        }
      }
    }
  };

  // Retrieve the HTMLWidget instance (i.e. the return value of an
  // HTMLWidget binding's initialize() or factory() function)
  // associated with an element, or null if none.
  window.HTMLWidgets.getInstance = function(el) {
    return elementData(el, "init_result");
  };

  // Finds the first element in the scope that matches the selector,
  // and returns the HTMLWidget instance (i.e. the return value of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with that element, if any. If no element matches the
  // selector, or the first matching element has no HTMLWidget
  // instance associated with it, then null is returned.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.find = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var el = scope.querySelector(selector);
    if (el === null) {
      return null;
    } else {
      return window.HTMLWidgets.getInstance(el);
    }
  };

  // Finds all elements in the scope that match the selector, and
  // returns the HTMLWidget instances (i.e. the return values of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with the elements, in an array. If elements that
  // match the selector don't have an associated HTMLWidget
  // instance, the returned array will contain nulls.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.findAll = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var nodes = scope.querySelectorAll(selector);
    var results = [];
    for (var i = 0; i < nodes.length; i++) {
      results.push(window.HTMLWidgets.getInstance(nodes[i]));
    }
    return results;
  };

  var postRenderHandlers = [];
  function invokePostRenderHandlers() {
    while (postRenderHandlers.length) {
      var handler = postRenderHandlers.shift();
      if (handler) {
        handler();
      }
    }
  }

  // Register the given callback function to be invoked after the
  // next time static widgets are rendered.
  window.HTMLWidgets.addPostRenderHandler = function(callback) {
    postRenderHandlers.push(callback);
  };

  // Takes a new-style instance-bound definition, and returns an
  // old-style class-bound definition. This saves us from having
  // to rewrite all the logic in this file to accomodate both
  // types of definitions.
  function createLegacyDefinitionAdapter(defn) {
    var result = {
      name: defn.name,
      type: defn.type,
      initialize: function(el, width, height) {
        return defn.factory(el, width, height);
      },
      renderValue: function(el, x, instance) {
        return instance.renderValue(x);
      },
      resize: function(el, width, height, instance) {
        return instance.resize(width, height);
      }
    };

    if (defn.find)
      result.find = defn.find;
    if (defn.renderError)
      result.renderError = defn.renderError;
    if (defn.clearError)
      result.clearError = defn.clearError;

    return result;
  }
})();

"></script>
<script src="data:application/x-javascript;base64,/*! jQuery v1.12.4 | (c) jQuery Foundation | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=a.document,e=c.slice,f=c.concat,g=c.push,h=c.indexOf,i={},j=i.toString,k=i.hasOwnProperty,l={},m="1.12.4",n=function(a,b){return new n.fn.init(a,b)},o=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,p=/^-ms-/,q=/-([\da-z])/gi,r=function(a,b){return b.toUpperCase()};n.fn=n.prototype={jquery:m,constructor:n,selector:"",length:0,toArray:function(){return e.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:e.call(this)},pushStack:function(a){var b=n.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a){return n.each(this,a)},map:function(a){return this.pushStack(n.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(e.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor()},push:g,sort:c.sort,splice:c.splice},n.extend=n.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||n.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(n.isPlainObject(c)||(b=n.isArray(c)))?(b?(b=!1,f=a&&n.isArray(a)?a:[]):f=a&&n.isPlainObject(a)?a:{},g[d]=n.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},n.extend({expando:"jQuery"+(m+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===n.type(a)},isArray:Array.isArray||function(a){return"array"===n.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){var b=a&&a.toString();return!n.isArray(a)&&b-parseFloat(b)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==n.type(a)||a.nodeType||n.isWindow(a))return!1;try{if(a.constructor&&!k.call(a,"constructor")&&!k.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(!l.ownFirst)for(b in a)return k.call(a,b);for(b in a);return void 0===b||k.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?i[j.call(a)]||"object":typeof a},globalEval:function(b){b&&n.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(p,"ms-").replace(q,r)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b){var c,d=0;if(s(a)){for(c=a.length;c>d;d++)if(b.call(a[d],d,a[d])===!1)break}else for(d in a)if(b.call(a[d],d,a[d])===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(o,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(s(Object(a))?n.merge(c,"string"==typeof a?[a]:a):g.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(h)return h.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,e,g=0,h=[];if(s(a))for(d=a.length;d>g;g++)e=b(a[g],g,c),null!=e&&h.push(e);else for(g in a)e=b(a[g],g,c),null!=e&&h.push(e);return f.apply([],h)},guid:1,proxy:function(a,b){var c,d,f;return"string"==typeof b&&(f=a[b],b=a,a=f),n.isFunction(a)?(c=e.call(arguments,2),d=function(){return a.apply(b||this,c.concat(e.call(arguments)))},d.guid=a.guid=a.guid||n.guid++,d):void 0},now:function(){return+new Date},support:l}),"function"==typeof Symbol&&(n.fn[Symbol.iterator]=c[Symbol.iterator]),n.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(a,b){i["[object "+b+"]"]=b.toLowerCase()});function s(a){var b=!!a&&"length"in a&&a.length,c=n.type(a);return"function"===c||n.isWindow(a)?!1:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var t=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ga(),z=ga(),A=ga(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+M+"))|)"+L+"*\\]",O=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+N+")*)|.*)\\)|)",P=new RegExp(L+"+","g"),Q=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),R=new RegExp("^"+L+"*,"+L+"*"),S=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),T=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),U=new RegExp(O),V=new RegExp("^"+M+"$"),W={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M+"|[*])"),ATTR:new RegExp("^"+N),PSEUDO:new RegExp("^"+O),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},X=/^(?:input|select|textarea|button)$/i,Y=/^h\d$/i,Z=/^[^{]+\{\s*\[native \w/,$=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,_=/[+~]/,aa=/'|\\/g,ba=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),ca=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},da=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(ea){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function fa(a,b,d,e){var f,h,j,k,l,o,r,s,w=b&&b.ownerDocument,x=b?b.nodeType:9;if(d=d||[],"string"!=typeof a||!a||1!==x&&9!==x&&11!==x)return d;if(!e&&((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,p)){if(11!==x&&(o=$.exec(a)))if(f=o[1]){if(9===x){if(!(j=b.getElementById(f)))return d;if(j.id===f)return d.push(j),d}else if(w&&(j=w.getElementById(f))&&t(b,j)&&j.id===f)return d.push(j),d}else{if(o[2])return H.apply(d,b.getElementsByTagName(a)),d;if((f=o[3])&&c.getElementsByClassName&&b.getElementsByClassName)return H.apply(d,b.getElementsByClassName(f)),d}if(c.qsa&&!A[a+" "]&&(!q||!q.test(a))){if(1!==x)w=b,s=a;else if("object"!==b.nodeName.toLowerCase()){(k=b.getAttribute("id"))?k=k.replace(aa,"\\$&"):b.setAttribute("id",k=u),r=g(a),h=r.length,l=V.test(k)?"#"+k:"[id='"+k+"']";while(h--)r[h]=l+" "+qa(r[h]);s=r.join(","),w=_.test(a)&&oa(b.parentNode)||b}if(s)try{return H.apply(d,w.querySelectorAll(s)),d}catch(y){}finally{k===u&&b.removeAttribute("id")}}}return i(a.replace(Q,"$1"),b,d,e)}function ga(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ha(a){return a[u]=!0,a}function ia(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ja(a,b){var c=a.split("|"),e=c.length;while(e--)d.attrHandle[c[e]]=b}function ka(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function la(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function na(a){return ha(function(b){return b=+b,ha(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function oa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=fa.support={},f=fa.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=fa.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=n.documentElement,p=!f(n),(e=n.defaultView)&&e.top!==e&&(e.addEventListener?e.addEventListener("unload",da,!1):e.attachEvent&&e.attachEvent("onunload",da)),c.attributes=ia(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ia(function(a){return a.appendChild(n.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=Z.test(n.getElementsByClassName),c.getById=ia(function(a){return o.appendChild(a).id=u,!n.getElementsByName||!n.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ba,ca);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ba,ca);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return"undefined"!=typeof b.getElementsByClassName&&p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=Z.test(n.querySelectorAll))&&(ia(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\r\\' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ia(function(a){var b=n.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=Z.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ia(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",O)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=Z.test(o.compareDocumentPosition),t=b||Z.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===n||a.ownerDocument===v&&t(v,a)?-1:b===n||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,g=[a],h=[b];if(!e||!f)return a===n?-1:b===n?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return ka(a,b);c=a;while(c=c.parentNode)g.unshift(c);c=b;while(c=c.parentNode)h.unshift(c);while(g[d]===h[d])d++;return d?ka(g[d],h[d]):g[d]===v?-1:h[d]===v?1:0},n):n},fa.matches=function(a,b){return fa(a,null,null,b)},fa.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(T,"='$1']"),c.matchesSelector&&p&&!A[b+" "]&&(!r||!r.test(b))&&(!q||!q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return fa(b,n,null,[a]).length>0},fa.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},fa.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},fa.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},fa.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=fa.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=fa.selectors={cacheLength:50,createPseudo:ha,match:W,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ba,ca),a[3]=(a[3]||a[4]||a[5]||"").replace(ba,ca),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||fa.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&fa.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return W.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&U.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ba,ca).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=fa.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(P," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h,t=!1;if(q){if(f){while(p){m=b;while(m=m[p])if(h?m.nodeName.toLowerCase()===r:1===m.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){m=q,l=m[u]||(m[u]={}),k=l[m.uniqueID]||(l[m.uniqueID]={}),j=k[a]||[],n=j[0]===w&&j[1],t=n&&j[2],m=n&&q.childNodes[n];while(m=++n&&m&&m[p]||(t=n=0)||o.pop())if(1===m.nodeType&&++t&&m===b){k[a]=[w,n,t];break}}else if(s&&(m=b,l=m[u]||(m[u]={}),k=l[m.uniqueID]||(l[m.uniqueID]={}),j=k[a]||[],n=j[0]===w&&j[1],t=n),t===!1)while(m=++n&&m&&m[p]||(t=n=0)||o.pop())if((h?m.nodeName.toLowerCase()===r:1===m.nodeType)&&++t&&(s&&(l=m[u]||(m[u]={}),k=l[m.uniqueID]||(l[m.uniqueID]={}),k[a]=[w,t]),m===b))break;return t-=e,t===d||t%d===0&&t/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||fa.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ha(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ha(function(a){var b=[],c=[],d=h(a.replace(Q,"$1"));return d[u]?ha(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ha(function(a){return function(b){return fa(a,b).length>0}}),contains:ha(function(a){return a=a.replace(ba,ca),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ha(function(a){return V.test(a||"")||fa.error("unsupported lang: "+a),a=a.replace(ba,ca).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Y.test(a.nodeName)},input:function(a){return X.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:na(function(){return[0]}),last:na(function(a,b){return[b-1]}),eq:na(function(a,b,c){return[0>c?c+b:c]}),even:na(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:na(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:na(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:na(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=la(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=ma(b);function pa(){}pa.prototype=d.filters=d.pseudos,d.setFilters=new pa,g=fa.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){c&&!(e=R.exec(h))||(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=S.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(Q," ")}),h=h.slice(c.length));for(g in d.filter)!(e=W[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?fa.error(a):z(a,i).slice(0)};function qa(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function ra(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j,k=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(j=b[u]||(b[u]={}),i=j[b.uniqueID]||(j[b.uniqueID]={}),(h=i[d])&&h[0]===w&&h[1]===f)return k[2]=h[2];if(i[d]=k,k[2]=a(b,c,g))return!0}}}function sa(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ta(a,b,c){for(var d=0,e=b.length;e>d;d++)fa(a,b[d],c);return c}function ua(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(c&&!c(f,d,e)||(g.push(f),j&&b.push(h)));return g}function va(a,b,c,d,e,f){return d&&!d[u]&&(d=va(d)),e&&!e[u]&&(e=va(e,f)),ha(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ta(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:ua(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=ua(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=ua(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function wa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=ra(function(a){return a===b},h,!0),l=ra(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[ra(sa(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return va(i>1&&sa(m),i>1&&qa(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(Q,"$1"),c,e>i&&wa(a.slice(i,e)),f>e&&wa(a=a.slice(e)),f>e&&qa(a))}m.push(c)}return sa(m)}function xa(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,o,q,r=0,s="0",t=f&&[],u=[],v=j,x=f||e&&d.find.TAG("*",k),y=w+=null==v?1:Math.random()||.1,z=x.length;for(k&&(j=g===n||g||k);s!==z&&null!=(l=x[s]);s++){if(e&&l){o=0,g||l.ownerDocument===n||(m(l),h=!p);while(q=a[o++])if(q(l,g||n,h)){i.push(l);break}k&&(w=y)}c&&((l=!q&&l)&&r--,f&&t.push(l))}if(r+=s,c&&s!==r){o=0;while(q=b[o++])q(t,u,g,h);if(f){if(r>0)while(s--)t[s]||u[s]||(u[s]=F.call(i));u=ua(u)}H.apply(i,u),k&&!f&&u.length>0&&r+b.length>1&&fa.uniqueSort(i)}return k&&(w=y,j=v),t};return c?ha(f):f}return h=fa.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=wa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,xa(e,d)),f.selector=a}return f},i=fa.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ba,ca),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=W.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ba,ca),_.test(j[0].type)&&oa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&qa(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,!b||_.test(a)&&oa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ia(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ia(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ja("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ia(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ja("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ia(function(a){return null==a.getAttribute("disabled")})||ja(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),fa}(a);n.find=t,n.expr=t.selectors,n.expr[":"]=n.expr.pseudos,n.uniqueSort=n.unique=t.uniqueSort,n.text=t.getText,n.isXMLDoc=t.isXML,n.contains=t.contains;var u=function(a,b,c){var d=[],e=void 0!==c;while((a=a[b])&&9!==a.nodeType)if(1===a.nodeType){if(e&&n(a).is(c))break;d.push(a)}return d},v=function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c},w=n.expr.match.needsContext,x=/^<([\w-]+)\s*\/?>(?:<\/\1>|)$/,y=/^.[^:#\[\.,]*$/;function z(a,b,c){if(n.isFunction(b))return n.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return n.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(y.test(b))return n.filter(b,a,c);b=n.filter(b,a)}return n.grep(a,function(a){return n.inArray(a,b)>-1!==c})}n.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?n.find.matchesSelector(d,a)?[d]:[]:n.find.matches(a,n.grep(b,function(a){return 1===a.nodeType}))},n.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(n(a).filter(function(){for(b=0;e>b;b++)if(n.contains(d[b],this))return!0}));for(b=0;e>b;b++)n.find(a,d[b],c);return c=this.pushStack(e>1?n.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(z(this,a||[],!1))},not:function(a){return this.pushStack(z(this,a||[],!0))},is:function(a){return!!z(this,"string"==typeof a&&w.test(a)?n(a):a||[],!1).length}});var A,B=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,C=n.fn.init=function(a,b,c){var e,f;if(!a)return this;if(c=c||A,"string"==typeof a){if(e="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:B.exec(a),!e||!e[1]&&b)return!b||b.jquery?(b||c).find(a):this.constructor(b).find(a);if(e[1]){if(b=b instanceof n?b[0]:b,n.merge(this,n.parseHTML(e[1],b&&b.nodeType?b.ownerDocument||b:d,!0)),x.test(e[1])&&n.isPlainObject(b))for(e in b)n.isFunction(this[e])?this[e](b[e]):this.attr(e,b[e]);return this}if(f=d.getElementById(e[2]),f&&f.parentNode){if(f.id!==e[2])return A.find(a);this.length=1,this[0]=f}return this.context=d,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):n.isFunction(a)?"undefined"!=typeof c.ready?c.ready(a):a(n):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),n.makeArray(a,this))};C.prototype=n.fn,A=n(d);var D=/^(?:parents|prev(?:Until|All))/,E={children:!0,contents:!0,next:!0,prev:!0};n.fn.extend({has:function(a){var b,c=n(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(n.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=w.test(a)||"string"!=typeof a?n(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&n.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?n.uniqueSort(f):f)},index:function(a){return a?"string"==typeof a?n.inArray(this[0],n(a)):n.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(n.uniqueSort(n.merge(this.get(),n(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function F(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}n.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return u(a,"parentNode")},parentsUntil:function(a,b,c){return u(a,"parentNode",c)},next:function(a){return F(a,"nextSibling")},prev:function(a){return F(a,"previousSibling")},nextAll:function(a){return u(a,"nextSibling")},prevAll:function(a){return u(a,"previousSibling")},nextUntil:function(a,b,c){return u(a,"nextSibling",c)},prevUntil:function(a,b,c){return u(a,"previousSibling",c)},siblings:function(a){return v((a.parentNode||{}).firstChild,a)},children:function(a){return v(a.firstChild)},contents:function(a){return n.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:n.merge([],a.childNodes)}},function(a,b){n.fn[a]=function(c,d){var e=n.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=n.filter(d,e)),this.length>1&&(E[a]||(e=n.uniqueSort(e)),D.test(a)&&(e=e.reverse())),this.pushStack(e)}});var G=/\S+/g;function H(a){var b={};return n.each(a.match(G)||[],function(a,c){b[c]=!0}),b}n.Callbacks=function(a){a="string"==typeof a?H(a):n.extend({},a);var b,c,d,e,f=[],g=[],h=-1,i=function(){for(e=a.once,d=b=!0;g.length;h=-1){c=g.shift();while(++h<f.length)f[h].apply(c[0],c[1])===!1&&a.stopOnFalse&&(h=f.length,c=!1)}a.memory||(c=!1),b=!1,e&&(f=c?[]:"")},j={add:function(){return f&&(c&&!b&&(h=f.length-1,g.push(c)),function d(b){n.each(b,function(b,c){n.isFunction(c)?a.unique&&j.has(c)||f.push(c):c&&c.length&&"string"!==n.type(c)&&d(c)})}(arguments),c&&!b&&i()),this},remove:function(){return n.each(arguments,function(a,b){var c;while((c=n.inArray(b,f,c))>-1)f.splice(c,1),h>=c&&h--}),this},has:function(a){return a?n.inArray(a,f)>-1:f.length>0},empty:function(){return f&&(f=[]),this},disable:function(){return e=g=[],f=c="",this},disabled:function(){return!f},lock:function(){return e=!0,c||j.disable(),this},locked:function(){return!!e},fireWith:function(a,c){return e||(c=c||[],c=[a,c.slice?c.slice():c],g.push(c),b||i()),this},fire:function(){return j.fireWith(this,arguments),this},fired:function(){return!!d}};return j},n.extend({Deferred:function(a){var b=[["resolve","done",n.Callbacks("once memory"),"resolved"],["reject","fail",n.Callbacks("once memory"),"rejected"],["notify","progress",n.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return n.Deferred(function(c){n.each(b,function(b,f){var g=n.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&n.isFunction(a.promise)?a.promise().progress(c.notify).done(c.resolve).fail(c.reject):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?n.extend(a,d):d}},e={};return d.pipe=d.then,n.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=e.call(arguments),d=c.length,f=1!==d||a&&n.isFunction(a.promise)?d:0,g=1===f?a:n.Deferred(),h=function(a,b,c){return function(d){b[a]=this,c[a]=arguments.length>1?e.call(arguments):d,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(d>1)for(i=new Array(d),j=new Array(d),k=new Array(d);d>b;b++)c[b]&&n.isFunction(c[b].promise)?c[b].promise().progress(h(b,j,i)).done(h(b,k,c)).fail(g.reject):--f;return f||g.resolveWith(k,c),g.promise()}});var I;n.fn.ready=function(a){return n.ready.promise().done(a),this},n.extend({isReady:!1,readyWait:1,holdReady:function(a){a?n.readyWait++:n.ready(!0)},ready:function(a){(a===!0?--n.readyWait:n.isReady)||(n.isReady=!0,a!==!0&&--n.readyWait>0||(I.resolveWith(d,[n]),n.fn.triggerHandler&&(n(d).triggerHandler("ready"),n(d).off("ready"))))}});function J(){d.addEventListener?(d.removeEventListener("DOMContentLoaded",K),a.removeEventListener("load",K)):(d.detachEvent("onreadystatechange",K),a.detachEvent("onload",K))}function K(){(d.addEventListener||"load"===a.event.type||"complete"===d.readyState)&&(J(),n.ready())}n.ready.promise=function(b){if(!I)if(I=n.Deferred(),"complete"===d.readyState||"loading"!==d.readyState&&!d.documentElement.doScroll)a.setTimeout(n.ready);else if(d.addEventListener)d.addEventListener("DOMContentLoaded",K),a.addEventListener("load",K);else{d.attachEvent("onreadystatechange",K),a.attachEvent("onload",K);var c=!1;try{c=null==a.frameElement&&d.documentElement}catch(e){}c&&c.doScroll&&!function f(){if(!n.isReady){try{c.doScroll("left")}catch(b){return a.setTimeout(f,50)}J(),n.ready()}}()}return I.promise(b)},n.ready.promise();var L;for(L in n(l))break;l.ownFirst="0"===L,l.inlineBlockNeedsLayout=!1,n(function(){var a,b,c,e;c=d.getElementsByTagName("body")[0],c&&c.style&&(b=d.createElement("div"),e=d.createElement("div"),e.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(e).appendChild(b),"undefined"!=typeof b.style.zoom&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",l.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(e))}),function(){var a=d.createElement("div");l.deleteExpando=!0;try{delete a.test}catch(b){l.deleteExpando=!1}a=null}();var M=function(a){var b=n.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b},N=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,O=/([A-Z])/g;function P(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(O,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:N.test(c)?n.parseJSON(c):c}catch(e){}n.data(a,b,c)}else c=void 0;
}return c}function Q(a){var b;for(b in a)if(("data"!==b||!n.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;return!0}function R(a,b,d,e){if(M(a)){var f,g,h=n.expando,i=a.nodeType,j=i?n.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||n.guid++:h),j[k]||(j[k]=i?{}:{toJSON:n.noop}),"object"!=typeof b&&"function"!=typeof b||(e?j[k]=n.extend(j[k],b):j[k].data=n.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[n.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[n.camelCase(b)])):f=g,f}}function S(a,b,c){if(M(a)){var d,e,f=a.nodeType,g=f?n.cache:a,h=f?a[n.expando]:n.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){n.isArray(b)?b=b.concat(n.map(b,n.camelCase)):b in d?b=[b]:(b=n.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!Q(d):!n.isEmptyObject(d))return}(c||(delete g[h].data,Q(g[h])))&&(f?n.cleanData([a],!0):l.deleteExpando||g!=g.window?delete g[h]:g[h]=void 0)}}}n.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?n.cache[a[n.expando]]:a[n.expando],!!a&&!Q(a)},data:function(a,b,c){return R(a,b,c)},removeData:function(a,b){return S(a,b)},_data:function(a,b,c){return R(a,b,c,!0)},_removeData:function(a,b){return S(a,b,!0)}}),n.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=n.data(f),1===f.nodeType&&!n._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=n.camelCase(d.slice(5)),P(f,d,e[d])));n._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){n.data(this,a)}):arguments.length>1?this.each(function(){n.data(this,a,b)}):f?P(f,a,n.data(f,a)):void 0},removeData:function(a){return this.each(function(){n.removeData(this,a)})}}),n.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=n._data(a,b),c&&(!d||n.isArray(c)?d=n._data(a,b,n.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=n.queue(a,b),d=c.length,e=c.shift(),f=n._queueHooks(a,b),g=function(){n.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return n._data(a,c)||n._data(a,c,{empty:n.Callbacks("once memory").add(function(){n._removeData(a,b+"queue"),n._removeData(a,c)})})}}),n.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?n.queue(this[0],a):void 0===b?this:this.each(function(){var c=n.queue(this,a,b);n._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&n.dequeue(this,a)})},dequeue:function(a){return this.each(function(){n.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=n.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=n._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}}),function(){var a;l.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,e;return c=d.getElementsByTagName("body")[0],c&&c.style?(b=d.createElement("div"),e=d.createElement("div"),e.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(e).appendChild(b),"undefined"!=typeof b.style.zoom&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(d.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(e),a):void 0}}();var T=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,U=new RegExp("^(?:([+-])=|)("+T+")([a-z%]*)$","i"),V=["Top","Right","Bottom","Left"],W=function(a,b){return a=b||a,"none"===n.css(a,"display")||!n.contains(a.ownerDocument,a)};function X(a,b,c,d){var e,f=1,g=20,h=d?function(){return d.cur()}:function(){return n.css(a,b,"")},i=h(),j=c&&c[3]||(n.cssNumber[b]?"":"px"),k=(n.cssNumber[b]||"px"!==j&&+i)&&U.exec(n.css(a,b));if(k&&k[3]!==j){j=j||k[3],c=c||[],k=+i||1;do f=f||".5",k/=f,n.style(a,b,k+j);while(f!==(f=h()/i)&&1!==f&&--g)}return c&&(k=+k||+i||0,e=c[1]?k+(c[1]+1)*c[2]:+c[2],d&&(d.unit=j,d.start=k,d.end=e)),e}var Y=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===n.type(c)){e=!0;for(h in c)Y(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,n.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(n(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},Z=/^(?:checkbox|radio)$/i,$=/<([\w:-]+)/,_=/^$|\/(?:java|ecma)script/i,aa=/^\s+/,ba="abbr|article|aside|audio|bdi|canvas|data|datalist|details|dialog|figcaption|figure|footer|header|hgroup|main|mark|meter|nav|output|picture|progress|section|summary|template|time|video";function ca(a){var b=ba.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}!function(){var a=d.createElement("div"),b=d.createDocumentFragment(),c=d.createElement("input");a.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",l.leadingWhitespace=3===a.firstChild.nodeType,l.tbody=!a.getElementsByTagName("tbody").length,l.htmlSerialize=!!a.getElementsByTagName("link").length,l.html5Clone="<:nav></:nav>"!==d.createElement("nav").cloneNode(!0).outerHTML,c.type="checkbox",c.checked=!0,b.appendChild(c),l.appendChecked=c.checked,a.innerHTML="<textarea>x</textarea>",l.noCloneChecked=!!a.cloneNode(!0).lastChild.defaultValue,b.appendChild(a),c=d.createElement("input"),c.setAttribute("type","radio"),c.setAttribute("checked","checked"),c.setAttribute("name","t"),a.appendChild(c),l.checkClone=a.cloneNode(!0).cloneNode(!0).lastChild.checked,l.noCloneEvent=!!a.addEventListener,a[n.expando]=1,l.attributes=!a.getAttribute(n.expando)}();var da={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:l.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]};da.optgroup=da.option,da.tbody=da.tfoot=da.colgroup=da.caption=da.thead,da.th=da.td;function ea(a,b){var c,d,e=0,f="undefined"!=typeof a.getElementsByTagName?a.getElementsByTagName(b||"*"):"undefined"!=typeof a.querySelectorAll?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||n.nodeName(d,b)?f.push(d):n.merge(f,ea(d,b));return void 0===b||b&&n.nodeName(a,b)?n.merge([a],f):f}function fa(a,b){for(var c,d=0;null!=(c=a[d]);d++)n._data(c,"globalEval",!b||n._data(b[d],"globalEval"))}var ga=/<|&#?\w+;/,ha=/<tbody/i;function ia(a){Z.test(a.type)&&(a.defaultChecked=a.checked)}function ja(a,b,c,d,e){for(var f,g,h,i,j,k,m,o=a.length,p=ca(b),q=[],r=0;o>r;r++)if(g=a[r],g||0===g)if("object"===n.type(g))n.merge(q,g.nodeType?[g]:g);else if(ga.test(g)){i=i||p.appendChild(b.createElement("div")),j=($.exec(g)||["",""])[1].toLowerCase(),m=da[j]||da._default,i.innerHTML=m[1]+n.htmlPrefilter(g)+m[2],f=m[0];while(f--)i=i.lastChild;if(!l.leadingWhitespace&&aa.test(g)&&q.push(b.createTextNode(aa.exec(g)[0])),!l.tbody){g="table"!==j||ha.test(g)?"<table>"!==m[1]||ha.test(g)?0:i:i.firstChild,f=g&&g.childNodes.length;while(f--)n.nodeName(k=g.childNodes[f],"tbody")&&!k.childNodes.length&&g.removeChild(k)}n.merge(q,i.childNodes),i.textContent="";while(i.firstChild)i.removeChild(i.firstChild);i=p.lastChild}else q.push(b.createTextNode(g));i&&p.removeChild(i),l.appendChecked||n.grep(ea(q,"input"),ia),r=0;while(g=q[r++])if(d&&n.inArray(g,d)>-1)e&&e.push(g);else if(h=n.contains(g.ownerDocument,g),i=ea(p.appendChild(g),"script"),h&&fa(i),c){f=0;while(g=i[f++])_.test(g.type||"")&&c.push(g)}return i=null,p}!function(){var b,c,e=d.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(l[b]=c in a)||(e.setAttribute(c,"t"),l[b]=e.attributes[c].expando===!1);e=null}();var ka=/^(?:input|select|textarea)$/i,la=/^key/,ma=/^(?:mouse|pointer|contextmenu|drag|drop)|click/,na=/^(?:focusinfocus|focusoutblur)$/,oa=/^([^.]*)(?:\.(.+)|)/;function pa(){return!0}function qa(){return!1}function ra(){try{return d.activeElement}catch(a){}}function sa(a,b,c,d,e,f){var g,h;if("object"==typeof b){"string"!=typeof c&&(d=d||c,c=void 0);for(h in b)sa(a,h,c,d,b[h],f);return a}if(null==d&&null==e?(e=c,d=c=void 0):null==e&&("string"==typeof c?(e=d,d=void 0):(e=d,d=c,c=void 0)),e===!1)e=qa;else if(!e)return a;return 1===f&&(g=e,e=function(a){return n().off(a),g.apply(this,arguments)},e.guid=g.guid||(g.guid=n.guid++)),a.each(function(){n.event.add(this,b,e,d,c)})}n.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,m,o,p,q,r=n._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=n.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return"undefined"==typeof n||a&&n.event.triggered===a.type?void 0:n.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(G)||[""],h=b.length;while(h--)f=oa.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=n.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=n.event.special[o]||{},l=n.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&n.expr.match.needsContext.test(e),namespace:p.join(".")},i),(m=g[o])||(m=g[o]=[],m.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?m.splice(m.delegateCount++,0,l):m.push(l),n.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,m,o,p,q,r=n.hasData(a)&&n._data(a);if(r&&(k=r.events)){b=(b||"").match(G)||[""],j=b.length;while(j--)if(h=oa.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=n.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,m=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=m.length;while(f--)g=m[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(m.splice(f,1),g.selector&&m.delegateCount--,l.remove&&l.remove.call(a,g));i&&!m.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||n.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)n.event.remove(a,o+b[j],c,d,!0);n.isEmptyObject(k)&&(delete r.handle,n._removeData(a,"events"))}},trigger:function(b,c,e,f){var g,h,i,j,l,m,o,p=[e||d],q=k.call(b,"type")?b.type:b,r=k.call(b,"namespace")?b.namespace.split("."):[];if(i=m=e=e||d,3!==e.nodeType&&8!==e.nodeType&&!na.test(q+n.event.triggered)&&(q.indexOf(".")>-1&&(r=q.split("."),q=r.shift(),r.sort()),h=q.indexOf(":")<0&&"on"+q,b=b[n.expando]?b:new n.Event(q,"object"==typeof b&&b),b.isTrigger=f?2:3,b.namespace=r.join("."),b.rnamespace=b.namespace?new RegExp("(^|\\.)"+r.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=e),c=null==c?[b]:n.makeArray(c,[b]),l=n.event.special[q]||{},f||!l.trigger||l.trigger.apply(e,c)!==!1)){if(!f&&!l.noBubble&&!n.isWindow(e)){for(j=l.delegateType||q,na.test(j+q)||(i=i.parentNode);i;i=i.parentNode)p.push(i),m=i;m===(e.ownerDocument||d)&&p.push(m.defaultView||m.parentWindow||a)}o=0;while((i=p[o++])&&!b.isPropagationStopped())b.type=o>1?j:l.bindType||q,g=(n._data(i,"events")||{})[b.type]&&n._data(i,"handle"),g&&g.apply(i,c),g=h&&i[h],g&&g.apply&&M(i)&&(b.result=g.apply(i,c),b.result===!1&&b.preventDefault());if(b.type=q,!f&&!b.isDefaultPrevented()&&(!l._default||l._default.apply(p.pop(),c)===!1)&&M(e)&&h&&e[q]&&!n.isWindow(e)){m=e[h],m&&(e[h]=null),n.event.triggered=q;try{e[q]()}catch(s){}n.event.triggered=void 0,m&&(e[h]=m)}return b.result}},dispatch:function(a){a=n.event.fix(a);var b,c,d,f,g,h=[],i=e.call(arguments),j=(n._data(this,"events")||{})[a.type]||[],k=n.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=n.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,c=0;while((g=f.handlers[c++])&&!a.isImmediatePropagationStopped())a.rnamespace&&!a.rnamespace.test(g.namespace)||(a.handleObj=g,a.data=g.data,d=((n.event.special[g.origType]||{}).handle||g.handler).apply(f.elem,i),void 0!==d&&(a.result=d)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&("click"!==a.type||isNaN(a.button)||a.button<1))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(d=[],c=0;h>c;c++)f=b[c],e=f.selector+" ",void 0===d[e]&&(d[e]=f.needsContext?n(e,this).index(i)>-1:n.find(e,this,null,[i]).length),d[e]&&d.push(f);d.length&&g.push({elem:i,handlers:d})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[n.expando])return a;var b,c,e,f=a.type,g=a,h=this.fixHooks[f];h||(this.fixHooks[f]=h=ma.test(f)?this.mouseHooks:la.test(f)?this.keyHooks:{}),e=h.props?this.props.concat(h.props):this.props,a=new n.Event(g),b=e.length;while(b--)c=e[b],a[c]=g[c];return a.target||(a.target=g.srcElement||d),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,h.filter?h.filter(a,g):a},props:"altKey bubbles cancelable ctrlKey currentTarget detail eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,e,f,g=b.button,h=b.fromElement;return null==a.pageX&&null!=b.clientX&&(e=a.target.ownerDocument||d,f=e.documentElement,c=e.body,a.pageX=b.clientX+(f&&f.scrollLeft||c&&c.scrollLeft||0)-(f&&f.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(f&&f.scrollTop||c&&c.scrollTop||0)-(f&&f.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&h&&(a.relatedTarget=h===a.target?b.toElement:h),a.which||void 0===g||(a.which=1&g?1:2&g?3:4&g?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ra()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ra()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return n.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return n.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c){var d=n.extend(new n.Event,c,{type:a,isSimulated:!0});n.event.trigger(d,null,b),d.isDefaultPrevented()&&c.preventDefault()}},n.removeEvent=d.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c)}:function(a,b,c){var d="on"+b;a.detachEvent&&("undefined"==typeof a[d]&&(a[d]=null),a.detachEvent(d,c))},n.Event=function(a,b){return this instanceof n.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?pa:qa):this.type=a,b&&n.extend(this,b),this.timeStamp=a&&a.timeStamp||n.now(),void(this[n.expando]=!0)):new n.Event(a,b)},n.Event.prototype={constructor:n.Event,isDefaultPrevented:qa,isPropagationStopped:qa,isImmediatePropagationStopped:qa,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=pa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=pa,a&&!this.isSimulated&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=pa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},n.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){n.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return e&&(e===d||n.contains(d,e))||(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),l.submit||(n.event.special.submit={setup:function(){return n.nodeName(this,"form")?!1:void n.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=n.nodeName(b,"input")||n.nodeName(b,"button")?n.prop(b,"form"):void 0;c&&!n._data(c,"submit")&&(n.event.add(c,"submit._submit",function(a){a._submitBubble=!0}),n._data(c,"submit",!0))})},postDispatch:function(a){a._submitBubble&&(delete a._submitBubble,this.parentNode&&!a.isTrigger&&n.event.simulate("submit",this.parentNode,a))},teardown:function(){return n.nodeName(this,"form")?!1:void n.event.remove(this,"._submit")}}),l.change||(n.event.special.change={setup:function(){return ka.test(this.nodeName)?("checkbox"!==this.type&&"radio"!==this.type||(n.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._justChanged=!0)}),n.event.add(this,"click._change",function(a){this._justChanged&&!a.isTrigger&&(this._justChanged=!1),n.event.simulate("change",this,a)})),!1):void n.event.add(this,"beforeactivate._change",function(a){var b=a.target;ka.test(b.nodeName)&&!n._data(b,"change")&&(n.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||n.event.simulate("change",this.parentNode,a)}),n._data(b,"change",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return n.event.remove(this,"._change"),!ka.test(this.nodeName)}}),l.focusin||n.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){n.event.simulate(b,a.target,n.event.fix(a))};n.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=n._data(d,b);e||d.addEventListener(a,c,!0),n._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=n._data(d,b)-1;e?n._data(d,b,e):(d.removeEventListener(a,c,!0),n._removeData(d,b))}}}),n.fn.extend({on:function(a,b,c,d){return sa(this,a,b,c,d)},one:function(a,b,c,d){return sa(this,a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,n(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return b!==!1&&"function"!=typeof b||(c=b,b=void 0),c===!1&&(c=qa),this.each(function(){n.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){n.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?n.event.trigger(a,b,c,!0):void 0}});var ta=/ jQuery\d+="(?:null|\d+)"/g,ua=new RegExp("<(?:"+ba+")[\\s/>]","i"),va=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:-]+)[^>]*)\/>/gi,wa=/<script|<style|<link/i,xa=/checked\s*(?:[^=]|=\s*.checked.)/i,ya=/^true\/(.*)/,za=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,Aa=ca(d),Ba=Aa.appendChild(d.createElement("div"));function Ca(a,b){return n.nodeName(a,"table")&&n.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function Da(a){return a.type=(null!==n.find.attr(a,"type"))+"/"+a.type,a}function Ea(a){var b=ya.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function Fa(a,b){if(1===b.nodeType&&n.hasData(a)){var c,d,e,f=n._data(a),g=n._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)n.event.add(b,c,h[c][d])}g.data&&(g.data=n.extend({},g.data))}}function Ga(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!l.noCloneEvent&&b[n.expando]){e=n._data(b);for(d in e.events)n.removeEvent(b,d,e.handle);b.removeAttribute(n.expando)}"script"===c&&b.text!==a.text?(Da(b).text=a.text,Ea(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),l.html5Clone&&a.innerHTML&&!n.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&Z.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:"input"!==c&&"textarea"!==c||(b.defaultValue=a.defaultValue)}}function Ha(a,b,c,d){b=f.apply([],b);var e,g,h,i,j,k,m=0,o=a.length,p=o-1,q=b[0],r=n.isFunction(q);if(r||o>1&&"string"==typeof q&&!l.checkClone&&xa.test(q))return a.each(function(e){var f=a.eq(e);r&&(b[0]=q.call(this,e,f.html())),Ha(f,b,c,d)});if(o&&(k=ja(b,a[0].ownerDocument,!1,a,d),e=k.firstChild,1===k.childNodes.length&&(k=e),e||d)){for(i=n.map(ea(k,"script"),Da),h=i.length;o>m;m++)g=k,m!==p&&(g=n.clone(g,!0,!0),h&&n.merge(i,ea(g,"script"))),c.call(a[m],g,m);if(h)for(j=i[i.length-1].ownerDocument,n.map(i,Ea),m=0;h>m;m++)g=i[m],_.test(g.type||"")&&!n._data(g,"globalEval")&&n.contains(j,g)&&(g.src?n._evalUrl&&n._evalUrl(g.src):n.globalEval((g.text||g.textContent||g.innerHTML||"").replace(za,"")));k=e=null}return a}function Ia(a,b,c){for(var d,e=b?n.filter(b,a):a,f=0;null!=(d=e[f]);f++)c||1!==d.nodeType||n.cleanData(ea(d)),d.parentNode&&(c&&n.contains(d.ownerDocument,d)&&fa(ea(d,"script")),d.parentNode.removeChild(d));return a}n.extend({htmlPrefilter:function(a){return a.replace(va,"<$1></$2>")},clone:function(a,b,c){var d,e,f,g,h,i=n.contains(a.ownerDocument,a);if(l.html5Clone||n.isXMLDoc(a)||!ua.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(Ba.innerHTML=a.outerHTML,Ba.removeChild(f=Ba.firstChild)),!(l.noCloneEvent&&l.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||n.isXMLDoc(a)))for(d=ea(f),h=ea(a),g=0;null!=(e=h[g]);++g)d[g]&&Ga(e,d[g]);if(b)if(c)for(h=h||ea(a),d=d||ea(f),g=0;null!=(e=h[g]);g++)Fa(e,d[g]);else Fa(a,f);return d=ea(f,"script"),d.length>0&&fa(d,!i&&ea(a,"script")),d=h=e=null,f},cleanData:function(a,b){for(var d,e,f,g,h=0,i=n.expando,j=n.cache,k=l.attributes,m=n.event.special;null!=(d=a[h]);h++)if((b||M(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)m[e]?n.event.remove(d,e):n.removeEvent(d,e,g.handle);j[f]&&(delete j[f],k||"undefined"==typeof d.removeAttribute?d[i]=void 0:d.removeAttribute(i),c.push(f))}}}),n.fn.extend({domManip:Ha,detach:function(a){return Ia(this,a,!0)},remove:function(a){return Ia(this,a)},text:function(a){return Y(this,function(a){return void 0===a?n.text(this):this.empty().append((this[0]&&this[0].ownerDocument||d).createTextNode(a))},null,a,arguments.length)},append:function(){return Ha(this,arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=Ca(this,a);b.appendChild(a)}})},prepend:function(){return Ha(this,arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=Ca(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return Ha(this,arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return Ha(this,arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&n.cleanData(ea(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&n.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return n.clone(this,a,b)})},html:function(a){return Y(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(ta,""):void 0;if("string"==typeof a&&!wa.test(a)&&(l.htmlSerialize||!ua.test(a))&&(l.leadingWhitespace||!aa.test(a))&&!da[($.exec(a)||["",""])[1].toLowerCase()]){a=n.htmlPrefilter(a);try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(n.cleanData(ea(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=[];return Ha(this,arguments,function(b){var c=this.parentNode;n.inArray(this,a)<0&&(n.cleanData(ea(this)),c&&c.replaceChild(b,this))},a)}}),n.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){n.fn[a]=function(a){for(var c,d=0,e=[],f=n(a),h=f.length-1;h>=d;d++)c=d===h?this:this.clone(!0),n(f[d])[b](c),g.apply(e,c.get());return this.pushStack(e)}});var Ja,Ka={HTML:"block",BODY:"block"};function La(a,b){var c=n(b.createElement(a)).appendTo(b.body),d=n.css(c[0],"display");return c.detach(),d}function Ma(a){var b=d,c=Ka[a];return c||(c=La(a,b),"none"!==c&&c||(Ja=(Ja||n("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ja[0].contentWindow||Ja[0].contentDocument).document,b.write(),b.close(),c=La(a,b),Ja.detach()),Ka[a]=c),c}var Na=/^margin/,Oa=new RegExp("^("+T+")(?!px)[a-z%]+$","i"),Pa=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e},Qa=d.documentElement;!function(){var b,c,e,f,g,h,i=d.createElement("div"),j=d.createElement("div");if(j.style){j.style.cssText="float:left;opacity:.5",l.opacity="0.5"===j.style.opacity,l.cssFloat=!!j.style.cssFloat,j.style.backgroundClip="content-box",j.cloneNode(!0).style.backgroundClip="",l.clearCloneStyle="content-box"===j.style.backgroundClip,i=d.createElement("div"),i.style.cssText="border:0;width:8px;height:0;top:0;left:-9999px;padding:0;margin-top:1px;position:absolute",j.innerHTML="",i.appendChild(j),l.boxSizing=""===j.style.boxSizing||""===j.style.MozBoxSizing||""===j.style.WebkitBoxSizing,n.extend(l,{reliableHiddenOffsets:function(){return null==b&&k(),f},boxSizingReliable:function(){return null==b&&k(),e},pixelMarginRight:function(){return null==b&&k(),c},pixelPosition:function(){return null==b&&k(),b},reliableMarginRight:function(){return null==b&&k(),g},reliableMarginLeft:function(){return null==b&&k(),h}});function k(){var k,l,m=d.documentElement;m.appendChild(i),j.style.cssText="-webkit-box-sizing:border-box;box-sizing:border-box;position:relative;display:block;margin:auto;border:1px;padding:1px;top:1%;width:50%",b=e=h=!1,c=g=!0,a.getComputedStyle&&(l=a.getComputedStyle(j),b="1%"!==(l||{}).top,h="2px"===(l||{}).marginLeft,e="4px"===(l||{width:"4px"}).width,j.style.marginRight="50%",c="4px"===(l||{marginRight:"4px"}).marginRight,k=j.appendChild(d.createElement("div")),k.style.cssText=j.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",k.style.marginRight=k.style.width="0",j.style.width="1px",g=!parseFloat((a.getComputedStyle(k)||{}).marginRight),j.removeChild(k)),j.style.display="none",f=0===j.getClientRects().length,f&&(j.style.display="",j.innerHTML="<table><tr><td></td><td>t</td></tr></table>",j.childNodes[0].style.borderCollapse="separate",k=j.getElementsByTagName("td"),k[0].style.cssText="margin:0;border:0;padding:0;display:none",f=0===k[0].offsetHeight,f&&(k[0].style.display="",k[1].style.display="none",f=0===k[0].offsetHeight)),m.removeChild(i)}}}();var Ra,Sa,Ta=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ra=function(b){var c=b.ownerDocument.defaultView;return c&&c.opener||(c=a),c.getComputedStyle(b)},Sa=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ra(a),g=c?c.getPropertyValue(b)||c[b]:void 0,""!==g&&void 0!==g||n.contains(a.ownerDocument,a)||(g=n.style(a,b)),c&&!l.pixelMarginRight()&&Oa.test(g)&&Na.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f),void 0===g?g:g+""}):Qa.currentStyle&&(Ra=function(a){return a.currentStyle},Sa=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ra(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Oa.test(g)&&!Ta.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function Ua(a,b){return{get:function(){return a()?void delete this.get:(this.get=b).apply(this,arguments)}}}var Va=/alpha\([^)]*\)/i,Wa=/opacity\s*=\s*([^)]*)/i,Xa=/^(none|table(?!-c[ea]).+)/,Ya=new RegExp("^("+T+")(.*)$","i"),Za={position:"absolute",visibility:"hidden",display:"block"},$a={letterSpacing:"0",fontWeight:"400"},_a=["Webkit","O","Moz","ms"],ab=d.createElement("div").style;function bb(a){if(a in ab)return a;var b=a.charAt(0).toUpperCase()+a.slice(1),c=_a.length;while(c--)if(a=_a[c]+b,a in ab)return a}function cb(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=n._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&W(d)&&(f[g]=n._data(d,"olddisplay",Ma(d.nodeName)))):(e=W(d),(c&&"none"!==c||!e)&&n._data(d,"olddisplay",e?c:n.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function db(a,b,c){var d=Ya.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function eb(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=n.css(a,c+V[f],!0,e)),d?("content"===c&&(g-=n.css(a,"padding"+V[f],!0,e)),"margin"!==c&&(g-=n.css(a,"border"+V[f]+"Width",!0,e))):(g+=n.css(a,"padding"+V[f],!0,e),"padding"!==c&&(g+=n.css(a,"border"+V[f]+"Width",!0,e)));return g}function fb(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ra(a),g=l.boxSizing&&"border-box"===n.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Sa(a,b,f),(0>e||null==e)&&(e=a.style[b]),Oa.test(e))return e;d=g&&(l.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+eb(a,b,c||(g?"border":"content"),d,f)+"px"}n.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Sa(a,"opacity");return""===c?"1":c}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":l.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=n.camelCase(b),i=a.style;if(b=n.cssProps[h]||(n.cssProps[h]=bb(h)||h),g=n.cssHooks[b]||n.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=U.exec(c))&&e[1]&&(c=X(a,b,e),f="number"),null!=c&&c===c&&("number"===f&&(c+=e&&e[3]||(n.cssNumber[h]?"":"px")),l.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=n.camelCase(b);return b=n.cssProps[h]||(n.cssProps[h]=bb(h)||h),g=n.cssHooks[b]||n.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Sa(a,b,d)),"normal"===f&&b in $a&&(f=$a[b]),""===c||c?(e=parseFloat(f),c===!0||isFinite(e)?e||0:f):f}}),n.each(["height","width"],function(a,b){n.cssHooks[b]={get:function(a,c,d){return c?Xa.test(n.css(a,"display"))&&0===a.offsetWidth?Pa(a,Za,function(){return fb(a,b,d)}):fb(a,b,d):void 0},set:function(a,c,d){var e=d&&Ra(a);return db(a,c,d?eb(a,b,d,l.boxSizing&&"border-box"===n.css(a,"boxSizing",!1,e),e):0)}}}),l.opacity||(n.cssHooks.opacity={get:function(a,b){return Wa.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=n.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===n.trim(f.replace(Va,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Va.test(f)?f.replace(Va,e):f+" "+e)}}),n.cssHooks.marginRight=Ua(l.reliableMarginRight,function(a,b){return b?Pa(a,{display:"inline-block"},Sa,[a,"marginRight"]):void 0}),n.cssHooks.marginLeft=Ua(l.reliableMarginLeft,function(a,b){return b?(parseFloat(Sa(a,"marginLeft"))||(n.contains(a.ownerDocument,a)?a.getBoundingClientRect().left-Pa(a,{
marginLeft:0},function(){return a.getBoundingClientRect().left}):0))+"px":void 0}),n.each({margin:"",padding:"",border:"Width"},function(a,b){n.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+V[d]+b]=f[d]||f[d-2]||f[0];return e}},Na.test(a)||(n.cssHooks[a+b].set=db)}),n.fn.extend({css:function(a,b){return Y(this,function(a,b,c){var d,e,f={},g=0;if(n.isArray(b)){for(d=Ra(a),e=b.length;e>g;g++)f[b[g]]=n.css(a,b[g],!1,d);return f}return void 0!==c?n.style(a,b,c):n.css(a,b)},a,b,arguments.length>1)},show:function(){return cb(this,!0)},hide:function(){return cb(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){W(this)?n(this).show():n(this).hide()})}});function gb(a,b,c,d,e){return new gb.prototype.init(a,b,c,d,e)}n.Tween=gb,gb.prototype={constructor:gb,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||n.easing._default,this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(n.cssNumber[c]?"":"px")},cur:function(){var a=gb.propHooks[this.prop];return a&&a.get?a.get(this):gb.propHooks._default.get(this)},run:function(a){var b,c=gb.propHooks[this.prop];return this.options.duration?this.pos=b=n.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):gb.propHooks._default.set(this),this}},gb.prototype.init.prototype=gb.prototype,gb.propHooks={_default:{get:function(a){var b;return 1!==a.elem.nodeType||null!=a.elem[a.prop]&&null==a.elem.style[a.prop]?a.elem[a.prop]:(b=n.css(a.elem,a.prop,""),b&&"auto"!==b?b:0)},set:function(a){n.fx.step[a.prop]?n.fx.step[a.prop](a):1!==a.elem.nodeType||null==a.elem.style[n.cssProps[a.prop]]&&!n.cssHooks[a.prop]?a.elem[a.prop]=a.now:n.style(a.elem,a.prop,a.now+a.unit)}}},gb.propHooks.scrollTop=gb.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},n.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2},_default:"swing"},n.fx=gb.prototype.init,n.fx.step={};var hb,ib,jb=/^(?:toggle|show|hide)$/,kb=/queueHooks$/;function lb(){return a.setTimeout(function(){hb=void 0}),hb=n.now()}function mb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=V[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function nb(a,b,c){for(var d,e=(qb.tweeners[b]||[]).concat(qb.tweeners["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ob(a,b,c){var d,e,f,g,h,i,j,k,m=this,o={},p=a.style,q=a.nodeType&&W(a),r=n._data(a,"fxshow");c.queue||(h=n._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,m.always(function(){m.always(function(){h.unqueued--,n.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=n.css(a,"display"),k="none"===j?n._data(a,"olddisplay")||Ma(a.nodeName):j,"inline"===k&&"none"===n.css(a,"float")&&(l.inlineBlockNeedsLayout&&"inline"!==Ma(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",l.shrinkWrapBlocks()||m.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],jb.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||n.style(a,d)}else j=void 0;if(n.isEmptyObject(o))"inline"===("none"===j?Ma(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=n._data(a,"fxshow",{}),f&&(r.hidden=!q),q?n(a).show():m.done(function(){n(a).hide()}),m.done(function(){var b;n._removeData(a,"fxshow");for(b in o)n.style(a,b,o[b])});for(d in o)g=nb(q?r[d]:0,d,m),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function pb(a,b){var c,d,e,f,g;for(c in a)if(d=n.camelCase(c),e=b[d],f=a[c],n.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=n.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function qb(a,b,c){var d,e,f=0,g=qb.prefilters.length,h=n.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=hb||lb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:n.extend({},b),opts:n.extend(!0,{specialEasing:{},easing:n.easing._default},c),originalProperties:b,originalOptions:c,startTime:hb||lb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=n.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?(h.notifyWith(a,[j,1,0]),h.resolveWith(a,[j,b])):h.rejectWith(a,[j,b]),this}}),k=j.props;for(pb(k,j.opts.specialEasing);g>f;f++)if(d=qb.prefilters[f].call(j,a,k,j.opts))return n.isFunction(d.stop)&&(n._queueHooks(j.elem,j.opts.queue).stop=n.proxy(d.stop,d)),d;return n.map(k,nb,j),n.isFunction(j.opts.start)&&j.opts.start.call(a,j),n.fx.timer(n.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}n.Animation=n.extend(qb,{tweeners:{"*":[function(a,b){var c=this.createTween(a,b);return X(c.elem,a,U.exec(b),c),c}]},tweener:function(a,b){n.isFunction(a)?(b=a,a=["*"]):a=a.match(G);for(var c,d=0,e=a.length;e>d;d++)c=a[d],qb.tweeners[c]=qb.tweeners[c]||[],qb.tweeners[c].unshift(b)},prefilters:[ob],prefilter:function(a,b){b?qb.prefilters.unshift(a):qb.prefilters.push(a)}}),n.speed=function(a,b,c){var d=a&&"object"==typeof a?n.extend({},a):{complete:c||!c&&b||n.isFunction(a)&&a,duration:a,easing:c&&b||b&&!n.isFunction(b)&&b};return d.duration=n.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in n.fx.speeds?n.fx.speeds[d.duration]:n.fx.speeds._default,null!=d.queue&&d.queue!==!0||(d.queue="fx"),d.old=d.complete,d.complete=function(){n.isFunction(d.old)&&d.old.call(this),d.queue&&n.dequeue(this,d.queue)},d},n.fn.extend({fadeTo:function(a,b,c,d){return this.filter(W).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=n.isEmptyObject(a),f=n.speed(b,c,d),g=function(){var b=qb(this,n.extend({},a),f);(e||n._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=n.timers,g=n._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&kb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));!b&&c||n.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=n._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=n.timers,g=d?d.length:0;for(c.finish=!0,n.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),n.each(["toggle","show","hide"],function(a,b){var c=n.fn[b];n.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(mb(b,!0),a,d,e)}}),n.each({slideDown:mb("show"),slideUp:mb("hide"),slideToggle:mb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){n.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),n.timers=[],n.fx.tick=function(){var a,b=n.timers,c=0;for(hb=n.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||n.fx.stop(),hb=void 0},n.fx.timer=function(a){n.timers.push(a),a()?n.fx.start():n.timers.pop()},n.fx.interval=13,n.fx.start=function(){ib||(ib=a.setInterval(n.fx.tick,n.fx.interval))},n.fx.stop=function(){a.clearInterval(ib),ib=null},n.fx.speeds={slow:600,fast:200,_default:400},n.fn.delay=function(b,c){return b=n.fx?n.fx.speeds[b]||b:b,c=c||"fx",this.queue(c,function(c,d){var e=a.setTimeout(c,b);d.stop=function(){a.clearTimeout(e)}})},function(){var a,b=d.createElement("input"),c=d.createElement("div"),e=d.createElement("select"),f=e.appendChild(d.createElement("option"));c=d.createElement("div"),c.setAttribute("className","t"),c.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",a=c.getElementsByTagName("a")[0],b.setAttribute("type","checkbox"),c.appendChild(b),a=c.getElementsByTagName("a")[0],a.style.cssText="top:1px",l.getSetAttribute="t"!==c.className,l.style=/top/.test(a.getAttribute("style")),l.hrefNormalized="/a"===a.getAttribute("href"),l.checkOn=!!b.value,l.optSelected=f.selected,l.enctype=!!d.createElement("form").enctype,e.disabled=!0,l.optDisabled=!f.disabled,b=d.createElement("input"),b.setAttribute("value",""),l.input=""===b.getAttribute("value"),b.value="t",b.setAttribute("type","radio"),l.radioValue="t"===b.value}();var rb=/\r/g,sb=/[\x20\t\r\n\f]+/g;n.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=n.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,n(this).val()):a,null==e?e="":"number"==typeof e?e+="":n.isArray(e)&&(e=n.map(e,function(a){return null==a?"":a+""})),b=n.valHooks[this.type]||n.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=n.valHooks[e.type]||n.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(rb,""):null==c?"":c)}}}),n.extend({valHooks:{option:{get:function(a){var b=n.find.attr(a,"value");return null!=b?b:n.trim(n.text(a)).replace(sb," ")}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],(c.selected||i===e)&&(l.optDisabled?!c.disabled:null===c.getAttribute("disabled"))&&(!c.parentNode.disabled||!n.nodeName(c.parentNode,"optgroup"))){if(b=n(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=n.makeArray(b),g=e.length;while(g--)if(d=e[g],n.inArray(n.valHooks.option.get(d),f)>-1)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),n.each(["radio","checkbox"],function(){n.valHooks[this]={set:function(a,b){return n.isArray(b)?a.checked=n.inArray(n(a).val(),b)>-1:void 0}},l.checkOn||(n.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var tb,ub,vb=n.expr.attrHandle,wb=/^(?:checked|selected)$/i,xb=l.getSetAttribute,yb=l.input;n.fn.extend({attr:function(a,b){return Y(this,n.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){n.removeAttr(this,a)})}}),n.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(3!==f&&8!==f&&2!==f)return"undefined"==typeof a.getAttribute?n.prop(a,b,c):(1===f&&n.isXMLDoc(a)||(b=b.toLowerCase(),e=n.attrHooks[b]||(n.expr.match.bool.test(b)?ub:tb)),void 0!==c?null===c?void n.removeAttr(a,b):e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:(a.setAttribute(b,c+""),c):e&&"get"in e&&null!==(d=e.get(a,b))?d:(d=n.find.attr(a,b),null==d?void 0:d))},attrHooks:{type:{set:function(a,b){if(!l.radioValue&&"radio"===b&&n.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(G);if(f&&1===a.nodeType)while(c=f[e++])d=n.propFix[c]||c,n.expr.match.bool.test(c)?yb&&xb||!wb.test(c)?a[d]=!1:a[n.camelCase("default-"+c)]=a[d]=!1:n.attr(a,c,""),a.removeAttribute(xb?c:d)}}),ub={set:function(a,b,c){return b===!1?n.removeAttr(a,c):yb&&xb||!wb.test(c)?a.setAttribute(!xb&&n.propFix[c]||c,c):a[n.camelCase("default-"+c)]=a[c]=!0,c}},n.each(n.expr.match.bool.source.match(/\w+/g),function(a,b){var c=vb[b]||n.find.attr;yb&&xb||!wb.test(b)?vb[b]=function(a,b,d){var e,f;return d||(f=vb[b],vb[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,vb[b]=f),e}:vb[b]=function(a,b,c){return c?void 0:a[n.camelCase("default-"+b)]?b.toLowerCase():null}}),yb&&xb||(n.attrHooks.value={set:function(a,b,c){return n.nodeName(a,"input")?void(a.defaultValue=b):tb&&tb.set(a,b,c)}}),xb||(tb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},vb.id=vb.name=vb.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},n.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:tb.set},n.attrHooks.contenteditable={set:function(a,b,c){tb.set(a,""===b?!1:b,c)}},n.each(["width","height"],function(a,b){n.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),l.style||(n.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var zb=/^(?:input|select|textarea|button|object)$/i,Ab=/^(?:a|area)$/i;n.fn.extend({prop:function(a,b){return Y(this,n.prop,a,b,arguments.length>1)},removeProp:function(a){return a=n.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),n.extend({prop:function(a,b,c){var d,e,f=a.nodeType;if(3!==f&&8!==f&&2!==f)return 1===f&&n.isXMLDoc(a)||(b=n.propFix[b]||b,e=n.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=n.find.attr(a,"tabindex");return b?parseInt(b,10):zb.test(a.nodeName)||Ab.test(a.nodeName)&&a.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),l.hrefNormalized||n.each(["href","src"],function(a,b){n.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),l.optSelected||(n.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null},set:function(a){var b=a.parentNode;b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex)}}),n.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){n.propFix[this.toLowerCase()]=this}),l.enctype||(n.propFix.enctype="encoding");var Bb=/[\t\r\n\f]/g;function Cb(a){return n.attr(a,"class")||""}n.fn.extend({addClass:function(a){var b,c,d,e,f,g,h,i=0;if(n.isFunction(a))return this.each(function(b){n(this).addClass(a.call(this,b,Cb(this)))});if("string"==typeof a&&a){b=a.match(G)||[];while(c=this[i++])if(e=Cb(c),d=1===c.nodeType&&(" "+e+" ").replace(Bb," ")){g=0;while(f=b[g++])d.indexOf(" "+f+" ")<0&&(d+=f+" ");h=n.trim(d),e!==h&&n.attr(c,"class",h)}}return this},removeClass:function(a){var b,c,d,e,f,g,h,i=0;if(n.isFunction(a))return this.each(function(b){n(this).removeClass(a.call(this,b,Cb(this)))});if(!arguments.length)return this.attr("class","");if("string"==typeof a&&a){b=a.match(G)||[];while(c=this[i++])if(e=Cb(c),d=1===c.nodeType&&(" "+e+" ").replace(Bb," ")){g=0;while(f=b[g++])while(d.indexOf(" "+f+" ")>-1)d=d.replace(" "+f+" "," ");h=n.trim(d),e!==h&&n.attr(c,"class",h)}}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):n.isFunction(a)?this.each(function(c){n(this).toggleClass(a.call(this,c,Cb(this),b),b)}):this.each(function(){var b,d,e,f;if("string"===c){d=0,e=n(this),f=a.match(G)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else void 0!==a&&"boolean"!==c||(b=Cb(this),b&&n._data(this,"__className__",b),n.attr(this,"class",b||a===!1?"":n._data(this,"__className__")||""))})},hasClass:function(a){var b,c,d=0;b=" "+a+" ";while(c=this[d++])if(1===c.nodeType&&(" "+Cb(c)+" ").replace(Bb," ").indexOf(b)>-1)return!0;return!1}}),n.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){n.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),n.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)}});var Db=a.location,Eb=n.now(),Fb=/\?/,Gb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;n.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=n.trim(b+"");return e&&!n.trim(e.replace(Gb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():n.error("Invalid JSON: "+b)},n.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new a.DOMParser,c=d.parseFromString(b,"text/xml")):(c=new a.ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||n.error("Invalid XML: "+b),c};var Hb=/#.*$/,Ib=/([?&])_=[^&]*/,Jb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Kb=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Lb=/^(?:GET|HEAD)$/,Mb=/^\/\//,Nb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Ob={},Pb={},Qb="*/".concat("*"),Rb=Db.href,Sb=Nb.exec(Rb.toLowerCase())||[];function Tb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(G)||[];if(n.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Ub(a,b,c,d){var e={},f=a===Pb;function g(h){var i;return e[h]=!0,n.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Vb(a,b){var c,d,e=n.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&n.extend(!0,a,c),a}function Wb(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Xb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}n.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:Rb,type:"GET",isLocal:Kb.test(Sb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Qb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":n.parseJSON,"text xml":n.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Vb(Vb(a,n.ajaxSettings),b):Vb(n.ajaxSettings,a)},ajaxPrefilter:Tb(Ob),ajaxTransport:Tb(Pb),ajax:function(b,c){"object"==typeof b&&(c=b,b=void 0),c=c||{};var d,e,f,g,h,i,j,k,l=n.ajaxSetup({},c),m=l.context||l,o=l.context&&(m.nodeType||m.jquery)?n(m):n.event,p=n.Deferred(),q=n.Callbacks("once memory"),r=l.statusCode||{},s={},t={},u=0,v="canceled",w={readyState:0,getResponseHeader:function(a){var b;if(2===u){if(!k){k={};while(b=Jb.exec(g))k[b[1].toLowerCase()]=b[2]}b=k[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===u?g:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return u||(a=t[c]=t[c]||a,s[a]=b),this},overrideMimeType:function(a){return u||(l.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>u)for(b in a)r[b]=[r[b],a[b]];else w.always(a[w.status]);return this},abort:function(a){var b=a||v;return j&&j.abort(b),y(0,b),this}};if(p.promise(w).complete=q.add,w.success=w.done,w.error=w.fail,l.url=((b||l.url||Rb)+"").replace(Hb,"").replace(Mb,Sb[1]+"//"),l.type=c.method||c.type||l.method||l.type,l.dataTypes=n.trim(l.dataType||"*").toLowerCase().match(G)||[""],null==l.crossDomain&&(d=Nb.exec(l.url.toLowerCase()),l.crossDomain=!(!d||d[1]===Sb[1]&&d[2]===Sb[2]&&(d[3]||("http:"===d[1]?"80":"443"))===(Sb[3]||("http:"===Sb[1]?"80":"443")))),l.data&&l.processData&&"string"!=typeof l.data&&(l.data=n.param(l.data,l.traditional)),Ub(Ob,l,c,w),2===u)return w;i=n.event&&l.global,i&&0===n.active++&&n.event.trigger("ajaxStart"),l.type=l.type.toUpperCase(),l.hasContent=!Lb.test(l.type),f=l.url,l.hasContent||(l.data&&(f=l.url+=(Fb.test(f)?"&":"?")+l.data,delete l.data),l.cache===!1&&(l.url=Ib.test(f)?f.replace(Ib,"$1_="+Eb++):f+(Fb.test(f)?"&":"?")+"_="+Eb++)),l.ifModified&&(n.lastModified[f]&&w.setRequestHeader("If-Modified-Since",n.lastModified[f]),n.etag[f]&&w.setRequestHeader("If-None-Match",n.etag[f])),(l.data&&l.hasContent&&l.contentType!==!1||c.contentType)&&w.setRequestHeader("Content-Type",l.contentType),w.setRequestHeader("Accept",l.dataTypes[0]&&l.accepts[l.dataTypes[0]]?l.accepts[l.dataTypes[0]]+("*"!==l.dataTypes[0]?", "+Qb+"; q=0.01":""):l.accepts["*"]);for(e in l.headers)w.setRequestHeader(e,l.headers[e]);if(l.beforeSend&&(l.beforeSend.call(m,w,l)===!1||2===u))return w.abort();v="abort";for(e in{success:1,error:1,complete:1})w[e](l[e]);if(j=Ub(Pb,l,c,w)){if(w.readyState=1,i&&o.trigger("ajaxSend",[w,l]),2===u)return w;l.async&&l.timeout>0&&(h=a.setTimeout(function(){w.abort("timeout")},l.timeout));try{u=1,j.send(s,y)}catch(x){if(!(2>u))throw x;y(-1,x)}}else y(-1,"No Transport");function y(b,c,d,e){var k,s,t,v,x,y=c;2!==u&&(u=2,h&&a.clearTimeout(h),j=void 0,g=e||"",w.readyState=b>0?4:0,k=b>=200&&300>b||304===b,d&&(v=Wb(l,w,d)),v=Xb(l,v,w,k),k?(l.ifModified&&(x=w.getResponseHeader("Last-Modified"),x&&(n.lastModified[f]=x),x=w.getResponseHeader("etag"),x&&(n.etag[f]=x)),204===b||"HEAD"===l.type?y="nocontent":304===b?y="notmodified":(y=v.state,s=v.data,t=v.error,k=!t)):(t=y,!b&&y||(y="error",0>b&&(b=0))),w.status=b,w.statusText=(c||y)+"",k?p.resolveWith(m,[s,y,w]):p.rejectWith(m,[w,y,t]),w.statusCode(r),r=void 0,i&&o.trigger(k?"ajaxSuccess":"ajaxError",[w,l,k?s:t]),q.fireWith(m,[w,y]),i&&(o.trigger("ajaxComplete",[w,l]),--n.active||n.event.trigger("ajaxStop")))}return w},getJSON:function(a,b,c){return n.get(a,b,c,"json")},getScript:function(a,b){return n.get(a,void 0,b,"script")}}),n.each(["get","post"],function(a,b){n[b]=function(a,c,d,e){return n.isFunction(c)&&(e=e||d,d=c,c=void 0),n.ajax(n.extend({url:a,type:b,dataType:e,data:c,success:d},n.isPlainObject(a)&&a))}}),n._evalUrl=function(a){return n.ajax({url:a,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,"throws":!0})},n.fn.extend({wrapAll:function(a){if(n.isFunction(a))return this.each(function(b){n(this).wrapAll(a.call(this,b))});if(this[0]){var b=n(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return n.isFunction(a)?this.each(function(b){n(this).wrapInner(a.call(this,b))}):this.each(function(){var b=n(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=n.isFunction(a);return this.each(function(c){n(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){n.nodeName(this,"body")||n(this).replaceWith(this.childNodes)}).end()}});function Yb(a){return a.style&&a.style.display||n.css(a,"display")}function Zb(a){if(!n.contains(a.ownerDocument||d,a))return!0;while(a&&1===a.nodeType){if("none"===Yb(a)||"hidden"===a.type)return!0;a=a.parentNode}return!1}n.expr.filters.hidden=function(a){return l.reliableHiddenOffsets()?a.offsetWidth<=0&&a.offsetHeight<=0&&!a.getClientRects().length:Zb(a)},n.expr.filters.visible=function(a){return!n.expr.filters.hidden(a)};var $b=/%20/g,_b=/\[\]$/,ac=/\r?\n/g,bc=/^(?:submit|button|image|reset|file)$/i,cc=/^(?:input|select|textarea|keygen)/i;function dc(a,b,c,d){var e;if(n.isArray(b))n.each(b,function(b,e){c||_b.test(a)?d(a,e):dc(a+"["+("object"==typeof e&&null!=e?b:"")+"]",e,c,d)});else if(c||"object"!==n.type(b))d(a,b);else for(e in b)dc(a+"["+e+"]",b[e],c,d)}n.param=function(a,b){var c,d=[],e=function(a,b){b=n.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=n.ajaxSettings&&n.ajaxSettings.traditional),n.isArray(a)||a.jquery&&!n.isPlainObject(a))n.each(a,function(){e(this.name,this.value)});else for(c in a)dc(c,a[c],b,e);return d.join("&").replace($b,"+")},n.fn.extend({serialize:function(){return n.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=n.prop(this,"elements");return a?n.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!n(this).is(":disabled")&&cc.test(this.nodeName)&&!bc.test(a)&&(this.checked||!Z.test(a))}).map(function(a,b){var c=n(this).val();return null==c?null:n.isArray(c)?n.map(c,function(a){return{name:b.name,value:a.replace(ac,"\r\n")}}):{name:b.name,value:c.replace(ac,"\r\n")}}).get()}}),n.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return this.isLocal?ic():d.documentMode>8?hc():/^(get|post|head|put|delete|options)$/i.test(this.type)&&hc()||ic()}:hc;var ec=0,fc={},gc=n.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in fc)fc[a](void 0,!0)}),l.cors=!!gc&&"withCredentials"in gc,gc=l.ajax=!!gc,gc&&n.ajaxTransport(function(b){if(!b.crossDomain||l.cors){var c;return{send:function(d,e){var f,g=b.xhr(),h=++ec;if(g.open(b.type,b.url,b.async,b.username,b.password),b.xhrFields)for(f in b.xhrFields)g[f]=b.xhrFields[f];b.mimeType&&g.overrideMimeType&&g.overrideMimeType(b.mimeType),b.crossDomain||d["X-Requested-With"]||(d["X-Requested-With"]="XMLHttpRequest");for(f in d)void 0!==d[f]&&g.setRequestHeader(f,d[f]+"");g.send(b.hasContent&&b.data||null),c=function(a,d){var f,i,j;if(c&&(d||4===g.readyState))if(delete fc[h],c=void 0,g.onreadystatechange=n.noop,d)4!==g.readyState&&g.abort();else{j={},f=g.status,"string"==typeof g.responseText&&(j.text=g.responseText);try{i=g.statusText}catch(k){i=""}f||!b.isLocal||b.crossDomain?1223===f&&(f=204):f=j.text?200:404}j&&e(f,i,j,g.getAllResponseHeaders())},b.async?4===g.readyState?a.setTimeout(c):g.onreadystatechange=fc[h]=c:c()},abort:function(){c&&c(void 0,!0)}}}});function hc(){try{return new a.XMLHttpRequest}catch(b){}}function ic(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}n.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(a){return n.globalEval(a),a}}}),n.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),n.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=d.head||n("head")[0]||d.documentElement;return{send:function(e,f){b=d.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||f(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var jc=[],kc=/(=)\?(?=&|$)|\?\?/;n.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=jc.pop()||n.expando+"_"+Eb++;return this[a]=!0,a}}),n.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(kc.test(b.url)?"url":"string"==typeof b.data&&0===(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&kc.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=n.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(kc,"$1"+e):b.jsonp!==!1&&(b.url+=(Fb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||n.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){void 0===f?n(a).removeProp(e):a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,jc.push(e)),g&&n.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),n.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||d;var e=x.exec(a),f=!c&&[];return e?[b.createElement(e[1])]:(e=ja([a],b,f),f&&f.length&&n(f).remove(),n.merge([],e.childNodes))};var lc=n.fn.load;n.fn.load=function(a,b,c){if("string"!=typeof a&&lc)return lc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>-1&&(d=n.trim(a.slice(h,a.length)),a=a.slice(0,h)),n.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(e="POST"),g.length>0&&n.ajax({url:a,type:e||"GET",dataType:"html",data:b}).done(function(a){f=arguments,g.html(d?n("<div>").append(n.parseHTML(a)).find(d):a)}).always(c&&function(a,b){g.each(function(){c.apply(this,f||[a.responseText,b,a])})}),this},n.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){n.fn[b]=function(a){return this.on(b,a)}}),n.expr.filters.animated=function(a){return n.grep(n.timers,function(b){return a===b.elem}).length};function mc(a){return n.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}n.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=n.css(a,"position"),l=n(a),m={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=n.css(a,"top"),i=n.css(a,"left"),j=("absolute"===k||"fixed"===k)&&n.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),n.isFunction(b)&&(b=b.call(a,c,n.extend({},h))),null!=b.top&&(m.top=b.top-h.top+g),null!=b.left&&(m.left=b.left-h.left+e),"using"in b?b.using.call(a,m):l.css(m)}},n.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){n.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,n.contains(b,e)?("undefined"!=typeof e.getBoundingClientRect&&(d=e.getBoundingClientRect()),c=mc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===n.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),n.nodeName(a[0],"html")||(c=a.offset()),c.top+=n.css(a[0],"borderTopWidth",!0),c.left+=n.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-n.css(d,"marginTop",!0),left:b.left-c.left-n.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent;while(a&&!n.nodeName(a,"html")&&"static"===n.css(a,"position"))a=a.offsetParent;return a||Qa})}}),n.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);n.fn[a]=function(d){return Y(this,function(a,d,e){var f=mc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?n(f).scrollLeft():e,c?e:n(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),n.each(["top","left"],function(a,b){n.cssHooks[b]=Ua(l.pixelPosition,function(a,c){return c?(c=Sa(a,b),Oa.test(c)?n(a).position()[b]+"px":c):void 0})}),n.each({Height:"height",Width:"width"},function(a,b){n.each({
padding:"inner"+a,content:b,"":"outer"+a},function(c,d){n.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return Y(this,function(b,c,d){var e;return n.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?n.css(b,c,g):n.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),n.fn.extend({bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}}),n.fn.size=function(){return this.length},n.fn.andSelf=n.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return n});var nc=a.jQuery,oc=a.$;return n.noConflict=function(b){return a.$===n&&(a.$=oc),b&&a.jQuery===n&&(a.jQuery=nc),n},b||(a.jQuery=a.$=n),n});
"></script>
<link href="data:text/css;charset=utf-8,%2Edt%2Dcrosstalk%2Dfade%20%7B%0Aopacity%3A%200%2E2%3B%0A%7D%0Ahtml%20body%20div%2EDTS%20div%2EdataTables%5FscrollBody%20%7B%0Abackground%3A%20none%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/x-javascript;base64,(function() {

// some helper functions: using a global object DTWidget so that it can be used
// in JS() code, e.g. datatable(options = list(foo = JS('code'))); unlike R's
// dynamic scoping, when 'code' is eval()'ed, JavaScript does not know objects
// from the "parent frame", e.g. JS('DTWidget') will not work unless it was made
// a global object
var DTWidget = {};

// 123456666.7890 -> 123,456,666.7890
var markInterval = function(d, digits, interval, mark, decMark, precision) {
  x = precision ? d.toPrecision(digits) : d.toFixed(digits);
  if (!/^-?[\d.]+$/.test(x)) return x;
  var xv = x.split('.');
  if (xv.length > 2) return x;  // should have at most one decimal point
  xv[0] = xv[0].replace(new RegExp('\\B(?=(\\d{' + interval + '})+(?!\\d))', 'g'), mark);
  return xv.join(decMark);
};

DTWidget.formatCurrency = function(thiz, row, data, col, currency, digits, interval, mark, decMark, before) {
  var d = parseFloat(data[col]);
  if (isNaN(d)) return;
  var res = markInterval(d, digits, interval, mark, decMark);
  res = before ? (/^-/.test(res) ? '-' + currency + res.replace(/^-/, '') : currency + res) :
    res + currency;
  $(thiz.api().cell(row, col).node()).html(res);
};

DTWidget.formatString = function(thiz, row, data, col, prefix, suffix) {
  var d = data[col];
  if (d === null) return;
  $(thiz.api().cell(row, col).node()).html(prefix + d + suffix);
};

DTWidget.formatPercentage = function(thiz, row, data, col, digits, interval, mark, decMark) {
  var d = parseFloat(data[col]);
  if (isNaN(d)) return;
  $(thiz.api().cell(row, col).node())
  .html(markInterval(d * 100, digits, interval, mark, decMark) + '%');
};

DTWidget.formatRound = function(thiz, row, data, col, digits, interval, mark, decMark) {
  var d = parseFloat(data[col]);
  if (isNaN(d)) return;
  $(thiz.api().cell(row, col).node()).html(markInterval(d, digits, interval, mark, decMark));
};

DTWidget.formatSignif = function(thiz, row, data, col, digits, interval, mark, decMark) {
  var d = parseFloat(data[col]);
  if (isNaN(d)) return;
  $(thiz.api().cell(row, col).node())
    .html(markInterval(d, digits, interval, mark, decMark, true));
};

DTWidget.formatDate = function(thiz, row, data, col, method, params) {
  var d = data[col];
  if (d === null) return;
  // (new Date('2015-10-28')).toDateString() may return 2015-10-27 because the
  // actual time created could be like 'Tue Oct 27 2015 19:00:00 GMT-0500 (CDT)',
  // i.e. the date-only string is treated as UTC time instead of local time
  if (method === 'toDateString' && /^\d{4,}\D\d{2}\D\d{2}$/.test(d)) {
    d = d.split(/\D/);
    d = new Date(d[0], d[1] - 1, d[2]);
  } else {
    d = new Date(d);
  }
  $(thiz.api().cell(row, col).node()).html(d[method].apply(d, params));
};

window.DTWidget = DTWidget;

var transposeArray2D = function(a) {
  return a.length === 0 ? a : HTMLWidgets.transposeArray2D(a);
};

var crosstalkPluginsInstalled = false;

function maybeInstallCrosstalkPlugins() {
  if (crosstalkPluginsInstalled)
    return;
  crosstalkPluginsInstalled = true;

  $.fn.dataTable.ext.afnFiltering.push(
    function(oSettings, aData, iDataIndex) {
      var ctfilter = oSettings.nTable.ctfilter;
      if (ctfilter && !ctfilter[iDataIndex])
        return false;

      var ctselect = oSettings.nTable.ctselect;
      if (ctselect && !ctselect[iDataIndex])
        return false;

      return true;
    }
  );
}

HTMLWidgets.widget({
  name: "datatables",
  type: "output",
  renderOnNullValue: true,
  initialize: function(el, width, height) {
    $(el).html('&nbsp;');
    return {
      data: null,
      ctfilterHandle: new crosstalk.FilterHandle(),
      ctfilterSubscription: null,
      ctselectHandle: new crosstalk.SelectionHandle(),
      ctselectSubscription: null
    };
  },
  renderValue: function(el, data, instance) {
    if (el.offsetWidth === 0 || el.offsetHeight === 0) {
      instance.data = data;
      return;
    }
    instance.data = null;
    var $el = $(el);
    $el.empty();

    if (data === null) {
      $el.append('&nbsp;');
      // clear previous Shiny inputs (if any)
      for (var i in instance.clearInputs) instance.clearInputs[i]();
      instance.clearInputs = {};
      return;
    }

    var crosstalkOptions = data.crosstalkOptions;
    if (!crosstalkOptions) crosstalkOptions = {
      'key': null, 'group': null
    };
    if (crosstalkOptions.group) {
      maybeInstallCrosstalkPlugins();
      instance.ctfilterHandle.setGroup(crosstalkOptions.group);
      instance.ctselectHandle.setGroup(crosstalkOptions.group);
    }

    // If we are in a flexdashboard scroll layout then we:
    //  (a) Always want to use pagination (otherwise we'll have
    //      a "double scroll bar" effect on the phone); and
    //  (b) Never want to fill the container (we want the pagination
    //      level to determine the size of the container)
    if (window.FlexDashboard && !window.FlexDashboard.isFillPage()) {
      data.options.bPaginate = true;
      data.fillContainer = false;
    }

    // if we are in the viewer then we always want to fillContainer and
    // and autoHideNavigation (unless the user has explicitly set these)
    if (window.HTMLWidgets.viewerMode) {
      if (!data.hasOwnProperty("fillContainer"))
        data.fillContainer = true;
      if (!data.hasOwnProperty("autoHideNavigation"))
        data.autoHideNavigation = true;
    }

    // propagate fillContainer to instance (so we have it in resize)
    instance.fillContainer = data.fillContainer;

    var cells = data.data;

    if (cells instanceof Array) cells = transposeArray2D(cells);

    $el.append(data.container);
    var $table = $el.find('table');
    if (data.class) $table.addClass(data.class);
    if (data.caption) $table.prepend(data.caption);

    if (HTMLWidgets.shinyMode && data.selection.mode !== 'none' &&
        data.selection.target === 'row+column') {
      if ($table.children('tfoot').length === 0) {
        $table.append($('<tfoot>'));
        $table.find('thead tr').clone().appendTo($table.find('tfoot'));
      }
    }

    // column filters
    var filterRow;
    switch (data.filter) {
      case 'top':
        $table.children('thead').append(data.filterHTML);
        filterRow = $table.find('thead tr:last td');
        break;
      case 'bottom':
        if ($table.children('tfoot').length === 0) {
          $table.append($('<tfoot>'));
        }
        $table.children('tfoot').prepend(data.filterHTML);
        filterRow = $table.find('tfoot tr:first td');
        break;
    }

    var options = { searchDelay: 1000 };
    if (cells !== null) $.extend(options, {
      data: cells
    });

    // options for fillContainer
    var bootstrapActive = typeof($.fn.popover) != 'undefined';
    if (instance.fillContainer) {

      // force scrollX/scrollY and turn off autoWidth
      options.scrollX = true;
      options.scrollY = "100px"; // can be any value, we'll adjust below

      // if we aren't paginating then move around the info/filter controls
      // to save space at the bottom and rephrase the info callback
      if (data.options.bPaginate === false) {

        // we know how to do this cleanly for bootstrap, not so much
        // for other themes/layouts
        if (bootstrapActive) {
          options.dom = "<'row'<'col-sm-4'i><'col-sm-8'f>>" +
                        "<'row'<'col-sm-12'tr>>";
        }

        options.fnInfoCallback = function(oSettings, iStart, iEnd,
                                           iMax, iTotal, sPre) {
          return Number(iTotal).toLocaleString() + " records";
        };
      }
    }

    // auto hide navigation if requested
    if (data.autoHideNavigation === true) {
      if (bootstrapActive && data.options.bPaginate !== false) {
        // strip all nav if length >= cells
        if ((cells instanceof Array) && data.options.iDisplayLength >= cells.length)
          options.dom = "<'row'<'col-sm-12'tr>>";
        // alternatively lean things out for flexdashboard mobile portrait
        else if (window.FlexDashboard && window.FlexDashboard.isMobilePhone())
          options.dom = "<'row'<'col-sm-12'f>>" +
                        "<'row'<'col-sm-12'tr>>"  +
                        "<'row'<'col-sm-12'p>>";
      }
    }

    $.extend(true, options, data.options || {});

    var searchCols = options.searchCols;
    if (searchCols) {
      searchCols = searchCols.map(function(x) {
        return x === null ? '' : x.search;
      });
      // FIXME: this means I don't respect the escapeRegex setting
      delete options.searchCols;
    }

    // server-side processing?
    var server = options.serverSide === true;

    // use the dataSrc function to pre-process JSON data returned from R
    var DT_rows_all = [], DT_rows_current = [];
    if (server && HTMLWidgets.shinyMode && typeof options.ajax === 'object' &&
        /^session\/[\da-z]+\/dataobj/.test(options.ajax.url) && !options.ajax.dataSrc) {
      options.ajax.dataSrc = function(json) {
        DT_rows_all = $.makeArray(json.DT_rows_all);
        DT_rows_current = $.makeArray(json.DT_rows_current);
        return json.data;
      };
    }

    var thiz = this;
    if (instance.fillContainer) $table.on('init.dt', function(e) {
      thiz.fillAvailableHeight(el, $(el).innerHeight());
    });

    var table = $table.DataTable(options);
    $el.data('datatable', table);

    // Unregister previous Crosstalk event subscriptions, if they exist
    if (instance.ctfilterSubscription) {
      instance.ctfilterHandle.off("change", instance.ctfilterSubscription);
      instance.ctfilterSubscription = null;
    }
    if (instance.ctselectSubscription) {
      instance.ctselectHandle.off("change", instance.ctselectSubscription);
      instance.ctselectSubscription = null;
    }

    if (!crosstalkOptions.group) {
      $table[0].ctfilter = null;
      $table[0].ctselect = null;
    } else {
      var key = crosstalkOptions.key;
      function keysToMatches(keys) {
        if (!keys) {
          return null;
        } else {
          var selectedKeys = {};
          for (var i = 0; i < keys.length; i++) {
            selectedKeys[keys[i]] = true;
          }
          var matches = {};
          for (var j = 0; j < key.length; j++) {
            if (selectedKeys[key[j]])
              matches[j] = true;
          }
          return matches;
        }
      }

      function applyCrosstalkFilter(e) {
        $table[0].ctfilter = keysToMatches(e.value);
        table.draw();
      }
      instance.ctfilterSubscription = instance.ctfilterHandle.on("change", applyCrosstalkFilter);
      applyCrosstalkFilter({value: instance.ctfilterHandle.filteredKeys});

      function applyCrosstalkSelection(e) {
        if (e.sender !== instance.ctselectHandle) {
          table
            .rows('.' + selClass, {search: 'applied'})
            .nodes()
            .to$()
            .removeClass(selClass);
          if (selectedRows)
            changeInput('rows_selected', selectedRows(), void 0, true);
        }

        if (e.sender !== instance.ctselectHandle && e.value && e.value.length) {
          $table[0].ctselect = keysToMatches(e.value);
          table.draw();
        } else {
          if ($table[0].ctselect) {
            $table[0].ctselect = null;
            table.draw();
          }
        }
      }
      instance.ctselectSubscription = instance.ctselectHandle.on("change", applyCrosstalkSelection);
      // TODO: This next line doesn't seem to work when renderDataTable is used
      applyCrosstalkSelection({value: instance.ctselectHandle.value});
    }

    var inArray = function(val, array) {
      return $.inArray(val, $.makeArray(array)) > -1;
    };

    // encode + to %2B when searching in the table on server side, because
    // shiny::parseQueryString() treats + as spaces, and DataTables does not
    // encode + to %2B (or % to %25) when sending the request
    var encode_plus = function(x) {
      return server ? x.replace(/%/g, '%25').replace(/\+/g, '%2B') : x;
    };

    // search the i-th column
    var searchColumn = function(i, value) {
      var regex = false, ci = true;
      if (options.search) {
        regex = options.search.regex,
        ci = options.search.caseInsensitive !== false;
      }
      return table.column(i).search(encode_plus(value), regex, !regex, ci);
    };

    if (data.filter !== 'none') {

      filterRow.each(function(i, td) {

        var $td = $(td), type = $td.data('type'), filter;
        var $input = $td.children('div').first().children('input');
        $input.prop('disabled', !table.settings()[0].aoColumns[i].bSearchable || type === 'disabled');
        $input.on('input blur', function() {
          $input.next('span').toggle(Boolean($input.val()));
        });
        // Bootstrap sets pointer-events to none and we won't be able to click
        // the clear button
        $input.next('span').css('pointer-events', 'auto').hide().click(function() {
          $(this).hide().prev('input').val('').trigger('input').focus();
        });
        var searchCol;  // search string for this column
        if (searchCols && searchCols[i]) {
          searchCol = searchCols[i];
          $input.val(searchCol).trigger('input');
        }
        var $x = $td.children('div').last();

        // remove the overflow: hidden attribute of the scrollHead
        // (otherwise the scrolling table body obscures the filters)
        var scrollHead = $(el).find('.dataTables_scrollHead,.dataTables_scrollFoot');
        var cssOverflow = scrollHead.css('overflow');
        if (cssOverflow === 'hidden') {
          $x.on('show hide', function(e) {
            scrollHead.css('overflow', e.type === 'show' ? '' : cssOverflow);
          });
          $x.css('z-index', 25);
        }

        if (inArray(type, ['factor', 'logical'])) {
          $input.on({
            click: function() {
              $input.parent().hide(); $x.show().trigger('show'); filter[0].selectize.focus();
            },
            input: function() {
              if ($input.val() === '') filter[0].selectize.setValue([]);
            }
          });
          var $input2 = $x.children('select');
          filter = $input2.selectize({
            options: $input2.data('options').map(function(v, i) {
              return ({text: v, value: v});
            }),
            plugins: ['remove_button'],
            hideSelected: true,
            onChange: function(value) {
              if (value === null) value = []; // compatibility with jQuery 3.0
              $input.val(value.length ? JSON.stringify(value) : '');
              if (value.length) $input.trigger('input');
              $input.attr('title', $input.val());
              if (server) {
                table.column(i).search(value.length ? encode_plus(JSON.stringify(value)) : '').draw();
                return;
              }
              // turn off filter if nothing selected
              $td.data('filter', value.length > 0);
              table.draw();  // redraw table, and filters will be applied
            }
          });
          if (searchCol) filter[0].selectize.setValue(JSON.parse(searchCol));
          // an ugly hack to deal with shiny: for some reason, the onBlur event
          // of selectize does not work in shiny
          $x.find('div > div.selectize-input > input').on('blur', function() {
            $x.hide().trigger('hide'); $input.parent().show(); $input.trigger('blur');
          });
          filter.next('div').css('margin-bottom', 'auto');
        } else if (type === 'character') {
          var fun = function() {
            searchColumn(i, $input.val()).draw();
          };
          if (server) {
            fun = $.fn.dataTable.util.throttle(fun, options.searchDelay);
          }
          $input.on('input', fun);
        } else if (inArray(type, ['number', 'integer', 'date', 'time'])) {
          var $x0 = $x;
          $x = $x0.children('div').first();
          $x0.css({
            'background-color': '#fff',
            'border': '1px #ddd solid',
            'border-radius': '4px',
            'padding': '20px 20px 10px 20px'
          });
          var $spans = $x0.children('span').css({
            'margin-top': '10px',
            'white-space': 'nowrap'
          });
          var $span1 = $spans.first(), $span2 = $spans.last();
          var r1 = +$x.data('min'), r2 = +$x.data('max');
          // when the numbers are too small or have many decimal places, the
          // slider may have numeric precision problems (#150)
          var scale = Math.pow(10, Math.max(0, +$x.data('scale') || 0));
          r1 = Math.round(r1 * scale); r2 = Math.round(r2 * scale);
          var scaleBack = function(x, scale) {
            if (scale === 1) return x;
            var d = Math.round(Math.log(scale) / Math.log(10));
            // to avoid problems like 3.423/100 -> 0.034230000000000003
            return (x / scale).toFixed(d);
          };
          $input.on({
            focus: function() {
              $x0.show().trigger('show');
              // first, make sure the slider div leaves at least 20px between
              // the two (slider value) span's
              $x0.width(Math.max(160, $span1.outerWidth() + $span2.outerWidth() + 20));
              // then, if the input is really wide, make the slider the same
              // width as the input
              if ($x0.outerWidth() < $input.outerWidth()) {
                $x0.outerWidth($input.outerWidth());
              }
              // make sure the slider div does not reach beyond the right margin
              if ($(window).width() < $x0.offset().left + $x0.width()) {
                $x0.offset({
                  'left': $input.offset().left + $input.outerWidth() - $x0.outerWidth()
                });
              }
            },
            blur: function() {
              $x0.hide().trigger('hide');
            },
            input: function() {
              if ($input.val() === '') filter.val([r1, r2]);
            },
            change: function() {
              var v = $input.val().replace(/\s/g, '');
              if (v === '') return;
              v = v.split('...');
              if (v.length !== 2) {
                $input.parent().addClass('has-error');
                return;
              }
              if (v[0] === '') v[0] = r1;
              if (v[1] === '') v[1] = r2;
              $input.parent().removeClass('has-error');
              // treat date as UTC time at midnight
              var strTime = function(x) {
                var s = type === 'date' ? 'T00:00:00Z' : '';
                var t = new Date(x + s).getTime();
                // add 10 minutes to date since it does not hurt the date, and
                // it helps avoid the tricky floating point arithmetic problems,
                // e.g. sometimes the date may be a few milliseconds earlier
                // than the midnight due to precision problems in noUiSlider
                return type === 'date' ? t + 3600000 : t;
              };
              if (inArray(type, ['date', 'time'])) {
                v[0] = strTime(v[0]);
                v[1] = strTime(v[1]);
              }
              if (v[0] != r1) v[0] *= scale;
              if (v[1] != r2) v[1] *= scale;
              filter.val(v);
            }
          });
          var formatDate = function(d) {
            d = scaleBack(d, scale);
            if (type === 'number') return d;
            if (type === 'integer') return parseInt(d);
            var x = new Date(+d);
            if (type === 'date') {
              var pad0 = function(x) {
                return ('0' + x).substr(-2, 2);
              };
              return x.getUTCFullYear() + '-' + pad0(1 + x.getUTCMonth())
                      + '-' + pad0(x.getUTCDate());
            } else {
              return x.toISOString();
            }
          };
          var opts = type === 'date' ? { step: 60 * 60 * 1000 } :
                     type === 'integer' ? { step: 1 } : {};
          filter = $x.noUiSlider($.extend({
            start: [r1, r2],
            range: {min: r1, max: r2},
            connect: true
          }, opts));
          if (scale > 1) (function() {
            var t1 = r1, t2 = r2;
            var val = filter.val();
            while (val[0] > r1 || val[1] < r2) {
              if (val[0] > r1) {
                t1 -= val[0] - r1;
              }
              if (val[1] < r2) {
                t2 += r2 - val[1];
              }
              filter = $x.noUiSlider($.extend({
                start: [t1, t2],
                range: {min: t1, max: t2},
                connect: true
              }, opts), true);
              val = filter.val();
            }
            r1  = t1; r2 = t2;
          })();
          $span1.text(formatDate(r1)); $span2.text(formatDate(r2));
          var updateSlider = function(e) {
            var val = filter.val();
            // turn off filter if in full range
            $td.data('filter', val[0] > r1 || val[1] < r2);
            var v1 = formatDate(val[0]), v2 = formatDate(val[1]), ival;
            if ($td.data('filter')) {
              ival = v1 + ' ... ' + v2;
              $input.attr('title', ival).val(ival).trigger('input');
            } else {
              $input.attr('title', '').val('');
            }
            $span1.text(v1); $span2.text(v2);
            if (e.type === 'slide') return;  // no searching when sliding only
            if (server) {
              table.column(i).search($td.data('filter') ? ival : '').draw();
              return;
            }
            table.draw();
          };
          filter.on({
            set: updateSlider,
            slide: updateSlider
          });
        }

        // server-side processing will be handled by R (or whatever server
        // language you use); the following code is only needed for client-side
        // processing
        if (server) {
          // if a search string has been pre-set, search now
          if (searchCol) searchColumn(i, searchCol).draw();
          return;
        }

        var customFilter = function(settings, data, dataIndex) {
          // there is no way to attach a search function to a specific table,
          // and we need to make sure a global search function is not applied to
          // all tables (i.e. a range filter in a previous table should not be
          // applied to the current table); we use the settings object to
          // determine if we want to perform searching on the current table,
          // since settings.sTableId will be different to different tables
          if (table.settings()[0] !== settings) return true;
          // no filter on this column or no need to filter this column
          if (typeof filter === 'undefined' || !$td.data('filter')) return true;

          var r = filter.val(), v, r0, r1;
          if (type === 'number' || type === 'integer') {
            v = parseFloat(data[i]);
            // how to handle NaN? currently exclude these rows
            if (isNaN(v)) return(false);
            r0 = parseFloat(scaleBack(r[0], scale))
            r1 = parseFloat(scaleBack(r[1], scale));
            if (v >= r0 && v <= r1) return true;
          } else if (type === 'date' || type === 'time') {
            v = new Date(data[i]);
            r0 = new Date(r[0] / scale); r1 = new Date(r[1] / scale);
            if (v >= r0 && v <= r1) return true;
          } else if (type === 'factor') {
            if (r.length === 0 || inArray(data[i], r)) return true;
          } else if (type === 'logical') {
            if (r.length === 0) return true;
            if (inArray(data[i] === '' ? 'na' : data[i], r)) return true;
          }
          return false;
        };

        $.fn.dataTable.ext.search.push(customFilter);

        // search for the preset search strings if it is non-empty
        if (searchCol) {
          if (inArray(type, ['factor', 'logical'])) {
            filter[0].selectize.setValue(JSON.parse(searchCol));
          } else if (type === 'character') {
            $input.trigger('input');
          } else if (inArray(type, ['number', 'integer', 'date', 'time'])) {
            $input.trigger('change');
          }
        }

      });

    }

    // highlight search keywords
    var highlight = function() {
      var body = $(table.table().body());
      // removing the old highlighting first
      body.unhighlight();

      // don't highlight the "not found" row, so we get the rows using the api
      if (table.rows({ filter: 'applied' }).data().length === 0) return;
      // highlight gloal search keywords
      body.highlight($.trim(table.search()).split(/\s+/));
      // then highlight keywords from individual column filters
      if (filterRow) filterRow.each(function(i, td) {
        var $td = $(td), type = $td.data('type');
        if (type !== 'character') return;
        var $input = $td.children('div').first().children('input');
        var column = table.column(i).nodes().to$(),
            val = $.trim($input.val());
        if (type !== 'character' || val === '') return;
        column.highlight(val.split(/\s+/));
      });
    };

    if (options.searchHighlight) {
      table
      .on('draw.dt.dth column-visibility.dt.dth column-reorder.dt.dth', highlight)
      .on('destroy', function() {
        // remove event handler
        table.off('draw.dt.dth column-visibility.dt.dth column-reorder.dt.dth');
      });

      // initial highlight for state saved conditions and initial states
      highlight();
    }

    // run the callback function on the table instance
    if (typeof data.callback === 'function') data.callback(table);

    // double click to edit the cell
    if (data.editable) table.on('dblclick.dt', 'tbody td', function() {
      var $input = $('<input type="text">');
      var $this = $(this), value = table.cell(this).data(), html = $this.html();
      var changed = false;
      $input.val(value);
      $this.empty().append($input);
      $input.css('width', '100%').focus().on('change', function() {
        changed = true;
        var valueNew = $input.val();
        if (valueNew != value) {
          table.cell($this).data(valueNew);
          if (HTMLWidgets.shinyMode) changeInput('cell_edit', cellInfo($this));
          // for server-side processing, users have to call replaceData() to update the table
          if (!server) table.draw(false);
        } else {
          $this.html(html);
        }
        $input.remove();
      }).on('blur', function() {
        if (!changed) $input.trigger('change');
      });
    });

    // interaction with shiny
    if (!HTMLWidgets.shinyMode && !crosstalkOptions.group) return;

    var methods = {};
    var shinyData = {};

    methods.updateCaption = function(caption) {
      if (!caption) return;
      $table.children('caption').replaceWith(caption);
    }

    // register clear functions to remove input values when the table is removed
    instance.clearInputs = {};

    var changeInput = function(id, value, type, noCrosstalk) {
      var event = id;
      id = el.id + '_' + id;
      if (type) id = id + ':' + type;
      // do not update if the new value is the same as old value
      if (shinyData.hasOwnProperty(id) && shinyData[id] === JSON.stringify(value))
        return;
      shinyData[id] = JSON.stringify(value);
      if (HTMLWidgets.shinyMode) {
        Shiny.onInputChange(id, value);
        if (!instance.clearInputs[id]) instance.clearInputs[id] = function() {
          Shiny.onInputChange(id, null);
        }
      }

      // HACK
      if (event === "rows_selected" && !noCrosstalk) {
        if (crosstalkOptions.group) {
          var keys = crosstalkOptions.key;
          var selectedKeys = null;
          if (value) {
            selectedKeys = [];
            for (var i = 0; i < value.length; i++) {
              // The value array's contents use 1-based row numbers, so we must
              // convert to 0-based before indexing into the keys array.
              selectedKeys.push(keys[value[i] - 1]);
            }
          }
          instance.ctselectHandle.set(selectedKeys);
        }
      }
    };

    var addOne = function(x) {
      return x.map(function(i) { return 1 + i; });
    };

    var unique = function(x) {
      var ux = [];
      $.each(x, function(i, el){
        if ($.inArray(el, ux) === -1) ux.push(el);
      });
      return ux;
    }

    // change the row index of a cell
    var tweakCellIndex = function(cell) {
      var info = cell.index();
      if (server) {
        info.row = DT_rows_current[info.row];
      } else {
        info.row += 1;
      }
      return {row: info.row, col: info.column};
    }

    var selMode = data.selection.mode, selTarget = data.selection.target;
    if (inArray(selMode, ['single', 'multiple'])) {
      var selClass = data.style === 'bootstrap' ? 'active' : 'selected';
      var selected = data.selection.selected, selected1, selected2;
      // selected1: row indices; selected2: column indices
      if (selected === null) {
        selected1 = selected2 = [];
      } else if (selTarget === 'row') {
        selected1 = $.makeArray(selected);
      } else if (selTarget === 'column') {
        selected2 = $.makeArray(selected);
      } else if (selTarget === 'row+column') {
        selected1 = $.makeArray(selected.rows);
        selected2 = $.makeArray(selected.cols);
      }

      // After users reorder the rows or filter the table, we cannot use the table index
      // directly. Instead, we need this function to find out the rows between the two clicks.
      // If user filter the table again between the start click and the end click, the behavior
      // would be undefined, but it should not be a problem.
      var shiftSelRowsIndex = function(start, end) {
        var indexes = server ? DT_rows_all : table.rows({ search: 'applied' }).indexes().toArray();
        start = indexes.indexOf(start); end = indexes.indexOf(end);
        // if start is larger than end, we need to swap
        if (start > end) {
          var tmp = end; end = start; start = tmp;
        }
        return indexes.slice(start, end + 1);
      }

      var serverRowIndex = function(clientRowIndex) {
        return server ? DT_rows_current[clientRowIndex] : clientRowIndex + 1;
      }

      // row, column, or cell selection
      var lastClickedRow;
      if (inArray(selTarget, ['row', 'row+column'])) {
        var selectedRows = function() {
          var rows = table.rows('.' + selClass);
          var idx = rows.indexes().toArray();
          if (!server) return addOne(idx);
          idx = idx.map(function(i) {
            return DT_rows_current[i];
          });
          selected1 = selMode === 'multiple' ? unique(selected1.concat(idx)) : idx;
          return selected1;
        }
        table.on('mousedown.dt', 'tbody tr', function(e) {
          var $this = $(this), thisRow = table.row(this);
          if (selMode === 'multiple') {
            if (e.shiftKey && lastClickedRow !== undefined) {
              // select or de-select depends on the last clicked row's status
              var flagSel = !$this.hasClass(selClass);
              var crtClickedRow = serverRowIndex(thisRow.index());
              if (server) {
                var rowsIndex = shiftSelRowsIndex(lastClickedRow, crtClickedRow);
                // update current page's selClass
                rowsIndex.map(function(i) {
                  var rowIndex = DT_rows_current.indexOf(i);
                  if (rowIndex >= 0) {
                    var row = table.row(rowIndex).nodes().to$();
                    var flagRowSel = !row.hasClass(selClass);
                    if (flagSel === flagRowSel) row.toggleClass(selClass);
                  }
                });
                // update selected1
                if (flagSel) {
                  selected1 = unique(selected1.concat(rowsIndex));
                } else {
                  selected1 = selected1.filter(function(index) {
                    return !inArray(index, rowsIndex);
                  });
                }
              } else {
                // js starts from 0
                shiftSelRowsIndex(lastClickedRow - 1, crtClickedRow - 1).map(function(value) {
                  var row = table.row(value).nodes().to$();
                  var flagRowSel = !row.hasClass(selClass);
                  if (flagSel === flagRowSel) row.toggleClass(selClass);
                });
              }
              e.preventDefault();
            } else {
              $this.toggleClass(selClass);
            }
          } else {
            if ($this.hasClass(selClass)) {
              $this.removeClass(selClass);
            } else {
              table.$('tr.' + selClass).removeClass(selClass);
              $this.addClass(selClass);
            }
          }
          if (server && !$this.hasClass(selClass)) {
            var id = DT_rows_current[thisRow.index()];
            // remove id from selected1 since its class .selected has been removed
            if (inArray(id, selected1)) selected1.splice($.inArray(id, selected1), 1);
          }
          changeInput('rows_selected', selectedRows());
          changeInput('row_last_clicked', serverRowIndex(thisRow.index()));
          lastClickedRow = serverRowIndex(thisRow.index());
        });
        changeInput('rows_selected', selected1);
        var selectRows = function() {
          table.$('tr.' + selClass).removeClass(selClass);
          if (selected1.length === 0) return;
          if (server) {
            table.rows({page: 'current'}).every(function() {
              if (inArray(DT_rows_current[this.index()], selected1)) {
                $(this.node()).addClass(selClass);
              }
            });
          } else {
            var selected0 = selected1.map(function(i) { return i - 1; });
            $(table.rows(selected0).nodes()).addClass(selClass);
          }
        }
        selectRows();  // in case users have specified pre-selected rows
        // restore selected rows after the table is redrawn (e.g. sort/search/page);
        // client-side tables will preserve the selections automatically; for
        // server-side tables, we have to *real* row indices are in `selected1`
        if (server) table.on('draw.dt', selectRows);
        methods.selectRows = function(selected) {
          selected1 = selected ? selected : [];
          selectRows();
          changeInput('rows_selected', selected1);
        }
      }

      if (inArray(selTarget, ['column', 'row+column'])) {
        if (selTarget === 'row+column') {
          $(table.columns().footer()).css('cursor', 'pointer');
        }
        table.on('click.dt', selTarget === 'column' ? 'tbody td' : 'tfoot tr th', function() {
          var colIdx = selTarget === 'column' ? table.cell(this).index().column :
              $.inArray(this, table.columns().footer()),
              thisCol = $(table.column(colIdx).nodes());
          if (colIdx === -1) return;
          if (thisCol.hasClass(selClass)) {
            thisCol.removeClass(selClass);
            selected2.splice($.inArray(colIdx, selected2), 1);
          } else {
            if (selMode === 'single') $(table.cells().nodes()).removeClass(selClass);
            thisCol.addClass(selClass);
            selected2 = selMode === 'single' ? [colIdx] : unique(selected2.concat([colIdx]));
          }
          changeInput('columns_selected', selected2);
        });
        changeInput('columns_selected', selected2);
        var selectCols = function() {
          table.columns().nodes().flatten().to$().removeClass(selClass);
          if (selected2.length > 0)
            table.columns(selected2).nodes().flatten().to$().addClass(selClass);
        }
        selectCols();  // in case users have specified pre-selected columns
        if (server) table.on('draw.dt', selectCols);
        methods.selectColumns = function(selected) {
          selected2 = selected ? selected : [];
          selectCols();
          changeInput('columns_selected', selected2);
        }
      }

      if (selTarget === 'cell') {
        var selected3;
        if (selected === null) {
          selected3 = [];
        } else {
          selected3 = selected;
        }
        var findIndex = function(ij) {
          for (var i = 0; i < selected3.length; i++) {
            if (ij[0] === selected3[i][0] && ij[1] === selected3[i][1]) return i;
          }
          return -1;
        }
        table.on('click.dt', 'tbody td', function() {
          var $this = $(this), info = tweakCellIndex(table.cell(this));
          if ($this.hasClass(selClass)) {
            $this.removeClass(selClass);
            selected3.splice(findIndex([info.row, info.col]), 1);
          } else {
            if (selMode === 'single') $(table.cells().nodes()).removeClass(selClass);
            $this.addClass(selClass);
            selected3 = selMode === 'single' ? [[info.row, info.col]] :
              unique(selected3.concat([[info.row, info.col]]));
          }
          changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');
        });
        changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');
        var selectCells = function() {
          table.$('td.' + selClass).removeClass(selClass);
          if (selected3.length === 0) return;
          if (server) {
            table.cells({page: 'current'}).every(function() {
              var info = tweakCellIndex(this);
              if (findIndex([info.row, info.col], selected3) > -1)
                $(this.node()).addClass(selClass);
            });
          } else {
            selected3.map(function(ij) {
              $(table.cell(ij[0] - 1, ij[1]).node()).addClass(selClass);
            });
          }
        };
        selectCells();  // in case users have specified pre-selected columns
        if (server) table.on('draw.dt', selectCells);
        methods.selectCells = function(selected) {
          selected3 = selected ? selected : [];
          selectCells();
          changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');
        }
      }
    }

    // expose some table info to Shiny
    var updateTableInfo = function(e, settings) {
      // TODO: is anyone interested in the page info?
      // changeInput('page_info', table.page.info());
      var updateRowInfo = function(id, modifier) {
        var idx;
        if (server) {
          idx = modifier.page === 'current' ? DT_rows_current : DT_rows_all;
        } else {
          var rows = table.rows($.extend({
            search: 'applied',
            page: 'all'
          }, modifier));
          idx = addOne(rows.indexes().toArray());
        }
        changeInput('rows' + '_' + id, idx);
      };
      updateRowInfo('current', {page: 'current'});
      updateRowInfo('all', {});
    }
    table.on('draw.dt', updateTableInfo);
    updateTableInfo();

    // state info
    table.on('draw.dt column-visibility.dt', function() {
      changeInput('state', table.state());
    });
    changeInput('state', table.state());

    // search info
    var updateSearchInfo = function() {
      changeInput('search', table.search());
      if (filterRow) changeInput('search_columns', filterRow.toArray().map(function(td) {
        return $(td).find('input').first().val();
      }));
    }
    table.on('draw.dt', updateSearchInfo);
    updateSearchInfo();

    var cellInfo = function(thiz) {
      var info = tweakCellIndex(table.cell(thiz));
      info.value = table.cell(thiz).data();
      return info;
    }
    // the current cell clicked on
    table.on('click.dt', 'tbody td', function() {
      changeInput('cell_clicked', cellInfo(this));
    })
    changeInput('cell_clicked', {});

    // do not trigger table selection when clicking on links unless they have classes
    table.on('click.dt', 'tbody td a', function(e) {
      if (this.className === '') e.stopPropagation();
    });

    methods.addRow = function(data, rowname) {
      var data0 = table.row(0).data(), n = data0.length, d = n - data.length;
      if (d === 1) {
        data = rowname.concat(data)
      } else if (d !== 0) {
        console.log(data);
        console.log(data0);
        throw 'New data must be of the same length as current data (' + n + ')';
      };
      table.row.add(data).draw();
    }

    methods.updateSearch = function(keywords) {
      if (keywords.global !== null)
        $(table.table().container()).find('input[type=search]').first()
             .val(keywords.global).trigger('input');
      var columns = keywords.columns;
      if (!filterRow || columns === null) return;
      filterRow.toArray().map(function(td, i) {
        var v = typeof columns === 'string' ? columns : columns[i];
        if (typeof v === 'undefined') {
          console.log('The search keyword for column ' + i + ' is undefined')
          return;
        }
        $(td).find('input').first().val(v);
        searchColumn(i, v);
      });
      table.draw();
    }

    methods.selectPage = function(page) {
      if (table.page.info().pages < page || page < 1) {
        throw 'Selected page is out of range';
      };
      table.page(page - 1).draw(false);
    }

    methods.reloadData = function(resetPaging, clearSelection) {
      // empty selections first if necessary
      if (methods.selectRows && inArray('row', clearSelection)) methods.selectRows([]);
      if (methods.selectColumns && inArray('column', clearSelection)) methods.selectColumns([]);
      if (methods.selectCells && inArray('cell', clearSelection)) methods.selectCells([]);
      table.ajax.reload(null, resetPaging);
    }

    table.shinyMethods = methods;
  },
  resize: function(el, width, height, instance) {
    if (instance.data) this.renderValue(el, instance.data, instance);

    // dynamically adjust height if fillContainer = TRUE
    if (instance.fillContainer)
      this.fillAvailableHeight(el, height);

    this.adjustWidth(el);
  },

  // dynamically set the scroll body to fill available height
  // (used with fillContainer = TRUE)
  fillAvailableHeight: function(el, availableHeight) {

    // see how much of the table is occupied by header/footer elements
    // and use that to compute a target scroll body height
    var dtWrapper = $(el).find('div.dataTables_wrapper');
    var dtScrollBody = $(el).find($('div.dataTables_scrollBody'));
    var framingHeight = dtWrapper.innerHeight() - dtScrollBody.innerHeight();
    var scrollBodyHeight = availableHeight - framingHeight;

    // set the height
    dtScrollBody.height(scrollBodyHeight + 'px');
  },

  // adjust the width of columns; remove the hard-coded widths on table and the
  // scroll header when scrollX/Y are enabled
  adjustWidth: function(el) {
    var $el = $(el), table = $el.data('datatable');
    if (table) table.columns.adjust();
    $el.find('.dataTables_scrollHeadInner').css('width', '')
        .children('table').css('margin-left', '');
  }
});

  if (!HTMLWidgets.shinyMode) return;

  Shiny.addCustomMessageHandler('datatable-calls', function(data) {
    var id = data.id;
    var el = document.getElementById(id);
    var table = el ? $(el).data('datatable') : null;
    if (!table) {
      console.log("Couldn't find table with id " + id);
      return;
    }

    var methods = table.shinyMethods, call = data.call;
    if (methods[call.method]) {
      methods[call.method].apply(table, call.args);
    } else {
      console.log("Unknown method " + call.method);
    }
  });

})();
"></script>
<link href="data:text/css;charset=utf-8,table%2EdataTable%7Bwidth%3A100%25%3Bmargin%3A0%20auto%3Bclear%3Aboth%3Bborder%2Dcollapse%3Aseparate%3Bborder%2Dspacing%3A0%7Dtable%2EdataTable%20thead%20th%2Ctable%2EdataTable%20tfoot%20th%7Bfont%2Dweight%3Abold%7Dtable%2EdataTable%20thead%20th%2Ctable%2EdataTable%20thead%20td%7Bpadding%3A10px%2018px%3Bborder%2Dbottom%3A1px%20solid%20%23111%7Dtable%2EdataTable%20thead%20th%3Aactive%2Ctable%2EdataTable%20thead%20td%3Aactive%7Boutline%3Anone%7Dtable%2EdataTable%20tfoot%20th%2Ctable%2EdataTable%20tfoot%20td%7Bpadding%3A10px%2018px%206px%2018px%3Bborder%2Dtop%3A1px%20solid%20%23111%7Dtable%2EdataTable%20thead%20%2Esorting%2Ctable%2EdataTable%20thead%20%2Esorting%5Fasc%2Ctable%2EdataTable%20thead%20%2Esorting%5Fdesc%2Ctable%2EdataTable%20thead%20%2Esorting%5Fasc%5Fdisabled%2Ctable%2EdataTable%20thead%20%2Esorting%5Fdesc%5Fdisabled%7Bcursor%3Apointer%3B%2Acursor%3Ahand%3Bbackground%2Drepeat%3Ano%2Drepeat%3Bbackground%2Dposition%3Acenter%20right%7Dtable%2EdataTable%20thead%20%2Esorting%7Bbackground%2Dimage%3Aurl%28data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAABMAAAATCAQAAADYWf5HAAAAkElEQVQoz7XQMQ5AQBCF4dWQSJxC5wwax1Cq1e7BAdxD5SL%2BTq%2FQCM1oNiJidwox0355mXnG%2FDrEtIQ6azioNZQxI0ykPhTQIwhCR%2BBmBYtlK7kLJYwWCcJA9M4qdrZrd8pPjZWPtOqdRQy320YSV17OatFC4euts6z39GYMKRPCTKY9UnPQ6P%2BGtMRfGtPnBCiqhAeJPmkqAAAAAElFTkSuQmCC%29%7Dtable%2EdataTable%20thead%20%2Esorting%5Fasc%7Bbackground%2Dimage%3Aurl%28data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAABMAAAATCAYAAAByUDbMAAAAZ0lEQVQ4y2NgGLKgquEuFxBPAGI2ahhWCsS%2FgDibUoO0gPgxEP8H4ttArEyuQYxAPBdqEAxPBImTY5gjEL9DM%2BwTENuQahAvEO9DMwiGdwAxOymGJQLxTyD%2BjgWDxCMZRsEoGAVoAADeemwtPcZI2wAAAABJRU5ErkJggg%3D%3D%29%7Dtable%2EdataTable%20thead%20%2Esorting%5Fdesc%7Bbackground%2Dimage%3Aurl%28data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAABMAAAATCAYAAAByUDbMAAAAZUlEQVQ4y2NgGAWjYBSggaqGu5FA%2FBOIv2PBIPFEUgxjB%2BIdQPwfC94HxLykus4GiD%2BhGfQOiB3J8SojEE9EM2wuSJzcsFMG4ttQgx4DsRalkZENxL%2BAuJQaMcsGxBOAmGvopk8AVz1sLZgg0bsAAAAASUVORK5CYII%3D%29%7Dtable%2EdataTable%20thead%20%2Esorting%5Fasc%5Fdisabled%7Bbackground%2Dimage%3Aurl%28data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAABMAAAATCAQAAADYWf5HAAAAW0lEQVQoz2NgoCm4w3Vnwh02wspK7%2Fy6k01Ikdadx3f%2B37l9RxmfIsY7c4GKQHDiHUbcyhzvvIMq%2B3THBpci3jv7oIpAcMcdduzKEu%2F8vPMdDn%2FeiWQYBYMKAAC3ykIEuYQJUgAAAABJRU5ErkJggg%3D%3D%29%7Dtable%2EdataTable%20thead%20%2Esorting%5Fdesc%5Fdisabled%7Bbackground%2Dimage%3Aurl%28data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAABMAAAATCAQAAADYWf5HAAAAWUlEQVQoz2NgGAWDCtyJvPPzznc4%2FHknEbsy9js77vyHw313eHGZZ3PnE1TRuzuOuK1lvDMRqmzuHUZ87lO%2Bcxuo6PEdLUIeyb7z604pYf%2By3Zlwh4u2YQoAc7ZCBHH4jigAAAAASUVORK5CYII%3D%29%7Dtable%2EdataTable%20tbody%20tr%7Bbackground%2Dcolor%3A%23ffffff%7Dtable%2EdataTable%20tbody%20tr%2Eselected%7Bbackground%2Dcolor%3A%23B0BED9%7Dtable%2EdataTable%20tbody%20th%2Ctable%2EdataTable%20tbody%20td%7Bpadding%3A8px%2010px%7Dtable%2EdataTable%2Erow%2Dborder%20tbody%20th%2Ctable%2EdataTable%2Erow%2Dborder%20tbody%20td%2Ctable%2EdataTable%2Edisplay%20tbody%20th%2Ctable%2EdataTable%2Edisplay%20tbody%20td%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7Dtable%2EdataTable%2Erow%2Dborder%20tbody%20tr%3Afirst%2Dchild%20th%2Ctable%2EdataTable%2Erow%2Dborder%20tbody%20tr%3Afirst%2Dchild%20td%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3Afirst%2Dchild%20th%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3Afirst%2Dchild%20td%7Bborder%2Dtop%3Anone%7Dtable%2EdataTable%2Ecell%2Dborder%20tbody%20th%2Ctable%2EdataTable%2Ecell%2Dborder%20tbody%20td%7Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dright%3A1px%20solid%20%23ddd%7Dtable%2EdataTable%2Ecell%2Dborder%20tbody%20tr%20th%3Afirst%2Dchild%2Ctable%2EdataTable%2Ecell%2Dborder%20tbody%20tr%20td%3Afirst%2Dchild%7Bborder%2Dleft%3A1px%20solid%20%23ddd%7Dtable%2EdataTable%2Ecell%2Dborder%20tbody%20tr%3Afirst%2Dchild%20th%2Ctable%2EdataTable%2Ecell%2Dborder%20tbody%20tr%3Afirst%2Dchild%20td%7Bborder%2Dtop%3Anone%7Dtable%2EdataTable%2Estripe%20tbody%20tr%2Eodd%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%7Bbackground%2Dcolor%3A%23f9f9f9%7Dtable%2EdataTable%2Estripe%20tbody%20tr%2Eodd%2Eselected%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%2Eselected%7Bbackground%2Dcolor%3A%23acbad4%7Dtable%2EdataTable%2Ehover%20tbody%20tr%3Ahover%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%7Bbackground%2Dcolor%3A%23f6f6f6%7Dtable%2EdataTable%2Ehover%20tbody%20tr%3Ahover%2Eselected%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%2Eselected%7Bbackground%2Dcolor%3A%23aab7d1%7Dtable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%3E%2Esorting%5F3%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3E%2Esorting%5F1%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3E%2Esorting%5F2%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23fafafa%7Dtable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%2Eselected%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%2Eselected%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%20tbody%20tr%2Eselected%3E%2Esorting%5F3%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%2Eselected%3E%2Esorting%5F1%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%2Eselected%3E%2Esorting%5F2%2Ctable%2EdataTable%2Edisplay%20tbody%20tr%2Eselected%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23acbad5%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23f1f1f1%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23f3f3f3%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%3E%2Esorting%5F3%7Bbackground%2Dcolor%3Awhitesmoke%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23a6b4cd%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23a8b5cf%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eodd%2Eselected%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23a9b7d1%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23fafafa%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23fcfcfc%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23fefefe%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23acbad5%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23aebcd6%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Estripe%20tbody%20tr%2Eeven%2Eselected%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23afbdd8%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23eaeaea%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23ececec%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23efefef%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F1%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F1%7Bbackground%2Dcolor%3A%23a2aec7%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F2%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F2%7Bbackground%2Dcolor%3A%23a3b0c9%7Dtable%2EdataTable%2Edisplay%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F3%2Ctable%2EdataTable%2Eorder%2Dcolumn%2Ehover%20tbody%20tr%3Ahover%2Eselected%3E%2Esorting%5F3%7Bbackground%2Dcolor%3A%23a5b2cb%7Dtable%2EdataTable%2Eno%2Dfooter%7Bborder%2Dbottom%3A1px%20solid%20%23111%7Dtable%2EdataTable%2Enowrap%20th%2Ctable%2EdataTable%2Enowrap%20td%7Bwhite%2Dspace%3Anowrap%7Dtable%2EdataTable%2Ecompact%20thead%20th%2Ctable%2EdataTable%2Ecompact%20thead%20td%7Bpadding%3A4px%2017px%204px%204px%7Dtable%2EdataTable%2Ecompact%20tfoot%20th%2Ctable%2EdataTable%2Ecompact%20tfoot%20td%7Bpadding%3A4px%7Dtable%2EdataTable%2Ecompact%20tbody%20th%2Ctable%2EdataTable%2Ecompact%20tbody%20td%7Bpadding%3A4px%7Dtable%2EdataTable%20th%2Edt%2Dleft%2Ctable%2EdataTable%20td%2Edt%2Dleft%7Btext%2Dalign%3Aleft%7Dtable%2EdataTable%20th%2Edt%2Dcenter%2Ctable%2EdataTable%20td%2Edt%2Dcenter%2Ctable%2EdataTable%20td%2EdataTables%5Fempty%7Btext%2Dalign%3Acenter%7Dtable%2EdataTable%20th%2Edt%2Dright%2Ctable%2EdataTable%20td%2Edt%2Dright%7Btext%2Dalign%3Aright%7Dtable%2EdataTable%20th%2Edt%2Djustify%2Ctable%2EdataTable%20td%2Edt%2Djustify%7Btext%2Dalign%3Ajustify%7Dtable%2EdataTable%20th%2Edt%2Dnowrap%2Ctable%2EdataTable%20td%2Edt%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7Dtable%2EdataTable%20thead%20th%2Edt%2Dhead%2Dleft%2Ctable%2EdataTable%20thead%20td%2Edt%2Dhead%2Dleft%2Ctable%2EdataTable%20tfoot%20th%2Edt%2Dhead%2Dleft%2Ctable%2EdataTable%20tfoot%20td%2Edt%2Dhead%2Dleft%7Btext%2Dalign%3Aleft%7Dtable%2EdataTable%20thead%20th%2Edt%2Dhead%2Dcenter%2Ctable%2EdataTable%20thead%20td%2Edt%2Dhead%2Dcenter%2Ctable%2EdataTable%20tfoot%20th%2Edt%2Dhead%2Dcenter%2Ctable%2EdataTable%20tfoot%20td%2Edt%2Dhead%2Dcenter%7Btext%2Dalign%3Acenter%7Dtable%2EdataTable%20thead%20th%2Edt%2Dhead%2Dright%2Ctable%2EdataTable%20thead%20td%2Edt%2Dhead%2Dright%2Ctable%2EdataTable%20tfoot%20th%2Edt%2Dhead%2Dright%2Ctable%2EdataTable%20tfoot%20td%2Edt%2Dhead%2Dright%7Btext%2Dalign%3Aright%7Dtable%2EdataTable%20thead%20th%2Edt%2Dhead%2Djustify%2Ctable%2EdataTable%20thead%20td%2Edt%2Dhead%2Djustify%2Ctable%2EdataTable%20tfoot%20th%2Edt%2Dhead%2Djustify%2Ctable%2EdataTable%20tfoot%20td%2Edt%2Dhead%2Djustify%7Btext%2Dalign%3Ajustify%7Dtable%2EdataTable%20thead%20th%2Edt%2Dhead%2Dnowrap%2Ctable%2EdataTable%20thead%20td%2Edt%2Dhead%2Dnowrap%2Ctable%2EdataTable%20tfoot%20th%2Edt%2Dhead%2Dnowrap%2Ctable%2EdataTable%20tfoot%20td%2Edt%2Dhead%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7Dtable%2EdataTable%20tbody%20th%2Edt%2Dbody%2Dleft%2Ctable%2EdataTable%20tbody%20td%2Edt%2Dbody%2Dleft%7Btext%2Dalign%3Aleft%7Dtable%2EdataTable%20tbody%20th%2Edt%2Dbody%2Dcenter%2Ctable%2EdataTable%20tbody%20td%2Edt%2Dbody%2Dcenter%7Btext%2Dalign%3Acenter%7Dtable%2EdataTable%20tbody%20th%2Edt%2Dbody%2Dright%2Ctable%2EdataTable%20tbody%20td%2Edt%2Dbody%2Dright%7Btext%2Dalign%3Aright%7Dtable%2EdataTable%20tbody%20th%2Edt%2Dbody%2Djustify%2Ctable%2EdataTable%20tbody%20td%2Edt%2Dbody%2Djustify%7Btext%2Dalign%3Ajustify%7Dtable%2EdataTable%20tbody%20th%2Edt%2Dbody%2Dnowrap%2Ctable%2EdataTable%20tbody%20td%2Edt%2Dbody%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7Dtable%2EdataTable%2Ctable%2EdataTable%20th%2Ctable%2EdataTable%20td%7Bbox%2Dsizing%3Acontent%2Dbox%7D%2EdataTables%5Fwrapper%7Bposition%3Arelative%3Bclear%3Aboth%3B%2Azoom%3A1%3Bzoom%3A1%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Flength%7Bfloat%3Aleft%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Ffilter%7Bfloat%3Aright%3Btext%2Dalign%3Aright%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Ffilter%20input%7Bmargin%2Dleft%3A0%2E5em%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Finfo%7Bclear%3Aboth%3Bfloat%3Aleft%3Bpadding%2Dtop%3A0%2E755em%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%7Bfloat%3Aright%3Btext%2Dalign%3Aright%3Bpadding%2Dtop%3A0%2E25em%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%7Bbox%2Dsizing%3Aborder%2Dbox%3Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A1%2E5em%3Bpadding%3A0%2E5em%201em%3Bmargin%2Dleft%3A2px%3Btext%2Dalign%3Acenter%3Btext%2Ddecoration%3Anone%20%21important%3Bcursor%3Apointer%3B%2Acursor%3Ahand%3Bcolor%3A%23333%20%21important%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A2px%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%2Ecurrent%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%2Ecurrent%3Ahover%7Bcolor%3A%23333%20%21important%3Bborder%3A1px%20solid%20%23979797%3Bbackground%2Dcolor%3Awhite%3Bbackground%3A%2Dwebkit%2Dgradient%28linear%2C%20left%20top%2C%20left%20bottom%2C%20color%2Dstop%280%25%2C%20%23fff%29%2C%20color%2Dstop%28100%25%2C%20%23dcdcdc%29%29%3Bbackground%3A%2Dwebkit%2Dlinear%2Dgradient%28top%2C%20%23fff%200%25%2C%20%23dcdcdc%20100%25%29%3Bbackground%3A%2Dmoz%2Dlinear%2Dgradient%28top%2C%20%23fff%200%25%2C%20%23dcdcdc%20100%25%29%3Bbackground%3A%2Dms%2Dlinear%2Dgradient%28top%2C%20%23fff%200%25%2C%20%23dcdcdc%20100%25%29%3Bbackground%3A%2Do%2Dlinear%2Dgradient%28top%2C%20%23fff%200%25%2C%20%23dcdcdc%20100%25%29%3Bbackground%3Alinear%2Dgradient%28to%20bottom%2C%20%23fff%200%25%2C%20%23dcdcdc%20100%25%29%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%2Edisabled%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%2Edisabled%3Ahover%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%2Edisabled%3Aactive%7Bcursor%3Adefault%3Bcolor%3A%23666%20%21important%3Bborder%3A1px%20solid%20transparent%3Bbackground%3Atransparent%3Bbox%2Dshadow%3Anone%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%3Ahover%7Bcolor%3Awhite%20%21important%3Bborder%3A1px%20solid%20%23111%3Bbackground%2Dcolor%3A%23585858%3Bbackground%3A%2Dwebkit%2Dgradient%28linear%2C%20left%20top%2C%20left%20bottom%2C%20color%2Dstop%280%25%2C%20%23585858%29%2C%20color%2Dstop%28100%25%2C%20%23111%29%29%3Bbackground%3A%2Dwebkit%2Dlinear%2Dgradient%28top%2C%20%23585858%200%25%2C%20%23111%20100%25%29%3Bbackground%3A%2Dmoz%2Dlinear%2Dgradient%28top%2C%20%23585858%200%25%2C%20%23111%20100%25%29%3Bbackground%3A%2Dms%2Dlinear%2Dgradient%28top%2C%20%23585858%200%25%2C%20%23111%20100%25%29%3Bbackground%3A%2Do%2Dlinear%2Dgradient%28top%2C%20%23585858%200%25%2C%20%23111%20100%25%29%3Bbackground%3Alinear%2Dgradient%28to%20bottom%2C%20%23585858%200%25%2C%20%23111%20100%25%29%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Epaginate%5Fbutton%3Aactive%7Boutline%3Anone%3Bbackground%2Dcolor%3A%232b2b2b%3Bbackground%3A%2Dwebkit%2Dgradient%28linear%2C%20left%20top%2C%20left%20bottom%2C%20color%2Dstop%280%25%2C%20%232b2b2b%29%2C%20color%2Dstop%28100%25%2C%20%230c0c0c%29%29%3Bbackground%3A%2Dwebkit%2Dlinear%2Dgradient%28top%2C%20%232b2b2b%200%25%2C%20%230c0c0c%20100%25%29%3Bbackground%3A%2Dmoz%2Dlinear%2Dgradient%28top%2C%20%232b2b2b%200%25%2C%20%230c0c0c%20100%25%29%3Bbackground%3A%2Dms%2Dlinear%2Dgradient%28top%2C%20%232b2b2b%200%25%2C%20%230c0c0c%20100%25%29%3Bbackground%3A%2Do%2Dlinear%2Dgradient%28top%2C%20%232b2b2b%200%25%2C%20%230c0c0c%20100%25%29%3Bbackground%3Alinear%2Dgradient%28to%20bottom%2C%20%232b2b2b%200%25%2C%20%230c0c0c%20100%25%29%3Bbox%2Dshadow%3Ainset%200%200%203px%20%23111%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%20%2Eellipsis%7Bpadding%3A0%201em%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fprocessing%7Bposition%3Aabsolute%3Btop%3A50%25%3Bleft%3A50%25%3Bwidth%3A100%25%3Bheight%3A40px%3Bmargin%2Dleft%3A%2D50%25%3Bmargin%2Dtop%3A%2D25px%3Bpadding%2Dtop%3A20px%3Btext%2Dalign%3Acenter%3Bfont%2Dsize%3A1%2E2em%3Bbackground%2Dcolor%3Awhite%3Bbackground%3A%2Dwebkit%2Dgradient%28linear%2C%20left%20top%2C%20right%20top%2C%20color%2Dstop%280%25%2C%20rgba%28255%2C255%2C255%2C0%29%29%2C%20color%2Dstop%2825%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%29%2C%20color%2Dstop%2875%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%29%2C%20color%2Dstop%28100%25%2C%20rgba%28255%2C255%2C255%2C0%29%29%29%3Bbackground%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2C%20rgba%28255%2C255%2C255%2C0%29%200%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2025%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2075%25%2C%20rgba%28255%2C255%2C255%2C0%29%20100%25%29%3Bbackground%3A%2Dmoz%2Dlinear%2Dgradient%28left%2C%20rgba%28255%2C255%2C255%2C0%29%200%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2025%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2075%25%2C%20rgba%28255%2C255%2C255%2C0%29%20100%25%29%3Bbackground%3A%2Dms%2Dlinear%2Dgradient%28left%2C%20rgba%28255%2C255%2C255%2C0%29%200%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2025%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2075%25%2C%20rgba%28255%2C255%2C255%2C0%29%20100%25%29%3Bbackground%3A%2Do%2Dlinear%2Dgradient%28left%2C%20rgba%28255%2C255%2C255%2C0%29%200%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2025%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2075%25%2C%20rgba%28255%2C255%2C255%2C0%29%20100%25%29%3Bbackground%3Alinear%2Dgradient%28to%20right%2C%20rgba%28255%2C255%2C255%2C0%29%200%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2025%25%2C%20rgba%28255%2C255%2C255%2C0%2E9%29%2075%25%2C%20rgba%28255%2C255%2C255%2C0%29%20100%25%29%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Flength%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Ffilter%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Finfo%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fprocessing%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%7Bcolor%3A%23333%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%7Bclear%3Aboth%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%7B%2Amargin%2Dtop%3A%2D1px%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Ethead%3Etr%3Eth%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Ethead%3Etr%3Etd%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Etbody%3Etr%3Eth%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Etbody%3Etr%3Etd%7Bvertical%2Dalign%3Amiddle%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Ethead%3Etr%3Eth%3Ediv%2EdataTables%5Fsizing%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Ethead%3Etr%3Etd%3Ediv%2EdataTables%5Fsizing%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Etbody%3Etr%3Eth%3Ediv%2EdataTables%5Fsizing%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fscroll%20div%2EdataTables%5FscrollBody%3Etable%3Etbody%3Etr%3Etd%3Ediv%2EdataTables%5Fsizing%7Bheight%3A0%3Boverflow%3Ahidden%3Bmargin%3A0%20%21important%3Bpadding%3A0%20%21important%7D%2EdataTables%5Fwrapper%2Eno%2Dfooter%20%2EdataTables%5FscrollBody%7Bborder%2Dbottom%3A1px%20solid%20%23111%7D%2EdataTables%5Fwrapper%2Eno%2Dfooter%20div%2EdataTables%5FscrollHead%20table%2EdataTable%2C%2EdataTables%5Fwrapper%2Eno%2Dfooter%20div%2EdataTables%5FscrollBody%3Etable%7Bborder%2Dbottom%3Anone%7D%2EdataTables%5Fwrapper%3Aafter%7Bvisibility%3Ahidden%3Bdisplay%3Ablock%3Bcontent%3A%22%22%3Bclear%3Aboth%3Bheight%3A0%7D%40media%20screen%20and%20%28max%2Dwidth%3A%20767px%29%7B%2EdataTables%5Fwrapper%20%2EdataTables%5Finfo%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%7Bfloat%3Anone%3Btext%2Dalign%3Acenter%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Fpaginate%7Bmargin%2Dtop%3A0%2E5em%7D%7D%40media%20screen%20and%20%28max%2Dwidth%3A%20640px%29%7B%2EdataTables%5Fwrapper%20%2EdataTables%5Flength%2C%2EdataTables%5Fwrapper%20%2EdataTables%5Ffilter%7Bfloat%3Anone%3Btext%2Dalign%3Acenter%7D%2EdataTables%5Fwrapper%20%2EdataTables%5Ffilter%7Bmargin%2Dtop%3A0%2E5em%7D%7D%0A" rel="stylesheet" />
<link href="data:text/css;charset=utf-8,%0Atable%2EdataTable%20tr%2Eselected%20td%2C%20table%2EdataTable%20td%2Eselected%20%7B%0Abackground%2Dcolor%3A%20%23b0bed9%20%21important%3B%0A%7D%0A%0A%2EdataTables%5FscrollBody%20%2EdataTables%5Fsizing%20%7B%0Avisibility%3A%20hidden%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/x-javascript;base64,/*!
 DataTables 1.10.16
 ©2008-2017 SpryMedia Ltd - datatables.net/license
*/
(function(h){"function"===typeof define&&define.amd?define(["jquery"],function(E){return h(E,window,document)}):"object"===typeof exports?module.exports=function(E,G){E||(E=window);G||(G="undefined"!==typeof window?require("jquery"):require("jquery")(E));return h(G,E,E.document)}:h(jQuery,window,document)})(function(h,E,G,k){function X(a){var b,c,d={};h.each(a,function(e){if((b=e.match(/^([^A-Z]+?)([A-Z])/))&&-1!=="a aa ai ao as b fn i m o s ".indexOf(b[1]+" "))c=e.replace(b[0],b[2].toLowerCase()),
d[c]=e,"o"===b[1]&&X(a[e])});a._hungarianMap=d}function I(a,b,c){a._hungarianMap||X(a);var d;h.each(b,function(e){d=a._hungarianMap[e];if(d!==k&&(c||b[d]===k))"o"===d.charAt(0)?(b[d]||(b[d]={}),h.extend(!0,b[d],b[e]),I(a[d],b[d],c)):b[d]=b[e]})}function Ca(a){var b=m.defaults.oLanguage,c=a.sZeroRecords;!a.sEmptyTable&&(c&&"No data available in table"===b.sEmptyTable)&&F(a,a,"sZeroRecords","sEmptyTable");!a.sLoadingRecords&&(c&&"Loading..."===b.sLoadingRecords)&&F(a,a,"sZeroRecords","sLoadingRecords");
a.sInfoThousands&&(a.sThousands=a.sInfoThousands);(a=a.sDecimal)&&cb(a)}function db(a){A(a,"ordering","bSort");A(a,"orderMulti","bSortMulti");A(a,"orderClasses","bSortClasses");A(a,"orderCellsTop","bSortCellsTop");A(a,"order","aaSorting");A(a,"orderFixed","aaSortingFixed");A(a,"paging","bPaginate");A(a,"pagingType","sPaginationType");A(a,"pageLength","iDisplayLength");A(a,"searching","bFilter");"boolean"===typeof a.sScrollX&&(a.sScrollX=a.sScrollX?"100%":"");"boolean"===typeof a.scrollX&&(a.scrollX=
a.scrollX?"100%":"");if(a=a.aoSearchCols)for(var b=0,c=a.length;b<c;b++)a[b]&&I(m.models.oSearch,a[b])}function eb(a){A(a,"orderable","bSortable");A(a,"orderData","aDataSort");A(a,"orderSequence","asSorting");A(a,"orderDataType","sortDataType");var b=a.aDataSort;"number"===typeof b&&!h.isArray(b)&&(a.aDataSort=[b])}function fb(a){if(!m.__browser){var b={};m.__browser=b;var c=h("<div/>").css({position:"fixed",top:0,left:-1*h(E).scrollLeft(),height:1,width:1,overflow:"hidden"}).append(h("<div/>").css({position:"absolute",
top:1,left:1,width:100,overflow:"scroll"}).append(h("<div/>").css({width:"100%",height:10}))).appendTo("body"),d=c.children(),e=d.children();b.barWidth=d[0].offsetWidth-d[0].clientWidth;b.bScrollOversize=100===e[0].offsetWidth&&100!==d[0].clientWidth;b.bScrollbarLeft=1!==Math.round(e.offset().left);b.bBounding=c[0].getBoundingClientRect().width?!0:!1;c.remove()}h.extend(a.oBrowser,m.__browser);a.oScroll.iBarWidth=m.__browser.barWidth}function gb(a,b,c,d,e,f){var g,j=!1;c!==k&&(g=c,j=!0);for(;d!==
e;)a.hasOwnProperty(d)&&(g=j?b(g,a[d],d,a):a[d],j=!0,d+=f);return g}function Da(a,b){var c=m.defaults.column,d=a.aoColumns.length,c=h.extend({},m.models.oColumn,c,{nTh:b?b:G.createElement("th"),sTitle:c.sTitle?c.sTitle:b?b.innerHTML:"",aDataSort:c.aDataSort?c.aDataSort:[d],mData:c.mData?c.mData:d,idx:d});a.aoColumns.push(c);c=a.aoPreSearchCols;c[d]=h.extend({},m.models.oSearch,c[d]);ja(a,d,h(b).data())}function ja(a,b,c){var b=a.aoColumns[b],d=a.oClasses,e=h(b.nTh);if(!b.sWidthOrig){b.sWidthOrig=
e.attr("width")||null;var f=(e.attr("style")||"").match(/width:\s*(\d+[pxem%]+)/);f&&(b.sWidthOrig=f[1])}c!==k&&null!==c&&(eb(c),I(m.defaults.column,c),c.mDataProp!==k&&!c.mData&&(c.mData=c.mDataProp),c.sType&&(b._sManualType=c.sType),c.className&&!c.sClass&&(c.sClass=c.className),c.sClass&&e.addClass(c.sClass),h.extend(b,c),F(b,c,"sWidth","sWidthOrig"),c.iDataSort!==k&&(b.aDataSort=[c.iDataSort]),F(b,c,"aDataSort"));var g=b.mData,j=Q(g),i=b.mRender?Q(b.mRender):null,c=function(a){return"string"===
typeof a&&-1!==a.indexOf("@")};b._bAttrSrc=h.isPlainObject(g)&&(c(g.sort)||c(g.type)||c(g.filter));b._setter=null;b.fnGetData=function(a,b,c){var d=j(a,b,k,c);return i&&b?i(d,b,a,c):d};b.fnSetData=function(a,b,c){return R(g)(a,b,c)};"number"!==typeof g&&(a._rowReadObject=!0);a.oFeatures.bSort||(b.bSortable=!1,e.addClass(d.sSortableNone));a=-1!==h.inArray("asc",b.asSorting);c=-1!==h.inArray("desc",b.asSorting);!b.bSortable||!a&&!c?(b.sSortingClass=d.sSortableNone,b.sSortingClassJUI=""):a&&!c?(b.sSortingClass=
d.sSortableAsc,b.sSortingClassJUI=d.sSortJUIAscAllowed):!a&&c?(b.sSortingClass=d.sSortableDesc,b.sSortingClassJUI=d.sSortJUIDescAllowed):(b.sSortingClass=d.sSortable,b.sSortingClassJUI=d.sSortJUI)}function Y(a){if(!1!==a.oFeatures.bAutoWidth){var b=a.aoColumns;Ea(a);for(var c=0,d=b.length;c<d;c++)b[c].nTh.style.width=b[c].sWidth}b=a.oScroll;(""!==b.sY||""!==b.sX)&&ka(a);r(a,null,"column-sizing",[a])}function Z(a,b){var c=la(a,"bVisible");return"number"===typeof c[b]?c[b]:null}function $(a,b){var c=
la(a,"bVisible"),c=h.inArray(b,c);return-1!==c?c:null}function aa(a){var b=0;h.each(a.aoColumns,function(a,d){d.bVisible&&"none"!==h(d.nTh).css("display")&&b++});return b}function la(a,b){var c=[];h.map(a.aoColumns,function(a,e){a[b]&&c.push(e)});return c}function Fa(a){var b=a.aoColumns,c=a.aoData,d=m.ext.type.detect,e,f,g,j,i,h,l,q,t;e=0;for(f=b.length;e<f;e++)if(l=b[e],t=[],!l.sType&&l._sManualType)l.sType=l._sManualType;else if(!l.sType){g=0;for(j=d.length;g<j;g++){i=0;for(h=c.length;i<h;i++){t[i]===
k&&(t[i]=B(a,i,e,"type"));q=d[g](t[i],a);if(!q&&g!==d.length-1)break;if("html"===q)break}if(q){l.sType=q;break}}l.sType||(l.sType="string")}}function hb(a,b,c,d){var e,f,g,j,i,n,l=a.aoColumns;if(b)for(e=b.length-1;0<=e;e--){n=b[e];var q=n.targets!==k?n.targets:n.aTargets;h.isArray(q)||(q=[q]);f=0;for(g=q.length;f<g;f++)if("number"===typeof q[f]&&0<=q[f]){for(;l.length<=q[f];)Da(a);d(q[f],n)}else if("number"===typeof q[f]&&0>q[f])d(l.length+q[f],n);else if("string"===typeof q[f]){j=0;for(i=l.length;j<
i;j++)("_all"==q[f]||h(l[j].nTh).hasClass(q[f]))&&d(j,n)}}if(c){e=0;for(a=c.length;e<a;e++)d(e,c[e])}}function M(a,b,c,d){var e=a.aoData.length,f=h.extend(!0,{},m.models.oRow,{src:c?"dom":"data",idx:e});f._aData=b;a.aoData.push(f);for(var g=a.aoColumns,j=0,i=g.length;j<i;j++)g[j].sType=null;a.aiDisplayMaster.push(e);b=a.rowIdFn(b);b!==k&&(a.aIds[b]=f);(c||!a.oFeatures.bDeferRender)&&Ga(a,e,c,d);return e}function ma(a,b){var c;b instanceof h||(b=h(b));return b.map(function(b,e){c=Ha(a,e);return M(a,
c.data,e,c.cells)})}function B(a,b,c,d){var e=a.iDraw,f=a.aoColumns[c],g=a.aoData[b]._aData,j=f.sDefaultContent,i=f.fnGetData(g,d,{settings:a,row:b,col:c});if(i===k)return a.iDrawError!=e&&null===j&&(J(a,0,"Requested unknown parameter "+("function"==typeof f.mData?"{function}":"'"+f.mData+"'")+" for row "+b+", column "+c,4),a.iDrawError=e),j;if((i===g||null===i)&&null!==j&&d!==k)i=j;else if("function"===typeof i)return i.call(g);return null===i&&"display"==d?"":i}function ib(a,b,c,d){a.aoColumns[c].fnSetData(a.aoData[b]._aData,
d,{settings:a,row:b,col:c})}function Ia(a){return h.map(a.match(/(\\.|[^\.])+/g)||[""],function(a){return a.replace(/\\\./g,".")})}function Q(a){if(h.isPlainObject(a)){var b={};h.each(a,function(a,c){c&&(b[a]=Q(c))});return function(a,c,f,g){var j=b[c]||b._;return j!==k?j(a,c,f,g):a}}if(null===a)return function(a){return a};if("function"===typeof a)return function(b,c,f,g){return a(b,c,f,g)};if("string"===typeof a&&(-1!==a.indexOf(".")||-1!==a.indexOf("[")||-1!==a.indexOf("("))){var c=function(a,
b,f){var g,j;if(""!==f){j=Ia(f);for(var i=0,n=j.length;i<n;i++){f=j[i].match(ba);g=j[i].match(U);if(f){j[i]=j[i].replace(ba,"");""!==j[i]&&(a=a[j[i]]);g=[];j.splice(0,i+1);j=j.join(".");if(h.isArray(a)){i=0;for(n=a.length;i<n;i++)g.push(c(a[i],b,j))}a=f[0].substring(1,f[0].length-1);a=""===a?g:g.join(a);break}else if(g){j[i]=j[i].replace(U,"");a=a[j[i]]();continue}if(null===a||a[j[i]]===k)return k;a=a[j[i]]}}return a};return function(b,e){return c(b,e,a)}}return function(b){return b[a]}}function R(a){if(h.isPlainObject(a))return R(a._);
if(null===a)return function(){};if("function"===typeof a)return function(b,d,e){a(b,"set",d,e)};if("string"===typeof a&&(-1!==a.indexOf(".")||-1!==a.indexOf("[")||-1!==a.indexOf("("))){var b=function(a,d,e){var e=Ia(e),f;f=e[e.length-1];for(var g,j,i=0,n=e.length-1;i<n;i++){g=e[i].match(ba);j=e[i].match(U);if(g){e[i]=e[i].replace(ba,"");a[e[i]]=[];f=e.slice();f.splice(0,i+1);g=f.join(".");if(h.isArray(d)){j=0;for(n=d.length;j<n;j++)f={},b(f,d[j],g),a[e[i]].push(f)}else a[e[i]]=d;return}j&&(e[i]=e[i].replace(U,
""),a=a[e[i]](d));if(null===a[e[i]]||a[e[i]]===k)a[e[i]]={};a=a[e[i]]}if(f.match(U))a[f.replace(U,"")](d);else a[f.replace(ba,"")]=d};return function(c,d){return b(c,d,a)}}return function(b,d){b[a]=d}}function Ja(a){return D(a.aoData,"_aData")}function na(a){a.aoData.length=0;a.aiDisplayMaster.length=0;a.aiDisplay.length=0;a.aIds={}}function oa(a,b,c){for(var d=-1,e=0,f=a.length;e<f;e++)a[e]==b?d=e:a[e]>b&&a[e]--; -1!=d&&c===k&&a.splice(d,1)}function ca(a,b,c,d){var e=a.aoData[b],f,g=function(c,d){for(;c.childNodes.length;)c.removeChild(c.firstChild);
c.innerHTML=B(a,b,d,"display")};if("dom"===c||(!c||"auto"===c)&&"dom"===e.src)e._aData=Ha(a,e,d,d===k?k:e._aData).data;else{var j=e.anCells;if(j)if(d!==k)g(j[d],d);else{c=0;for(f=j.length;c<f;c++)g(j[c],c)}}e._aSortData=null;e._aFilterData=null;g=a.aoColumns;if(d!==k)g[d].sType=null;else{c=0;for(f=g.length;c<f;c++)g[c].sType=null;Ka(a,e)}}function Ha(a,b,c,d){var e=[],f=b.firstChild,g,j,i=0,n,l=a.aoColumns,q=a._rowReadObject,d=d!==k?d:q?{}:[],t=function(a,b){if("string"===typeof a){var c=a.indexOf("@");
-1!==c&&(c=a.substring(c+1),R(a)(d,b.getAttribute(c)))}},m=function(a){if(c===k||c===i)j=l[i],n=h.trim(a.innerHTML),j&&j._bAttrSrc?(R(j.mData._)(d,n),t(j.mData.sort,a),t(j.mData.type,a),t(j.mData.filter,a)):q?(j._setter||(j._setter=R(j.mData)),j._setter(d,n)):d[i]=n;i++};if(f)for(;f;){g=f.nodeName.toUpperCase();if("TD"==g||"TH"==g)m(f),e.push(f);f=f.nextSibling}else{e=b.anCells;f=0;for(g=e.length;f<g;f++)m(e[f])}if(b=b.firstChild?b:b.nTr)(b=b.getAttribute("id"))&&R(a.rowId)(d,b);return{data:d,cells:e}}
function Ga(a,b,c,d){var e=a.aoData[b],f=e._aData,g=[],j,i,n,l,q;if(null===e.nTr){j=c||G.createElement("tr");e.nTr=j;e.anCells=g;j._DT_RowIndex=b;Ka(a,e);l=0;for(q=a.aoColumns.length;l<q;l++){n=a.aoColumns[l];i=c?d[l]:G.createElement(n.sCellType);i._DT_CellIndex={row:b,column:l};g.push(i);if((!c||n.mRender||n.mData!==l)&&(!h.isPlainObject(n.mData)||n.mData._!==l+".display"))i.innerHTML=B(a,b,l,"display");n.sClass&&(i.className+=" "+n.sClass);n.bVisible&&!c?j.appendChild(i):!n.bVisible&&c&&i.parentNode.removeChild(i);
n.fnCreatedCell&&n.fnCreatedCell.call(a.oInstance,i,B(a,b,l),f,b,l)}r(a,"aoRowCreatedCallback",null,[j,f,b])}e.nTr.setAttribute("role","row")}function Ka(a,b){var c=b.nTr,d=b._aData;if(c){var e=a.rowIdFn(d);e&&(c.id=e);d.DT_RowClass&&(e=d.DT_RowClass.split(" "),b.__rowc=b.__rowc?qa(b.__rowc.concat(e)):e,h(c).removeClass(b.__rowc.join(" ")).addClass(d.DT_RowClass));d.DT_RowAttr&&h(c).attr(d.DT_RowAttr);d.DT_RowData&&h(c).data(d.DT_RowData)}}function jb(a){var b,c,d,e,f,g=a.nTHead,j=a.nTFoot,i=0===
h("th, td",g).length,n=a.oClasses,l=a.aoColumns;i&&(e=h("<tr/>").appendTo(g));b=0;for(c=l.length;b<c;b++)f=l[b],d=h(f.nTh).addClass(f.sClass),i&&d.appendTo(e),a.oFeatures.bSort&&(d.addClass(f.sSortingClass),!1!==f.bSortable&&(d.attr("tabindex",a.iTabIndex).attr("aria-controls",a.sTableId),La(a,f.nTh,b))),f.sTitle!=d[0].innerHTML&&d.html(f.sTitle),Ma(a,"header")(a,d,f,n);i&&da(a.aoHeader,g);h(g).find(">tr").attr("role","row");h(g).find(">tr>th, >tr>td").addClass(n.sHeaderTH);h(j).find(">tr>th, >tr>td").addClass(n.sFooterTH);
if(null!==j){a=a.aoFooter[0];b=0;for(c=a.length;b<c;b++)f=l[b],f.nTf=a[b].cell,f.sClass&&h(f.nTf).addClass(f.sClass)}}function ea(a,b,c){var d,e,f,g=[],j=[],i=a.aoColumns.length,n;if(b){c===k&&(c=!1);d=0;for(e=b.length;d<e;d++){g[d]=b[d].slice();g[d].nTr=b[d].nTr;for(f=i-1;0<=f;f--)!a.aoColumns[f].bVisible&&!c&&g[d].splice(f,1);j.push([])}d=0;for(e=g.length;d<e;d++){if(a=g[d].nTr)for(;f=a.firstChild;)a.removeChild(f);f=0;for(b=g[d].length;f<b;f++)if(n=i=1,j[d][f]===k){a.appendChild(g[d][f].cell);
for(j[d][f]=1;g[d+i]!==k&&g[d][f].cell==g[d+i][f].cell;)j[d+i][f]=1,i++;for(;g[d][f+n]!==k&&g[d][f].cell==g[d][f+n].cell;){for(c=0;c<i;c++)j[d+c][f+n]=1;n++}h(g[d][f].cell).attr("rowspan",i).attr("colspan",n)}}}}function N(a){var b=r(a,"aoPreDrawCallback","preDraw",[a]);if(-1!==h.inArray(!1,b))C(a,!1);else{var b=[],c=0,d=a.asStripeClasses,e=d.length,f=a.oLanguage,g=a.iInitDisplayStart,j="ssp"==y(a),i=a.aiDisplay;a.bDrawing=!0;g!==k&&-1!==g&&(a._iDisplayStart=j?g:g>=a.fnRecordsDisplay()?0:g,a.iInitDisplayStart=
-1);var g=a._iDisplayStart,n=a.fnDisplayEnd();if(a.bDeferLoading)a.bDeferLoading=!1,a.iDraw++,C(a,!1);else if(j){if(!a.bDestroying&&!kb(a))return}else a.iDraw++;if(0!==i.length){f=j?a.aoData.length:n;for(j=j?0:g;j<f;j++){var l=i[j],q=a.aoData[l];null===q.nTr&&Ga(a,l);l=q.nTr;if(0!==e){var t=d[c%e];q._sRowStripe!=t&&(h(l).removeClass(q._sRowStripe).addClass(t),q._sRowStripe=t)}r(a,"aoRowCallback",null,[l,q._aData,c,j]);b.push(l);c++}}else c=f.sZeroRecords,1==a.iDraw&&"ajax"==y(a)?c=f.sLoadingRecords:
f.sEmptyTable&&0===a.fnRecordsTotal()&&(c=f.sEmptyTable),b[0]=h("<tr/>",{"class":e?d[0]:""}).append(h("<td />",{valign:"top",colSpan:aa(a),"class":a.oClasses.sRowEmpty}).html(c))[0];r(a,"aoHeaderCallback","header",[h(a.nTHead).children("tr")[0],Ja(a),g,n,i]);r(a,"aoFooterCallback","footer",[h(a.nTFoot).children("tr")[0],Ja(a),g,n,i]);d=h(a.nTBody);d.children().detach();d.append(h(b));r(a,"aoDrawCallback","draw",[a]);a.bSorted=!1;a.bFiltered=!1;a.bDrawing=!1}}function S(a,b){var c=a.oFeatures,d=c.bFilter;
c.bSort&&lb(a);d?fa(a,a.oPreviousSearch):a.aiDisplay=a.aiDisplayMaster.slice();!0!==b&&(a._iDisplayStart=0);a._drawHold=b;N(a);a._drawHold=!1}function mb(a){var b=a.oClasses,c=h(a.nTable),c=h("<div/>").insertBefore(c),d=a.oFeatures,e=h("<div/>",{id:a.sTableId+"_wrapper","class":b.sWrapper+(a.nTFoot?"":" "+b.sNoFooter)});a.nHolding=c[0];a.nTableWrapper=e[0];a.nTableReinsertBefore=a.nTable.nextSibling;for(var f=a.sDom.split(""),g,j,i,n,l,q,k=0;k<f.length;k++){g=null;j=f[k];if("<"==j){i=h("<div/>")[0];
n=f[k+1];if("'"==n||'"'==n){l="";for(q=2;f[k+q]!=n;)l+=f[k+q],q++;"H"==l?l=b.sJUIHeader:"F"==l&&(l=b.sJUIFooter);-1!=l.indexOf(".")?(n=l.split("."),i.id=n[0].substr(1,n[0].length-1),i.className=n[1]):"#"==l.charAt(0)?i.id=l.substr(1,l.length-1):i.className=l;k+=q}e.append(i);e=h(i)}else if(">"==j)e=e.parent();else if("l"==j&&d.bPaginate&&d.bLengthChange)g=nb(a);else if("f"==j&&d.bFilter)g=ob(a);else if("r"==j&&d.bProcessing)g=pb(a);else if("t"==j)g=qb(a);else if("i"==j&&d.bInfo)g=rb(a);else if("p"==
j&&d.bPaginate)g=sb(a);else if(0!==m.ext.feature.length){i=m.ext.feature;q=0;for(n=i.length;q<n;q++)if(j==i[q].cFeature){g=i[q].fnInit(a);break}}g&&(i=a.aanFeatures,i[j]||(i[j]=[]),i[j].push(g),e.append(g))}c.replaceWith(e);a.nHolding=null}function da(a,b){var c=h(b).children("tr"),d,e,f,g,j,i,n,l,q,k;a.splice(0,a.length);f=0;for(i=c.length;f<i;f++)a.push([]);f=0;for(i=c.length;f<i;f++){d=c[f];for(e=d.firstChild;e;){if("TD"==e.nodeName.toUpperCase()||"TH"==e.nodeName.toUpperCase()){l=1*e.getAttribute("colspan");
q=1*e.getAttribute("rowspan");l=!l||0===l||1===l?1:l;q=!q||0===q||1===q?1:q;g=0;for(j=a[f];j[g];)g++;n=g;k=1===l?!0:!1;for(j=0;j<l;j++)for(g=0;g<q;g++)a[f+g][n+j]={cell:e,unique:k},a[f+g].nTr=d}e=e.nextSibling}}}function ra(a,b,c){var d=[];c||(c=a.aoHeader,b&&(c=[],da(c,b)));for(var b=0,e=c.length;b<e;b++)for(var f=0,g=c[b].length;f<g;f++)if(c[b][f].unique&&(!d[f]||!a.bSortCellsTop))d[f]=c[b][f].cell;return d}function sa(a,b,c){r(a,"aoServerParams","serverParams",[b]);if(b&&h.isArray(b)){var d={},
e=/(.*?)\[\]$/;h.each(b,function(a,b){var c=b.name.match(e);c?(c=c[0],d[c]||(d[c]=[]),d[c].push(b.value)):d[b.name]=b.value});b=d}var f,g=a.ajax,j=a.oInstance,i=function(b){r(a,null,"xhr",[a,b,a.jqXHR]);c(b)};if(h.isPlainObject(g)&&g.data){f=g.data;var n=h.isFunction(f)?f(b,a):f,b=h.isFunction(f)&&n?n:h.extend(!0,b,n);delete g.data}n={data:b,success:function(b){var c=b.error||b.sError;c&&J(a,0,c);a.json=b;i(b)},dataType:"json",cache:!1,type:a.sServerMethod,error:function(b,c){var d=r(a,null,"xhr",
[a,null,a.jqXHR]);-1===h.inArray(!0,d)&&("parsererror"==c?J(a,0,"Invalid JSON response",1):4===b.readyState&&J(a,0,"Ajax error",7));C(a,!1)}};a.oAjaxData=b;r(a,null,"preXhr",[a,b]);a.fnServerData?a.fnServerData.call(j,a.sAjaxSource,h.map(b,function(a,b){return{name:b,value:a}}),i,a):a.sAjaxSource||"string"===typeof g?a.jqXHR=h.ajax(h.extend(n,{url:g||a.sAjaxSource})):h.isFunction(g)?a.jqXHR=g.call(j,b,i,a):(a.jqXHR=h.ajax(h.extend(n,g)),g.data=f)}function kb(a){return a.bAjaxDataGet?(a.iDraw++,C(a,
!0),sa(a,tb(a),function(b){ub(a,b)}),!1):!0}function tb(a){var b=a.aoColumns,c=b.length,d=a.oFeatures,e=a.oPreviousSearch,f=a.aoPreSearchCols,g,j=[],i,n,l,k=V(a);g=a._iDisplayStart;i=!1!==d.bPaginate?a._iDisplayLength:-1;var t=function(a,b){j.push({name:a,value:b})};t("sEcho",a.iDraw);t("iColumns",c);t("sColumns",D(b,"sName").join(","));t("iDisplayStart",g);t("iDisplayLength",i);var pa={draw:a.iDraw,columns:[],order:[],start:g,length:i,search:{value:e.sSearch,regex:e.bRegex}};for(g=0;g<c;g++)n=b[g],
l=f[g],i="function"==typeof n.mData?"function":n.mData,pa.columns.push({data:i,name:n.sName,searchable:n.bSearchable,orderable:n.bSortable,search:{value:l.sSearch,regex:l.bRegex}}),t("mDataProp_"+g,i),d.bFilter&&(t("sSearch_"+g,l.sSearch),t("bRegex_"+g,l.bRegex),t("bSearchable_"+g,n.bSearchable)),d.bSort&&t("bSortable_"+g,n.bSortable);d.bFilter&&(t("sSearch",e.sSearch),t("bRegex",e.bRegex));d.bSort&&(h.each(k,function(a,b){pa.order.push({column:b.col,dir:b.dir});t("iSortCol_"+a,b.col);t("sSortDir_"+
a,b.dir)}),t("iSortingCols",k.length));b=m.ext.legacy.ajax;return null===b?a.sAjaxSource?j:pa:b?j:pa}function ub(a,b){var c=ta(a,b),d=b.sEcho!==k?b.sEcho:b.draw,e=b.iTotalRecords!==k?b.iTotalRecords:b.recordsTotal,f=b.iTotalDisplayRecords!==k?b.iTotalDisplayRecords:b.recordsFiltered;if(d){if(1*d<a.iDraw)return;a.iDraw=1*d}na(a);a._iRecordsTotal=parseInt(e,10);a._iRecordsDisplay=parseInt(f,10);d=0;for(e=c.length;d<e;d++)M(a,c[d]);a.aiDisplay=a.aiDisplayMaster.slice();a.bAjaxDataGet=!1;N(a);a._bInitComplete||
ua(a,b);a.bAjaxDataGet=!0;C(a,!1)}function ta(a,b){var c=h.isPlainObject(a.ajax)&&a.ajax.dataSrc!==k?a.ajax.dataSrc:a.sAjaxDataProp;return"data"===c?b.aaData||b[c]:""!==c?Q(c)(b):b}function ob(a){var b=a.oClasses,c=a.sTableId,d=a.oLanguage,e=a.oPreviousSearch,f=a.aanFeatures,g='<input type="search" class="'+b.sFilterInput+'"/>',j=d.sSearch,j=j.match(/_INPUT_/)?j.replace("_INPUT_",g):j+g,b=h("<div/>",{id:!f.f?c+"_filter":null,"class":b.sFilter}).append(h("<label/>").append(j)),f=function(){var b=!this.value?
"":this.value;b!=e.sSearch&&(fa(a,{sSearch:b,bRegex:e.bRegex,bSmart:e.bSmart,bCaseInsensitive:e.bCaseInsensitive}),a._iDisplayStart=0,N(a))},g=null!==a.searchDelay?a.searchDelay:"ssp"===y(a)?400:0,i=h("input",b).val(e.sSearch).attr("placeholder",d.sSearchPlaceholder).on("keyup.DT search.DT input.DT paste.DT cut.DT",g?Na(f,g):f).on("keypress.DT",function(a){if(13==a.keyCode)return!1}).attr("aria-controls",c);h(a.nTable).on("search.dt.DT",function(b,c){if(a===c)try{i[0]!==G.activeElement&&i.val(e.sSearch)}catch(d){}});
return b[0]}function fa(a,b,c){var d=a.oPreviousSearch,e=a.aoPreSearchCols,f=function(a){d.sSearch=a.sSearch;d.bRegex=a.bRegex;d.bSmart=a.bSmart;d.bCaseInsensitive=a.bCaseInsensitive};Fa(a);if("ssp"!=y(a)){vb(a,b.sSearch,c,b.bEscapeRegex!==k?!b.bEscapeRegex:b.bRegex,b.bSmart,b.bCaseInsensitive);f(b);for(b=0;b<e.length;b++)wb(a,e[b].sSearch,b,e[b].bEscapeRegex!==k?!e[b].bEscapeRegex:e[b].bRegex,e[b].bSmart,e[b].bCaseInsensitive);xb(a)}else f(b);a.bFiltered=!0;r(a,null,"search",[a])}function xb(a){for(var b=
m.ext.search,c=a.aiDisplay,d,e,f=0,g=b.length;f<g;f++){for(var j=[],i=0,n=c.length;i<n;i++)e=c[i],d=a.aoData[e],b[f](a,d._aFilterData,e,d._aData,i)&&j.push(e);c.length=0;h.merge(c,j)}}function wb(a,b,c,d,e,f){if(""!==b){for(var g=[],j=a.aiDisplay,d=Oa(b,d,e,f),e=0;e<j.length;e++)b=a.aoData[j[e]]._aFilterData[c],d.test(b)&&g.push(j[e]);a.aiDisplay=g}}function vb(a,b,c,d,e,f){var d=Oa(b,d,e,f),f=a.oPreviousSearch.sSearch,g=a.aiDisplayMaster,j,e=[];0!==m.ext.search.length&&(c=!0);j=yb(a);if(0>=b.length)a.aiDisplay=
g.slice();else{if(j||c||f.length>b.length||0!==b.indexOf(f)||a.bSorted)a.aiDisplay=g.slice();b=a.aiDisplay;for(c=0;c<b.length;c++)d.test(a.aoData[b[c]]._sFilterRow)&&e.push(b[c]);a.aiDisplay=e}}function Oa(a,b,c,d){a=b?a:Pa(a);c&&(a="^(?=.*?"+h.map(a.match(/"[^"]+"|[^ ]+/g)||[""],function(a){if('"'===a.charAt(0))var b=a.match(/^"(.*)"$/),a=b?b[1]:a;return a.replace('"',"")}).join(")(?=.*?")+").*$");return RegExp(a,d?"i":"")}function yb(a){var b=a.aoColumns,c,d,e,f,g,j,i,h,l=m.ext.type.search;c=!1;
d=0;for(f=a.aoData.length;d<f;d++)if(h=a.aoData[d],!h._aFilterData){j=[];e=0;for(g=b.length;e<g;e++)c=b[e],c.bSearchable?(i=B(a,d,e,"filter"),l[c.sType]&&(i=l[c.sType](i)),null===i&&(i=""),"string"!==typeof i&&i.toString&&(i=i.toString())):i="",i.indexOf&&-1!==i.indexOf("&")&&(va.innerHTML=i,i=Wb?va.textContent:va.innerText),i.replace&&(i=i.replace(/[\r\n]/g,"")),j.push(i);h._aFilterData=j;h._sFilterRow=j.join("  ");c=!0}return c}function zb(a){return{search:a.sSearch,smart:a.bSmart,regex:a.bRegex,
caseInsensitive:a.bCaseInsensitive}}function Ab(a){return{sSearch:a.search,bSmart:a.smart,bRegex:a.regex,bCaseInsensitive:a.caseInsensitive}}function rb(a){var b=a.sTableId,c=a.aanFeatures.i,d=h("<div/>",{"class":a.oClasses.sInfo,id:!c?b+"_info":null});c||(a.aoDrawCallback.push({fn:Bb,sName:"information"}),d.attr("role","status").attr("aria-live","polite"),h(a.nTable).attr("aria-describedby",b+"_info"));return d[0]}function Bb(a){var b=a.aanFeatures.i;if(0!==b.length){var c=a.oLanguage,d=a._iDisplayStart+
1,e=a.fnDisplayEnd(),f=a.fnRecordsTotal(),g=a.fnRecordsDisplay(),j=g?c.sInfo:c.sInfoEmpty;g!==f&&(j+=" "+c.sInfoFiltered);j+=c.sInfoPostFix;j=Cb(a,j);c=c.fnInfoCallback;null!==c&&(j=c.call(a.oInstance,a,d,e,f,g,j));h(b).html(j)}}function Cb(a,b){var c=a.fnFormatNumber,d=a._iDisplayStart+1,e=a._iDisplayLength,f=a.fnRecordsDisplay(),g=-1===e;return b.replace(/_START_/g,c.call(a,d)).replace(/_END_/g,c.call(a,a.fnDisplayEnd())).replace(/_MAX_/g,c.call(a,a.fnRecordsTotal())).replace(/_TOTAL_/g,c.call(a,
f)).replace(/_PAGE_/g,c.call(a,g?1:Math.ceil(d/e))).replace(/_PAGES_/g,c.call(a,g?1:Math.ceil(f/e)))}function ga(a){var b,c,d=a.iInitDisplayStart,e=a.aoColumns,f;c=a.oFeatures;var g=a.bDeferLoading;if(a.bInitialised){mb(a);jb(a);ea(a,a.aoHeader);ea(a,a.aoFooter);C(a,!0);c.bAutoWidth&&Ea(a);b=0;for(c=e.length;b<c;b++)f=e[b],f.sWidth&&(f.nTh.style.width=v(f.sWidth));r(a,null,"preInit",[a]);S(a);e=y(a);if("ssp"!=e||g)"ajax"==e?sa(a,[],function(c){var f=ta(a,c);for(b=0;b<f.length;b++)M(a,f[b]);a.iInitDisplayStart=
d;S(a);C(a,!1);ua(a,c)},a):(C(a,!1),ua(a))}else setTimeout(function(){ga(a)},200)}function ua(a,b){a._bInitComplete=!0;(b||a.oInit.aaData)&&Y(a);r(a,null,"plugin-init",[a,b]);r(a,"aoInitComplete","init",[a,b])}function Qa(a,b){var c=parseInt(b,10);a._iDisplayLength=c;Ra(a);r(a,null,"length",[a,c])}function nb(a){for(var b=a.oClasses,c=a.sTableId,d=a.aLengthMenu,e=h.isArray(d[0]),f=e?d[0]:d,d=e?d[1]:d,e=h("<select/>",{name:c+"_length","aria-controls":c,"class":b.sLengthSelect}),g=0,j=f.length;g<j;g++)e[0][g]=
new Option("number"===typeof d[g]?a.fnFormatNumber(d[g]):d[g],f[g]);var i=h("<div><label/></div>").addClass(b.sLength);a.aanFeatures.l||(i[0].id=c+"_length");i.children().append(a.oLanguage.sLengthMenu.replace("_MENU_",e[0].outerHTML));h("select",i).val(a._iDisplayLength).on("change.DT",function(){Qa(a,h(this).val());N(a)});h(a.nTable).on("length.dt.DT",function(b,c,d){a===c&&h("select",i).val(d)});return i[0]}function sb(a){var b=a.sPaginationType,c=m.ext.pager[b],d="function"===typeof c,e=function(a){N(a)},
b=h("<div/>").addClass(a.oClasses.sPaging+b)[0],f=a.aanFeatures;d||c.fnInit(a,b,e);f.p||(b.id=a.sTableId+"_paginate",a.aoDrawCallback.push({fn:function(a){if(d){var b=a._iDisplayStart,i=a._iDisplayLength,h=a.fnRecordsDisplay(),l=-1===i,b=l?0:Math.ceil(b/i),i=l?1:Math.ceil(h/i),h=c(b,i),k,l=0;for(k=f.p.length;l<k;l++)Ma(a,"pageButton")(a,f.p[l],l,h,b,i)}else c.fnUpdate(a,e)},sName:"pagination"}));return b}function Sa(a,b,c){var d=a._iDisplayStart,e=a._iDisplayLength,f=a.fnRecordsDisplay();0===f||-1===
e?d=0:"number"===typeof b?(d=b*e,d>f&&(d=0)):"first"==b?d=0:"previous"==b?(d=0<=e?d-e:0,0>d&&(d=0)):"next"==b?d+e<f&&(d+=e):"last"==b?d=Math.floor((f-1)/e)*e:J(a,0,"Unknown paging action: "+b,5);b=a._iDisplayStart!==d;a._iDisplayStart=d;b&&(r(a,null,"page",[a]),c&&N(a));return b}function pb(a){return h("<div/>",{id:!a.aanFeatures.r?a.sTableId+"_processing":null,"class":a.oClasses.sProcessing}).html(a.oLanguage.sProcessing).insertBefore(a.nTable)[0]}function C(a,b){a.oFeatures.bProcessing&&h(a.aanFeatures.r).css("display",
b?"block":"none");r(a,null,"processing",[a,b])}function qb(a){var b=h(a.nTable);b.attr("role","grid");var c=a.oScroll;if(""===c.sX&&""===c.sY)return a.nTable;var d=c.sX,e=c.sY,f=a.oClasses,g=b.children("caption"),j=g.length?g[0]._captionSide:null,i=h(b[0].cloneNode(!1)),n=h(b[0].cloneNode(!1)),l=b.children("tfoot");l.length||(l=null);i=h("<div/>",{"class":f.sScrollWrapper}).append(h("<div/>",{"class":f.sScrollHead}).css({overflow:"hidden",position:"relative",border:0,width:d?!d?null:v(d):"100%"}).append(h("<div/>",
{"class":f.sScrollHeadInner}).css({"box-sizing":"content-box",width:c.sXInner||"100%"}).append(i.removeAttr("id").css("margin-left",0).append("top"===j?g:null).append(b.children("thead"))))).append(h("<div/>",{"class":f.sScrollBody}).css({position:"relative",overflow:"auto",width:!d?null:v(d)}).append(b));l&&i.append(h("<div/>",{"class":f.sScrollFoot}).css({overflow:"hidden",border:0,width:d?!d?null:v(d):"100%"}).append(h("<div/>",{"class":f.sScrollFootInner}).append(n.removeAttr("id").css("margin-left",
0).append("bottom"===j?g:null).append(b.children("tfoot")))));var b=i.children(),k=b[0],f=b[1],t=l?b[2]:null;if(d)h(f).on("scroll.DT",function(){var a=this.scrollLeft;k.scrollLeft=a;l&&(t.scrollLeft=a)});h(f).css(e&&c.bCollapse?"max-height":"height",e);a.nScrollHead=k;a.nScrollBody=f;a.nScrollFoot=t;a.aoDrawCallback.push({fn:ka,sName:"scrolling"});return i[0]}function ka(a){var b=a.oScroll,c=b.sX,d=b.sXInner,e=b.sY,b=b.iBarWidth,f=h(a.nScrollHead),g=f[0].style,j=f.children("div"),i=j[0].style,n=j.children("table"),
j=a.nScrollBody,l=h(j),q=j.style,t=h(a.nScrollFoot).children("div"),m=t.children("table"),o=h(a.nTHead),p=h(a.nTable),s=p[0],r=s.style,u=a.nTFoot?h(a.nTFoot):null,x=a.oBrowser,T=x.bScrollOversize,Xb=D(a.aoColumns,"nTh"),O,K,P,w,Ta=[],y=[],z=[],A=[],B,C=function(a){a=a.style;a.paddingTop="0";a.paddingBottom="0";a.borderTopWidth="0";a.borderBottomWidth="0";a.height=0};K=j.scrollHeight>j.clientHeight;if(a.scrollBarVis!==K&&a.scrollBarVis!==k)a.scrollBarVis=K,Y(a);else{a.scrollBarVis=K;p.children("thead, tfoot").remove();
u&&(P=u.clone().prependTo(p),O=u.find("tr"),P=P.find("tr"));w=o.clone().prependTo(p);o=o.find("tr");K=w.find("tr");w.find("th, td").removeAttr("tabindex");c||(q.width="100%",f[0].style.width="100%");h.each(ra(a,w),function(b,c){B=Z(a,b);c.style.width=a.aoColumns[B].sWidth});u&&H(function(a){a.style.width=""},P);f=p.outerWidth();if(""===c){r.width="100%";if(T&&(p.find("tbody").height()>j.offsetHeight||"scroll"==l.css("overflow-y")))r.width=v(p.outerWidth()-b);f=p.outerWidth()}else""!==d&&(r.width=
v(d),f=p.outerWidth());H(C,K);H(function(a){z.push(a.innerHTML);Ta.push(v(h(a).css("width")))},K);H(function(a,b){if(h.inArray(a,Xb)!==-1)a.style.width=Ta[b]},o);h(K).height(0);u&&(H(C,P),H(function(a){A.push(a.innerHTML);y.push(v(h(a).css("width")))},P),H(function(a,b){a.style.width=y[b]},O),h(P).height(0));H(function(a,b){a.innerHTML='<div class="dataTables_sizing" style="height:0;overflow:hidden;">'+z[b]+"</div>";a.style.width=Ta[b]},K);u&&H(function(a,b){a.innerHTML='<div class="dataTables_sizing" style="height:0;overflow:hidden;">'+
A[b]+"</div>";a.style.width=y[b]},P);if(p.outerWidth()<f){O=j.scrollHeight>j.offsetHeight||"scroll"==l.css("overflow-y")?f+b:f;if(T&&(j.scrollHeight>j.offsetHeight||"scroll"==l.css("overflow-y")))r.width=v(O-b);(""===c||""!==d)&&J(a,1,"Possible column misalignment",6)}else O="100%";q.width=v(O);g.width=v(O);u&&(a.nScrollFoot.style.width=v(O));!e&&T&&(q.height=v(s.offsetHeight+b));c=p.outerWidth();n[0].style.width=v(c);i.width=v(c);d=p.height()>j.clientHeight||"scroll"==l.css("overflow-y");e="padding"+
(x.bScrollbarLeft?"Left":"Right");i[e]=d?b+"px":"0px";u&&(m[0].style.width=v(c),t[0].style.width=v(c),t[0].style[e]=d?b+"px":"0px");p.children("colgroup").insertBefore(p.children("thead"));l.scroll();if((a.bSorted||a.bFiltered)&&!a._drawHold)j.scrollTop=0}}function H(a,b,c){for(var d=0,e=0,f=b.length,g,j;e<f;){g=b[e].firstChild;for(j=c?c[e].firstChild:null;g;)1===g.nodeType&&(c?a(g,j,d):a(g,d),d++),g=g.nextSibling,j=c?j.nextSibling:null;e++}}function Ea(a){var b=a.nTable,c=a.aoColumns,d=a.oScroll,
e=d.sY,f=d.sX,g=d.sXInner,j=c.length,i=la(a,"bVisible"),n=h("th",a.nTHead),l=b.getAttribute("width"),k=b.parentNode,t=!1,m,o,p=a.oBrowser,d=p.bScrollOversize;(m=b.style.width)&&-1!==m.indexOf("%")&&(l=m);for(m=0;m<i.length;m++)o=c[i[m]],null!==o.sWidth&&(o.sWidth=Db(o.sWidthOrig,k),t=!0);if(d||!t&&!f&&!e&&j==aa(a)&&j==n.length)for(m=0;m<j;m++)i=Z(a,m),null!==i&&(c[i].sWidth=v(n.eq(m).width()));else{j=h(b).clone().css("visibility","hidden").removeAttr("id");j.find("tbody tr").remove();var s=h("<tr/>").appendTo(j.find("tbody"));
j.find("thead, tfoot").remove();j.append(h(a.nTHead).clone()).append(h(a.nTFoot).clone());j.find("tfoot th, tfoot td").css("width","");n=ra(a,j.find("thead")[0]);for(m=0;m<i.length;m++)o=c[i[m]],n[m].style.width=null!==o.sWidthOrig&&""!==o.sWidthOrig?v(o.sWidthOrig):"",o.sWidthOrig&&f&&h(n[m]).append(h("<div/>").css({width:o.sWidthOrig,margin:0,padding:0,border:0,height:1}));if(a.aoData.length)for(m=0;m<i.length;m++)t=i[m],o=c[t],h(Eb(a,t)).clone(!1).append(o.sContentPadding).appendTo(s);h("[name]",
j).removeAttr("name");o=h("<div/>").css(f||e?{position:"absolute",top:0,left:0,height:1,right:0,overflow:"hidden"}:{}).append(j).appendTo(k);f&&g?j.width(g):f?(j.css("width","auto"),j.removeAttr("width"),j.width()<k.clientWidth&&l&&j.width(k.clientWidth)):e?j.width(k.clientWidth):l&&j.width(l);for(m=e=0;m<i.length;m++)k=h(n[m]),g=k.outerWidth()-k.width(),k=p.bBounding?Math.ceil(n[m].getBoundingClientRect().width):k.outerWidth(),e+=k,c[i[m]].sWidth=v(k-g);b.style.width=v(e);o.remove()}l&&(b.style.width=
v(l));if((l||f)&&!a._reszEvt)b=function(){h(E).on("resize.DT-"+a.sInstance,Na(function(){Y(a)}))},d?setTimeout(b,1E3):b(),a._reszEvt=!0}function Db(a,b){if(!a)return 0;var c=h("<div/>").css("width",v(a)).appendTo(b||G.body),d=c[0].offsetWidth;c.remove();return d}function Eb(a,b){var c=Fb(a,b);if(0>c)return null;var d=a.aoData[c];return!d.nTr?h("<td/>").html(B(a,c,b,"display"))[0]:d.anCells[b]}function Fb(a,b){for(var c,d=-1,e=-1,f=0,g=a.aoData.length;f<g;f++)c=B(a,f,b,"display")+"",c=c.replace(Yb,
""),c=c.replace(/&nbsp;/g," "),c.length>d&&(d=c.length,e=f);return e}function v(a){return null===a?"0px":"number"==typeof a?0>a?"0px":a+"px":a.match(/\d$/)?a+"px":a}function V(a){var b,c,d=[],e=a.aoColumns,f,g,j,i;b=a.aaSortingFixed;c=h.isPlainObject(b);var n=[];f=function(a){a.length&&!h.isArray(a[0])?n.push(a):h.merge(n,a)};h.isArray(b)&&f(b);c&&b.pre&&f(b.pre);f(a.aaSorting);c&&b.post&&f(b.post);for(a=0;a<n.length;a++){i=n[a][0];f=e[i].aDataSort;b=0;for(c=f.length;b<c;b++)g=f[b],j=e[g].sType||
"string",n[a]._idx===k&&(n[a]._idx=h.inArray(n[a][1],e[g].asSorting)),d.push({src:i,col:g,dir:n[a][1],index:n[a]._idx,type:j,formatter:m.ext.type.order[j+"-pre"]})}return d}function lb(a){var b,c,d=[],e=m.ext.type.order,f=a.aoData,g=0,j,i=a.aiDisplayMaster,h;Fa(a);h=V(a);b=0;for(c=h.length;b<c;b++)j=h[b],j.formatter&&g++,Gb(a,j.col);if("ssp"!=y(a)&&0!==h.length){b=0;for(c=i.length;b<c;b++)d[i[b]]=b;g===h.length?i.sort(function(a,b){var c,e,g,j,i=h.length,k=f[a]._aSortData,m=f[b]._aSortData;for(g=
0;g<i;g++)if(j=h[g],c=k[j.col],e=m[j.col],c=c<e?-1:c>e?1:0,0!==c)return"asc"===j.dir?c:-c;c=d[a];e=d[b];return c<e?-1:c>e?1:0}):i.sort(function(a,b){var c,g,j,i,k=h.length,m=f[a]._aSortData,o=f[b]._aSortData;for(j=0;j<k;j++)if(i=h[j],c=m[i.col],g=o[i.col],i=e[i.type+"-"+i.dir]||e["string-"+i.dir],c=i(c,g),0!==c)return c;c=d[a];g=d[b];return c<g?-1:c>g?1:0})}a.bSorted=!0}function Hb(a){for(var b,c,d=a.aoColumns,e=V(a),a=a.oLanguage.oAria,f=0,g=d.length;f<g;f++){c=d[f];var j=c.asSorting;b=c.sTitle.replace(/<.*?>/g,
"");var i=c.nTh;i.removeAttribute("aria-sort");c.bSortable&&(0<e.length&&e[0].col==f?(i.setAttribute("aria-sort","asc"==e[0].dir?"ascending":"descending"),c=j[e[0].index+1]||j[0]):c=j[0],b+="asc"===c?a.sSortAscending:a.sSortDescending);i.setAttribute("aria-label",b)}}function Ua(a,b,c,d){var e=a.aaSorting,f=a.aoColumns[b].asSorting,g=function(a,b){var c=a._idx;c===k&&(c=h.inArray(a[1],f));return c+1<f.length?c+1:b?null:0};"number"===typeof e[0]&&(e=a.aaSorting=[e]);c&&a.oFeatures.bSortMulti?(c=h.inArray(b,
D(e,"0")),-1!==c?(b=g(e[c],!0),null===b&&1===e.length&&(b=0),null===b?e.splice(c,1):(e[c][1]=f[b],e[c]._idx=b)):(e.push([b,f[0],0]),e[e.length-1]._idx=0)):e.length&&e[0][0]==b?(b=g(e[0]),e.length=1,e[0][1]=f[b],e[0]._idx=b):(e.length=0,e.push([b,f[0]]),e[0]._idx=0);S(a);"function"==typeof d&&d(a)}function La(a,b,c,d){var e=a.aoColumns[c];Va(b,{},function(b){!1!==e.bSortable&&(a.oFeatures.bProcessing?(C(a,!0),setTimeout(function(){Ua(a,c,b.shiftKey,d);"ssp"!==y(a)&&C(a,!1)},0)):Ua(a,c,b.shiftKey,d))})}
function wa(a){var b=a.aLastSort,c=a.oClasses.sSortColumn,d=V(a),e=a.oFeatures,f,g;if(e.bSort&&e.bSortClasses){e=0;for(f=b.length;e<f;e++)g=b[e].src,h(D(a.aoData,"anCells",g)).removeClass(c+(2>e?e+1:3));e=0;for(f=d.length;e<f;e++)g=d[e].src,h(D(a.aoData,"anCells",g)).addClass(c+(2>e?e+1:3))}a.aLastSort=d}function Gb(a,b){var c=a.aoColumns[b],d=m.ext.order[c.sSortDataType],e;d&&(e=d.call(a.oInstance,a,b,$(a,b)));for(var f,g=m.ext.type.order[c.sType+"-pre"],j=0,i=a.aoData.length;j<i;j++)if(c=a.aoData[j],
c._aSortData||(c._aSortData=[]),!c._aSortData[b]||d)f=d?e[j]:B(a,j,b,"sort"),c._aSortData[b]=g?g(f):f}function xa(a){if(a.oFeatures.bStateSave&&!a.bDestroying){var b={time:+new Date,start:a._iDisplayStart,length:a._iDisplayLength,order:h.extend(!0,[],a.aaSorting),search:zb(a.oPreviousSearch),columns:h.map(a.aoColumns,function(b,d){return{visible:b.bVisible,search:zb(a.aoPreSearchCols[d])}})};r(a,"aoStateSaveParams","stateSaveParams",[a,b]);a.oSavedState=b;a.fnStateSaveCallback.call(a.oInstance,a,
b)}}function Ib(a,b,c){var d,e,f=a.aoColumns,b=function(b){if(b&&b.time){var g=r(a,"aoStateLoadParams","stateLoadParams",[a,b]);if(-1===h.inArray(!1,g)&&(g=a.iStateDuration,!(0<g&&b.time<+new Date-1E3*g)&&!(b.columns&&f.length!==b.columns.length))){a.oLoadedState=h.extend(!0,{},b);b.start!==k&&(a._iDisplayStart=b.start,a.iInitDisplayStart=b.start);b.length!==k&&(a._iDisplayLength=b.length);b.order!==k&&(a.aaSorting=[],h.each(b.order,function(b,c){a.aaSorting.push(c[0]>=f.length?[0,c[1]]:c)}));b.search!==
k&&h.extend(a.oPreviousSearch,Ab(b.search));if(b.columns){d=0;for(e=b.columns.length;d<e;d++)g=b.columns[d],g.visible!==k&&(f[d].bVisible=g.visible),g.search!==k&&h.extend(a.aoPreSearchCols[d],Ab(g.search))}r(a,"aoStateLoaded","stateLoaded",[a,b])}}c()};if(a.oFeatures.bStateSave){var g=a.fnStateLoadCallback.call(a.oInstance,a,b);g!==k&&b(g)}else c()}function ya(a){var b=m.settings,a=h.inArray(a,D(b,"nTable"));return-1!==a?b[a]:null}function J(a,b,c,d){c="DataTables warning: "+(a?"table id="+a.sTableId+
" - ":"")+c;d&&(c+=". For more information about this error, please see http://datatables.net/tn/"+d);if(b)E.console&&console.log&&console.log(c);else if(b=m.ext,b=b.sErrMode||b.errMode,a&&r(a,null,"error",[a,d,c]),"alert"==b)alert(c);else{if("throw"==b)throw Error(c);"function"==typeof b&&b(a,d,c)}}function F(a,b,c,d){h.isArray(c)?h.each(c,function(c,d){h.isArray(d)?F(a,b,d[0],d[1]):F(a,b,d)}):(d===k&&(d=c),b[c]!==k&&(a[d]=b[c]))}function Jb(a,b,c){var d,e;for(e in b)b.hasOwnProperty(e)&&(d=b[e],
h.isPlainObject(d)?(h.isPlainObject(a[e])||(a[e]={}),h.extend(!0,a[e],d)):a[e]=c&&"data"!==e&&"aaData"!==e&&h.isArray(d)?d.slice():d);return a}function Va(a,b,c){h(a).on("click.DT",b,function(b){a.blur();c(b)}).on("keypress.DT",b,function(a){13===a.which&&(a.preventDefault(),c(a))}).on("selectstart.DT",function(){return!1})}function z(a,b,c,d){c&&a[b].push({fn:c,sName:d})}function r(a,b,c,d){var e=[];b&&(e=h.map(a[b].slice().reverse(),function(b){return b.fn.apply(a.oInstance,d)}));null!==c&&(b=h.Event(c+
".dt"),h(a.nTable).trigger(b,d),e.push(b.result));return e}function Ra(a){var b=a._iDisplayStart,c=a.fnDisplayEnd(),d=a._iDisplayLength;b>=c&&(b=c-d);b-=b%d;if(-1===d||0>b)b=0;a._iDisplayStart=b}function Ma(a,b){var c=a.renderer,d=m.ext.renderer[b];return h.isPlainObject(c)&&c[b]?d[c[b]]||d._:"string"===typeof c?d[c]||d._:d._}function y(a){return a.oFeatures.bServerSide?"ssp":a.ajax||a.sAjaxSource?"ajax":"dom"}function ha(a,b){var c=[],c=Kb.numbers_length,d=Math.floor(c/2);b<=c?c=W(0,b):a<=d?(c=W(0,
c-2),c.push("ellipsis"),c.push(b-1)):(a>=b-1-d?c=W(b-(c-2),b):(c=W(a-d+2,a+d-1),c.push("ellipsis"),c.push(b-1)),c.splice(0,0,"ellipsis"),c.splice(0,0,0));c.DT_el="span";return c}function cb(a){h.each({num:function(b){return za(b,a)},"num-fmt":function(b){return za(b,a,Wa)},"html-num":function(b){return za(b,a,Aa)},"html-num-fmt":function(b){return za(b,a,Aa,Wa)}},function(b,c){x.type.order[b+a+"-pre"]=c;b.match(/^html\-/)&&(x.type.search[b+a]=x.type.search.html)})}function Lb(a){return function(){var b=
[ya(this[m.ext.iApiIndex])].concat(Array.prototype.slice.call(arguments));return m.ext.internal[a].apply(this,b)}}var m=function(a){this.$=function(a,b){return this.api(!0).$(a,b)};this._=function(a,b){return this.api(!0).rows(a,b).data()};this.api=function(a){return a?new s(ya(this[x.iApiIndex])):new s(this)};this.fnAddData=function(a,b){var c=this.api(!0),d=h.isArray(a)&&(h.isArray(a[0])||h.isPlainObject(a[0]))?c.rows.add(a):c.row.add(a);(b===k||b)&&c.draw();return d.flatten().toArray()};this.fnAdjustColumnSizing=
function(a){var b=this.api(!0).columns.adjust(),c=b.settings()[0],d=c.oScroll;a===k||a?b.draw(!1):(""!==d.sX||""!==d.sY)&&ka(c)};this.fnClearTable=function(a){var b=this.api(!0).clear();(a===k||a)&&b.draw()};this.fnClose=function(a){this.api(!0).row(a).child.hide()};this.fnDeleteRow=function(a,b,c){var d=this.api(!0),a=d.rows(a),e=a.settings()[0],h=e.aoData[a[0][0]];a.remove();b&&b.call(this,e,h);(c===k||c)&&d.draw();return h};this.fnDestroy=function(a){this.api(!0).destroy(a)};this.fnDraw=function(a){this.api(!0).draw(a)};
this.fnFilter=function(a,b,c,d,e,h){e=this.api(!0);null===b||b===k?e.search(a,c,d,h):e.column(b).search(a,c,d,h);e.draw()};this.fnGetData=function(a,b){var c=this.api(!0);if(a!==k){var d=a.nodeName?a.nodeName.toLowerCase():"";return b!==k||"td"==d||"th"==d?c.cell(a,b).data():c.row(a).data()||null}return c.data().toArray()};this.fnGetNodes=function(a){var b=this.api(!0);return a!==k?b.row(a).node():b.rows().nodes().flatten().toArray()};this.fnGetPosition=function(a){var b=this.api(!0),c=a.nodeName.toUpperCase();
return"TR"==c?b.row(a).index():"TD"==c||"TH"==c?(a=b.cell(a).index(),[a.row,a.columnVisible,a.column]):null};this.fnIsOpen=function(a){return this.api(!0).row(a).child.isShown()};this.fnOpen=function(a,b,c){return this.api(!0).row(a).child(b,c).show().child()[0]};this.fnPageChange=function(a,b){var c=this.api(!0).page(a);(b===k||b)&&c.draw(!1)};this.fnSetColumnVis=function(a,b,c){a=this.api(!0).column(a).visible(b);(c===k||c)&&a.columns.adjust().draw()};this.fnSettings=function(){return ya(this[x.iApiIndex])};
this.fnSort=function(a){this.api(!0).order(a).draw()};this.fnSortListener=function(a,b,c){this.api(!0).order.listener(a,b,c)};this.fnUpdate=function(a,b,c,d,e){var h=this.api(!0);c===k||null===c?h.row(b).data(a):h.cell(b,c).data(a);(e===k||e)&&h.columns.adjust();(d===k||d)&&h.draw();return 0};this.fnVersionCheck=x.fnVersionCheck;var b=this,c=a===k,d=this.length;c&&(a={});this.oApi=this.internal=x.internal;for(var e in m.ext.internal)e&&(this[e]=Lb(e));this.each(function(){var e={},g=1<d?Jb(e,a,!0):
a,j=0,i,e=this.getAttribute("id"),n=!1,l=m.defaults,q=h(this);if("table"!=this.nodeName.toLowerCase())J(null,0,"Non-table node initialisation ("+this.nodeName+")",2);else{db(l);eb(l.column);I(l,l,!0);I(l.column,l.column,!0);I(l,h.extend(g,q.data()));var t=m.settings,j=0;for(i=t.length;j<i;j++){var o=t[j];if(o.nTable==this||o.nTHead.parentNode==this||o.nTFoot&&o.nTFoot.parentNode==this){var s=g.bRetrieve!==k?g.bRetrieve:l.bRetrieve;if(c||s)return o.oInstance;if(g.bDestroy!==k?g.bDestroy:l.bDestroy){o.oInstance.fnDestroy();
break}else{J(o,0,"Cannot reinitialise DataTable",3);return}}if(o.sTableId==this.id){t.splice(j,1);break}}if(null===e||""===e)this.id=e="DataTables_Table_"+m.ext._unique++;var p=h.extend(!0,{},m.models.oSettings,{sDestroyWidth:q[0].style.width,sInstance:e,sTableId:e});p.nTable=this;p.oApi=b.internal;p.oInit=g;t.push(p);p.oInstance=1===b.length?b:q.dataTable();db(g);g.oLanguage&&Ca(g.oLanguage);g.aLengthMenu&&!g.iDisplayLength&&(g.iDisplayLength=h.isArray(g.aLengthMenu[0])?g.aLengthMenu[0][0]:g.aLengthMenu[0]);
g=Jb(h.extend(!0,{},l),g);F(p.oFeatures,g,"bPaginate bLengthChange bFilter bSort bSortMulti bInfo bProcessing bAutoWidth bSortClasses bServerSide bDeferRender".split(" "));F(p,g,["asStripeClasses","ajax","fnServerData","fnFormatNumber","sServerMethod","aaSorting","aaSortingFixed","aLengthMenu","sPaginationType","sAjaxSource","sAjaxDataProp","iStateDuration","sDom","bSortCellsTop","iTabIndex","fnStateLoadCallback","fnStateSaveCallback","renderer","searchDelay","rowId",["iCookieDuration","iStateDuration"],
["oSearch","oPreviousSearch"],["aoSearchCols","aoPreSearchCols"],["iDisplayLength","_iDisplayLength"]]);F(p.oScroll,g,[["sScrollX","sX"],["sScrollXInner","sXInner"],["sScrollY","sY"],["bScrollCollapse","bCollapse"]]);F(p.oLanguage,g,"fnInfoCallback");z(p,"aoDrawCallback",g.fnDrawCallback,"user");z(p,"aoServerParams",g.fnServerParams,"user");z(p,"aoStateSaveParams",g.fnStateSaveParams,"user");z(p,"aoStateLoadParams",g.fnStateLoadParams,"user");z(p,"aoStateLoaded",g.fnStateLoaded,"user");z(p,"aoRowCallback",
g.fnRowCallback,"user");z(p,"aoRowCreatedCallback",g.fnCreatedRow,"user");z(p,"aoHeaderCallback",g.fnHeaderCallback,"user");z(p,"aoFooterCallback",g.fnFooterCallback,"user");z(p,"aoInitComplete",g.fnInitComplete,"user");z(p,"aoPreDrawCallback",g.fnPreDrawCallback,"user");p.rowIdFn=Q(g.rowId);fb(p);var u=p.oClasses;h.extend(u,m.ext.classes,g.oClasses);q.addClass(u.sTable);p.iInitDisplayStart===k&&(p.iInitDisplayStart=g.iDisplayStart,p._iDisplayStart=g.iDisplayStart);null!==g.iDeferLoading&&(p.bDeferLoading=
!0,e=h.isArray(g.iDeferLoading),p._iRecordsDisplay=e?g.iDeferLoading[0]:g.iDeferLoading,p._iRecordsTotal=e?g.iDeferLoading[1]:g.iDeferLoading);var v=p.oLanguage;h.extend(!0,v,g.oLanguage);v.sUrl&&(h.ajax({dataType:"json",url:v.sUrl,success:function(a){Ca(a);I(l.oLanguage,a);h.extend(true,v,a);ga(p)},error:function(){ga(p)}}),n=!0);null===g.asStripeClasses&&(p.asStripeClasses=[u.sStripeOdd,u.sStripeEven]);var e=p.asStripeClasses,x=q.children("tbody").find("tr").eq(0);-1!==h.inArray(!0,h.map(e,function(a){return x.hasClass(a)}))&&
(h("tbody tr",this).removeClass(e.join(" ")),p.asDestroyStripes=e.slice());e=[];t=this.getElementsByTagName("thead");0!==t.length&&(da(p.aoHeader,t[0]),e=ra(p));if(null===g.aoColumns){t=[];j=0;for(i=e.length;j<i;j++)t.push(null)}else t=g.aoColumns;j=0;for(i=t.length;j<i;j++)Da(p,e?e[j]:null);hb(p,g.aoColumnDefs,t,function(a,b){ja(p,a,b)});if(x.length){var w=function(a,b){return a.getAttribute("data-"+b)!==null?b:null};h(x[0]).children("th, td").each(function(a,b){var c=p.aoColumns[a];if(c.mData===
a){var d=w(b,"sort")||w(b,"order"),e=w(b,"filter")||w(b,"search");if(d!==null||e!==null){c.mData={_:a+".display",sort:d!==null?a+".@data-"+d:k,type:d!==null?a+".@data-"+d:k,filter:e!==null?a+".@data-"+e:k};ja(p,a)}}})}var T=p.oFeatures,e=function(){if(g.aaSorting===k){var a=p.aaSorting;j=0;for(i=a.length;j<i;j++)a[j][1]=p.aoColumns[j].asSorting[0]}wa(p);T.bSort&&z(p,"aoDrawCallback",function(){if(p.bSorted){var a=V(p),b={};h.each(a,function(a,c){b[c.src]=c.dir});r(p,null,"order",[p,a,b]);Hb(p)}});
z(p,"aoDrawCallback",function(){(p.bSorted||y(p)==="ssp"||T.bDeferRender)&&wa(p)},"sc");var a=q.children("caption").each(function(){this._captionSide=h(this).css("caption-side")}),b=q.children("thead");b.length===0&&(b=h("<thead/>").appendTo(q));p.nTHead=b[0];b=q.children("tbody");b.length===0&&(b=h("<tbody/>").appendTo(q));p.nTBody=b[0];b=q.children("tfoot");if(b.length===0&&a.length>0&&(p.oScroll.sX!==""||p.oScroll.sY!==""))b=h("<tfoot/>").appendTo(q);if(b.length===0||b.children().length===0)q.addClass(u.sNoFooter);
else if(b.length>0){p.nTFoot=b[0];da(p.aoFooter,p.nTFoot)}if(g.aaData)for(j=0;j<g.aaData.length;j++)M(p,g.aaData[j]);else(p.bDeferLoading||y(p)=="dom")&&ma(p,h(p.nTBody).children("tr"));p.aiDisplay=p.aiDisplayMaster.slice();p.bInitialised=true;n===false&&ga(p)};g.bStateSave?(T.bStateSave=!0,z(p,"aoDrawCallback",xa,"state_save"),Ib(p,g,e)):e()}});b=null;return this},x,s,o,u,Xa={},Mb=/[\r\n]/g,Aa=/<.*?>/g,Zb=/^\d{2,4}[\.\/\-]\d{1,2}[\.\/\-]\d{1,2}([T ]{1}\d{1,2}[:\.]\d{2}([\.:]\d{2})?)?$/,$b=RegExp("(\\/|\\.|\\*|\\+|\\?|\\||\\(|\\)|\\[|\\]|\\{|\\}|\\\\|\\$|\\^|\\-)",
"g"),Wa=/[',$£€¥%\u2009\u202F\u20BD\u20a9\u20BArfk]/gi,L=function(a){return!a||!0===a||"-"===a?!0:!1},Nb=function(a){var b=parseInt(a,10);return!isNaN(b)&&isFinite(a)?b:null},Ob=function(a,b){Xa[b]||(Xa[b]=RegExp(Pa(b),"g"));return"string"===typeof a&&"."!==b?a.replace(/\./g,"").replace(Xa[b],"."):a},Ya=function(a,b,c){var d="string"===typeof a;if(L(a))return!0;b&&d&&(a=Ob(a,b));c&&d&&(a=a.replace(Wa,""));return!isNaN(parseFloat(a))&&isFinite(a)},Pb=function(a,b,c){return L(a)?!0:!(L(a)||"string"===
typeof a)?null:Ya(a.replace(Aa,""),b,c)?!0:null},D=function(a,b,c){var d=[],e=0,f=a.length;if(c!==k)for(;e<f;e++)a[e]&&a[e][b]&&d.push(a[e][b][c]);else for(;e<f;e++)a[e]&&d.push(a[e][b]);return d},ia=function(a,b,c,d){var e=[],f=0,g=b.length;if(d!==k)for(;f<g;f++)a[b[f]][c]&&e.push(a[b[f]][c][d]);else for(;f<g;f++)e.push(a[b[f]][c]);return e},W=function(a,b){var c=[],d;b===k?(b=0,d=a):(d=b,b=a);for(var e=b;e<d;e++)c.push(e);return c},Qb=function(a){for(var b=[],c=0,d=a.length;c<d;c++)a[c]&&b.push(a[c]);
return b},qa=function(a){var b;a:{if(!(2>a.length)){b=a.slice().sort();for(var c=b[0],d=1,e=b.length;d<e;d++){if(b[d]===c){b=!1;break a}c=b[d]}}b=!0}if(b)return a.slice();b=[];var e=a.length,f,g=0,d=0;a:for(;d<e;d++){c=a[d];for(f=0;f<g;f++)if(b[f]===c)continue a;b.push(c);g++}return b};m.util={throttle:function(a,b){var c=b!==k?b:200,d,e;return function(){var b=this,g=+new Date,j=arguments;d&&g<d+c?(clearTimeout(e),e=setTimeout(function(){d=k;a.apply(b,j)},c)):(d=g,a.apply(b,j))}},escapeRegex:function(a){return a.replace($b,
"\\$1")}};var A=function(a,b,c){a[b]!==k&&(a[c]=a[b])},ba=/\[.*?\]$/,U=/\(\)$/,Pa=m.util.escapeRegex,va=h("<div>")[0],Wb=va.textContent!==k,Yb=/<.*?>/g,Na=m.util.throttle,Rb=[],w=Array.prototype,ac=function(a){var b,c,d=m.settings,e=h.map(d,function(a){return a.nTable});if(a){if(a.nTable&&a.oApi)return[a];if(a.nodeName&&"table"===a.nodeName.toLowerCase())return b=h.inArray(a,e),-1!==b?[d[b]]:null;if(a&&"function"===typeof a.settings)return a.settings().toArray();"string"===typeof a?c=h(a):a instanceof
h&&(c=a)}else return[];if(c)return c.map(function(){b=h.inArray(this,e);return-1!==b?d[b]:null}).toArray()};s=function(a,b){if(!(this instanceof s))return new s(a,b);var c=[],d=function(a){(a=ac(a))&&(c=c.concat(a))};if(h.isArray(a))for(var e=0,f=a.length;e<f;e++)d(a[e]);else d(a);this.context=qa(c);b&&h.merge(this,b);this.selector={rows:null,cols:null,opts:null};s.extend(this,this,Rb)};m.Api=s;h.extend(s.prototype,{any:function(){return 0!==this.count()},concat:w.concat,context:[],count:function(){return this.flatten().length},
each:function(a){for(var b=0,c=this.length;b<c;b++)a.call(this,this[b],b,this);return this},eq:function(a){var b=this.context;return b.length>a?new s(b[a],this[a]):null},filter:function(a){var b=[];if(w.filter)b=w.filter.call(this,a,this);else for(var c=0,d=this.length;c<d;c++)a.call(this,this[c],c,this)&&b.push(this[c]);return new s(this.context,b)},flatten:function(){var a=[];return new s(this.context,a.concat.apply(a,this.toArray()))},join:w.join,indexOf:w.indexOf||function(a,b){for(var c=b||0,
d=this.length;c<d;c++)if(this[c]===a)return c;return-1},iterator:function(a,b,c,d){var e=[],f,g,j,h,n,l=this.context,m,o,u=this.selector;"string"===typeof a&&(d=c,c=b,b=a,a=!1);g=0;for(j=l.length;g<j;g++){var r=new s(l[g]);if("table"===b)f=c.call(r,l[g],g),f!==k&&e.push(f);else if("columns"===b||"rows"===b)f=c.call(r,l[g],this[g],g),f!==k&&e.push(f);else if("column"===b||"column-rows"===b||"row"===b||"cell"===b){o=this[g];"column-rows"===b&&(m=Ba(l[g],u.opts));h=0;for(n=o.length;h<n;h++)f=o[h],f=
"cell"===b?c.call(r,l[g],f.row,f.column,g,h):c.call(r,l[g],f,g,h,m),f!==k&&e.push(f)}}return e.length||d?(a=new s(l,a?e.concat.apply([],e):e),b=a.selector,b.rows=u.rows,b.cols=u.cols,b.opts=u.opts,a):this},lastIndexOf:w.lastIndexOf||function(a,b){return this.indexOf.apply(this.toArray.reverse(),arguments)},length:0,map:function(a){var b=[];if(w.map)b=w.map.call(this,a,this);else for(var c=0,d=this.length;c<d;c++)b.push(a.call(this,this[c],c));return new s(this.context,b)},pluck:function(a){return this.map(function(b){return b[a]})},
pop:w.pop,push:w.push,reduce:w.reduce||function(a,b){return gb(this,a,b,0,this.length,1)},reduceRight:w.reduceRight||function(a,b){return gb(this,a,b,this.length-1,-1,-1)},reverse:w.reverse,selector:null,shift:w.shift,slice:function(){return new s(this.context,this)},sort:w.sort,splice:w.splice,toArray:function(){return w.slice.call(this)},to$:function(){return h(this)},toJQuery:function(){return h(this)},unique:function(){return new s(this.context,qa(this))},unshift:w.unshift});s.extend=function(a,
b,c){if(c.length&&b&&(b instanceof s||b.__dt_wrapper)){var d,e,f,g=function(a,b,c){return function(){var d=b.apply(a,arguments);s.extend(d,d,c.methodExt);return d}};d=0;for(e=c.length;d<e;d++)f=c[d],b[f.name]="function"===typeof f.val?g(a,f.val,f):h.isPlainObject(f.val)?{}:f.val,b[f.name].__dt_wrapper=!0,s.extend(a,b[f.name],f.propExt)}};s.register=o=function(a,b){if(h.isArray(a))for(var c=0,d=a.length;c<d;c++)s.register(a[c],b);else for(var e=a.split("."),f=Rb,g,j,c=0,d=e.length;c<d;c++){g=(j=-1!==
e[c].indexOf("()"))?e[c].replace("()",""):e[c];var i;a:{i=0;for(var n=f.length;i<n;i++)if(f[i].name===g){i=f[i];break a}i=null}i||(i={name:g,val:{},methodExt:[],propExt:[]},f.push(i));c===d-1?i.val=b:f=j?i.methodExt:i.propExt}};s.registerPlural=u=function(a,b,c){s.register(a,c);s.register(b,function(){var a=c.apply(this,arguments);return a===this?this:a instanceof s?a.length?h.isArray(a[0])?new s(a.context,a[0]):a[0]:k:a})};o("tables()",function(a){var b;if(a){b=s;var c=this.context;if("number"===
typeof a)a=[c[a]];else var d=h.map(c,function(a){return a.nTable}),a=h(d).filter(a).map(function(){var a=h.inArray(this,d);return c[a]}).toArray();b=new b(a)}else b=this;return b});o("table()",function(a){var a=this.tables(a),b=a.context;return b.length?new s(b[0]):a});u("tables().nodes()","table().node()",function(){return this.iterator("table",function(a){return a.nTable},1)});u("tables().body()","table().body()",function(){return this.iterator("table",function(a){return a.nTBody},1)});u("tables().header()",
"table().header()",function(){return this.iterator("table",function(a){return a.nTHead},1)});u("tables().footer()","table().footer()",function(){return this.iterator("table",function(a){return a.nTFoot},1)});u("tables().containers()","table().container()",function(){return this.iterator("table",function(a){return a.nTableWrapper},1)});o("draw()",function(a){return this.iterator("table",function(b){"page"===a?N(b):("string"===typeof a&&(a="full-hold"===a?!1:!0),S(b,!1===a))})});o("page()",function(a){return a===
k?this.page.info().page:this.iterator("table",function(b){Sa(b,a)})});o("page.info()",function(){if(0===this.context.length)return k;var a=this.context[0],b=a._iDisplayStart,c=a.oFeatures.bPaginate?a._iDisplayLength:-1,d=a.fnRecordsDisplay(),e=-1===c;return{page:e?0:Math.floor(b/c),pages:e?1:Math.ceil(d/c),start:b,end:a.fnDisplayEnd(),length:c,recordsTotal:a.fnRecordsTotal(),recordsDisplay:d,serverSide:"ssp"===y(a)}});o("page.len()",function(a){return a===k?0!==this.context.length?this.context[0]._iDisplayLength:
k:this.iterator("table",function(b){Qa(b,a)})});var Sb=function(a,b,c){if(c){var d=new s(a);d.one("draw",function(){c(d.ajax.json())})}if("ssp"==y(a))S(a,b);else{C(a,!0);var e=a.jqXHR;e&&4!==e.readyState&&e.abort();sa(a,[],function(c){na(a);for(var c=ta(a,c),d=0,e=c.length;d<e;d++)M(a,c[d]);S(a,b);C(a,!1)})}};o("ajax.json()",function(){var a=this.context;if(0<a.length)return a[0].json});o("ajax.params()",function(){var a=this.context;if(0<a.length)return a[0].oAjaxData});o("ajax.reload()",function(a,
b){return this.iterator("table",function(c){Sb(c,!1===b,a)})});o("ajax.url()",function(a){var b=this.context;if(a===k){if(0===b.length)return k;b=b[0];return b.ajax?h.isPlainObject(b.ajax)?b.ajax.url:b.ajax:b.sAjaxSource}return this.iterator("table",function(b){h.isPlainObject(b.ajax)?b.ajax.url=a:b.ajax=a})});o("ajax.url().load()",function(a,b){return this.iterator("table",function(c){Sb(c,!1===b,a)})});var Za=function(a,b,c,d,e){var f=[],g,j,i,n,l,m;i=typeof b;if(!b||"string"===i||"function"===
i||b.length===k)b=[b];i=0;for(n=b.length;i<n;i++){j=b[i]&&b[i].split&&!b[i].match(/[\[\(:]/)?b[i].split(","):[b[i]];l=0;for(m=j.length;l<m;l++)(g=c("string"===typeof j[l]?h.trim(j[l]):j[l]))&&g.length&&(f=f.concat(g))}a=x.selector[a];if(a.length){i=0;for(n=a.length;i<n;i++)f=a[i](d,e,f)}return qa(f)},$a=function(a){a||(a={});a.filter&&a.search===k&&(a.search=a.filter);return h.extend({search:"none",order:"current",page:"all"},a)},ab=function(a){for(var b=0,c=a.length;b<c;b++)if(0<a[b].length)return a[0]=
a[b],a[0].length=1,a.length=1,a.context=[a.context[b]],a;a.length=0;return a},Ba=function(a,b){var c,d,e,f=[],g=a.aiDisplay;c=a.aiDisplayMaster;var j=b.search;d=b.order;e=b.page;if("ssp"==y(a))return"removed"===j?[]:W(0,c.length);if("current"==e){c=a._iDisplayStart;for(d=a.fnDisplayEnd();c<d;c++)f.push(g[c])}else if("current"==d||"applied"==d)f="none"==j?c.slice():"applied"==j?g.slice():h.map(c,function(a){return-1===h.inArray(a,g)?a:null});else if("index"==d||"original"==d){c=0;for(d=a.aoData.length;c<
d;c++)"none"==j?f.push(c):(e=h.inArray(c,g),(-1===e&&"removed"==j||0<=e&&"applied"==j)&&f.push(c))}return f};o("rows()",function(a,b){a===k?a="":h.isPlainObject(a)&&(b=a,a="");var b=$a(b),c=this.iterator("table",function(c){var e=b,f;return Za("row",a,function(a){var b=Nb(a);if(b!==null&&!e)return[b];f||(f=Ba(c,e));if(b!==null&&h.inArray(b,f)!==-1)return[b];if(a===null||a===k||a==="")return f;if(typeof a==="function")return h.map(f,function(b){var e=c.aoData[b];return a(b,e._aData,e.nTr)?b:null});
b=Qb(ia(c.aoData,f,"nTr"));if(a.nodeName){if(a._DT_RowIndex!==k)return[a._DT_RowIndex];if(a._DT_CellIndex)return[a._DT_CellIndex.row];b=h(a).closest("*[data-dt-row]");return b.length?[b.data("dt-row")]:[]}if(typeof a==="string"&&a.charAt(0)==="#"){var i=c.aIds[a.replace(/^#/,"")];if(i!==k)return[i.idx]}return h(b).filter(a).map(function(){return this._DT_RowIndex}).toArray()},c,e)},1);c.selector.rows=a;c.selector.opts=b;return c});o("rows().nodes()",function(){return this.iterator("row",function(a,
b){return a.aoData[b].nTr||k},1)});o("rows().data()",function(){return this.iterator(!0,"rows",function(a,b){return ia(a.aoData,b,"_aData")},1)});u("rows().cache()","row().cache()",function(a){return this.iterator("row",function(b,c){var d=b.aoData[c];return"search"===a?d._aFilterData:d._aSortData},1)});u("rows().invalidate()","row().invalidate()",function(a){return this.iterator("row",function(b,c){ca(b,c,a)})});u("rows().indexes()","row().index()",function(){return this.iterator("row",function(a,
b){return b},1)});u("rows().ids()","row().id()",function(a){for(var b=[],c=this.context,d=0,e=c.length;d<e;d++)for(var f=0,g=this[d].length;f<g;f++){var h=c[d].rowIdFn(c[d].aoData[this[d][f]]._aData);b.push((!0===a?"#":"")+h)}return new s(c,b)});u("rows().remove()","row().remove()",function(){var a=this;this.iterator("row",function(b,c,d){var e=b.aoData,f=e[c],g,h,i,n,l;e.splice(c,1);g=0;for(h=e.length;g<h;g++)if(i=e[g],l=i.anCells,null!==i.nTr&&(i.nTr._DT_RowIndex=g),null!==l){i=0;for(n=l.length;i<
n;i++)l[i]._DT_CellIndex.row=g}oa(b.aiDisplayMaster,c);oa(b.aiDisplay,c);oa(a[d],c,!1);0<b._iRecordsDisplay&&b._iRecordsDisplay--;Ra(b);c=b.rowIdFn(f._aData);c!==k&&delete b.aIds[c]});this.iterator("table",function(a){for(var c=0,d=a.aoData.length;c<d;c++)a.aoData[c].idx=c});return this});o("rows.add()",function(a){var b=this.iterator("table",function(b){var c,f,g,h=[];f=0;for(g=a.length;f<g;f++)c=a[f],c.nodeName&&"TR"===c.nodeName.toUpperCase()?h.push(ma(b,c)[0]):h.push(M(b,c));return h},1),c=this.rows(-1);
c.pop();h.merge(c,b);return c});o("row()",function(a,b){return ab(this.rows(a,b))});o("row().data()",function(a){var b=this.context;if(a===k)return b.length&&this.length?b[0].aoData[this[0]]._aData:k;b[0].aoData[this[0]]._aData=a;ca(b[0],this[0],"data");return this});o("row().node()",function(){var a=this.context;return a.length&&this.length?a[0].aoData[this[0]].nTr||null:null});o("row.add()",function(a){a instanceof h&&a.length&&(a=a[0]);var b=this.iterator("table",function(b){return a.nodeName&&
"TR"===a.nodeName.toUpperCase()?ma(b,a)[0]:M(b,a)});return this.row(b[0])});var bb=function(a,b){var c=a.context;if(c.length&&(c=c[0].aoData[b!==k?b:a[0]])&&c._details)c._details.remove(),c._detailsShow=k,c._details=k},Tb=function(a,b){var c=a.context;if(c.length&&a.length){var d=c[0].aoData[a[0]];if(d._details){(d._detailsShow=b)?d._details.insertAfter(d.nTr):d._details.detach();var e=c[0],f=new s(e),g=e.aoData;f.off("draw.dt.DT_details column-visibility.dt.DT_details destroy.dt.DT_details");0<D(g,
"_details").length&&(f.on("draw.dt.DT_details",function(a,b){e===b&&f.rows({page:"current"}).eq(0).each(function(a){a=g[a];a._detailsShow&&a._details.insertAfter(a.nTr)})}),f.on("column-visibility.dt.DT_details",function(a,b){if(e===b)for(var c,d=aa(b),f=0,h=g.length;f<h;f++)c=g[f],c._details&&c._details.children("td[colspan]").attr("colspan",d)}),f.on("destroy.dt.DT_details",function(a,b){if(e===b)for(var c=0,d=g.length;c<d;c++)g[c]._details&&bb(f,c)}))}}};o("row().child()",function(a,b){var c=this.context;
if(a===k)return c.length&&this.length?c[0].aoData[this[0]]._details:k;if(!0===a)this.child.show();else if(!1===a)bb(this);else if(c.length&&this.length){var d=c[0],c=c[0].aoData[this[0]],e=[],f=function(a,b){if(h.isArray(a)||a instanceof h)for(var c=0,k=a.length;c<k;c++)f(a[c],b);else a.nodeName&&"tr"===a.nodeName.toLowerCase()?e.push(a):(c=h("<tr><td/></tr>").addClass(b),h("td",c).addClass(b).html(a)[0].colSpan=aa(d),e.push(c[0]))};f(a,b);c._details&&c._details.detach();c._details=h(e);c._detailsShow&&
c._details.insertAfter(c.nTr)}return this});o(["row().child.show()","row().child().show()"],function(){Tb(this,!0);return this});o(["row().child.hide()","row().child().hide()"],function(){Tb(this,!1);return this});o(["row().child.remove()","row().child().remove()"],function(){bb(this);return this});o("row().child.isShown()",function(){var a=this.context;return a.length&&this.length?a[0].aoData[this[0]]._detailsShow||!1:!1});var bc=/^([^:]+):(name|visIdx|visible)$/,Ub=function(a,b,c,d,e){for(var c=
[],d=0,f=e.length;d<f;d++)c.push(B(a,e[d],b));return c};o("columns()",function(a,b){a===k?a="":h.isPlainObject(a)&&(b=a,a="");var b=$a(b),c=this.iterator("table",function(c){var e=a,f=b,g=c.aoColumns,j=D(g,"sName"),i=D(g,"nTh");return Za("column",e,function(a){var b=Nb(a);if(a==="")return W(g.length);if(b!==null)return[b>=0?b:g.length+b];if(typeof a==="function"){var e=Ba(c,f);return h.map(g,function(b,f){return a(f,Ub(c,f,0,0,e),i[f])?f:null})}var k=typeof a==="string"?a.match(bc):"";if(k)switch(k[2]){case "visIdx":case "visible":b=
parseInt(k[1],10);if(b<0){var m=h.map(g,function(a,b){return a.bVisible?b:null});return[m[m.length+b]]}return[Z(c,b)];case "name":return h.map(j,function(a,b){return a===k[1]?b:null});default:return[]}if(a.nodeName&&a._DT_CellIndex)return[a._DT_CellIndex.column];b=h(i).filter(a).map(function(){return h.inArray(this,i)}).toArray();if(b.length||!a.nodeName)return b;b=h(a).closest("*[data-dt-column]");return b.length?[b.data("dt-column")]:[]},c,f)},1);c.selector.cols=a;c.selector.opts=b;return c});u("columns().header()",
"column().header()",function(){return this.iterator("column",function(a,b){return a.aoColumns[b].nTh},1)});u("columns().footer()","column().footer()",function(){return this.iterator("column",function(a,b){return a.aoColumns[b].nTf},1)});u("columns().data()","column().data()",function(){return this.iterator("column-rows",Ub,1)});u("columns().dataSrc()","column().dataSrc()",function(){return this.iterator("column",function(a,b){return a.aoColumns[b].mData},1)});u("columns().cache()","column().cache()",
function(a){return this.iterator("column-rows",function(b,c,d,e,f){return ia(b.aoData,f,"search"===a?"_aFilterData":"_aSortData",c)},1)});u("columns().nodes()","column().nodes()",function(){return this.iterator("column-rows",function(a,b,c,d,e){return ia(a.aoData,e,"anCells",b)},1)});u("columns().visible()","column().visible()",function(a,b){var c=this.iterator("column",function(b,c){if(a===k)return b.aoColumns[c].bVisible;var f=b.aoColumns,g=f[c],j=b.aoData,i,n,l;if(a!==k&&g.bVisible!==a){if(a){var m=
h.inArray(!0,D(f,"bVisible"),c+1);i=0;for(n=j.length;i<n;i++)l=j[i].nTr,f=j[i].anCells,l&&l.insertBefore(f[c],f[m]||null)}else h(D(b.aoData,"anCells",c)).detach();g.bVisible=a;ea(b,b.aoHeader);ea(b,b.aoFooter);xa(b)}});a!==k&&(this.iterator("column",function(c,e){r(c,null,"column-visibility",[c,e,a,b])}),(b===k||b)&&this.columns.adjust());return c});u("columns().indexes()","column().index()",function(a){return this.iterator("column",function(b,c){return"visible"===a?$(b,c):c},1)});o("columns.adjust()",
function(){return this.iterator("table",function(a){Y(a)},1)});o("column.index()",function(a,b){if(0!==this.context.length){var c=this.context[0];if("fromVisible"===a||"toData"===a)return Z(c,b);if("fromData"===a||"toVisible"===a)return $(c,b)}});o("column()",function(a,b){return ab(this.columns(a,b))});o("cells()",function(a,b,c){h.isPlainObject(a)&&(a.row===k?(c=a,a=null):(c=b,b=null));h.isPlainObject(b)&&(c=b,b=null);if(null===b||b===k)return this.iterator("table",function(b){var d=a,e=$a(c),f=
b.aoData,g=Ba(b,e),j=Qb(ia(f,g,"anCells")),i=h([].concat.apply([],j)),l,n=b.aoColumns.length,m,o,u,s,r,v;return Za("cell",d,function(a){var c=typeof a==="function";if(a===null||a===k||c){m=[];o=0;for(u=g.length;o<u;o++){l=g[o];for(s=0;s<n;s++){r={row:l,column:s};if(c){v=f[l];a(r,B(b,l,s),v.anCells?v.anCells[s]:null)&&m.push(r)}else m.push(r)}}return m}if(h.isPlainObject(a))return[a];c=i.filter(a).map(function(a,b){return{row:b._DT_CellIndex.row,column:b._DT_CellIndex.column}}).toArray();if(c.length||
!a.nodeName)return c;v=h(a).closest("*[data-dt-row]");return v.length?[{row:v.data("dt-row"),column:v.data("dt-column")}]:[]},b,e)});var d=this.columns(b,c),e=this.rows(a,c),f,g,j,i,n,l=this.iterator("table",function(a,b){f=[];g=0;for(j=e[b].length;g<j;g++){i=0;for(n=d[b].length;i<n;i++)f.push({row:e[b][g],column:d[b][i]})}return f},1);h.extend(l.selector,{cols:b,rows:a,opts:c});return l});u("cells().nodes()","cell().node()",function(){return this.iterator("cell",function(a,b,c){return(a=a.aoData[b])&&
a.anCells?a.anCells[c]:k},1)});o("cells().data()",function(){return this.iterator("cell",function(a,b,c){return B(a,b,c)},1)});u("cells().cache()","cell().cache()",function(a){a="search"===a?"_aFilterData":"_aSortData";return this.iterator("cell",function(b,c,d){return b.aoData[c][a][d]},1)});u("cells().render()","cell().render()",function(a){return this.iterator("cell",function(b,c,d){return B(b,c,d,a)},1)});u("cells().indexes()","cell().index()",function(){return this.iterator("cell",function(a,
b,c){return{row:b,column:c,columnVisible:$(a,c)}},1)});u("cells().invalidate()","cell().invalidate()",function(a){return this.iterator("cell",function(b,c,d){ca(b,c,a,d)})});o("cell()",function(a,b,c){return ab(this.cells(a,b,c))});o("cell().data()",function(a){var b=this.context,c=this[0];if(a===k)return b.length&&c.length?B(b[0],c[0].row,c[0].column):k;ib(b[0],c[0].row,c[0].column,a);ca(b[0],c[0].row,"data",c[0].column);return this});o("order()",function(a,b){var c=this.context;if(a===k)return 0!==
c.length?c[0].aaSorting:k;"number"===typeof a?a=[[a,b]]:a.length&&!h.isArray(a[0])&&(a=Array.prototype.slice.call(arguments));return this.iterator("table",function(b){b.aaSorting=a.slice()})});o("order.listener()",function(a,b,c){return this.iterator("table",function(d){La(d,a,b,c)})});o("order.fixed()",function(a){if(!a){var b=this.context,b=b.length?b[0].aaSortingFixed:k;return h.isArray(b)?{pre:b}:b}return this.iterator("table",function(b){b.aaSortingFixed=h.extend(!0,{},a)})});o(["columns().order()",
"column().order()"],function(a){var b=this;return this.iterator("table",function(c,d){var e=[];h.each(b[d],function(b,c){e.push([c,a])});c.aaSorting=e})});o("search()",function(a,b,c,d){var e=this.context;return a===k?0!==e.length?e[0].oPreviousSearch.sSearch:k:this.iterator("table",function(e){e.oFeatures.bFilter&&fa(e,h.extend({},e.oPreviousSearch,{sSearch:a+"",bRegex:null===b?!1:b,bSmart:null===c?!0:c,bCaseInsensitive:null===d?!0:d}),1)})});u("columns().search()","column().search()",function(a,
b,c,d){return this.iterator("column",function(e,f){var g=e.aoPreSearchCols;if(a===k)return g[f].sSearch;e.oFeatures.bFilter&&(h.extend(g[f],{sSearch:a+"",bRegex:null===b?!1:b,bSmart:null===c?!0:c,bCaseInsensitive:null===d?!0:d}),fa(e,e.oPreviousSearch,1))})});o("state()",function(){return this.context.length?this.context[0].oSavedState:null});o("state.clear()",function(){return this.iterator("table",function(a){a.fnStateSaveCallback.call(a.oInstance,a,{})})});o("state.loaded()",function(){return this.context.length?
this.context[0].oLoadedState:null});o("state.save()",function(){return this.iterator("table",function(a){xa(a)})});m.versionCheck=m.fnVersionCheck=function(a){for(var b=m.version.split("."),a=a.split("."),c,d,e=0,f=a.length;e<f;e++)if(c=parseInt(b[e],10)||0,d=parseInt(a[e],10)||0,c!==d)return c>d;return!0};m.isDataTable=m.fnIsDataTable=function(a){var b=h(a).get(0),c=!1;if(a instanceof m.Api)return!0;h.each(m.settings,function(a,e){var f=e.nScrollHead?h("table",e.nScrollHead)[0]:null,g=e.nScrollFoot?
h("table",e.nScrollFoot)[0]:null;if(e.nTable===b||f===b||g===b)c=!0});return c};m.tables=m.fnTables=function(a){var b=!1;h.isPlainObject(a)&&(b=a.api,a=a.visible);var c=h.map(m.settings,function(b){if(!a||a&&h(b.nTable).is(":visible"))return b.nTable});return b?new s(c):c};m.camelToHungarian=I;o("$()",function(a,b){var c=this.rows(b).nodes(),c=h(c);return h([].concat(c.filter(a).toArray(),c.find(a).toArray()))});h.each(["on","one","off"],function(a,b){o(b+"()",function(){var a=Array.prototype.slice.call(arguments);
a[0]=h.map(a[0].split(/\s/),function(a){return!a.match(/\.dt\b/)?a+".dt":a}).join(" ");var d=h(this.tables().nodes());d[b].apply(d,a);return this})});o("clear()",function(){return this.iterator("table",function(a){na(a)})});o("settings()",function(){return new s(this.context,this.context)});o("init()",function(){var a=this.context;return a.length?a[0].oInit:null});o("data()",function(){return this.iterator("table",function(a){return D(a.aoData,"_aData")}).flatten()});o("destroy()",function(a){a=a||
!1;return this.iterator("table",function(b){var c=b.nTableWrapper.parentNode,d=b.oClasses,e=b.nTable,f=b.nTBody,g=b.nTHead,j=b.nTFoot,i=h(e),f=h(f),k=h(b.nTableWrapper),l=h.map(b.aoData,function(a){return a.nTr}),o;b.bDestroying=!0;r(b,"aoDestroyCallback","destroy",[b]);a||(new s(b)).columns().visible(!0);k.off(".DT").find(":not(tbody *)").off(".DT");h(E).off(".DT-"+b.sInstance);e!=g.parentNode&&(i.children("thead").detach(),i.append(g));j&&e!=j.parentNode&&(i.children("tfoot").detach(),i.append(j));
b.aaSorting=[];b.aaSortingFixed=[];wa(b);h(l).removeClass(b.asStripeClasses.join(" "));h("th, td",g).removeClass(d.sSortable+" "+d.sSortableAsc+" "+d.sSortableDesc+" "+d.sSortableNone);f.children().detach();f.append(l);g=a?"remove":"detach";i[g]();k[g]();!a&&c&&(c.insertBefore(e,b.nTableReinsertBefore),i.css("width",b.sDestroyWidth).removeClass(d.sTable),(o=b.asDestroyStripes.length)&&f.children().each(function(a){h(this).addClass(b.asDestroyStripes[a%o])}));c=h.inArray(b,m.settings);-1!==c&&m.settings.splice(c,
1)})});h.each(["column","row","cell"],function(a,b){o(b+"s().every()",function(a){var d=this.selector.opts,e=this;return this.iterator(b,function(f,g,h,i,n){a.call(e[b](g,"cell"===b?h:d,"cell"===b?d:k),g,h,i,n)})})});o("i18n()",function(a,b,c){var d=this.context[0],a=Q(a)(d.oLanguage);a===k&&(a=b);c!==k&&h.isPlainObject(a)&&(a=a[c]!==k?a[c]:a._);return a.replace("%d",c)});m.version="1.10.16";m.settings=[];m.models={};m.models.oSearch={bCaseInsensitive:!0,sSearch:"",bRegex:!1,bSmart:!0};m.models.oRow=
{nTr:null,anCells:null,_aData:[],_aSortData:null,_aFilterData:null,_sFilterRow:null,_sRowStripe:"",src:null,idx:-1};m.models.oColumn={idx:null,aDataSort:null,asSorting:null,bSearchable:null,bSortable:null,bVisible:null,_sManualType:null,_bAttrSrc:!1,fnCreatedCell:null,fnGetData:null,fnSetData:null,mData:null,mRender:null,nTh:null,nTf:null,sClass:null,sContentPadding:null,sDefaultContent:null,sName:null,sSortDataType:"std",sSortingClass:null,sSortingClassJUI:null,sTitle:null,sType:null,sWidth:null,
sWidthOrig:null};m.defaults={aaData:null,aaSorting:[[0,"asc"]],aaSortingFixed:[],ajax:null,aLengthMenu:[10,25,50,100],aoColumns:null,aoColumnDefs:null,aoSearchCols:[],asStripeClasses:null,bAutoWidth:!0,bDeferRender:!1,bDestroy:!1,bFilter:!0,bInfo:!0,bLengthChange:!0,bPaginate:!0,bProcessing:!1,bRetrieve:!1,bScrollCollapse:!1,bServerSide:!1,bSort:!0,bSortMulti:!0,bSortCellsTop:!1,bSortClasses:!0,bStateSave:!1,fnCreatedRow:null,fnDrawCallback:null,fnFooterCallback:null,fnFormatNumber:function(a){return a.toString().replace(/\B(?=(\d{3})+(?!\d))/g,
this.oLanguage.sThousands)},fnHeaderCallback:null,fnInfoCallback:null,fnInitComplete:null,fnPreDrawCallback:null,fnRowCallback:null,fnServerData:null,fnServerParams:null,fnStateLoadCallback:function(a){try{return JSON.parse((-1===a.iStateDuration?sessionStorage:localStorage).getItem("DataTables_"+a.sInstance+"_"+location.pathname))}catch(b){}},fnStateLoadParams:null,fnStateLoaded:null,fnStateSaveCallback:function(a,b){try{(-1===a.iStateDuration?sessionStorage:localStorage).setItem("DataTables_"+a.sInstance+
"_"+location.pathname,JSON.stringify(b))}catch(c){}},fnStateSaveParams:null,iStateDuration:7200,iDeferLoading:null,iDisplayLength:10,iDisplayStart:0,iTabIndex:0,oClasses:{},oLanguage:{oAria:{sSortAscending:": activate to sort column ascending",sSortDescending:": activate to sort column descending"},oPaginate:{sFirst:"First",sLast:"Last",sNext:"Next",sPrevious:"Previous"},sEmptyTable:"No data available in table",sInfo:"Showing _START_ to _END_ of _TOTAL_ entries",sInfoEmpty:"Showing 0 to 0 of 0 entries",
sInfoFiltered:"(filtered from _MAX_ total entries)",sInfoPostFix:"",sDecimal:"",sThousands:",",sLengthMenu:"Show _MENU_ entries",sLoadingRecords:"Loading...",sProcessing:"Processing...",sSearch:"Search:",sSearchPlaceholder:"",sUrl:"",sZeroRecords:"No matching records found"},oSearch:h.extend({},m.models.oSearch),sAjaxDataProp:"data",sAjaxSource:null,sDom:"lfrtip",searchDelay:null,sPaginationType:"simple_numbers",sScrollX:"",sScrollXInner:"",sScrollY:"",sServerMethod:"GET",renderer:null,rowId:"DT_RowId"};
X(m.defaults);m.defaults.column={aDataSort:null,iDataSort:-1,asSorting:["asc","desc"],bSearchable:!0,bSortable:!0,bVisible:!0,fnCreatedCell:null,mData:null,mRender:null,sCellType:"td",sClass:"",sContentPadding:"",sDefaultContent:null,sName:"",sSortDataType:"std",sTitle:null,sType:null,sWidth:null};X(m.defaults.column);m.models.oSettings={oFeatures:{bAutoWidth:null,bDeferRender:null,bFilter:null,bInfo:null,bLengthChange:null,bPaginate:null,bProcessing:null,bServerSide:null,bSort:null,bSortMulti:null,
bSortClasses:null,bStateSave:null},oScroll:{bCollapse:null,iBarWidth:0,sX:null,sXInner:null,sY:null},oLanguage:{fnInfoCallback:null},oBrowser:{bScrollOversize:!1,bScrollbarLeft:!1,bBounding:!1,barWidth:0},ajax:null,aanFeatures:[],aoData:[],aiDisplay:[],aiDisplayMaster:[],aIds:{},aoColumns:[],aoHeader:[],aoFooter:[],oPreviousSearch:{},aoPreSearchCols:[],aaSorting:null,aaSortingFixed:[],asStripeClasses:null,asDestroyStripes:[],sDestroyWidth:0,aoRowCallback:[],aoHeaderCallback:[],aoFooterCallback:[],
aoDrawCallback:[],aoRowCreatedCallback:[],aoPreDrawCallback:[],aoInitComplete:[],aoStateSaveParams:[],aoStateLoadParams:[],aoStateLoaded:[],sTableId:"",nTable:null,nTHead:null,nTFoot:null,nTBody:null,nTableWrapper:null,bDeferLoading:!1,bInitialised:!1,aoOpenRows:[],sDom:null,searchDelay:null,sPaginationType:"two_button",iStateDuration:0,aoStateSave:[],aoStateLoad:[],oSavedState:null,oLoadedState:null,sAjaxSource:null,sAjaxDataProp:null,bAjaxDataGet:!0,jqXHR:null,json:k,oAjaxData:k,fnServerData:null,
aoServerParams:[],sServerMethod:null,fnFormatNumber:null,aLengthMenu:null,iDraw:0,bDrawing:!1,iDrawError:-1,_iDisplayLength:10,_iDisplayStart:0,_iRecordsTotal:0,_iRecordsDisplay:0,oClasses:{},bFiltered:!1,bSorted:!1,bSortCellsTop:null,oInit:null,aoDestroyCallback:[],fnRecordsTotal:function(){return"ssp"==y(this)?1*this._iRecordsTotal:this.aiDisplayMaster.length},fnRecordsDisplay:function(){return"ssp"==y(this)?1*this._iRecordsDisplay:this.aiDisplay.length},fnDisplayEnd:function(){var a=this._iDisplayLength,
b=this._iDisplayStart,c=b+a,d=this.aiDisplay.length,e=this.oFeatures,f=e.bPaginate;return e.bServerSide?!1===f||-1===a?b+d:Math.min(b+a,this._iRecordsDisplay):!f||c>d||-1===a?d:c},oInstance:null,sInstance:null,iTabIndex:0,nScrollHead:null,nScrollFoot:null,aLastSort:[],oPlugins:{},rowIdFn:null,rowId:null};m.ext=x={buttons:{},classes:{},builder:"-source-",errMode:"alert",feature:[],search:[],selector:{cell:[],column:[],row:[]},internal:{},legacy:{ajax:null},pager:{},renderer:{pageButton:{},header:{}},
order:{},type:{detect:[],search:{},order:{}},_unique:0,fnVersionCheck:m.fnVersionCheck,iApiIndex:0,oJUIClasses:{},sVersion:m.version};h.extend(x,{afnFiltering:x.search,aTypes:x.type.detect,ofnSearch:x.type.search,oSort:x.type.order,afnSortData:x.order,aoFeatures:x.feature,oApi:x.internal,oStdClasses:x.classes,oPagination:x.pager});h.extend(m.ext.classes,{sTable:"dataTable",sNoFooter:"no-footer",sPageButton:"paginate_button",sPageButtonActive:"current",sPageButtonDisabled:"disabled",sStripeOdd:"odd",
sStripeEven:"even",sRowEmpty:"dataTables_empty",sWrapper:"dataTables_wrapper",sFilter:"dataTables_filter",sInfo:"dataTables_info",sPaging:"dataTables_paginate paging_",sLength:"dataTables_length",sProcessing:"dataTables_processing",sSortAsc:"sorting_asc",sSortDesc:"sorting_desc",sSortable:"sorting",sSortableAsc:"sorting_asc_disabled",sSortableDesc:"sorting_desc_disabled",sSortableNone:"sorting_disabled",sSortColumn:"sorting_",sFilterInput:"",sLengthSelect:"",sScrollWrapper:"dataTables_scroll",sScrollHead:"dataTables_scrollHead",
sScrollHeadInner:"dataTables_scrollHeadInner",sScrollBody:"dataTables_scrollBody",sScrollFoot:"dataTables_scrollFoot",sScrollFootInner:"dataTables_scrollFootInner",sHeaderTH:"",sFooterTH:"",sSortJUIAsc:"",sSortJUIDesc:"",sSortJUI:"",sSortJUIAscAllowed:"",sSortJUIDescAllowed:"",sSortJUIWrapper:"",sSortIcon:"",sJUIHeader:"",sJUIFooter:""});var Kb=m.ext.pager;h.extend(Kb,{simple:function(){return["previous","next"]},full:function(){return["first","previous","next","last"]},numbers:function(a,b){return[ha(a,
b)]},simple_numbers:function(a,b){return["previous",ha(a,b),"next"]},full_numbers:function(a,b){return["first","previous",ha(a,b),"next","last"]},first_last_numbers:function(a,b){return["first",ha(a,b),"last"]},_numbers:ha,numbers_length:7});h.extend(!0,m.ext.renderer,{pageButton:{_:function(a,b,c,d,e,f){var g=a.oClasses,j=a.oLanguage.oPaginate,i=a.oLanguage.oAria.paginate||{},n,l,m=0,o=function(b,d){var k,s,u,r,v=function(b){Sa(a,b.data.action,true)};k=0;for(s=d.length;k<s;k++){r=d[k];if(h.isArray(r)){u=
h("<"+(r.DT_el||"div")+"/>").appendTo(b);o(u,r)}else{n=null;l="";switch(r){case "ellipsis":b.append('<span class="ellipsis">&#x2026;</span>');break;case "first":n=j.sFirst;l=r+(e>0?"":" "+g.sPageButtonDisabled);break;case "previous":n=j.sPrevious;l=r+(e>0?"":" "+g.sPageButtonDisabled);break;case "next":n=j.sNext;l=r+(e<f-1?"":" "+g.sPageButtonDisabled);break;case "last":n=j.sLast;l=r+(e<f-1?"":" "+g.sPageButtonDisabled);break;default:n=r+1;l=e===r?g.sPageButtonActive:""}if(n!==null){u=h("<a>",{"class":g.sPageButton+
" "+l,"aria-controls":a.sTableId,"aria-label":i[r],"data-dt-idx":m,tabindex:a.iTabIndex,id:c===0&&typeof r==="string"?a.sTableId+"_"+r:null}).html(n).appendTo(b);Va(u,{action:r},v);m++}}}},s;try{s=h(b).find(G.activeElement).data("dt-idx")}catch(u){}o(h(b).empty(),d);s!==k&&h(b).find("[data-dt-idx="+s+"]").focus()}}});h.extend(m.ext.type.detect,[function(a,b){var c=b.oLanguage.sDecimal;return Ya(a,c)?"num"+c:null},function(a){if(a&&!(a instanceof Date)&&!Zb.test(a))return null;var b=Date.parse(a);
return null!==b&&!isNaN(b)||L(a)?"date":null},function(a,b){var c=b.oLanguage.sDecimal;return Ya(a,c,!0)?"num-fmt"+c:null},function(a,b){var c=b.oLanguage.sDecimal;return Pb(a,c)?"html-num"+c:null},function(a,b){var c=b.oLanguage.sDecimal;return Pb(a,c,!0)?"html-num-fmt"+c:null},function(a){return L(a)||"string"===typeof a&&-1!==a.indexOf("<")?"html":null}]);h.extend(m.ext.type.search,{html:function(a){return L(a)?a:"string"===typeof a?a.replace(Mb," ").replace(Aa,""):""},string:function(a){return L(a)?
a:"string"===typeof a?a.replace(Mb," "):a}});var za=function(a,b,c,d){if(0!==a&&(!a||"-"===a))return-Infinity;b&&(a=Ob(a,b));a.replace&&(c&&(a=a.replace(c,"")),d&&(a=a.replace(d,"")));return 1*a};h.extend(x.type.order,{"date-pre":function(a){return Date.parse(a)||-Infinity},"html-pre":function(a){return L(a)?"":a.replace?a.replace(/<.*?>/g,"").toLowerCase():a+""},"string-pre":function(a){return L(a)?"":"string"===typeof a?a.toLowerCase():!a.toString?"":a.toString()},"string-asc":function(a,b){return a<
b?-1:a>b?1:0},"string-desc":function(a,b){return a<b?1:a>b?-1:0}});cb("");h.extend(!0,m.ext.renderer,{header:{_:function(a,b,c,d){h(a.nTable).on("order.dt.DT",function(e,f,g,h){if(a===f){e=c.idx;b.removeClass(c.sSortingClass+" "+d.sSortAsc+" "+d.sSortDesc).addClass(h[e]=="asc"?d.sSortAsc:h[e]=="desc"?d.sSortDesc:c.sSortingClass)}})},jqueryui:function(a,b,c,d){h("<div/>").addClass(d.sSortJUIWrapper).append(b.contents()).append(h("<span/>").addClass(d.sSortIcon+" "+c.sSortingClassJUI)).appendTo(b);
h(a.nTable).on("order.dt.DT",function(e,f,g,h){if(a===f){e=c.idx;b.removeClass(d.sSortAsc+" "+d.sSortDesc).addClass(h[e]=="asc"?d.sSortAsc:h[e]=="desc"?d.sSortDesc:c.sSortingClass);b.find("span."+d.sSortIcon).removeClass(d.sSortJUIAsc+" "+d.sSortJUIDesc+" "+d.sSortJUI+" "+d.sSortJUIAscAllowed+" "+d.sSortJUIDescAllowed).addClass(h[e]=="asc"?d.sSortJUIAsc:h[e]=="desc"?d.sSortJUIDesc:c.sSortingClassJUI)}})}}});var Vb=function(a){return"string"===typeof a?a.replace(/</g,"&lt;").replace(/>/g,"&gt;").replace(/"/g,
"&quot;"):a};m.render={number:function(a,b,c,d,e){return{display:function(f){if("number"!==typeof f&&"string"!==typeof f)return f;var g=0>f?"-":"",h=parseFloat(f);if(isNaN(h))return Vb(f);h=h.toFixed(c);f=Math.abs(h);h=parseInt(f,10);f=c?b+(f-h).toFixed(c).substring(2):"";return g+(d||"")+h.toString().replace(/\B(?=(\d{3})+(?!\d))/g,a)+f+(e||"")}}},text:function(){return{display:Vb}}};h.extend(m.ext.internal,{_fnExternApiFunc:Lb,_fnBuildAjax:sa,_fnAjaxUpdate:kb,_fnAjaxParameters:tb,_fnAjaxUpdateDraw:ub,
_fnAjaxDataSrc:ta,_fnAddColumn:Da,_fnColumnOptions:ja,_fnAdjustColumnSizing:Y,_fnVisibleToColumnIndex:Z,_fnColumnIndexToVisible:$,_fnVisbleColumns:aa,_fnGetColumns:la,_fnColumnTypes:Fa,_fnApplyColumnDefs:hb,_fnHungarianMap:X,_fnCamelToHungarian:I,_fnLanguageCompat:Ca,_fnBrowserDetect:fb,_fnAddData:M,_fnAddTr:ma,_fnNodeToDataIndex:function(a,b){return b._DT_RowIndex!==k?b._DT_RowIndex:null},_fnNodeToColumnIndex:function(a,b,c){return h.inArray(c,a.aoData[b].anCells)},_fnGetCellData:B,_fnSetCellData:ib,
_fnSplitObjNotation:Ia,_fnGetObjectDataFn:Q,_fnSetObjectDataFn:R,_fnGetDataMaster:Ja,_fnClearTable:na,_fnDeleteIndex:oa,_fnInvalidate:ca,_fnGetRowElements:Ha,_fnCreateTr:Ga,_fnBuildHead:jb,_fnDrawHead:ea,_fnDraw:N,_fnReDraw:S,_fnAddOptionsHtml:mb,_fnDetectHeader:da,_fnGetUniqueThs:ra,_fnFeatureHtmlFilter:ob,_fnFilterComplete:fa,_fnFilterCustom:xb,_fnFilterColumn:wb,_fnFilter:vb,_fnFilterCreateSearch:Oa,_fnEscapeRegex:Pa,_fnFilterData:yb,_fnFeatureHtmlInfo:rb,_fnUpdateInfo:Bb,_fnInfoMacros:Cb,_fnInitialise:ga,
_fnInitComplete:ua,_fnLengthChange:Qa,_fnFeatureHtmlLength:nb,_fnFeatureHtmlPaginate:sb,_fnPageChange:Sa,_fnFeatureHtmlProcessing:pb,_fnProcessingDisplay:C,_fnFeatureHtmlTable:qb,_fnScrollDraw:ka,_fnApplyToChildren:H,_fnCalculateColumnWidths:Ea,_fnThrottle:Na,_fnConvertToWidth:Db,_fnGetWidestNode:Eb,_fnGetMaxLenString:Fb,_fnStringToCss:v,_fnSortFlatten:V,_fnSort:lb,_fnSortAria:Hb,_fnSortListener:Ua,_fnSortAttachListener:La,_fnSortingClasses:wa,_fnSortData:Gb,_fnSaveState:xa,_fnLoadState:Ib,_fnSettingsFromNode:ya,
_fnLog:J,_fnMap:F,_fnBindAction:Va,_fnCallbackReg:z,_fnCallbackFire:r,_fnLengthOverflow:Ra,_fnRenderer:Ma,_fnDataSource:y,_fnRowAttributes:Ka,_fnCalculateEnd:function(){}});h.fn.dataTable=m;m.$=h;h.fn.dataTableSettings=m.settings;h.fn.dataTableExt=m.ext;h.fn.DataTable=function(a){return h(this).dataTable(a).api()};h.each(m,function(a,b){h.fn.DataTable[a]=b});return h.fn.dataTable});
"></script>
<link href="data:text/css;charset=utf-8,%0A%2Econtainer%2Dfluid%2Ecrosstalk%2Dbscols%20%7B%0Amargin%2Dleft%3A%20%2D30px%3B%0Amargin%2Dright%3A%20%2D30px%3B%0Awhite%2Dspace%3A%20normal%3B%0A%7D%0A%0Abody%20%3E%20%2Econtainer%2Dfluid%2Ecrosstalk%2Dbscols%20%7B%0Amargin%2Dleft%3A%20auto%3B%0Amargin%2Dright%3A%20auto%3B%0A%7D%0A%2Ecrosstalk%2Dinput%2Dcheckboxgroup%20%2Ecrosstalk%2Doptions%2Dgroup%20%2Ecrosstalk%2Doptions%2Dcolumn%20%7B%0Adisplay%3A%20inline%2Dblock%3B%0Apadding%2Dright%3A%2012px%3B%0Avertical%2Dalign%3A%20top%3B%0A%7D%0A%40media%20only%20screen%20and%20%28max%2Dwidth%3A480px%29%20%7B%0A%2Ecrosstalk%2Dinput%2Dcheckboxgroup%20%2Ecrosstalk%2Doptions%2Dgroup%20%2Ecrosstalk%2Doptions%2Dcolumn%20%7B%0Adisplay%3A%20block%3B%0Apadding%2Dright%3A%20inherit%3B%0A%7D%0A%7D%0A" rel="stylesheet" />
<script src="data:application/x-javascript;base64,!function a(b,c,d){function e(g,h){if(!c[g]){if(!b[g]){var i="function"==typeof require&&require;if(!h&&i)return i(g,!0);if(f)return f(g,!0);var j=new Error("Cannot find module '"+g+"'");throw j.code="MODULE_NOT_FOUND",j}var k=c[g]={exports:{}};b[g][0].call(k.exports,function(a){var c=b[g][1][a];return e(c?c:a)},k,k.exports,a,b,c,d)}return c[g].exports}for(var f="function"==typeof require&&require,g=0;g<d.length;g++)e(d[g]);return e}({1:[function(a,b,c){"use strict";function d(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}Object.defineProperty(c,"__esModule",{value:!0});var e=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),f=function(){function a(){d(this,a),this._types={},this._seq=0}return e(a,[{key:"on",value:function(a,b){var c=this._types[a];c||(c=this._types[a]={});var d="sub"+this._seq++;return c[d]=b,d}},{key:"off",value:function(a,b){var c=this._types[a];if("function"==typeof b){for(var d in c)if(c.hasOwnProperty(d)&&c[d]===b)return delete c[d],d;return!1}if("string"==typeof b)return!(!c||!c[b])&&(delete c[b],b);throw new Error("Unexpected type for listener")}},{key:"trigger",value:function(a,b,c){var d=this._types[a];for(var e in d)d.hasOwnProperty(e)&&d[e].call(c,b)}}]),a}();c.default=f},{}],2:[function(a,b,c){"use strict";function d(a){if(a&&a.__esModule)return a;var b={};if(null!=a)for(var c in a)Object.prototype.hasOwnProperty.call(a,c)&&(b[c]=a[c]);return b.default=a,b}function e(a){return a&&a.__esModule?a:{default:a}}function f(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}function g(a){var b=a.var("filterset"),c=b.get();return c||(c=new m.default,b.set(c)),c}function h(){return r++}Object.defineProperty(c,"__esModule",{value:!0}),c.FilterHandle=void 0;var i=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),j=a("./events"),k=e(j),l=a("./filterset"),m=e(l),n=a("./group"),o=e(n),p=a("./util"),q=d(p),r=1;c.FilterHandle=function(){function a(b,c){f(this,a),this._eventRelay=new k.default,this._emitter=new q.SubscriptionTracker(this._eventRelay),this._group=null,this._filterSet=null,this._filterVar=null,this._varOnChangeSub=null,this._extraInfo=q.extend({sender:this},c),this._id="filter"+h(),this.setGroup(b)}return i(a,[{key:"setGroup",value:function(a){var b=this;if(this._group!==a&&(this._group||a)&&(this._filterVar&&(this._filterVar.off("change",this._varOnChangeSub),this.clear(),this._varOnChangeSub=null,this._filterVar=null,this._filterSet=null),this._group=a,a)){a=(0,o.default)(a),this._filterSet=g(a),this._filterVar=(0,o.default)(a).var("filter");var c=this._filterVar.on("change",function(a){b._eventRelay.trigger("change",a,b)});this._varOnChangeSub=c}}},{key:"_mergeExtraInfo",value:function(a){return q.extend({},this._extraInfo?this._extraInfo:null,a?a:null)}},{key:"close",value:function(){this._emitter.removeAllListeners(),this.clear(),this.setGroup(null)}},{key:"clear",value:function(a){this._filterSet&&(this._filterSet.clear(this._id),this._onChange(a))}},{key:"set",value:function(a,b){this._filterSet&&(this._filterSet.update(this._id,a),this._onChange(b))}},{key:"on",value:function(a,b){return this._emitter.on(a,b)}},{key:"off",value:function(a,b){return this._emitter.off(a,b)}},{key:"_onChange",value:function(a){this._filterSet&&this._filterVar.set(this._filterSet.value,this._mergeExtraInfo(a))}},{key:"filteredKeys",get:function(){return this._filterSet?this._filterSet.value:null}}]),a}()},{"./events":1,"./filterset":3,"./group":4,"./util":11}],3:[function(a,b,c){"use strict";function d(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}function e(a,b){return a===b?0:a<b?-1:a>b?1:void 0}Object.defineProperty(c,"__esModule",{value:!0});var f=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),g=a("./util"),h=function(){function a(){d(this,a),this.reset()}return f(a,[{key:"reset",value:function(){this._handles={},this._keys={},this._value=null,this._activeHandles=0}},{key:"update",value:function(a,b){null!==b&&(b=b.slice(0),b.sort(e));var c=(0,g.diffSortedLists)(this._handles[a],b),d=c.added,f=c.removed;this._handles[a]=b;for(var h=0;h<d.length;h++)this._keys[d[h]]=(this._keys[d[h]]||0)+1;for(var i=0;i<f.length;i++)this._keys[f[i]]--;this._updateValue(b)}},{key:"_updateValue",value:function(){var a=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this._allKeys,b=Object.keys(this._handles).length;if(0===b)this._value=null;else{this._value=[];for(var c=0;c<a.length;c++){var d=this._keys[a[c]];d===b&&this._value.push(a[c])}}}},{key:"clear",value:function(a){if("undefined"!=typeof this._handles[a]){var b=this._handles[a];b||(b=[]);for(var c=0;c<b.length;c++)this._keys[b[c]]--;delete this._handles[a],this._updateValue()}}},{key:"value",get:function(){return this._value}},{key:"_allKeys",get:function(){var a=Object.keys(this._keys);return a.sort(e),a}}]),a}();c.default=h},{"./util":11}],4:[function(a,b,c){(function(b){"use strict";function d(a){return a&&a.__esModule?a:{default:a}}function e(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}function f(a){if(a&&"string"==typeof a)return k.hasOwnProperty(a)||(k[a]=new l(a)),k[a];if("object"===("undefined"==typeof a?"undefined":h(a))&&a._vars&&a.var)return a;if(Array.isArray(a)&&1==a.length&&"string"==typeof a[0])return f(a[0]);throw new Error("Invalid groupName argument")}Object.defineProperty(c,"__esModule",{value:!0});var g=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),h="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(a){return typeof a}:function(a){return a&&"function"==typeof Symbol&&a.constructor===Symbol&&a!==Symbol.prototype?"symbol":typeof a};c.default=f;var i=a("./var"),j=d(i);b.__crosstalk_groups=b.__crosstalk_groups||{};var k=b.__crosstalk_groups,l=function(){function a(b){e(this,a),this.name=b,this._vars={}}return g(a,[{key:"var",value:function(a){if(!a||"string"!=typeof a)throw new Error("Invalid var name");return this._vars.hasOwnProperty(a)||(this._vars[a]=new j.default(this,a)),this._vars[a]}},{key:"has",value:function(a){if(!a||"string"!=typeof a)throw new Error("Invalid var name");return this._vars.hasOwnProperty(a)}}]),a}()}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./var":12}],5:[function(a,b,c){(function(b){"use strict";function d(a){return a&&a.__esModule?a:{default:a}}function e(a){return k.var(a)}function f(a){return k.has(a)}Object.defineProperty(c,"__esModule",{value:!0});var g=a("./group"),h=d(g),i=a("./selection"),j=a("./filter");a("./input"),a("./input_selectize"),a("./input_checkboxgroup"),a("./input_slider");var k=(0,h.default)("default");b.Shiny&&b.Shiny.addCustomMessageHandler("update-client-value",function(a){"string"==typeof a.group?(0,h.default)(a.group).var(a.name).set(a.value):e(a.name).set(a.value)});var l={group:h.default,var:e,has:f,SelectionHandle:i.SelectionHandle,FilterHandle:j.FilterHandle};c.default=l,b.crosstalk=l}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./group":4,"./input":6,"./input_checkboxgroup":7,"./input_selectize":8,"./input_slider":9,"./selection":10}],6:[function(a,b,c){(function(a){"use strict";function b(b){i[b.className]=b,a.document&&"complete"!==a.document.readyState?h(function(){d()}):a.document&&setTimeout(d,100)}function d(){Object.keys(i).forEach(function(a){var b=i[a];h("."+b.className).not(".crosstalk-input-bound").each(function(a,c){g(b,c)})})}function e(a){return a.replace(/([!"#$%&'()*+,.\/:;<=>?@\[\\\]^`{|}~])/g,"\\$1")}function f(a){var b=h(a);Object.keys(i).forEach(function(c){if(b.hasClass(c)&&!b.hasClass("crosstalk-input-bound")){var d=i[c];g(d,a)}})}function g(a,b){var c=h(b).find("script[type='application/json'][data-for='"+e(b.id)+"']"),d=JSON.parse(c[0].innerText),f=a.factory(b,d);h(b).data("crosstalk-instance",f),h(b).addClass("crosstalk-input-bound")}Object.defineProperty(c,"__esModule",{value:!0}),c.register=b;var h=a.jQuery,i={};a.Shiny&&!function(){var b=new a.Shiny.InputBinding,c=a.jQuery;c.extend(b,{find:function(a){return c(a).find(".crosstalk-input")},initialize:function(a){c(a).hasClass("crosstalk-input-bound")||f(a)},getId:function(a){return a.id},getValue:function(a){},setValue:function(a,b){},receiveMessage:function(a,b){},subscribe:function(a,b){c(a).data("crosstalk-instance").resume()},unsubscribe:function(a){c(a).data("crosstalk-instance").suspend()}}),a.Shiny.inputBindings.register(b,"crosstalk.inputBinding")}()}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{}],7:[function(a,b,c){(function(b){"use strict";function c(a){if(a&&a.__esModule)return a;var b={};if(null!=a)for(var c in a)Object.prototype.hasOwnProperty.call(a,c)&&(b[c]=a[c]);return b.default=a,b}var d=a("./input"),e=c(d),f=a("./filter"),g=b.jQuery;e.register({className:"crosstalk-input-checkboxgroup",factory:function(a,b){var c=new f.FilterHandle(b.group),d=void 0,e=g(a);return e.on("change","input[type='checkbox']",function(){var a=e.find("input[type='checkbox']:checked");0===a.length?(d=null,c.clear()):!function(){var e={};a.each(function(){b.map[this.value].forEach(function(a){e[a]=!0})});var f=Object.keys(e);f.sort(),d=f,c.set(f)}()}),{suspend:function(){c.clear()},resume:function(){d&&c.set(d)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6}],8:[function(a,b,c){(function(b){"use strict";function c(a){if(a&&a.__esModule)return a;var b={};if(null!=a)for(var c in a)Object.prototype.hasOwnProperty.call(a,c)&&(b[c]=a[c]);return b.default=a,b}var d=a("./input"),e=c(d),f=a("./util"),g=c(f),h=a("./filter"),i=b.jQuery;e.register({className:"crosstalk-input-select",factory:function(a,b){var c=[{value:"",label:"(All)"}],d=g.dataframeToD3(b.items),e={options:c.concat(d),valueField:"value",labelField:"label",searchField:"label"},f=i(a).find("select")[0],j=i(f).selectize(e)[0].selectize,k=new h.FilterHandle(b.group),l=void 0;return j.on("change",function(){0===j.items.length?(l=null,k.clear()):!function(){var a={};j.items.forEach(function(c){b.map[c].forEach(function(b){a[b]=!0})});var c=Object.keys(a);c.sort(),l=c,k.set(c)}()}),{suspend:function(){k.clear()},resume:function(){l&&k.set(l)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6,"./util":11}],9:[function(a,b,c){(function(b){"use strict";function c(a){if(a&&a.__esModule)return a;var b={};if(null!=a)for(var c in a)Object.prototype.hasOwnProperty.call(a,c)&&(b[c]=a[c]);return b.default=a,b}function d(a,b){for(var c=a.toString();c.length<b;)c="0"+c;return c}function e(a){return a instanceof Date?a.getUTCFullYear()+"-"+d(a.getUTCMonth()+1,2)+"-"+d(a.getUTCDate(),2):null}var f=function(){function a(a,b){var c=[],d=!0,e=!1,f=void 0;try{for(var g,h=a[Symbol.iterator]();!(d=(g=h.next()).done)&&(c.push(g.value),!b||c.length!==b);d=!0);}catch(a){e=!0,f=a}finally{try{!d&&h.return&&h.return()}finally{if(e)throw f}}return c}return function(b,c){if(Array.isArray(b))return b;if(Symbol.iterator in Object(b))return a(b,c);throw new TypeError("Invalid attempt to destructure non-iterable instance")}}(),g=a("./input"),h=c(g),i=a("./filter"),j=b.jQuery,k=b.strftime;h.register({className:"crosstalk-input-slider",factory:function(a,b){function c(){var a=h.data("ionRangeSlider").result,b=void 0,c=h.data("data-type");return b="date"===c?function(a){return e(new Date(+a))}:"datetime"===c?function(a){return+a/1e3}:function(a){return+a},"double"===h.data("ionRangeSlider").options.type?[b(a.from),b(a.to)]:b(a.from)}var d=new i.FilterHandle(b.group),g={},h=j(a).find("input"),l=h.data("data-type"),m=h.data("time-format"),n=void 0;if("date"===l)n=k.utc(),g.prettify=function(a){return n(m,new Date(a))};else if("datetime"===l){var o=h.data("timezone");n=o?k.timezone(o):k,g.prettify=function(a){return n(m,new Date(a))}}h.ionRangeSlider(g);var p=null;return h.on("change.crosstalkSliderInput",function(a){if(!h.data("updating")&&!h.data("animating")){for(var e=c(),g=f(e,2),i=g[0],j=g[1],k=[],l=0;l<b.values.length;l++){var m=b.values[l];m>=i&&m<=j&&k.push(b.keys[l])}k.sort(),d.set(k),p=k}}),{suspend:function(){d.clear()},resume:function(){p&&d.set(p)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6}],10:[function(a,b,c){"use strict";function d(a){if(a&&a.__esModule)return a;var b={};if(null!=a)for(var c in a)Object.prototype.hasOwnProperty.call(a,c)&&(b[c]=a[c]);return b.default=a,b}function e(a){return a&&a.__esModule?a:{default:a}}function f(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}Object.defineProperty(c,"__esModule",{value:!0}),c.SelectionHandle=void 0;var g=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),h=a("./events"),i=e(h),j=a("./group"),k=e(j),l=a("./util"),m=d(l);c.SelectionHandle=function(){function a(){var b=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,c=arguments.length>1&&void 0!==arguments[1]?arguments[1]:null;f(this,a),this._eventRelay=new i.default,this._emitter=new m.SubscriptionTracker(this._eventRelay),this._group=null,this._var=null,this._varOnChangeSub=null,this._extraInfo=m.extend({sender:this},c),this.setGroup(b)}return g(a,[{key:"setGroup",value:function(a){var b=this;if(this._group!==a&&(this._group||a)&&(this._var&&(this._var.off("change",this._varOnChangeSub),this._var=null,this._varOnChangeSub=null),this._group=a,a)){this._var=(0,k.default)(a).var("selection");var c=this._var.on("change",function(a){b._eventRelay.trigger("change",a,b)});this._varOnChangeSub=c}}},{key:"_mergeExtraInfo",value:function(a){return m.extend({},this._extraInfo?this._extraInfo:null,a?a:null)}},{key:"set",value:function(a,b){this._var&&this._var.set(a,this._mergeExtraInfo(b))}},{key:"clear",value:function(a){this._var&&this.set(void 0,this._mergeExtraInfo(a))}},{key:"on",value:function(a,b){return this._emitter.on(a,b)}},{key:"off",value:function(a,b){return this._emitter.off(a,b)}},{key:"close",value:function(){this._emitter.removeAllListeners(),this.setGroup(null)}},{key:"value",get:function(){return this._var?this._var.get():null}}]),a}()},{"./events":1,"./group":4,"./util":11}],11:[function(a,b,c){"use strict";function d(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}function e(a){for(var b=arguments.length,c=Array(b>1?b-1:0),d=1;d<b;d++)c[d-1]=arguments[d];for(var e=0;e<c.length;e++){var f=c[e];if("undefined"!=typeof f&&null!==f)for(var g in f)f.hasOwnProperty(g)&&(a[g]=f[g])}return a}function f(a){for(var b=1;b<a.length;b++)if(a[b]<=a[b-1])throw new Error("List is not sorted or contains duplicate")}function g(a,b){var c=0,d=0;a||(a=[]),b||(b=[]);var e=[],g=[];for(f(a),f(b);c<a.length&&d<b.length;)a[c]===b[d]?(c++,d++):a[c]<b[d]?e.push(a[c++]):g.push(b[d++]);return c<a.length&&(e=e.concat(a.slice(c))),d<b.length&&(g=g.concat(b.slice(d))),{removed:e,added:g}}function h(a){var b=[],c=void 0;for(var d in a){if(a.hasOwnProperty(d)&&b.push(d),"object"!==j(a[d])||"undefined"==typeof a[d].length)throw new Error("All fields must be arrays");if("undefined"!=typeof c&&c!==a[d].length)throw new Error("All fields must be arrays of the same length");c=a[d].length}for(var e=[],f=void 0,g=0;g<c;g++){f={};for(var h=0;h<b.length;h++)f[b[h]]=a[b[h]][g];e.push(f)}return e}Object.defineProperty(c,"__esModule",{value:!0});var i=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),j="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(a){return typeof a}:function(a){return a&&"function"==typeof Symbol&&a.constructor===Symbol&&a!==Symbol.prototype?"symbol":typeof a};c.extend=e,c.checkSorted=f,c.diffSortedLists=g,c.dataframeToD3=h;c.SubscriptionTracker=function(){function a(b){d(this,a),this._emitter=b,this._subs={}}return i(a,[{key:"on",value:function(a,b){var c=this._emitter.on(a,b);return this._subs[c]=a,c}},{key:"off",value:function(a,b){var c=this._emitter.off(a,b);return c&&delete this._subs[c],c}},{key:"removeAllListeners",value:function(){var a=this,b=this._subs;this._subs={},Object.keys(b).forEach(function(c){a._emitter.off(b[c],c)})}}]),a}()},{}],12:[function(a,b,c){(function(b){"use strict";function d(a){return a&&a.__esModule?a:{default:a}}function e(a,b){if(!(a instanceof b))throw new TypeError("Cannot call a class as a function")}Object.defineProperty(c,"__esModule",{value:!0});var f="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(a){return typeof a}:function(a){return a&&"function"==typeof Symbol&&a.constructor===Symbol&&a!==Symbol.prototype?"symbol":typeof a},g=function(){function a(a,b){for(var c=0;c<b.length;c++){var d=b[c];d.enumerable=d.enumerable||!1,d.configurable=!0,"value"in d&&(d.writable=!0),Object.defineProperty(a,d.key,d)}}return function(b,c,d){return c&&a(b.prototype,c),d&&a(b,d),b}}(),h=a("./events"),i=d(h),j=function(){function a(b,c,d){e(this,a),this._group=b,this._name=c,this._value=d,this._events=new i.default}return g(a,[{key:"get",value:function(){return this._value}},{key:"set",value:function(a,c){if(this._value!==a){var d=this._value;this._value=a;var e={};if(c&&"object"===("undefined"==typeof c?"undefined":f(c)))for(var g in c)c.hasOwnProperty(g)&&(e[g]=c[g]);e.oldValue=d,e.value=a,this._events.trigger("change",e,this),b.Shiny&&b.Shiny.onInputChange&&b.Shiny.onInputChange(".clientValue-"+(null!==this._group.name?this._group.name+"-":"")+this._name,"undefined"==typeof a?null:a)}}},{key:"on",value:function(a,b){return this._events.on(a,b)}},{key:"off",value:function(a,b){return this._events.off(a,b)}}]),a}();c.default=j}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./events":1}]},{},[5]);
//# sourceMappingURL=crosstalk.min.js.map"></script>

</head>
<body style="background-color:white;">
<div id="htmlwidget_container">
  <div id="htmlwidget-f08fdf9aa10ee606c4ff" style="width:960px;height:500px;" class="datatables html-widget"></div>
</div>
<script type="application/json" data-for="htmlwidget-f08fdf9aa10ee606c4ff">{"x":{"filter":"none","data":[["E-MTAB-6682","E-MTAB-6681","E-MTAB-5552","E-MTAB-5543","E-MTAB-5541","E-MTAB-6001","E-MTAB-6371","E-MTAB-6368","E-MTAB-6151","E-MTAB-6326","E-MTAB-4969","E-MTAB-6316","E-MTAB-5299","E-MTAB-5297","E-MTAB-5528","E-MTAB-3983","E-MTAB-5713","E-MTAB-5871","E-MTAB-4898","E-MTAB-3258","E-MTAB-5797","E-MTAB-3239","E-MTAB-5171","E-MTAB-4455","E-PROT-2","E-MTAB-4771","E-MTAB-4804","E-MTAB-4803","E-MTAB-3865","E-MTAB-5109","E-MTAB-5098","E-MTAB-5092","E-GEOD-76070","E-GEOD-73895","E-GEOD-77053","E-GEOD-58277","E-GEOD-66388","E-GEOD-64072","E-GEOD-63537","E-GEOD-63534","E-GEOD-63533","E-GEOD-76786","E-GEOD-74571","E-GEOD-80137","E-GEOD-62714","E-GEOD-84010","E-GEOD-73556","E-GEOD-71116","E-GEOD-59967","E-MTAB-3948","E-GEOD-39292","E-GEOD-83344","E-GEOD-83294","E-GEOD-82009","E-GEOD-79338","E-MTAB-3886","E-GEOD-51281","E-GEOD-79478","E-ERAD-448","E-GEOD-77530","E-GEOD-79122","E-MTAB-3907","E-MTAB-3905","E-MTAB-3903","E-MTAB-3901","E-MTAB-3892","E-GEOD-74561","E-GEOD-73801","E-GEOD-73038","E-GEOD-77998","E-GEOD-70038","E-GEOD-72951","E-GEOD-43378","E-GEOD-64667","E-GEOD-62802","E-GEOD-70991","E-GEOD-73721","E-GEOD-75789","E-GEOD-42657","E-GEOD-67633","E-GEOD-75685","E-GEOD-75678","E-GEOD-75669","E-MTAB-3082","E-GEOD-60705","E-GEOD-71786","E-GEOD-60818","E-GEOD-60706","E-MTAB-3666","E-GEOD-63296","E-MTAB-3085","E-GEOD-51411","E-GEOD-51395","E-GEOD-51413","E-GEOD-74610","E-GEOD-72955","E-GEOD-74462","E-GEOD-68086","E-GEOD-62731","E-GEOD-74304","E-MTAB-3867","E-MTAB-3868","E-MTAB-3864","E-GEOD-73270","E-GEOD-73199","E-GEOD-72468","E-GEOD-51062","E-GEOD-72269","E-GEOD-61852","E-MTAB-3476","E-GEOD-71769","E-MTAB-3732","E-GEOD-71224","E-GEOD-65576","E-GEOD-68800","E-GEOD-70231","E-GEOD-67502","E-GEOD-70175","E-GEOD-53800","E-GEOD-57091","E-GEOD-54162","E-GEOD-69081","E-GEOD-68995","E-GEOD-68994","E-GEOD-68950","E-GEOD-68936","E-GEOD-68928","E-GEOD-68850","E-GEOD-68848","E-GEOD-37985","E-GEOD-60867","E-GEOD-60866","E-GEOD-57978","E-GEOD-63963","E-GEOD-60530","E-GEOD-61079","E-GEOD-61078","E-GEOD-52319","E-GEOD-63712","E-GEOD-55362","E-GEOD-66493","E-GEOD-28220","E-GEOD-58525","E-GEOD-62215","E-GEOD-61706","E-GEOD-61705","E-GEOD-61704","E-GEOD-56517","E-MTAB-2478","E-MTAB-2861","E-GEOD-60507","E-GEOD-60274","E-MTAB-2694","E-MTAB-2693","E-MTAB-2706","E-GEOD-63387","E-GEOD-51663","E-MTAB-1928","E-GEOD-62212","E-GEOD-62211","E-GEOD-51301","E-GEOD-32466","E-GEOD-61710","E-MTAB-1900","E-GEOD-51332","E-GEOD-61445","E-GEOD-61388","E-GEOD-53124","E-GEOD-50173","E-GEOD-60921","E-GEOD-60806","E-GEOD-60184","E-GEOD-57488","E-GEOD-59678","E-GEOD-59612","E-GEOD-51441","E-GEOD-48865","E-GEOD-58298","E-GEOD-59484","E-GEOD-52777","E-GEOD-58601","E-GEOD-58401","E-GEOD-58400","E-GEOD-58399","E-GEOD-57872","E-GEOD-58218","E-GEOD-44561","E-MEXP-3914","E-GEOD-42420","E-GEOD-49822","E-GEOD-54077","E-GEOD-57083","E-GEOD-39223","E-GEOD-37956","E-GEOD-54791","E-GEOD-54792","E-GEOD-54047","E-GEOD-45874","E-GEOD-56316","E-GEOD-53733","E-MTAB-1840","E-GEOD-55712","E-GEOD-44099","E-GEOD-51253","E-GEOD-53220","E-GEOD-43911","E-GEOD-52419","E-GEOD-52363","E-GEOD-53014","E-GEOD-53504","E-GEOD-52582","E-GEOD-52581","E-GEOD-52230","E-GEOD-53229","E-GEOD-53228","E-GEOD-53227","E-GEOD-53042","E-GEOD-43674","E-GEOD-51822","E-MEXP-3802","E-GEOD-52009","E-GEOD-46531","E-GEOD-41980","E-GEOD-51481","E-GEOD-50923","E-GEOD-50047","E-MTAB-1852","E-GEOD-51146","E-GEOD-50924","E-GEOD-50756","E-GEOD-40614","E-GEOD-49416","E-GEOD-50412","E-GEOD-50227","E-GEOD-48462","E-GEOD-48461","E-GEOD-48460","E-GEOD-50161","E-GEOD-41470","E-GEOD-41467","E-GEOD-49162","E-GEOD-49161","E-GEOD-49009","E-GEOD-49810","E-GEOD-49808","E-GEOD-49412","E-GEOD-42658","E-GEOD-42656","E-GEOD-31262","E-GEOD-49224","E-GEOD-30700","E-GEOD-48433","E-GEOD-46028","E-GEOD-45161","E-GEOD-48079","E-GEOD-47997","E-GEOD-47945","E-MTAB-2770","E-GEOD-46016","E-GEOD-46015","E-GEOD-46014","E-GEOD-45899","E-GEOD-33912","E-GEOD-29796","E-GEOD-46538","E-GEOD-44713","E-GEOD-45301","E-MTAB-1275","E-MTAB-1274","E-MTAB-1273","E-MTAB-1271","E-GEOD-32335","E-GEOD-41875","E-GEOD-41824","E-GEOD-44843","E-GEOD-44842","E-GEOD-44841","E-GEOD-44728","E-GEOD-44726","E-GEOD-25012","E-MTAB-1129","E-MTAB-1380","E-MTAB-1215","E-GEOD-43388","E-GEOD-43115","E-GEOD-43113","E-GEOD-43107","E-GEOD-43762","E-GEOD-35493","E-GEOD-42670","E-GEOD-42669","E-GEOD-42577","E-MTAB-951","E-GEOD-43452","E-GEOD-42355","E-GEOD-36902","E-GEOD-36901","E-GEOD-36900","E-GEOD-40299","E-GEOD-35208","E-GEOD-35500","E-GEOD-35454","E-GEOD-35453","E-GEOD-42402","E-GEOD-42401","E-GEOD-42400","E-GEOD-36278","E-GEOD-36245","E-GEOD-36426","E-GEOD-37634","E-MEXP-3296","E-MTAB-972","E-MTAB-971","E-GEOD-40770","E-GEOD-40776","E-GEOD-16805","E-GEOD-36947","E-GEOD-38330","E-GEOD-31133","E-GEOD-31126","E-GEOD-40051","E-GEOD-36782","E-MTAB-1185","E-GEOD-36201","E-GEOD-38008","E-GEOD-25631","E-GEOD-25630","E-GEOD-39242","E-GEOD-38815","E-GEOD-38814","E-GEOD-30472","E-MTAB-776","E-GEOD-27144","E-GEOD-32283","E-GEOD-32286","E-GEOD-31545","E-GEOD-22772","E-GEOD-32374","E-GEOD-36619","E-GEOD-36247","E-GEOD-37737","E-GEOD-18892","E-GEOD-37120","E-GEOD-29384","E-GEOD-29738","E-GEOD-34242","E-GEOD-36139","E-GEOD-36138","E-GEOD-36133","E-GEOD-29494","E-GEOD-34824","E-MTAB-989","E-GEOD-27523","E-GEOD-35158","E-TABM-1122","E-GEOD-35811","E-GEOD-35444","E-GEOD-33483","E-MTAB-583","E-MEXP-3200","E-GEOD-26283","E-GEOD-25965","E-GEOD-26344","E-GEOD-24084","E-GEOD-30034","E-GEOD-33442","E-GEOD-20306","E-GEOD-33362","E-GEOD-24100","E-GEOD-33328","E-GEOD-28271","E-GEOD-30448","E-GEOD-32692","E-GEOD-32883","E-GEOD-32876","E-GEOD-32482","E-GEOD-32465","E-GEOD-28026","E-GEOD-26576","E-TABM-1148","E-GEOD-31586","E-GEOD-30043","E-GEOD-30800","E-GEOD-19678","E-GEOD-30563","E-GEOD-27671","E-GEOD-22692","E-GEOD-22891","E-MEXP-3020","E-TABM-1121","E-GEOD-29692","E-GEOD-21514","E-GEOD-28618","E-GEOD-20723","E-GEOD-21336","E-GEOD-22927","E-GEOD-15824","E-GEOD-27931","E-GEOD-27584","E-GEOD-20736","E-GEOD-25411","E-MEXP-2891","E-GEOD-23806","E-GEOD-23935","E-GEOD-22867","E-GEOD-22866","E-MTAB-327","E-GEOD-23839","E-GEOD-23838","E-GEOD-23795","E-TABM-890","E-TABM-889","E-GEOD-19870","E-GEOD-19720","E-GEOD-26328","E-GEOD-26313","E-GEOD-26196","E-GEOD-20395","E-TABM-858","E-GEOD-21420","E-GEOD-24558","E-GEOD-24557","E-GEOD-24452","E-GEOD-24446","E-GEOD-24244","E-GEOD-24717","E-GEOD-24716","E-GEOD-19846","E-GEOD-24072","E-GEOD-18166","E-GEOD-22385","E-MTAB-62","E-GEOD-22821","E-GEOD-17227","E-GEOD-10547","E-TABM-898","E-TABM-857","E-TABM-897","E-GEOD-13991","E-GEOD-13808","E-GEOD-4328","E-GEOD-18638","E-GEOD-19578","E-GEOD-1991","E-GEOD-21570","E-GEOD-19363","E-GEOD-12689","E-GEOD-13030","E-GEOD-14822","E-GEOD-14821","E-GEOD-14819","E-GEOD-14878","E-GEOD-16011","E-GEOD-19612","E-GEOD-17047","E-GEOD-15846","E-GEOD-14581","E-GEOD-21026","E-GEOD-14945","E-GEOD-16666","E-GEOD-14824","E-GEOD-14823","E-GEOD-14820","E-GEOD-14818","E-MEXP-2567","E-GEOD-19728","E-GEOD-18150","E-GEOD-14889","E-TABM-579","E-GEOD-13276","E-GEOD-8692","E-GEOD-11100","E-GEOD-3521","E-GEOD-14805","E-GEOD-10922","E-MTAB-3073","E-TABM-390","E-GEOD-14507","E-GEOD-11285","E-MEXP-1330","E-GEOD-13021","E-MEXP-1562","E-GEOD-12305","E-MEXP-1796","E-MTAB-38","E-GEOD-13470","E-GEOD-13041","E-GEOD-12949","E-GEOD-7696","E-MTAB-37","E-TABM-315","E-GEOD-9885","E-GEOD-9171","E-GEOD-8049","E-GEOD-7835","E-GEOD-7806","E-GEOD-7602","E-GEOD-6109","E-GEOD-6014","E-GEOD-5107","E-GEOD-5082","E-GEOD-4536","E-GEOD-4218","E-GEOD-4217","E-GEOD-10007","E-MEXP-1507","E-GEOD-9200","E-GEOD-9177","E-GEOD-9385","E-GEOD-4412","E-GEOD-1923","E-TABM-185","E-GEOD-3185","E-GEOD-7181","E-GEOD-4717","E-GEOD-4817","E-GEOD-2485","E-GEOD-4290","E-TABM-167","E-MEXP-1063","E-MEXP-903","E-MEXP-567","E-MEXP-551","E-MEXP-751","E-MEXP-741","E-GEOD-4058","E-MEXP-273","E-MEXP-272","E-TABM-65","E-SMDB-2677","E-SMDB-3152","E-TABM-37"],["E-MTAB-6682","E-MTAB-6681","E-MTAB-5552","E-MTAB-5543","E-MTAB-5541","E-MTAB-6001","E-MTAB-6371","E-MTAB-6368","E-MTAB-6151","E-MTAB-6326","E-MTAB-4969","E-MTAB-6316","E-MTAB-5299","E-MTAB-5297","E-MTAB-5528","E-MTAB-3983","E-MTAB-5713","E-MTAB-5871","E-MTAB-4898","E-MTAB-3258","E-MTAB-5797","E-MTAB-3239","E-MTAB-5171","E-MTAB-4455","E-PROT-2","E-MTAB-4771","E-MTAB-4804","E-MTAB-4803","E-MTAB-3865","E-MTAB-5109","E-MTAB-5098","E-MTAB-5092","E-GEOD-76070","E-GEOD-73895","E-GEOD-77053","E-GEOD-58277","E-GEOD-66388","E-GEOD-64072","E-GEOD-63537","E-GEOD-63534","E-GEOD-63533","E-GEOD-76786","E-GEOD-74571","E-GEOD-80137","E-GEOD-62714","E-GEOD-84010","E-GEOD-73556","E-GEOD-71116","E-GEOD-59967","E-MTAB-3948","E-GEOD-39292","E-GEOD-83344","E-GEOD-83294","E-GEOD-82009","E-GEOD-79338","E-MTAB-3886","E-GEOD-51281","E-GEOD-79478","E-ERAD-448","E-GEOD-77530","E-GEOD-79122","E-MTAB-3907","E-MTAB-3905","E-MTAB-3903","E-MTAB-3901","E-MTAB-3892","E-GEOD-74561","E-GEOD-73801","E-GEOD-73038","E-GEOD-77998","E-GEOD-70038","E-GEOD-72951","E-GEOD-43378","E-GEOD-64667","E-GEOD-62802","E-GEOD-70991","E-GEOD-73721","E-GEOD-75789","E-GEOD-42657","E-GEOD-67633","E-GEOD-75685","E-GEOD-75678","E-GEOD-75669","E-MTAB-3082","E-GEOD-60705","E-GEOD-71786","E-GEOD-60818","E-GEOD-60706","E-MTAB-3666","E-GEOD-63296","E-MTAB-3085","E-GEOD-51411","E-GEOD-51395","E-GEOD-51413","E-GEOD-74610","E-GEOD-72955","E-GEOD-74462","E-GEOD-68086","E-GEOD-62731","E-GEOD-74304","E-MTAB-3867","E-MTAB-3868","E-MTAB-3864","E-GEOD-73270","E-GEOD-73199","E-GEOD-72468","E-GEOD-51062","E-GEOD-72269","E-GEOD-61852","E-MTAB-3476","E-GEOD-71769","E-MTAB-3732","E-GEOD-71224","E-GEOD-65576","E-GEOD-68800","E-GEOD-70231","E-GEOD-67502","E-GEOD-70175","E-GEOD-53800","E-GEOD-57091","E-GEOD-54162","E-GEOD-69081","E-GEOD-68995","E-GEOD-68994","E-GEOD-68950","E-GEOD-68936","E-GEOD-68928","E-GEOD-68850","E-GEOD-68848","E-GEOD-37985","E-GEOD-60867","E-GEOD-60866","E-GEOD-57978","E-GEOD-63963","E-GEOD-60530","E-GEOD-61079","E-GEOD-61078","E-GEOD-52319","E-GEOD-63712","E-GEOD-55362","E-GEOD-66493","E-GEOD-28220","E-GEOD-58525","E-GEOD-62215","E-GEOD-61706","E-GEOD-61705","E-GEOD-61704","E-GEOD-56517","E-MTAB-2478","E-MTAB-2861","E-GEOD-60507","E-GEOD-60274","E-MTAB-2694","E-MTAB-2693","E-MTAB-2706","E-GEOD-63387","E-GEOD-51663","E-MTAB-1928","E-GEOD-62212","E-GEOD-62211","E-GEOD-51301","E-GEOD-32466","E-GEOD-61710","E-MTAB-1900","E-GEOD-51332","E-GEOD-61445","E-GEOD-61388","E-GEOD-53124","E-GEOD-50173","E-GEOD-60921","E-GEOD-60806","E-GEOD-60184","E-GEOD-57488","E-GEOD-59678","E-GEOD-59612","E-GEOD-51441","E-GEOD-48865","E-GEOD-58298","E-GEOD-59484","E-GEOD-52777","E-GEOD-58601","E-GEOD-58401","E-GEOD-58400","E-GEOD-58399","E-GEOD-57872","E-GEOD-58218","E-GEOD-44561","E-MEXP-3914","E-GEOD-42420","E-GEOD-49822","E-GEOD-54077","E-GEOD-57083","E-GEOD-39223","E-GEOD-37956","E-GEOD-54791","E-GEOD-54792","E-GEOD-54047","E-GEOD-45874","E-GEOD-56316","E-GEOD-53733","E-MTAB-1840","E-GEOD-55712","E-GEOD-44099","E-GEOD-51253","E-GEOD-53220","E-GEOD-43911","E-GEOD-52419","E-GEOD-52363","E-GEOD-53014","E-GEOD-53504","E-GEOD-52582","E-GEOD-52581","E-GEOD-52230","E-GEOD-53229","E-GEOD-53228","E-GEOD-53227","E-GEOD-53042","E-GEOD-43674","E-GEOD-51822","E-MEXP-3802","E-GEOD-52009","E-GEOD-46531","E-GEOD-41980","E-GEOD-51481","E-GEOD-50923","E-GEOD-50047","E-MTAB-1852","E-GEOD-51146","E-GEOD-50924","E-GEOD-50756","E-GEOD-40614","E-GEOD-49416","E-GEOD-50412","E-GEOD-50227","E-GEOD-48462","E-GEOD-48461","E-GEOD-48460","E-GEOD-50161","E-GEOD-41470","E-GEOD-41467","E-GEOD-49162","E-GEOD-49161","E-GEOD-49009","E-GEOD-49810","E-GEOD-49808","E-GEOD-49412","E-GEOD-42658","E-GEOD-42656","E-GEOD-31262","E-GEOD-49224","E-GEOD-30700","E-GEOD-48433","E-GEOD-46028","E-GEOD-45161","E-GEOD-48079","E-GEOD-47997","E-GEOD-47945","E-MTAB-2770","E-GEOD-46016","E-GEOD-46015","E-GEOD-46014","E-GEOD-45899","E-GEOD-33912","E-GEOD-29796","E-GEOD-46538","E-GEOD-44713","E-GEOD-45301","E-MTAB-1275","E-MTAB-1274","E-MTAB-1273","E-MTAB-1271","E-GEOD-32335","E-GEOD-41875","E-GEOD-41824","E-GEOD-44843","E-GEOD-44842","E-GEOD-44841","E-GEOD-44728","E-GEOD-44726","E-GEOD-25012","E-MTAB-1129","E-MTAB-1380","E-MTAB-1215","E-GEOD-43388","E-GEOD-43115","E-GEOD-43113","E-GEOD-43107","E-GEOD-43762","E-GEOD-35493","E-GEOD-42670","E-GEOD-42669","E-GEOD-42577","E-MTAB-951","E-GEOD-43452","E-GEOD-42355","E-GEOD-36902","E-GEOD-36901","E-GEOD-36900","E-GEOD-40299","E-GEOD-35208","E-GEOD-35500","E-GEOD-35454","E-GEOD-35453","E-GEOD-42402","E-GEOD-42401","E-GEOD-42400","E-GEOD-36278","E-GEOD-36245","E-GEOD-36426","E-GEOD-37634","E-MEXP-3296","E-MTAB-972","E-MTAB-971","E-GEOD-40770","E-GEOD-40776","E-GEOD-16805","E-GEOD-36947","E-GEOD-38330","E-GEOD-31133","E-GEOD-31126","E-GEOD-40051","E-GEOD-36782","E-MTAB-1185","E-GEOD-36201","E-GEOD-38008","E-GEOD-25631","E-GEOD-25630","E-GEOD-39242","E-GEOD-38815","E-GEOD-38814","E-GEOD-30472","E-MTAB-776","E-GEOD-27144","E-GEOD-32283","E-GEOD-32286","E-GEOD-31545","E-GEOD-22772","E-GEOD-32374","E-GEOD-36619","E-GEOD-36247","E-GEOD-37737","E-GEOD-18892","E-GEOD-37120","E-GEOD-29384","E-GEOD-29738","E-GEOD-34242","E-GEOD-36139","E-GEOD-36138","E-GEOD-36133","E-GEOD-29494","E-GEOD-34824","E-MTAB-989","E-GEOD-27523","E-GEOD-35158","E-TABM-1122","E-GEOD-35811","E-GEOD-35444","E-GEOD-33483","E-MTAB-583","E-MEXP-3200","E-GEOD-26283","E-GEOD-25965","E-GEOD-26344","E-GEOD-24084","E-GEOD-30034","E-GEOD-33442","E-GEOD-20306","E-GEOD-33362","E-GEOD-24100","E-GEOD-33328","E-GEOD-28271","E-GEOD-30448","E-GEOD-32692","E-GEOD-32883","E-GEOD-32876","E-GEOD-32482","E-GEOD-32465","E-GEOD-28026","E-GEOD-26576","E-TABM-1148","E-GEOD-31586","E-GEOD-30043","E-GEOD-30800","E-GEOD-19678","E-GEOD-30563","E-GEOD-27671","E-GEOD-22692","E-GEOD-22891","E-MEXP-3020","E-TABM-1121","E-GEOD-29692","E-GEOD-21514","E-GEOD-28618","E-GEOD-20723","E-GEOD-21336","E-GEOD-22927","E-GEOD-15824","E-GEOD-27931","E-GEOD-27584","E-GEOD-20736","E-GEOD-25411","E-MEXP-2891","E-GEOD-23806","E-GEOD-23935","E-GEOD-22867","E-GEOD-22866","E-MTAB-327","E-GEOD-23839","E-GEOD-23838","E-GEOD-23795","E-TABM-890","E-TABM-889","E-GEOD-19870","E-GEOD-19720","E-GEOD-26328","E-GEOD-26313","E-GEOD-26196","E-GEOD-20395","E-TABM-858","E-GEOD-21420","E-GEOD-24558","E-GEOD-24557","E-GEOD-24452","E-GEOD-24446","E-GEOD-24244","E-GEOD-24717","E-GEOD-24716","E-GEOD-19846","E-GEOD-24072","E-GEOD-18166","E-GEOD-22385","E-MTAB-62","E-GEOD-22821","E-GEOD-17227","E-GEOD-10547","E-TABM-898","E-TABM-857","E-TABM-897","E-GEOD-13991","E-GEOD-13808","E-GEOD-4328","E-GEOD-18638","E-GEOD-19578","E-GEOD-1991","E-GEOD-21570","E-GEOD-19363","E-GEOD-12689","E-GEOD-13030","E-GEOD-14822","E-GEOD-14821","E-GEOD-14819","E-GEOD-14878","E-GEOD-16011","E-GEOD-19612","E-GEOD-17047","E-GEOD-15846","E-GEOD-14581","E-GEOD-21026","E-GEOD-14945","E-GEOD-16666","E-GEOD-14824","E-GEOD-14823","E-GEOD-14820","E-GEOD-14818","E-MEXP-2567","E-GEOD-19728","E-GEOD-18150","E-GEOD-14889","E-TABM-579","E-GEOD-13276","E-GEOD-8692","E-GEOD-11100","E-GEOD-3521","E-GEOD-14805","E-GEOD-10922","E-MTAB-3073","E-TABM-390","E-GEOD-14507","E-GEOD-11285","E-MEXP-1330","E-GEOD-13021","E-MEXP-1562","E-GEOD-12305","E-MEXP-1796","E-MTAB-38","E-GEOD-13470","E-GEOD-13041","E-GEOD-12949","E-GEOD-7696","E-MTAB-37","E-TABM-315","E-GEOD-9885","E-GEOD-9171","E-GEOD-8049","E-GEOD-7835","E-GEOD-7806","E-GEOD-7602","E-GEOD-6109","E-GEOD-6014","E-GEOD-5107","E-GEOD-5082","E-GEOD-4536","E-GEOD-4218","E-GEOD-4217","E-GEOD-10007","E-MEXP-1507","E-GEOD-9200","E-GEOD-9177","E-GEOD-9385","E-GEOD-4412","E-GEOD-1923","E-TABM-185","E-GEOD-3185","E-GEOD-7181","E-GEOD-4717","E-GEOD-4817","E-GEOD-2485","E-GEOD-4290","E-TABM-167","E-MEXP-1063","E-MEXP-903","E-MEXP-567","E-MEXP-551","E-MEXP-751","E-MEXP-741","E-GEOD-4058","E-MEXP-273","E-MEXP-272","E-TABM-65","E-SMDB-2677","E-SMDB-3152","E-TABM-37"],["no","no","yes","yes","no","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","no","no","yes","yes","no","yes","no","no","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","no","no","no","yes","yes","yes","no","no","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","no","yes","no","yes","no","no","no","yes","yes","no","no","yes","yes","no","yes","yes","no","no","yes","yes","yes","no","no","yes","no","no","yes","no","yes","yes","no","yes","no","no","yes","yes","yes","no","yes","yes","yes","no","yes","no","no","yes","no","no","yes","no","yes","no","yes","yes","no","yes","yes","no","yes","yes","no","yes","no","no","no","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","no","no","no","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","no","yes","yes","yes","no","no","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","no","yes","no","no","no","no","yes","yes","yes","yes","yes","yes","no","no","yes","yes","no","yes","yes","yes","yes","yes","no","no","no","no","yes","yes","yes","no","yes","no","no","yes","no","yes","no","yes","no","no","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","no","yes","no","no","yes","yes","no","no","no","yes","no","no","no","no","no","yes","no","no","yes","yes","yes","yes","yes","yes","no","no","yes","no","yes","yes","yes","yes","no","no","yes","no","yes","no","no","yes","no","yes","yes","no","no","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","no","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","no","no","yes","yes","no","no","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","no","no","yes","yes","yes","yes","no","no","no","no","yes","yes","yes","yes","no","no","yes","yes","yes","no","no","yes","yes","yes","yes","yes","yes","yes","no","yes","no","no","yes","yes","yes","no","no","yes","yes","no","yes","yes","yes","yes","no","yes","yes","no","no","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","no","no","no","yes","yes","no","yes","yes","no","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","no","no","no","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","no","no","yes","no","no","no","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","no","no","yes","no","yes","yes","yes","yes","yes","yes","yes","no","yes","yes","yes","yes","yes","yes"],["no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no","no"],["2018-05-31","2018-05-31","2018-05-11","2018-04-24","2018-04-24","2018-03-03","2018-02-27","2018-01-25","2018-01-15","2018-01-09","2017-12-15","2017-12-07","2017-11-29","2017-11-29","2017-09-28","2017-09-25","2017-09-01","2017-08-27","2017-07-05","2017-06-29","2017-06-24","2017-03-08","2017-02-24","2017-02-05","2017-01-27","2016-11-07","2016-11-01","2016-11-01","2016-11-01","2016-09-19","2016-09-19","2016-09-19","2016-09-01","2016-08-22","2016-08-01","2016-07-29","2016-07-26","2016-07-26","2016-07-26","2016-07-26","2016-07-26","2016-07-24","2016-07-21","2016-07-19","2016-07-15","2016-07-06","2016-07-03","2016-07-01","2016-07-01","2016-06-30","2016-06-23","2016-06-15","2016-06-14","2016-05-28","2016-05-18","2016-04-30","2016-04-13","2016-03-23","2016-03-22","2016-03-17","2016-03-12","2016-03-11","2016-03-11","2016-03-11","2016-03-11","2016-03-11","2016-03-10","2016-02-25","2016-02-25","2016-02-18","2016-02-15","2016-01-19","2016-01-08","2016-01-05","2015-12-31","2015-12-23","2015-12-11","2015-12-10","2015-12-10","2015-12-08","2015-12-04","2015-12-04","2015-12-04","2015-11-30","2015-11-26","2015-11-25","2015-11-23","2015-11-23","2015-11-21","2015-11-11","2015-11-10","2015-11-09","2015-11-09","2015-11-07","2015-11-04","2015-11-01","2015-10-30","2015-10-30","2015-10-27","2015-10-24","2015-10-02","2015-10-01","2015-10-01","2015-09-22","2015-09-19","2015-09-14","2015-09-08","2015-08-25","2015-08-25","2015-08-10","2015-08-07","2015-07-23","2015-07-23","2015-07-01","2015-06-29","2015-06-25","2015-06-25","2015-06-24","2015-06-16","2015-06-15","2015-05-26","2015-05-21","2015-05-21","2015-05-21","2015-05-16","2015-05-16","2015-05-16","2015-05-14","2015-05-14","2015-05-13","2015-05-04","2015-05-04","2015-04-17","2015-04-16","2015-04-09","2015-04-07","2015-04-07","2015-03-28","2015-03-11","2015-03-11","2015-03-05","2015-02-27","2015-02-23","2015-02-20","2015-02-04","2015-02-04","2015-02-04","2015-01-30","2015-01-16","2015-01-06","2015-01-06","2015-01-06","2015-01-03","2015-01-03","2014-11-25","2014-11-19","2014-10-20","2014-10-10","2014-10-10","2014-10-10","2014-09-30","2014-09-28","2014-09-26","2014-09-23","2014-09-23","2014-09-17","2014-09-13","2014-09-05","2014-09-01","2014-08-30","2014-08-30","2014-08-08","2014-08-05","2014-07-24","2014-07-22","2014-07-22","2014-07-20","2014-07-18","2014-07-17","2014-07-01","2014-06-18","2014-06-12","2014-06-12","2014-06-12","2014-06-12","2014-06-06","2014-06-04","2014-05-24","2014-05-15","2014-05-14","2014-05-02","2014-04-28","2014-04-25","2014-04-25","2014-04-14","2014-04-11","2014-04-10","2014-04-03","2014-03-28","2014-03-27","2014-03-15","2014-03-09","2014-03-04","2014-03-01","2014-02-11","2014-02-04","2014-01-16","2014-01-16","2014-01-01","2013-12-20","2013-12-15","2013-12-15","2013-12-15","2013-12-12","2013-12-12","2013-12-12","2013-12-06","2013-12-02","2013-11-14","2013-11-12","2013-11-07","2013-11-01","2013-11-01","2013-10-22","2013-10-18","2013-10-03","2013-10-01","2013-09-26","2013-09-18","2013-09-12","2013-09-05","2013-09-01","2013-08-29","2013-08-28","2013-08-26","2013-08-26","2013-08-26","2013-08-25","2013-08-19","2013-08-19","2013-08-15","2013-08-15","2013-08-15","2013-08-13","2013-08-13","2013-08-13","2013-07-29","2013-07-29","2013-07-27","2013-07-26","2013-07-14","2013-07-01","2013-07-01","2013-07-01","2013-06-19","2013-06-17","2013-06-15","2013-05-31","2013-05-28","2013-05-28","2013-05-28","2013-05-28","2013-05-21","2013-05-16","2013-05-02","2013-03-29","2013-03-20","2013-03-15","2013-03-15","2013-03-15","2013-03-15","2013-03-13","2013-03-08","2013-03-08","2013-03-05","2013-03-05","2013-03-05","2013-03-01","2013-03-01","2013-02-28","2013-02-16","2013-02-15","2013-02-15","2013-02-01","2013-02-01","2013-02-01","2013-02-01","2013-01-26","2013-01-21","2013-01-18","2013-01-18","2013-01-18","2013-01-15","2013-01-12","2013-01-02","2013-01-01","2013-01-01","2013-01-01","2012-12-31","2012-12-31","2012-12-10","2012-12-10","2012-12-10","2012-12-01","2012-12-01","2012-12-01","2012-10-16","2012-10-16","2012-10-05","2012-10-01","2012-09-30","2012-09-21","2012-09-21","2012-09-12","2012-09-11","2012-09-11","2012-08-25","2012-08-24","2012-08-13","2012-08-13","2012-08-10","2012-08-01","2012-07-31","2012-07-30","2012-07-19","2012-07-12","2012-07-12","2012-07-10","2012-07-10","2012-07-10","2012-06-30","2012-06-29","2012-06-15","2012-06-10","2012-06-09","2012-06-02","2012-05-31","2012-05-20","2012-05-19","2012-05-06","2012-05-03","2012-04-29","2012-04-08","2012-04-03","2012-03-29","2012-03-26","2012-03-20","2012-03-20","2012-03-20","2012-03-15","2012-03-01","2012-02-28","2012-02-25","2012-02-24","2012-02-18","2012-02-15","2012-01-31","2012-01-01","2011-12-31","2011-12-26","2011-12-20","2011-12-07","2011-12-01","2011-12-01","2011-11-16","2011-11-05","2011-11-03","2011-11-02","2011-10-31","2011-10-30","2011-10-24","2011-10-20","2011-10-18","2011-10-17","2011-10-11","2011-09-30","2011-09-29","2011-09-21","2011-09-20","2011-08-27","2011-08-23","2011-07-31","2011-07-19","2011-07-19","2011-07-12","2011-07-01","2011-06-30","2011-06-29","2011-06-26","2011-06-18","2011-06-03","2011-05-26","2011-04-16","2011-04-07","2011-04-06","2011-03-23","2011-03-18","2011-03-14","2011-03-01","2011-03-01","2011-02-28","2011-02-18","2011-02-12","2011-01-27","2011-01-19","2011-01-19","2011-01-10","2011-01-10","2011-01-10","2011-01-10","2011-01-08","2011-01-08","2011-01-07","2011-01-02","2010-12-29","2010-12-28","2010-12-21","2010-12-20","2010-12-03","2010-12-01","2010-11-21","2010-11-21","2010-11-21","2010-11-21","2010-11-21","2010-10-16","2010-10-16","2010-10-15","2010-09-30","2010-09-14","2010-08-08","2010-08-04","2010-07-31","2010-07-20","2010-07-20","2010-07-07","2010-07-01","2010-06-30","2010-06-24","2010-06-24","2010-06-24","2010-06-22","2010-06-15","2010-06-10","2010-05-27","2010-05-18","2010-05-18","2010-05-17","2010-05-14","2010-05-14","2010-05-14","2010-05-06","2010-04-26","2010-04-21","2010-04-19","2010-04-09","2010-04-09","2010-03-30","2010-02-22","2010-02-12","2010-02-12","2010-02-12","2010-02-12","2010-02-12","2010-01-28","2010-01-05","2009-12-14","2009-10-16","2009-09-21","2009-06-15","2009-04-25","2009-04-11","2009-03-31","2009-03-07","2009-03-01","2009-02-10","2009-02-03","2009-01-23","2009-01-14","2009-01-13","2009-01-04","2008-12-31","2008-12-31","2008-11-19","2008-11-17","2008-11-15","2008-10-26","2008-10-26","2008-10-18","2008-07-01","2008-06-25","2008-06-17","2008-06-16","2008-06-15","2008-06-15","2008-06-15","2008-06-15","2008-06-15","2008-06-14","2008-06-13","2008-06-13","2008-06-13","2008-06-12","2008-06-12","2008-06-11","2008-05-01","2008-04-29","2008-04-29","2008-01-28","2007-12-20","2007-12-12","2007-11-20","2007-11-02","2007-11-01","2007-11-01","2007-10-26","2007-08-21","2007-06-24","2007-06-01","2007-05-31","2007-05-16","2007-03-01","2006-12-31","2006-09-30","2006-09-30","2006-01-18","2006-01-16","2006-01-06","2005-11-23","2005-11-11","2005-10-06","2005-09-23"],["29844126","29844126","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","28638988","NA","NA","NA","24727770","27364552","NA","NA","26607953","25940437 | 28049185","25940437 | 28049185","25940437 | 28049185","NA","NA","NA","NA","27434182","27434182","27434182","27434182","27434182","NA","27345406","NA","NA","26124478","NA","NA","NA","NA","NA","NA","15374961","12670911","NA","NA","NA","NA","NA","26973881","NA","27090007","27090007","27090007","27090007","27090007","26934681","NA","NA","NA","26673326","NA","NA","NA","NA","NA","NA","NA","NA","26626085","NA","NA","NA","NA","NA","26549022","NA","NA","NA","NA","25932951","NA","NA","NA","NA","NA","NA","26525104","NA","NA","26607953","26607953","NA","NA","NA","NA","25934697","NA","26295846","26224161","21169257","NA","NA","NA","26100017","11559565","25991676","NA","NA","25722303","24691054","NA","NA","NA","NA","11553813","11742071","NA","NA","NA","NA","NA","25590811","25601206","NA","25627976","25627976","NA","25620562","25751603","NA","NA","NA","25381154","NA","25648896","25648896","25762636","NA","25277523","NA","NA","25561528","25561528","25485619","NA","NA","NA","NA","NA","NA","NA","NA","NA","24974128","NA","NA","25149900","NA","NA","25163646","NA","24998913","NA","25114226","24726753","NA","25012071","NA","NA","NA","NA","NA","NA","24925914","NA","NA","NA","24814343","24183680","24662514","NA","23871637","23871637","NA","NA","NA","NA","NA","24615357","25279461","NA","24587218","NA","24465609","NA","24440720","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","24367102 | 23530502","NA","NA","NA","NA","NA","NA","24189182","NA","NA","NA","NA","NA","NA","NA","23948976","23948976","23948976","24078694","23967194","23967194","NA","NA","NA","NA","NA","NA","NA","NA","23791939","NA","NA","24885658","NA","23804423","NA","23474544","23474544","22460905","23707066","23707066","23707066","23707066","23680149","NA","NA","NA","NA","23512659","23512659","23512659","23512659","23477542","23468990","23468990","NA","NA","NA","NA","NA","NA","25406193 | 23412337","23307858","23412337 | 25406193 | 23412337","23269986 | 24553142","23269986 | 24553142","23269986 | 24553142","23269986 | 24553142","NA","23382118","23333277","23333277","23333277","24804210","NA","NA","NA","NA","NA","NA","23034333","22894900","22894900","22894900","NA","23298836","NA","NA","NA","22738909","NA","22472177","23046790","23046790","NA","20179017","22901239","NA","NA","NA","NA","NA","NA","23874576","22736761","22781553","22570426","22570426","NA","NA","NA","NA","22147553","22172638","NA","NA","NA","23451269","NA","22494416","22678294","NA","NA","NA","22282654","22467206","NA","NA","NA","NA","22431710","22286061","22375056","NA","NA","23720055","NA","NA","NA","NA","NA","NA","NA","NA","NA","22068913","NA","20215515","NA","21928115","22199257","NA","22174890","22090374","NA","22929615","NA","NA","NA","21931021","22006998","NA","NA","NA","NA","NA","NA","NA","21156036","21738796","23720055","22955828 | 22955617","20976148","21600039","NA","21383690","21397855","21406405","20085741","22955980","NA","21555877","NA","21294158","21156287","21156036","21156036","23209617","21211035","21211035","21211035","20935218","21659463","NA","NA","22955618 | 21854988","NA","NA","21163902","20935218","NA","NA","NA","NA","NA","NA","NA","NA","20683904","NA","NA","20702765","22977115 | 20379172 | 23563154","21531700 | 20442302","NA","18483266","NA","NA","20822523","19139068","19098899","18827820","19946270","21659463 | 20479398","15899798","NA","NA","NA","NA","NA","NA","NA","20419098","19920198","20385361","20593488","NA","19861404","20435671","NA","NA","NA","NA","NA","NA","20227367","NA","NA","NA","20935218 | 19365568","23472076","17726534","20539758","19291283","19139420","NA","19208739","19176381","19073608","NA","22580610","19074898","NA","NA","19010882","NA","19011622","18940004","19199360","21642372 | 18565887","23118487 | 26107615","18566237","NA","18394558","18037961","17708671","NA","17515920","17018597","17222789","16966431","16966431","16697959","17127033","17127033","NA","18492260","18394558","18394558","17575129","15374961","15994924","25887585 | 20379172","NA","17483311","16909125","NA","16254489","16616334","18852145","NA","17292826 | 25356585","24176859","17079441","18694480","18694480","15827123","16618578","16618578","16648555","15827123","16204036","NA"],["Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mesocricetus auratus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Gallus gallus | Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens | Mus musculus","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens","Homo sapiens"],["binding site identification design","cell type comparison design | compound treatment design","disease state design","cellular modification design","binding site identification design | genotype design | strain or line design","cell type comparison design | cellular modification design | growth condition design | observational design","NA","strain or line design","cellular modification design","disease state design","disease state design","genetic modification design","genetic modification design | replicate design","genetic modification design | replicate design","disease state design","NA","compound treatment design | replicate design","genetic modification design","cellular modification design | genetic modification design","case control design | disease state design | validation by real time PCR design | validation by reverse transcription PCR design","NA","disease state design","NA","genotype design","cell type comparison design","cell type comparison design","case control design","case control design","NA","cell type comparison design","cell type comparison design","cell type comparison design","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","disease state design","NA","NA","NA","NA","NA","cellular modification design","NA","NA","NA","NA","NA","NA","NA","normalization testing design","NA","normalization testing design","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","cell type comparison design | growth condition design","NA","NA","NA","NA","cell type comparison design | compound treatment design","NA","cell type comparison design | stimulus or stress design","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","observational design","NA","array specific design | cell type comparison design | disease state design | organism part comparison design","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | disease state design | ex vivo","genotyping design","NA","NA","genotyping design","NA","in vitro design","NA","NA","clinical history design | co-expression | disease state","NA","NA","NA","NA","NA","cell type comparison | co-expression | compound treatment | replicate","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","cellular process | co-expression | in vitro","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | disease state | ex vivo","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","cell type comparison | co-expression | compound treatment | in vivo","NA","NA","NA","NA","NA","NA","co-expression | disease state | in vivo","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","disease state design","NA","NA","NA","NA","NA","NA","NA","NA","NA","disease state | replicate","disease state | replicate","co-expression | disease state | replicate","genotyping | individual genetic characteristics | reference","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | disease state | ex vivo","clinical history design | co-expression | disease state","disease state | ex vivo","NA","NA","NA","NA","NA","NA","NA","NA","NA","disease state | genotyping","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | disease state","comparative genome hybridization | disease state | dye swap | individual genetic characteristics","co-expression | disease state | in vitro","NA","NA","NA","NA","NA","NA","NA","NA","NA","disease state","NA","NA","NA","NA","NA","NA","NA","NA","cellular modification | co-expression | in vitro | is expressed","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","differential expression | genetic modification | transfection","NA","NA","cell type comparison, in vitro, binding site identification","NA","NA","NA","co-expression | compound treatment | genetic modification | in vitro","cell type comparison | co-expression | genetic modification | in vitro","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","compound treatment | in vitro | replicate | stimulus or stress","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | in vitro | stimulus or stress","cell type comparison, in vitro, co-expression","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","cell type comparison | co-expression | in vitro","NA","NA","NA","NA","co-expression | in vitro | strain or line","NA","NA","NA","co-expression | compound treatment | in vivo | transcription profiling by array","co-expression | compound treatment | transcription profiling by array","NA","NA","NA","NA","NA","NA","co-expression | in vitro | individual genetic characteristics","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | data integration","NA","NA","NA","co-expression","comparative genome hybridization | dye swap | individual genetic characteristics | tiling path","ChIP-chip by array | co-expression","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","co-expression | growth condition | in vitro","NA","unknown experiment type","unknown experiment type","cell type comparison | co-expression | genotyping | in vitro","NA","disease state","stimulus or stress design","NA","NA","NA","NA","dose response | strain or line design","NA","NA","cell type comparison | disease state | ex vivo | genotyping | in vitro | in vivo","NA","comparative genome hybridization | disease state | dye swap","NA","co-expression | disease state","co-expression | disease state","NA","unknown experiment type","compound treatment design","unknown experiment type","co-expression | disease state","co-expression | compound treatment","unknown experiment type","unknown experiment type","unknown experiment type","RNAi profiling by array | unknown experiment type","unknown experiment type","unknown experiment type","unknown experiment type","cell type comparison | compound treatment","unknown experiment type","unknown experiment type","unknown experiment type","unknown experiment type","unknown experiment type","unknown experiment type","co-expression | disease state | in vivo","NA","NA","NA","co-expression | disease state","co-expression | compound treatment | individual genetic characteristics","co-expression","co-expression | disease state","cell type comparison | co-expression | in vitro","co-expression | compound treatment | individual comparison","co-expression | compound treatment | in vitro","cell type comparison | co-expression | disease state","co-expression | disease state | organism part comparison","co-expression | disease state | reference","co-expression | disease state | dye swap","compound treatment","disease state","cell type comparison","compound treatment | dose response | dye swap | reference | time series","compound treatment | dye swap | reference | time series | transcription profiling by array","NA","dose response | strain or line","dose response | strain or line | transcription profiling by array","comparative genome hybridization","disease state","Expression (Type I) | unknown experiment type","disease state"],["cell line=E14TG2a.4 | cell line=G144 | cell line=not applicable | cell type=embryonic stem cell | cell type=glial cell | cell type=neural stem cell | compound=none | compound=PD0325901 | compound=PD0325902 | compound=PD0325903 | compound=PD0325904 | compound=PD0325905 | compound=PD0325906 | compound=PD0325907 | compound=PD0325908 | compound=PD0325909 | compound=PD0325910 | compound=PD0325911 | compound=PD0325912 | compound=PD0325913 | compound=PD0325914 | compound=PD0325915 | compound=PD0325916 | dose=1 micromolar | genotype=CRISPR/Cas9 mediated knockout of CIC | genotype=wild type genotype | immunoprecipitate=CIC (Bethyl_#A301-204A) | immunoprecipitate=H3K27ac (Abcam_ab4729) | immunoprecipitate=H3K4me1 (CellSig_#_5326) | immunoprecipitate=H3K9ac (Abcam_ab4441) | immunoprecipitate=IgG (Sigma # I5006) | immunoprecipitate=IgG (Sigma_#I5006) | time=24 hour | time=4 hour","compound=none | compound=PD0325901 | dose=1 micromolar | genotype=CRISPR/Cas9 mediated knockout of CIC | genotype=wild type genotype | time=24 hour | time=4 hour","histone mutation=H3.3_G34 | histone mutation=H3.3_K27 | histone mutation=wild type | methylation subclass=GBM_G34 | methylation subclass=GBM_K27 | methylation subclass=GBM_Other | methylation subclass=IDH1 | methylation subclass=LGG-like | methylation subclass=PXA-like | methylation subclass=zOther | MGMT promoter methylation=methylated | MGMT promoter methylation=unmethylated | resection=biopsy | resection=other | resection=total or near total resection | response to treatment=complete response | response to treatment=no change | response to treatment=partial response | response to treatment=progressive disease | response to treatment=stable disease | treatment=bevacizumab | treatment=chemotherapy","RNA interference=GFP shRNA | RNA interference=ZEB1 shRNA","genotype=NCH421k | genotype=wild type genotype","genotype=scramble control | genotype=TET3 overexpression | protocol=bisulfite conversion | protocol=oxidated bisulfite conversion","individual=1 | individual=10 | individual=100 | individual=101 | individual=102 | individual=103 | individual=104 | individual=105 | individual=106 | individual=107 | individual=108 | individual=109 | individual=11 | individual=110 | individual=111 | individual=112 | individual=113 | individual=114 | individual=115 | individual=116 | individual=117 | individual=118 | individual=119 | individual=12 | individual=120 | individual=121 | individual=122 | individual=123 | individual=13 | individual=14 | individual=15 | individual=16 | individual=17 | individual=18 | individual=19 | individual=2 | individual=20 | individual=21 | individual=22 | individual=23 | individual=24 | individual=25 | individual=26 | individual=27 | individual=28 | individual=29 | individual=3 | individual=30 | individual=31 | individual=32 | individual=33 | individual=34 | individual=35 | individual=36 | individual=37 | individual=38 | individual=39 | individual=4 | individual=40 | individual=41 | individual=42 | individual=43 | individual=44 | individual=45 | individual=46 | individual=47 | individual=48 | individual=49 | individual=5 | individual=50 | individual=51 | individual=52 | individual=53 | individual=54 | individual=55 | individual=56 | individual=57 | individual=58 | individual=59 | individual=6 | individual=60 | individual=61 | individual=62 | individual=63 | individual=64 | individual=65 | individual=66 | individual=67 | individual=68 | individual=69 | individual=7 | individual=70 | individual=71 | individual=72 | individual=73 | individual=74 | individual=75 | individual=76 | individual=77 | individual=78 | individual=79 | individual=8 | individual=80 | individual=81 | individual=82 | individual=83 | individual=84 | individual=85 | individual=86 | individual=87 | individual=88 | individual=89 | individual=9 | individual=90 | individual=91 | individual=92 | individual=93 | individual=94 | individual=95 | individual=96 | individual=97 | individual=98 | individual=99","cell line=Hep3B | cell line=HL7702 | genotype=NUDT21 knockdown by shRNA | genotype=NUDT21 overexpression | genotype=wild type genotype","phenotype=Snail1 overexpression | phenotype=wild type","IRE1 signature=IRE1high | IRE1 signature=IRE1low | RIDD score=RIDD^high | RIDD score=RIDD^low | RIDD score=RIDD^mid | RIDD signature=RIDDhigh | RIDD signature=RIDDlow | XBP1s score=XBP1s^high | XBP1s score=XBP1s^low | XBP1s score=XBP1s^mid | XBP1s signature=XBP1shigh | XBP1s signature=XBP1slow","MGMT biomarker status=methylated | MGMT biomarker status=unmethylated","RNA interference=control shRNA | RNA interference=LAPTM5 shRNA","phenotype=control | phenotype=CPE overexpression","phenotype=control | phenotype=CPE overexpression","disease=anaplastic astrocytoma | disease=anaplastic ganglioglioma | disease=anaplastic oligodendroglioma | disease=anaplastic pilomyxoid astrocytoma | disease=diffuse intrinsic pontine glioma | disease=glioblastoma | disease=gliosarcoma | disease=pleomorphic anaplastic xanthoastrocytoma | histone mutation=H3.1_K27M | histone mutation=H3.3_G34R | histone mutation=H3.3_K27M | histone mutation=wt | location=brainstem | location=hemispheric | location=midline","cell line=143b | cell line=201T | cell line=451Lu | cell line=A388 | cell line=A427 | cell line=A431 | cell line=ACN | cell line=ALL-PO | cell line=ARH-77 | cell line=ASH-3 | cell line=ATN-1 | cell line=BALL-1 | cell line=BB30-HNC | cell line=BB49-HNC | cell line=BB65-RCC | cell line=BC-1 | cell line=BC-3 | cell line=BE-13 | cell line=BE2-M17 | cell line=Becker | cell line=BICR10 | cell line=BICR78 | cell line=BONNA-12 | cell line=BPH-1 | cell line=BV-173 | cell line=C-33-A | cell line=C-4-I | cell line=C2BBe1 | cell line=C3A | cell line=Ca-Ski | cell line=Ca9-22 | cell line=CAL-39 | cell line=CAL-72 | cell line=CAL-78 | cell line=CaR-1 | cell line=CCK-81 | cell line=CCRF-CEM | cell line=CESS | cell line=CGTH-W-1 | cell line=CHL-1 | cell line=CHP-134 | cell line=CHSA0011 | cell line=CHSA0108 | cell line=CHSA8926 | cell line=CL-40 | cell line=CML-T1 | cell line=COLO-205 | cell line=COLO-320-HSR | cell line=COLO-741 | cell line=COLO-824 | cell line=COR-L303 | cell line=COR-L32 | cell line=COR-L321 | cell line=CP50-MEL-B | cell line=CP66-MEL | cell line=CP67-MEL | cell line=CPC-N | cell line=CRO-AP2 | cell line=CRO-AP3 | cell line=CS1 | cell line=CTB-1 | cell line=CTV-1 | cell line=D-247MG | cell line=D-263MG | cell line=D-336MG | cell line=D-392MG | cell line=D-423MG | cell line=D-502MG | cell line=D-542MG | cell line=D-566MG | cell line=DG-75 | cell line=DIFI | cell line=DJM-1 | cell line=DND-41 | cell line=DOK | cell line=DoTc2-4510 | cell line=DOV13 | cell line=DSH1 | cell line=DU-145 | cell line=EB-3 | cell line=EB2 | cell line=EGI-1 | cell line=EM-2 | cell line=EMC-BAC-1 | cell line=EMC-BAC-2 | cell line=EoL-1-cell | cell line=ES1 | cell line=ES3 | cell line=ES4 | cell line=ES5 | cell line=ES6 | cell line=ES7 | cell line=ES8 | cell line=ESO26 | cell line=ESO51 | cell line=ETK-1 | cell line=EVSA-T | cell line=EW-1 | cell line=EW-11 | cell line=EW-12 | cell line=EW-13 | cell line=EW-16 | cell line=EW-18 | cell line=EW-22 | cell line=EW-24 | cell line=EW-3 | cell line=EW-7 | cell line=Farage | cell line=FLO-1 | cell line=G-MEL | cell line=GAK | cell line=GCIY | cell line=GEO | cell line=GI-ME-N | cell line=GOTO | cell line=GP5d | cell line=GR-ST | cell line=GT3TKB | cell line=H-EMC-SS | cell line=H2369 | cell line=H2373 | cell line=H2461 | cell line=H2591 | cell line=H2595 | cell line=H2722 | cell line=H2731 | cell line=H2795 | cell line=H2803 | cell line=H2804 | cell line=H2810 | cell line=H2818 | cell line=H2869 | cell line=H290 | cell line=H3118 | cell line=H513 | cell line=H9 | cell line=HA7-RCC | cell line=HAL | cell line=HAL-01 | cell line=HC-1 | cell line=HCC1187 | cell line=HCC1806 | cell line=HCC2998 | cell line=HCE-4 | cell line=HCT-116 | cell line=HCT-15 | cell line=HDLM-2 | cell line=HEC-1 | cell line=HeLa | cell line=Hey | cell line=HLE | cell line=HMV-II | cell line=HN | cell line=HO-1-N-1 | cell line=HO-1-u-1 | cell line=HOSMNNG | cell line=Hs-445 | cell line=Hs633T | cell line=HSC-39 | cell line=HT-115 | cell line=HT-29 | cell line=HT-3 | cell line=HT55 | cell line=HTC-C3 | cell line=HUH-6-clone5 | cell line=HuO-3N1 | cell line=HuO9 | cell line=IHH-4 | cell line=IM-9 | cell line=IMR-5 | cell line=IST-MEL1 | cell line=IST-MES1 | cell line=IST-SL1 | cell line=IST-SL2 | cell line=JAR | cell line=JEG-3 | cell line=JHOS-3 | cell line=JHU-011 | cell line=JHU-022 | cell line=JHU-029 | cell line=JiyoyeP-2003 | cell line=JSC-1 | cell line=K2 | cell line=K5 | cell line=KARPAS-1106P | cell line=KARPAS-231 | cell line=KARPAS-45 | cell line=KARPAS-620 | cell line=KGN | cell line=KINGS-1 | cell line=KMH-2 | cell line=KMOE-2 | cell line=KNS-62 | cell line=KNS-81-FD | cell line=KO52 | cell line=KON | cell line=KOSC-2 | cell line=KP-1N | cell line=KP-N-YS | cell line=KPD | cell line=KU812 | cell line=KY821 | cell line=KYAE-1 | cell line=KYSE-220 | cell line=KYSE-50 | cell line=LAMA-84 | cell line=LAN-6 | cell line=LB1047-RCC | cell line=LB2241-RCC | cell line=LB2518-MEL | cell line=LB373-MEL-D | cell line=LB647-SCLC | cell line=LB771-HNC | cell line=LB831-BLC | cell line=LB996-RCC | cell line=LC-1-sq | cell line=LC-2-ad | cell line=LC4-1 | cell line=LIM1215 | cell line=LN-405 | cell line=LNZTA3WT4 | cell line=LS-180 | cell line=LS-513 | cell line=LU-134-A | cell line=LU-135 | cell line=LU-139 | cell line=LU-165 | cell line=M059J | cell line=M14 | cell line=MC-1010 | cell line=MC-CAR | cell line=MC-IXC | cell line=MCC13 | cell line=MCC26 | cell line=MDA-MB-330 | cell line=MDA-MB-361 | cell line=MDST8 | cell line=ME-180 | cell line=MFH-ino | cell line=MFM-223 | cell line=MHH-PREB-1 | cell line=MHM | cell line=MKN28 | cell line=ML-2 | cell line=MLMA | cell line=MMAC-SF | cell line=MN-60 | cell line=Mo-T | cell line=MOG-G-CCM | cell line=MOG-G-UVW | cell line=MOLT-4 | cell line=MRK-nu-1 | cell line=MS-1 | cell line=MS751 | cell line=MY-M12 | cell line=MZ1-PC | cell line=MZ2-MEL | cell line=MZ7-mel | cell line=NB-TU-1-10 | cell line=NB10 | cell line=NB12 | cell line=NB13 | cell line=NB14 | cell line=NB17 | cell line=NB5 | cell line=NB6 | cell line=NB69 | cell line=NB7 | cell line=NBsusSR | cell line=NCC010 | cell line=NCC021 | cell line=NCCIT | cell line=NCI-H128 | cell line=NCI-H1304 | cell line=NCI-H1417 | cell line=NCI-H1688 | cell line=NCI-H1770 | cell line=NCI-H1836 | cell line=NCI-H187 | cell line=NCI-H1993 | cell line=NCI-H2135 | cell line=NCI-H2141 | cell line=NCI-H250 | cell line=NCI-H3122 | cell line=NCI-H345 | cell line=NCI-H378 | cell line=NCI-H510A | cell line=NCI-H630 | cell line=NCI-H64 | cell line=NCI-H661 | cell line=NCI-H720 | cell line=NCI-H740 | cell line=NCI-H748 | cell line=NCI-H820 | cell line=NCI-H835 | cell line=NCI-H847 | cell line=NCI-SNU-1 | cell line=NCI-SNU-16 | cell line=NEC8 | cell line=NH-12 | cell line=NKM-1 | cell line=no-10 | cell line=no-11 | cell line=NOS-1 | cell line=NTERA-2cl-D1 | cell line=NY | cell line=OACM5-1 | cell line=OACp4C | cell line=OCI-LY7 | cell line=OCUB-M | cell line=OHS | cell line=OMC-1 | cell line=OSC-19 | cell line=OSC-20 | cell line=OST | cell line=OV-17R | cell line=OVCA420 | cell line=OVCA433 | cell line=OVCAR-5 | cell line=OVKATE | cell line=OVMIU | cell line=P30-OHK | cell line=P32-ISH | cell line=PA-1 | cell line=PCI-15A | cell line=PCI-30 | cell line=PCI-38 | cell line=PCI-4B | cell line=PCI-6A | cell line=PEO1 | cell line=PFSK-1 | cell line=PL18 | cell line=PL4 | cell line=PWR-1E | cell line=QIMR-WIL | cell line=Ramos-2G6-4C10 | cell line=RC-K8 | cell line=RCC-AB | cell line=RCC-ER | cell line=RCC-FG2 | cell line=RCC-JF | cell line=RCC-JW | cell line=RCC-MF | cell line=RF-48 | cell line=RH-1 | cell line=RKO | cell line=RO82-W-1 | cell line=ROS-50 | cell line=RPMI-2650 | cell line=RPMI-6666 | cell line=RPMI-8866 | cell line=RVH-421 | cell line=RXF393 | cell line=Sarc9371 | cell line=SAS | cell line=SAT | cell line=SBC-1 | cell line=SBC-3 | cell line=SC-1 | cell line=SCC-3 | cell line=SCC90 | cell line=SCH | cell line=Set2 | cell line=SiHa | cell line=SISO | cell line=SJRH30 | cell line=SK-GT-2 | cell line=SK-GT-4 | cell line=SK-MEL-2 | cell line=SK-MG-1 | cell line=SK-N-SH | cell line=SK-NEP-1 | cell line=SK-PN-DW | cell line=SKG-IIIa | cell line=SKN | cell line=SKN-3 | cell line=SLVL | cell line=SN12C | cell line=SNU-175 | cell line=SNU-283 | cell line=SNU-407 | cell line=SNU-81 | cell line=SNU-C1 | cell line=SNU-C2B | cell line=SNU-C5 | cell line=SR | cell line=ST486 | cell line=STS-0421 | cell line=SU-DHL-10 | cell line=SU-DHL-16 | cell line=SU-DHL-5 | cell line=SU-DHL-6 | cell line=SUIT-2 | cell line=SUP-B8 | cell line=SUP-HD1 | cell line=SW1088 | cell line=SW1116 | cell line=SW13 | cell line=SW1463 | cell line=SW156 | cell line=SW1573 | cell line=SW1710 | cell line=SW403 | cell line=SW48 | cell line=SW620 | cell line=SW626 | cell line=SW684 | cell line=SW756 | cell line=SW780 | cell line=SW837 | cell line=SW872 | cell line=SW948 | cell line=SW954 | cell line=SW962 | cell line=SW982 | cell line=TASK1 | cell line=TC-YIK | cell line=TE-10 | cell line=TE-12 | cell line=TE-4 | cell line=TE-441-T | cell line=TE-6 | cell line=TE-8 | cell line=TGBC11TKB | cell line=TGBC1TKB | cell line=TGBC24TKB | cell line=TGW | cell line=TK | cell line=TK10 | cell line=TMK-1 | cell line=TT2609-C02 | cell line=TUR | cell line=U-266 | cell line=U-698-M | cell line=U-CH2 | cell line=U031 | cell line=U251 | cell line=UACC-812 | cell line=UDSCC2 | cell line=UMC-11 | cell line=UWB1-289 | cell line=VA-ES-BJ | cell line=VAL | cell line=VM-CUB-1 | cell line=VMRC-LCD | cell line=VMRC-MELG | cell line=VMRC-RCZ | cell line=WIL2-NS | cell line=WM1552C | cell line=WM278 | cell line=WM35 | cell line=WM793B | cell line=WSU-DLCL2 | cell line=WSU-NHL | cell line=YAPC | cell line=YH-13 | cell line=YT | cell line=ZR-75-30 | disease=acute leukemia | disease=acute lymphoblastic leukemia | disease=acute myeloid leukemia | disease=acute myelomonocytic leukemia | disease=adrenal gland neuroblastoma | disease=adrenocortical carcinoma | disease=anaplastic astrocytoma | disease=Askin tumor | disease=atypical carcinoid tumor | disease=B-cell acute lymphoblastic leukemia | disease=benign prostatic hyperplasia | disease=bladder carcinoma | disease=bladder transitional cell carcinoma | disease=bone neoplasm | disease=brain glioma | disease=breast adenocarcinoma | disease=breast carcinoma | disease=Burkitts lymphoma | disease=carcinoid tumor | disease=carcinoma | disease=cervical carcinoma | disease=cervical small cell carcinoma | disease=cervical squamous cell carcinoma | disease=cholangiocarcinoma | disease=chondrosarcoma | disease=chordoma | disease=choriocarcinoma | disease=chronic myelogenous leukemia | disease=clear cell renal carcinoma | disease=colorectal adenocarcinoma | disease=colorectal carcinoma | disease=cutaneous T-cell lymphoma | disease=diffuse large B cell lymphoma | disease=diffuse large B-cell lymphoma | disease=ductal carcinoma | disease=endometrial adenocarcinoma | disease=eosinophilic leukemia | disease=esophageal adenocarcinoma | disease=esophageal carcinoma | disease=esophageal squamous cell carcinoma | disease=essential thrombocythemia | disease=Ewing sarcoma | disease=fibrosarcoma | disease=follicular thyroid carcinoma | disease=gallbladder adenocarcinoma | disease=gastric adenocarcinoma | disease=glioblastoma multiforme | disease=glioma | disease=hairy cell leukemia | disease=head and neck squamous cell carcinoma | disease=hepatocellular carcinoma | disease=histiocytoma | disease=Hodgkins lymphoma | disease=invasive ductal carcinoma | disease=invasive lobular carcinoma | disease=large cell immunoblastic lymphoma | disease=large cell lung carcinoma | disease=leiomyoma | disease=liposarcoma | disease=lung adenocarcinoma | disease=lung carcinoma | disease=lymphoma | disease=medulloblastoma | disease=melanoma | disease=Merkel cell carcinoma | disease=mesothelioma | disease=multiple myeloma | disease=neuroblastoma | disease=non-small cell lung adenocarcinoma | disease=non-small cell lung carcinoma | disease=normal | disease=not available | disease=osteosarcoma | disease=ovarian adenocarcinoma | disease=ovarian carcinoma | disease=ovarian germ cell tumour | disease=ovarian granulosa tumour | disease=ovarian serous adenocarcinoma | disease=pancreatic adenocarcinoma | disease=pancreatic carcinoma | disease=papillary lung adenocarcinoma | disease=plasma cell leukemia | disease=plasmacytoma | disease=prostate adenocarcinoma | disease=renal cell carcinoma | disease=rhabdomyosarcoma | disease=salivary gland neoplasm | disease=sarcoma | disease=small cell lung carcinoma | disease=squamous cell breast carcinoma | disease=squamous cell carcinoma | disease=squamous cell lung carcinoma | disease=synovial sarcoma | disease=T-cell leukemia | disease=testicular germ cell tumor | disease=thyroid carcinoma | disease=undifferentiated gallbladder carcinoma | disease=vulvar carcinoma | disease=vulvar squamous cell carcinoma | organism part=adrenal gland | organism part=bile duct | organism part=bone | organism part=brain | organism part=breast | organism part=connective tissue | organism part=esophagus | organism part=gall bladder | organism part=hematopoietic system | organism part=kidney | organism part=large intestine | organism part=liver | organism part=lung | organism part=mucosa | organism part=musculature | organism part=ovary | organism part=pancreas | organism part=peripheral nervous system | organism part=placenta | organism part=prostate gland | organism part=skin | organism part=stomach | organism part=testis | organism part=thyroid gland | organism part=urinary bladder | organism part=uterine cervix | organism part=uterus | organism part=vulva","compound=DMSO | compound=KHS101 | dose=7.5 micromolar","phenotype=Lin7A knock down | phenotype=Lin7A knock down complemented by wild type Lin7A | phenotype=scrambled shRNA expression | RNA interference=Lin7A shRNA | RNA interference=scrambled shRNA","genotype=dominant negative EGFR | genotype=EGFR amplification","cancer site=central | cancer site=healthy control | cancer site=Peritumoral | survival probability=long term | survival probability=short term | survival probability=White Matter","individual=2197T | individual=3427T | individual=3523T | individual=3718T | individual=3719T","tumor grading=Control | tumor grading=Long Term | tumor grading=Short Term | tumor location=Central | tumor location=Peritumoral | tumor location=White Matter","clinical information=not applicable | clinical information=Surgical sample taken from the enhancing tumour mass | clinical information=Surgical sample taken from the non-enhancing margin | disease=glioblastoma multiforme | disease=normal | organism part=blood | organism part=brain","genotype=IDH1 mutant | genotype=IDH1 wild type","cell line=786-O | cell line=A498 | cell line=A549 | cell line=ACHN | cell line=BT549 | cell line=CAKI1 | cell line=CCRFCEM | cell line=COLO205 | cell line=DU 145 | cell line=EKVX | cell line=HCC2998 | cell line=HCT116 | cell line=HCT15 | cell line=HL-60 | cell line=HOP-62 | cell line=HOP-92 | cell line=HS578T | cell line=HT-29 | cell line=IGROV-1 | cell line=K-562 | cell line=KM12 | cell line=LOX IMVI | cell line=M14 | cell line=MALME3M | cell line=MCF-7 | cell line=MDAMB231 | cell line=MDAMB435 | cell line=MDAMB468 | cell line=MOLT4 | cell line=NCI-H226 | cell line=NCI-H23 | cell line=NCI-H322M | cell line=NCI-H460 | cell line=NCI-H522 | cell line=NCI/ADR-RES | cell line=OVCAR3 | cell line=OVCAR4 | cell line=OVCAR5 | cell line=OVCAR8 | cell line=PC-3 | cell line=RPMI8226 | cell line=RXF393 | cell line=SF268 | cell line=SF295 | cell line=SF539 | cell line=SK-MEL-2 | cell line=SK-MEL-28 | cell line=SK-MEL-5 | cell line=SKOV3 | cell line=SN12C | cell line=SNB19 | cell line=SNB75 | cell line=SR | cell line=SW620 | cell line=T47D | cell line=TK-10 | cell line=U-251 MG | cell line=UACC-257 | cell line=UACC-62 | cell line=UO-31 | disease=acute lymphoblastic leukemia | disease=acute T lymphoblastic leukaemia | disease=astrocytoma, glioma | disease=B-cell plasmacytoma; myeloma | disease=breast adenocarcinoma | disease=breast carcinoma | disease=breast ductal adenocarcinoma | disease=chronic myelogenic leukemia | disease=colon adenocarcinoma | disease=colon carcinoma | disease=glioblastoma astrocytoma | disease=glioma | disease=immunoblastic large cell lymphoma | disease=kidney clear cell carcinoma | disease=large cell lung carcinoma | disease=lung carcinoma | disease=malignant melanoma | disease=melanoma | disease=mesothelioma | disease=non-small cell lung carcinoma | disease=ovarian adenocarcinoma | disease=ovarian carcinoma | disease=ovarian serous cystadenocarcinoma | disease=promyelocytic leukemia | disease=prostate adenocarcinoma | disease=renal adenocarcinoma | disease=renal carcinoma | disease=renal cell adenocarcinoma | disease=renal cell carcinoma | disease=renal clear cell adenocarcinoma | disease=skin cutaneous melanoma | organism part=blood | organism part=brain | organism part=breast | organism part=kidney | organism part=large intestine | organism part=lung | organism part=ovary | organism part=prostate | organism part=skin","phenotype=astrocyte overexpressing 4 iPSC-inducing and oncogenic factors | phenotype=astrocyte overexpressing 7 iPSC-inducing and oncogenic factors | phenotype=glioblastoma cell line | phenotype=normal astrocyte | phenotype=patient-derived glioma stem cell line","clinical information=patient-derived cell line | clinical information=tumour | individual=2197 | individual=2211 | individual=3427 | individual=3523 | individual=3716 | individual=3718 | individual=3719 | individual=3722 | individual=3724 | individual=4724","clinical information=patient-derived cell line | clinical information=tumour | individual=2197 | individual=2211 | individual=3427 | individual=3716 | individual=3718 | individual=3719 | individual=3722 | individual=3724 | individual=4724","disease=glioblastoma multiforme | disease=normal","sampling site=interface | sampling site=necrosis zone | sampling site=not available | sampling site=peripheral brain zone | sampling site=tumor zone","sampling site=interface | sampling site=necrotic zone | sampling site=peripheral brain zone | sampling site=tumor zone","sampling site=interface | sampling site=necrotic zone | sampling site=not available | sampling site=peripheral brain zone | sampling site=tumor zone","organism part=Non-fluorescence brain | organism part=Red fluorescence glioma","sex=female | sex=male | subject age=34.4 | subject age=45.3 | subject age=46.5 | subject age=53.6 | subject age=55 | subject age=56.2 | subject age=56.9 | subject age=57.8 | subject age=58.3 | subject age=58.8 | subject age=62.7 | subject age=63.9 | subject age=66.4 | subject age=67.3 | subject age=67.5 | subject age=67.6 | subject age=68.1 | subject age=68.9 | subject age=69.4 | subject age=69.7 | subject age=70.9 | subject age=74.3 | subject age=75.3 | subject age=75.6 | subject age=77.4 | subject age=77.6 | subject age=80.5 | subject age=83.7 | subject age=84.3 | subject age=84.9 | survival time months=0.1 | survival time months=0.6 | survival time months=0.7 | survival time months=1.1 | survival time months=1.5 | survival time months=1.8 | survival time months=11.8 | survival time months=14 | survival time months=14.2 | survival time months=15 | survival time months=17.7 | survival time months=18.1 | survival time months=2.2 | survival time months=2.4 | survival time months=21.3 | survival time months=24.1 | survival time months=25.7 | survival time months=25.9 | survival time months=3.1 | survival time months=30.2 | survival time months=33.1 | survival time months=33.6 | survival time months=4.7 | survival time months=5 | survival time months=53.3 | survival time months=8.5 | survival time months=9.7 | survival time months=9.8","transfection=BCL6 siRNA | transfection=non-targeting siRNA","hybrid=: Homo sapiens-Mesocricetus auratus hybrids | hybrid=Mesocricetus auratus | organism=Homo sapiens | organism=Mesocricetus auratus | original tumor type=glioblastoma multiforme | original tumor type=Hodgkin Lymphoma | original tumor type=melanoma | sample type=Cultured monolayer | sample type=FFPE","trans-gene=empty vector | trans-gene=LATS2 kinase-dead | trans-gene=LATS2 wild-type","genotype=LATS2+/+ | genotype=LATS2-/-","genotype=LATS2+/+ | genotype=LATS2-/-","genotype=LATS2+/+ | genotype=LATS2-/-","NA","antibody=antibody anti-ANXA2 | antibody=isotype control","cell/tissue type=Adipose tissue mesenchymal stem cells | cell/tissue type=adult human brain cell culture in 1% serum | cell/tissue type=Bone marrow mesenchymal stem cells | cell/tissue type=fresh GBM tissue | cell/tissue type=fresh Normal human brain tissue | cell/tissue type=GBM adherent cell culture in 1% serum | cell/tissue type=GBM adherent cell culture in 10% serum | cell/tissue type=GBM cell culture in 1% serum; mixture of cells from adherent and sphere cultured | cell/tissue type=GBM cell culture in 10% serum; mixture of cells from adherent and sphere cultured | cell/tissue type=GBM sphere cultures | culture type=adherent 1% FBS+TGF-a | culture type=adherent 10% FBS | culture type=adherent in 1% FBS+TGF-a | culture type=adherent in 10% FBS | culture type=adipose tissue-MSC | culture type=bone marrow-MSC | culture type=control normal in 1% FBS+TGF-a | culture type=Grown as spheres | culture type=not specified","cell line=LNT-229 | cell line=T98G | cell line=U-87 | treatment=Cells following treatment with Decitabine | treatment=Not treated","NA","age=21 | age=22 | age=28 | age=31 | age=32 | age=33 | age=34 | age=35 | age=36 | age=37 | age=38 | age=39 | age=41 | age=42 | age=44 | age=45 | age=46 | age=47 | age=48 | age=49 | age=50 | age=51 | age=52 | age=53 | age=54 | age=55 | age=56 | age=57 | age=58 | age=59 | age=60 | age=61 | age=62 | age=63 | age=64 | age=65 | age=66 | age=67 | age=68 | age=69 | age=70 | age=71 | age=72 | age=73 | age=74 | age=75 | age=76 | age=77 | age=78 | age=79 | age=84 | corticosteroids=NA | corticosteroids=Off | corticosteroids=On | idh1 status=Mutant | idh1 status=Wild type | kps=50-80 | kps=90-100 | mgmt status=Methylated | mgmt status=Missing | mgmt status=Non-methylated | mmse=&lt;27 | mmse=&gt;=27 | mmse=NA | os event type 0 = censored=0 | os event type 0 = censored=1 | os time to event months=1.28 | os time to event months=1.41 | os time to event months=1.91 | os time to event months=1.94 | os time to event months=10.02 | os time to event months=10.05 | os time to event months=10.18 | os time to event months=10.28 | os time to event months=10.32 | os time to event months=10.51 | os time to event months=10.64 | os time to event months=10.84 | os time to event months=10.87 | os time to event months=10.91 | os time to event months=10.94 | os time to event months=10.97 | os time to event months=11.04 | os time to event months=11.07 | os time to event months=11.1 | os time to event months=11.17 | os time to event months=11.24 | os time to event months=11.33 | os time to event months=11.5 | os time to event months=11.56 | os time to event months=11.6 | os time to event months=11.63 | os time to event months=11.66 | os time to event months=11.73 | os time to event months=11.79 | os time to event months=11.83 | os time to event months=11.96 | os time to event months=11.99 | os time to event months=12.12 | os time to event months=12.19 | os time to event months=12.25 | os time to event months=12.29 | os time to event months=12.32 | os time to event months=12.42 | os time to event months=12.55 | os time to event months=12.68 | os time to event months=12.78 | os time to event months=12.94 | os time to event months=12.98 | os time to event months=13.01 | os time to event months=13.04 | os time to event months=13.08 | os time to event months=13.31 | os time to event months=13.4 | os time to event months=13.44 | os time to event months=13.47 | os time to event months=13.6 | os time to event months=13.67 | os time to event months=13.7 | os time to event months=13.73 | os time to event months=13.77 | os time to event months=14.09 | os time to event months=14.16 | os time to event months=14.23 | os time to event months=14.26 | os time to event months=14.29 | os time to event months=14.32 | os time to event months=14.39 | os time to event months=14.52 | os time to event months=14.59 | os time to event months=14.62 | os time to event months=14.65 | os time to event months=14.69 | os time to event months=14.75 | os time to event months=14.95 | os time to event months=15.05 | os time to event months=15.08 | os time to event months=15.11 | os time to event months=15.38 | os time to event months=15.41 | os time to event months=15.54 | os time to event months=15.67 | os time to event months=15.74 | os time to event months=15.77 | os time to event months=15.8 | os time to event months=16.03 | os time to event months=16.13 | os time to event months=16.3 | os time to event months=16.33 | os time to event months=16.39 | os time to event months=16.59 | os time to event months=16.69 | os time to event months=16.76 | os time to event months=16.79 | os time to event months=16.85 | os time to event months=17.05 | os time to event months=17.12 | os time to event months=17.15 | os time to event months=17.22 | os time to event months=17.28 | os time to event months=17.35 | os time to event months=17.45 | os time to event months=17.48 | os time to event months=17.51 | os time to event months=17.74 | os time to event months=17.84 | os time to event months=18.07 | os time to event months=18.23 | os time to event months=18.33 | os time to event months=18.5 | os time to event months=18.6 | os time to event months=19.12 | os time to event months=19.29 | os time to event months=19.35 | os time to event months=19.65 | os time to event months=19.78 | os time to event months=19.81 | os time to event months=2.2 | os time to event months=2.43 | os time to event months=2.69 | os time to event months=2.79 | os time to event months=2.89 | os time to event months=20.04 | os time to event months=20.21 | os time to event months=20.27 | os time to event months=20.53 | os time to event months=20.67 | os time to event months=20.83 | os time to event months=20.86 | os time to event months=21.06 | os time to event months=21.36 | os time to event months=21.55 | os time to event months=21.62 | os time to event months=21.68 | os time to event months=21.72 | os time to event months=21.88 | os time to event months=21.95 | os time to event months=21.98 | os time to event months=22.24 | os time to event months=22.31 | os time to event months=22.47 | os time to event months=22.57 | os time to event months=22.67 | os time to event months=22.83 | os time to event months=22.9 | os time to event months=23.06 | os time to event months=23.13 | os time to event months=23.16 | os time to event months=23.2 | os time to event months=23.23 | os time to event months=23.36 | os time to event months=23.49 | os time to event months=23.62 | os time to event months=23.69 | os time to event months=23.89 | os time to event months=23.92 | os time to event months=23.95 | os time to event months=24.02 | os time to event months=24.05 | os time to event months=24.08 | os time to event months=24.15 | os time to event months=24.21 | os time to event months=24.28 | os time to event months=24.31 | os time to event months=24.34 | os time to event months=24.41 | os time to event months=24.48 | os time to event months=24.64 | os time to event months=24.71 | os time to event months=24.97 | os time to event months=25.17 | os time to event months=25.2 | os time to event months=25.36 | os time to event months=25.43 | os time to event months=25.46 | os time to event months=25.53 | os time to event months=25.79 | os time to event months=26.05 | os time to event months=26.15 | os time to event months=26.25 | os time to event months=26.32 | os time to event months=26.61 | os time to event months=26.84 | os time to event months=26.94 | os time to event months=27.07 | os time to event months=27.2 | os time to event months=27.27 | os time to event months=27.43 | os time to event months=27.66 | os time to event months=27.7 | os time to event months=27.83 | os time to event months=28.09 | os time to event months=28.12 | os time to event months=28.29 | os time to event months=28.39 | os time to event months=28.42 | os time to event months=28.55 | os time to event months=28.68 | os time to event months=28.81 | os time to event months=28.88 | os time to event months=28.94 | os time to event months=29.17 | os time to event months=29.57 | os time to event months=29.77 | os time to event months=29.8 | os time to event months=3.06 | os time to event months=3.25 | os time to event months=3.32 | os time to event months=3.42 | os time to event months=3.45 | os time to event months=3.58 | os time to event months=3.61 | os time to event months=3.75 | os time to event months=3.78 | os time to event months=3.84 | os time to event months=30.09 | os time to event months=30.16 | os time to event months=30.26 | os time to event months=30.32 | os time to event months=30.39 | os time to event months=30.46 | os time to event months=30.59 | os time to event months=31.11 | os time to event months=31.74 | os time to event months=32.03 | os time to event months=32.46 | os time to event months=32.56 | os time to event months=32.69 | os time to event months=32.79 | os time to event months=32.95 | os time to event months=33.12 | os time to event months=33.35 | os time to event months=34.1 | os time to event months=34.17 | os time to event months=34.5 | os time to event months=34.56 | os time to event months=34.89 | os time to event months=35.45 | os time to event months=36.24 | os time to event months=36.4 | os time to event months=36.83 | os time to event months=37.72 | os time to event months=37.98 | os time to event months=38.08 | os time to event months=39.1 | os time to event months=4.17 | os time to event months=4.5 | os time to event months=4.53 | os time to event months=4.6 | os time to event months=4.93 | os time to event months=41.43 | os time to event months=41.49 | os time to event months=41.69 | os time to event months=5.03 | os time to event months=5.22 | os time to event months=5.45 | os time to event months=5.75 | os time to event months=5.85 | os time to event months=5.88 | os time to event months=5.95 | os time to event months=6.01 | os time to event months=6.05 | os time to event months=6.28 | os time to event months=6.34 | os time to event months=6.51 | os time to event months=6.57 | os time to event months=6.7 | os time to event months=6.93 | os time to event months=6.97 | os time to event months=7.16 | os time to event months=7.26 | os time to event months=7.36 | os time to event months=7.72 | os time to event months=7.89 | os time to event months=7.95 | os time to event months=8.11 | os time to event months=8.18 | os time to event months=8.25 | os time to event months=8.31 | os time to event months=8.34 | os time to event months=8.38 | os time to event months=8.44 | os time to event months=8.64 | os time to event months=8.71 | os time to event months=8.74 | os time to event months=8.84 | os time to event months=8.87 | os time to event months=8.94 | os time to event months=9 | os time to event months=9.03 | os time to event months=9.07 | os time to event months=9.46 | os time to event months=9.69 | os time to event months=9.76 | os time to event months=9.86 | os time to event months=9.89 | os time to event months=9.92 | os time to event months=9.95 | pfs event type 0 = censored=0 | pfs event type 0 = censored=1 | pfs time to event months=0 | pfs time to event months=0.8 | pfs time to event months=1 | pfs time to event months=1.3 | pfs time to event months=1.4 | pfs time to event months=1.6 | pfs time to event months=1.9 | pfs time to event months=10 | pfs time to event months=10.1 | pfs time to event months=10.2 | pfs time to event months=10.3 | pfs time to event months=10.4 | pfs time to event months=10.5 | pfs time to event months=10.6 | pfs time to event months=10.9 | pfs time to event months=11 | pfs time to event months=11.1 | pfs time to event months=11.2 | pfs time to event months=11.3 | pfs time to event months=11.4 | pfs time to event months=11.5 | pfs time to event months=11.7 | pfs time to event months=11.8 | pfs time to event months=11.9 | pfs time to event months=12 | pfs time to event months=12.1 | pfs time to event months=12.2 | pfs time to event months=12.4 | pfs time to event months=12.5 | pfs time to event months=12.7 | pfs time to event months=12.9 | pfs time to event months=13 | pfs time to event months=13.1 | pfs time to event months=13.4 | pfs time to event months=13.5 | pfs time to event months=13.6 | pfs time to event months=13.7 | pfs time to event months=13.9 | pfs time to event months=14 | pfs time to event months=14.1 | pfs time to event months=14.2 | pfs time to event months=14.3 | pfs time to event months=14.4 | pfs time to event months=14.5 | pfs time to event months=14.6 | pfs time to event months=14.7 | pfs time to event months=14.8 | pfs time to event months=14.9 | pfs time to event months=15 | pfs time to event months=15.2 | pfs time to event months=15.5 | pfs time to event months=15.9 | pfs time to event months=16 | pfs time to event months=16.2 | pfs time to event months=16.3 | pfs time to event months=16.4 | pfs time to event months=16.5 | pfs time to event months=16.6 | pfs time to event months=16.7 | pfs time to event months=17 | pfs time to event months=17.4 | pfs time to event months=17.5 | pfs time to event months=17.8 | pfs time to event months=17.9 | pfs time to event months=18.1 | pfs time to event months=18.2 | pfs time to event months=18.3 | pfs time to event months=18.4 | pfs time to event months=18.5 | pfs time to event months=19.1 | pfs time to event months=19.3 | pfs time to event months=19.4 | pfs time to event months=2 | pfs time to event months=2.1 | pfs time to event months=2.2 | pfs time to event months=2.3 | pfs time to event months=2.4 | pfs time to event months=2.5 | pfs time to event months=2.6 | pfs time to event months=2.8 | pfs time to event months=20 | pfs time to event months=20.1 | pfs time to event months=20.3 | pfs time to event months=20.5 | pfs time to event months=20.6 | pfs time to event months=20.9 | pfs time to event months=21 | pfs time to event months=21.5 | pfs time to event months=21.7 | pfs time to event months=22.1 | pfs time to event months=22.2 | pfs time to event months=22.4 | pfs time to event months=22.5 | pfs time to event months=22.8 | pfs time to event months=23 | pfs time to event months=23.7 | pfs time to event months=23.9 | pfs time to event months=24.3 | pfs time to event months=25.1 | pfs time to event months=26.7 | pfs time to event months=29.5 | pfs time to event months=3.1 | pfs time to event months=3.2 | pfs time to event months=3.3 | pfs time to event months=3.4 | pfs time to event months=3.6 | pfs time to event months=3.7 | pfs time to event months=3.8 | pfs time to event months=3.9 | pfs time to event months=31.4 | pfs time to event months=4 | pfs time to event months=4.1 | pfs time to event months=4.2 | pfs time to event months=4.3 | pfs time to event months=4.4 | pfs time to event months=4.5 | pfs time to event months=4.6 | pfs time to event months=4.7 | pfs time to event months=4.8 | pfs time to event months=5 | pfs time to event months=5.1 | pfs time to event months=5.2 | pfs time to event months=5.3 | pfs time to event months=5.5 | pfs time to event months=5.6 | pfs time to event months=5.7 | pfs time to event months=5.8 | pfs time to event months=5.9 | pfs time to event months=6 | pfs time to event months=6.1 | pfs time to event months=6.2 | pfs time to event months=6.3 | pfs time to event months=7 | pfs time to event months=7.2 | pfs time to event months=7.3 | pfs time to event months=7.4 | pfs time to event months=7.6 | pfs time to event months=7.7 | pfs time to event months=7.8 | pfs time to event months=7.9 | pfs time to event months=8 | pfs time to event months=8.1 | pfs time to event months=8.2 | pfs time to event months=8.3 | pfs time to event months=8.4 | pfs time to event months=8.6 | pfs time to event months=8.7 | pfs time to event months=8.8 | pfs time to event months=8.9 | pfs time to event months=9 | pfs time to event months=9.3 | pfs time to event months=9.5 | pfs time to event months=9.7 | pfs time to event months=9.8 | pfs time to event months=9.9 | phillips subtype=Mesenchymal | phillips subtype=Proliferative | phillips subtype=Proneural | phillips subtype=Unclassified | rpa class=Grade III | rpa class=Grade IV | rpa class=Grade V | rpa class=NA | Sex=female | Sex=male | surgical status=Biopsy | surgical status=Complete resection | surgical status=NA | surgical status=Partial resection | tcga subtype=Classical | tcga subtype=Mesenchymal | tcga subtype=Neural | tcga subtype=Proneural | tcga subtype=Unclassified | treatment=Bevacizumab | treatment=placebo | who=0 | who=1 | who=2 | who=NA","NA","density gradient region=bottom | density gradient region=middle | density gradient region=top | patient=12 | patient=14 | patient=34 | patient=43 | patient=5","reference=not specified | reference=Promega commercial genomic DNA P/N G1471 | reference=Promega commercial genomic DNA P/N G1521 | sex=female | sex=male | sex=not specified | tissue type=brain | tissue type=not specified | tissue type=primary cell line","individual=P13 | individual=P3 | individual=P8 | phenotype=angiogenic | phenotype=intermediate | phenotype=invasive","cell line=HCC827-Del | cell line=HCC827-Del-TM | compound=control | compound=Decitabine+Vorinostat | genotype=EGFR L747-S752 | genotype=EGFR L747-S752/T790M","genotype=control | genotype=GUCY1B3 overexpression","^sample=ASTRO III 1425 | ^sample=ASTRO III 1704 | ^sample=ASTRO III 1723 | ^sample=ASTRO III 587 | ^sample=ASTRO III 659 | ^sample=ASTRO III 671 | ^sample=ASTRO III 672 | ^sample=ASTRO III 747 | ^sample=GBM 1022 | ^sample=GBM 1028 | ^sample=GBM 1032 | ^sample=GBM 1038 | ^sample=GBM 1043 | ^sample=GBM 1334 | ^sample=GBM 1342 | ^sample=GBM 1354 | ^sample=GBM 1398 | ^sample=GBM 1406 | ^sample=GBM 1414 | ^sample=GBM 1423 | ^sample=GBM 1463 | ^sample=GBM 1469 | ^sample=GBM 1478 | ^sample=GBM 1495 | ^sample=GBM 1511 | ^sample=GBM 1516 | ^sample=GBM 1521 | ^sample=GBM 1544 | ^sample=GBM 1656 | ^sample=GBM 1667 | ^sample=GBM 1675 | ^sample=GBM 1681 | ^sample=GBM 1745 | ^sample=GBM 1798 | ^sample=GBM 1900 | ^sample=GBM 1902 | ^sample=GBM 1905 | ^sample=GBM 2013 | ^sample=GBM 2015 | ^sample=GBM 2017 | ^sample=GBM 2028 | ^sample=GBM 2029 | ^sample=GBM 2067 | ^sample=GBM 2068 | ^sample=GBM 2079 | ^sample=GBM 2098 | ^sample=GBM 2158 | ^sample=GBM 2166 | ^sample=GBM 585 | ^sample=GBM 597 | ^sample=GBM 604 | ^sample=GBM 636 | ^sample=GBM 660 | ^sample=GBM 697 | ^sample=GBM 706 | ^sample=GBM 712 | ^sample=GBM 746 | ^sample=GBM 749 | ^sample=GBM 782 | ^sample=GBM 824 | ^sample=GBM 839 | ^sample=GBM 931 | ^sample=GBM 932 | ^sample=GBM 938 | ^sample=GBM 976 | ^sample=GBM 995 | ^sample=GBM 996 | ^sample=MIXED III 1721 | ^sample=MIXED III 615 | ^sample=MIXED III 664 | ^sample=MIXED III 713 | ^sample=MIXED III 799 | ^sample=MIXED III 886 | ^sample=MIXED III 912 | ^sample=OLIGO III 1433 | ^sample=OLIGO III 1804 | ^sample=OLIGO III 613 | ^sample=OLIGO III 650 | ^sample=OLIGO III 695 | ^sample=OLIGO III 742 | ^sample=OLIGO III 744 | ^sample=OLIGO III 744.1 | ^sample=OLIGO III 840 | ^sample=OLIGO III 975 | ^sample=OLIGO III 975.1 | age=1.0 | age=18.0 | age=20.0 | age=23.0 | age=24.0 | age=27.0 | age=28.0 | age=29.0 | age=30.0 | age=31.0 | age=32.0 | age=33.0 | age=34.0 | age=35.0 | age=36.0 | age=37.0 | age=39.0 | age=40.0 | age=41.0 | age=42.0 | age=43.0 | age=44.0 | age=45.0 | age=47.0 | age=48.0 | age=49.0 | age=50.0 | age=51.0 | age=52.0 | age=54.0 | age=56.0 | age=58.0 | age=60.0 | age=61.0 | age=62.0 | age=63.0 | age=64.0 | age=65.0 | age=66.0 | age=69.0 | age=70.0 | age=75.0 | age=76.0 | age=78.0 | age=82.0 | diseaselocation=LEFT FRONTAL LOBE | diseaselocation=LEFT FRONTAL TEMPORAL | diseaselocation=LEFT PARIETAL LOBE | diseaselocation=LEFT PARIETAL OCCIPITAL | diseaselocation=LEFT TEMPORAL LOBE | diseaselocation=LEFT TEMPORAL PARIETAL LOB | diseaselocation=LEFT THALAMIC | diseaselocation=RIGHT ANTERIOR TEMPORAL LOBE | diseaselocation=RIGHT CEREBELLUM | diseaselocation=RIGHT FRONTAL LOBE | diseaselocation=RIGHT FRONTAL PARIETAL | diseaselocation=RIGHT FRONTAL TEMPORAL | diseaselocation=RIGHT PARIETAL LOBE | diseaselocation=RIGHT PARIETAL OCCIPITAL | diseaselocation=RIGHT TEMPORAL LOBE | diseaselocation=RIGHT TEMPORAL PARIETAL LOB | diseasestate=Astrocytomas | diseasestate=Glioblastoma | diseasestate=Glioma | diseasestate=Oligodendroglial Tumor | histology=AA | histology=AM | histology=AO | histology=GBM | Sex=female | Sex=male | tumorgrading=Grade 3 | tumorgrading=Grade 4","diseasestate=Classic anaplastic oligodendroglioma | diseasestate=Classic glioblastoma | diseasestate=Non-classic anaplastic oligodendroglioma | diseasestate=Non-classic glioblastoma | survival days=103.0 | survival days=1100.0 | survival days=1137.0 | survival days=1162.0 | survival days=1354.0 | survival days=1375.0 | survival days=157.0 | survival days=1604.0 | survival days=1644.0 | survival days=1674.0 | survival days=171.0 | survival days=177.0 | survival days=1804.0 | survival days=21.0 | survival days=213.0 | survival days=215.0 | survival days=219.0 | survival days=231.0 | survival days=242.0 | survival days=263.0 | survival days=272.0 | survival days=276.0 | survival days=281.0 | survival days=308.0 | survival days=323.0 | survival days=359.0 | survival days=368.0 | survival days=406.0 | survival days=408.0 | survival days=41.0 | survival days=439.0 | survival days=498.0 | survival days=501.0 | survival days=519.0 | survival days=559.0 | survival days=585.0 | survival days=63.0 | survival days=630.0 | survival days=638.0 | survival days=670.0 | survival days=729.0 | survival days=789.0 | survival days=790.0 | survival days=793.0 | survival days=795.0 | survival days=803.0 | survival days=916.0 | survival days=97.0 | survival days=992.0 | vital status=alive | vital status=dead","individual=patient 1 (non-glioma) | individual=patient 10 (glioblastoma) | individual=patient 11 (glioblastoma) | individual=patient 12 (glioblastoma) | individual=patient 13 (glioblastoma) | individual=patient 14 (glioblastoma) | individual=patient 2 (non-glioma) | individual=patient 3 (non-glioma) | individual=patient 4 (low-grade glioma) | individual=patient 5 (low-grade glioma) | individual=patient 6 (low-grade glioma) | individual=patient 7 (glioblastoma) | individual=patient 8 (glioblastoma) | individual=patient 9 (glioblastoma) | individual=subject 15 (healthy) | organism part=brain | organism part=peripheral blood | tcr repertoire=not specified | tcr repertoire=TCR-alpha | tcr repertoire=TCR-beta","growth condition=hypoxia | growth condition=normoxia","cell line=astrocyte | cell line=Glioblastoma | chip antibody=IgG (Millipore, Cat # 12-370) | chip antibody=not specified | chip antibody=STAT3 antibody (Cell Signaling Technology, Cat# 9132) | derivation=Cell line generated by culture of surgically excised tumor in defined culture media | derivation=EGFRvIII-expressing astrocytes were established as previously described (de La Iglesia et al 2008, Genes and Dev, 22(4):449-62.). | derivation=MSCV-expressing astrocytes were established as previously described (de La Iglesia et al 2008, Genes and Dev, 22(4):449-62.). | genotype=EGFRvIII expressing | genotype=EGFRvIII negative | genotype=EGFRvIII positive | genotype=EGFRvIII-expressing STAT3 floxed | genotype=EGFRvIII-expressing STAT3 knockout | genotype=MSCV-expressing STAT3 floxed | genotype=MSCV-expressing STAT3 knockout | genotype=OSMR-KD1_EGFRvIII expressing | genotype=OSMR-KD2 EGFRvIII expressing | genotype=Scramble control-EGFRvIII expressing | genotype=Vector-control-EGFRvIII expressing | organism=Homo sapiens | organism=Mus musculus","culture status=differentiated | culture status=undifferentiated | treated with=none (untreated) | treated with=TWS119 (LW)","cell type=Blood | cell type=Cancer | cell type=Neual | sex=female | sex=male | sex=not applicable | sex=unknown","NA","age yrs=15 | age yrs=19 | age yrs=20 | age yrs=22 | age yrs=23 | age yrs=24 | age yrs=25 | age yrs=26 | age yrs=28 | age yrs=30 | age yrs=31 | age yrs=32 | age yrs=33 | age yrs=34 | age yrs=35 | age yrs=36 | age yrs=37 | age yrs=38 | age yrs=39 | age yrs=40 | age yrs=43 | age yrs=45 | age yrs=46 | age yrs=48 | age yrs=49 | age yrs=50 | age yrs=51 | age yrs=54 | age yrs=55 | age yrs=56 | age yrs=58 | age yrs=59 | age yrs=60 | age yrs=61 | age yrs=62 | age yrs=63 | age yrs=65 | age yrs=70 | age yrs=NA | egfr status=0.2 | egfr status=0.35 | egfr status=0.5 | egfr status=0.6 | egfr status=0.65 | egfr status=0.7 | egfr status=0.75 | egfr status=NA | egfr status=Negative | gfap status=NA | gfap status=ND | gfap status=Negative | gfap status=Positive | gfap status=positive | mib=0.02 | mib=0.03 | mib=0.045 | mib=0.05 | mib=0.055 | mib=0.06 | mib=0.065 | mib=0.07 | mib=0.08 | mib=0.1 | mib=0.12 | mib=0.14 | mib=0.15 | mib=0.18 | mib=0.2 | mib=0.22 | mib=0.25 | mib=0.35 | mib=0.4 | mib=0.5 | mib=0.6 | mib=2-5% | mib=3-4% | mib=3-5% | mib=5-8% | mib=7-8% | mib=Low | mib=NA | organism part=Anaplastic Astrocytoma (grade III) | organism part=Control brain | organism part=Diffuse Astrocytoma (grade II) | organism part=Glioblastoma | p53 status=NA | p53 status=Negative | p53 status=Positive | p53 status=positive | sex=female | sex=male | sex=NA | site=corpus callosum | site=Frontal | site=Left basifrontal | site=Left frontal | site=Left frontal lobe | site=Left fronto parietal | site=Left fronto temporal | site=Left Insular | site=Left insular | site=Left insular with basifrontal extension | site=Left medial frontal | site=Left parietal cystic lesion | site=Left parieto occipital lesion | site=Left parieto occiptal | site=Left posterior frontal | site=Left posterior fronto parietal | site=Left posterior temporal | site=Left tempero parietal | site=Left tempero parietal occipital | site=Left temporal | site=Left temporal frontal | site=Left temporal pole | site=Medial temporal | site=NA | site=Posterior frontal | site=Right frontal | site=Right fronto parietal | site=Right insular | site=Right parietal | site=Right parieto occipital | site=Right tempero parietal | site=Right temporal | site=Right thalamus | site=Supramarginal/angular gyrus","1p/19q co-deletion=0 | 1p/19q co-deletion=1 | histology=GBMO | histology=Glioblastoma | histology=High grade oligoastrocytoma with necrosis | histology=High-grade oligoastrocytoma | histology=High-grade oligodendroglioma | histology=Low-grade oligoastrocytoma | histology=Low-grade oligodendroglioma | histology grade=0 | histology grade=1 | idh1.gene.mutation.status=M | idh1.gene.mutation.status=WT | idh2.gene_mutation.status=M | idh2.gene_mutation.status=WT","1p/19q co-deletion=0 | 1p/19q co-deletion=1 | histology=GBMO | histology=Glioblastoma | histology=High grade oligoastrocytoma with necrosis | histology=High-grade oligoastrocytoma | histology=High-grade oligodendroglioma | histology=Low-grade oligoastrocytoma | histology=Low-grade oligodendroglioma | histology=NOS | histology.grade=2 | histology.grade=3 | histology.grade=4 | idh1.gene.mutation=M | idh1.gene.mutation=WT | idh2.gene_mutation=M | idh2.gene_mutation=WT","1p/19q codeletion=0 | 1p/19q codeletion=1 | histology=GBMO | histology=Glioblastoma | histology=High-grade Oligoastrocytoma | histology=High-grade Oligodendroglioma | histology=Low-grade Oligodendroglioma | histology grade=2 | histology grade=3 | histology grade=4 | idh1.gene.mutation=M | idh1.gene.mutation=WT | idh2.gene.mutation=M | idh2.gene.mutation=WT","1p/19q codeletion=0 | 1p/19q codeletion=1 | histology grade=2 | histology grade=3 | histology grade=4 | idh1.gene.mutation=mutation | idh1.gene.mutation=wild type genotype | idh2.gene.mutation=mutation | idh2.gene.mutation=wild type genotype","1p/19q co-deletion=0 | 1p/19q co-deletion=1 | histology=Diffuse astrocytoma | histology=GBMO | histology=Glioblastoma | histology=High-grade Oligoastrocytoma | histology=High-grade Oligodendroglioma | histology=Low-grade Oligoastrocytoma | histology=Low-grade Oligodendroglioma | histology=Normal | histology=normal | histology=NOS | histology_grade=2 | histology_grade=3 | histology_grade=4 | idh1.gene.mutation=M | idh1.gene.mutation=WT | idh2.gene.mutation=M | idh2.gene.mutation=WT | os.event=0 | os.event=1","clinical_subgroup=long-term survivor (LTS) | clinical_subgroup=not specified | clinical_subgroup=short-term survivor (STS) | tissue type=Glioblastoma | tissue type=normal brain","age years=1 | age years=10 | age years=11 | age years=12 | age years=13 | age years=14 | age years=15 | age years=16 | age years=17 | age years=18 | age years=19 | age years=2 | age years=20 | age years=21 | age years=22 | age years=23 | age years=24 | age years=25 | age years=26 | age years=27 | age years=28 | age years=3 | age years=30 | age years=31 | age years=32 | age years=33 | age years=34 | age years=35 | age years=36 | age years=37 | age years=38 | age years=39 | age years=4 | age years=40 | age years=41 | age years=42 | age years=43 | age years=44 | age years=45 | age years=48 | age years=49 | age years=5 | age years=51 | age years=52 | age years=53 | age years=55 | age years=56 | age years=57 | age years=58 | age years=59 | age years=6 | age years=62 | age years=63 | age years=66 | age years=69 | age years=7 | age years=70 | age years=71 | age years=73 | age years=75 | age years=78 | age years=8 | age years=81 | age years=9 | age years=&lt;1 | age years=NA | institutional tumor diagnosis=AA | institutional tumor diagnosis=ABM | institutional tumor diagnosis=AT/RT | institutional tumor diagnosis=CNS-PNET | institutional tumor diagnosis=CPC | institutional tumor diagnosis=DIG | institutional tumor diagnosis=EPN | institutional tumor diagnosis=ETMR | institutional tumor diagnosis=EWS | institutional tumor diagnosis=GBM | institutional tumor diagnosis=malignant neuroepithelial tumour | institutional tumor diagnosis=MB | institutional tumor diagnosis=MNG | institutional tumor diagnosis=NA | institutional tumor diagnosis=PINEAL TUMOUR | institutional tumor diagnosis=PXA | institutional tumor diagnosis=SARCOMA (NOS) | institutional tumor diagnosis=unclear histology | molecular subgroup=AT/RT | molecular subgroup=CNS_EFT-CIC | molecular subgroup=CNS_HGNET-BCOR | molecular subgroup=CNS_HGNET-MN1 | molecular subgroup=CNS_NB-FOXR2 | molecular subgroup=CPC | molecular subgroup=CTRL | molecular subgroup=DIG | molecular subgroup=EPN_RELA | molecular subgroup=EPN_YAP | molecular subgroup=ETMR | molecular subgroup=EWS | molecular subgroup=HGG_G34 | molecular subgroup=HGG_IDH | molecular subgroup=HGG_K27 | molecular subgroup=HGG_MYCN | molecular subgroup=HGG_RTK | molecular subgroup=MB_GRP3 | molecular subgroup=MB_GRP4 | molecular subgroup=MB_SHH | molecular subgroup=MB_WNT | molecular subgroup=MNG | molecular subgroup=pineal | molecular subgroup=PXA | molecular subgroup=unclassifiable | sex=female | sex=male | sex=NA | tumor location=brainstem | tumor location=brainstem/cerebellopontine angle | tumor location=central region, bilateral | tumor location=central region, right | tumor location=cerebellar | tumor location=cerebellar/brainstem | tumor location=cerebellopontine angle | tumor location=cerebral (NOS) | tumor location=choroid plexus | tumor location=corpus callosum/parietal lobe | tumor location=duraadherent (NOS) | tumor location=falx cerebri | tumor location=fourth ventricle | tumor location=fourth ventricle/brainstem | tumor location=fourth ventricle/vermis | tumor location=frontal lobe | tumor location=frontal lobe, bilateral | tumor location=frontal lobe, left | tumor location=frontal lobe, right | tumor location=frontal/parietal lobe | tumor location=frontal/parietal lobe, left | tumor location=frontal/parietal lobe, right | tumor location=frontal/temporal lobe | tumor location=frontal/temporal lobe and basal ganglia | tumor location=frontal/temporal lobe, left | tumor location=frontal/temporal lobe, right | tumor location=frontal/temporal lobe, right and pineal region | tumor location=fronto-basal | tumor location=fronto-basal, right | tumor location=fronto-central | tumor location=fronto-dorsal, left | tumor location=fronto-lateral | tumor location=hemispheric (NOS) | tumor location=hemispheric, left | tumor location=hemispheric, right (NOS) | tumor location=hypothalamic, leptomeningeal spread | tumor location=infra-/supratentorial (no cerebellar lesion) | tumor location=intraventricular | tumor location=intraventricular, left | tumor location=lateral ventricle | tumor location=lateral ventricle, left | tumor location=leptomeningeal craniospinal | tumor location=multilocular; spinal, cerebral, and cerebellar lesions | tumor location=NA | tumor location=nucleus caudatus, left | tumor location=occipital lobe | tumor location=occipital lobe, left | tumor location=occipital/parietal lobe | tumor location=occipital/parietal lobe, right | tumor location=optic chiasm | tumor location=parasagittal/postcentral, right | tumor location=parietal lobe | tumor location=parietal lobe, left | tumor location=parietal lobe, right | tumor location=parietal/occipital lobe | tumor location=parietal/occipital lobe, left | tumor location=parietal/occipital lobe, right | tumor location=parietal/parasaggital | tumor location=parietal/temporal lobe | tumor location=parietal/temporal lobe, left | tumor location=parietal/temporal lobe, right | tumor location=parietal/temporal/occipital lobe | tumor location=parieto-central | tumor location=peduncular | tumor location=pineal region | tumor location=pons | tumor location=pons/mesencephalon | tumor location=postcentral | tumor location=posterior fossa | tumor location=precentral | tumor location=protuberans/bulb | tumor location=sellar | tumor location=spinal (C2) | tumor location=spinal (L2/3) | tumor location=spinal (L3-S2) | tumor location=spinal (L5) | tumor location=spinal (L5/S1) | tumor location=spinal (NOS) | tumor location=spinal (T12/L1) | tumor location=spinal (T5-7) | tumor location=spinal (T6/7) | tumor location=spinal (T8) | tumor location=supra-/intrasellar | tumor location=supratentorial (NOS) | tumor location=sylvian fissure, left | tumor location=tectum | tumor location=temporal lobe | tumor location=temporal lobe, left | tumor location=temporal lobe, right | tumor location=temporal/occipital lobe, left | tumor location=temporal/occipital lobe, right | tumor location=temporal/parietal lobe | tumor location=temporal/parietal lobe, left | tumor location=temporal/parietal lobe, right | tumor location=temporal/parietal/occipital lobe | tumor location=temporo-basal, right | tumor location=thalamic | tumor location=thalamic, left | tumor location=thalamic, right | tumor location=thalamic/lateral ventricle | tumor location=third ventricle | tumor location=third ventricle/pineal region","affymetrix id=dkfz0004 | affymetrix id=dkfz0005 | affymetrix id=dkfz0022 | affymetrix id=dkfz0031 | affymetrix id=dkfz0045 | affymetrix id=dkfz0047 | affymetrix id=dkfz0055 | affymetrix id=dkfz0067 | affymetrix id=dkfz0069 | affymetrix id=dkfz0077 | affymetrix id=dkfz0094 | affymetrix id=dkfz0103 | affymetrix id=dkfz0107 | affymetrix id=dkfz0111 | affymetrix id=dkfz0115 | affymetrix id=dkfz0124 | affymetrix id=dkfz0200 | affymetrix id=dkfz0203 | affymetrix id=dkfz0207 | affymetrix id=dkfz0211 | affymetrix id=dkfz0213 | affymetrix id=dkfz0216 | affymetrix id=dkfz0222 | affymetrix id=dkfz0226 | affymetrix id=dkfz0227 | affymetrix id=dkfz0229 | affymetrix id=dkfz0235 | affymetrix id=dkfz0242 | affymetrix id=dkfz0300 | affymetrix id=dkfz0313 | affymetrix id=dkfz0314 | affymetrix id=dkfz0316 | affymetrix id=dkfz0318 | affymetrix id=dkfz0319 | affymetrix id=dkfz0324 | affymetrix id=dkfz0325 | affymetrix id=dkfz0329 | affymetrix id=dkfz0330 | affymetrix id=dkfz0332 | affymetrix id=dkfz0333 | affymetrix id=dkfz0335 | affymetrix id=dkfz0339 | affymetrix id=dkfz0349 | affymetrix id=dkfz0362 | affymetrix id=dkfz0366 | affymetrix id=dkfz0368 | affymetrix id=dkfz0373 | affymetrix id=dkfz0383 | affymetrix id=dkfz0384 | affymetrix id=dkfz0385 | affymetrix id=dkfz0386 | affymetrix id=dkfz0387 | affymetrix id=dkfz0389 | affymetrix id=dkfz0390 | affymetrix id=dkfz0391 | affymetrix id=dkfz0392 | affymetrix id=dkfz0417 | affymetrix id=dkfz0418 | affymetrix id=dkfz0420 | affymetrix id=dkfz0429 | affymetrix id=dkfz0430 | affymetrix id=dkfz0431 | affymetrix id=dkfz0439 | affymetrix id=dkfz0440 | affymetrix id=dkfz0449 | affymetrix id=dkfz0456 | affymetrix id=dkfz0465 | affymetrix id=dkfz0479 | affymetrix id=dkfz0480 | affymetrix id=dkfz0482 | affymetrix id=dkfz0487 | affymetrix id=dkfz0509 | affymetrix id=dkfz0510 | affymetrix id=dkfz0524 | affymetrix id=dkfz0525 | affymetrix id=dkfz0526 | affymetrix id=dkfz0527 | affymetrix id=dkfz0528 | affymetrix id=dkfz0529 | affymetrix id=dkfz0530 | affymetrix id=dkfz0531 | affymetrix id=dkfz0532 | affymetrix id=dkfz0534 | affymetrix id=dkfz0535 | affymetrix id=dkfz0536 | affymetrix id=dkfz0557 | affymetrix id=dkfz0566 | affymetrix id=dkfz0570 | affymetrix id=dkfz0571 | affymetrix id=dkfz0582 | affymetrix id=dkfz0588 | affymetrix id=dkfz0589 | affymetrix id=dkfz0590 | affymetrix id=dkfz0591 | affymetrix id=dkfz0602 | affymetrix id=dkfz0764 | affymetrix id=dkfz0768 | affymetrix id=dkfz0769 | affymetrix id=dkfz0770 | affymetrix id=dkfz0771 | affymetrix id=dkfz0772 | affymetrix id=dkfz0774 | affymetrix id=dkfz0775 | affymetrix id=dkfz0776 | affymetrix id=dkfz0777 | affymetrix id=dkfz0778 | affymetrix id=dkfz0788 | affymetrix id=dkfz0861 | affymetrix id=dkfz0901 | affymetrix id=dkfz0902 | affymetrix id=dkfz0903 | affymetrix id=dkfz0926 | affymetrix id=dkfz0928 | affymetrix id=dkfz0929 | affymetrix id=dkfz0930 | affymetrix id=dkfz0931 | affymetrix id=dkfz0932 | affymetrix id=dkfz0933 | affymetrix id=dkfz0934 | affymetrix id=dkfz0939 | affymetrix id=dkfz0941 | affymetrix id=dkfz1040 | affymetrix id=dkfz1041 | affymetrix id=dkfz1042 | affymetrix id=dkfz1043 | affymetrix id=dkfz1044 | affymetrix id=dkfz1045 | affymetrix id=dkfz1046 | affymetrix id=dkfz1047 | affymetrix id=dkfz1048 | affymetrix id=dkfz1050 | affymetrix id=dkfz1052 | affymetrix id=dkfz1053 | affymetrix id=dkfz1054 | affymetrix id=dkfz1055 | affymetrix id=dkfz1099 | affymetrix id=dkfz1110 | affymetrix id=dkfz1111 | affymetrix id=dkfz1112 | affymetrix id=dkfz1118 | affymetrix id=dkfz1119 | affymetrix id=dkfz1161 | affymetrix id=dkfz1164 | affymetrix id=dkfz1184 | affymetrix id=dkfz1185 | affymetrix id=dkfz1274 | affymetrix id=dkfz1280 | affymetrix id=dkfz1281 | affymetrix id=dkfz1284 | affymetrix id=dkfz1300 | affymetrix id=dkfz1313 | affymetrix id=dkfz1315 | affymetrix id=dkfz1318 | affymetrix id=dkfz1329 | affymetrix id=dkfz1349 | affymetrix id=dkfz1364 | affymetrix id=dkfz1384 | affymetrix id=dkfz1429 | affymetrix id=dkfz1434 | affymetrix id=dkfz1444 | affymetrix id=dkfz1448 | affymetrix id=dkfz1458 | affymetrix id=dkfz1461 | affymetrix id=dkfz1467 | affymetrix id=dkfz1477 | affymetrix id=dkfz1487 | affymetrix id=dkfz1517 | affymetrix id=dkfz1518 | affymetrix id=dkfz1519 | affymetrix id=dkfz1520 | affymetrix id=dkfz1662 | affymetrix id=dkfz1684 | affymetrix id=dkfz1910 | affymetrix id=dkfz1971 | affymetrix id=dkfz1986 | affymetrix id=MED13 | affymetrix id=PNET16 | affymetrix id=PNET38 | affymetrix id=PNET39 | affymetrix id=PNET41 | affymetrix id=PNET44 | affymetrix id=PNET70 | age years=1 | age years=10 | age years=11 | age years=12 | age years=13 | age years=14 | age years=15 | age years=16 | age years=17 | age years=18 | age years=19 | age years=2 | age years=20 | age years=21 | age years=23 | age years=24 | age years=25 | age years=27 | age years=3 | age years=31 | age years=32 | age years=33 | age years=35 | age years=36 | age years=38 | age years=39 | age years=4 | age years=40 | age years=42 | age years=48 | age years=49 | age years=5 | age years=51 | age years=6 | age years=7 | age years=75 | age years=8 | age years=81 | age years=9 | age years=&lt;1 | age years=NA | institutional tumor diagnosis=AT/RT | institutional tumor diagnosis=CNS-PNET | institutional tumor diagnosis=EPN | institutional tumor diagnosis=ETMR | institutional tumor diagnosis=GBM | institutional tumor diagnosis=MB | molecular subgroup=AT/RT | molecular subgroup=CNS_EFT-CIC | molecular subgroup=CNS_HGNET-BCOR | molecular subgroup=CNS_HGNET-MN1 | molecular subgroup=CNS_NB-FOXR2 | molecular subgroup=EPN_RELA | molecular subgroup=EPN_YAP | molecular subgroup=ETMR | molecular subgroup=EWS | molecular subgroup=HGG_G34 | molecular subgroup=HGG_IDH | molecular subgroup=HGG_K27 | molecular subgroup=HGG_MYCN | molecular subgroup=HGG_RTK | molecular subgroup=MB_GRP3 | molecular subgroup=MB_GRP4 | molecular subgroup=MB_SHH | molecular subgroup=MB_WNT | molecular subgroup=pineal | molecular subgroup=unclassifiable | sex=female | sex=male | sex=NA | tumor location=brainstem | tumor location=brainstem/cerebellopontine angle | tumor location=cerebellar | tumor location=cerebellar/brainstem | tumor location=cerebellopontine angle | tumor location=corpus callosum/parietal lobe | tumor location=fourth ventricle/brainstem | tumor location=fourth ventricle/vermis | tumor location=frontal lobe | tumor location=frontal lobe, left | tumor location=frontal lobe, right | tumor location=frontal/parietal lobe | tumor location=frontal/parietal lobe, left | tumor location=frontal/parietal lobe, right | tumor location=hemispheric (NOS) | tumor location=hemispheric, left | tumor location=hypothalamic, leptomeningeal spread | tumor location=intraventricular | tumor location=intraventricular, left | tumor location=lateral ventricle | tumor location=NA | tumor location=occipital lobe | tumor location=optic chiasm | tumor location=parietal lobe | tumor location=parietal lobe, left | tumor location=parietal/occipital lobe | tumor location=parietal/parasaggital | tumor location=parietal/temporal lobe, left | tumor location=parietal/temporal lobe, right | tumor location=parietal/temporal/occipital lobe | tumor location=peduncular | tumor location=pons | tumor location=posterior fossa | tumor location=spinal (L3-S2) | tumor location=spinal (L5) | tumor location=spinal (T5-7) | tumor location=supra-/intrasellar | tumor location=supratentorial (NOS) | tumor location=temporal lobe | tumor location=temporal lobe, left | tumor location=temporal lobe, right | tumor location=temporal/parietal lobe | tumor location=temporal/parietal lobe, right | tumor location=temporal/parietal/occipital lobe | tumor location=thalamic | tumor location=thalamic, left | tumor location=thalamic/lateral ventricle","compound=control without treatment | compound=PK 11195 (25 uM) | time=1 hour exposure | time=24 hour exposure | time=3 hour exposure | time=not specified","age=adult | age=Fetal | cell type=GBM stem-like cells | cell type=neural stem cell | gbm subtype=Mesenchymal | gbm subtype=not specified | gbm subtype=Proneural | isolate=GSC-0131 | isolate=GSC-0827 | isolate=NSC-CB660 | isolate=NSC-U5 | time=Day 0 | time=Day 21 | time=Day 23","patient id=B1 | patient id=B10 | patient id=B100 | patient id=B101 | patient id=B102 | patient id=B104 | patient id=B105 | patient id=B106 | patient id=B108 | patient id=B109 | patient id=B110 | patient id=B111 | patient id=B112 | patient id=B113 | patient id=B114 | patient id=B117 | patient id=B118 | patient id=B12 | patient id=B120 | patient id=B121 | patient id=B123 | patient id=B124 | patient id=B126 | patient id=B128 | patient id=B13 | patient id=B131 | patient id=B133 | patient id=B138 | patient id=B139 | patient id=B14 | patient id=B141 | patient id=B142 | patient id=B143 | patient id=B144 | patient id=B146 | patient id=B147 | patient id=B148 | patient id=B15 | patient id=B150 | patient id=B151 | patient id=B152 | patient id=B155 | patient id=B16 | patient id=B17 | patient id=B19 | patient id=B2 | patient id=B20 | patient id=B21 | patient id=B22 | patient id=B23 | patient id=B24 | patient id=B26 | patient id=B27 | patient id=B28 | patient id=B30 | patient id=B31 | patient id=B32 | patient id=B33 | patient id=B34 | patient id=B35 | patient id=B37 | patient id=B38 | patient id=B39 | patient id=B4 | patient id=B40 | patient id=B41 | patient id=B42 | patient id=B43 | patient id=B44 | patient id=B45 | patient id=B46 | patient id=B47 | patient id=B48 | patient id=B49 | patient id=B5 | patient id=B51 | patient id=B52 | patient id=B54 | patient id=B55 | patient id=B56 | patient id=B58 | patient id=B60 | patient id=B63 | patient id=B64 | patient id=B66 | patient id=B67 | patient id=B68 | patient id=B7 | patient id=B70 | patient id=B74 | patient id=B75 | patient id=B76 | patient id=B77 | patient id=B78 | patient id=B79 | patient id=B8 | patient id=B80 | patient id=B82 | patient id=B83 | patient id=B84 | patient id=B86 | patient id=B88 | patient id=B89 | patient id=B9 | patient id=B90 | patient id=B92 | patient id=B93 | patient id=B94 | patient id=B95 | patient id=B96 | patient id=B98 | patient id=B99 | sensor=alive | sensor=dead | sensor=not specified | survival months=1.248459935 | survival months=1.314168334 | survival months=1.774127364 | survival months=1.839835763 | survival months=10.05338764 | survival months=10.61190987 | survival months=10.67761803 | survival months=10.84188938 | survival months=11.30184841 | survival months=11.43326473 | survival months=11.46611881 | survival months=11.92607784 | survival months=12.25462055 | survival months=12.28747463 | survival months=12.35318279 | survival months=12.48459911 | survival months=12.68172455 | survival months=12.74743366 | survival months=12.78028774 | survival months=13.07597542 | survival months=13.20739174 | survival months=13.47022629 | survival months=13.76591396 | survival months=13.83162212 | survival months=13.93018436 | survival months=14.29158115 | survival months=14.32443523 | survival months=14.52156067 | survival months=14.58726883 | survival months=14.62012291 | survival months=14.7186861 | survival months=14.78439426 | survival months=15.24435329 | survival months=15.86858273 | survival months=15.90143776 | survival months=17.11704254 | survival months=17.54414749 | survival months=18.8911705 | survival months=19.02258682 | survival months=19.54825401 | survival months=19.81108856 | survival months=19.87679672 | survival months=2.036961079 | survival months=2.628336668 | survival months=2.825462103 | survival months=2.891170502 | survival months=2.924024582 | survival months=22.6365509 | survival months=23.32648849 | survival months=24.54209518 | survival months=24.77207375 | survival months=26.31622124 | survival months=28.91170502 | survival months=3.482546091 | survival months=3.613963127 | survival months=3.646817207 | survival months=3.745379925 | survival months=33.14989853 | survival months=33.57700348 | survival months=35.15400314 | survival months=37.4538002 | survival months=4.073922157 | survival months=4.238193035 | survival months=4.369609833 | survival months=4.43531847 | survival months=4.46817255 | survival months=4.698152065 | survival months=4.763860226 | survival months=5.059548378 | survival months=5.125256538 | survival months=5.190965176 | survival months=5.256673336 | survival months=5.322381973 | survival months=5.388090134 | survival months=5.585215569 | survival months=5.848049164 | survival months=5.880903721 | survival months=6.078028679 | survival months=6.143737316 | survival months=6.209445477 | survival months=6.275154114 | survival months=6.373716831 | survival months=6.472279072 | survival months=6.537987709 | survival months=6.636550426 | survival months=7.260780334 | survival months=7.589322567 | survival months=7.753593445 | survival months=7.852156162 | survival months=7.885010242 | survival months=8.01642704 | survival months=8.082135201 | survival months=8.180698395 | survival months=8.312114716 | survival months=8.37782383 | survival months=8.574948311 | survival months=8.706365585 | survival months=8.837781906 | survival months=8.87063694 | survival months=9.264886856 | survival months=9.494866371 | survival months=9.593429565 | survival months=9.691991806 | survival months=not specified | tcga subtype=Classical | tcga subtype=Mesenchymal | tcga subtype=Neural | tcga subtype=Proneural | treatment=BC 90/110 (combination treatment of beva and CCNU) | treatment=Beva (bevacizumab monotherapy) | treatment=CCNU (Lomustine) monotherapy | treatment=not specified | tumor subtype=IGS-0 | tumor subtype=IGS-0 (17) | tumor subtype=IGS-0 (9) | tumor subtype=IGS-17 | tumor subtype=IGS-18 | tumor subtype=IGS-22 | tumor subtype=IGS-23 | tumor subtype=IGS-9","age years=18 | age years=20 | age years=24 | age years=26 | age years=27 | age years=28 | age years=31 | age years=32 | age years=33 | age years=42 | age years=45 | age years=47 | age years=49 | age years=52 | age years=54 | age years=55 | age years=56 | age years=57 | age years=58 | age years=59 | age years=60 | age years=62 | age years=63 | age years=64 | age years=65 | age years=67 | age years=68 | age years=69 | age years=71 | age years=72 | age years=73 | age years=74 | age years=77 | age years=78 | age years=80 | kps=100 | kps=40 | kps=50 | kps=60 | kps=70 | kps=80 | kps=90 | outcome=alive | outcome=dead | pathological diagnosis=anaplastic astrocytoma | pathological diagnosis=anaplastic oligoastrocytoma | pathological diagnosis=anaplastic oligodendroglioma | pathological diagnosis=astrocytoma | pathological diagnosis=GBM | sex=female | sex=male | survival time days=1082 | survival time days=111 | survival time days=1189 | survival time days=1300 | survival time days=1356 | survival time days=1411 | survival time days=1427 | survival time days=144 | survival time days=1519 | survival time days=154 | survival time days=1710 | survival time days=1737 | survival time days=1768 | survival time days=1922 | survival time days=20 | survival time days=2034 | survival time days=2134 | survival time days=261 | survival time days=263 | survival time days=268 | survival time days=286 | survival time days=3020 | survival time days=305 | survival time days=308 | survival time days=323 | survival time days=33 | survival time days=347 | survival time days=350 | survival time days=352 | survival time days=358 | survival time days=396 | survival time days=405 | survival time days=417 | survival time days=427 | survival time days=432 | survival time days=436 | survival time days=474 | survival time days=506 | survival time days=525 | survival time days=565 | survival time days=587 | survival time days=617 | survival time days=630 | survival time days=641 | survival time days=653 | survival time days=698 | survival time days=811 | survival time days=827 | survival time days=900 | survival time days=988 | who grade=2 | who grade=3 | who grade=4","cell line=DBM2 | cell line=SF295 | cell line=U118 | cell line=U251M2 | cell line=U87M2 | organism=Homo sapiens | organism=Mus musculus","age=42 | age=56 | age=80 | patientid=HGG1 | patientid=HGG6 | patientid=HGG7 | sex=female | sex=male | tumor=anaplastic astrocytoma | tumor=glioblastoma multiforme","cell line=BT142 | cell line=GSC119 | cell line=GSC4 | cell line=GSC6 | cell line=not specified | chip antibody=CTCF (D31H2), Cell Signaling #3418 | chip antibody=H3K27ac (cat 39133), Active Motif | chip antibody=NA | idh1 status=Mutant (R132H) | idh1 status=Wild Type | material type=Anaplastic Astrocytoma Surgical Resection | material type=Frozen Anaplastic Astrocytoma Surgical Resection | material type=Frozen GBM Autopsy Specimen | material type=Frozen GBM Surgical Resection | material type=GBM Surgical Resection | material type=not specified | material type=Oligodendroglioma Surgical Resection","age=13 years old | age=16 years old | age=18 gestational weeks | age=18.1 gestational weeks | age=18.5 gestational weeks | age=21 years old | age=22 years old | age=25 years old | age=35 years old | age=45 years old | age=47 years old | age=51 years old | age=53 years old | age=59 years old | age=60 years old | age=63 years old | age=64 years old | age=65 years old | age=8 years old | age=post natal day 120 | age=post natal day 210 | age=post natal day 270 | age=post natal day 30 | cell subtype=BSL bound cells | cell subtype=CD45 positive cells | cell subtype=GalC positive cells | cell subtype=HepaCAM positive cells | cell subtype=O4 positive cells | cell subtype=Thy1 positive cells | cell subtype=Whole cortex | cell type=astrocyte | cell type=Endothelial | cell type=Myeloid | cell type=neuron | cell type=oligodendrocyte | cell type=Whole cortex | organism=Homo sapiens | organism=Mus musculus","cell line=A172 | cell line=T98G | cell line=U87MG | transfected with=miR338-5p | transfected with=negative control","age=1 | age=10 | age=10 months | age=11 | age=12 | age=14 | age=15 | age=16 | age=2 | age=2 months | age=21 | age=22 | age=25 | age=26 | age=27 | age=3 | age=4 | age=41 | age=6 | age=6 months | age=7 | age=7 months | age=8 | age=82 | age=9 | age=9 months | age=nd | grade=I | grade=II | grade=III | grade=IV | grade=ND | grade=not specified | organism part=Adult control cerebellum | organism part=Adult control frontal lobe | organism part=anaplastic astrocytoma | organism part=Atypical teratoid/rhabdoid tumour | organism part=Choroid Plexus Papilloma | organism part=Diffuse astrocytoma | organism part=ependymoma | organism part=Glioblastoma | organism part=medulloblastoma | organism part=Papillary glioneuronal | organism part=Pilocytic Astrocytoma | Sex=female | Sex=male","transfection construct=EGFP | transfection construct=epigenetic regulator","age at diagnosis=31 | age at diagnosis=35 | age at diagnosis=36 | age at diagnosis=40 | age at diagnosis=41 | age at diagnosis=42 | age at diagnosis=43 | age at diagnosis=44 | age at diagnosis=45 | age at diagnosis=46 | age at diagnosis=48 | age at diagnosis=49 | age at diagnosis=50 | age at diagnosis=51 | age at diagnosis=53 | age at diagnosis=54 | age at diagnosis=55 | age at diagnosis=56 | age at diagnosis=57 | age at diagnosis=58 | age at diagnosis=59 | age at diagnosis=62 | age at diagnosis=66 | age at diagnosis=68 | age at diagnosis=70 | age at diagnosis=71 | age at diagnosis=87 | age at menarche=11 | age at menarche=12 | age at menarche=13 | age at menarche=14 | age at menarche=15 | age at menarche=18 | birads=2 | birads=4 | birads=5 | birads=6 | birads=N/A | breast affected=Both | breast affected=left | breast affected=right | chemotherapy1=Adriamicin | chemotherapy1=doxorubicin | chemotherapy1=Epirubicin | chemotherapy1=N/A | chemotherapy1=paclitaxel | chemotherapy1=tamoxifen | chemotherapy1=TAXOL | chemotherapy1=Trastuzumab | chemotherapy2=Adriamicin | chemotherapy2=cyclophosphamide | chemotherapy2=doxorubicin | chemotherapy2=Epirrubicin | chemotherapy2=N/A | chemotherapy2=TAXOL | chemotherapy2=Trastazumab | chemotherapy3=Adramicin | chemotherapy3=Adriamicin | chemotherapy3=cyclophosphamide | chemotherapy3=N/A | chemotherapy3=paclitaxel | chemotherapy3=TAXOL | chemotherapy3=Trastuzumab | chemotherapy4=N/A | chemotherapy4=TAXOL | chemotherapy4=Trastuzumab | data at diagnosis=2012-12-05 | data at diagnosis=2013-05-09 | data at diagnosis=2013-05-13 | data at diagnosis=2013-05-21 | data at diagnosis=2013-05-24 | data at diagnosis=2013-05-29 | data at diagnosis=2013-06-04 | data at diagnosis=2013-06-06 | data at diagnosis=2013-06-17 | data at diagnosis=2013-06-18 | data at diagnosis=2013-06-23 | data at diagnosis=2013-07-08 | data at diagnosis=2013-07-11 | data at diagnosis=2013-07-23 | data at diagnosis=2013-07-29 | data at diagnosis=2013-08-01 | data at diagnosis=2013-08-06 | data at diagnosis=2013-08-08 | data at diagnosis=2013-08-22 | data at diagnosis=2013-08-24 | data at diagnosis=2013-09-02 | data at diagnosis=2013-09-03 | data at diagnosis=2013-09-09 | data at diagnosis=2013-09-10 | data at diagnosis=2013-10-02 | data at diagnosis=2013-10-03 | data at diagnosis=2013-10-15 | data at diagnosis=2013-11-04 | data at diagnosis=2013-11-12 | data at diagnosis=2013-11-20 | data at diagnosis=2013-12-09 | data at diagnosis=2014-02-21 | data at diagnosis=2014-03-10 | data at diagnosis=2014-03-12 | data at diagnosis=2014-03-18 | data at diagnosis=2014-03-25 | data at diagnosis=2014-04-01 | data at diagnosis=2014-04-02 | data at diagnosis=2014-04-04 | data at diagnosis=2014-04-15 | data at diagnosis=2014-04-16 | data at diagnosis=2014-05-14 | data at diagnosis=2014-07-23 | data at diagnosis=2014-08-01 | data at diagnosis=2014-10-31 | data at diagnosis=2014-11-07 | data at diagnosis=2014-11-14 | data at diagnosis=2014-11-21 | data at diagnosis=2014-12-05 | data at diagnosis=NA | date at death=2014-08-01 | date at death=N/A | date at death=not specified | date at relapse=2014-04-24 | date at relapse=2014-09-09 | date at relapse=2014-10-15 | date at relapse=N/A | diagnosis=Carcinoma in situ associated with comedo necrosis | diagnosis=Ductal carcinoma in situ comedonicus type | diagnosis=High grade invasive ductal carcinoma | diagnosis=High nuclear grade ductal carcinoma associated with carcinoma in situ | diagnosis=Infiltrating Ductal Adenocarcinoma | diagnosis=Infiltrating Ductal Carcinoma | diagnosis=Infiltrating ductal carcinoma high | diagnosis=Infiltrating lobular carcinoma high nuclear grade | diagnosis=Invasive Ductal Adenocarcinoma | diagnosis=Invasive ductal adenocarcinoma high nuclear grade | diagnosis=invasive ductal carcinoma | diagnosis=Invasive ductal carcinoma, carcinoma in situ associated with comedo necrosis | diagnosis=Moderately differentiated infiltrating ductal adenocarcinoma | diagnosis=Moderately differentiated invasive ductal carcinoma | diagnosis=Poorly differentiated ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal carcinoma | diagnosis=Poorly differentiated invasive carcinoma with chondroid metaplasia | diagnosis=Poorly differentiated invasive ductal adenocarcinoma | diagnosis=Poorly differentiated invasive ductal carcinoma | diagnosis=Right Breast Ductal carcinoma in situ Left Breast infiltrating ductal adenocarcinoma poorly differentiated | diagnosis=undifferentiated carcinoma | e-cadherina ihc=N/A | e-cadherina ihc=Pos | estrogen receptor immunohistochemestry=Neg | estrogen receptor immunohistochemestry=Pos | final clinical size in mm by palpation=0 | final clinical size in mm by palpation=10 | final clinical size in mm by palpation=150 | final clinical size in mm by palpation=30 | final clinical size in mm by palpation=50 | final clinical size in mm by palpation=80 | final number of positive ganglia=0 | final number of positive ganglia=1 | final number of positive ganglia=12 | final number of positive ganglia=17 | final number of positive ganglia=2 | final number of positive ganglia=3 | final number of positive ganglia=4 | final number of positive ganglia=5 | final number of positive ganglia=6 | final number of positive ganglia=7 | final number of positive ganglia=8 | final number of positive ganglia=9 | final number of resected ganglia=0 | final number of resected ganglia=10 | final number of resected ganglia=11 | final number of resected ganglia=12 | final number of resected ganglia=13 | final number of resected ganglia=14 | final number of resected ganglia=15 | final number of resected ganglia=16 | final number of resected ganglia=17 | final number of resected ganglia=18 | final number of resected ganglia=19 | final number of resected ganglia=2 | final number of resected ganglia=20 | final number of resected ganglia=22 | final number of resected ganglia=23 | final number of resected ganglia=24 | final number of resected ganglia=26 | final number of resected ganglia=27 | final number of resected ganglia=29 | final number of resected ganglia=3 | final number of resected ganglia=33 | final number of resected ganglia=34 | final number of resected ganglia=37 | final number of resected ganglia=4 | final number of resected ganglia=41 | final number of resected ganglia=5 | final number of resected ganglia=6 | final pathology size in mm=0 | final pathology size in mm=10 | final pathology size in mm=110 | final pathology size in mm=15 | final pathology size in mm=18 | final pathology size in mm=2 | final pathology size in mm=20 | final pathology size in mm=25 | final pathology size in mm=30 | final pathology size in mm=35 | final pathology size in mm=38 | final pathology size in mm=40 | final pathology size in mm=45 | final pathology size in mm=5 | final pathology size in mm=50 | final pathology size in mm=55 | final pathology size in mm=7 | final pathology size in mm=80 | final surgery date=2013-06-19 | final surgery date=2013-10-18 | final surgery date=2014-01-27 | final surgery date=2014-02-04 | final surgery date=2014-02-05 | final surgery date=2014-02-11 | final surgery date=2014-02-13 | final surgery date=2014-02-17 | final surgery date=2014-02-21 | final surgery date=2014-02-24 | final surgery date=2014-03-10 | final surgery date=2014-03-20 | final surgery date=2014-03-26 | final surgery date=2014-04-19 | final surgery date=2014-04-24 | final surgery date=2014-04-25 | final surgery date=2014-04-26 | final surgery date=2014-04-28 | final surgery date=2014-04-29 | final surgery date=2014-05-15 | final surgery date=2014-05-19 | final surgery date=2014-06-02 | final surgery date=2014-06-05 | final surgery date=2014-06-11 | final surgery date=2014-06-20 | final surgery date=2014-07-14 | final surgery date=2014-07-16 | final surgery date=2014-07-23 | final surgery date=2014-07-27 | final surgery date=2014-07-31 | final surgery date=2014-08-06 | final surgery date=2014-08-22 | final surgery date=2014-09-06 | final surgery date=2014-10-07 | final surgery date=2014-10-10 | final surgery date=2014-10-15 | final surgery date=2014-10-16 | final surgery date=2014-10-20 | final surgery date=2014-10-22 | final surgery date=2014-10-27 | final surgery date=2014-10-29 | final surgery date=2014-11-06 | final surgery date=2014-11-07 | final surgery date=2014-11-10 | final surgery date=2014-11-11 | final surgery date=2014-11-13 | final surgery date=2014-11-19 | final surgery date=2014-11-21 | final surgery date=NA | her2 fish=N/A | her2 fish=Neg | her2 fish=Pos | her2 immunohistochemestry=N/A | her2 immunohistochemestry=Neg | her2 immunohistochemestry=Pos | histological grade=1 | histological grade=2 | histological grade=3 | histological grade=N/A | initial clinical size in mm by palpation=0 | initial clinical size in mm by palpation=100 | initial clinical size in mm by palpation=15 | initial clinical size in mm by palpation=150 | initial clinical size in mm by palpation=20 | initial clinical size in mm by palpation=30 | initial clinical size in mm by palpation=35 | initial clinical size in mm by palpation=40 | initial clinical size in mm by palpation=50 | initial clinical size in mm by palpation=60 | initial clinical size in mm by palpation=70 | initial clinical size in mm by palpation=80 | initial clinical size in mm by palpation=90 | initial highest diameter in mm by image=100 | initial highest diameter in mm by image=14 | initial highest diameter in mm by image=150 | initial highest diameter in mm by image=16 | initial highest diameter in mm by image=20 | initial highest diameter in mm by image=200 | initial highest diameter in mm by image=22 | initial highest diameter in mm by image=25 | initial highest diameter in mm by image=27 | initial highest diameter in mm by image=30 | initial highest diameter in mm by image=32 | initial highest diameter in mm by image=33 | initial highest diameter in mm by image=34 | initial highest diameter in mm by image=35 | initial highest diameter in mm by image=36 | initial highest diameter in mm by image=37 | initial highest diameter in mm by image=39 | initial highest diameter in mm by image=4 | initial highest diameter in mm by image=40 | initial highest diameter in mm by image=41 | initial highest diameter in mm by image=42 | initial highest diameter in mm by image=48 | initial highest diameter in mm by image=50 | initial highest diameter in mm by image=51 | initial highest diameter in mm by image=57 | initial highest diameter in mm by image=60 | initial highest diameter in mm by image=67 | initial highest diameter in mm by image=7 | initial highest diameter in mm by image=70 | initial highest diameter in mm by image=80 | initial highest diameter in mm by image=86 | initial highest diameter in mm by image=90 | m=0 | m=1 | m=x | n=0 | n=1 | n=2 | n=3 | p63 ihc=Absent | p63 ihc=N/A | p63 ihc=Neg | p63 ihc=Pos | pathological family history=Diabetes | pathological family history=Diabetes and Heart Disease | pathological family history=Fater Liver Cancer | pathological family history=Father Laringeal Cancer | pathological family history=Father Lung Cancer | pathological family history=Father Pancreas Cancer. Maternal Aunt Breast Cancer. Father Aunts Ovarian Cancer. Cousin Breast Cancer | pathological family history=hypertension | pathological family history=Liver Cancer | pathological family history=Maternal Aunt Breast Cancer | pathological family history=Mother and Sister Ovarian Cancer | pathological family history=Mother Breast Cancer | pathological family history=Mother Endometrial Cancer | pathological family history=Neg | pathological family history=NEV | pathological family history=Paternal Grandmother Breast Cancer | pathological family history=Pos | pathological family history=Sister Brain Cancer | pathological family history=Sister Breast Cancer, Brother Prostate Cancer | pathological family history=Sister GBM and Breast Cancer | pathological family history=Sister Liver Cancer | pathological family history=Sister Pancreatic Cancer | percentage ki67 ihc=0.0022 | percentage ki67 ihc=0.01 | percentage ki67 ihc=0.02 | percentage ki67 ihc=0.03 | percentage ki67 ihc=0.04 | percentage ki67 ihc=0.05 | percentage ki67 ihc=0.06 | percentage ki67 ihc=0.07 | percentage ki67 ihc=0.08 | percentage ki67 ihc=0.1 | percentage ki67 ihc=0.12 | percentage ki67 ihc=0.15 | percentage ki67 ihc=0.2 | percentage ki67 ihc=0.22 | percentage ki67 ihc=0.25 | percentage ki67 ihc=0.35 | percentage ki67 ihc=0.4 | percentage ki67 ihc=0.45 | percentage ki67 ihc=0.6 | percentage ki67 ihc=0.7 | percentage ki67 ihc=0.8 | percentage ki67 ihc=0.85 | percentage ki67 ihc=N/A | personal pathological hystory=0 | personal pathological hystory=3 C sections | personal pathological hystory=Apendicitis | personal pathological hystory=C section | personal pathological hystory=Diabetes | personal pathological hystory=dyslipidemia | personal pathological hystory=hypertension | personal pathological hystory=Hypertension and Diabetes | personal pathological hystory=Hypertension and Rheumatoid Artritis | personal pathological hystory=hypothyroidism | personal pathological hystory=Hysterechtomy | personal pathological hystory=Knee Surgery | personal pathological hystory=Neg | personal pathological hystory=Ocular Surgery | personal pathological hystory=rheumatoid arthritis | personal pathological hystory=Venous insuficiency | place to metastasis=liver | place to metastasis=lung | place to metastasis=N/A | progesteron receptor immunohistochemestry=Neg | progesteron receptor immunohistochemestry=POs | progesteron receptor immunohistochemestry=Pos | radiotherapy=N/A | radiotherapy=No | radiotherapy=Yes | response to treatment=Complete | response to treatment=Partial | response to treatment=Poor | response to treatment=Progresive | rna 260/230 nanodrop=0.89 | rna 260/230 nanodrop=1.01 | rna 260/230 nanodrop=1.03 | rna 260/230 nanodrop=1.06 | rna 260/230 nanodrop=1.13 | rna 260/230 nanodrop=1.18 | rna 260/230 nanodrop=1.22 | rna 260/230 nanodrop=1.27 | rna 260/230 nanodrop=1.33 | rna 260/230 nanodrop=1.37 | rna 260/230 nanodrop=1.52 | rna 260/230 nanodrop=1.63 | rna 260/230 nanodrop=1.65 | rna 260/230 nanodrop=1.68 | rna 260/230 nanodrop=1.69 | rna 260/230 nanodrop=1.7 | rna 260/230 nanodrop=1.72 | rna 260/230 nanodrop=1.78 | rna 260/230 nanodrop=1.79 | rna 260/230 nanodrop=1.82 | rna 260/230 nanodrop=1.89 | rna 260/230 nanodrop=1.94 | rna 260/230 nanodrop=1.98 | rna 260/230 nanodrop=2.01 | rna 260/230 nanodrop=2.06 | rna 260/230 nanodrop=2.08 | rna 260/230 nanodrop=2.1 | rna 260/230 nanodrop=2.11 | rna 260/230 nanodrop=2.13 | rna 260/230 nanodrop=2.15 | rna 260/230 nanodrop=2.16 | rna 260/230 nanodrop=2.18 | rna 260/230 nanodrop=2.2 | rna 260/230 nanodrop=2.21 | rna 260/230 nanodrop=2.22 | rna 260/230 nanodrop=2.23 | rna 260/230 nanodrop=2.25 | rna 260/230 nanodrop=2.26 | rna 260/230 nanodrop=2.27 | rna 260/230 nanodrop=2.29 | rna 260/230 nanodrop=2.3 | rna 260/230 nanodrop=2.32 | rna 260/230 nanodrop=2.38 | rna 260/280 nanodrop=1.79 | rna 260/280 nanodrop=1.96 | rna 260/280 nanodrop=2.05 | rna 260/280 nanodrop=2.06 | rna 260/280 nanodrop=2.07 | rna 260/280 nanodrop=2.08 | rna 260/280 nanodrop=2.09 | rna 260/280 nanodrop=2.1 | rna 260/280 nanodrop=2.11 | rna 260/280 nanodrop=2.12 | rna 260/280 nanodrop=2.13 | rna 260/280 nanodrop=2.14 | rna 260/280 nanodrop=2.15 | rna 260/280 nanodrop=2.16 | rna 260/280 nanodrop=2.17 | rna 260/280 nanodrop=2.18 | rna 260/280 nanodrop=2.19 | rna 260/280 nanodrop=2.24 | rna 260/280 nanodrop=2.35 | rna ng/ul=1011.5 | rna ng/ul=1083 | rna ng/ul=111 | rna ng/ul=1116.8 | rna ng/ul=1187 | rna ng/ul=126.9 | rna ng/ul=127.7 | rna ng/ul=1365 | rna ng/ul=143.6 | rna ng/ul=1458.3 | rna ng/ul=146.7 | rna ng/ul=151.6 | rna ng/ul=1545 | rna ng/ul=1566.4 | rna ng/ul=158.3 | rna ng/ul=164 | rna ng/ul=178.2 | rna ng/ul=182.1 | rna ng/ul=1830 | rna ng/ul=2055.6 | rna ng/ul=224.7 | rna ng/ul=268.6 | rna ng/ul=291.4 | rna ng/ul=307 | rna ng/ul=333.9 | rna ng/ul=343 | rna ng/ul=352.9 | rna ng/ul=370.2 | rna ng/ul=375.6 | rna ng/ul=397.7 | rna ng/ul=401 | rna ng/ul=419.5 | rna ng/ul=431.4 | rna ng/ul=433.4 | rna ng/ul=437.4 | rna ng/ul=439 | rna ng/ul=475 | rna ng/ul=497.3 | rna ng/ul=524.9 | rna ng/ul=543 | rna ng/ul=60 | rna ng/ul=625.4 | rna ng/ul=646.4 | rna ng/ul=670 | rna ng/ul=682 | rna ng/ul=69 | rna ng/ul=693.6 | rna ng/ul=725 | rna ng/ul=728 | rna ng/ul=774.2 | rna ng/ul=81.1 | rna ng/ul=840.6 | rqi experion=10 | rqi experion=6.4 | rqi experion=6.6 | rqi experion=6.8 | rqi experion=7.2 | rqi experion=7.4 | rqi experion=7.6 | rqi experion=7.7 | rqi experion=7.8 | rqi experion=7.9 | rqi experion=8 | rqi experion=8.1 | rqi experion=8.2 | rqi experion=8.3 | rqi experion=8.4 | rqi experion=8.5 | rqi experion=8.6 | rqi experion=8.7 | rqi experion=8.8 | rqi experion=8.9 | rqi experion=9 | rqi experion=9.1 | rqi experion=9.2 | rqi experion=9.3 | rqi experion=9.4 | rqi experion=9.6 | rqi experion=9.9 | t=1 | t=2 | t=3 | t=4 | tabaquism=Neg | tabaquism=Pos","age at diagnosis=31 | age at diagnosis=35 | age at diagnosis=36 | age at diagnosis=40 | age at diagnosis=41 | age at diagnosis=42 | age at diagnosis=43 | age at diagnosis=44 | age at diagnosis=45 | age at diagnosis=46 | age at diagnosis=48 | age at diagnosis=49 | age at diagnosis=50 | age at diagnosis=51 | age at diagnosis=53 | age at diagnosis=54 | age at diagnosis=55 | age at diagnosis=56 | age at diagnosis=57 | age at diagnosis=58 | age at diagnosis=59 | age at diagnosis=62 | age at diagnosis=66 | age at diagnosis=68 | age at diagnosis=70 | age at diagnosis=71 | age at diagnosis=87 | age at menarche=11 | age at menarche=12 | age at menarche=13 | age at menarche=14 | age at menarche=15 | age at menarche=18 | birads=2 | birads=4 | birads=5 | birads=6 | birads=N/A | breast affected=Both | breast affected=left | breast affected=right | chemotherapy1=Adriamicin | chemotherapy1=doxorubicin | chemotherapy1=Epirubicin | chemotherapy1=N/A | chemotherapy1=paclitaxel | chemotherapy1=tamoxifen | chemotherapy1=TAXOL | chemotherapy1=Trastuzumab | chemotherapy2=Adriamicin | chemotherapy2=cyclophosphamide | chemotherapy2=doxorubicin | chemotherapy2=Epirrubicin | chemotherapy2=N/A | chemotherapy2=TAXOL | chemotherapy2=Trastazumab | chemotherapy3=Adramicin | chemotherapy3=Adriamicin | chemotherapy3=cyclophosphamide | chemotherapy3=N/A | chemotherapy3=paclitaxel | chemotherapy3=TAXOL | chemotherapy3=Trastuzumab | chemotherapy4=N/A | chemotherapy4=TAXOL | chemotherapy4=Trastuzumab | data at diagnosis=2012-12-05 | data at diagnosis=2013-05-09 | data at diagnosis=2013-05-13 | data at diagnosis=2013-05-21 | data at diagnosis=2013-05-24 | data at diagnosis=2013-05-29 | data at diagnosis=2013-06-04 | data at diagnosis=2013-06-06 | data at diagnosis=2013-06-17 | data at diagnosis=2013-06-18 | data at diagnosis=2013-06-23 | data at diagnosis=2013-07-08 | data at diagnosis=2013-07-11 | data at diagnosis=2013-07-23 | data at diagnosis=2013-07-29 | data at diagnosis=2013-08-01 | data at diagnosis=2013-08-06 | data at diagnosis=2013-08-08 | data at diagnosis=2013-08-22 | data at diagnosis=2013-08-24 | data at diagnosis=2013-09-02 | data at diagnosis=2013-09-03 | data at diagnosis=2013-09-09 | data at diagnosis=2013-09-10 | data at diagnosis=2013-10-02 | data at diagnosis=2013-10-03 | data at diagnosis=2013-10-15 | data at diagnosis=2013-11-04 | data at diagnosis=2013-11-12 | data at diagnosis=2013-11-20 | data at diagnosis=2013-12-09 | data at diagnosis=2014-02-21 | data at diagnosis=2014-03-10 | data at diagnosis=2014-03-12 | data at diagnosis=2014-03-18 | data at diagnosis=2014-03-25 | data at diagnosis=2014-04-01 | data at diagnosis=2014-04-02 | data at diagnosis=2014-04-04 | data at diagnosis=2014-04-15 | data at diagnosis=2014-04-16 | data at diagnosis=2014-05-14 | data at diagnosis=2014-07-23 | data at diagnosis=2014-08-01 | data at diagnosis=2014-10-31 | data at diagnosis=2014-11-07 | data at diagnosis=2014-11-14 | data at diagnosis=2014-11-21 | data at diagnosis=2014-12-05 | data at diagnosis=NA | date at death=2014-08-01 | date at death=N/A | date at death=not specified | date at relapse=2014-04-24 | date at relapse=2014-09-09 | date at relapse=2014-10-15 | date at relapse=N/A | diagnosis=Carcinoma in situ associated with comedo necrosis | diagnosis=Ductal carcinoma in situ comedonicus type | diagnosis=High grade invasive ductal carcinoma | diagnosis=High nuclear grade ductal carcinoma associated with carcinoma in situ | diagnosis=Infiltrating Ductal Adenocarcinoma | diagnosis=Infiltrating Ductal Carcinoma | diagnosis=Infiltrating ductal carcinoma high | diagnosis=Infiltrating lobular carcinoma high nuclear grade | diagnosis=Invasive Ductal Adenocarcinoma | diagnosis=Invasive ductal adenocarcinoma high nuclear grade | diagnosis=invasive ductal carcinoma | diagnosis=Invasive ductal carcinoma, carcinoma in situ associated with comedo necrosis | diagnosis=Moderately differentiated infiltrating ductal adenocarcinoma | diagnosis=Moderately differentiated invasive ductal carcinoma | diagnosis=Poorly differentiated ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal carcinoma | diagnosis=Poorly differentiated invasive carcinoma with chondroid metaplasia | diagnosis=Poorly differentiated invasive ductal adenocarcinoma | diagnosis=Poorly differentiated invasive ductal carcinoma | diagnosis=Right Breast Ductal carcinoma in situ Left Breast infiltrating ductal adenocarcinoma poorly differentiated | diagnosis=undifferentiated carcinoma | e-cadherina ihc=N/A | e-cadherina ihc=Pos | estrogen receptor immunohistochemestry=Neg | estrogen receptor immunohistochemestry=Pos | final clinical size in mm by palpation=0 | final clinical size in mm by palpation=10 | final clinical size in mm by palpation=150 | final clinical size in mm by palpation=30 | final clinical size in mm by palpation=50 | final clinical size in mm by palpation=80 | final number of positive ganglia=0 | final number of positive ganglia=1 | final number of positive ganglia=12 | final number of positive ganglia=17 | final number of positive ganglia=2 | final number of positive ganglia=3 | final number of positive ganglia=4 | final number of positive ganglia=5 | final number of positive ganglia=6 | final number of positive ganglia=7 | final number of positive ganglia=8 | final number of positive ganglia=9 | final number of resected ganglia=0 | final number of resected ganglia=10 | final number of resected ganglia=11 | final number of resected ganglia=12 | final number of resected ganglia=13 | final number of resected ganglia=14 | final number of resected ganglia=15 | final number of resected ganglia=16 | final number of resected ganglia=17 | final number of resected ganglia=18 | final number of resected ganglia=19 | final number of resected ganglia=2 | final number of resected ganglia=20 | final number of resected ganglia=22 | final number of resected ganglia=23 | final number of resected ganglia=24 | final number of resected ganglia=26 | final number of resected ganglia=27 | final number of resected ganglia=29 | final number of resected ganglia=3 | final number of resected ganglia=33 | final number of resected ganglia=34 | final number of resected ganglia=37 | final number of resected ganglia=4 | final number of resected ganglia=41 | final number of resected ganglia=5 | final number of resected ganglia=6 | final pathology size in mm=0 | final pathology size in mm=10 | final pathology size in mm=110 | final pathology size in mm=15 | final pathology size in mm=18 | final pathology size in mm=2 | final pathology size in mm=20 | final pathology size in mm=25 | final pathology size in mm=30 | final pathology size in mm=35 | final pathology size in mm=38 | final pathology size in mm=40 | final pathology size in mm=45 | final pathology size in mm=5 | final pathology size in mm=50 | final pathology size in mm=55 | final pathology size in mm=7 | final pathology size in mm=80 | final surgery date=2013-06-19 | final surgery date=2013-10-18 | final surgery date=2014-01-27 | final surgery date=2014-02-04 | final surgery date=2014-02-05 | final surgery date=2014-02-11 | final surgery date=2014-02-13 | final surgery date=2014-02-17 | final surgery date=2014-02-21 | final surgery date=2014-02-24 | final surgery date=2014-03-10 | final surgery date=2014-03-20 | final surgery date=2014-03-26 | final surgery date=2014-04-19 | final surgery date=2014-04-24 | final surgery date=2014-04-25 | final surgery date=2014-04-26 | final surgery date=2014-04-28 | final surgery date=2014-04-29 | final surgery date=2014-05-15 | final surgery date=2014-05-19 | final surgery date=2014-06-02 | final surgery date=2014-06-05 | final surgery date=2014-06-11 | final surgery date=2014-06-20 | final surgery date=2014-07-14 | final surgery date=2014-07-16 | final surgery date=2014-07-23 | final surgery date=2014-07-27 | final surgery date=2014-07-31 | final surgery date=2014-08-06 | final surgery date=2014-08-22 | final surgery date=2014-09-06 | final surgery date=2014-10-07 | final surgery date=2014-10-10 | final surgery date=2014-10-15 | final surgery date=2014-10-16 | final surgery date=2014-10-20 | final surgery date=2014-10-22 | final surgery date=2014-10-27 | final surgery date=2014-10-29 | final surgery date=2014-11-06 | final surgery date=2014-11-07 | final surgery date=2014-11-10 | final surgery date=2014-11-11 | final surgery date=2014-11-13 | final surgery date=2014-11-19 | final surgery date=2014-11-21 | final surgery date=NA | her2 fish=N/A | her2 fish=Neg | her2 fish=Pos | her2 immunohistochemestry=N/A | her2 immunohistochemestry=Neg | her2 immunohistochemestry=Pos | histological grade=1 | histological grade=2 | histological grade=3 | histological grade=N/A | initial clinical size in mm by palpation=0 | initial clinical size in mm by palpation=100 | initial clinical size in mm by palpation=15 | initial clinical size in mm by palpation=150 | initial clinical size in mm by palpation=20 | initial clinical size in mm by palpation=30 | initial clinical size in mm by palpation=35 | initial clinical size in mm by palpation=40 | initial clinical size in mm by palpation=50 | initial clinical size in mm by palpation=60 | initial clinical size in mm by palpation=70 | initial clinical size in mm by palpation=80 | initial clinical size in mm by palpation=90 | initial highest diameter in mm by image=100 | initial highest diameter in mm by image=14 | initial highest diameter in mm by image=150 | initial highest diameter in mm by image=16 | initial highest diameter in mm by image=20 | initial highest diameter in mm by image=200 | initial highest diameter in mm by image=22 | initial highest diameter in mm by image=25 | initial highest diameter in mm by image=27 | initial highest diameter in mm by image=30 | initial highest diameter in mm by image=32 | initial highest diameter in mm by image=33 | initial highest diameter in mm by image=34 | initial highest diameter in mm by image=35 | initial highest diameter in mm by image=36 | initial highest diameter in mm by image=37 | initial highest diameter in mm by image=39 | initial highest diameter in mm by image=4 | initial highest diameter in mm by image=40 | initial highest diameter in mm by image=41 | initial highest diameter in mm by image=42 | initial highest diameter in mm by image=48 | initial highest diameter in mm by image=50 | initial highest diameter in mm by image=51 | initial highest diameter in mm by image=57 | initial highest diameter in mm by image=60 | initial highest diameter in mm by image=67 | initial highest diameter in mm by image=7 | initial highest diameter in mm by image=70 | initial highest diameter in mm by image=80 | initial highest diameter in mm by image=86 | initial highest diameter in mm by image=90 | m=0 | m=1 | m=x | n=0 | n=1 | n=2 | n=3 | p63 ihc=Absent | p63 ihc=N/A | p63 ihc=Neg | p63 ihc=Pos | pathological family history=Diabetes | pathological family history=Diabetes and Heart Disease | pathological family history=Fater Liver Cancer | pathological family history=Father Laringeal Cancer | pathological family history=Father Lung Cancer | pathological family history=Father Pancreas Cancer. Maternal Aunt Breast Cancer. Father Aunts Ovarian Cancer. Cousin Breast Cancer | pathological family history=hypertension | pathological family history=Liver Cancer | pathological family history=Maternal Aunt Breast Cancer | pathological family history=Mother and Sister Ovarian Cancer | pathological family history=Mother Breast Cancer | pathological family history=Mother Endometrial Cancer | pathological family history=Neg | pathological family history=NEV | pathological family history=Paternal Grandmother Breast Cancer | pathological family history=Pos | pathological family history=Sister Brain Cancer | pathological family history=Sister Breast Cancer, Brother Prostate Cancer | pathological family history=Sister GBM and Breast Cancer | pathological family history=Sister Liver Cancer | pathological family history=Sister Pancreatic Cancer | percentage ki67 ihc=0.0022 | percentage ki67 ihc=0.01 | percentage ki67 ihc=0.02 | percentage ki67 ihc=0.03 | percentage ki67 ihc=0.04 | percentage ki67 ihc=0.05 | percentage ki67 ihc=0.06 | percentage ki67 ihc=0.07 | percentage ki67 ihc=0.08 | percentage ki67 ihc=0.1 | percentage ki67 ihc=0.12 | percentage ki67 ihc=0.15 | percentage ki67 ihc=0.2 | percentage ki67 ihc=0.22 | percentage ki67 ihc=0.25 | percentage ki67 ihc=0.35 | percentage ki67 ihc=0.4 | percentage ki67 ihc=0.45 | percentage ki67 ihc=0.6 | percentage ki67 ihc=0.7 | percentage ki67 ihc=0.8 | percentage ki67 ihc=0.85 | percentage ki67 ihc=N/A | personal pathological hystory=0 | personal pathological hystory=3 C sections | personal pathological hystory=Apendicitis | personal pathological hystory=C section | personal pathological hystory=Diabetes | personal pathological hystory=dyslipidemia | personal pathological hystory=hypertension | personal pathological hystory=Hypertension and Diabetes | personal pathological hystory=Hypertension and Rheumatoid Artritis | personal pathological hystory=hypothyroidism | personal pathological hystory=Hysterechtomy | personal pathological hystory=Knee Surgery | personal pathological hystory=Neg | personal pathological hystory=Ocular Surgery | personal pathological hystory=rheumatoid arthritis | personal pathological hystory=Venous insuficiency | place to metastasis=liver | place to metastasis=lung | place to metastasis=N/A | progesteron receptor immunohistochemestry=Neg | progesteron receptor immunohistochemestry=POs | progesteron receptor immunohistochemestry=Pos | radiotherapy=N/A | radiotherapy=No | radiotherapy=Yes | response to treatment=Complete | response to treatment=Partial | response to treatment=Poor | response to treatment=Progresive | rna 260/230 nanodrop=0.89 | rna 260/230 nanodrop=1.01 | rna 260/230 nanodrop=1.03 | rna 260/230 nanodrop=1.06 | rna 260/230 nanodrop=1.13 | rna 260/230 nanodrop=1.18 | rna 260/230 nanodrop=1.22 | rna 260/230 nanodrop=1.27 | rna 260/230 nanodrop=1.33 | rna 260/230 nanodrop=1.37 | rna 260/230 nanodrop=1.52 | rna 260/230 nanodrop=1.63 | rna 260/230 nanodrop=1.65 | rna 260/230 nanodrop=1.68 | rna 260/230 nanodrop=1.69 | rna 260/230 nanodrop=1.7 | rna 260/230 nanodrop=1.72 | rna 260/230 nanodrop=1.78 | rna 260/230 nanodrop=1.79 | rna 260/230 nanodrop=1.82 | rna 260/230 nanodrop=1.89 | rna 260/230 nanodrop=1.94 | rna 260/230 nanodrop=1.98 | rna 260/230 nanodrop=2.01 | rna 260/230 nanodrop=2.06 | rna 260/230 nanodrop=2.08 | rna 260/230 nanodrop=2.1 | rna 260/230 nanodrop=2.11 | rna 260/230 nanodrop=2.13 | rna 260/230 nanodrop=2.15 | rna 260/230 nanodrop=2.16 | rna 260/230 nanodrop=2.18 | rna 260/230 nanodrop=2.2 | rna 260/230 nanodrop=2.21 | rna 260/230 nanodrop=2.22 | rna 260/230 nanodrop=2.23 | rna 260/230 nanodrop=2.25 | rna 260/230 nanodrop=2.26 | rna 260/230 nanodrop=2.27 | rna 260/230 nanodrop=2.29 | rna 260/230 nanodrop=2.3 | rna 260/230 nanodrop=2.32 | rna 260/230 nanodrop=2.38 | rna 260/280 nanodrop=1.79 | rna 260/280 nanodrop=1.96 | rna 260/280 nanodrop=2.05 | rna 260/280 nanodrop=2.06 | rna 260/280 nanodrop=2.07 | rna 260/280 nanodrop=2.08 | rna 260/280 nanodrop=2.09 | rna 260/280 nanodrop=2.1 | rna 260/280 nanodrop=2.11 | rna 260/280 nanodrop=2.12 | rna 260/280 nanodrop=2.13 | rna 260/280 nanodrop=2.14 | rna 260/280 nanodrop=2.15 | rna 260/280 nanodrop=2.16 | rna 260/280 nanodrop=2.17 | rna 260/280 nanodrop=2.18 | rna 260/280 nanodrop=2.19 | rna 260/280 nanodrop=2.24 | rna 260/280 nanodrop=2.35 | rna ng/ul=1011.5 | rna ng/ul=1083 | rna ng/ul=111 | rna ng/ul=1116.8 | rna ng/ul=1187 | rna ng/ul=126.9 | rna ng/ul=127.7 | rna ng/ul=1365 | rna ng/ul=143.6 | rna ng/ul=1458.3 | rna ng/ul=146.7 | rna ng/ul=151.6 | rna ng/ul=1545 | rna ng/ul=1566.4 | rna ng/ul=158.3 | rna ng/ul=164 | rna ng/ul=178.2 | rna ng/ul=182.1 | rna ng/ul=1830 | rna ng/ul=2055.6 | rna ng/ul=224.7 | rna ng/ul=268.6 | rna ng/ul=291.4 | rna ng/ul=307 | rna ng/ul=333.9 | rna ng/ul=343 | rna ng/ul=352.9 | rna ng/ul=370.2 | rna ng/ul=375.6 | rna ng/ul=397.7 | rna ng/ul=401 | rna ng/ul=419.5 | rna ng/ul=431.4 | rna ng/ul=433.4 | rna ng/ul=437.4 | rna ng/ul=439 | rna ng/ul=475 | rna ng/ul=497.3 | rna ng/ul=524.9 | rna ng/ul=543 | rna ng/ul=60 | rna ng/ul=625.4 | rna ng/ul=646.4 | rna ng/ul=670 | rna ng/ul=682 | rna ng/ul=69 | rna ng/ul=693.6 | rna ng/ul=725 | rna ng/ul=728 | rna ng/ul=774.2 | rna ng/ul=81.1 | rna ng/ul=840.6 | rqi experion=10 | rqi experion=6.4 | rqi experion=6.6 | rqi experion=6.8 | rqi experion=7.2 | rqi experion=7.4 | rqi experion=7.6 | rqi experion=7.7 | rqi experion=7.8 | rqi experion=7.9 | rqi experion=8 | rqi experion=8.1 | rqi experion=8.2 | rqi experion=8.3 | rqi experion=8.4 | rqi experion=8.5 | rqi experion=8.6 | rqi experion=8.7 | rqi experion=8.8 | rqi experion=8.9 | rqi experion=9 | rqi experion=9.1 | rqi experion=9.2 | rqi experion=9.3 | rqi experion=9.4 | rqi experion=9.6 | rqi experion=9.9 | t=1 | t=2 | t=3 | t=4 | tabaquism=Neg | tabaquism=Pos","age at diagnosis=31 | age at diagnosis=35 | age at diagnosis=36 | age at diagnosis=40 | age at diagnosis=41 | age at diagnosis=42 | age at diagnosis=43 | age at diagnosis=44 | age at diagnosis=45 | age at diagnosis=46 | age at diagnosis=48 | age at diagnosis=49 | age at diagnosis=50 | age at diagnosis=51 | age at diagnosis=53 | age at diagnosis=54 | age at diagnosis=55 | age at diagnosis=56 | age at diagnosis=57 | age at diagnosis=58 | age at diagnosis=59 | age at diagnosis=62 | age at diagnosis=66 | age at diagnosis=68 | age at diagnosis=70 | age at diagnosis=71 | age at diagnosis=87 | age at menarche=11 | age at menarche=12 | age at menarche=13 | age at menarche=14 | age at menarche=15 | age at menarche=18 | birads=2 | birads=4 | birads=5 | birads=6 | birads=N/A | breast affected=Both | breast affected=left | breast affected=right | chemotherapy1=Adriamicin | chemotherapy1=doxorubicin | chemotherapy1=Epirubicin | chemotherapy1=N/A | chemotherapy1=paclitaxel | chemotherapy1=tamoxifen | chemotherapy1=TAXOL | chemotherapy1=Trastuzumab | chemotherapy2=Adriamicin | chemotherapy2=cyclophosphamide | chemotherapy2=doxorubicin | chemotherapy2=Epirrubicin | chemotherapy2=N/A | chemotherapy2=TAXOL | chemotherapy2=Trastazumab | chemotherapy3=Adramicin | chemotherapy3=Adriamicin | chemotherapy3=cyclophosphamide | chemotherapy3=N/A | chemotherapy3=paclitaxel | chemotherapy3=TAXOL | chemotherapy3=Trastuzumab | chemotherapy4=N/A | chemotherapy4=TAXOL | chemotherapy4=Trastuzumab | data at diagnosis=2012-12-05 | data at diagnosis=2013-05-09 | data at diagnosis=2013-05-13 | data at diagnosis=2013-05-21 | data at diagnosis=2013-05-24 | data at diagnosis=2013-05-29 | data at diagnosis=2013-06-04 | data at diagnosis=2013-06-06 | data at diagnosis=2013-06-17 | data at diagnosis=2013-06-18 | data at diagnosis=2013-06-23 | data at diagnosis=2013-07-08 | data at diagnosis=2013-07-11 | data at diagnosis=2013-07-23 | data at diagnosis=2013-07-29 | data at diagnosis=2013-08-01 | data at diagnosis=2013-08-06 | data at diagnosis=2013-08-08 | data at diagnosis=2013-08-22 | data at diagnosis=2013-08-24 | data at diagnosis=2013-09-02 | data at diagnosis=2013-09-03 | data at diagnosis=2013-09-09 | data at diagnosis=2013-09-10 | data at diagnosis=2013-10-02 | data at diagnosis=2013-10-03 | data at diagnosis=2013-10-15 | data at diagnosis=2013-11-04 | data at diagnosis=2013-11-12 | data at diagnosis=2013-11-20 | data at diagnosis=2013-12-09 | data at diagnosis=2014-02-21 | data at diagnosis=2014-03-10 | data at diagnosis=2014-03-12 | data at diagnosis=2014-03-18 | data at diagnosis=2014-03-25 | data at diagnosis=2014-04-01 | data at diagnosis=2014-04-02 | data at diagnosis=2014-04-04 | data at diagnosis=2014-04-15 | data at diagnosis=2014-04-16 | data at diagnosis=2014-05-14 | data at diagnosis=2014-07-23 | data at diagnosis=2014-08-01 | data at diagnosis=2014-10-31 | data at diagnosis=2014-11-07 | data at diagnosis=2014-11-14 | data at diagnosis=2014-11-21 | data at diagnosis=2014-12-05 | data at diagnosis=NA | date at death=2014-08-01 | date at death=N/A | date at death=not specified | date at relapse=2014-04-24 | date at relapse=2014-09-09 | date at relapse=2014-10-15 | date at relapse=N/A | diagnosis=Carcinoma in situ associated with comedo necrosis | diagnosis=Ductal carcinoma in situ comedonicus type | diagnosis=High grade invasive ductal carcinoma | diagnosis=High nuclear grade ductal carcinoma associated with carcinoma in situ | diagnosis=Infiltrating Ductal Adenocarcinoma | diagnosis=Infiltrating Ductal Carcinoma | diagnosis=Infiltrating ductal carcinoma high | diagnosis=Infiltrating lobular carcinoma high nuclear grade | diagnosis=Invasive Ductal Adenocarcinoma | diagnosis=Invasive ductal adenocarcinoma high nuclear grade | diagnosis=invasive ductal carcinoma | diagnosis=Invasive ductal carcinoma, carcinoma in situ associated with comedo necrosis | diagnosis=Moderately differentiated infiltrating ductal adenocarcinoma | diagnosis=Moderately differentiated invasive ductal carcinoma | diagnosis=Poorly differentiated ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal adenocarcinoma | diagnosis=Poorly differentiated infiltrating ductal carcinoma | diagnosis=Poorly differentiated invasive carcinoma with chondroid metaplasia | diagnosis=Poorly differentiated invasive ductal adenocarcinoma | diagnosis=Poorly differentiated invasive ductal carcinoma | diagnosis=Right Breast Ductal carcinoma in situ Left Breast infiltrating ductal adenocarcinoma poorly differentiated | diagnosis=undifferentiated carcinoma | e-cadherina ihc=N/A | e-cadherina ihc=Pos | estrogen receptor immunohistochemestry=Neg | estrogen receptor immunohistochemestry=Pos | final clinical size in mm by palpation=0 | final clinical size in mm by palpation=10 | final clinical size in mm by palpation=150 | final clinical size in mm by palpation=30 | final clinical size in mm by palpation=50 | final clinical size in mm by palpation=80 | final number of positive ganglia=0 | final number of positive ganglia=1 | final number of positive ganglia=12 | final number of positive ganglia=17 | final number of positive ganglia=2 | final number of positive ganglia=3 | final number of positive ganglia=4 | final number of positive ganglia=5 | final number of positive ganglia=6 | final number of positive ganglia=7 | final number of positive ganglia=8 | final number of positive ganglia=9 | final number of resected ganglia=0 | final number of resected ganglia=10 | final number of resected ganglia=11 | final number of resected ganglia=12 | final number of resected ganglia=13 | final number of resected ganglia=14 | final number of resected ganglia=15 | final number of resected ganglia=16 | final number of resected ganglia=17 | final number of resected ganglia=18 | final number of resected ganglia=19 | final number of resected ganglia=2 | final number of resected ganglia=20 | final number of resected ganglia=22 | final number of resected ganglia=23 | final number of resected ganglia=24 | final number of resected ganglia=26 | final number of resected ganglia=27 | final number of resected ganglia=29 | final number of resected ganglia=3 | final number of resected ganglia=33 | final number of resected ganglia=34 | final number of resected ganglia=37 | final number of resected ganglia=4 | final number of resected ganglia=41 | final number of resected ganglia=5 | final number of resected ganglia=6 | final pathology size in mm=0 | final pathology size in mm=10 | final pathology size in mm=110 | final pathology size in mm=15 | final pathology size in mm=18 | final pathology size in mm=2 | final pathology size in mm=20 | final pathology size in mm=25 | final pathology size in mm=30 | final pathology size in mm=35 | final pathology size in mm=38 | final pathology size in mm=40 | final pathology size in mm=45 | final pathology size in mm=5 | final pathology size in mm=50 | final pathology size in mm=55 | final pathology size in mm=7 | final pathology size in mm=80 | final surgery date=2013-06-19 | final surgery date=2013-10-18 | final surgery date=2014-01-27 | final surgery date=2014-02-04 | final surgery date=2014-02-05 | final surgery date=2014-02-11 | final surgery date=2014-02-13 | final surgery date=2014-02-17 | final surgery date=2014-02-21 | final surgery date=2014-02-24 | final surgery date=2014-03-10 | final surgery date=2014-03-20 | final surgery date=2014-03-26 | final surgery date=2014-04-19 | final surgery date=2014-04-24 | final surgery date=2014-04-25 | final surgery date=2014-04-26 | final surgery date=2014-04-28 | final surgery date=2014-04-29 | final surgery date=2014-05-15 | final surgery date=2014-05-19 | final surgery date=2014-06-02 | final surgery date=2014-06-05 | final surgery date=2014-06-11 | final surgery date=2014-06-20 | final surgery date=2014-07-14 | final surgery date=2014-07-16 | final surgery date=2014-07-23 | final surgery date=2014-07-27 | final surgery date=2014-07-31 | final surgery date=2014-08-06 | final surgery date=2014-08-22 | final surgery date=2014-09-06 | final surgery date=2014-10-07 | final surgery date=2014-10-10 | final surgery date=2014-10-15 | final surgery date=2014-10-16 | final surgery date=2014-10-20 | final surgery date=2014-10-22 | final surgery date=2014-10-27 | final surgery date=2014-10-29 | final surgery date=2014-11-06 | final surgery date=2014-11-07 | final surgery date=2014-11-10 | final surgery date=2014-11-11 | final surgery date=2014-11-13 | final surgery date=2014-11-19 | final surgery date=2014-11-21 | final surgery date=NA | her2 fish=N/A | her2 fish=Neg | her2 fish=Pos | her2 immunohistochemestry=N/A | her2 immunohistochemestry=Neg | her2 immunohistochemestry=Pos | histological grade=1 | histological grade=2 | histological grade=3 | histological grade=N/A | initial clinical size in mm by palpation=0 | initial clinical size in mm by palpation=100 | initial clinical size in mm by palpation=15 | initial clinical size in mm by palpation=150 | initial clinical size in mm by palpation=20 | initial clinical size in mm by palpation=30 | initial clinical size in mm by palpation=35 | initial clinical size in mm by palpation=40 | initial clinical size in mm by palpation=50 | initial clinical size in mm by palpation=60 | initial clinical size in mm by palpation=70 | initial clinical size in mm by palpation=80 | initial clinical size in mm by palpation=90 | initial highest diameter in mm by image=100 | initial highest diameter in mm by image=14 | initial highest diameter in mm by image=150 | initial highest diameter in mm by image=16 | initial highest diameter in mm by image=20 | initial highest diameter in mm by image=200 | initial highest diameter in mm by image=22 | initial highest diameter in mm by image=25 | initial highest diameter in mm by image=27 | initial highest diameter in mm by image=30 | initial highest diameter in mm by image=32 | initial highest diameter in mm by image=33 | initial highest diameter in mm by image=34 | initial highest diameter in mm by image=35 | initial highest diameter in mm by image=36 | initial highest diameter in mm by image=37 | initial highest diameter in mm by image=39 | initial highest diameter in mm by image=4 | initial highest diameter in mm by image=40 | initial highest diameter in mm by image=41 | initial highest diameter in mm by image=42 | initial highest diameter in mm by image=48 | initial highest diameter in mm by image=50 | initial highest diameter in mm by image=51 | initial highest diameter in mm by image=57 | initial highest diameter in mm by image=60 | initial highest diameter in mm by image=67 | initial highest diameter in mm by image=7 | initial highest diameter in mm by image=70 | initial highest diameter in mm by image=80 | initial highest diameter in mm by image=86 | initial highest diameter in mm by image=90 | m=0 | m=1 | m=x | n=0 | n=1 | n=2 | n=3 | p63 ihc=Absent | p63 ihc=N/A | p63 ihc=Neg | p63 ihc=Pos | pathological family history=Diabetes | pathological family history=Diabetes and Heart Disease | pathological family history=Fater Liver Cancer | pathological family history=Father Laringeal Cancer | pathological family history=Father Lung Cancer | pathological family history=Father Pancreas Cancer. Maternal Aunt Breast Cancer. Father Aunts Ovarian Cancer. Cousin Breast Cancer | pathological family history=hypertension | pathological family history=Liver Cancer | pathological family history=Maternal Aunt Breast Cancer | pathological family history=Mother and Sister Ovarian Cancer | pathological family history=Mother Breast Cancer | pathological family history=Mother Endometrial Cancer | pathological family history=Neg | pathological family history=NEV | pathological family history=Paternal Grandmother Breast Cancer | pathological family history=Pos | pathological family history=Sister Brain Cancer | pathological family history=Sister Breast Cancer, Brother Prostate Cancer | pathological family history=Sister GBM and Breast Cancer | pathological family history=Sister Liver Cancer | pathological family history=Sister Pancreatic Cancer | percentage ki67 ihc=0.0022 | percentage ki67 ihc=0.01 | percentage ki67 ihc=0.02 | percentage ki67 ihc=0.03 | percentage ki67 ihc=0.04 | percentage ki67 ihc=0.05 | percentage ki67 ihc=0.06 | percentage ki67 ihc=0.07 | percentage ki67 ihc=0.08 | percentage ki67 ihc=0.1 | percentage ki67 ihc=0.12 | percentage ki67 ihc=0.15 | percentage ki67 ihc=0.2 | percentage ki67 ihc=0.22 | percentage ki67 ihc=0.25 | percentage ki67 ihc=0.35 | percentage ki67 ihc=0.4 | percentage ki67 ihc=0.45 | percentage ki67 ihc=0.6 | percentage ki67 ihc=0.7 | percentage ki67 ihc=0.8 | percentage ki67 ihc=0.85 | percentage ki67 ihc=N/A | personal pathological hystory=0 | personal pathological hystory=3 C sections | personal pathological hystory=Apendicitis | personal pathological hystory=C section | personal pathological hystory=Diabetes | personal pathological hystory=dyslipidemia | personal pathological hystory=hypertension | personal pathological hystory=Hypertension and Diabetes | personal pathological hystory=Hypertension and Rheumatoid Artritis | personal pathological hystory=hypothyroidism | personal pathological hystory=Hysterechtomy | personal pathological hystory=Knee Surgery | personal pathological hystory=Neg | personal pathological hystory=Ocular Surgery | personal pathological hystory=rheumatoid arthritis | personal pathological hystory=Venous insuficiency | place to metastasis=liver | place to metastasis=lung | place to metastasis=N/A | progesteron receptor immunohistochemestry=Neg | progesteron receptor immunohistochemestry=POs | progesteron receptor immunohistochemestry=Pos | radiotherapy=N/A | radiotherapy=No | radiotherapy=Yes | response to treatment=Complete | response to treatment=Partial | response to treatment=Poor | response to treatment=Progresive | rna 260/230 nanodrop=0.89 | rna 260/230 nanodrop=1.01 | rna 260/230 nanodrop=1.03 | rna 260/230 nanodrop=1.06 | rna 260/230 nanodrop=1.13 | rna 260/230 nanodrop=1.18 | rna 260/230 nanodrop=1.22 | rna 260/230 nanodrop=1.27 | rna 260/230 nanodrop=1.33 | rna 260/230 nanodrop=1.37 | rna 260/230 nanodrop=1.52 | rna 260/230 nanodrop=1.63 | rna 260/230 nanodrop=1.65 | rna 260/230 nanodrop=1.68 | rna 260/230 nanodrop=1.69 | rna 260/230 nanodrop=1.7 | rna 260/230 nanodrop=1.72 | rna 260/230 nanodrop=1.78 | rna 260/230 nanodrop=1.79 | rna 260/230 nanodrop=1.82 | rna 260/230 nanodrop=1.89 | rna 260/230 nanodrop=1.94 | rna 260/230 nanodrop=1.98 | rna 260/230 nanodrop=2.01 | rna 260/230 nanodrop=2.06 | rna 260/230 nanodrop=2.08 | rna 260/230 nanodrop=2.1 | rna 260/230 nanodrop=2.11 | rna 260/230 nanodrop=2.13 | rna 260/230 nanodrop=2.15 | rna 260/230 nanodrop=2.16 | rna 260/230 nanodrop=2.18 | rna 260/230 nanodrop=2.2 | rna 260/230 nanodrop=2.21 | rna 260/230 nanodrop=2.22 | rna 260/230 nanodrop=2.23 | rna 260/230 nanodrop=2.25 | rna 260/230 nanodrop=2.26 | rna 260/230 nanodrop=2.27 | rna 260/230 nanodrop=2.29 | rna 260/230 nanodrop=2.3 | rna 260/230 nanodrop=2.32 | rna 260/230 nanodrop=2.38 | rna 260/280 nanodrop=1.79 | rna 260/280 nanodrop=1.96 | rna 260/280 nanodrop=2.05 | rna 260/280 nanodrop=2.06 | rna 260/280 nanodrop=2.07 | rna 260/280 nanodrop=2.08 | rna 260/280 nanodrop=2.09 | rna 260/280 nanodrop=2.1 | rna 260/280 nanodrop=2.11 | rna 260/280 nanodrop=2.12 | rna 260/280 nanodrop=2.13 | rna 260/280 nanodrop=2.14 | rna 260/280 nanodrop=2.15 | rna 260/280 nanodrop=2.16 | rna 260/280 nanodrop=2.17 | rna 260/280 nanodrop=2.18 | rna 260/280 nanodrop=2.19 | rna 260/280 nanodrop=2.24 | rna 260/280 nanodrop=2.35 | rna ng/ul=1011.5 | rna ng/ul=1083 | rna ng/ul=111 | rna ng/ul=1116.8 | rna ng/ul=1187 | rna ng/ul=126.9 | rna ng/ul=127.7 | rna ng/ul=1365 | rna ng/ul=143.6 | rna ng/ul=1458.3 | rna ng/ul=146.7 | rna ng/ul=151.6 | rna ng/ul=1545 | rna ng/ul=1566.4 | rna ng/ul=158.3 | rna ng/ul=164 | rna ng/ul=178.2 | rna ng/ul=182.1 | rna ng/ul=1830 | rna ng/ul=2055.6 | rna ng/ul=224.7 | rna ng/ul=268.6 | rna ng/ul=291.4 | rna ng/ul=307 | rna ng/ul=333.9 | rna ng/ul=343 | rna ng/ul=352.9 | rna ng/ul=370.2 | rna ng/ul=375.6 | rna ng/ul=397.7 | rna ng/ul=401 | rna ng/ul=419.5 | rna ng/ul=431.4 | rna ng/ul=433.4 | rna ng/ul=437.4 | rna ng/ul=439 | rna ng/ul=475 | rna ng/ul=497.3 | rna ng/ul=524.9 | rna ng/ul=543 | rna ng/ul=60 | rna ng/ul=625.4 | rna ng/ul=646.4 | rna ng/ul=670 | rna ng/ul=682 | rna ng/ul=69 | rna ng/ul=693.6 | rna ng/ul=725 | rna ng/ul=728 | rna ng/ul=774.2 | rna ng/ul=81.1 | rna ng/ul=840.6 | rqi experion=10 | rqi experion=6.4 | rqi experion=6.6 | rqi experion=6.8 | rqi experion=7.2 | rqi experion=7.4 | rqi experion=7.6 | rqi experion=7.7 | rqi experion=7.8 | rqi experion=7.9 | rqi experion=8 | rqi experion=8.1 | rqi experion=8.2 | rqi experion=8.3 | rqi experion=8.4 | rqi experion=8.5 | rqi experion=8.6 | rqi experion=8.7 | rqi experion=8.8 | rqi experion=8.9 | rqi experion=9 | rqi experion=9.1 | rqi experion=9.2 | rqi experion=9.3 | rqi experion=9.4 | rqi experion=9.6 | rqi experion=9.9 | t=1 | t=2 | t=3 | t=4 | tabaquism=Neg | tabaquism=Pos","cell line=NCH421k | cell line=NCH644 | cell line=U251 | cell line=U87 | growth condition=hypoxia (0.1 percent oxygen) | growth condition=normoxia (21 percent oxygen) | time=0.5 day | time=7 day","cell type=GBM-tissue | cell type=GSC culture-spheres | cell type=NFC cultures-spheres","treatment=Chronophin shRNA | treatment=Chronophin shRNA plus rescue | treatment=Control shRNA | treatment=not specified","cell type=GBM-tissue | cell type=glioblastoma stem-like cell line T08 | cell type=glioblastoma stem-like cell line T65 | cell type=GSC culture-spheres | cell type=NFC cultures-spheres | passage number=not specified | passage number=p12 | passage number=p15 | passage number=p16 | passage number=p17 | passage number=p5p10 | passage number=p5p5 | passage number=p5p8 | passage number=p5p9 | treatment=Non-silencing construct | treatment=none | treatment=shRNA construct 1 | treatment=shRNA construct 2","cell type=glioblastoma stem-like cell line T08 | cell type=glioblastoma stem-like cell line T65 | passage number=p12 | passage number=p15 | passage number=p16 | passage number=p17 | passage number=p5p10 | passage number=p5p5 | passage number=p5p8 | passage number=p5p9 | treatment=Non-silencing construct | treatment=shRNA construct 1 | treatment=shRNA construct 2","compound 1=cannabidiol | compound 1=none | compound 2=none | compound 2=tetrahydrocannabinol | dose 1=10 micromolar | dose 1=2 micromolar | dose 1=5 micromolar | dose 1=8 micromolar | dose 2=10 micromolar | dose 2=2 micromolar | dose 2=5 micromolar | dose 2=8 micromolar","genotype=EGFP-expressing | genotype=MLL5-overexpressing","growth condition=Hypoxia | growth condition=Normoxia | time=day | time=0.5 day | time=7 day","grade=III | grade=IV | histology=anaplastic oligodendroglioma | histology=GBM | pna=PNA.hi | pna=PNA.neg | replicate=A | replicate=B | replicate=C | replicate=D | replicate=E | replicate=F | replicate=G | replicate=H","grade=III | grade=IV | histology=anaplastic oligoastrocytoma | histology=glioblastoma multiforme | replicate=replicate1 | replicate=replicate2","grade=III | grade=IV | histology=anaplastic oligoastrocytoma | histology=anaplastic oligodendroglioma | histology=GBM | histology=glioblastoma multiforme | pna=not specified | pna=PNA.hi | pna=PNA.neg | replicate=A | replicate=B | replicate=C | replicate=D | replicate=E | replicate=F | replicate=G | replicate=H | replicate=replicate1 | replicate=replicate2","cell line=U251 | cell line=U87","cell line=42-MG | cell line=8-MG | cell line=AU565 | cell line=COLO 205 | cell line=HTB-38 | cell line=MB-157 | cell line=NCI-H508 | cell line=T98G | cell line=U-87 | cell type=breast adenocarcinoma | cell type=breast medullary carcinoma | cell type=colorectal metastatic adenocarcinoma | cell type=colorectal primary adenocarcinoma | cell type=Glioblastoma | cell type=human colorectal metastatic adenocarcinoma | growth media=DMEM | growth media=L-15 Leibovitz | growth media=McCoy’s 5A | growth media=RPM1-1640","age at diagnosis yrs=21 | age at diagnosis yrs=30 | age at diagnosis yrs=32 | age at diagnosis yrs=34 | age at diagnosis yrs=35 | age at diagnosis yrs=36 | age at diagnosis yrs=38 | age at diagnosis yrs=40 | age at diagnosis yrs=41 | age at diagnosis yrs=42 | age at diagnosis yrs=43 | age at diagnosis yrs=44 | age at diagnosis yrs=45 | age at diagnosis yrs=48 | age at diagnosis yrs=50 | age at diagnosis yrs=55 | age at diagnosis yrs=58 | age at diagnosis yrs=65 | morphological diagnosis=anaplastic oligoastrocytoma III | morphological diagnosis=astrocytoma II | morphological diagnosis=GBM IV | morphological diagnosis=oligoastrocytoma II | morphological diagnosis=oligodendrocytoma II | rmpa signature=RMPAhigh | rmpa signature=RMPAlow | sex=female | sex=male | survivalday=185 | survivalday=195 | survivalday=202 | survivalday=204 | survivalday=210 | survivalday=213 | survivalday=240 | survivalday=339 | survivalday=353 | survivalday=370 | survivalday=377 | survivalday=381 | survivalday=384 | survivalday=388 | survivalday=402 | survivalday=574 | survivalday=N/A","block=Batch01 | block=Batch02 | block=Batch03 | block=Batch04 | block=Batch05 | block=Batch06 | disease=breast carcinoma | disease=colorectal carcinoma | disease=glioblastoma | disease=hepatobiliary carcinoma | disease=non-small cell lung carcinoma | disease=normal | disease=pancreatic adenocarcinoma","tumor stage=Glioma Grade IV | tumor stage=NA","cell type=differentiated non-stem glioma cells (NSGCs) | cell type=glioma stem cells (GSCs) | cell type=senescent non-stem glioma cells (NSGCs) | source id=GBM146 | source id=GBM157 | time=day 0 | time=day 30 after serum exposure | time=day 7 after serum exposure","disease=glioblastoma multiforme | disease=Normal | stimulus=bone morphogenic protein | time=32 day | time=64 day | time=8 day","disease=glioblastoma multiforme | stimulus=bone morphogenic protein","disease=glioblastoma multiforme | disease=normal","idh1=mutant | idh1=wild-type | tissue/cell type=control | tissue/cell type=fibrosarcoma | tissue/cell type=glioblastoma tumorsphere | tissue/cell type=patient-derived glioblastoma tumorsphere | treated with=DMSO (0.1%) for 10 months | treated with=DMSO (0.1%) for 10 months + 2 days | treated with=IDH1i (5uM) for 10 months | treated with=not specified","NA","organism part=dorsolateral prefrontal cortex | organism part=Gliobmastoma biopsy | organism part=hippocampus | organism part=not specified","egfrviii statue=+ | egfrviii statue=-","tumor grade=Control Tissue | tumor grade=GBM | tumor grade=Pilocitic astrocitoma","cell line=IMR90 | cell line=NCI-H2052 | cell line=SF268 | cell type=Glioblastoma cells | cell type=malignant pleural mesothelioma cells | cell type=Mesothelioma cells | chip antibody=Anti-YAP1 antibody [EP1674Y] | chip antibody=Histone H3K27ac antibody | chip antibody=none | chip antibody=not specified | chip antibody=TEF-1 | chip antibody cat. #=39133 | chip antibody cat. #=610922 | chip antibody cat. #=ab52771 | chip antibody cat. #=not specified | chip antibody vendor=Abcam | chip antibody vendor=Active Motif | chip antibody vendor=BD Transduction Laboratories | chip antibody vendor=not specified","clinical history=surgery number 1 | clinical history=surgery number 2 | clinical history=surgery number 3 | individual=4608078188 | individual=4608137902 | individual=4709051835 | individual=4709093862 | individual=4810015201","cell line=GBM1 | cell line=GBM10 | cell line=GBM14 | cell line=GBM2","cell line=(pool of 16 cancer cell lines) | cell line=04-147 | cell line=10 | cell line=1089 luminal | cell line=10A | cell line=11 | cell line=11A | cell line=1205-Lu | cell line=184B5 MeM | cell line=1Cc8 | cell line=22Rv1 | cell line=36M2 | cell line=5-8F | cell line=527MEL | cell line=6-10B | cell line=624MEL | cell line=697 | cell line=6a | cell line=76N | cell line=76N RhoA | cell line=786-O | cell line=786-VHL | cell line=8226/S | cell line=888MEL | cell line=8d | cell line=90-8 | cell line=92,1 | cell line=928MEL | cell line=9A | cell line=A02 | cell line=A04 | cell line=A06 | cell line=A1 | cell line=A11 | cell line=A13 | cell line=A15 | cell line=A172 | cell line=A2058 | cell line=A2780 | cell line=A3-Kawakami | cell line=A375 | cell line=A375M2 | cell line=A375P | cell line=A375SM | cell line=A427 | cell line=A431 | cell line=A4_Fukada | cell line=A549 | cell line=A6 | cell line=ABC1 | cell line=abl | cell line=AF6 | cell line=AG04147 | cell line=AG05416 | cell line=AG06237 | cell line=AG07139 | cell line=AG07307 | cell line=AG08046 | cell line=AG08048 | cell line=AG09699 | cell line=AG09877 | cell line=AG10049 | cell line=AG10941 | cell line=AG11364 | cell line=AG11696 | cell line=AG11726 | cell line=AG13066 | cell line=AG13145 | cell line=AG13150 | cell line=AG14446 | cell line=AGS | cell line=AGS and MKN-45 | cell line=AMO-1 | cell line=ANBL-6 | cell line=ARPE-19 | cell line=AsPC-1 | cell line=AU565 | cell line=Awells | cell line=AZ521 | cell line=B41 | cell line=BattP12 | cell line=BC-3 | cell line=BCN | cell line=BCWM1 | cell line=BE(2)-C | cell line=BEAS-2B | cell line=BJ | cell line=BJ1 | cell line=BJAB | cell line=BL | cell line=BPLER | cell line=BT-474 | cell line=BT-474-EI | cell line=BT-483 | cell line=BT-549 | cell line=BT-5491 | cell line=BT/HerR0.2D clone (Her2-positive BT474) | cell line=BT/HerR0.2J clone (Her2-positive BT474) | cell line=BT/HerR1.0C clone (Her2-positive BT474) | cell line=BT/HerR1.0E clone (Her2-positive BT474) | cell line=BxPC-3 | cell line=C-32 | cell line=C1 | cell line=C32 | cell line=C33-A | cell line=C4-2 | cell line=C7H2 | cell line=C7H2-R10E7 | cell line=C7H2-R19E5 | cell line=C7H2-R19E7 | cell line=C7H2-R19F2 | cell line=C7H2-R3B5 | cell line=C7H2-R9C10 | cell line=C7H2-S10 | cell line=C7H2-S11 | cell line=C7H2-S12 | cell line=C7H2-S15 | cell line=C7H2-S2 | cell line=C7H2-S27 | cell line=C7H2-S27(ZR) | cell line=CA1 | cell line=CA2 | cell line=Caco-2 | cell line=Caki-1 | cell line=CAL-120 | cell line=CAL-1201 | cell line=CAL-148 | cell line=CAL-51 | cell line=CAL-851 | cell line=Calu-1 | cell line=Calu-3 | cell line=Calu-3 subclone 2B4 | cell line=Calu-6 | cell line=CAMA-1 | cell line=Caov-3 | cell line=Capan-1 | cell line=Capan-2 | cell line=CCD-1079Sk | cell line=CCD-1108SK | cell line=CCD-13Lu | cell line=CCD-16Lu | cell line=CCD-18Co | cell line=CCD-19Lu | cell line=CCD-25Lu | cell line=CCD-29Lu | cell line=CCD-8Lu | cell line=CCRF-CEM | cell line=CCRF-CEM-c1 | cell line=CCRF-CEM-C7R1 | cell line=CEM | cell line=CFPAC | cell line=CFT-2 | cell line=CI-1 | cell line=CJM | cell line=CL-11 | cell line=CL-40 | cell line=CL1-5 | cell line=CLS145 | cell line=CMK | cell line=CNE2 | cell line=CNMel | cell line=COLO-201 | cell line=COLO-205 | cell line=Colo-206 | cell line=Colo-320 DM | cell line=Colo-320 HSR | cell line=Colo-357 | cell line=Colo-678 | cell line=COLO-704 | cell line=Colo-741 | cell line=Colo-829 | cell line=Con1 | cell line=CP-A hTERT | cell line=CRL-2054 | cell line=CRMel | cell line=CS-1 | cell line=CS-1/ER | cell line=CS-1/PR | cell line=CWR22Rv1 | cell line=CX-1 | cell line=D01 | cell line=D04 | cell line=D05 | cell line=D08 | cell line=D10 | cell line=D11 | cell line=D14 | cell line=D17 | cell line=D20 | cell line=D22 | cell line=D24 | cell line=D25 | cell line=D28 | cell line=D29 | cell line=D32 | cell line=D35 | cell line=D36 | cell line=D38 | cell line=D40 | cell line=D41 | cell line=DAOY | cell line=DB | cell line=DBTRG-05MG | cell line=Detroit 551 | cell line=Detroit 562 | cell line=dH1F | cell line=DLD-1 | cell line=DM175 | cell line=DM366 | cell line=DM368 | cell line=DM382 | cell line=DM391 | cell line=DM401p | cell line=DM414 | cell line=DM422 | cell line=DM424 | cell line=DM425 | cell line=DM440 | cell line=DM443 | cell line=DM451 | cell line=DM459 | cell line=DM467 | cell line=DM497 | cell line=DM555 | cell line=DM578 | cell line=DM589 | cell line=DM59 | cell line=DM598 | cell line=DM6 | cell line=DM602 | cell line=DM608 | cell line=DM636 | cell line=DM643 | cell line=DM646 | cell line=DM711 | cell line=DM733 | cell line=DM738 | cell line=DM745 | cell line=DM751 | cell line=DM779 | cell line=DM787 | cell line=DM792 | cell line=DM798 | cell line=DM806 | cell line=DM833 | cell line=DM868 | cell line=DoHH2 | cell line=DU145 | cell line=DU4475 | cell line=EBC1 | cell line=EBV-LCL 721 | cell line=EC109 | cell line=EES-1 | cell line=EFM19 | cell line=EFM192A | cell line=EFO21 | cell line=EKVX | cell line=Eol1 | cell line=EREB2-5 | cell line=ES-2 | cell line=EVSA | cell line=FaDu | cell line=Farage | cell line=FarageX1 | cell line=FG | cell line=fibroblast derived cell line | cell line=FL | cell line=FU-OV-1 | cell line=Fu97 | cell line=G111 | cell line=G112 | cell line=G118 | cell line=G120 | cell line=G121 | cell line=G122 | cell line=G124 | cell line=G130 | cell line=G140 | cell line=G141 | cell line=G142 | cell line=G144-NS | cell line=G166-NS | cell line=G174-NS | cell line=G179-NS | cell line=G22 | cell line=G28T | cell line=G361 | cell line=G44 | cell line=G59 | cell line=G61 | cell line=G63 | cell line=G84 | cell line=G96 | cell line=GBS6 | cell line=GI-LI-N | cell line=GI-ME-N | cell line=GliNS1 | cell line=GliNS2 | cell line=GM | cell line=GM00144 | cell line=GM01652C | cell line=GM02036A | cell line=GM02767 | cell line=GM03348E | cell line=GM03349C | cell line=GM03377 | cell line=GM04981 | cell line=GM06944 | cell line=GM06985 | cell line=GM06993 | cell line=GM06994 | cell line=GM07000 | cell line=GM07022 | cell line=GM07034 | cell line=GM07055 | cell line=GM07056 | cell line=GM07345 | cell line=GM07357 | cell line=GM08398A | cell line=GM11829 | cell line=GM11830 | cell line=GM11831 | cell line=GM11832 | cell line=GM11839 | cell line=GM11840 | cell line=GM11881 | cell line=GM11882 | cell line=GM11992 | cell line=GM11993 | cell line=GM11994 | cell line=GM11995 | cell line=GM12003 | cell line=GM12004 | cell line=GM12005 | cell line=GM12006 | cell line=GM12043 | cell line=GM12044 | cell line=GM12056 | cell line=GM12057 | cell line=GM12144 | cell line=GM12145 | cell line=GM12146 | cell line=GM12154 | cell line=GM12155 | cell line=GM12156 | cell line=GM12234 | cell line=GM12236 | cell line=GM12239 | cell line=GM12248 | cell line=GM12249 | cell line=GM12264 | cell line=GM12716 | cell line=GM12717 | cell line=GM12750 | cell line=GM12751 | cell line=GM12760 | cell line=GM12761 | cell line=GM12762 | cell line=GM12763 | cell line=GM12812 | cell line=GM12813 | cell line=GM12814 | cell line=GM12815 | cell line=GM12872 | cell line=GM12873 | cell line=GM12874 | cell line=GM12875 | cell line=GM12891 | cell line=GM12892 | cell line=GM14381 | cell line=GM14382 | cell line=GM14405 | cell line=GM14406 | cell line=GM14408 | cell line=GM14409 | cell line=GM14414 | cell line=GM14417 | cell line=GM14432 | cell line=GM14433 | cell line=GM14439 | cell line=GM14440 | cell line=GM14447 | cell line=GM14448 | cell line=GM14452 | cell line=GM14453 | cell line=GM14454 | cell line=GM14455 | cell line=GM14464 | cell line=GM14465 | cell line=GM14467 | cell line=GM14468 | cell line=GM14474 | cell line=GM14475 | cell line=GM14476 | cell line=GM14477 | cell line=GM14478 | cell line=GM14479 | cell line=GM14480 | cell line=GM14481 | cell line=GM14501 | cell line=GM14502 | cell line=GM14503 | cell line=GM14504 | cell line=GM14506 | cell line=GM14507 | cell line=GM14508 | cell line=GM14509 | cell line=GM14520 | cell line=GM14521 | cell line=GM14532 | cell line=GM14533 | cell line=GM14535 | cell line=GM14536 | cell line=GM14568 | cell line=GM14569 | cell line=GM14581 | cell line=GM14582 | cell line=GM14583 | cell line=GM14584 | cell line=GM15029 | cell line=GM15036 | cell line=GM15038 | cell line=GM15056 | cell line=GM15061 | cell line=GM15072 | cell line=GM15144 | cell line=GM15213 | cell line=GM15215 | cell line=GM15216 | cell line=GM15221 | cell line=GM15223 | cell line=GM15224 | cell line=GM15226 | cell line=GM15227 | cell line=GM15236 | cell line=GM15242 | cell line=GM15245 | cell line=GM15268 | cell line=GM15324 | cell line=GM15385 | cell line=GM15386 | cell line=GM15510 | cell line=GM15590 | cell line=GM15850 | cell line=GM15851 | cell line=GM17102 | cell line=GM17103 | cell line=GM17104 | cell line=GM17105 | cell line=GM17106 | cell line=GM17107 | cell line=GM17108 | cell line=GM17109 | cell line=GM17110 | cell line=GM17111 | cell line=GM17112 | cell line=GM17113 | cell line=GM17114 | cell line=GM17115 | cell line=GM17116 | cell line=GM17117 | cell line=GM17118 | cell line=GM17119 | cell line=GM17121 | cell line=GM17122 | cell line=GM17124 | cell line=GM17125 | cell line=GM17126 | cell line=GM17127 | cell line=GM17129 | cell line=GM17130 | cell line=GM17131 | cell line=GM17132 | cell line=GM17133 | cell line=GM17134 | cell line=GM17135 | cell line=GM17136 | cell line=GM17137 | cell line=GM17138 | cell line=GM17139 | cell line=GM17140 | cell line=GM17141 | cell line=GM17142 | cell line=GM17143 | cell line=GM17144 | cell line=GM17145 | cell line=GM17146 | cell line=GM17147 | cell line=GM17148 | cell line=GM17149 | cell line=GM17150 | cell line=GM17154 | cell line=GM17155 | cell line=GM17156 | cell line=GM17157 | cell line=GM17158 | cell line=GM17159 | cell line=GM17160 | cell line=GM17161 | cell line=GM17162 | cell line=GM17163 | cell line=GM17164 | cell line=GM17165 | cell line=GM17166 | cell line=GM17167 | cell line=GM17168 | cell line=GM17170 | cell line=GM17171 | cell line=GM17172 | cell line=GM17176 | cell line=GM17177 | cell line=GM17179 | cell line=GM17180 | cell line=GM17181 | cell line=GM17182 | cell line=GM17183 | cell line=GM17184 | cell line=GM17185 | cell line=GM17186 | cell line=GM17187 | cell line=GM17188 | cell line=GM17189 | cell line=GM17190 | cell line=GM17192 | cell line=GM17196 | cell line=GM17197 | cell line=GM17198 | cell line=GM17199 | cell line=GM17201 | cell line=GM17202 | cell line=GM17203 | cell line=GM17204 | cell line=GM17205 | cell line=GM17206 | cell line=GM17207 | cell line=GM17208 | cell line=GM17209 | cell line=GM17210 | cell line=GM17211 | cell line=GM17212 | cell line=GM17213 | cell line=GM17214 | cell line=GM17215 | cell line=GM17216 | cell line=GM17217 | cell line=GM17218 | cell line=GM17220 | cell line=GM17221 | cell line=GM17222 | cell line=GM17223 | cell line=GM17224 | cell line=GM17225 | cell line=GM17226 | cell line=GM17227 | cell line=GM17228 | cell line=GM17229 | cell line=GM17230 | cell line=GM17231 | cell line=GM17232 | cell line=GM17233 | cell line=GM17234 | cell line=GM17235 | cell line=GM17236 | cell line=GM17237 | cell line=GM17238 | cell line=GM17239 | cell line=GM17240 | cell line=GM17241 | cell line=GM17242 | cell line=GM17243 | cell line=GM17244 | cell line=GM17245 | cell line=GM17246 | cell line=GM17247 | cell line=GM17248 | cell line=GM17249 | cell line=GM17250 | cell line=GM17251 | cell line=GM17252 | cell line=GM17253 | cell line=GM17254 | cell line=GM17255 | cell line=GM17256 | cell line=GM17257 | cell line=GM17258 | cell line=GM17259 | cell line=GM17260 | cell line=GM17261 | cell line=GM17263 | cell line=GM17264 | cell line=GM17265 | cell line=GM17266 | cell line=GM17267 | cell line=GM17268 | cell line=GM17269 | cell line=GM17270 | cell line=GM17272 | cell line=GM17274 | cell line=GM17275 | cell line=GM17276 | cell line=GM17278 | cell line=GM17281 | cell line=GM17282 | cell line=GM17283 | cell line=GM17284 | cell line=GM17285 | cell line=GM17286 | cell line=GM17288 | cell line=GM17290 | cell line=GM17733 | cell line=GM17734 | cell line=GM17735 | cell line=GM17736 | cell line=GM17737 | cell line=GM17738 | cell line=GM17739 | cell line=GM17741 | cell line=GM17742 | cell line=GM17743 | cell line=GM17744 | cell line=GM17745 | cell line=GM17746 | cell line=GM17747 | cell line=GM17749 | cell line=GM17752 | cell line=GM17753 | cell line=GM17754 | cell line=GM17755 | cell line=GM17757 | cell line=GM17759 | cell line=GM17761 | cell line=GM17762 | cell line=GM17764 | cell line=GM17765 | cell line=GM17766 | cell line=GM17767 | cell line=GM17768 | cell line=GM17769 | cell line=GM17770 | cell line=GM17771 | cell line=GM17773 | cell line=GM17774 | cell line=GM17775 | cell line=GM17776 | cell line=GM17779 | cell line=GM17780 | cell line=GM17782 | cell line=GM17783 | cell line=GM17785 | cell line=GM17787 | cell line=GM17789 | cell line=GM17790 | cell line=GM17791 | cell line=GM17792 | cell line=GM17793 | cell line=GM17794 | cell line=GM17795 | cell line=GM17796 | cell line=GM17797 | cell line=GM17798 | cell line=GM17799 | cell line=GM17800 | cell line=GM17801 | cell line=GM17802 | cell line=GM17803 | cell line=GM17804 | cell line=GM17805 | cell line=GM17806 | cell line=GM17807 | cell line=GM17808 | cell line=GM17809 | cell line=GM17810 | cell line=GM17811 | cell line=GM17812 | cell line=GM17814 | cell line=GM17815 | cell line=GM17816 | cell line=GM17817 | cell line=GM17818 | cell line=GM17823 | cell line=GM17825 | cell line=GM17826 | cell line=GM17828 | cell line=GM17833 | cell line=GM17835 | cell line=GM17838 | cell line=GM2036A | cell line=GM5659 | cell line=GOTO | cell line=Granta-519 | cell line=GS-1 | cell line=GS-10 | cell line=GS-11 | cell line=GS-12 | cell line=GS-2 | cell line=GS-3 | cell line=GS-3 clone | cell line=GS-4 | cell line=GS-5 | cell line=GS-6 | cell line=GS-7 | cell line=GS-7 clone | cell line=GS-8 | cell line=GS-9 | cell line=H1 | cell line=H1112 | cell line=H1155 | cell line=H125 | cell line=H13B | cell line=H1435 | cell line=H1437 | cell line=H14A | cell line=H1568 | cell line=H157 | cell line=H1618 | cell line=H1650 | cell line=H1651 | cell line=H1666 | cell line=H1703 | cell line=H1781 | cell line=H1793 | cell line=H1819 | cell line=H1838 | cell line=H187 | cell line=H1993 | cell line=H1L | cell line=H2009 | cell line=H2030 | cell line=H209 | cell line=H2122 | cell line=H2126 | cell line=H226 | cell line=H23 | cell line=H2347 | cell line=H2405 | cell line=H292 | cell line=H295R | cell line=H322c | cell line=H322T | cell line=H358 | cell line=H4 | cell line=H441 | cell line=H446 | cell line=H460 | cell line=H520 | cell line=H522 | cell line=H526 | cell line=H596 | cell line=H647 | cell line=H650 | cell line=H661 | cell line=H69 | cell line=H720 | cell line=H82 | cell line=H838 | cell line=H9 | cell line=H9-derived | cell line=H929 | cell line=HaCaT | cell line=HANK | cell line=hBEC | cell line=HBEC2 | cell line=HBEC2-E | cell line=HBEC2-KT | cell line=HBEC3 | cell line=HBEC3-ET | cell line=HBEC3-KT | cell line=HBEC4 | cell line=HBEC4-KT | cell line=HBEC5-KT | cell line=HBL-2 | cell line=HCC-1008 | cell line=HCC-1143 | cell line=HCC-1395 | cell line=HCC-1396 | cell line=HCC-1402 | cell line=HCC-1419 | cell line=HCC-1428 | cell line=HCC-1500 | cell line=HCC-1569 | cell line=HCC-1599 | cell line=HCC-1806 | cell line=HCC-1937 | cell line=HCC-1954 | cell line=HCC-202 | cell line=HCC-2218 | cell line=HCC-38 | cell line=HCC-70 | cell line=HCT-116 | cell line=HCT-15 | cell line=HCT-29 | cell line=HCT-8 | cell line=HCT-8Sa | cell line=HD90/FE07-142-L1 | cell line=HDLM-2 | cell line=HDQP1 | cell line=Hec50 | cell line=Hec50co | cell line=HEK-293 | cell line=HEK-293 clone | cell line=HEK-293-2C6 | cell line=HEK-293H | cell line=HEK-293T | cell line=HEK-TLR2 | cell line=HeLa | cell line=HeLa clone | cell line=HeLa-S3 | cell line=Hep-3B | cell line=HepaRG | cell line=HepG2 | cell line=HepG2/C3A | cell line=hES-T3 | cell line=hESC BG01 | cell line=hESC BG03 | cell line=HET-1A | cell line=HeyA8 | cell line=hf240-NS | cell line=hf286-NS | cell line=hf289-NS | cell line=HFF1 | cell line=hFOB | cell line=HG23 | cell line=HGADFN003 | cell line=HGADFN127 | cell line=HGADFN155 | cell line=HGADFN167 | cell line=HGADFN188 | cell line=HGC-27 | cell line=HIGK | cell line=hiPS | cell line=hiPS 17914 line E | cell line=hiPS 17914 line G | cell line=hiPS 3975 | cell line=hiPS line 1 | cell line=hiPS line 18 | cell line=hiPS line 2 | cell line=HK-2 | cell line=HK-Hep1 | cell line=HL60 | cell line=HLF-A | cell line=HME | cell line=HMEC | cell line=HMF3A | cell line=HMLER | cell line=HOP18 | cell line=HOP62 | cell line=HOP92 | cell line=Hotz | cell line=HP75 | cell line=HPAC | cell line=HPAF-II | cell line=HS181 | cell line=HS27a | cell line=Hs294T | cell line=HS5 | cell line=HS578T | cell line=HS683 | cell line=Hs683 | cell line=Hs695T | cell line=Hs746T | cell line=HS766t | cell line=HSB2 | cell line=HSC-3 | cell line=HSF1 | cell line=HT | cell line=HT-29 | cell line=HT1080 | cell line=HT144 | cell line=HT29 CL.16E | cell line=HT55 | cell line=HTB-58 | cell line=hTERT-immortalized BPEC | cell line=HTETOP | cell line=HTR8 | cell line=Hues9 | cell line=Huh7 | cell line=Huh7.5 | cell line=HuPT3 | cell line=HuT-102 | cell line=HuT-78 | cell line=huvec | cell line=I83E95 | cell line=IGROV | cell line=IGROV-1 | cell line=IM-9 | cell line=IM-95 | cell line=IMC-1 | cell line=IMR-32 | cell line=IMR-32-DKK1 | cell line=IMR90 | cell line=IOSE | cell line=iPSC 15 | cell line=iPSC 1i | cell line=iPSC 1M | cell line=iPSC 4 | cell line=iPSC 9 | cell line=iPSC clone 3975.4 | cell line=iPSC clone IMR9.4 | cell line=iPSC T4 | cell line=Ishikawa | cell line=Ishikawa H | cell line=Ist1 | cell line=JEG-3 | cell line=JeKo-1 | cell line=Jeko-1 | cell line=JIM3 | cell line=Jurkat | cell line=Jurkat/IM-9/Raji/THP-1 | cell line=K562 | cell line=KAI3 | cell line=Karpas-1106P | cell line=Karpas-422 | cell line=KG1 | cell line=KHYG1 | cell line=Kit225 | cell line=KM12 | cell line=KMH2 | cell line=KMS11 | cell line=KMS12 | cell line=KNS62 | cell line=KPL-1 | cell line=KPL-4 | cell line=KTCL 140 | cell line=KTCL 26 | cell line=KYSE-140 | cell line=L-1236 | cell line=L-428 | cell line=L-540 | cell line=L3.6pl | cell line=LAN-1 | cell line=LB84-1 | cell line=LI90 | cell line=line 18 | cell line=line1 | cell line=line2 | cell line=LL24 | cell line=LL47 | cell line=LL86 | cell line=LM1 | cell line=LM2 | cell line=LN18 | cell line=LN215 | cell line=LN229 | cell line=LN235 | cell line=LN319 | cell line=LN340 | cell line=LN382 | cell line=LN443 | cell line=LN444 | cell line=LN464 | cell line=LNCaP | cell line=LNCaP late passage (LP50) | cell line=LNZ308 | cell line=LOVO | cell line=LOX-IMVI | cell line=LP1 | cell line=LS1034 | cell line=LS174T | cell line=LS180 | cell line=LS2 derived | cell line=LXFL529 | cell line=M059J | cell line=M059K | cell line=M12 | cell line=M202 | cell line=M202R1 | cell line=M29 | cell line=Malme-3M | cell line=MC116 | cell line=MCF-10A | cell line=MCF-10A MycER | cell line=MCF-10F | cell line=MCF-7 | cell line=MCF-7-14 | cell line=MCF-7-DN-CLIM-TetOff | cell line=MCF-7-FR | cell line=MCF-7-G11TamR | cell line=MCF-7:2A | cell line=MCF-7:5C | cell line=MCF-7R4 | cell line=MCH58 | cell line=MDA-MB-134VI | cell line=MDA-MB-157 | cell line=MDA-MB-175 | cell line=MDA-MB-231 | cell line=MDA-MB-361 | cell line=MDA-MB-415 | cell line=MDA-MB-435 | cell line=MDA-MB-436 | cell line=MDA-MB-453 | cell line=MDA-MB-468 | cell line=MDA-MB-468GFP-LN | cell line=MDST8 | cell line=ME180 | cell line=ME181 | cell line=ME182 | cell line=ME183 | cell line=ME184 | cell line=ME185 | cell line=MEG-01 | cell line=Met5A | cell line=MeWo | cell line=MFM-223 | cell line=MHH-PREB-1 | cell line=MIA PaCa2 | cell line=Mino | cell line=MKN-1 | cell line=MKN-28 | cell line=MKN-45 | cell line=MKN-7 | cell line=MKN-74 | cell line=MkTBr | cell line=ML-4 | cell line=ML-5 | cell line=ML-8 | cell line=ML-9 | cell line=MM.1R | cell line=MM.1S | cell line=MM.1s | cell line=MM127 | cell line=MM170 | cell line=MM200 | cell line=MM229 | cell line=MM253 | cell line=MM329 | cell line=MM370 | cell line=MM383 | cell line=MM386 | cell line=MM415 | cell line=MM426 | cell line=MM455 | cell line=MM466 | cell line=MM473 | cell line=MM485 | cell line=MM537 | cell line=MM540 | cell line=MM548 | cell line=MM576 | cell line=MM595 | cell line=MM603 | cell line=MM608 | cell line=MM622 | cell line=MM648 | cell line=MM649 | cell line=MM96L | cell line=MOLT-3 | cell line=MOLT4 | cell line=MonoMac 6 | cell line=Mpanc-96 | cell line=MRC-5 | cell line=MSK-Leuk1 | cell line=MT-1 | cell line=MT-2 | cell line=MT-3 | cell line=MT-4 | cell line=N1 | cell line=N2 | cell line=N3 | cell line=N4 | cell line=N5 | cell line=Namalwa | cell line=NAN | cell line=NB4 | cell line=NB69 | cell line=NB9 | cell line=NCI-H1299 | cell line=NCI-N87 | cell line=NCR-EW2 | cell line=NCR-EW3 | cell line=NGP | cell line=NHDF 17914 | cell line=NHDF1 | cell line=NK-YS | cell line=NK92 | cell line=NOMO-1 | cell line=Nor-P1 | cell line=NPC 5-8F | cell line=NPrEC | cell line=NRS-1 | cell line=NT-1 | cell line=NT2/D1 | cell line=NU-DHL-1 | cell line=NU-DUL-1 | cell line=NUGC3 | cell line=NUGC4 | cell line=NZM12 | cell line=NZM15 | cell line=OCI AML2 | cell line=Oci-Ly-19 | cell line=OCM-1 | cell line=OCUB-M | cell line=OCUM1 | cell line=OPM1 | cell line=OPM2 | cell line=OV90 | cell line=OVCA429 | cell line=OVCAR-8 | cell line=OVCAR3 | cell line=P493-6 | cell line=Panc 1 | cell line=Panc 10.05 | cell line=Panc 2.03 | cell line=Panc 2.13 | cell line=Panc 3.03 | cell line=Panc 3.27 | cell line=Panc 4.03 | cell line=Panc 5.04 | cell line=Panc 8.13 | cell line=PaTu8902 | cell line=PaTu8988s | cell line=PaTu8988t | cell line=PC-3 | cell line=PC-3MM2 | cell line=PCSC-1 | cell line=PCSC-2 | cell line=PCSC-3 | cell line=PDB | cell line=PDB1lox_17 | cell line=PDB1lox_21 | cell line=PDB1lox_22 | cell line=PDB1lox_5 | cell line=PEER | cell line=Pfeiffer | cell line=PGF | cell line=PL45 | cell line=PLC-PRL | cell line=PLC/PRF/5 | cell line=PLC8024 | cell line=pMIP3 line 3 | cell line=PreB 697 R4G4 | cell line=PRMel | cell line=PSN1 | cell line=Ptci | cell line=R11 | cell line=R18 | cell line=R28 | cell line=R43 | cell line=R46 | cell line=R8 | cell line=Raji | cell line=Ramos | cell line=RC-K8 | cell line=RCC4 | cell line=RD-ES | cell line=REC-1 | cell line=Reh | cell line=ReNCell | cell line=RERF-LC-AD1 | cell line=RERF-LC-KJ | cell line=RERF-LC-MS | cell line=RERF-LC-OK | cell line=RerfGC1B | cell line=RI-1 | cell line=RKO | cell line=RKOAS451 | cell line=RL | cell line=round5 A2780 | cell line=RPMI-7951 | cell line=RPMI-8226 | cell line=RWPE1 | cell line=S462 | cell line=SA01 | cell line=SACHI | cell line=SAOS | cell line=Saos-2 | cell line=SC-1 | cell line=SCC-3 | cell line=SCC1 | cell line=SCC4 | cell line=SCC47 | cell line=SCC74A | cell line=SCCH-196 | cell line=SCH | cell line=Sez-4 | cell line=SF268 | cell line=SF539 | cell line=SF763 | cell line=SH-EP2 | cell line=SH-SY5Y | cell line=SH-SY5Y-A | cell line=SH-SY5Y-E | cell line=SH-SY5Y/TrkA | cell line=SHEP-21N | cell line=SHEP-Tet21N | cell line=SiHa | cell line=Sk-Br-3 | cell line=Sk-Br-31 | cell line=SK-CO-1 | cell line=SK-ES-1 | cell line=SK-MEL-13 | cell line=SK-Mel-28 | cell line=Sk-Mel-28 | cell line=SK-MEL-31 | cell line=SK-MEL-5 | cell line=SK-N-AS | cell line=SK-N-AS-NmycER | cell line=SK-N-BE2(C) | cell line=SK-N-F1 | cell line=SK-N-MC | cell line=SK-N-SH | cell line=SK23 | cell line=SKGT4 | cell line=SKM-1 | cell line=SKOV | cell line=SKOV-3 | cell line=SKRC39 | cell line=SKRC45 | cell line=SKRC47 | cell line=SKRC54 | cell line=SKVCR 2.0 | cell line=SN12C | cell line=SNK-6 | cell line=SNK1 | cell line=SNT-13 | cell line=SNT-15 | cell line=SNT-8 | cell line=SNU1 | cell line=SNU5 | cell line=SNU719 | cell line=Sosp-9607 | cell line=SR | cell line=ST88-14 | cell line=SU-DHL-1 | cell line=SU-DHL-10 | cell line=SU-DHL-16 | cell line=SU-DHL-4 | cell line=SU-DHL-5 | cell line=SU-DHL-6 | cell line=SU-DHL-8 | cell line=SU86.86 | cell line=Susa | cell line=SW 1783 | cell line=SW1116 | cell line=SW1463 | cell line=SW1573 | cell line=SW1990 | cell line=SW2 | cell line=SW403 | cell line=SW480 | cell line=SW527 | cell line=SW620 | cell line=T112D | cell line=T265 | cell line=T3 | cell line=T3ES | cell line=T47D | cell line=T47D1 | cell line=T84 | cell line=T98G | cell line=Takigawa | cell line=TaY | cell line=TaY-E10 | cell line=TC-252 | cell line=TEM2-5 | cell line=TEM4-18 | cell line=Tesi | cell line=TF-1 | cell line=TGCT-833K | cell line=TGCT-GCT27 | cell line=THP-1 | cell line=TIG-1 | cell line=TIG3 TERT/deltaB-RAF:ER | cell line=TK | cell line=TK6 | cell line=TMK1 | cell line=Toledo | cell line=TOV112D | cell line=TOV21G | cell line=U-118 MG | cell line=U-698-M | cell line=U-937 | cell line=U1752 | cell line=U2-OS | cell line=U251 | cell line=U266 | cell line=U343 | cell line=U373 | cell line=U87 | cell line=U87L4 | cell line=U87MG | cell line=U87R4 | cell line=U937 | cell line=U937 NB4 | cell line=U937 PR-9 | cell line=U937T | cell line=UACC-893 | cell line=UET-13 | cell line=UET-13TR-EWS/ERG | cell line=UET-13TR-EWS/FLI1 | cell line=UMCL01-101 | cell line=UMRC2 | cell line=UMRC3 | cell line=UPN-1 | cell line=UROtsa | cell line=UT-15 | cell line=UT-7 | cell line=UW-1 | cell line=VMRCLCD | cell line=WI38 | cell line=WIBR1 | cell line=WIBR2 | cell line=WIBR3 | cell line=WIBR7 | cell line=WM-266-4 | cell line=WS1 | cell line=WSB | cell line=WSU-FSCCL | cell line=WSU-NHL | cell line=WSUDLCL2 | cell line=XG | cell line=YCC1 | cell line=YCC11 | cell line=YCC16 | cell line=YCC17 | cell line=YCC19 | cell line=YCC2 | cell line=YCC20 | cell line=YCC6 | cell line=YCC7 | cell line=YCC9 | cell line=YT-N | cell line=Z138 | cell line=ZL25 | cell line=ZR-75 | cell line=ZR-75-1 | cell type=activated B-cell | cell type=acute monocytic leukaemia cell line | cell type=adipose-derived stem cell | cell type=adrenocortical carcinoma cell line | cell type=adult T-cell leukaemia cell line | cell type=AIDS-NHL-derived cell line | cell type=airway epithelial cell | cell type=ALL cell line | cell type=alveolar cell carcinoma cell line | cell type=alveolar epithelial progenitor cell | cell type=alveolar leukocyte | cell type=alveolar macrophage | cell type=AMKL cell line | cell type=AML cell line | cell type=amniocyte | cell type=amnion cell line | cell type=aortic vascular smooth muscle cell | cell type=ascites cell | cell type=astrocyte  derived from cell line H9 | cell type=ATL-derived cell line | cell type=atypical ductal hyperplasia cell line | cell type=B-cell | cell type=B-cell derived cell line | cell type=B-cell lymphoma cell line | cell type=B-lymphoblastoid cell line | cell type=B-lymphocyte | cell type=B-lymphocyte cell line | cell type=Barrett's syndrome cell line | cell type=BDCA1+ dendritic cell | cell type=BDCA3+ dendritic cell | cell type=BJ-derived hIPS | cell type=blast | cell type=blast derived from cell line H9 | cell type=blast/proerythroblast | cell type=blast/promonocyte | cell type=blast/promyelocyte | cell type=blasts and mononuclear cells | cell type=blood vessel endothelial cell | cell type=bone marrow derived cell line | cell type=bone marrow stromal cell line | cell type=bone sarcoma cell line | cell type=brain cancer cell line | cell type=breast cancer cell line | cell type=breast cell line | cell type=breast epithelial cell derived cell line | cell type=breast tumor cell | cell type=breast tumor cell line | cell type=bronchial epithelial cell derived cell line | cell type=bronchioalveolar carcinoma cell line | cell type=bronchiole epithelial cell line | cell type=Burkitt lymphoma cell line | cell type=cancer cell lines | cell type=CD133+ prostate epithelial cells | cell type=CD133-/alpha2 integrin low prostate epithelial cells | cell type=CD133-/aplha2 integrin low prostate epithelial cells | cell type=CD138 plasma cell | cell type=CD138+ plasma cell | cell type=CD138+ selected plasma cells | cell type=CD138-purified plasma cells | cell type=CD138-selected cells | cell type=CD14 cells | cell type=CD14 positive mononuclear cell | cell type=CD14+ CD16- monocyte | cell type=CD14+ monocyte | cell type=CD14-positive monocyte | cell type=CD14low CD16+ monocyte | cell type=CD15 cells | cell type=CD16 negative mononuclear cell | cell type=CD16 positive mononuclear cell | cell type=CD16+ dendritic | cell type=CD16+ monocyte | cell type=CD16- monocyte | cell type=CD19+ B-cell | cell type=CD19+ cell | cell type=cd19+ tumor cell | cell type=CD1c+ dendritic cell | cell type=CD21hi transitional B cell | cell type=CD21lo transitional B cell | cell type=CD3 cells | cell type=CD3+ T-cell | cell type=CD3-positive T cell | cell type=CD34 positive mononuclear | cell type=CD34+ cell | cell type=CD34+ cells | cell type=CD34+ haematopoietic stem cell | cell type=CD34+ hematopoietic progenitor cell | cell type=CD34+ progenitor cell, erythrocyte | cell type=CD34+ progenitor cell, proerythroblast | cell type=CD34+CD19+ pro-B-cell | cell type=CD34-derived erythroid progenitors | cell type=CD34-negative | cell type=CD36+ erythroid progenitor cell | cell type=CD4 positive T-cell | cell type=CD4 T cell line | cell type=CD4 T-cell | cell type=CD4+ cell | cell type=CD4+ T-cell | cell type=CD41 negative portion | cell type=CD41+ cord blood derived megakaryocytes | cell type=CD4CD45RO T-cell | cell type=CD8 positive T-cell | cell type=CD8 T-cell | cell type=CD8+ cell | cell type=CD8+ central memory T cell | cell type=CD8+ effector memory RA T cell | cell type=CD8+ effector memory T cell | cell type=CD8+ naive CD8 T cell | cell type=CD8+ T-cell | cell type=CD8+CD28+ T-cell | cell type=CD8+CD28- T-cell | cell type=cell line derived from HT1080 | cell type=cell line derived from primary cancer associated fibroblasts | cell type=cell line derived from primary pancreatic ductal adenocarcinoma | cell type=cell line mixture | cell type=central memory T-cell | cell type=centroblast | cell type=centrocyte | cell type=cervical carcinoma cell line | cell type=chondrocyte | cell type=chondrogenic progenitor cells | cell type=chondrosarcoma cell line | cell type=choroid | cell type=chronic lymphocytic leukemia cell | cell type=clear cell renal carcinoma cell line | cell type=CLL cell line | cell type=cloned fibroblast cell line | cell type=CML cell line | cell type=colon cancer stem cell | cell type=colon fibroblast derived cell line | cell type=colonic cancer cell line | cell type=colonic epithelial cancer cell line | cell type=colonic epithelial cell | cell type=colorectal adenocarcinoma cell line | cell type=colorectal cancer cell line | cell type=coronary endothelial cell | cell type=cumulus cell | cell type=cutaneous T-cell lymphoma cell line | cell type=dendritic cell | cell type=dendritic cell derived from mature monocyte | cell type=dental pulp stem cell | cell type=dermal dendritic cell | cell type=dermal fibroblast | cell type=dermal microvascular endothelial cell line | cell type=dermal microvascular lymphatic endothelial cell | cell type=diffuse histiocytic lymphoma cell line | cell type=diffuse large B-cell lymphoma cell | cell type=diffuse large cell lymphoma cell line | cell type=diffuse mixed lymphoma cell line | cell type=DS-AMKL cell line | cell type=EBV+ lymphoblastoid cell line | cell type=EBV+ natural killer cell line | cell type=EBV+ T-cell line | cell type=EBV-immortalized B-cell line | cell type=EBV-immortalized B-lymphoblastoid cell line | cell type=EBV-transformed B-cell line | cell type=EBV-transformed lymphoblastoid cell line | cell type=EBV-transformed natural killer cell line | cell type=effector memory T-cell | cell type=embryoid body derived from cell line H9 | cell type=embryoid body derived from cell line hES-T3 | cell type=embryonal carcinoma cell line | cell type=embryonic kidney cell line | cell type=embryonic kidney derived cell line | cell type=endometrial adenocarcinoma cell line | cell type=endometrial cancer cell line | cell type=endometrial cell | cell type=endothelial cell | cell type=endothelial cell differentiated from human umbilical cord blood derived-EPCs | cell type=endothelial precursor cell derived from human umbilical cord blood | cell type=eosinophilic cell line | cell type=epidermal keratinocyte cell line | cell type=epidermal melanocyte | cell type=epidermoid carcinoma cell line | cell type=epithelial cell | cell type=epithelial cell line | cell type=epithelium | cell type=erythroblast | cell type=erythrocyte | cell type=erythroleukaemia cell line | cell type=esophageal adenocarcinoma cell line | cell type=esophageal carcinoma cell line | cell type=esophageal epithelial cell | cell type=esophageal squamous carcinoma cell line | cell type=esophageal squamous cell | cell type=esophageal squamous epithelium cell line | cell type=esophagus | cell type=Ewing family tumor cell line | cell type=extranodal NK/T-cell lymphoma cell | cell type=fetal cortex derived cell line | cell type=fetal fibroblast | cell type=fetal gamma-delta T-cell | cell type=fetal lung fibroblast derived cell line | cell type=fetal osteoblast derived cell line | cell type=fetal retinal pigment epithelium | cell type=fibroblast | cell type=fibroblast cell line | cell type=fibroblast cell lines pool | cell type=fibroblast derived cell line | cell type=fibroblast differentiated from H1 | cell type=fibroblast-derived iPSC | cell type=fibroblast-like synovial cell | cell type=fibroblastic cell line | cell type=fibrosarcoma derived cell line | cell type=forelimb leiomyosarcoma cell line | cell type=foreskin fibroblast derived cell line | cell type=foreskin-derived iPSC | cell type=gamma-delta T-cell | cell type=gastric adenocarcinoma cell line | cell type=gastric adenocarcinoma cell lines | cell type=gastric cancer cell line | cell type=geminal center centroblast | cell type=germinal center B-cell | cell type=giant cell glioblatoma derived cell line | cell type=gingival fibroblast | cell type=gingival keratinocyte cell line | cell type=glioblastoma cell line | cell type=glioblastoma derived cell line | cell type=glioblastoma derived neurosphere culture cell line | cell type=glioblastoma stem-like cell line | cell type=glioblastoma-derived stem cell | cell type=glioma cell line | cell type=glomerular podocyte | cell type=granulopoietic cell | cell type=granulosa cell | cell type=head and neck cancer cell line | cell type=head and neck squamous cell carcinoma cell line | cell type=hematopoietic cell | cell type=hematopoietic stem cell | cell type=hematopoietic stem cell/progenitor cell | cell type=hepatic stellate | cell type=hepatocellular carcinoma cell line | cell type=hepatocyte | cell type=hepatoma cell line | cell type=hESC | cell type=hESC-derived endothelial cell | cell type=HLA-DR negative T-cell | cell type=HLA-DR+ T-cell | cell type=Hodgkins lymphoma B-cell line | cell type=Hodgkins lymphoma cell line | cell type=hTERT-immortalized breast primary epithelial cell line | cell type=hTERT-immortalized human mammary epithelial cell line | cell type=human embryonic carcinoma cell | cell type=human embryonic kidney cell | cell type=human embryonic stem cell line | cell type=human embryonic stem cell line (post hepatic differentiation) | cell type=human umbilical cord lining epithelial cell | cell type=human umbilical vein endothelial cell line | cell type=human umbilical vein smooth muscle cell | cell type=human vascular adventitial fibroblast | cell type=huvec | cell type=hypopharyngeal tumor cell line | cell type=ileocecal carcinoma cell line | cell type=ileum mucosa | cell type=immature dendritic cell | cell type=immature monocyte-derived dendritic cell | cell type=immortalised T lymphocyte cell line | cell type=immortalized B-cell | cell type=immortalized bronchial epithelial cell | cell type=immortalized bronchial epithelial cell line | cell type=immortalized ovarian surface epithelial cell line | cell type=immunoblastic large cell lymphoma cell line | cell type=in vitro generated osteoclasts | cell type=induced pluripotent stem cell line | cell type=intermediate cell derived from dendritic cells | cell type=intermediate cell derived from monocytes | cell type=intestinal adenocarcinoma cell line | cell type=intestinal epithelial cell line | cell type=intestinal mucosa | cell type=intestine epithelial cell | cell type=iPSC | cell type=iPSC cell line from cord blood mononuclear cell | cell type=iPSC derived from cell line CCD-1079Sk | cell type=iPSC derived from fibroblast | cell type=iPSC derived from fibroblast cell line BJ | cell type=iPSC derived from fibroblast cell line dH1CF | cell type=iPSC derived from fibroblast cell line dH1F | cell type=iPSC derived from fibroblast cell line IMR90 | cell type=iPSC derived from fibroblast cell line MRC-5 | cell type=iPSC derived from fibroblast cell line MRC-6 | cell type=iPSC derived from fibroblast cell line MRC-7 | cell type=iPSC derived from fibroblast cell line MRC-8 | cell type=iPSC derived from fibroblast cell line MRC-9 | cell type=iPSC derived from human adipose stem cells | cell type=iPSC from bone marrow mononuclear cell | cell type=iPSC from CML bone marrow mononuclear cell | cell type=islet beta cell | cell type=keratinocyte | cell type=Langerhans cell | cell type=large vessel endothelial cell derived from embryoid body | cell type=leukaemia cell line | cell type=leukemic lymphoblast | cell type=leukocyte | cell type=lipoma derived mesenchymal stem cell | cell type=liposarcoma cell line | cell type=liver mesenchymal tumor cell line | cell type=luminal epithelial cell | cell type=lung adenocarcinoma cell line | cell type=lung cancer cell line | cell type=lung fibroblast derived cell line | cell type=lung squamous cell carcinoma cell line | cell type=lung tissue-derived fibroblast | cell type=lymphatic endothelial cell | cell type=lymphoblast | cell type=lymphoblast cell line | cell type=lymphoblastoid cell line | cell type=lymphocyte | cell type=lymphocytic leukaemia cell line | cell type=lymphoid cell | cell type=lymphoid RNA reference | cell type=lymphoma | cell type=lymphoma cell | cell type=lymphoma cell line | cell type=macrophage | cell type=malignant mesothelioma cell line | cell type=malignant peripheral nerve sheath cell line | cell type=malignant peripheral nerve sheath tumor cell line | cell type=mammary epithelial cell | cell type=mammary epithelial cell derived cell line | cell type=mammary epithelial cell line | cell type=mammary fibroblast derived cell line | cell type=mammospheres derived from breast tumor | cell type=mantle cell lymphoma cell line | cell type=marrow stromal cell | cell type=medulloblastoma cell line | cell type=megakaryoblast | cell type=megakaryoblastic leukaemia cell line | cell type=megakaryocyte | cell type=melanocyte | cell type=melanoma cell line | cell type=melanoma derived cell line | cell type=memory B-cell | cell type=mesenchymal progenitor cell line | cell type=mesenchymal stem cell | cell type=mesenchymal stem cell clone | cell type=mesenchymal stem cell from iliac crest | cell type=mesenchymal stem cell-derived adipocyte | cell type=mesenchymal stem cell-derived stromal | cell type=mesenchymal stem cell-derived stromal and adipocyte | cell type=mesenchymal stromal cell | cell type=mesendoderm/endoderm progenitor cell | cell type=mesodermal precursor cell derived from hES cells line SA01 | cell type=mesodermal precursor cell derived from hES cells line VUB01 | cell type=mesodermal precursor cell derived from hES cells line VUB03_DM1 | cell type=mesothelioma cell line | cell type=mesothelium cell line | cell type=metamyelocyte/granulocyte | cell type=metastatic breast cancer in bone | cell type=metastatic breast cancer in brain | cell type=metastatic breast cancer in lung | cell type=metastatic clear-cell renal cell carcinoma in lung | cell type=metastatic colorectal cancer in liver | cell type=metastatic lung cancer in brain | cell type=metastatic melanoma cell line | cell type=metastatic midgut carcinoid in liver | cell type=metastatic pancreatic cancer cell line | cell type=metastatic prostate cancer cell line | cell type=microvascular endothelial cell | cell type=midgut carcinoid | cell type=mixed somatic cell types | cell type=monocyte | cell type=monocyte-derived dendritic cell | cell type=monocyte-derived macrophage | cell type=monocyte/macrophage | cell type=mononuclear cell | cell type=multiple myeloma cell line | cell type=multipotent stromal cell | cell type=myelocyte/metamyelocyte | cell type=myelodysplasia cell line | cell type=myeloid cell | cell type=myeloid monocytic cell | cell type=myeloma cell line | cell type=myoepithelial | cell type=myoepithelial cells differentiated from hTERT-immortalized K5+K19- mammary epithelial cell | cell type=myometrial cell | cell type=naive B cell | cell type=naive B-cell | cell type=naive CD4+ T-cell | cell type=naive T-cell | cell type=nasopharingeal carcinoma cell line | cell type=nasopharyngeal carcinoma cell line | cell type=natural killer cell line | cell type=natural killer leukaemia cell line | cell type=neonatal foreskin-derived | cell type=neural crest cell line | cell type=neural epithelial cell from embryonic stem cell line H9 | cell type=neural progenitor cell from developing cortex | cell type=neural progenitor cell from ventral midbrain | cell type=neural progenitor cell line | cell type=neural progenitor cells | cell type=neuroblastic tumor cell | cell type=neuroblastoma cell line | cell type=neuroblastoma tumor cell | cell type=neutrophil | cell type=NK cell | cell type=NK/T-cell lymphoma cell line | cell type=nodal diffuse large B-cell lymphoma cell | cell type=non-Hodgkin's lymphoma cell line | cell type=non-Hodgkins lymphoma cell line | cell type=non-small cell carcinoma cell line | cell type=non-small cell lung adenocarcinoma cell line | cell type=non-small cell lung cancer cell line | cell type=non-small cell lung carcinoma cell line | cell type=Norwalk virus replicon-bearing hepatoma cell line | cell type=NSCLC cell line | cell type=odontoblast | cell type=oligoastrocytoma derived cell line | cell type=oocyte | cell type=oral keratinocyte | cell type=osteoblast | cell type=osteoclast derived from dendritic cells | cell type=osteoclast derived from monocytes | cell type=osteosarcoma cell line | cell type=ovarian adenocarcinoma cell line | cell type=ovarian cancer cell line | cell type=ovarian carcinoma cell line | cell type=ovarian serous carcinoma cell line | cell type=pancreatic adenocarcinoma cell line | cell type=pancreatic cancer cell line | cell type=pancreatic carcinoma cell line | cell type=pancreatic islet-like cell clusters derived from cell line T3ES | cell type=periodontal ligament cell | cell type=pharyngeal carcinoma cell line | cell type=pharyngeal tumor cell line | cell type=pituitary adenoma cell line | cell type=placenta choriocarcinoma cell line | cell type=plasma B-cell | cell type=plasma cell | cell type=plasmablast | cell type=plasmacytoid dendritic cell | cell type=polymorphonuclear leukocyte | cell type=Pre-B leukaemia cell line | cell type=precursor B-cell | cell type=prenatal chorion villus cell | cell type=primary fibroblast culture | cell type=primary hematopoietic CD34+ cells | cell type=primary T lymphocyte | cell type=primitive neural epithelial cell from embryonic stem cell line H9 | cell type=promyelocyte | cell type=prostate adenocarcinoma cell line | cell type=prostate cancer cell line | cell type=prostate cancer stem cell line | cell type=prostate carcinoma cell line | cell type=prostate epithelial cell | cell type=prostate epithelial cell line | cell type=prostate stromal cell | cell type=prostatic cancer cell line | cell type=proximal tubular epithelial cell | cell type=pulmonary microvascular endothelial cell | cell type=regulatory T-cell | cell type=renal cancer cell line | cell type=renal proximal tubular cell line | cell type=renal proximal tubular epithelial cell | cell type=retinal pigment epithelial cell | cell type=retinal pigment epithelial cell line | cell type=retinal pigment epithelium | cell type=rhabdomyosarcoma cell | cell type=rhabdomyosarcoma cell line | cell type=scalp fibroblast | cell type=skin derived fibroblast cell line | cell type=skin fibroblast | cell type=skin fibroblast cell line | cell type=skin fibroblast derived cell line | cell type=skin melanoma cell line | cell type=small cell lung cancer cell line | cell type=small cell lung carcinoma cell line | cell type=smooth muscle cell | cell type=squamous cell carcinoma cell line | cell type=stem cell line | cell type=stromal cell | cell type=T-ALL cell | cell type=T-ALL cell line | cell type=T-cell | cell type=T-cell and retinal pigment epithelial cell (co-cultured) | cell type=T-cell leukaemia cell line | cell type=T-cell line | cell type=T-cell lymphoma cell line | cell type=tarsal conjuntiva | cell type=TCRVgamma9+ gamma delta T cells | cell type=testicular diffuse large B-cell lymphoma tissue | cell type=testicular germ-cell tumor cell line | cell type=tracheal epithelial cell line | cell type=transformed lymphocyte | cell type=trophoblast cell line | cell type=tumorigenic,hTERT-immortalized breast primary epithelial cell; | cell type=tumorigenic,hTERT-immortalized human mammary epithelial cell; | cell type=umbilical cord blood derived endothelial colony | cell type=umbilical cord blood derived mesenchymal stem cell | cell type=undifferentiated induced pluripotent stem cell | cell type=universal human reference RNA | cell type=unrestricted somatic stem cell | cell type=urothelial | cell type=urothelial cell line | cell type=vascular endothelial cell | cell type=vascular smooth muscle cell | cell type=virus-transformed lung/bronchus epithelial cell line | cell type=white blood cell | disease=absense epilepsy | disease=active Crohn's disease | disease=active ulcerative colitis | disease=acute graft-versus-host disease | disease=acute lymphoblastic leukaemia | disease=acute malaria | disease=acute megakaryocytic leukaemia, Down syndrome | disease=acute monocytic leukaemia | disease=acute myeloid leukaemia | disease=acute promyelocytic leukaemia | disease=acyanotic Tetralogy of Fallot | disease=adenocarcinoma | disease=adenocarcinoma with spindle cell metaplasia | disease=adenoma | disease=adenoma with high-grade dysplasia | disease=adenomyosis | disease=adenosquamous carcinoma | disease=adrenocortical carcinoma | disease=adrenocortical tumor | disease=adult T-cell leukaemia | disease=AIDS-related non-Hodgkins lymphoma | disease=AIDS/activated B-cell-like diffuse large B-cell lymphoma | disease=AIDS/Burkitt lymphoma | disease=AIDS/DLBCL | disease=AIDS/GCB-DLBCL | disease=Alagille syndrome | disease=aldosterone-producing adenoma | disease=ALL | disease=ALL with hyperdiploid karyotype | disease=ALL with MLL rearrangement | disease=ALL with t(1, 19) | disease=ALL with t(12, 21) | disease=ALL without MLL rearrangement | disease=ALL/hyperdiploid karyotype | disease=allograft rejection | disease=alveolar cell carcinoma | disease=alveolar soft-part sarcoma | disease=Alzheimer's disease | disease=AMD | disease=AML with MLL rearrangement | disease=AML with normal karyotype and other abnormalities | disease=AML with t 11q23, MLL | disease=AML without MLL rearrangement | disease=AML(FAB-M0) | disease=AML-TLS | disease=AML/aberrant karyotype | disease=AML/chemotherapy-induced oral mucositis | disease=AML/MLL | disease=AML/other abnormalities | disease=anaplastic astrocytoma | disease=anaplastic carcinoma | disease=anaplastic large cell lymphoma | disease=angina/coronary atherosclerosis | disease=angioimmunoblastic T-cell lymphoma | disease=ankylosing spondylitis | disease=Apert syndrome | disease=apilocytic astrocytoma, juvenile pilocytic astrocytoma, or cystic cerebellar astrocytoma | disease=apocrine adenocarcinoma | disease=asthma | disease=asthma with exercise induced bronchoconstriction | disease=astrocytoma | disease=asymptomatic HIV-1 infection | disease=ATL | disease=atopic dermatitis | disease=atopy | disease=atrial fibrillation | disease=atypical carcinoid | disease=atypical ductal hyperplasia | disease=autism spectrum disorder | disease=autoimmune lymphoproliferative syndrome | disease=autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy | disease=autosomal dominant monocytopenia | disease=B-ALL | disease=B-cell chronic lymphocytic leukaemia | disease=B-cell lymphoma | disease=bacteremia/suppurative arthritis/methicillin-resistant Staphylococcus aureus infection | disease=Barret's syndrome | disease=basal cell carcinoma | disease=basal-like breast cancer | disease=benign prostate tumor | disease=benign prostatic hyperplasia | disease=bilateral cryptorchid | disease=biliary atresia | disease=bipolar disorder | disease=birch pollen allergy | disease=bladder cancer | disease=bone sarcoma | disease=borderline tuberculoid leprosy | disease=BRCA1-deficient breast cancer | disease=breast adenocarcinoma | disease=breast cancer | disease=breast cancer, node metastasis | disease=breast carcinoma | disease=breast carcinoma/cystic change | disease=breast ductal adenocarcinoma | disease=breast ductal carcinoma | disease=breast fibrocystic disease | disease=breast medullary carcinoma | disease=breast metaplastic carcinoma | disease=breast squamous cell carcinoma | disease=Brief Psychotic Disorder | disease=bronchioalveolar carcinoma | disease=bronchopulmonary dysplasia | disease=Burkitt lymphoma | disease=burn | disease=c-ALL, Pre-B-ALL with t 9,22 | disease=c-ALL, Pre-B-ALL without t 9,22 | disease=cancer | disease=carcinoid | disease=carcinoma | disease=CCRCC | disease=cecum carcinoma | disease=celiac | disease=cervical adenocarcinoma | disease=cervical cancer | disease=cervical carcinoma | disease=childhood B-cell precursor ALL | disease=chondrosarcoma | disease=choroideremia | disease=chromophobe renal cell carcinoma | disease=chronic allograft nephropathy grade I | disease=chronic fatigue | disease=chronic graft versus host disease | disease=chronic Hodgkin's lymphoma | disease=chronic lymphocytic leukaemia | disease=chronic malaria | disease=chronic myelogenous leukaemia | disease=chronic myeloid leukaemia | disease=chronic rhinosinusitis | disease=clear-cell renal cell carcinoma | disease=clinically isolated syndrome | disease=CNS affected | disease=cocoon affected | disease=colon adenocarcinoma | disease=colon adenoma | disease=colon cancer | disease=colon carcinoma | disease=colon tumor | disease=colorectal adenocarcinoma | disease=colorectal adenoma | disease=colorectal cancer | disease=colorectal cancer - B | disease=colorectal cancer - CD | disease=colorectal carcinoma | disease=common ALL | disease=contralateral testicular aplasia | disease=conventional mantle cell lymphoma | disease=COPD | disease=COPD/emphysema | disease=COPD/giant bullae | disease=COPD/giant cell tumor | disease=COPD/non-small cell adenocarcinoma | disease=COPD/non-small cell squamous cell carcinoma | disease=Cornelia de Lange Syndrome | disease=corticosteroid resistant asthma | disease=corticosteroid sensitive asthma | disease=Crohn's disease | disease=Crohn's disease, non-inflamed site | disease=cutaneous T-cell lymphoma | disease=cystic fibrosis | disease=cystic fibrosis/chronic rhinosinusitis | disease=cytomegalovirus | disease=dedifferentiated liposarcoma | disease=desmoplastic cerebellar medulloblastoma | disease=Diamond-Blackfan Anemia | disease=diarrhea-irritable bowel syndrome | disease=differentiated liposarcoma | disease=diffuse glioma | disease=diffuse histiocytic lymphoma | disease=diffuse large B-cell lymphoma | disease=diffuse large cell lymphoma | disease=diffuse mixed lymphoma | disease=diffusely infiltrating astrocytic glioma | disease=dilated cardiomyopathy | disease=disease | disease=diseased (bleeding on probing) | disease=disseminated/methicillin-resistant Staphylococcus aureus infection | disease=disseminated/pneumonia/methicillin-sensitive Staphylococcus aureus infection | disease=dominant retinitis pigmentosa | disease=ductal carcinoma | disease=ductal carcinoma/lobular carcinoma | disease=ejaculatory azoospermia/cryptorchidism | disease=ejaculatory azoospermia/idiopathic infertility | disease=embryonic carcinoma | disease=encephalitis/influenza A infection | disease=endemic Burkitt lymphoma | disease=endometrial adenocarcinoma | disease=endometrial cancer | disease=endometrioid ovarian cancer | disease=endometriosis | disease=eosinophilic esophagitis | disease=eosinophilic leukaemia | disease=ependymoma | disease=epidermoid carcinoma | disease=epilepsy | disease=epitheloidal angiolipoma | disease=erosive gastritis | disease=erythroleukaemia | disease=esophageal adenocarcinoma | disease=esophageal squamous carcinoma | disease=esophageal squamous cell carcinoma | disease=Ewing's sarcoma | disease=extranodal NK/T-Cell lymphoma | disease=extranodal NK/T-cell lymphoma | disease=extranodal NK/T-Cell lymphoma derived cell line | disease=extraskeletal Ewing's sarcoma | disease=facial tumor | disease=facioscapulohumeral muscular dystrophy | disease=familial hypercholesterolemia | disease=familial hyperplastic polyposis | disease=fetal adenoma | disease=fever/influenza A infection | disease=fever/influenza B infection | disease=fever/upper respiratory infection/influenza A infection | disease=fever/upper respiratory infection/influenza B infection | disease=fibrocystic disease | disease=fibrosarcoma | disease=folicular lymphoma | disease=follicular adenoma | disease=follicular carcinoma | disease=follicular hyperplasia | disease=Freidriech's ataxia | disease=ganglioneuroblastoma | disease=ganglioneuroma | disease=gastric adenocarcinoma | disease=gastric cancer | disease=gastric carcinoma | disease=gastric papillary adenocarcinoma | disease=gastrointestinal stromal tumor | disease=germinoma | disease=germinoma/teratoma | disease=germioma/yolk sac tumor | disease=giant cell glioblastoma | disease=glioblastoma | disease=glioblastoma multiforme | disease=glioblastoma with EGFR amplification | disease=glioma | disease=gonadotrope tumor | disease=graft versus host disease | disease=graft-versus host disease | disease=graft-versus-host disease | disease=Graves' disease | disease=gulf war illness | disease=Haemophilus ducreyi infection | disease=hairy cell leukaemia | disease=HBV/hepatocellular carcinoma | disease=HCV | disease=HCV, hepatoma | disease=HCV/hepatocellular carcinoma | disease=head and neck cancer | disease=head and neck squamous cell carcinoma | disease=HeLa cell contamination | disease=hematoma | disease=hepatitis C virus-induced hepatocellular carcinoma | disease=hepatocellular carcinoma | disease=hepatoma | disease=her2+ breast cancer | disease=hereditary gingival fibromatosis | disease=hereditary spherocytosis | disease=high risk B-precurser ALL | disease=high-grade prostatic intraepithelial neoplasia | disease=highly invasive glioma | disease=hip arthroplasty | disease=HIV | disease=HIV-1 | disease=Hodgkins lymphoma | disease=house dust mite allergy | disease=Huntington's disease | disease=Hutchinson-Gilford Progeria Syndrome | disease=hydrolethalus syndrome | disease=hyperplastic polyp | disease=hyperplastic polyposis syndrome | disease=hypertriglyceridemia | disease=hypopharynx squamous cell carcinoma | disease=ICA (appearance of autoantibodies against islet cells) | disease=idiopathic chronic fatigue | disease=idiopathic pulmonary arterial hypertension | disease=idipathic pulmonary fibrosis | disease=IFTA | disease=IFTA/inflammation | disease=ileocecal carcinoma | disease=immunoblastic large cell lymphoma | disease=immunodeficiency associated Burkitt lymphoma | disease=in-transit extremity melanoma | disease=indolent mantle cell lymphoma | disease=infiltrating ductal carcinoma | disease=infiltrating lobular carcinoma | disease=inflamed tonsil | disease=inflammation | disease=inflammatory bowel disease | disease=inflammatory lung disease | disease=interstitial cystitis | disease=intestinal adenocarcinoma | disease=intracranial arterial aneurysm (unruptured) | disease=invasive ductal carcinoma | disease=invasive ductal/lobular carcinoma | disease=irritable bowel syndrome | disease=ischemic cardiomyopathy | disease=Job's syndrome | disease=juvenile idiopathic arthritis | disease=juvenile myelomonocytic leukaemia | disease=Kaposi's sarcoma | disease=Kawasaki disease | disease=kidney carcinoma | disease=kidney transplant recipient | disease=large cell lung cancer | disease=large cell lymphoma | disease=large cell neuroendocrine carcinoma | disease=larynx squamous cell carcinoma | disease=leiomyoma | disease=leiomyosarcoma | disease=lepromatous leprosy | disease=leukaemia | disease=leukemic-state lymphoma | disease=lipoma | disease=liposarcoma | disease=liver adenoma | disease=liver mesenchymal tumor | disease=lobular carcinoma | disease=lung adenocarcinoma | disease=lung anaplastic carcinoma | disease=lung cancer | disease=lung cancer (pathology not available) | disease=lung carcinoma | disease=lung fibrosarcoma | disease=lung squamous cell carcinoma | disease=lymph node metastasis | disease=lymphocytic leukaemia | disease=lymphoid neoplasm | disease=lymphoma | disease=malignant Burkitt's lymphoma | disease=malignant melanoma | disease=malignant mesothelioma | disease=malignant non-Hodgkin's lymphoma | disease=malignant peripheral nerve sheath tumor | disease=malignant pheochromocytoma | disease=malignant pluripotent embryonal carcinoma | disease=malignant testicular teratoma | disease=MALT lymphoma | disease=mantle cell lymphoma | disease=MCI | disease=medulloblastoma | disease=melanoma | disease=meningioma | disease=meningococcal sepsis | disease=mental retardation or developmental delay | disease=mesothelioma | disease=metastatic CCRCC | disease=metastatic colorectal cancer in liver | disease=metastatic gastrointestinal stromal tumor in liver | disease=metastatic kidney carcinoma in liver | disease=metastatic mammary carcinoma in liver | disease=metastatic melanoma | disease=metastatic prostate cancer | disease=metastatic stomach cancer in liver | disease=midgut carcinoid | disease=mild chronic allograft nephropathy | disease=mixture | disease=MLL | disease=MLL rearrangement | disease=moderate chronic allograft nephropathy | disease=moderately differentiated head and neck squamous cell carcinoma | disease=monoclonal gammopathy of undetermined significance | disease=monoclonal gammopathy of unknown significance | disease=morbidly obese | disease=mucinous adenocarcinoma | disease=mucoepidermoid lung cancer | disease=mucoid ductal carcinoma | disease=Muenke syndrome | disease=multiple myeloma | disease=multiple sclerosis | disease=multiple sclerosis or clinically isolated syndrome | disease=muscular dystrophy | disease=mycosis fungoide (cutaneus T-cell lymphoma) | disease=mycosis fungoides | disease=myelodisplastic syndrome | disease=myelodysplasia | disease=myelodysplastic syndrome | disease=myelodysplastic syndrome/refractory anemia | disease=myelodysplastic syndrome/refractory anemia with excess blasts | disease=myelodysplastic syndrome/refractory anemia with ringed sideroblasts | disease=myeloma | disease=myxoid liposarcoma | disease=myxoid round cell liposarcoma | disease=nasopharingeal carcinoma | disease=nasopharyngeal carcinoma | disease=nasopharyngeal squamous cell carcinoma | disease=neuroaxonal injury in cerebral palsy patient | disease=neuroblastoma | disease=neuroblastoma (Ewing sarcoma) | disease=neuroepithelioma | disease=neuromuscular pain | disease=nickel allergy | disease=Nijmegen breakage syndrome | disease=NK leukaemia | disease=NK/T-cell lymphoma | disease=no rejection | disease=nodal diffuse large B-cell lymphoma | disease=nodal peripheral T-cell lymphoma | disease=nodular goiter | disease=nodular lymphocyte predominant Hodgkin's lymphoma | disease=nodular melanoma | disease=non active Crohn's disease | disease=non-active ulcerative colitis | disease=non-basal like breast cancer | disease=non-Hodgkins lymphoma | disease=non-inflammatory bowel disease | disease=non-inflammatory neurological disease | disease=non-invasive glioma | disease=non-small cell lung cancer | disease=nonsyndromic sagittal synostosis | disease=normal | disease=NSCLC | disease=null cell tumor | disease=obesity | disease=obstruction | disease=oculo-facio-cardio-dental syndrome | disease=oligoarticular juvenile idiopathic arthritis | disease=oligoastrocytoma | disease=oligoastrocytoma (grade 3) with EGFR amplification | disease=oligodendroglioma | disease=oligodendroglioma (grade 3) with 1p19q codeletion | disease=oligodendroglioma (grade 3) with EGFR amplification | disease=oral cavity squamous cell carcinoma | disease=organ donor | disease=oropharynx squamous cell carcinoma | disease=osteoarthritis | disease=osteomyelitis | disease=osteomyelitis/bacteremia/methicillin-resistant Staphylococcus aureus infection | disease=osteomyelitis/suppurative arthritis/methicillin-resistant Staphylococcus aureus infection | disease=osteosarcoma | disease=ovarian adenocarcinoma | disease=ovarian cancer | disease=ovarian carcinoma | disease=ovarian papillary serous adenocarcinoma | disease=ovarian serous carcinoma | disease=ovary carcinoma | disease=pancreatic adenocarcinoma | disease=pancreatic cancer | disease=pancreatic carcinoma | disease=pancreatic ductal adenocarcinoma | disease=papillary carcinoma | disease=papillary serous ovarian adenocarcinoma | disease=papillary thyroid cancer | disease=parathyroid tumour | disease=Parkinson's disease | disease=pediatric acute leukaemia | disease=pediatric T-ALL | disease=pediatric-high grade glioma/anaplastic astrocytoma | disease=pediatric-high grade glioma/anaplastic oligodendroglioma | disease=pediatric-high grade glioma/glioblastoma | disease=pediatric-high grade glioma/glioblastoma variant | disease=pediatric-high grade glioma/pleomorphic xanthoastrocytoma | disease=periodontitis | disease=peripheral T-cell lymphoma | disease=pharyngeal carcinoma | disease=Pick's disease | disease=pilocytic astrocytoma | disease=pituitary adenoma | disease=pituitary adenoma predisposition | disease=pituitary tumor | disease=placenta choriocarcinoma | disease=pleomorphic liposarcoma | disease=pneumonia/bacteremia/S. Pneumoniae infection | disease=pneumonia/empyema/S. Pneumoniae infection | disease=pneumonia/influenza A infection | disease=polyarticular juvenile idiopathic arthritis | disease=polycystic ovary syndrome | disease=poorly differentiated head and neck squamous cell carcinoma | disease=post-transplant | disease=pre B-ALL | disease=Pre-B-ALL/c-ALL | disease=pre-diabetes | disease=pre-transplant | disease=precursor B-cell acute lymphoblastic leukaemia | disease=preeclampsia | disease=previous malaria infection | disease=primary breast tumor | disease=primary glioblastoma | disease=primary prostate cancer | disease=primary unilateral non-metastatic breast cancer | disease=Pro-B-ALL | disease=Pro-B-ALL with t 11q23, MLL | disease=Pro-B-ALL/MLL | disease=progressive multiple sclerosis | disease=Progressive supranuclear palsy | disease=prolapse | disease=prostate adenocarcinoma | disease=prostate cancer | disease=prostate carcinoma | disease=psoriasis | disease=pulmonary arterial hypertension | disease=pulmonary MALT lymphoma | disease=pulmonary tuberculosis | disease=RCC | disease=recessive retinitis pigmentosa | disease=rectal adenocarcinoma | disease=recurrent glioblastoma | disease=recurrent glioblastoma multiforme | disease=renal adenocarcinoma | disease=renal cancer | disease=renal carcinoma | disease=renal cell carcinoma | disease=renal clear cell carcinoma | disease=renal disease | disease=renal oncocytoma | disease=Rett syndrome | disease=rhabdomyosarcoma | disease=rheumatoid arthriris | disease=rheumatoid arthritis | disease=Roberts syndrome | disease=sarcoidosis | disease=sarcoma | disease=schizophrenia | disease=schyzophrenia | disease=scleroderma with pulmonary hypertension | disease=scleroderma without pulmonary hypertension | disease=sepsis | disease=septic arthritis/osteomyelitis/bacteremia/methicillin-sensitive Staphylococcus aureus infection | disease=septic patient | disease=septic shock | disease=serous borderline ovarian cancer | disease=serous epithelial ovarian cancer | disease=Setleis syndrome | disease=severe chronic allograft nephropathy | disease=Sezary syndrome | disease=sickle cell anaemia | disease=Sjogren syndrome | disease=small cell lung cancer | disease=small cell lung carcinoma | disease=Soetre-Chotzen syndrome | disease=soft tissue sarcoma | disease=spina bifida | disease=spinal muscular atrophy | disease=splenic marginal zone lymphoma | disease=sporadic Burkitt lymphoma | disease=squamous cell carcinoma | disease=squamous cell lung carcinoma | disease=Stevens-Johnson syndrome/toxic epidermal necrolysis | disease=stress incontinence | disease=subclinical interstitial fibrosis | disease=subependymal giant cell astrocytoma | disease=systemic inflammatory response syndrome | disease=systemic inflammatory response syndrome resolved | disease=systemic juvenile idiopathic arthritis | disease=T-ALL | disease=T-cell leukaemia | disease=T-cell lymphoma | disease=T-cell/histiocyte rich B-cell lymphoma | disease=T-LGL lymphocytosis | disease=teratoma/germ cell tumor | disease=teratoma/yolk sac tumor | disease=testicular diffuse large B-cell lymphoma | disease=testicular germ-cell tumor | disease=thalassemia | disease=thanatophoric dysplasia | disease=Thompson disease, grade 1 | disease=Thompson disease, grade 1/2 | disease=Thompson disease, grade 3 | disease=Thompson disease, grade 4 | disease=tongue squamous cell carcinoma | disease=trachoma | disease=tuberous sclerosis | disease=tumorigenic | disease=type 1 diabetes | disease=type 1 diabetes clinical onset | disease=type 1 diabetes longstanding | disease=type 1 diabetes recent onset | disease=type 2 diabetes | disease=type 2 diabetes mellitus | disease=ulcerative colitis | disease=ulcerative colitis with inflammation | disease=ulcerative colitis without inflammation | disease=undifferentiated bone sarcoma | disease=undifferentiated sarcoma | disease=undifferentiated soft tissue sarcoma | disease=unilateral cryptorchid | disease=unknown | disease=Usher syndrome | disease=uterine fibroid | disease=uterine leiomyoma | disease=vessel ischemic heart disease | disease=villitis | disease=vulvar intraepithelial neoplasia | disease=Waldenstrom Macroglobulinemia | disease=Waldenstršms macroglobulinemia | disease=well differentiated head and neck squamous cell carcinoma | disease=well-differentiated soft tissue sarcoma | disease=Williams-Beuren Syndrome","treatment=13-cis retinoic acid + thalidomide | treatment=13-cis-retinoic acid | treatment=no drug | treatment=thalidomide","organism part=GBM6 cells | organism part=xenograft tumor | subgroup=GLam | subgroup=GMono | subgroup=GSph","genotype=Msi1 KD | genotype=wild type (control)","clinical_history=-- | clinical_history=astrocytoma | disease_state=normal | disease_state=Primary Glioma | tumor_grading=-- | tumor_grading=Grade 1 | tumor_grading=Grade 2 | tumor_grading=Grade 4","cell line=U251 | cell line=U87 | treatment=control | treatment=Drug MPS1 inhibitor treated for 24h | treatment=Drug MPS1 inhibitor treated for 48h | treatment=siNegative control | treatment=siTTK gene at 24h | treatment=siTTK gene at 48h","cell types=Brain tissue | cell types=GBM stem cells | cell types=GBM xenograft tumor tissue | cell types=neural stem cell | tumorgenecity=normal | tumorgenecity=Tumor","cell line=T08 | cell line=T59 | cell line=T65 | treated with=5 uM PBK-inhibitor (HI-TOPK-032) | treated with=non-silencing vector | treated with=none (non-treated control) | treated with=PBK-shRNA construct 2 | treated with=PBK-shRNA construct3","timie=24 h | timie=48 h | timie=6 h | treatment=none | treatment=siMPS1 | treatment=siNegative","phenotype=healthy control | phenotype=multi-organ epithelial inflammation associated with an inherited loss-of-function mutation in EGFR | Stage=adult | Stage=infant","NA","NA","NA","affy_batch=1 | affy_batch=2 | cell line code=1 | cell line code=10 | cell line code=101 | cell line code=102 | cell line code=103 | cell line code=104 | cell line code=105 | cell line code=106 | cell line code=109 | cell line code=11 | cell line code=110 | cell line code=111 | cell line code=112 | cell line code=113 | cell line code=114 | cell line code=115 | cell line code=116 | cell line code=117 | cell line code=118 | cell line code=119 | cell line code=12 | cell line code=120 | cell line code=121 | cell line code=122 | cell line code=123 | cell line code=124 | cell line code=125 | cell line code=126 | cell line code=127 | cell line code=128 | cell line code=129 | cell line code=13 | cell line code=130 | cell line code=131 | cell line code=132 | cell line code=133 | cell line code=134 | cell line code=135 | cell line code=136 | cell line code=137 | cell line code=138 | cell line code=139 | cell line code=14 | cell line code=140 | cell line code=141 | cell line code=142 | cell line code=143 | cell line code=144 | cell line code=145 | cell line code=146 | cell line code=147 | cell line code=148 | cell line code=149 | cell line code=15 | cell line code=151 | cell line code=152 | cell line code=153 | cell line code=154 | cell line code=155 | cell line code=156 | cell line code=157 | cell line code=158 | cell line code=159 | cell line code=16 | cell line code=160 | cell line code=161 | cell line code=162 | cell line code=163 | cell line code=164 | cell line code=165 | cell line code=166 | cell line code=167 | cell line code=168 | cell line code=169 | cell line code=17 | cell line code=170 | cell line code=171 | cell line code=172 | cell line code=173 | cell line code=174 | cell line code=175 | cell line code=176 | cell line code=177 | cell line code=178 | cell line code=179 | cell line code=18 | cell line code=180 | cell line code=181 | cell line code=182 | cell line code=183 | cell line code=184 | cell line code=185 | cell line code=186 | cell line code=187 | cell line code=188 | cell line code=189 | cell line code=19 | cell line code=190 | cell line code=191 | cell line code=192 | cell line code=193 | cell line code=194 | cell line code=195 | cell line code=196 | cell line code=197 | cell line code=198 | cell line code=199 | cell line code=2 | cell line code=20 | cell line code=200 | cell line code=201 | cell line code=202 | cell line code=203 | cell line code=204 | cell line code=205 | cell line code=206 | cell line code=207 | cell line code=208 | cell line code=209 | cell line code=21 | cell line code=210 | cell line code=212 | cell line code=213 | cell line code=214 | cell line code=215 | cell line code=216 | cell line code=218 | cell line code=219 | cell line code=22 | cell line code=220 | cell line code=221 | cell line code=222 | cell line code=223 | cell line code=224 | cell line code=225 | cell line code=226 | cell line code=227 | cell line code=228 | cell line code=229 | cell line code=23 | cell line code=230 | cell line code=231 | cell line code=232 | cell line code=233 | cell line code=234 | cell line code=235 | cell line code=236 | cell line code=237 | cell line code=238 | cell line code=239 | cell line code=24 | cell line code=240 | cell line code=241 | cell line code=242 | cell line code=243 | cell line code=244 | cell line code=245 | cell line code=246 | cell line code=247 | cell line code=248 | cell line code=249 | cell line code=25 | cell line code=250 | cell line code=251 | cell line code=252 | cell line code=253 | cell line code=255 | cell line code=256 | cell line code=257 | cell line code=258 | cell line code=259 | cell line code=26 | cell line code=260 | cell line code=261 | cell line code=262 | cell line code=263 | cell line code=264 | cell line code=265 | cell line code=266 | cell line code=267 | cell line code=268 | cell line code=269 | cell line code=27 | cell line code=270 | cell line code=271 | cell line code=272 | cell line code=273 | cell line code=274 | cell line code=275 | cell line code=276 | cell line code=277 | cell line code=278 | cell line code=279 | cell line code=28 | cell line code=280 | cell line code=281 | cell line code=282 | cell line code=283 | cell line code=284 | cell line code=285 | cell line code=286 | cell line code=287 | cell line code=288 | cell line code=289 | cell line code=29 | cell line code=290 | cell line code=291 | cell line code=292 | cell line code=293 | cell line code=294 | cell line code=295 | cell line code=296 | cell line code=297 | cell line code=298 | cell line code=299 | cell line code=3 | cell line code=30 | cell line code=300 | cell line code=301 | cell line code=302 | cell line code=303 | cell line code=304 | cell line code=305 | cell line code=306 | cell line code=307 | cell line code=308 | cell line code=309 | cell line code=31 | cell line code=310 | cell line code=311 | cell line code=312 | cell line code=313 | cell line code=314 | cell line code=315 | cell line code=316 | cell line code=317 | cell line code=318 | cell line code=319 | cell line code=32 | cell line code=320 | cell line code=321 | cell line code=322 | cell line code=323 | cell line code=324 | cell line code=326 | cell line code=327 | cell line code=328 | cell line code=329 | cell line code=33 | cell line code=330 | cell line code=331 | cell line code=332 | cell line code=333 | cell line code=334 | cell line code=335 | cell line code=336 | cell line code=337 | cell line code=338 | cell line code=339 | cell line code=34 | cell line code=341 | cell line code=342 | cell line code=343 | cell line code=344 | cell line code=345 | cell line code=346 | cell line code=347 | cell line code=348 | cell line code=349 | cell line code=35 | cell line code=350 | cell line code=351 | cell line code=352 | cell line code=353 | cell line code=354 | cell line code=355 | cell line code=356 | cell line code=357 | cell line code=358 | cell line code=359 | cell line code=36 | cell line code=360 | cell line code=363 | cell line code=365 | cell line code=366 | cell line code=367 | cell line code=368 | cell line code=369 | cell line code=37 | cell line code=370 | cell line code=371 | cell line code=372 | cell line code=373 | cell line code=374 | cell line code=376 | cell line code=377 | cell line code=378 | cell line code=379 | cell line code=38 | cell line code=380 | cell line code=381 | cell line code=382 | cell line code=383 | cell line code=384 | cell line code=385 | cell line code=386 | cell line code=387 | cell line code=388 | cell line code=389 | cell line code=39 | cell line code=390 | cell line code=391 | cell line code=392 | cell line code=393 | cell line code=394 | cell line code=395 | cell line code=396 | cell line code=397 | cell line code=398 | cell line code=399 | cell line code=4 | cell line code=40 | cell line code=400 | cell line code=401 | cell line code=402 | cell line code=403 | cell line code=404 | cell line code=405 | cell line code=406 | cell line code=408 | cell line code=41 | cell line code=410 | cell line code=411 | cell line code=412 | cell line code=413 | cell line code=414 | cell line code=415 | cell line code=416 | cell line code=417 | cell line code=418 | cell line code=419 | cell line code=42 | cell line code=420 | cell line code=421 | cell line code=422 | cell line code=423 | cell line code=424 | cell line code=425 | cell line code=426 | cell line code=427 | cell line code=429 | cell line code=43 | cell line code=430 | cell line code=431 | cell line code=432 | cell line code=433 | cell line code=434 | cell line code=435 | cell line code=436 | cell line code=437 | cell line code=438 | cell line code=439 | cell line code=440 | cell line code=441 | cell line code=442 | cell line code=443 | cell line code=444 | cell line code=445 | cell line code=446 | cell line code=447 | cell line code=448 | cell line code=449 | cell line code=45 | cell line code=450 | cell line code=451 | cell line code=452 | cell line code=453 | cell line code=454 | cell line code=455 | cell line code=456 | cell line code=457 | cell line code=458 | cell line code=459 | cell line code=46 | cell line code=460 | cell line code=461 | cell line code=462 | cell line code=463 | cell line code=464 | cell line code=465 | cell line code=466 | cell line code=467 | cell line code=468 | cell line code=469 | cell line code=47 | cell line code=470 | cell line code=471 | cell line code=472 | cell line code=473 | cell line code=474 | cell line code=475 | cell line code=476 | cell line code=477 | cell line code=478 | cell line code=479 | cell line code=48 | cell line code=480 | cell line code=481 | cell line code=482 | cell line code=483 | cell line code=484 | cell line code=485 | cell line code=486 | cell line code=487 | cell line code=488 | cell line code=489 | cell line code=49 | cell line code=490 | cell line code=491 | cell line code=492 | cell line code=493 | cell line code=494 | cell line code=495 | cell line code=496 | cell line code=497 | cell line code=498 | cell line code=499 | cell line code=5 | cell line code=50 | cell line code=500 | cell line code=501 | cell line code=502 | cell line code=503 | cell line code=504 | cell line code=505 | cell line code=506 | cell line code=507 | cell line code=508 | cell line code=509 | cell line code=510 | cell line code=511 | cell line code=512 | cell line code=514 | cell line code=515 | cell line code=516 | cell line code=518 | cell line code=519 | cell line code=52 | cell line code=520 | cell line code=521 | cell line code=522 | cell line code=523 | cell line code=524 | cell line code=525 | cell line code=527 | cell line code=528 | cell line code=529 | cell line code=53 | cell line code=530 | cell line code=532 | cell line code=533 | cell line code=534 | cell line code=535 | cell line code=536 | cell line code=537 | cell line code=538 | cell line code=539 | cell line code=54 | cell line code=540 | cell line code=541 | cell line code=542 | cell line code=543 | cell line code=544 | cell line code=545 | cell line code=546 | cell line code=547 | cell line code=548 | cell line code=549 | cell line code=55 | cell line code=550 | cell line code=551 | cell line code=552 | cell line code=553 | cell line code=554 | cell line code=555 | cell line code=556 | cell line code=557 | cell line code=558 | cell line code=559 | cell line code=56 | cell line code=560 | cell line code=561 | cell line code=562 | cell line code=563 | cell line code=564 | cell line code=565 | cell line code=566 | cell line code=567 | cell line code=568 | cell line code=569 | cell line code=57 | cell line code=570 | cell line code=571 | cell line code=573 | cell line code=574 | cell line code=575 | cell line code=576 | cell line code=577 | cell line code=578 | cell line code=579 | cell line code=58 | cell line code=580 | cell line code=581 | cell line code=582 | cell line code=583 | cell line code=584 | cell line code=585 | cell line code=586 | cell line code=587 | cell line code=588 | cell line code=589 | cell line code=59 | cell line code=590 | cell line code=591 | cell line code=592 | cell line code=593 | cell line code=594 | cell line code=595 | cell line code=596 | cell line code=597 | cell line code=598 | cell line code=599 | cell line code=6 | cell line code=60 | cell line code=600 | cell line code=601 | cell line code=602 | cell line code=603 | cell line code=604 | cell line code=605 | cell line code=606 | cell line code=607 | cell line code=608 | cell line code=609 | cell line code=61 | cell line code=610 | cell line code=611 | cell line code=613 | cell line code=614 | cell line code=615 | cell line code=616 | cell line code=617 | cell line code=618 | cell line code=619 | cell line code=62 | cell line code=620 | cell line code=621 | cell line code=622 | cell line code=623 | cell line code=624 | cell line code=625 | cell line code=626 | cell line code=627 | cell line code=628 | cell line code=629 | cell line code=63 | cell line code=630 | cell line code=631 | cell line code=632 | cell line code=633 | cell line code=634 | cell line code=635 | cell line code=636 | cell line code=637 | cell line code=638 | cell line code=639 | cell line code=64 | cell line code=640 | cell line code=642 | cell line code=643 | cell line code=644 | cell line code=645 | cell line code=646 | cell line code=647 | cell line code=648 | cell line code=649 | cell line code=65 | cell line code=650 | cell line code=651 | cell line code=652 | cell line code=654 | cell line code=655 | cell line code=656 | cell line code=657 | cell line code=658 | cell line code=659 | cell line code=66 | cell line code=660 | cell line code=661 | cell line code=662 | cell line code=663 | cell line code=664 | cell line code=665 | cell line code=666 | cell line code=667 | cell line code=668 | cell line code=669 | cell line code=670 | cell line code=671 | cell line code=673 | cell line code=674 | cell line code=675 | cell line code=676 | cell line code=678 | cell line code=679 | cell line code=68 | cell line code=680 | cell line code=681 | cell line code=682 | cell line code=684 | cell line code=685 | cell line code=686 | cell line code=687 | cell line code=688 | cell line code=689 | cell line code=69 | cell line code=690 | cell line code=691 | cell line code=692 | cell line code=693 | cell line code=694 | cell line code=695 | cell line code=696 | cell line code=697 | cell line code=698 | cell line code=699 | cell line code=70 | cell line code=700 | cell line code=702 | cell line code=703 | cell line code=704 | cell line code=705 | cell line code=706 | cell line code=707 | cell line code=708 | cell line code=709 | cell line code=71 | cell line code=710 | cell line code=711 | cell line code=712 | cell line code=713 | cell line code=714 | cell line code=715 | cell line code=716 | cell line code=717 | cell line code=718 | cell line code=719 | cell line code=72 | cell line code=720 | cell line code=721 | cell line code=722 | cell line code=723 | cell line code=724 | cell line code=725 | cell line code=726 | cell line code=727 | cell line code=728 | cell line code=729 | cell line code=73 | cell line code=730 | cell line code=731 | cell line code=732 | cell line code=733 | cell line code=734 | cell line code=735 | cell line code=736 | cell line code=737 | cell line code=738 | cell line code=739 | cell line code=74 | cell line code=740 | cell line code=741 | cell line code=742 | cell line code=743 | cell line code=744 | cell line code=746 | cell line code=748 | cell line code=749 | cell line code=75 | cell line code=750 | cell line code=751 | cell line code=753 | cell line code=754 | cell line code=756 | cell line code=757 | cell line code=758 | cell line code=759 | cell line code=76 | cell line code=760 | cell line code=762 | cell line code=763 | cell line code=764 | cell line code=765 | cell line code=766 | cell line code=767 | cell line code=768 | cell line code=769 | cell line code=77 | cell line code=770 | cell line code=78 | cell line code=79 | cell line code=8 | cell line code=80 | cell line code=81 | cell line code=82 | cell line code=83 | cell line code=84 | cell line code=85 | cell line code=86 | cell line code=87 | cell line code=88 | cell line code=89 | cell line code=9 | cell line code=90 | cell line code=91 | cell line code=92 | cell line code=93 | cell line code=94 | cell line code=95 | cell line code=96 | cell line code=97 | cell line code=98 | cosmic id=#N/A | cosmic id=683667 | cosmic id=684052 | cosmic id=684055 | cosmic id=684057 | cosmic id=684059 | cosmic id=684062 | cosmic id=684681 | cosmic id=687452 | cosmic id=687457 | cosmic id=687459 | cosmic id=687505 | cosmic id=687509 | cosmic id=687514 | cosmic id=687562 | cosmic id=687563 | cosmic id=687586 | cosmic id=687588 | cosmic id=687590 | cosmic id=687592 | cosmic id=687596 | cosmic id=687777 | cosmic id=687780 | cosmic id=687787 | cosmic id=687794 | cosmic id=687800 | cosmic id=687802 | cosmic id=687804 | cosmic id=687807 | cosmic id=687814 | cosmic id=687815 | cosmic id=687816 | cosmic id=687819 | cosmic id=687820 | cosmic id=687821 | cosmic id=687829 | cosmic id=687983 | cosmic id=687984 | cosmic id=687985 | cosmic id=687995 | cosmic id=687997 | cosmic id=688011 | cosmic id=688013 | cosmic id=688014 | cosmic id=688015 | cosmic id=688018 | cosmic id=688019 | cosmic id=688021 | cosmic id=688022 | cosmic id=688023 | cosmic id=688025 | cosmic id=688026 | cosmic id=688031 | cosmic id=688033 | cosmic id=688058 | cosmic id=688086 | cosmic id=688087 | cosmic id=688121 | cosmic id=713878 | cosmic id=713880 | cosmic id=713885 | cosmic id=713899 | cosmic id=722045 | cosmic id=722066 | cosmic id=724812 | cosmic id=724828 | cosmic id=724831 | cosmic id=724834 | cosmic id=724838 | cosmic id=724855 | cosmic id=724858 | cosmic id=724859 | cosmic id=724863 | cosmic id=724866 | cosmic id=724868 | cosmic id=724869 | cosmic id=724870 | cosmic id=724872 | cosmic id=724873 | cosmic id=724874 | cosmic id=724878 | cosmic id=724879 | cosmic id=735784 | cosmic id=749709 | cosmic id=749710 | cosmic id=749711 | cosmic id=749712 | cosmic id=749713 | cosmic id=749714 | cosmic id=749715 | cosmic id=749716 | cosmic id=749717 | cosmic id=753531 | cosmic id=753532 | cosmic id=753533 | cosmic id=753534 | cosmic id=753535 | cosmic id=753536 | cosmic id=753538 | cosmic id=753540 | cosmic id=753541 | cosmic id=753546 | cosmic id=753547 | cosmic id=753548 | cosmic id=753549 | cosmic id=753551 | cosmic id=753552 | cosmic id=753553 | cosmic id=753555 | cosmic id=753556 | cosmic id=753558 | cosmic id=753559 | cosmic id=753562 | cosmic id=753563 | cosmic id=753564 | cosmic id=753565 | cosmic id=753566 | cosmic id=753568 | cosmic id=753569 | cosmic id=753570 | cosmic id=753572 | cosmic id=753573 | cosmic id=753574 | cosmic id=753575 | cosmic id=753576 | cosmic id=753577 | cosmic id=753578 | cosmic id=753579 | cosmic id=753581 | cosmic id=753582 | cosmic id=753583 | cosmic id=753584 | cosmic id=753585 | cosmic id=753586 | cosmic id=753588 | cosmic id=753592 | cosmic id=753594 | cosmic id=753596 | cosmic id=753599 | cosmic id=753600 | cosmic id=753601 | cosmic id=753604 | cosmic id=753605 | cosmic id=753608 | cosmic id=753611 | cosmic id=753612 | cosmic id=753614 | cosmic id=753615 | cosmic id=753619 | cosmic id=753620 | cosmic id=753621 | cosmic id=753622 | cosmic id=753623 | cosmic id=753624 | cosmic id=905933 | cosmic id=905934 | cosmic id=905935 | cosmic id=905936 | cosmic id=905937 | cosmic id=905938 | cosmic id=905939 | cosmic id=905941 | cosmic id=905942 | cosmic id=905943 | cosmic id=905944 | cosmic id=905945 | cosmic id=905946 | cosmic id=905947 | cosmic id=905948 | cosmic id=905949 | cosmic id=905950 | cosmic id=905951 | cosmic id=905952 | cosmic id=905953 | cosmic id=905954 | cosmic id=905955 | cosmic id=905956 | cosmic id=905957 | cosmic id=905958 | cosmic id=905959 | cosmic id=905960 | cosmic id=905961 | cosmic id=905962 | cosmic id=905963 | cosmic id=905964 | cosmic id=905965 | cosmic id=905966 | cosmic id=905968 | cosmic id=905969 | cosmic id=905970 | cosmic id=905971 | cosmic id=905972 | cosmic id=905973 | cosmic id=905974 | cosmic id=905975 | cosmic id=905976 | cosmic id=905977 | cosmic id=905978 | cosmic id=905979 | cosmic id=905980 | cosmic id=905981 | cosmic id=905983 | cosmic id=905984 | cosmic id=905985 | cosmic id=905986 | cosmic id=905987 | cosmic id=905988 | cosmic id=905989 | cosmic id=905990 | cosmic id=905991 | cosmic id=906693 | cosmic id=906695 | cosmic id=906696 | cosmic id=906746 | cosmic id=906763 | cosmic id=906765 | cosmic id=906790 | cosmic id=906791 | cosmic id=906792 | cosmic id=906793 | cosmic id=906794 | cosmic id=906797 | cosmic id=906798 | cosmic id=906800 | cosmic id=906801 | cosmic id=906803 | cosmic id=906804 | cosmic id=906805 | cosmic id=906806 | cosmic id=906807 | cosmic id=906808 | cosmic id=906812 | cosmic id=906813 | cosmic id=906814 | cosmic id=906815 | cosmic id=906817 | cosmic id=906818 | cosmic id=906820 | cosmic id=906821 | cosmic id=906823 | cosmic id=906824 | cosmic id=906825 | cosmic id=906826 | cosmic id=906827 | cosmic id=906828 | cosmic id=906829 | cosmic id=906830 | cosmic id=906831 | cosmic id=906832 | cosmic id=906833 | cosmic id=906834 | cosmic id=906835 | cosmic id=906836 | cosmic id=906837 | cosmic id=906838 | cosmic id=906839 | cosmic id=906841 | cosmic id=906842 | cosmic id=906843 | cosmic id=906844 | cosmic id=906846 | cosmic id=906847 | cosmic id=906848 | cosmic id=906849 | cosmic id=906850 | cosmic id=906851 | cosmic id=906852 | cosmic id=906853 | cosmic id=906854 | cosmic id=906855 | cosmic id=906856 | cosmic id=906861 | cosmic id=906862 | cosmic id=906863 | cosmic id=906864 | cosmic id=906865 | cosmic id=906866 | cosmic id=906867 | cosmic id=906868 | cosmic id=906869 | cosmic id=906870 | cosmic id=906871 | cosmic id=906872 | cosmic id=906873 | cosmic id=906875 | cosmic id=906876 | cosmic id=906877 | cosmic id=906999 | cosmic id=907000 | cosmic id=907041 | cosmic id=907042 | cosmic id=907043 | cosmic id=907044 | cosmic id=907045 | cosmic id=907047 | cosmic id=907048 | cosmic id=907049 | cosmic id=907050 | cosmic id=907051 | cosmic id=907053 | cosmic id=907055 | cosmic id=907056 | cosmic id=907057 | cosmic id=907058 | cosmic id=907059 | cosmic id=907060 | cosmic id=907061 | cosmic id=907062 | cosmic id=907063 | cosmic id=907064 | cosmic id=907065 | cosmic id=907066 | cosmic id=907067 | cosmic id=907068 | cosmic id=907069 | cosmic id=907070 | cosmic id=907071 | cosmic id=907072 | cosmic id=907073 | cosmic id=907169 | cosmic id=907170 | cosmic id=907171 | cosmic id=907172 | cosmic id=907173 | cosmic id=907175 | cosmic id=907176 | cosmic id=907268 | cosmic id=907269 | cosmic id=907270 | cosmic id=907271 | cosmic id=907272 | cosmic id=907273 | cosmic id=907274 | cosmic id=907275 | cosmic id=907276 | cosmic id=907277 | cosmic id=907279 | cosmic id=907280 | cosmic id=907282 | cosmic id=907285 | cosmic id=907286 | cosmic id=907287 | cosmic id=907290 | cosmic id=907291 | cosmic id=907292 | cosmic id=907295 | cosmic id=907299 | cosmic id=907300 | cosmic id=907312 | cosmic id=907313 | cosmic id=907314 | cosmic id=907315 | cosmic id=907317 | cosmic id=907318 | cosmic id=907319 | cosmic id=907320 | cosmic id=907321 | cosmic id=907322 | cosmic id=907323 | cosmic id=907391 | cosmic id=907783 | cosmic id=907784 | cosmic id=907785 | cosmic id=907787 | cosmic id=907788 | cosmic id=907789 | cosmic id=907790 | cosmic id=907791 | cosmic id=907792 | cosmic id=907793 | cosmic id=907794 | cosmic id=907795 | cosmic id=907796 | cosmic id=907798 | cosmic id=908118 | cosmic id=908119 | cosmic id=908120 | cosmic id=908121 | cosmic id=908122 | cosmic id=908123 | cosmic id=908124 | cosmic id=908125 | cosmic id=908126 | cosmic id=908127 | cosmic id=908128 | cosmic id=908129 | cosmic id=908130 | cosmic id=908131 | cosmic id=908132 | cosmic id=908133 | cosmic id=908134 | cosmic id=908135 | cosmic id=908136 | cosmic id=908137 | cosmic id=908138 | cosmic id=908139 | cosmic id=908141 | cosmic id=908143 | cosmic id=908144 | cosmic id=908145 | cosmic id=908146 | cosmic id=908147 | cosmic id=908148 | cosmic id=908150 | cosmic id=908151 | cosmic id=908152 | cosmic id=908155 | cosmic id=908157 | cosmic id=908158 | cosmic id=908440 | cosmic id=908441 | cosmic id=908442 | cosmic id=908443 | cosmic id=908444 | cosmic id=908445 | cosmic id=908446 | cosmic id=908447 | cosmic id=908448 | cosmic id=908449 | cosmic id=908450 | cosmic id=908451 | cosmic id=908452 | cosmic id=908454 | cosmic id=908455 | cosmic id=908456 | cosmic id=908457 | cosmic id=908458 | cosmic id=908459 | cosmic id=908460 | cosmic id=908461 | cosmic id=908462 | cosmic id=908463 | cosmic id=908464 | cosmic id=908465 | cosmic id=908466 | cosmic id=908467 | cosmic id=908468 | cosmic id=908469 | cosmic id=908470 | cosmic id=908472 | cosmic id=908473 | cosmic id=908474 | cosmic id=908475 | cosmic id=908476 | cosmic id=908477 | cosmic id=908480 | cosmic id=908481 | cosmic id=908482 | cosmic id=908483 | cosmic id=909248 | cosmic id=909249 | cosmic id=909250 | cosmic id=909251 | cosmic id=909252 | cosmic id=909253 | cosmic id=909255 | cosmic id=909256 | cosmic id=909257 | cosmic id=909260 | cosmic id=909262 | cosmic id=909263 | cosmic id=909264 | cosmic id=909696 | cosmic id=909697 | cosmic id=909698 | cosmic id=909699 | cosmic id=909700 | cosmic id=909701 | cosmic id=909702 | cosmic id=909703 | cosmic id=909704 | cosmic id=909705 | cosmic id=909706 | cosmic id=909707 | cosmic id=909708 | cosmic id=909709 | cosmic id=909710 | cosmic id=909711 | cosmic id=909712 | cosmic id=909716 | cosmic id=909717 | cosmic id=909718 | cosmic id=909719 | cosmic id=909720 | cosmic id=909721 | cosmic id=909722 | cosmic id=909724 | cosmic id=909725 | cosmic id=909726 | cosmic id=909728 | cosmic id=909729 | cosmic id=909730 | cosmic id=909732 | cosmic id=909735 | cosmic id=909736 | cosmic id=909737 | cosmic id=909738 | cosmic id=909739 | cosmic id=909740 | cosmic id=909742 | cosmic id=909743 | cosmic id=909744 | cosmic id=909745 | cosmic id=909746 | cosmic id=909747 | cosmic id=909748 | cosmic id=909749 | cosmic id=909750 | cosmic id=909751 | cosmic id=909753 | cosmic id=909754 | cosmic id=909755 | cosmic id=909756 | cosmic id=909757 | cosmic id=909758 | cosmic id=909759 | cosmic id=909761 | cosmic id=909762 | cosmic id=909763 | cosmic id=909765 | cosmic id=909769 | cosmic id=909770 | cosmic id=909771 | cosmic id=909773 | cosmic id=909774 | cosmic id=909776 | cosmic id=909777 | cosmic id=909779 | cosmic id=909780 | cosmic id=909781 | cosmic id=909782 | cosmic id=909784 | cosmic id=909785 | cosmic id=909904 | cosmic id=909905 | cosmic id=909907 | cosmic id=909974 | cosmic id=909975 | cosmic id=909976 | cosmic id=909977 | cosmic id=910079 | cosmic id=910209 | cosmic id=910399 | cosmic id=910401 | cosmic id=910544 | cosmic id=910545 | cosmic id=910546 | cosmic id=910548 | cosmic id=910549 | cosmic id=910553 | cosmic id=910554 | cosmic id=910555 | cosmic id=910566 | cosmic id=910567 | cosmic id=910568 | cosmic id=910569 | cosmic id=910687 | cosmic id=910688 | cosmic id=910689 | cosmic id=910691 | cosmic id=910692 | cosmic id=910694 | cosmic id=910695 | cosmic id=910696 | cosmic id=910698 | cosmic id=910700 | cosmic id=910701 | cosmic id=910702 | cosmic id=910703 | cosmic id=910705 | cosmic id=910706 | cosmic id=910707 | cosmic id=910710 | cosmic id=910779 | cosmic id=910780 | cosmic id=910781 | cosmic id=910784 | cosmic id=910849 | cosmic id=910850 | cosmic id=910851 | cosmic id=910852 | cosmic id=910853 | cosmic id=910861 | cosmic id=910899 | cosmic id=910900 | cosmic id=910903 | cosmic id=910904 | cosmic id=910905 | cosmic id=910906 | cosmic id=910907 | cosmic id=910908 | cosmic id=910910 | cosmic id=910911 | cosmic id=910916 | cosmic id=910918 | cosmic id=910919 | cosmic id=910920 | cosmic id=910921 | cosmic id=910922 | cosmic id=910924 | cosmic id=910925 | cosmic id=910926 | cosmic id=910927 | cosmic id=910929 | cosmic id=910930 | cosmic id=910931 | cosmic id=910932 | cosmic id=910933 | cosmic id=910934 | cosmic id=910935 | cosmic id=910936 | cosmic id=910937 | cosmic id=910941 | cosmic id=910942 | cosmic id=910943 | cosmic id=910944 | cosmic id=910946 | cosmic id=910947 | cosmic id=910948 | cosmic id=910951 | cosmic id=910952 | cosmic id=911847 | cosmic id=911904 | cosmic id=911905 | cosmic id=917486 | cosmic id=924100 | cosmic id=924101 | cosmic id=924102 | cosmic id=924104 | cosmic id=924105 | cosmic id=924106 | cosmic id=924107 | cosmic id=924108 | cosmic id=924110 | cosmic id=924111 | cosmic id=924151 | cosmic id=924163 | cosmic id=924164 | cosmic id=924186 | cosmic id=924187 | cosmic id=924188 | cosmic id=924189 | cosmic id=924238 | cosmic id=924239 | cosmic id=924240 | cosmic id=924241 | cosmic id=924244 | cosmic id=924245 | cosmic id=924246 | cosmic id=924247 | cosmic id=924250 | cosmic id=925338 | cosmic id=925339 | cosmic id=925340 | cosmic id=925341 | cosmic id=925342 | cosmic id=925343 | cosmic id=925344 | cosmic id=925345 | cosmic id=925346 | cosmic id=925347 | cosmic id=925348 | cosmic id=925349 | cosmic id=930081 | cosmic id=930082 | cosmic id=930083 | cosmic id=930297 | cosmic id=930298 | cosmic id=930299 | cosmic id=930301 | cosmic id=946353 | cosmic id=946354 | cosmic id=946355 | cosmic id=946356 | cosmic id=946357 | cosmic id=946360 | cosmic id=946361 | cosmic id=946363 | cosmic id=946366 | cosmic id=946367 | cosmic id=946368 | cosmic id=946369 | cosmic id=946370 | cosmic id=946371 | cosmic id=946372 | cosmic id=946373 | cosmic id=946376 | cosmic id=946377 | cosmic id=946379 | cosmic id=946380 | cosmic id=946381 | cosmic id=946382 | cosmic id=949088 | cosmic id=949089 | cosmic id=949090 | cosmic id=949092 | cosmic id=949094 | cosmic id=949153 | cosmic id=949154 | cosmic id=949155 | cosmic id=949157 | cosmic id=949158 | cosmic id=949160 | cosmic id=949161 | cosmic id=949162 | cosmic id=949163 | cosmic id=949164 | cosmic id=949165 | cosmic id=949166 | cosmic id=949167 | cosmic id=949168 | cosmic id=949170 | cosmic id=949171 | cosmic id=949172 | cosmic id=949173 | cosmic id=949174 | cosmic id=949175 | cosmic id=949176 | cosmic id=949177 | cosmic id=949178 | cosmic id=949179 | cosmic id=971773 | cosmic id=971774 | cosmic id=971776 | cosmic id=971777 | crna plate=11 | crna plate=12 | crna plate=2 | crna plate=3 | crna plate=4 | crna plate=5 | crna plate=6 | crna plate=7 | crna plate=8 | disease location=#N/A | disease location=abdomen | disease location=adipose tissue | disease location=adrenal gland | disease location=autonomic ganglia | disease location=axilla | disease location=bile duct | disease location=bladder | disease location=bone | disease location=brain | disease location=breast | disease location=bronchus | disease location=buccal mucosa | disease location=caecum | disease location=central nervous system | disease location=cerebrum | disease location=cervix | disease location=colon | disease location=Connective and Soft Tissue | disease location=duodenum | disease location=endometrium | disease location=esophagus | disease location=extraskeletal | disease location=femur | disease location=frontal lobe | disease location=gallbladder | disease location=gastrointestinal tract (site indeterminate) | disease location=gingiva | disease location=head neck | disease location=Hematopoietic and Lymphoid Tissue | disease location=hypopharynx | disease location=kidney | disease location=liver | disease location=lower third | disease location=lung | disease location=Lung left upper lobe | disease location=Lymph node | disease location=middle third | disease location=mouth | disease location=mouth floor | disease location=mouth roof | disease location=ovary | disease location=pancreas | disease location=parietal lobe | disease location=pelvis | disease location=Pharynx | disease location=placenta | disease location=pleura | disease location=posterior fossa | disease location=prostate | disease location=rectum | disease location=retina | disease location=sinonasal and nasal cavity | disease location=sinus | disease location=skin | disease location=stomach | disease location=striated muscle | disease location=submaxillary | disease location=temporal lobe | disease location=testis | disease location=thyroid | disease location=tibia | disease location=tongue | disease location=upper leg | disease location=upper third | disease location=ureter | disease location=uterus | disease location=vulva | disease state=#N/A | disease state=acute leukemia | disease state=Acute Leukemia of Ambiguous Lineage | disease state=acute lymphoblastic leukemia | disease state=acute myeloid leukemia | disease state=Acute T-Cell Lymphoblastic Leukemia | disease state=adenocarcinoma | disease state=adenosquamous carcinoma | disease state=adrenocortical carcinoma | disease state=Adult T-Cell Leukemia-Lymphoma | disease state=anaplastic astrocytoma | disease state=anaplastic carcinoma | disease state=anaplastic large cell lymphoma | disease state=astrocytoma | disease state=B cell lymphoma unspecified | disease state=biphasic mesothelioma | disease state=blast phase chronic myeloid leukemia | disease state=Bronchioloalveolar adenocarcinoma | disease state=Burkitt Lymphoma | disease state=carcinoid-endocrine tumor | disease state=carcinoma | disease state=carcinosarcoma-malignant mesodermal mixed tumor | disease state=chondrosarcoma | disease state=choriocarcinoma | disease state=chronic eosinophilic leukemia-hypereosinophilic syndrome | disease state=chronic lymphocytic leukemia-small lymphocytic lymphoma | disease state=chronic myeloid leukemia | disease state=clear cell carcinoma | disease state=Clear Cell Renal Cell Carcinoma | disease state=desmoplastic | disease state=Diffuse Large Cell Lymphoma | disease state=Ductal Carcinoma | disease state=embryonal carcinoma | disease state=embryonal rhabdomyosarcoma | disease state=epithelial dysplasia | disease state=epithelioid sarcoma | disease state=Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | disease state=fibrosarcoma | disease state=Follicular carcinoma | disease state=Follicular Lymphoma | disease state=giant cell carcinoma | disease state=glioblastoma multiforme | disease state=Glioma | disease state=gliosarcoma | disease state=granulosa cell tumor | disease state=hairy cell leukemia | disease state=hepatocellular carcinoma | disease state=Hodgkin Lymphoma | disease state=hyperplasia | disease state=Large Cell Carcinoma | disease state=leiomyosarcoma | disease state=liposarcoma | disease state=lymphoid neoplasm | disease state=M1 Acute Myeloid Leukemia | disease state=M2 Therapy-Related Myeloid Neoplasm | disease state=malignant fibrous histiocytoma-pleomorphic sarcoma | disease state=Malignant Melanoma | disease state=malignant trichilemmal cyst | disease state=medullary breast carcinoma | disease state=medullary carcinoma | disease state=mesothelioma | disease state=metaplasia | disease state=micropapillary carcinoma | disease state=Micropapillary Serous Carcinoma | disease state=mucinous carcinoma | disease state=mucoepidermoid carcinoma | disease state=multipotential sarcoma | disease state=Mycosis Fungoides and Sezary Syndrome | disease state=myelodysplastic syndrome | disease state=neuroblastoma | disease state=Non-Small Cell Carcinoma | disease state=Osteoblastic osteosarcoma | disease state=osteosarcoma | disease state=papillary carcinoma | disease state=papillary ductal carcinoma | disease state=papillary transitional cell carcinoma | disease state=Plasma Cell Myeloma | disease state=primitive neuroectodermal tumor-medulloblastoma | disease state=refractory anemia with excess blasts | disease state=renal cell carcinoma | disease state=Retinoblastoma | disease state=rhabdoid tumor | disease state=rhabdomyosarcoma | disease state=sarcoma | disease state=small cell adenocarcinoma | disease state=Small Cell Carcinoma | disease state=squamous cell carcinoma | disease state=synovial sarcoma | disease state=T Acute Lymphoblastic Leukemia | disease state=teratocarcinoma | disease state=teratoma | disease state=transitional cell carcinoma | disease state=Tubular Adenocarcinoma | disease state=undifferentiated carcinoma | disease state=Wilms tumor | organism part=adrenal gland | organism part=Autonomic Ganglion | organism part=BiliaryTract | organism part=bone | organism part=brain | organism part=breast | organism part=cervix | organism part=Colorectal | organism part=Connective and Soft Tissue | organism part=endometrium | organism part=eye | organism part=Head and Neck | organism part=kidney | organism part=leukemia | organism part=liver | organism part=lung | organism part=lymphoma | organism part=muscle | organism part=oesophagus | organism part=ovary | organism part=pancreas | organism part=placenta | organism part=pleura | organism part=prostate | organism part=skin | organism part=Smooth Muscle Tissue | organism part=stomach | organism part=testis | organism part=thyroid gland | organism part=Unknow | organism part=Urinary tract | organism part=vulva | sample=1 | sample=10 | sample=100 | sample=101 | sample=102 | sample=103 | sample=104 | sample=105 | sample=106 | sample=107 | sample=108 | sample=109 | sample=11 | sample=110 | sample=111 | sample=112 | sample=113 | sample=114 | sample=115 | sample=116 | sample=117 | sample=118 | sample=119 | sample=12 | sample=120 | sample=121 | sample=122 | sample=123 | sample=124 | sample=125 | sample=126 | sample=127 | sample=128 | sample=129 | sample=13 | sample=130 | sample=131 | sample=132 | sample=133 | sample=134 | sample=135 | sample=136 | sample=137 | sample=138 | sample=139 | sample=14 | sample=140 | sample=141 | sample=142 | sample=143 | sample=144 | sample=145 | sample=146 | sample=147 | sample=148 | sample=149 | sample=15 | sample=150 | sample=151 | sample=152 | sample=153 | sample=154 | sample=155 | sample=156 | sample=157 | sample=158 | sample=159 | sample=16 | sample=160 | sample=161 | sample=162 | sample=163 | sample=164 | sample=165 | sample=166 | sample=167 | sample=168 | sample=169 | sample=17 | sample=170 | sample=171 | sample=172 | sample=173 | sample=174 | sample=175 | sample=176 | sample=177 | sample=178 | sample=179 | sample=18 | sample=180 | sample=181 | sample=182 | sample=183 | sample=184 | sample=185 | sample=186 | sample=187 | sample=188 | sample=189 | sample=19 | sample=190 | sample=191 | sample=192 | sample=193 | sample=194 | sample=195 | sample=196 | sample=197 | sample=198 | sample=199 | sample=2 | sample=20 | sample=200 | sample=201 | sample=202 | sample=203 | sample=204 | sample=205 | sample=206 | sample=207 | sample=208 | sample=209 | sample=21 | sample=210 | sample=211 | sample=212 | sample=213 | sample=214 | sample=215 | sample=216 | sample=217 | sample=218 | sample=219 | sample=22 | sample=220 | sample=221 | sample=222 | sample=223 | sample=224 | sample=225 | sample=226 | sample=227 | sample=228 | sample=229 | sample=23 | sample=230 | sample=231 | sample=232 | sample=233 | sample=234 | sample=235 | sample=236 | sample=237 | sample=238 | sample=239 | sample=24 | sample=240 | sample=241 | sample=242 | sample=243 | sample=244 | sample=245 | sample=246 | sample=247 | sample=248 | sample=249 | sample=25 | sample=250 | sample=251 | sample=252 | sample=253 | sample=254 | sample=255 | sample=256 | sample=257 | sample=258 | sample=259 | sample=26 | sample=260 | sample=261 | sample=262 | sample=263 | sample=264 | sample=265 | sample=266 | sample=267 | sample=268 | sample=269 | sample=27 | sample=270 | sample=271 | sample=272 | sample=273 | sample=274 | sample=275 | sample=276 | sample=277 | sample=278 | sample=279 | sample=28 | sample=280 | sample=281 | sample=282 | sample=283 | sample=284 | sample=285 | sample=286 | sample=287 | sample=288 | sample=289 | sample=29 | sample=290 | sample=291 | sample=292 | sample=293 | sample=294 | sample=295 | sample=296 | sample=297 | sample=298 | sample=299 | sample=3 | sample=30 | sample=300 | sample=301 | sample=302 | sample=303 | sample=304 | sample=305 | sample=306 | sample=307 | sample=308 | sample=309 | sample=31 | sample=310 | sample=311 | sample=312 | sample=313 | sample=314 | sample=315 | sample=316 | sample=317 | sample=318 | sample=319 | sample=32 | sample=320 | sample=321 | sample=322 | sample=323 | sample=324 | sample=325 | sample=326 | sample=327 | sample=328 | sample=329 | sample=33 | sample=330 | sample=331 | sample=332 | sample=333 | sample=334 | sample=335 | sample=336 | sample=337 | sample=338 | sample=339 | sample=34 | sample=340 | sample=341 | sample=342 | sample=343 | sample=344 | sample=345 | sample=346 | sample=347 | sample=348 | sample=349 | sample=35 | sample=350 | sample=351 | sample=352 | sample=353 | sample=354 | sample=355 | sample=356 | sample=357 | sample=358 | sample=359 | sample=36 | sample=360 | sample=361 | sample=362 | sample=363 | sample=364 | sample=365 | sample=366 | sample=367 | sample=368 | sample=369 | sample=37 | sample=370 | sample=371 | sample=372 | sample=373 | sample=374 | sample=375 | sample=376 | sample=377 | sample=378 | sample=379 | sample=38 | sample=380 | sample=381 | sample=382 | sample=383 | sample=384 | sample=385 | sample=386 | sample=387 | sample=388 | sample=389 | sample=39 | sample=390 | sample=391 | sample=392 | sample=393 | sample=394 | sample=395 | sample=396 | sample=397 | sample=398 | sample=399 | sample=4 | sample=40 | sample=400 | sample=401 | sample=402 | sample=403 | sample=404 | sample=405 | sample=406 | sample=407 | sample=408 | sample=409 | sample=41 | sample=410 | sample=411 | sample=412 | sample=413 | sample=414 | sample=415 | sample=416 | sample=417 | sample=418 | sample=419 | sample=42 | sample=420 | sample=421 | sample=422 | sample=423 | sample=424 | sample=425 | sample=426 | sample=427 | sample=428 | sample=429 | sample=43 | sample=430 | sample=431 | sample=432 | sample=433 | sample=434 | sample=435 | sample=436 | sample=437 | sample=438 | sample=439 | sample=44 | sample=440 | sample=441 | sample=442 | sample=443 | sample=444 | sample=445 | sample=446 | sample=447 | sample=448 | sample=449 | sample=45 | sample=450 | sample=451 | sample=452 | sample=453 | sample=454 | sample=455 | sample=456 | sample=457 | sample=458 | sample=459 | sample=46 | sample=460 | sample=461 | sample=462 | sample=463 | sample=464 | sample=465 | sample=466 | sample=467 | sample=468 | sample=469 | sample=47 | sample=470 | sample=471 | sample=472 | sample=473 | sample=474 | sample=475 | sample=476 | sample=477 | sample=478 | sample=479 | sample=48 | sample=480 | sample=481 | sample=482 | sample=483 | sample=484 | sample=485 | sample=486 | sample=487 | sample=488 | sample=489 | sample=49 | sample=490 | sample=491 | sample=492 | sample=493 | sample=494 | sample=495 | sample=496 | sample=497 | sample=498 | sample=499 | sample=5 | sample=50 | sample=500 | sample=501 | sample=502 | sample=503 | sample=504 | sample=505 | sample=506 | sample=507 | sample=508 | sample=509 | sample=51 | sample=510 | sample=511 | sample=512 | sample=513 | sample=514 | sample=515 | sample=516 | sample=517 | sample=518 | sample=519 | sample=52 | sample=520 | sample=521 | sample=522 | sample=523 | sample=524 | sample=525 | sample=526 | sample=527 | sample=528 | sample=529 | sample=53 | sample=530 | sample=531 | sample=532 | sample=533 | sample=534 | sample=535 | sample=536 | sample=537 | sample=538 | sample=539 | sample=54 | sample=540 | sample=541 | sample=542 | sample=543 | sample=544 | sample=545 | sample=546 | sample=547 | sample=548 | sample=549 | sample=55 | sample=550 | sample=551 | sample=552 | sample=553 | sample=554 | sample=555 | sample=556 | sample=557 | sample=558 | sample=559 | sample=56 | sample=560 | sample=561 | sample=562 | sample=563 | sample=564 | sample=565 | sample=566 | sample=567 | sample=568 | sample=569 | sample=57 | sample=570 | sample=571 | sample=572 | sample=573 | sample=574 | sample=575 | sample=576 | sample=577 | sample=578 | sample=579 | sample=58 | sample=580 | sample=581 | sample=582 | sample=583 | sample=584 | sample=585 | sample=586 | sample=587 | sample=588 | sample=589 | sample=59 | sample=590 | sample=591 | sample=592 | sample=593 | sample=594 | sample=595 | sample=596 | sample=597 | sample=598 | sample=599 | sample=6 | sample=60 | sample=600 | sample=601 | sample=602 | sample=603 | sample=604 | sample=605 | sample=606 | sample=607 | sample=608 | sample=609 | sample=61 | sample=610 | sample=611 | sample=612 | sample=613 | sample=614 | sample=615 | sample=616 | sample=617 | sample=618 | sample=619 | sample=62 | sample=620 | sample=621 | sample=622 | sample=623 | sample=624 | sample=625 | sample=626 | sample=627 | sample=628 | sample=629 | sample=63 | sample=630 | sample=631 | sample=632 | sample=633 | sample=634 | sample=635 | sample=636 | sample=637 | sample=638 | sample=639 | sample=64 | sample=640 | sample=641 | sample=642 | sample=643 | sample=644 | sample=645 | sample=646 | sample=647 | sample=648 | sample=649 | sample=65 | sample=650 | sample=651 | sample=652 | sample=653 | sample=654 | sample=655 | sample=656 | sample=657 | sample=658 | sample=659 | sample=66 | sample=660 | sample=661 | sample=662 | sample=663 | sample=664 | sample=665 | sample=666 | sample=667 | sample=668 | sample=669 | sample=67 | sample=670 | sample=671 | sample=672 | sample=673 | sample=674 | sample=675 | sample=676 | sample=677 | sample=678 | sample=679 | sample=68 | sample=680 | sample=681 | sample=682 | sample=683 | sample=684 | sample=685 | sample=686 | sample=687 | sample=688 | sample=689 | sample=69 | sample=690 | sample=691 | sample=692 | sample=693 | sample=694 | sample=695 | sample=696 | sample=697 | sample=698 | sample=699 | sample=7 | sample=70 | sample=700 | sample=701 | sample=702 | sample=703 | sample=704 | sample=705 | sample=706 | sample=707 | sample=708 | sample=709 | sample=71 | sample=710 | sample=711 | sample=712 | sample=713 | sample=714 | sample=715 | sample=716 | sample=717 | sample=718 | sample=719 | sample=72 | sample=720 | sample=721 | sample=722 | sample=723 | sample=724 | sample=725 | sample=726 | sample=727 | sample=728 | sample=729 | sample=73 | sample=730 | sample=731 | sample=732 | sample=733 | sample=734 | sample=735 | sample=736 | sample=737 | sample=738 | sample=739 | sample=74 | sample=740 | sample=741 | sample=742 | sample=743 | sample=744 | sample=745 | sample=746 | sample=747 | sample=748 | sample=749 | sample=75 | sample=750 | sample=751 | sample=752 | sample=753 | sample=754 | sample=755 | sample=756 | sample=76 | sample=77 | sample=78 | sample=79 | sample=8 | sample=80 | sample=81 | sample=82 | sample=83 | sample=84 | sample=85 | sample=86 | sample=87 | sample=88 | sample=89 | sample=9 | sample=90 | sample=91 | sample=92 | sample=93 | sample=94 | sample=95 | sample=96 | sample=97 | sample=98 | sample=99 | supplier=ATCC | supplier=DSMZ | supplier=DTP | supplier=ECCC | supplier=HSRRB | supplier=ICLC | supplier=JCRB | supplier=RIKEN | supplier=Unspecified","cell line=BREAST_BT549 | cell line=BREAST_HS578T | cell line=BREAST_MCF7 | cell line=BREAST_MCF7ADRr | cell line=BREAST_MDAMB231 | cell line=BREAST_MDAMB435 | cell line=BREAST_MDN | cell line=BREAST_T47D | cell line=CNS_SF268 | cell line=CNS_SF295 | cell line=CNS_SF539 | cell line=CNS_SNB19 | cell line=CNS_SNB75 | cell line=CNS_U251 | cell line=COLON_COLO205 | cell line=COLON_HCC-2998 | cell line=COLON_HCT116 | cell line=COLON_HCT15 | cell line=COLON_HT29 | cell line=COLON_KM12 | cell line=COLON_SW620 | cell line=LEUK_CCRFCEM | cell line=LEUK_HL60 | cell line=LEUK_K562 | cell line=LEUK_MOLT4 | cell line=LEUK_RPMI8226 | cell line=LEUK_SR | cell line=MELAN_LOXIMVI | cell line=MELAN_M14 | cell line=MELAN_MALME3M | cell line=MELAN_SKMEL2 | cell line=MELAN_SKMEL28 | cell line=MELAN_SKMEL5 | cell line=MELAN_UACC257 | cell line=MELAN_UACC62 | cell line=NSCLC_A549ATCC | cell line=NSCLC_EKVX | cell line=NSCLC_H460 | cell line=NSCLC_HOP62 | cell line=NSCLC_HOP92 | cell line=NSCLC_NCIH226 | cell line=NSCLC_NCIH23 | cell line=NSCLC_NCIH322M | cell line=NSCLC_NCIH522 | cell line=OVAR_IGROV1 | cell line=OVAR_OVCAR3 | cell line=OVAR_OVCAR4 | cell line=OVAR_OVCAR5 | cell line=OVAR_OVCAR8 | cell line=OVAR_SKOV3 | cell line=PROSTATE_DU145 | cell line=PROSTATE_PC3 | cell line=RENAL_7860 | cell line=RENAL_A498 | cell line=RENAL_ACHN | cell line=RENAL_CAKI1 | cell line=RENAL_RXF393 | cell line=RENAL_SN12C | cell line=RENAL_TK10 | cell line=RENAL_UO31 | cell type=-- | cell type=epithelial cell | disease state=adenocarcinoma | disease state=Amelanotic Melanoma | disease state=Bronchogenic Carcinoma | disease state=carcinoma | disease state=Carcinosarcoma | disease state=chronic myelogenous leukemia | disease state=Glioblastoma | disease state=Large Cell Carcinoma | disease state=lymphoma | disease state=melanoma | disease state=Myeloid Leukemia | disease state=Plasma Cell Myeloma | disease state=Precursor Lymphoblastic Leukemia | disease state=squamous cell carcinoma | organism part=blood | organism part=brain | organism part=breast | organism part=colon | organism part=kidney | organism part=lung | organism part=ovary | organism part=prostate | organism part=skin","disease state=acute myeloid leukemia | disease state=B-cell ALL | disease state=bladder transitional cell carcinoma | disease state=bladder transitonal cell carcinoma | disease state=breast adenocarcinoma | disease state=colorectal adenocarcinoma | disease state=Follicular Lymphoma | disease state=Glioblastoma | disease state=large B-cell lymphoma | disease state=Large-Cell Lymphoma | disease state=lung adenocarcinoma | disease state=medulloblastoma | disease state=melanoma | disease state=mesothelioma | disease state=normal | disease state=ovarian adenocarcinoma | disease state=pancreatic adenocarcinoma | disease state=prostate adenocarcinoma | disease state=renal cell carcinoma | disease state=T-cell ALL | disease state=uterine adenocarcinoma | organism part=bladder | organism part=blood | organism part=bone marrow | organism part=brain | organism part=breast | organism part=colon | organism part=Kideny | organism part=kidney | organism part=lung | organism part=Lymphod Tissue | organism part=Lymphoid | organism part=lymphoid tissue | organism part=Mesothelium | organism part=ovary | organism part=pancreas | organism part=prostate | organism part=skin | organism part=uterus","clinical diagnosis=GBM | clinical diagnosis=NOT SPECIFIED | disease state=glioblastoma multiforme | disease state=NOT SPECIFIED | histologic diagnosis=anaplastic astrocytoma | histologic diagnosis=Glioblastoma | histologic diagnosis=glioblastoma multiforme | histologic diagnosis=GLIOMA MIXED | histologic diagnosis=NOT SPECIFIED | individual=TCGA-02-0001 | individual=TCGA-02-0002 | individual=TCGA-02-0003 | individual=TCGA-02-0004 | individual=TCGA-02-0006 | individual=TCGA-02-0007 | individual=TCGA-02-0009 | individual=TCGA-02-0010 | individual=TCGA-02-0011 | individual=TCGA-02-0014 | individual=TCGA-02-0015 | individual=TCGA-02-0016 | individual=TCGA-02-0021 | individual=TCGA-02-0023 | individual=TCGA-02-0024 | individual=TCGA-02-0025 | individual=TCGA-02-0026 | individual=TCGA-02-0027 | individual=TCGA-02-0028 | individual=TCGA-02-0033 | individual=TCGA-02-0034 | individual=TCGA-02-0037 | individual=TCGA-02-0038 | individual=TCGA-02-0039 | individual=TCGA-02-0043 | individual=TCGA-02-0046 | individual=TCGA-02-0047 | individual=TCGA-02-0048 | individual=TCGA-02-0051 | individual=TCGA-02-0052 | individual=TCGA-02-0054 | individual=TCGA-02-0055 | individual=TCGA-02-0057 | individual=TCGA-02-0058 | individual=TCGA-02-0059 | individual=TCGA-02-0060 | individual=TCGA-02-0064 | individual=TCGA-02-0068 | individual=TCGA-02-0069 | individual=TCGA-02-0070 | individual=TCGA-02-0071 | individual=TCGA-02-0074 | individual=TCGA-02-0075 | individual=TCGA-02-0079 | individual=TCGA-02-0080 | individual=TCGA-02-0083 | individual=TCGA-02-0084 | individual=TCGA-02-0085 | individual=TCGA-02-0086 | individual=TCGA-02-0087 | individual=TCGA-02-0089 | individual=TCGA-02-0099 | individual=TCGA-02-0102 | individual=TCGA-02-0104 | individual=TCGA-02-0106 | individual=TCGA-02-0107 | individual=TCGA-02-0111 | individual=TCGA-02-0113 | individual=TCGA-02-0114 | individual=TCGA-02-0115 | individual=TCGA-02-0116 | individual=TCGA-02-0258 | individual=TCGA-02-0260 | individual=TCGA-02-0266 | individual=TCGA-02-0269 | individual=TCGA-02-0271 | individual=TCGA-02-0281 | individual=TCGA-02-0285 | individual=TCGA-02-0289 | individual=TCGA-02-0290 | individual=TCGA-02-0317 | individual=TCGA-02-0321 | individual=TCGA-02-0324 | individual=TCGA-02-0325 | individual=TCGA-02-0326 | individual=TCGA-02-0330 | individual=TCGA-02-0332 | individual=TCGA-02-0333 | individual=TCGA-02-0337 | individual=TCGA-02-0338 | individual=TCGA-02-0339 | individual=TCGA-02-0422 | individual=TCGA-02-0430 | individual=TCGA-02-0432 | individual=TCGA-02-0439 | individual=TCGA-02-0440 | individual=TCGA-02-0446 | individual=TCGA-02-0451 | individual=TCGA-02-0456 | individual=TCGA-06-0122 | individual=TCGA-06-0124 | individual=TCGA-06-0125 | individual=TCGA-06-0126 | individual=TCGA-06-0127 | individual=TCGA-06-0128 | individual=TCGA-06-0129 | individual=TCGA-06-0130 | individual=TCGA-06-0132 | individual=TCGA-06-0133 | individual=TCGA-06-0137 | individual=TCGA-06-0138 | individual=TCGA-06-0139 | individual=TCGA-06-0140 | individual=TCGA-06-0141 | individual=TCGA-06-0142 | individual=TCGA-06-0143 | individual=TCGA-06-0145 | individual=TCGA-06-0146 | individual=TCGA-06-0147 | individual=TCGA-06-0148 | individual=TCGA-06-0149 | individual=TCGA-06-0152 | individual=TCGA-06-0154 | individual=TCGA-06-0156 | individual=TCGA-06-0157 | individual=TCGA-06-0158 | individual=TCGA-06-0160 | individual=TCGA-06-0162 | individual=TCGA-06-0164 | individual=TCGA-06-0166 | individual=TCGA-06-0167 | individual=TCGA-06-0168 | individual=TCGA-06-0169 | individual=TCGA-06-0171 | individual=TCGA-06-0173 | individual=TCGA-06-0174 | individual=TCGA-06-0175 | individual=TCGA-06-0176 | individual=TCGA-06-0177 | individual=TCGA-06-0178 | individual=TCGA-06-0179 | individual=TCGA-06-0182 | individual=TCGA-06-0184 | individual=TCGA-06-0185 | individual=TCGA-06-0187 | individual=TCGA-06-0188 | individual=TCGA-06-0189 | individual=TCGA-06-0190 | individual=TCGA-06-0194 | individual=TCGA-06-0195 | individual=TCGA-06-0197 | individual=TCGA-06-0206 | individual=TCGA-06-0208 | individual=TCGA-06-0210 | individual=TCGA-06-0211 | individual=TCGA-06-0214 | individual=TCGA-06-0219 | individual=TCGA-06-0221 | individual=TCGA-06-0237 | individual=TCGA-06-0238 | individual=TCGA-06-0240 | individual=TCGA-06-0241 | individual=TCGA-06-0394 | individual=TCGA-06-0397 | individual=TCGA-06-0402 | individual=TCGA-06-0409 | individual=TCGA-06-0410 | individual=TCGA-06-0412 | individual=TCGA-06-0413 | individual=TCGA-06-0414 | individual=TCGA-06-0644 | individual=TCGA-06-0645 | individual=TCGA-06-0646 | individual=TCGA-06-0648 | individual=TCGA-07-0249 | individual=TCGA-08-0244 | individual=TCGA-08-0245 | individual=TCGA-08-0246 | individual=TCGA-08-0344 | individual=TCGA-08-0345 | individual=TCGA-08-0346 | individual=TCGA-08-0347 | individual=TCGA-08-0348 | individual=TCGA-08-0349 | individual=TCGA-08-0350 | individual=TCGA-08-0351 | individual=TCGA-08-0352 | individual=TCGA-08-0353 | individual=TCGA-08-0354 | individual=TCGA-08-0355 | individual=TCGA-08-0356 | individual=TCGA-08-0357 | individual=TCGA-08-0358 | individual=TCGA-08-0359 | individual=TCGA-08-0360 | individual=TCGA-08-0373 | individual=TCGA-08-0375 | individual=TCGA-08-0380 | individual=TCGA-08-0385 | individual=TCGA-08-0386 | individual=TCGA-08-0389 | individual=TCGA-08-0390 | individual=TCGA-08-0392 | individual=TCGA-08-0509 | individual=TCGA-08-0510 | individual=TCGA-08-0511 | individual=TCGA-08-0512 | individual=TCGA-08-0514 | individual=TCGA-08-0516 | individual=TCGA-08-0517 | individual=TCGA-08-0518 | individual=TCGA-08-0520 | individual=TCGA-08-0521 | individual=TCGA-08-0522 | individual=TCGA-08-0524 | individual=TCGA-08-0525 | individual=TCGA-08-0529 | individual=TCGA-08-0531 | individual=TCGA-12-0615 | individual=TCGA-12-0616 | individual=TCGA-12-0618 | individual=TCGA-12-0619 | individual=TCGA-12-0620 | organism part=-- | organism part=brain | pathologic status=MALIGNANT | pathologic status=NOT SPECIFIED | sample=TCGA-02-0001-01C | sample=TCGA-02-0002-01A | sample=TCGA-02-0003-01A | sample=TCGA-02-0004-01A | sample=TCGA-02-0006-01B | sample=TCGA-02-0007-01A | sample=TCGA-02-0009-01A | sample=TCGA-02-0010-01A | sample=TCGA-02-0011-01B | sample=TCGA-02-0014-01A | sample=TCGA-02-0015-01A | sample=TCGA-02-0016-01A | sample=TCGA-02-0021-01A | sample=TCGA-02-0023-01B | sample=TCGA-02-0024-01B | sample=TCGA-02-0025-01A | sample=TCGA-02-0026-01B | sample=TCGA-02-0027-01A | sample=TCGA-02-0028-01A | sample=TCGA-02-0033-01A | sample=TCGA-02-0034-01A | sample=TCGA-02-0037-01A | sample=TCGA-02-0038-01A | sample=TCGA-02-0039-01A | sample=TCGA-02-0043-01A | sample=TCGA-02-0046-01A | sample=TCGA-02-0047-01A | sample=TCGA-02-0048-01A | sample=TCGA-02-0051-01A | sample=TCGA-02-0052-01A | sample=TCGA-02-0054-01A | sample=TCGA-02-0055-01A | sample=TCGA-02-0057-01A | sample=TCGA-02-0058-01A | sample=TCGA-02-0059-01A | sample=TCGA-02-0060-01A | sample=TCGA-02-0064-01A | sample=TCGA-02-0068-01A | sample=TCGA-02-0069-01A | sample=TCGA-02-0070-01A | sample=TCGA-02-0071-01A | sample=TCGA-02-0074-01A | sample=TCGA-02-0075-01A | sample=TCGA-02-0079-01A | sample=TCGA-02-0080-01A | sample=TCGA-02-0083-01A | sample=TCGA-02-0084-01A | sample=TCGA-02-0085-01A | sample=TCGA-02-0086-01A | sample=TCGA-02-0087-01A | sample=TCGA-02-0089-01A | sample=TCGA-02-0099-01A | sample=TCGA-02-0102-01A | sample=TCGA-02-0104-01A | sample=TCGA-02-0106-01A | sample=TCGA-02-0107-01A | sample=TCGA-02-0111-01A | sample=TCGA-02-0113-01A | sample=TCGA-02-0114-01A | sample=TCGA-02-0115-01A | sample=TCGA-02-0116-01A | sample=TCGA-02-0258-01A | sample=TCGA-02-0260-01A | sample=TCGA-02-0266-01A | sample=TCGA-02-0269-01B | sample=TCGA-02-0271-01A | sample=TCGA-02-0281-01A | sample=TCGA-02-0285-01A | sample=TCGA-02-0289-01A | sample=TCGA-02-0290-01A | sample=TCGA-02-0317-01A | sample=TCGA-02-0321-01A | sample=TCGA-02-0324-01A | sample=TCGA-02-0325-01A | sample=TCGA-02-0326-01A | sample=TCGA-02-0330-01A | sample=TCGA-02-0332-01A | sample=TCGA-02-0333-01A | sample=TCGA-02-0337-01A | sample=TCGA-02-0338-01A | sample=TCGA-02-0339-01A | sample=TCGA-02-0422-01A | sample=TCGA-02-0430-01A | sample=TCGA-02-0432-01A | sample=TCGA-02-0439-01A | sample=TCGA-02-0440-01A | sample=TCGA-02-0446-01A | sample=TCGA-02-0451-01A | sample=TCGA-02-0456-01A | sample=TCGA-06-0122-01A | sample=TCGA-06-0124-01A | sample=TCGA-06-0125-01A | sample=TCGA-06-0126-01A | sample=TCGA-06-0127-01A | sample=TCGA-06-0128-01A | sample=TCGA-06-0129-01A | sample=TCGA-06-0130-01A | sample=TCGA-06-0132-01A | sample=TCGA-06-0133-01A | sample=TCGA-06-0137-01A | sample=TCGA-06-0138-01A | sample=TCGA-06-0139-01A | sample=TCGA-06-0140-01A | sample=TCGA-06-0141-01A | sample=TCGA-06-0142-01A | sample=TCGA-06-0143-01A | sample=TCGA-06-0145-01A | sample=TCGA-06-0146-01A | sample=TCGA-06-0147-01A | sample=TCGA-06-0148-01A | sample=TCGA-06-0149-01A | sample=TCGA-06-0152-01A | sample=TCGA-06-0154-01A | sample=TCGA-06-0156-01A | sample=TCGA-06-0157-01A | sample=TCGA-06-0158-01A | sample=TCGA-06-0160-01A | sample=TCGA-06-0162-01A | sample=TCGA-06-0164-01A | sample=TCGA-06-0166-01A | sample=TCGA-06-0167-01A | sample=TCGA-06-0168-01A | sample=TCGA-06-0169-01A | sample=TCGA-06-0171-01A | sample=TCGA-06-0173-01A | sample=TCGA-06-0174-01A | sample=TCGA-06-0175-01A | sample=TCGA-06-0176-01A | sample=TCGA-06-0177-01A | sample=TCGA-06-0178-01A | sample=TCGA-06-0179-01A | sample=TCGA-06-0182-01A | sample=TCGA-06-0184-01A | sample=TCGA-06-0185-01A | sample=TCGA-06-0187-01A | sample=TCGA-06-0188-01A | sample=TCGA-06-0189-01A | sample=TCGA-06-0190-01A | sample=TCGA-06-0194-01A | sample=TCGA-06-0195-01B | sample=TCGA-06-0197-01A | sample=TCGA-06-0206-01A | sample=TCGA-06-0208-01A | sample=TCGA-06-0208-01B | sample=TCGA-06-0210-01A | sample=TCGA-06-0211-01A | sample=TCGA-06-0211-01B | sample=TCGA-06-0214-01A | sample=TCGA-06-0219-01A | sample=TCGA-06-0221-01A | sample=TCGA-06-0237-01A | sample=TCGA-06-0238-01A | sample=TCGA-06-0240-01A | sample=TCGA-06-0241-01A | sample=TCGA-06-0394-01A | sample=TCGA-06-0397-01A | sample=TCGA-06-0402-01A | sample=TCGA-06-0409-01A | sample=TCGA-06-0410-01A | sample=TCGA-06-0412-01A | sample=TCGA-06-0413-01A | sample=TCGA-06-0414-01A | sample=TCGA-06-0644-01A | sample=TCGA-06-0645-01A | sample=TCGA-06-0646-01A | sample=TCGA-06-0648-01A | sample=TCGA-07-0249-20A | sample=TCGA-08-0244-01A | sample=TCGA-08-0245-01A | sample=TCGA-08-0246-01A | sample=TCGA-08-0344-01A | sample=TCGA-08-0345-01A | sample=TCGA-08-0346-01A | sample=TCGA-08-0347-01A | sample=TCGA-08-0348-01A | sample=TCGA-08-0349-01A | sample=TCGA-08-0350-01A | sample=TCGA-08-0351-01A | sample=TCGA-08-0352-01A | sample=TCGA-08-0353-01A | sample=TCGA-08-0354-01A | sample=TCGA-08-0355-01A | sample=TCGA-08-0356-01A | sample=TCGA-08-0357-01A | sample=TCGA-08-0358-01A | sample=TCGA-08-0359-01A | sample=TCGA-08-0360-01A | sample=TCGA-08-0373-01A | sample=TCGA-08-0375-01A | sample=TCGA-08-0380-01A | sample=TCGA-08-0385-01A | sample=TCGA-08-0386-01A | sample=TCGA-08-0389-01A | sample=TCGA-08-0390-01A | sample=TCGA-08-0392-01A | sample=TCGA-08-0509-01A | sample=TCGA-08-0510-01A | sample=TCGA-08-0511-01A | sample=TCGA-08-0512-01A | sample=TCGA-08-0514-01A | sample=TCGA-08-0516-01A | sample=TCGA-08-0517-01A | sample=TCGA-08-0518-01A | sample=TCGA-08-0520-01A | sample=TCGA-08-0521-01A | sample=TCGA-08-0522-01A | sample=TCGA-08-0524-01A | sample=TCGA-08-0525-01A | sample=TCGA-08-0529-01A | sample=TCGA-08-0531-01A | sample=TCGA-12-0615-01A | sample=TCGA-12-0616-01A | sample=TCGA-12-0618-01A | sample=TCGA-12-0619-01A | sample=TCGA-12-0620-01A | tissue anatomic site=BRAIN, NOS | tissue anatomic site=cerebrum | tissue anatomic site=frontal lobe | tissue anatomic site=NOT SPECIFIED | tissue anatomic site=occipital lobe | tissue anatomic site=OVERLAPPING LESION OF BRAIN | tissue anatomic site=parietal lobe | tissue anatomic site=temporal lobe","disease state=-- | disease state=astrocytoma | disease state=GBM | disease state=MIXED | disease state=NON_TUMOR | disease state=oligodendroglioma | disease state=UNCLASSIFIED | disease state=UNKNOWN | organism part=-- | organism part=brain | sample=00518392_T | sample=00641238_T | sample=00715851_T | sample=00860772_T | sample=01074569_T | sample=01113810_T | sample=03089254_T | sample=03184579_T | sample=03272709_T | sample=03352571_T | sample=03418160_T | sample=03421536_T | sample=03421899_T | sample=03425149_T | sample=03431712_T | sample=03431774_T | sample=03433293_T | sample=03434766_T | sample=03436958_T | sample=03437595_T | sample=03437691_T | sample=03439543_T | sample=03441358_T | sample=03441740_T | sample=03444255_T | sample=03448110_T | sample=03448110B_T | sample=03450728_T | sample=03451592_T | sample=03460111_T | sample=03461078_T | sample=03461404_T | sample=03463522_T | sample=03463812_T | sample=03465304_T | sample=03466950_T | sample=03468400_T | sample=03471616_T | sample=03473067_T | sample=03473405_T | sample=03474525_T | sample=03476542_T | sample=03477889_T | sample=03479212_T | sample=03480779_T | sample=03484270_T | sample=03484586_T | sample=03486876_T | sample=03495697_T | sample=03497265_T | sample=03504050_T | sample=03506280_T | sample=03512529_T | sample=03513138_T | sample=03513467_T | sample=03514945_T | sample=03522254_T | sample=03523498_T | sample=03525342_T | sample=03822538_T | sample=81668782_T | sample=88295267_T | sample=88375506_T | sample=E07733_T | sample=E08021_T | sample=E09137_T | sample=E09137B_T | sample=E09138_T | sample=E09139_T | sample=E09151_T | sample=E09167_T | sample=E09192_T | sample=E09212_T | sample=E09214_T | sample=E09231_T | sample=E09233_T | sample=E09238_T | sample=E09239_T | sample=E09262_T | sample=E09263_T | sample=E09263B_T | sample=E09264_T | sample=E09278_T | sample=E09278B_T | sample=E09289_T | sample=E09296_T | sample=E09331_T | sample=E09334_T | sample=E09348_T | sample=E09358_T | sample=E09369_T | sample=E09378_T | sample=E09393_T | sample=E09394_T | sample=E09398_T | sample=E09405_T | sample=E09408_T | sample=E09419_T | sample=E09430_T | sample=E09440_T | sample=E09448_T | sample=E09449_T | sample=E09451_T | sample=E09454_T | sample=E09471_T | sample=E09478_T | sample=E09483_T | sample=E09489_T | sample=E09494_T | sample=E09495_T | sample=E09503_T | sample=E09511_T | sample=E09513_T | sample=E09515_T | sample=E09531_T | sample=E09535_T | sample=E09542_T | sample=E09546_T | sample=E09569_T | sample=E09587_T | sample=E09595_T | sample=E09601_T | sample=E09602_T | sample=E09605_T | sample=E09606_T | sample=E09610_T | sample=E09611B_T | sample=E09615_T | sample=E09622_T | sample=E09623_T | sample=E09624_T | sample=E09629_T | sample=E09641_T | sample=E09644_T | sample=E09645_T | sample=E09647_T | sample=E09649_T | sample=E09654_T | sample=E09655_T | sample=E09656_T | sample=E09657_T | sample=E09661_T | sample=E09664_T | sample=E09670_T | sample=E09673_T | sample=E09680_T | sample=E09681_T | sample=E09688_T | sample=E09690_T | sample=E09698_T | sample=E09699_T | sample=E09704_T | sample=E09708_T | sample=E09722_T | sample=E09730_T | sample=E09740_T | sample=E09742_T | sample=E09743_T | sample=E09744_T | sample=E09752_T | sample=E09755_T | sample=E09756_T | sample=E09759_T | sample=E09770_T | sample=E09774_T | sample=E09782_T | sample=E09786_T | sample=E09787_T | sample=E09791_T | sample=E09797_T | sample=E09800_T | sample=E09801_T | sample=E09802_T | sample=E09804_T | sample=E09810_T | sample=E09811_T | sample=E09818_T | sample=E09819_T | sample=E09825_T | sample=E09826_T | sample=E09829_T | sample=E09832_T | sample=E09833_T | sample=E09833B_T | sample=E09842_T | sample=E09846_T | sample=E09847_T | sample=E09848_T | sample=E09852_T | sample=E09855_T | sample=E09857_T | sample=E09858_T | sample=E09860_T | sample=E09862_T | sample=E09867_T | sample=E09868_T | sample=E09885_T | sample=E09888_T | sample=E09890_T | sample=E09892_T | sample=E09893_T | sample=E09894_T | sample=E09899_T | sample=E09900_T | sample=E09906_T | sample=E09907_T | sample=E09907B_T | sample=E09910_T | sample=E09914_T | sample=E09916_T | sample=E09917_T | sample=E09920_T | sample=E09921_T | sample=E09922_T | sample=E09923_T | sample=E09924_T | sample=E09928_T | sample=E09930_T | sample=E09935_T | sample=E09937_T | sample=E09938_T | sample=E09945_T | sample=E09948_T | sample=E09949_T | sample=E09951_T | sample=E09955_T | sample=E09956_T | sample=E09958_T | sample=E09959_T | sample=E09960_T | sample=E09963_T | sample=E09964_T | sample=E09965_T | sample=E09966_T | sample=E09967_T | sample=E09971_T | sample=E09975_T | sample=E09978_T | sample=E09982_T | sample=E09985_T | sample=E09988_T | sample=E09989_T | sample=E09990_T | sample=E09993_T | sample=E09996_T | sample=E09997_T | sample=E09998_T | sample=E10001_T | sample=E10002_T | sample=E10003_T | sample=E10008_T | sample=E10011_T | sample=E10012_T | sample=E10013_T | sample=E10016_T | sample=E10019_T | sample=E10021_T | sample=E10022_T | sample=E10023_T | sample=E10024_T | sample=E10025_T | sample=E10026_T | sample=E10027_T | sample=E10029_T | sample=E10030_T | sample=E10031_T | sample=E10036_T | sample=E10037_T | sample=E10038_T | sample=E10041_T | sample=E10044_T | sample=E10054_T | sample=E10058_T | sample=E10059_T | sample=E10062_T | sample=E10067_T | sample=E10072_T | sample=E10076_T | sample=E10077_T | sample=E10080_T | sample=E10097_T | sample=E10102_T | sample=E10103_T | sample=E10105_T | sample=E10110_T | sample=E10136_T | sample=E10138_T | sample=E10140_T | sample=E10144_T | sample=E10158_T | sample=E10162_T | sample=E10163_T | sample=E10172_T | sample=E10182_T | sample=E10184_T | sample=E10191_T | sample=E10192_T | sample=E10193_T | sample=E10196_T | sample=E10203_T | sample=E10210_T | sample=E10211_T | sample=E10216_T | sample=E10226_T | sample=E10227_T | sample=E10235_T | sample=E10248_T | sample=E10249_T | sample=E10250_T | sample=E10252_T | sample=E10252B_T | sample=E10252C_NT | sample=E10252C_T | sample=E10253_T | sample=E10258_T | sample=E10262_T | sample=E10264_T | sample=E10265_T | sample=E10267_T | sample=E10271_T | sample=E10278_T | sample=E10284_T | sample=E10285_T | sample=E10286_T | sample=E10287_T | sample=E10290_T | sample=E10292_T | sample=E10299_T | sample=E10300_T | sample=E10305_T | sample=E10306_T | sample=E10312_T | sample=E10313_T | sample=E10318_T | sample=E10362_T | sample=E10433_T | sample=E10444_T | sample=E10462_T | sample=E10470_T | sample=E10476_T | sample=E10482_T | sample=E10483_T | sample=E10488_T | sample=E10494_T | sample=E10512_T | sample=E10514_T | sample=E10540_T | sample=E10551_T | sample=E10556_T | sample=E10595_T | sample=E10596_T | sample=E10615_T | sample=E10622_T | sample=E10645_T | sample=E10662_T | sample=E10662B_T | sample=E10690_T | sample=E10691_T | sample=E10692_T | sample=E10710_T | sample=E50057_T | sample=E50074_T | sample=E50091_T | sample=E50123_T | sample=HF0017_T | sample=HF0022_T | sample=HF0024_T | sample=HF0026_T | sample=HF0031_T | sample=HF0048_T | sample=HF0050_T | sample=HF0066_T | sample=HF0087_T | sample=HF0088_T | sample=HF0089_T | sample=HF0108_T | sample=HF0120_T | sample=HF0131_T | sample=HF0137_T | sample=HF0138_T | sample=HF0142_T | sample=HF0151_T | sample=HF0152_T | sample=HF0163_T | sample=HF0171_T | sample=HF0178_T | sample=HF0180_T | sample=HF0183_T | sample=HF0184_T | sample=HF0211_T | sample=HF0212_T | sample=HF0218_T | sample=HF0223_T | sample=HF0232_T | sample=HF0244_T | sample=HF0251_T | sample=HF0252_T | sample=HF0268_T | sample=HF0285_T | sample=HF0291_T | sample=HF0295_T | sample=HF0300.3_T | sample=HF0303_T | sample=HF0305_T | sample=HF0316_T | sample=HF0327_T | sample=HF0329_T | sample=HF0332_T | sample=HF0377_T | sample=HF0383_T | sample=HF0408_T | sample=HF0434_T | sample=HF0435_T | sample=HF0442.5_T | sample=HF0445_T | sample=HF0450_T | sample=HF0460_T | sample=HF0467_T | sample=HF0488_T | sample=HF0491_T | sample=HF0505_T | sample=HF0510_T | sample=HF0512_T | sample=HF0520_T | sample=HF0523_T | sample=HF0526_T | sample=HF0533_T | sample=HF0543_T | sample=HF0583_T | sample=HF0593_T | sample=HF0599_T | sample=HF0606_T | sample=HF0608_T | sample=HF0616_T | sample=HF0627_T | sample=HF0639_T | sample=HF0654_T | sample=HF0670_T | sample=HF0702_T | sample=HF0726_T | sample=HF0757_T | sample=HF0778_T | sample=HF0790_T | sample=HF0802_T | sample=HF0816_T | sample=HF0822_T | sample=HF0828_T | sample=HF0835_T | sample=HF0844_T | sample=HF0850_T | sample=HF0855_T | sample=HF0891_T | sample=HF0894_T | sample=HF0897_T | sample=HF0899_T | sample=HF0914_T | sample=HF0920_T | sample=HF0931_T | sample=HF0936_T | sample=HF0953_T | sample=HF0954.2_T | sample=HF0960_T | sample=HF0962_T | sample=HF0963_T | sample=HF0966_T | sample=HF0975_T | sample=HF0982_T | sample=HF0986_T | sample=HF0990_T | sample=HF0992_T | sample=HF0996_T | sample=HF1000_T | sample=HF1032_T | sample=HF1057_T | sample=HF1058_T | sample=HF1077_T | sample=HF1078_T | sample=HF1090_T | sample=HF1097_T | sample=HF1122_T | sample=HF1136_T | sample=HF1137_T | sample=HF1139_T | sample=HF1150_T | sample=HF1156_T | sample=HF1167_T | sample=HF1178_T | sample=HF1185_T | sample=HF1186_T | sample=HF1191_T | sample=HF1220_T | sample=HF1227_T | sample=HF1232_T | sample=HF1235_T | sample=HF1242_T | sample=HF1246_T | sample=HF1255_T | sample=HF1262_T | sample=HF1269_T | sample=HF1280_T | sample=HF1286_T | sample=HF1292_T | sample=HF1295_T | sample=HF1297_T | sample=HF1316_T | sample=HF1318_T | sample=HF1319_T | sample=HF1325_T | sample=HF1334_T | sample=HF1338_T | sample=HF1344_T | sample=HF1345_T | sample=HF1356_T | sample=HF1357_T | sample=HF1366_T | sample=HF1380_T | sample=HF1381_T | sample=HF1382_T | sample=HF1397_T | sample=HF1407_T | sample=HF1409_T | sample=HF1442_T | sample=HF1458_T | sample=HF1469_T | sample=HF1475_T | sample=HF1487_T | sample=HF1489_T | sample=HF1490_T | sample=HF1492_T | sample=HF1493_T | sample=HF1494_T | sample=HF1502_T | sample=HF1509_T | sample=HF1511_T | sample=HF1517_T | sample=HF1534_T | sample=HF1538_T | sample=HF1540_T | sample=HF1551_T | sample=HF1568_T | sample=HF1581_T | sample=HF1585_T | sample=HF1587_T | sample=HF1588_T | sample=HF1589_T | sample=HF1606_T | sample=HF1608_T | sample=HF1613_T | sample=HF1618_T | sample=HF1628_T | sample=HF1640_T | sample=HF1667_T | sample=HF1671_T | sample=HF1677_T | sample=HF1702_T | sample=HF1708_T | sample=MD508984_T | sample=MD545226_T | sample=MD547038_T | sample=MD548092_T | sample=MD548457_T | sample=MD549279_T | sample=MD550239_T | sample=MD550715_T | sample=MD552910_T | sample=MD554082_T | sample=MD570013_T | sample=MD602958_T | sample=MD607103_T | sample=MD607216_T | sample=MD608660_T | sample=MD621233_T | sample=NT1_T | sample=NT2_T | sample=NT3_T | sample=NT4_T | sample=NT5_T | sample=NT6_T | sample=NT7_T | tumor grading=-- | tumor grading=Grade 1 | tumor grading=Grade 2 | tumor grading=Grade 3 | tumor grading=Grade 4","tissue type=PT (peritumoral tissue surrounding the tumor mass) | tissue type=TM (tumor mass)","drug treatment=Metronomic cyclophosphamide, 6 days after 2 cycles | drug treatment=Metronomic cyclophosphamide, 6 days after 3 cycles | drug treatment=Untreated control","drug treatment=Metronomic cyclophosphamide, 6 days after 2 cycles | drug treatment=Metronomic cyclophosphamide, 6 days after 3 cycles | drug treatment=Untreated control","NA","transfection=pLKO 1.0- shFoxm1 | transfection=pLKO 1.0- shFoxm1+ EZH2 Overexpression vector | transfection=pLKO 1.0- shMELK | transfection=pLKO 1.0- shMELK+EZH2 overexpression vector | transfection=pLKO 1.0- shNon-targeting vector","transfected with=empty vector (V0) | transfected with=vectors coding for Flag-p50 | transfected with=vectors coding for Myc-KPC1","cell line=AO | cell line=Da | cell line=GBM-E2 | cell line=GBM-E3 | cell line=GBM-E6 | cell line=NSC | cell line=U251 | cell line=U87 | cell type=glioma cell lines | cell type=glioma-initiating cells (GICs) diffuse astrocytoma | cell type=glioma-initiating cells (GICs) from anaplastic oligodendroglioma | cell type=glioma-initiating cells (GICs) from glioblastomas | cell type=neural stem cell","cell line=AO | cell line=Da | cell line=GBM-E2 | cell line=GBM-E2-miR340 | cell line=GBM-E3 | cell line=GBM-E3-miR340 | cell line=GBM-E5-miR340 | cell line=GBM-E6 | cell line=U251 | cell line=U251-miR340 | cell line=U87 | cell type=glioma cell lines | cell type=glioma-initiating cells (GICs) diffuse astrocytoma | cell type=glioma-initiating cells (GICs) from anaplastic oligodendroglioma | cell type=glioma-initiating cells (GICs) from glioblastomas | cell type=miR340 overexpressed glioma cell lines | cell type=miR340 overexpressed glioma-initiating cells (GICs)","age at study entry, in yrs=22 | age at study entry, in yrs=23 | age at study entry, in yrs=25 | age at study entry, in yrs=26 | age at study entry, in yrs=28 | age at study entry, in yrs=29 | age at study entry, in yrs=32 | age at study entry, in yrs=35 | age at study entry, in yrs=38 | age at study entry, in yrs=39 | age at study entry, in yrs=40 | age at study entry, in yrs=42 | age at study entry, in yrs=43 | age at study entry, in yrs=44 | age at study entry, in yrs=45 | age at study entry, in yrs=46 | age at study entry, in yrs=47 | age at study entry, in yrs=48 | age at study entry, in yrs=49 | age at study entry, in yrs=50 | age at study entry, in yrs=51 | age at study entry, in yrs=52 | age at study entry, in yrs=53 | age at study entry, in yrs=54 | age at study entry, in yrs=55 | age at study entry, in yrs=56 | age at study entry, in yrs=57 | age at study entry, in yrs=58 | age at study entry, in yrs=59 | age at study entry, in yrs=60 | age at study entry, in yrs=61 | age at study entry, in yrs=62 | age at study entry, in yrs=63 | age at study entry, in yrs=64 | age at study entry, in yrs=65 | age at study entry, in yrs=66 | age at study entry, in yrs=67 | age at study entry, in yrs=68 | age at study entry, in yrs=71 | age at study entry, in yrs=72 | age at study entry, in yrs=75 | age at study entry, in yrs=77 | age at study entry, in yrs=78 | age at study entry, in yrs=80 | alcohol drinks per week=0 | alcohol drinks per week=1 | alcohol drinks per week=16 | alcohol drinks per week=2 | alcohol drinks per week=3 | alcohol drinks per week=4 | alcohol drinks per week=5 | alcohol drinks per week=6 | alcohol drinks per week=8 | education=0 | education=1 | education=2 | education=3 | education=4 | education=5 | education=6 | education=NA | ethnicity=Caucasian | ethnicity=Non-Caucasian | exercise min per wk of brisk physical activity=0 | exercise min per wk of brisk physical activity=10 | exercise min per wk of brisk physical activity=105 | exercise min per wk of brisk physical activity=120 | exercise min per wk of brisk physical activity=135 | exercise min per wk of brisk physical activity=150 | exercise min per wk of brisk physical activity=160 | exercise min per wk of brisk physical activity=165 | exercise min per wk of brisk physical activity=180 | exercise min per wk of brisk physical activity=188 | exercise min per wk of brisk physical activity=200 | exercise min per wk of brisk physical activity=240 | exercise min per wk of brisk physical activity=270 | exercise min per wk of brisk physical activity=280 | exercise min per wk of brisk physical activity=30 | exercise min per wk of brisk physical activity=300 | exercise min per wk of brisk physical activity=315 | exercise min per wk of brisk physical activity=360 | exercise min per wk of brisk physical activity=40 | exercise min per wk of brisk physical activity=420 | exercise min per wk of brisk physical activity=450 | exercise min per wk of brisk physical activity=495 | exercise min per wk of brisk physical activity=540 | exercise min per wk of brisk physical activity=60 | exercise min per wk of brisk physical activity=600 | exercise min per wk of brisk physical activity=630 | exercise min per wk of brisk physical activity=840 | participant id=CG-001 | participant id=CG-002 | participant id=CG-003 | participant id=CG-004 | participant id=CG-005 | participant id=CG-006 | participant id=CG-007 | participant id=CG-008 | participant id=CG-009 | participant id=CG-010 | participant id=CG-011 | participant id=CG-012 | participant id=CG-013 | participant id=CG-014 | participant id=CG-015 | participant id=CG-016 | participant id=CG-017 | participant id=CG-018 | participant id=CG-019 | participant id=CG-020 | participant id=CG-021 | participant id=CG-022 | participant id=CG-024 | participant id=CG-025 | participant id=CG-026 | participant id=CG-027 | participant id=CG-028 | participant id=CG-029 | participant id=CG-030 | participant id=CG-031 | participant id=CG-032 | participant id=CG-033 | participant id=CG-034 | participant id=CG-601 | participant id=CG-602 | participant id=CG-603 | participant id=CG-604 | participant id=CG-605 | participant id=CG-606 | participant id=CG-607 | participant id=CG-608 | participant id=CG-609 | participant id=CG-610 | participant id=CG-611 | participant id=CG-612 | participant id=CG-613 | participant id=CG-614 | participant id=CG-615 | participant id=CG-616 | participant id=CG-617 | participant id=CG-618 | participant id=CG-619 | participant id=CG-620 | participant id=CG-621 | participant id=CG-622 | participant id=CG-623 | participant id=CG-624 | participant id=CG-625 | participant id=CG-626 | participant id=CG-627 | participant id=CG-628 | participant id=CG-629 | participant id=CG-630 | participant id=CG-631 | participant id=CG-632 | participant id=CG-633 | participant id=CG-634 | participant id=CG-635 | participant id=CG-636 | participant id=CG-637 | participant id=CG-638 | participant id=CG-639 | participant id=CG-640 | participant id=CG-641 | participant id=CG-642 | participant id=CG-643 | participant id=CG-644 | participant id=CG-645 | participant id=CG-646 | participant id=CG-647 | sample group=caregiver group | sample group=non-stressed control group | sex=female | sex=male | smoke=daily smoker | smoke=non-smoker | study visit range 1-4 in 6-mo intervals=1 | study visit range 1-4 in 6-mo intervals=2 | study visit range 1-4 in 6-mo intervals=3 | study visit range 1-4 in 6-mo intervals=4 | waistcm waist circumfrence in cm=100.3 | waistcm waist circumfrence in cm=100.5 | waistcm waist circumfrence in cm=101.5 | waistcm waist circumfrence in cm=103 | waistcm waist circumfrence in cm=104 | waistcm waist circumfrence in cm=106 | waistcm waist circumfrence in cm=107 | waistcm waist circumfrence in cm=108 | waistcm waist circumfrence in cm=108.5 | waistcm waist circumfrence in cm=109 | waistcm waist circumfrence in cm=110 | waistcm waist circumfrence in cm=110.5 | waistcm waist circumfrence in cm=111 | waistcm waist circumfrence in cm=112 | waistcm waist circumfrence in cm=112.2 | waistcm waist circumfrence in cm=118.5 | waistcm waist circumfrence in cm=124 | waistcm waist circumfrence in cm=66 | waistcm waist circumfrence in cm=68 | waistcm waist circumfrence in cm=69 | waistcm waist circumfrence in cm=69.9 | waistcm waist circumfrence in cm=70 | waistcm waist circumfrence in cm=70.5 | waistcm waist circumfrence in cm=71.5 | waistcm waist circumfrence in cm=72 | waistcm waist circumfrence in cm=73 | waistcm waist circumfrence in cm=75 | waistcm waist circumfrence in cm=75.2 | waistcm waist circumfrence in cm=76 | waistcm waist circumfrence in cm=77 | waistcm waist circumfrence in cm=78 | waistcm waist circumfrence in cm=78.5 | waistcm waist circumfrence in cm=79.5 | waistcm waist circumfrence in cm=80 | waistcm waist circumfrence in cm=81 | waistcm waist circumfrence in cm=82 | waistcm waist circumfrence in cm=82.5 | waistcm waist circumfrence in cm=82.8 | waistcm waist circumfrence in cm=83 | waistcm waist circumfrence in cm=84 | waistcm waist circumfrence in cm=84.5 | waistcm waist circumfrence in cm=85 | waistcm waist circumfrence in cm=88.5 | waistcm waist circumfrence in cm=89 | waistcm waist circumfrence in cm=91 | waistcm waist circumfrence in cm=91.5 | waistcm waist circumfrence in cm=92 | waistcm waist circumfrence in cm=92.5 | waistcm waist circumfrence in cm=92.7 | waistcm waist circumfrence in cm=93 | waistcm waist circumfrence in cm=93.5 | waistcm waist circumfrence in cm=94 | waistcm waist circumfrence in cm=95 | waistcm waist circumfrence in cm=95.2 | waistcm waist circumfrence in cm=95.5 | waistcm waist circumfrence in cm=97 | waistcm waist circumfrence in cm=99","cell line=HeLa | cell line=T98G | cell type=adenocarcinoma | cell type=Glioblastoma | chip antibody=DYRK1A antibody (ab69811) | chip antibody=rabbit IgG (sc-2027) | chip antibody vendor=Abcam | chip antibody vendor=Santa Cruz Biotechnology | tissue origin=brain | tissue origin=cervix","transfected with=: ADAR1E912A | transfected with=ADAR1 overexpression vector | transfected with=ADAR1 RNA binding mutant (EAA) | transfected with=ADAR1 siRNA | transfected with=control siRNA | transfected with=control vector (pcDNA4)","compound=cisplatin | compound=none | compound=ruthenium-based compound | time=0 hour | time=24 hour | time=6 hour","culture condition=culture in stem cell medium | culture condition=culture under differentiated conditions for 1 day | culture condition=culture under differentiated conditions for 3 day | culture condition=culture under differentiated conditions for 7 day","treated with=Doxocyclin (to express WIF1) for 48hr | treated with=none (control)","biospecimen=blood | biospecimen=not specified | biospecimen=saliva | cohort=Utah1 | cohort=Utah2 | cohort=WashU | sample source=HCI_CONTROL | sample source=NYU | sample source=TOR | sample source=UT | sample source=WU | tumor=CTRL | tumor=NT | tumor=T","NA","phenotype=control | phenotype=MITF-RFP-HA overexpression","phenotype=control | phenotype=TEN1-ICD-GFP-His overexpression","cell line=GBML18 | cell line=hTERT/E6/E7 | cell line=U251 | cell line=U87MG | phenotype=control | phenotype=MSCV-HOXA9 | RNA interference=control | RNA interference=shHOXA9","epidermal growth factor receptor amplification status=amplified | epidermal growth factor receptor amplification status=no amplification | epidermal growth factor receptor amplification status=pre-amplification | tumor infiltration pattern=diffuse | tumor infiltration pattern=no borders | tumor infiltration pattern=nodular","irradiate=irradiated | irradiate=non irradiated","age=26 | age=27 | age=32 | age=36 | age=37 | age=41 | age=43 | age=44 | age=45 | age=48 | age=49 | age=50 | age=51 | age=52 | age=53 | age=54 | age=55 | age=56 | age=57 | age=58 | age=59 | age=60 | age=61 | age=62 | age=63 | age=64 | age=65 | age=68 | age=NA | age=not specified | clinical trial phase=II | clinical trial phase=III | clinical trial phase=NA | clinical trial phase=not specified | geo_sample_id=GSM187153 | geo_sample_id=GSM187155 | geo_sample_id=GSM187157 | geo_sample_id=GSM187159 | geo_sample_id=GSM187160 | geo_sample_id=GSM187161 | geo_sample_id=GSM187162 | geo_sample_id=GSM187163 | geo_sample_id=GSM187164 | geo_sample_id=GSM187165 | geo_sample_id=GSM187166 | geo_sample_id=GSM187167 | geo_sample_id=GSM187169 | geo_sample_id=GSM187171 | geo_sample_id=GSM187172 | geo_sample_id=GSM187175 | geo_sample_id=GSM187176 | geo_sample_id=GSM187177 | geo_sample_id=GSM187178 | geo_sample_id=GSM187179 | geo_sample_id=GSM187185 | geo_sample_id=GSM187188 | geo_sample_id=GSM187189 | geo_sample_id=GSM187190 | geo_sample_id=GSM187191 | geo_sample_id=GSM187192 | geo_sample_id=GSM187194 | geo_sample_id=GSM187195 | geo_sample_id=GSM187196 | geo_sample_id=GSM187197 | geo_sample_id=GSM187200 | geo_sample_id=GSM187201 | geo_sample_id=GSM187202 | geo_sample_id=GSM187203 | geo_sample_id=GSM187205 | geo_sample_id=GSM187206 | geo_sample_id=GSM187207 | geo_sample_id=GSM187208 | geo_sample_id=GSM187209 | geo_sample_id=GSM187210 | geo_sample_id=GSM187211 | geo_sample_id=GSM187212 | geo_sample_id=GSM187213 | geo_sample_id=GSM187214 | geo_sample_id=GSM187217 | geo_sample_id=GSM187218 | geo_sample_id=GSM187219 | geo_sample_id=GSM187220 | geo_sample_id=GSM187221 | geo_sample_id=GSM187222 | geo_sample_id=GSM187223 | geo_sample_id=GSM187224 | geo_sample_id=GSM187225 | geo_sample_id=GSM187229 | geo_sample_id=GSM187230 | geo_sample_id=GSM187231 | geo_sample_id=GSM187233 | geo_sample_id=GSM187234 | geo_sample_id=GSM187236 | geo_sample_id=NA | geo_sample_id=not specified | methylation_geo_id=GSM1468969 | methylation_geo_id=GSM1468970 | methylation_geo_id=GSM1468971 | methylation_geo_id=GSM1468972 | methylation_geo_id=GSM1468973 | methylation_geo_id=GSM1468974 | methylation_geo_id=GSM1468975 | methylation_geo_id=GSM1468976 | methylation_geo_id=GSM1468977 | methylation_geo_id=GSM1468978 | methylation_geo_id=GSM1468979 | methylation_geo_id=GSM1468980 | methylation_geo_id=GSM1468981 | methylation_geo_id=GSM1468982 | methylation_geo_id=GSM1468983 | methylation_geo_id=GSM1468984 | methylation_geo_id=GSM1468985 | methylation_geo_id=GSM1468986 | methylation_geo_id=GSM1468987 | methylation_geo_id=GSM1468988 | methylation_geo_id=GSM1468989 | methylation_geo_id=GSM1468990 | methylation_geo_id=GSM1468991 | methylation_geo_id=GSM1468992 | methylation_geo_id=GSM1468993 | methylation_geo_id=GSM1468994 | methylation_geo_id=GSM1468995 | methylation_geo_id=GSM1468996 | methylation_geo_id=GSM1468997 | methylation_geo_id=GSM1468998 | methylation_geo_id=GSM1468999 | methylation_geo_id=GSM1469000 | methylation_geo_id=GSM1469001 | methylation_geo_id=GSM1469002 | methylation_geo_id=GSM1469003 | methylation_geo_id=GSM1469004 | methylation_geo_id=GSM1469005 | methylation_geo_id=GSM1469006 | methylation_geo_id=GSM1469007 | methylation_geo_id=GSM1469008 | methylation_geo_id=GSM1469009 | methylation_geo_id=GSM1469010 | methylation_geo_id=GSM1469011 | methylation_geo_id=GSM1469012 | methylation_geo_id=GSM1469013 | methylation_geo_id=GSM1469014 | methylation_geo_id=GSM1469015 | methylation_geo_id=GSM1469016 | methylation_geo_id=GSM1469017 | methylation_geo_id=GSM1469018 | methylation_geo_id=GSM1469019 | methylation_geo_id=GSM1469020 | methylation_geo_id=GSM1469021 | methylation_geo_id=GSM1469022 | methylation_geo_id=GSM1469023 | methylation_geo_id=GSM1469024 | methylation_geo_id=GSM1469025 | methylation_geo_id=GSM1469026 | methylation_geo_id=GSM1469027 | methylation_geo_id=GSM1469028 | methylation_geo_id=GSM1469029 | methylation_geo_id=GSM1469030 | methylation_geo_id=GSM1469031 | methylation_geo_id=GSM1469032 | methylation_geo_id=not specified | mgmt_status=M | mgmt_status=NA | mgmt_status=not specified | mgmt_status=U | os=1.45 | os=10.45 | os=10.62 | os=11.38 | os=11.87 | os=12.36 | os=14.37 | os=14.43 | os=14.5 | os=14.76 | os=15 | os=15.09 | os=15.65 | os=15.68 | os=16 | os=16.01 | os=16.31 | os=16.41 | os=17 | os=17.39 | os=23 | os=23.05 | os=24.1 | os=24.26 | os=25 | os=26.76 | os=27 | os=28 | os=3.78 | os=3.81 | os=32.48 | os=36 | os=4.47 | os=41.19 | os=43.59 | os=5.33 | os=5.59 | os=5.65 | os=5.75 | os=5.98 | os=6.48 | os=6.97 | os=60 | os=7.53 | os=76.5 | os=8.09 | os=8.61 | os=8.78 | os=8.94 | os=9 | os=9.21 | os=9.37 | os=9.73 | os=NA | os=not specified | sex=female | sex=male | sex=not specified | survival_status=0 | survival_status=1 | survival_status=NA | survival_status=not specified","age=26 | age=27 | age=32 | age=34 | age=36 | age=37 | age=41 | age=42 | age=43 | age=44 | age=45 | age=48 | age=49 | age=50 | age=51 | age=52 | age=53 | age=54 | age=55 | age=56 | age=57 | age=58 | age=59 | age=60 | age=61 | age=62 | age=63 | age=64 | age=65 | age=68 | age=69 | age=70 | age=79 | age=NA | disease state=GBM | disease state=Non-tumor brain | geo expression data=GSM187153 | geo expression data=GSM187155 | geo expression data=GSM187157 | geo expression data=GSM187159 | geo expression data=GSM187160 | geo expression data=GSM187161 | geo expression data=GSM187162 | geo expression data=GSM187163 | geo expression data=GSM187164 | geo expression data=GSM187165 | geo expression data=GSM187166 | geo expression data=GSM187167 | geo expression data=GSM187169 | geo expression data=GSM187171 | geo expression data=GSM187172 | geo expression data=GSM187175 | geo expression data=GSM187176 | geo expression data=GSM187177 | geo expression data=GSM187178 | geo expression data=GSM187179 | geo expression data=GSM187185 | geo expression data=GSM187188 | geo expression data=GSM187189 | geo expression data=GSM187190 | geo expression data=GSM187191 | geo expression data=GSM187192 | geo expression data=GSM187194 | geo expression data=GSM187195 | geo expression data=GSM187196 | geo expression data=GSM187197 | geo expression data=GSM187200 | geo expression data=GSM187201 | geo expression data=GSM187202 | geo expression data=GSM187203 | geo expression data=GSM187205 | geo expression data=GSM187206 | geo expression data=GSM187207 | geo expression data=GSM187208 | geo expression data=GSM187209 | geo expression data=GSM187210 | geo expression data=GSM187211 | geo expression data=GSM187212 | geo expression data=GSM187213 | geo expression data=GSM187214 | geo expression data=GSM187217 | geo expression data=GSM187218 | geo expression data=GSM187219 | geo expression data=GSM187220 | geo expression data=GSM187221 | geo expression data=GSM187222 | geo expression data=GSM187223 | geo expression data=GSM187224 | geo expression data=GSM187225 | geo expression data=GSM187229 | geo expression data=GSM187230 | geo expression data=GSM187231 | geo expression data=GSM187233 | geo expression data=GSM187234 | geo expression data=GSM187236 | geo expression data=NA | mgmt_status=M | mgmt_status=NA | mgmt_status=U | os=1.45 | os=10.45 | os=10.62 | os=11.38 | os=11.87 | os=12.36 | os=13 | os=14.37 | os=14.43 | os=14.5 | os=14.76 | os=15 | os=15.09 | os=15.65 | os=15.68 | os=16 | os=16.01 | os=16.31 | os=16.41 | os=17 | os=17.39 | os=23 | os=23.05 | os=24.1 | os=24.26 | os=25 | os=26.76 | os=27 | os=28 | os=3.78 | os=3.81 | os=32.48 | os=35 | os=36 | os=4.47 | os=41.19 | os=43.59 | os=5.33 | os=5.59 | os=5.65 | os=5.75 | os=5.98 | os=52 | os=6.48 | os=6.97 | os=60 | os=7.53 | os=76.5 | os=8.09 | os=8.61 | os=8.78 | os=8.94 | os=9 | os=9.21 | os=9.37 | os=9.73 | os=NA | sex=female | sex=male | sex=U | survival_status=0 | survival_status=1 | survival_status=NA","sample type=blood | sample type=single cell derived culture | sample type=tumor derived from patient | sample type=unsorted tumor culture","phenotype=TMZ resistant | phenotype=TMZ sensitive","cell line=105KC | cell line=143B | cell line=23132/87 | cell line=501A | cell line=537 MEL | cell line=59M | cell line=624 mel | cell line=769-P | cell line=786-O | cell line=888 | cell line=928 mel | cell line=A-375 | cell line=A-427 | cell line=A-431 | cell line=A-498 | cell line=A-673 | cell line=A172 | cell line=A2058 | cell line=A2780 | cell line=A3/KAW | cell line=A4/Fuk | cell line=A549 | cell line=ABC-1 | cell line=ACHN | cell line=AGS | cell line=AMO-1 | cell line=AN3 CA | cell line=AsPC-1 | cell line=ATRFLOX | cell line=BEN | cell line=BFTC-905 | cell line=BFTC-909 | cell line=BHY | cell line=BICR 10 | cell line=BICR 22 | cell line=BICR 31 | cell line=BICR 78 | cell line=BJAB | cell line=BT-20 | cell line=BT-474 | cell line=BT-483 | cell line=BT-549 | cell line=BxPC-3 | cell line=C-33 A | cell line=C170 | cell line=C2BBe1 | cell line=C32 | cell line=C32TG | cell line=C3A | cell line=Ca Ski | cell line=CA46 | cell line=Caco-2 | cell line=Caki-1 | cell line=Caki-2 | cell line=CAL 27 | cell line=CAL 54 | cell line=CAL-120 | cell line=CAL-12T | cell line=CAL-148 | cell line=CAL-85-1 | cell line=CAL51 | cell line=Calu-1 | cell line=Calu-3 | cell line=Calu-6 | cell line=CAMA-1 | cell line=Caov-3 | cell line=Capan-1 | cell line=Capan-2 | cell line=CaR-1 | cell line=CCRF-SB | cell line=CFPAC-1 | cell line=ChaGo-K-1 | cell line=CHL-1 | cell line=CHP-212 | cell line=CI-1 | cell line=CL-11 | cell line=CL-34 | cell line=CL-40 | cell line=COLO 201 | cell line=COLO 205 | cell line=COLO 206F | cell line=COLO 320DM | cell line=COLO 678 | cell line=COLO 679 | cell line=COLO 680N | cell line=COLO 699 | cell line=COLO 741 | cell line=COLO 792 | cell line=COLO 794 | cell line=COLO 800 | cell line=COLO 829 | cell line=COLO 849 | cell line=COLO 853 | cell line=COLO 857 | cell line=COLO-704 | cell line=COLO-783 | cell line=COLO-818 | cell line=COR-L26 | cell line=COR-L279 | cell line=COR-L47 | cell line=COR-L88 | cell line=COV318 | cell line=COV362 | cell line=COV413A | cell line=COV413B | cell line=COV434 | cell line=COV504 | cell line=COV644 | cell line=CPC-N | cell line=CW-2 | cell line=CX-1 | cell line=DAN-G | cell line=Daudi | cell line=DB | cell line=DEOC-1 | cell line=Detroit 562 | cell line=DLD-1 | cell line=DMS 273 | cell line=DMS 454 | cell line=DMS 53 | cell line=DMS 79 | cell line=DOHH-2 | cell line=DOK | cell line=DOR 13 | cell line=DU 145 | cell line=DU4475 | cell line=DV-90 | cell line=EB-3 | cell line=EB1 | cell line=EB2 | cell line=EBC-1 | cell line=EFM-19 | cell line=EFM-192A | cell line=EFM-192B | cell line=EFM-192C | cell line=EFO-27 | cell line=EJM | cell line=EKVX | cell line=EPLC-272H | cell line=ES-2 | cell line=EVSA-T | cell line=FaDu | cell line=Farage | cell line=FU97 | cell line=G-361 | cell line=G-402 | cell line=G111 | cell line=G112 | cell line=G118 | cell line=G120 | cell line=G121 | cell line=G122 | cell line=G124 | cell line=G130 | cell line=G140 | cell line=G141 | cell line=G142 | cell line=G22 | cell line=G28T | cell line=G44 | cell line=G59 | cell line=G61 | cell line=G84 | cell line=G96 | cell line=GA-10 | cell line=GP2d | cell line=GP5d | cell line=GR-M | cell line=GRANTA-519 | cell line=GTL-16 | cell line=H322T | cell line=HBL-100 | cell line=HCA-7 | cell line=HCC-15 | cell line=HCC1011 | cell line=HCC1143 | cell line=HCC1162 | cell line=HCC1171 | cell line=HCC1187 | cell line=HCC12 | cell line=HCC1263 | cell line=HCC1319 | cell line=HCC1359 | cell line=HCC1395 | cell line=HCC1419 | cell line=HCC1428 | cell line=HCC1482 | cell line=HCC1493 | cell line=HCC1500 | cell line=HCC1534 | cell line=HCC1569 | cell line=HCC1576 | cell line=HCC1599 | cell line=HCC1806 | cell line=HCC193 | cell line=HCC1937 | cell line=HCC1954 | cell line=HCC202 | cell line=HCC2157 | cell line=HCC2218 | cell line=HCC2270 | cell line=HCC2279 | cell line=HCC2302 | cell line=HCC2688 | cell line=HCC2885 | cell line=HCC2911 | cell line=HCC2935 | cell line=HCC33 | cell line=HCC364 | cell line=HCC366 | cell line=HCC38 | cell line=HCC4006 | cell line=HCC4011 | cell line=HCC4017 | cell line=HCC44 | cell line=HCC461 | cell line=HCC515 | cell line=HCC60 | cell line=HCC630 | cell line=HCC70 | cell line=HCC78 | cell line=HCC827 | cell line=HCC89 | cell line=HCT 116 | cell line=HCT-15 | cell line=HCT-8 | cell line=HEC-1-A | cell line=HEL | cell line=HeLa | cell line=Hep G2 | cell line=HEp-2 | cell line=HEY | cell line=HGC-27 | cell line=HL-60 | cell line=HM7 | cell line=HMY-1 | cell line=HN | cell line=HNT-34 | cell line=HOP-62 | cell line=HOP-92 | cell line=HPAC | cell line=HPAF-II | cell line=Hs 255.T | cell line=Hs 294T | cell line=Hs 38.T | cell line=Hs 578T | cell line=Hs 675.T | cell line=Hs 683 | cell line=Hs 695T | cell line=Hs 69ST | cell line=Hs 746T | cell line=Hs 766T | cell line=Hs 839.T | cell line=Hs 852.T | cell line=Hs 895.T | cell line=Hs 936.T | cell line=Hs 940.T | cell line=HS-Sultan | cell line=HT | cell line=HT-1080 | cell line=HT-115 | cell line=HT-144 | cell line=HT-29 | cell line=HT-55 | cell line=huH-1 | cell line=HuH-7 | cell line=HUP-T3 | cell line=HUP-T4 | cell line=IGR-37 | cell line=IGROV-1 | cell line=IM-95 | cell line=IM-95m | cell line=IMR-32 | cell line=IPC-298 | cell line=JEKO-1 | cell line=JHH-1 | cell line=JHH-2 | cell line=JHH-4 | cell line=JHH-5 | cell line=JHH-7 | cell line=JIMT-1 | cell line=Jiyoye | cell line=JJ012 | cell line=JJN-3 | cell line=JL-1 | cell line=Jurkat, Clone E6-1 | cell line=K-562 | cell line=KARPAS-1106P | cell line=KARPAS-422 | cell line=KARPAS-620 | cell line=Kasumi-1 | cell line=KATO III | cell line=KCI-MOH1 | cell line=KELLY | cell line=KG-1 | cell line=KHM-1B | cell line=KLE | cell line=KLM-1 | cell line=KM-12 | cell line=KMM-1 | cell line=KMS-11 | cell line=KMS-12-BM | cell line=KMS-12-PE | cell line=KMS-21BM | cell line=KMS-26 | cell line=KMS-27 | cell line=KMS-28BM | cell line=KMS-28PE | cell line=KMS-34 | cell line=KNS-62 | cell line=KP-2 | cell line=KP-3 | cell line=KP4 | cell line=KPL-1 | cell line=KPL-4 | cell line=KU812 | cell line=KURAMOCHI | cell line=KYSE-140 | cell line=KYSE-150 | cell line=KYSE-180 | cell line=KYSE-270 | cell line=KYSE-30 | cell line=KYSE-450 | cell line=KYSE-510 | cell line=KYSE-520 | cell line=KYSE-70 | cell line=L-363 | cell line=LCLC-103H | cell line=LCLC-97TM1 | cell line=LN-18 | cell line=LN-229 | cell line=LNCAP | cell line=LOU-NH91 | cell line=LoVo | cell line=LOX-IMVI | cell line=LP-1 | cell line=LS 174T | cell line=LS 180 | cell line=LS1034 | cell line=LXF-289 | cell line=LXFL529 | cell line=M059J | cell line=M059K | cell line=MC116 | cell line=MCAS | cell line=MCF 10A | cell line=MCF-7 | cell line=MCF10DCIS.com | cell line=MDA-MB-134-VI | cell line=MDA-MB-157 | cell line=MDA-MB-175-VII | cell line=MDA-MB-231 | cell line=MDA-MB-330 | cell line=MDA-MB-361 | cell line=MDA-MB-415 | cell line=MDA-MB-435 | cell line=MDA-MB-436 | cell line=MDA-MB-453 | cell line=MDA-MB-468 | cell line=MDST8 | cell line=ME-1 | cell line=ME-180 | cell line=MEL-HO | cell line=MeWo | cell line=MFM-223 | cell line=MG-63 | cell line=MHH-ES-1 | cell line=MHH-NB-11 | cell line=MHH-PREB-1 | cell line=MIA Paca-2 | cell line=MKN-1 | cell line=MKN-45 | cell line=MKN-7 | cell line=MKN-74 | cell line=ML-2 | cell line=MM.1S | cell line=MOLM-16 | cell line=MOLP-2 | cell line=MOLP-8 | cell line=MOR | cell line=MS751 | cell line=MT-3 | cell line=MV-4-11 | cell line=MX-1 | cell line=NALM-6 | cell line=NAMALWA | cell line=NCI-H1048 | cell line=NCI-H1092 | cell line=NCI-H1155 | cell line=NCI-H1299 | cell line=NCI-H1355 | cell line=NCI-H1373 | cell line=NCI-H1395 | cell line=NCI-H1435 | cell line=NCI-H1437 | cell line=NCI-H146 | cell line=NCI-H1568 | cell line=NCI-H1573 | cell line=NCI-H1581 | cell line=NCI-H1623 | cell line=NCI-H1648 | cell line=NCI-H1650 | cell line=NCI-H1651 | cell line=NCI-H1666 | cell line=NCI-H1693 | cell line=NCI-H1703 | cell line=NCI-H1734 | cell line=NCI-H1770 | cell line=NCI-H1781 | cell line=NCI-H1792 | cell line=NCI-H1793 | cell line=NCI-H1838 | cell line=NCI-H1869 | cell line=NCI-H187 | cell line=NCI-H1882 | cell line=NCI-H1915 | cell line=NCI-H1930 | cell line=NCI-H1944 | cell line=NCI-H196 | cell line=NCI-H1975 | cell line=NCI-H2009 | cell line=NCI-H2023 | cell line=NCI-H2030 | cell line=NCI-H2052 | cell line=NCI-H2073 | cell line=NCI-H2081 | cell line=NCI-H209 | cell line=NCI-H2106 | cell line=NCI-H2110 | cell line=NCI-H2122 | cell line=NCI-H2126 | cell line=NCI-H2135 | cell line=NCI-H2170 | cell line=NCI-H2171 | cell line=NCI-H2172 | cell line=NCI-H2196 | cell line=NCI-H2198 | cell line=NCI-H2228 | cell line=NCI-H226 | cell line=NCI-H23 | cell line=NCI-H2347 | cell line=NCI-H2369 | cell line=NCI-H2373 | cell line=NCI-H2452 | cell line=NCI-H2461 | cell line=NCI-H2595 | cell line=NCI-H2596 | cell line=NCI-H2722 | cell line=NCI-H2795 | cell line=NCI-H28 | cell line=NCI-H2803 | cell line=NCI-H2804 | cell line=NCI-H2810 | cell line=NCI-H292 | cell line=NCI-H322T | cell line=NCI-H345 | cell line=NCI-H358 | cell line=NCI-H441 | cell line=NCI-H446 | cell line=NCI-H460 | cell line=NCI-H510A | cell line=NCI-H520 | cell line=NCI-H522 | cell line=NCI-H596 | cell line=NCI-H650 | cell line=NCI-H716 | cell line=NCI-H727 | cell line=NCI-H810 | cell line=NCI-H82 | cell line=NCI-H820 | cell line=NCI-H847 | cell line=NCI-H889 | cell line=NCI-H920 | cell line=NCI-H929 | cell line=NCI-N417 | cell line=NCI-N87 | cell line=NIH:OVCAR-3 | cell line=NTERA-2 | cell line=NU-DUL-1 | cell line=NUGC-2 | cell line=NUGC-3 | cell line=NUGC-4 | cell line=OAW28 | cell line=OAW42 | cell line=OCI-AML2 | cell line=OCI-AML3 | cell line=OCI-AML5 | cell line=OCI-LY-10 | cell line=OCI-LY-19 | cell line=OCI-LY-3 | cell line=OCI-LY-7 | cell line=OCI-M1 | cell line=OCI-M2 | cell line=OCUM-1 | cell line=Okajima | cell line=OPM-2 | cell line=OUMS-23 | cell line=OV-90 | cell line=OV56 | cell line=OV7 | cell line=OVCA 420 | cell line=OvCA 429 | cell line=OvCA 432 | cell line=OVCAR-4 | cell line=OVCAR-5 | cell line=OVCAR-8 | cell line=OVCAR433 | cell line=OVISE | cell line=OVKATE | cell line=OVMANA | cell line=OVSAHO | cell line=OVTOKO | cell line=PA-1 | cell line=PA-TU-8902 | cell line=PA-TU-8988S | cell line=PA-TU-8988T | cell line=Panc 02.03 | cell line=Panc 03.27 | cell line=Panc 04.03 | cell line=Panc 05.04 | cell line=Panc 08.13 | cell line=PANC-1 | cell line=PC-3 | cell line=PE/CA-PJ15 | cell line=PE01 | cell line=Pfeiffer | cell line=PK-45H | cell line=PK-45P | cell line=PK-59 | cell line=PK-8 | cell line=PL-21 | cell line=PL45 | cell line=PLC/PRF/5 | cell line=PSN1 | cell line=QGP-1 | cell line=RAJI | cell line=RAMOS | cell line=RC-K8 | cell line=RCM-1 | cell line=REC-1 | cell line=RERF-GC-1B | cell line=RERF-LC-KJ | cell line=RERF-LC-MS | cell line=RERF-LC-OK | cell line=RI-1 | cell line=RKN | cell line=RKO | cell line=RKO-E6 | cell line=RL | cell line=RMG-I | cell line=RMUG-S | cell line=RPMI 2650 | cell line=RPMI 8226 | cell line=RPMI-7951 | cell line=RT-112 | cell line=RT4 | cell line=SC-1 | cell line=SCC-15 | cell line=SCC-25 | cell line=SCC-3 | cell line=SCC-9 | cell line=SCLC-21H | cell line=SCLC-22H | cell line=SET-2 | cell line=SF268 | cell line=SF539 | cell line=SIG-M5 | cell line=SiHa | cell line=SJCRH30 | cell line=SK-BR-3 | cell line=SK-CO-1 | cell line=SK-MEL-1 | cell line=SK-MEL-2 | cell line=SK-MEL-24 | cell line=SK-MEL-28 | cell line=SK-MEL-3 | cell line=SK-MEL-30 | cell line=SK-MEL-31 | cell line=SK-MEL-5 | cell line=SK-MES-1 | cell line=SK-MM-2 | cell line=SK-N-AS | cell line=SK-N-DZ | cell line=SK-N-FI | cell line=SK-N-SH | cell line=SK-OV-3 | cell line=SK23 | cell line=SKM-1 | cell line=SNU-1 | cell line=SNU-16 | cell line=SNU-182 | cell line=SNU-216 | cell line=SNU-387 | cell line=SNU-398 | cell line=SNU-423 | cell line=SNU-449 | cell line=SNU-475 | cell line=SNU-484 | cell line=SNU-5 | cell line=SNU-601 | cell line=SNU-620 | cell line=SNU-638 | cell line=SNU-668 | cell line=SNU-719 | cell line=SNU-C1 | cell line=SR | cell line=SR-786 | cell line=SU-DHL-1 | cell line=SU-DHL-10 | cell line=SU-DHL-16 | cell line=SU-DHL-4 | cell line=SU-DHL-5 | cell line=SU-DHL-6 | cell line=SU-DHL-8 | cell line=SU.86.86 | cell line=SUIT-2 | cell line=SUM 1315M02 | cell line=SUM 149PT | cell line=SUM 159PT | cell line=SUM 229PE | cell line=SUM 52PE | cell line=SUP-B15 | cell line=SW 1116 | cell line=SW 1417 | cell line=SW 1463 | cell line=SW 1573 | cell line=SW 1990 | cell line=SW 403 | cell line=SW 48 | cell line=SW 480 | cell line=SW 527 | cell line=SW 620 | cell line=SW 780 | cell line=SW 837 | cell line=SW 900 | cell line=SW 948 | cell line=SW 982 | cell line=T-47D | cell line=T84 | cell line=T98G | cell line=TC-71 | cell line=TCC-PAN2 | cell line=THP-1 | cell line=TK | cell line=TK-10 | cell line=TMD8 | cell line=Toledo | cell line=TOV-112D | cell line=TYK-nu | cell line=TYK-nu.CP-r | cell line=U-2 OS | cell line=U-2932 | cell line=U-698-M | cell line=U-937 | cell line=U266B1 | cell line=UACC-257 | cell line=UACC-812 | cell line=UACC-893 | cell line=UCSD-242l | cell line=UKE-1 | cell line=UM-UC-1 | cell line=UM-UC-3 | cell line=UMC-11 | cell line=VMRC-LCD | cell line=WiDr | cell line=WM-115 | cell line=WM-266-4 | cell line=WSU-DLCL2 | cell line=WSU-FSCCL | cell line=WSU-NHL | cell line=YAPC | cell line=YMB-1 | cell line=YMB-1-E | cell line=ZR-75-1 | cell line=ZR-75-30 | organism part=adrenal | organism part=blood | organism part=bone | organism part=bone marrow | organism part=brain | organism part=breast | organism part=cartilage | organism part=cecum | organism part=cervix | organism part=colon | organism part=esophagus | organism part=ileum | organism part=kidney | organism part=liver | organism part=lung | organism part=lymph node | organism part=nasal pharynx | organism part=oral cavity | organism part=ovary | organism part=pancreas | organism part=pleura | organism part=prostate | organism part=rectum | organism part=septum | organism part=skeletal muscle | organism part=skin | organism part=stomach | organism part=testis | organism part=tongue | organism part=urinary bladder | organism part=uterus | sex=female | sex=male | sex=not available | tissue supergroup=brain | tissue supergroup=breast | tissue supergroup=cervix | tissue supergroup=colo-rectal | tissue supergroup=head-neck | tissue supergroup=kidney | tissue supergroup=liver | tissue supergroup=lung | tissue supergroup=lymphoid | tissue supergroup=other | tissue supergroup=ovary | tissue supergroup=pancreas | tissue supergroup=sarcomatiod | tissue supergroup=skin | tissue supergroup=stomach | tissue supergroup=urinary bladder | tissue supergroup=uterus","tissue subtype=CC214-2-treated, CC214-2- resistant | tissue subtype=vehicle-treated control","genotype=control | genotype=Flag-SOX4-HA","tumor grading=high grade tumor | tumor grading=low grade tumor","CELL LINE=GBM1A | CELL LINE=GBM1B","CELL LINE=GBM1A | CELL LINE=GBM1B","EXPRESSING=pBrit-Flag-HA | EXPRESSING=pBrit-Flag-SOX4-HA | GENOTYPE=control | GENOTYPE=SOX4 overexpression","CELL TYPE=primary GBM tissue | CELL TYPE=recurrent GBM tissue","AGE=30y | AGE=32y | AGE=50y | AGE=53y | AGE=54y | AGE=56y | AGE=57y | AGE=58y | AGE=59y | AGE=60y | AGE=68y | AGE=70y | AGE=multiple, healthy donors 23-86y | HISTOLOGY=anaplastic astrocytoma recidivans | HISTOLOGY=Glioblastoma | HISTOLOGY=glioblastoma recidivans | HISTOLOGY=gliosarcoma | HISTOLOGY=peritumoral area of anaplastic astrocytoma | HISTOLOGY=peritumoral area of anaplastic oligoastrocytoma | HISTOLOGY=peritumoral area of glioblastoma | HISTOLOGY=pooled from multiple, healthy donors and several brain regions | ORGANISM PART=Glioma peritumoral tissue | ORGANISM PART=Human malignant glioma | ORGANISM PART=Human normal brain, Commercial mRNA for normal human tissue | ORGANISM PART=Malignant glioma tissue | SEX=female | SEX=male | SEX=mixed M and F | TUMOR LOCATION=Left fronto-parietal parasagittal | TUMOR LOCATION=Left parietal | TUMOR LOCATION=Left parieto-occipital | TUMOR LOCATION=Left temporal | TUMOR LOCATION=Left temporo-parieto-occipital | TUMOR LOCATION=Right fronto-parietal | TUMOR LOCATION=Right fronto-parietal with corpus callosum infiltration | TUMOR LOCATION=Right fronto-temporal | TUMOR LOCATION=Right fronto-temporo-parietal | TUMOR LOCATION=Right parietal | TUMOR LOCATION=Right temporal | TUMOR LOCATION=Several brain regions | TUMOR STAGE=Human normal brain, Commercial mRNA for normal human tissue | TUMOR STAGE=Peritumoral area of WHO grade III | TUMOR STAGE=Peritumoral area of WHO grade IV | TUMOR STAGE=WHO grade III | TUMOR STAGE=WHO grade IV","cell line=A549 | cell line=Jurkat | cell line=MCF-7 | cell line=U251 | compound=antofine N-oxide | compound=none | dose=50 micromolar","CELL TYPE=peripheral monocytes | CELL TYPE=tumor-infiltrating macrophages | DIAGNOSIS=- | DIAGNOSIS=glioblastoma multiforme | DONOR=GBM patient BT | DONOR=GBM patient CD | DONOR=GBM patient MW | DONOR=GBM patient PL | DONOR=healthy donor #1 | DONOR=healthy donor #2 | DONOR=healthy donor #3 | DONOR=healthy donor #4 | ORGANISM PART=peripheral blood | ORGANISM PART=Tumor | WHO GRADE=- | WHO GRADE=IV","TISSUE TYPE=adjacent normal tissue | TISSUE TYPE=Tumor","TREATMENT=control siRNA | TREATMENT=siRNA against CASP2","CELL LINE=DK-MG | CELL LINE=GaMG | CELL LINE=SNB19 | CELL LINE=U373-MG | CELL LINE=U87-MG | GROWTH MEDIUM=Dulbecco's Modified Eagle Medium | GROWTH MEDIUM=Minimum Essential Medium | INVASIVE BEHAVIOR=invasive | INVASIVE BEHAVIOR=Non-invasive | P53 STATUS=mutated | P53 STATUS=wild type | PTEN STATUS=mutated | PTEN STATUS=wild type","GENOTYPE=control overexpression | GENOTYPE=miR-127-3p overexpression","TREATED WITH=FG-3019 + irradiation for 6hrs | TREATED WITH=FG-3019 for 6hrs | TREATED WITH=irradiation for 6hrs | TREATED WITH=none for 6h (untreated control)","CELL LINE=B12 | CELL LINE=B25 | CELL LINE=B48 | CELL LINE=B73 | CELL LINE=fNSC | CELL TYPE=brain tumor stem cells (BTSCs) | CELL TYPE=fetal neural stem cells (fNSCs) | CHIP ANTIBODY=Anti-Histone H3 (tri methyl K9) antibody | CHIP ANTIBODY=Anti-trimethyl-Histone H3 (Lys27) Antibody | CHIP ANTIBODY=H3K4me3 polyclonal antibody | CHIP ANTIBODY=methylated DNA (meC) antibody | CHIP ANTIBODY=none, input DNA | CHIP ANTIBODY CAT. #=07-449 | CHIP ANTIBODY CAT. #=ab8898 | CHIP ANTIBODY CAT. #=BI-MECY-0500 | CHIP ANTIBODY CAT. #=not specified | CHIP ANTIBODY CAT. #=PAb-003-050 | CHIP ANTIBODY VENDOR=Abcam | CHIP ANTIBODY VENDOR=Diagenode | CHIP ANTIBODY VENDOR=Eurogentec | CHIP ANTIBODY VENDOR=not specified | CHIP ANTIBODY VENDOR=Upstate","NA","compound=1 millimolar glucose | compound=1 millimolar glucose and 5 millimolar sodium acetate | compound=10 millimolar glucose","HISTOLOGY=anaplastic astrocytoma | HISTOLOGY=Glioblastoma","biopsy site=contrast-enhancing core | biopsy site=non-enhancing margin | disease=glioma | disease=normal","SAMPLE GROUP=miR scambled control | SAMPLE GROUP=monolayer early passage | SAMPLE GROUP=neurosphere cultured | SAMPLE GROUP=shRNA scambled control | SAMPLE GROUP=SOX2 knockdown | TRANSFECTED WITH=miR scambled control Sox2 | TRANSFECTED WITH=miR Sox2 2B | TRANSFECTED WITH=miR Sox2 3A | TRANSFECTED WITH=not specified | TRANSFECTED WITH=shRNA scambled control Sox2 | TRANSFECTED WITH=shRNA Sox2 30 | TRANSFECTED WITH=shRNA Sox2 32","HISTORY=Anaplastic Astrocytomas | HISTORY=anaplastic oligodendroastrocytomas | HISTORY=Anaplastic Oligodendrogliomas | HISTORY=Astrocytomas | HISTORY=oligodendroastrocytomas | HISTORY=Oligodendrogliomas | HISTORY=primary Glioblastomas | HISTORY=recurrent anaplastic astrocytomas | HISTORY=recurrent anaplastic oligodendroastrocytomas | HISTORY=recurrent anaplastic oligodendrogliomas | HISTORY=recurrent astrocytomas | HISTORY=recurrent Glioblastomas | HISTORY=recurrent oligodendroastrocytomas | HISTORY=secondary Glioblastomas","TUMOUR STAGE=astrocyotma grade II | TUMOUR STAGE=Astrocytoma, Grade II | TUMOUR STAGE=Astrocytoma, Grade III | TUMOUR STAGE=secondary glioblastoma grade IV","NA","compound=DMSO | compound=JQ1 | dose=100 nanomolar | genotype=SUZ12 overexpression | genotype=wild type","NA","STAGE=GBM (IV) | STAGE=R-GBM (IV)","STAGE=GBM (IV) | STAGE=R-GBM (IV)","STAGE=GBM (IV) | STAGE=R-GBM (IV)","CELL LINE=CSC6 | CELL LINE=CSC8 | CELL LINE=MGH26 | CELL LINE=MGH28 | CELL LINE=MGH31 | CELL LINE=not specified | CELL TYPE=Differentiated Glioma Cell Line | CELL TYPE=Glioblastoma | CELL TYPE=Gliomasphere Cell Line | PATIENT ID=MGH26 | PATIENT ID=MGH28 | PATIENT ID=MGH29 | PATIENT ID=MGH30 | PATIENT ID=MGH31 | PATIENT ID=not specified | SUBTYPE=Cla | SUBTYPE=Cla+Mes | SUBTYPE=Mes | SUBTYPE=NEU | SUBTYPE=Neu+Cla | SUBTYPE=Neu+Mes | SUBTYPE=None | SUBTYPE=not specified | SUBTYPE=Pro | SUBTYPE=Pro+Cla | SUBTYPE=Pro+Neu","1P/19Q STATUS=codel | 1P/19Q STATUS=intact | IDH STATUS=mut | IDH STATUS=not specified | IDH STATUS=wt | MOLECULAR CLASSIFICATION=CIMP-A | MOLECULAR CLASSIFICATION=CIMP-O | MOLECULAR CLASSIFICATION=CIMPneg","CELL TYPE=embryonic human neural stem cells | CELL TYPE=Gb4 glioma cancer stem cells | CELL TYPE=Gb7 glioma cancer stem cells | CELL TYPE=glioma cell line | LENTIVIRUS=YFP | LENTIVIRUS=YFP-NICD","compound=doxycycline | compound=none | dose=100 nanomolar | RNAi=control siRNA | RNAi=HIF2A siRNA","TREATMENT=CFIm25 knockdown | TREATMENT=control","AGE=10 | AGE=11 | AGE=12 | AGE=14 | AGE=18 | AGE=24 | AGE=5 | AGE=6 | AGE=8 | AGE=not specified | AGE AT DIAGNOSIS YEARS=10 | AGE AT DIAGNOSIS YEARS=11 | AGE AT DIAGNOSIS YEARS=13 | AGE AT DIAGNOSIS YEARS=23 | AGE AT DIAGNOSIS YEARS=34 | AGE AT DIAGNOSIS YEARS=36 | AGE AT DIAGNOSIS YEARS=38 | AGE AT DIAGNOSIS YEARS=46 | AGE AT DIAGNOSIS YEARS=6 | AGE AT DIAGNOSIS YEARS=7 | AGE AT DIAGNOSIS YEARS=not specified | H3.3_STATUS=K27M | H3.3_STATUS=not specified | H3.3_STATUS=wt | H3F3A STATUS=K27M | H3F3A STATUS=not specified | H3F3A STATUS=WT | IDH1 STATUS=MUT | IDH1 STATUS=not specified | IDH1 STATUS=WT | LOCATION=frontal lobe | LOCATION=not specified | LOCATION=parieto-occipital | LOCATION=temporal lobe | LOCATION=thalamus | LOCATION=the fourth ventricle &amp; brain stem | SEX=female | SEX=male | SUBGROUP=K27 | SUBGROUP=Mesenchymal | SUBGROUP=not specified | TUMOR LOCATION=frontal lobe | TUMOR LOCATION=NA | TUMOR LOCATION=not specified | TUMOR LOCATION=pons | TUMOR LOCATION=thalamic | TUMOR LOCATION=Ventricular","SUBTYPE=Classical | SUBTYPE=Mesenchymal | SUBTYPE=Neural | SUBTYPE=Proneural | SURVIVAL MONTHS=138.30 | SURVIVAL MONTHS=50.60 | SURVIVAL MONTHS=58.57 | SURVIVAL MONTHS=62.20 | SURVIVAL MONTHS=62.50 | SURVIVAL MONTHS=64.30 | SURVIVAL MONTHS=92.07","CELL LINE=1321N1 | CELL LINE=1A6 | CELL LINE=22Rv1 | CELL LINE=2313287 | CELL LINE=5637 | CELL LINE=59M | CELL LINE=647V | CELL LINE=977 | CELL LINE=A172 | CELL LINE=A2058 | CELL LINE=A2780 | CELL LINE=A375 | CELL LINE=A427 | CELL LINE=A431 | CELL LINE=A549 | CELL LINE=AGS | CELL LINE=AML143D10 | CELL LINE=AMO1 | CELL LINE=ARH77 | CELL LINE=AsPC1 | CELL LINE=AZ521 | CELL LINE=BE | CELL LINE=BEL7402 | CELL LINE=BEL7404 | CELL LINE=BEL7405 | CELL LINE=BFTC905 | CELL LINE=BGC823 | CELL LINE=BPH1 | CELL LINE=BT20 | CELL LINE=BT474 | CELL LINE=BT474C1 | CELL LINE=BT549 | CELL LINE=BV173 | CELL LINE=BxPC3 | CELL LINE=C10 | CELL LINE=C106 | CELL LINE=C125PM | CELL LINE=C32COLON | CELL LINE=C75 | CELL LINE=C80 | CELL LINE=C84 | CELL LINE=C99 | CELL LINE=CACO2 | CELL LINE=CAL27 | CELL LINE=CAL51 | CELL LINE=Calu1 | CELL LINE=Calu3 | CELL LINE=Calu6 | CELL LINE=CAMA1 | CELL LINE=Capan1 | CELL LINE=Capan2 | CELL LINE=CAR1 | CELL LINE=CC20 | CELL LINE=CCFSTTG1 | CELL LINE=CCK81 | CELL LINE=CCRFCEM | CELL LINE=CFPAC1 | CELL LINE=CMK | CELL LINE=COLO201 | CELL LINE=COLO205 | CELL LINE=COLO206 | CELL LINE=COLO320DM | CELL LINE=COLO678 | CELL LINE=COLO741 | CELL LINE=CTV1 | CELL LINE=Daudi | CELL LINE=DERL2 | CELL LINE=Detroit562 | CELL LINE=DLD1 | CELL LINE=DMS114 | CELL LINE=DOHH2 | CELL LINE=DOK | CELL LINE=DU145 | CELL LINE=EBC1 | CELL LINE=EHEB | CELL LINE=EJ138 | CELL LINE=EM2 | CELL LINE=EOL1 | CELL LINE=ESKOL | CELL LINE=EVSAT | CELL LINE=F36P | CELL LINE=FaDu | CELL LINE=FARAGE | CELL LINE=G361 | CELL LINE=GP2D | CELL LINE=GRANTA519 | CELL LINE=GTL16 | CELL LINE=HARA | CELL LINE=HARAB | CELL LINE=HBL1 | CELL LINE=HCA46 | CELL LINE=HCA7 | CELL LINE=HCC1143 | CELL LINE=HCC1187 | CELL LINE=HCC1395 | CELL LINE=HCC1419 | CELL LINE=HCC15 | CELL LINE=HCC1500 | CELL LINE=HCC1569 | CELL LINE=HCC1588 | CELL LINE=HCC1806 | CELL LINE=HCC1937 | CELL LINE=HCC1954 | CELL LINE=HCC202 | CELL LINE=HCC38 | CELL LINE=HCC70 | CELL LINE=HCC95 | CELL LINE=HCCC9810 | CELL LINE=HCCLM3 | CELL LINE=HCT116 | CELL LINE=HCT15 | CELL LINE=HCT8 | CELL LINE=HEK293 | CELL LINE=HEL9217 | CELL LINE=HeLa | CELL LINE=HEP2 | CELL LINE=Hep3B | CELL LINE=HepG2 | CELL LINE=HGC27 | CELL LINE=HL60 | CELL LINE=HLE | CELL LINE=HLF | CELL LINE=HLY1 | CELL LINE=HN5 | CELL LINE=HOP62 | CELL LINE=HPAC | CELL LINE=HPAFII | CELL LINE=HRA19 | CELL LINE=HS578T | CELL LINE=HS683 | CELL LINE=HS746T | CELL LINE=HS766T | CELL LINE=HS840T | CELL LINE=HT | CELL LINE=HT1197 | CELL LINE=HT1376 | CELL LINE=HT29 | CELL LINE=HUH1 | CELL LINE=HUH7 | CELL LINE=HUPT3 | CELL LINE=HuPT4 | CELL LINE=HuT78 | CELL LINE=HX147 | CELL LINE=IGROV1 | CELL LINE=IM9 | CELL LINE=IM95 | CELL LINE=IM95M | CELL LINE=J82 | CELL LINE=JEKO1 | CELL LINE=JIMT1 | CELL LINE=JJN3 | CELL LINE=Jurkat | CELL LINE=JVM2 | CELL LINE=JVM3 | CELL LINE=K562 | CELL LINE=KARPAS1106P | CELL LINE=KARPAS231 | CELL LINE=KARPAS422 | CELL LINE=KARPAS620 | CELL LINE=KASUMI1 | CELL LINE=KASUMI3 | CELL LINE=KASUMI6 | CELL LINE=KATOIII | CELL LINE=KB | CELL LINE=KG1 | CELL LINE=KG1A | CELL LINE=KIT225 | CELL LINE=KK47 | CELL LINE=KMS12BM | CELL LINE=KP4 | CELL LINE=KPL1 | CELL LINE=KPL4 | CELL LINE=KU1919 | CELL LINE=KU812 | CELL LINE=KYSE140 | CELL LINE=KYSE180 | CELL LINE=KYSE30 | CELL LINE=KYSE450 | CELL LINE=KYSE70 | CELL LINE=L115CLONE1 | CELL LINE=L363 | CELL LINE=LAPC4 | CELL LINE=LB61 | CELL LINE=LC1SQ | CELL LINE=LK2 | CELL LINE=LN18 | CELL LINE=LN229 | CELL LINE=LNCAP | CELL LINE=LNCAPAI | CELL LINE=LNCAPCASRES | CELL LINE=LNCAPCASRESNEWCASTLE | CELL LINE=LNCAPCLONEFGC | CELL LINE=LOVO | CELL LINE=LP1 | CELL LINE=LS174T | CELL LINE=LS180 | CELL LINE=LS411 | CELL LINE=LS513 | CELL LINE=LUDLU1 | CELL LINE=M059J | CELL LINE=M059K | CELL LINE=MC116 | CELL LINE=MCF7 | CELL LINE=MCF7MDRPOS | CELL LINE=MDAMB134VI | CELL LINE=MDAMB157 | CELL LINE=MDAMB175 | CELL LINE=MDAMB231 | CELL LINE=MDAMB361 | CELL LINE=MDAMB415 | CELL LINE=MDAMB435S | CELL LINE=MDAMB436 | CELL LINE=MDAMB453 | CELL LINE=MDAMB468 | CELL LINE=ME1 | CELL LINE=MEC1 | CELL LINE=MEC2 | CELL LINE=MEG01 | CELL LINE=MELJUSO | CELL LINE=MGC803 | CELL LINE=MGHU3 | CELL LINE=MHCC97 | CELL LINE=MHCC97H | CELL LINE=MHCC97L | CELL LINE=MIAPACA2 | CELL LINE=MKN1 | CELL LINE=MKN45 | CELL LINE=MKN74 | CELL LINE=ML2 | CELL LINE=MM1R | CELL LINE=MM1S | CELL LINE=MOGGCCM | CELL LINE=MOGGUVW | CELL LINE=MOLM13 | CELL LINE=MOLM16 | CELL LINE=MOLP8 | CELL LINE=MONOMAC6 | CELL LINE=MUTZ3 | CELL LINE=MV411 | CELL LINE=NAMALWA | CELL LINE=NB4 | CELL LINE=NCIH1299 | CELL LINE=NCIH1437 | CELL LINE=NCIH1623 | CELL LINE=NCIH1650 | CELL LINE=NCIH1651 | CELL LINE=NCIH1666 | CELL LINE=NCIH1703 | CELL LINE=NCIH1734 | CELL LINE=NCIH1755 | CELL LINE=NCIH1781 | CELL LINE=NCIH1793 | CELL LINE=NCIH1838 | CELL LINE=NCIH1869 | CELL LINE=NCIH1975 | CELL LINE=NCIH2030 | CELL LINE=NCIH2066 | CELL LINE=NCIH2073 | CELL LINE=NCIH2085 | CELL LINE=NCIH209 | CELL LINE=NCIH2122 | CELL LINE=NCIH2126 | CELL LINE=NCIH2135 | CELL LINE=NCIH2172 | CELL LINE=NCIH2228 | CELL LINE=NCIH226 | CELL LINE=NCIH2286 | CELL LINE=NCIH2291 | CELL LINE=NCIH23 | CELL LINE=NCIH2342 | CELL LINE=NCIH2347 | CELL LINE=NCIH2444 | CELL LINE=NCIH3122 | CELL LINE=NCIH322 | CELL LINE=NCIH322M | CELL LINE=NCIH3255 | CELL LINE=NCIH358 | CELL LINE=NCIH366 | CELL LINE=NCIH460 | CELL LINE=NCIH460DNP53 | CELL LINE=NCIH520 | CELL LINE=NCIH522 | CELL LINE=NCIH526 | CELL LINE=NCIH548 | CELL LINE=NCIH596 | CELL LINE=NCIH647 | CELL LINE=NCIH716 | CELL LINE=NCIH727 | CELL LINE=NCIH747 | CELL LINE=NCIH810 | CELL LINE=NCIH82 | CELL LINE=NCIH838 | CELL LINE=NCIH929 | CELL LINE=NCIN87 | CELL LINE=NIHOVCAR3 | CELL LINE=NOMO1 | CELL LINE=NUDHL1 | CELL LINE=NUGC3 | CELL LINE=NUGC4 | CELL LINE=OAW28 | CELL LINE=OAW42 | CELL LINE=OCIAML2 | CELL LINE=OCIAML5 | CELL LINE=OCILY1 | CELL LINE=OCILY10 | CELL LINE=OCILY18 | CELL LINE=OCILY19 | CELL LINE=OCILY3 | CELL LINE=OCILY4 | CELL LINE=OCILY7 | CELL LINE=OCILY8 | CELL LINE=OCIM1 | CELL LINE=OCIM2 | CELL LINE=OCIMY1 | CELL LINE=OCIMY5 | CELL LINE=OCUM1 | CELL LINE=OE21 | CELL LINE=OKAC1 | CELL LINE=OPM2 | CELL LINE=OV90 | CELL LINE=OVCAR4 | CELL LINE=OVCAR5 | CELL LINE=OVCAR8 | CELL LINE=PA1 | CELL LINE=PAMC82 | CELL LINE=Panc1 | CELL LINE=PANC1005 | CELL LINE=PANC203 | CELL LINE=PANC327 | CELL LINE=PANC403 | CELL LINE=PANC813 | CELL LINE=Panc89 | CELL LINE=PC3 | CELL LINE=PC346C | CELL LINE=PC346FLU1 | CELL LINE=PC9 | CELL LINE=PC9ZD | CELL LINE=PCJW | CELL LINE=PECAPJ15 | CELL LINE=PECAPJ34CLONEC12 | CELL LINE=PECAPJ34CLONED2 | CELL LINE=PECAPJ49 | CELL LINE=PL21 | CELL LINE=PNT1A | CELL LINE=PSN1 | CELL LINE=QGP1 | CELL LINE=QGY7701 | CELL LINE=QGY7703 | CELL LINE=Raji | CELL LINE=Ramos | CELL LINE=RCK8 | CELL LINE=RCM1 | CELL LINE=REH | CELL LINE=RERFLCSQ1 | CELL LINE=RI1 | CELL LINE=RKO | CELL LINE=RPMI2650 | CELL LINE=RPMI8226 | CELL LINE=RS411 | CELL LINE=RT112 | CELL LINE=RT4 | CELL LINE=RWPE1 | CELL LINE=SC1 | CELL LINE=SCaBER | CELL LINE=SCC25 | CELL LINE=SCC4 | CELL LINE=SCC9 | CELL LINE=SD148 | CELL LINE=SET2 | CELL LINE=SGC7901 | CELL LINE=SHP77 | CELL LINE=SIGM5 | CELL LINE=SKBR3 | CELL LINE=SKCO1 | CELL LINE=SKGT4 | CELL LINE=SKHEP1 | CELL LINE=SKM1 | CELL LINE=SKMES1 | CELL LINE=SKMM2 | CELL LINE=SKOV3 | CELL LINE=SMMC7721 | CELL LINE=SNU1 | CELL LINE=SNU16 | CELL LINE=SNU216 | CELL LINE=SNU354 | CELL LINE=SNU368 | CELL LINE=SNU398 | CELL LINE=SNU449 | CELL LINE=SNU484 | CELL LINE=SNU5 | CELL LINE=SNU601 | CELL LINE=SNU620 | CELL LINE=SNU638 | CELL LINE=SNU668 | CELL LINE=SNU739 | CELL LINE=SNU761 | CELL LINE=SNU878 | CELL LINE=SNU886 | CELL LINE=SNUC2B | CELL LINE=SU8686 | CELL LINE=SUDHL10 | CELL LINE=SUDHL2 | CELL LINE=SUDHL4 | CELL LINE=SUDHL5 | CELL LINE=SUDHL6 | CELL LINE=SUDHL8 | CELL LINE=SUM1315MO2 | CELL LINE=SUM149PT | CELL LINE=SUM52PE | CELL LINE=SUPB15 | CELL LINE=SW1088 | CELL LINE=SW1116 | CELL LINE=SW1222 | CELL LINE=SW1417 | CELL LINE=SW1710 | CELL LINE=SW1783 | CELL LINE=SW403 | CELL LINE=SW48 | CELL LINE=SW480 | CELL LINE=SW579 | CELL LINE=SW620 | CELL LINE=SW780 | CELL LINE=SW837 | CELL LINE=SW948 | CELL LINE=T24 | CELL LINE=T24NEO1 | CELL LINE=T24NEO3 | CELL LINE=T24R2WTK10 | CELL LINE=T24SAUVAGE | CELL LINE=T24WTK6 | CELL LINE=T3M4 | CELL LINE=T47D | CELL LINE=T84 | CELL LINE=T98G | CELL LINE=TCCSUP | CELL LINE=TE10 | CELL LINE=TE12 | CELL LINE=TE3 | CELL LINE=TE7 | CELL LINE=TF1 | CELL LINE=THP1 | CELL LINE=TMD8 | CELL LINE=TOV112D | CELL LINE=TOV21G | CELL LINE=TT | CELL LINE=TTN | CELL LINE=U118MG | CELL LINE=U266B1 | CELL LINE=U2932 | CELL LINE=U2940 | CELL LINE=U698M | CELL LINE=U87MG | CELL LINE=U937 | CELL LINE=UKE1 | CELL LINE=ULA | CELL LINE=UMUC3 | CELL LINE=UT7 | CELL LINE=VACO10MS | CELL LINE=VACO4A | CELL LINE=VACO4S | CELL LINE=VACO5 | CELL LINE=VCAP | CELL LINE=VMCUB1 | CELL LINE=VMRCLCP | CELL LINE=WIDR | CELL LINE=WILL1 | CELL LINE=WILL2 | CELL LINE=WSUDLCL2 | CELL LINE=WSUNHL | CELL LINE=ZR751 | DISEASE=acute lymphoblastic leukemia | DISEASE=acute myeloid leukemia | DISEASE=acute promyelocytic leukemia | DISEASE=adenocarcinoma | DISEASE=adenocarcinoma Derived from metastatic site: ascites | DISEASE=adenocarcinoma Derived from metastatic site: brain | DISEASE=adenocarcinoma Derived from metastatic site: liver | DISEASE=adenocarcinoma Derived from metastatic site: pleural effusion | DISEASE=adenocarcinoma; bronchoalveolar carcinoma | DISEASE=adenocarcinoma; non-small cell lung cancer | DISEASE=adenocarcinoma; non-small cell lung cancer Derived from metastatic site: lymph node | DISEASE=adenosquamous carcinoma | DISEASE=adenosquamous carcinoma; non-small cell lung cancer | DISEASE=ALL | DISEASE=AML | DISEASE=AML (Acute Myeloid Leukemia) | DISEASE=anaplastic carcinoma | DISEASE=APL | DISEASE=asian squamous cell carcinoma | DISEASE=astrocytoma | DISEASE=B-ALL (B-cell Acute Lymphoblastic Leukemia ) | DISEASE=B-CLL (Chronic Lymphocytic B-Leukemia ) | DISEASE=B-NHL (B-cell non-Hodgkins Lymphoma) | DISEASE=B-NHL (B-cell non-Hodgkins Lymphoma) (Mantle Cell) | DISEASE=B-NHL (B-cell non-Hodgkins Lymphoma) / DLBL (Diffuse Large B-cell Lymphoma ) | DISEASE=B-NHL (B-cell non-Hodgkins Lymphoma) / DLCL (Diffuse Large Cell Lymphoma) | DISEASE=B-NHL (B-cell non-Hodgkins Lymphoma) / FL (Follicular Lymphoma) | DISEASE=basaloid squamous cell carcinoma | DISEASE=breast adenocarcinoma | DISEASE=Breast Ductal Carcinoma | DISEASE=bronchioalveolar carcinoma; non-small cell lung cancer | DISEASE=Bronchioloalveolar adenocarcinoma | DISEASE=Burkitts lymphoma | DISEASE=carcinoid | DISEASE=carcinoma | DISEASE=carcinoma Derived from metastatic site: brain | DISEASE=carcinoma Derived from metastatic site: left supraclavicular lymph node | DISEASE=carcinoma from pleural effusion | DISEASE=carcinoma; large cell lung cancer | DISEASE=carcinoma; large cell lung cancer Derived from metastatic site: pleural effusion | DISEASE=Carcinoma; mammary gland | DISEASE=carcinoma; non-small cell lung cancer | DISEASE=carcinoma; non-small cell lung cancer Derived from metastatic site: lymph node | DISEASE=carcinoma; small cell lung cancer | DISEASE=carcinoma; small cell lung cancer Derived from metastatic site: pleural effusion | DISEASE=Cecum carcinoma | DISEASE=CEL | DISEASE=CML | DISEASE=CML (Chronic Myeloid Leukemia) | DISEASE=colon adenocarcinoma | DISEASE=colon carcinoma | DISEASE=colorectal adenocarcinoma | DISEASE=colorectal adenocarcinoma Derived from metastatic site: ascites | DISEASE=Colorectal Carcinoma | DISEASE=DLBCL | DISEASE=ductal adenocarcinoma; cystic fibrosis | DISEASE=Ductal Carcinoma | DISEASE=ductal carcinoma Derived from metastatic site: ascites | DISEASE=ductal carcinoma Derived from metastatic site: pleural effusion | DISEASE=Dysplastic oral keratinocyte | DISEASE=Epidermoid Carcinoma | DISEASE=Epidermoid carcinoma with HeLa markers (poss contamination) | DISEASE=epithelioid carcinoma | DISEASE=Erythroleukemia | DISEASE=Esophageal Cancer | DISEASE=gastric adenocarcinoma | DISEASE=gastric cancer | DISEASE=gastric carcinoma | DISEASE=Glioblastoma | DISEASE=glioblastoma multiforme | DISEASE=glioblastoma; astrocytoma | DISEASE=glioblastoma; glioma | DISEASE=Glioma | DISEASE=Histiocytic Lymphoma | DISEASE=ileocecal colorectal adenocarcinoma | DISEASE=invasive ductal carcinoma | DISEASE=invasive esophageal squamous cell carcinoma | DISEASE=Large Cell Carcinoma | DISEASE=Liver Cancer | DISEASE=lung carcinoma | DISEASE=Lung Large Cell Carcinoma | DISEASE=lymphoma | DISEASE=malignant glioblastoma; glioma; glial cell | DISEASE=Malignant Melanoma | DISEASE=malignant papillary serous adenocarcinoma | DISEASE=medulallary carcinoma | DISEASE=melanoma | DISEASE=melanoma Derived from metastatic site: lymph node | DISEASE=metastatic carcinoma | DISEASE=metastatic carcinoma Derived from metastatic site: pericardial effusion | DISEASE=Metastatic Ductal Carcinoma | DISEASE=Mucinous colon carcinoma | DISEASE=Myeloma | DISEASE=NA | DISEASE=Non-Small Cell Lung Cancer | DISEASE=not specified | DISEASE=NSCLC | DISEASE=oesophageal squamous cell carcinoma | DISEASE=oral squamous cell carcinoma | DISEASE=ovarian carcinoma | DISEASE=ovarian cystadenocarcinoma | DISEASE=Papilloma | DISEASE=papilloma | DISEASE=Primary Acantholytic Squamous Cell Carcinoma | DISEASE=Primary Ductal Carcinoma | DISEASE=primary ductal carcinoma | DISEASE=primary human embryonal kidney transformed by sheared human adenovirus type 5 (Ad 5) DNA | DISEASE=primary malignant adenocarcinoma; clear cell carcinoma | DISEASE=primary malignant adenocarcinoma; endometrioid carcinoma | DISEASE=Primary Metaplastic Carcinoma | DISEASE=rectum | DISEASE=rectum adenocarcinoma | DISEASE=Rectum carcinoma | DISEASE=small cell lung cancer; carcinoma | DISEASE=SqLC | DISEASE=squamous cell carcinoma | DISEASE=squamous cell carcinoma from pleural effusion | DISEASE=squamous cell carcinoma; mesothelioma | DISEASE=squamous cell carcinoma; mesothelioma [23570] Derived from metastatic site: pleural effusion | DISEASE=squamous cell; adenocarcinoma; non-small cell lung cancer | DISEASE=T-cell leukemia | DISEASE=teratocarcinoma | DISEASE=variant small cell lung cancer; carcinoma | ORGANISM PART=bladder | ORGANISM PART=brain | ORGANISM PART=breast | ORGANISM PART=cervix | ORGANISM PART=colon | ORGANISM PART=esophagus | ORGANISM PART=Hematopoietic System | ORGANISM PART=kidney | ORGANISM PART=larynx | ORGANISM PART=liver | ORGANISM PART=lung | ORGANISM PART=Nasal Septum | ORGANISM PART=Nasopharynx | ORGANISM PART=Oral cavity | ORGANISM PART=ovary | ORGANISM PART=pancreas | ORGANISM PART=Pharynx | ORGANISM PART=prostate | ORGANISM PART=skin | ORGANISM PART=stomach | ORGANISM PART=thyroid gland | ORGANISM PART=tongue","compound=bevacizumab | compound=control | compound=dibenzazepine","compound=bevacizumab | compound=control","NA","CHIP ANTIBODY=H3K27ac (Active Motif) | CHIP ANTIBODY=not specified | CHIP ANTIBODY=Olig2 (R&amp;D) | CHIP ANTIBODY=Pou3f2/Brn2 (Epitomics) | CHIP ANTIBODY=Sall2 (Bethyll) | CHIP ANTIBODY=Sox2 (R&amp;D)","CHIP ANTIBODY=H3K27ac (Active Motif) | CHIP ANTIBODY=Olig2 (R&amp;D) | CHIP ANTIBODY=Pou3f2/Brn2 (Epitomics) | CHIP ANTIBODY=Sall2 (Bethyll) | CHIP ANTIBODY=Sox2 (R&amp;D)","BATCH=11 | BATCH=5 | BATCH=6 | BATCH=7 | BATCH=8 | BATCH=not specified | ORGANISM=Homo sapiens | ORGANISM=Mus musculus | RCAS VECTOR=10_J12COsh_1 | RCAS VECTOR=11_J12COsh_2 | RCAS VECTOR=12_J12COsh_3 | RCAS VECTOR=1_J12GL2sh_1 | RCAS VECTOR=2_J12GL2sh_2 | RCAS VECTOR=3_J12GL2sh_3 | RCAS VECTOR=4_J12Nf1sh_1 | RCAS VECTOR=5_J12Nf1sh_2 | RCAS VECTOR=6_J12Nf1sh_3 | RCAS VECTOR=7_J12P53sh_1 | RCAS VECTOR=8_J12P53sh_2 | RCAS VECTOR=9_J12P53sh_3 | RCAS VECTOR=NA | RCAS VECTOR=not specified | RCAS VECTOR=PDGF-A-myc/His | RCAS VECTOR=PDGF-A-myc/His + shNf1 (GR249) | RCAS VECTOR=PDGF-A-myc/His + shp53 (mR696) | RCAS VECTOR=PDGF-A-myc/His + shp53 (mR696) + shNf1 (GR249) | RCAS VECTOR=PDGF-B-HA | RCAS VECTOR=shNf1 (GF249) + shp53 (mR696) | RCAS VECTOR=shNf1 (GF249) + shp53 (R696) | RCAS VECTOR=shNf1 (GR249) + cre | RCAS VECTOR=shNf1 (GR249) + shp53 (mR696) | RCAS VECTOR=shNf1 (GR249) + shp53 (R696) | SAMPLE ID=1118 | SAMPLE ID=1120_200 | SAMPLE ID=1121 | SAMPLE ID=1122 | SAMPLE ID=1129 | SAMPLE ID=1162 | SAMPLE ID=1182_new | SAMPLE ID=1183 | SAMPLE ID=1197 | SAMPLE ID=1212 | SAMPLE ID=1213 | SAMPLE ID=1218 | SAMPLE ID=1288 | SAMPLE ID=1293 | SAMPLE ID=1294 | SAMPLE ID=1322 | SAMPLE ID=1323 | SAMPLE ID=1324 | SAMPLE ID=1446 | SAMPLE ID=1447 | SAMPLE ID=1475 | SAMPLE ID=1484 | SAMPLE ID=1485 | SAMPLE ID=1486 | SAMPLE ID=1598 | SAMPLE ID=1603 | SAMPLE ID=1732 | SAMPLE ID=1733 | SAMPLE ID=1734 | SAMPLE ID=1742 | SAMPLE ID=1743 | SAMPLE ID=1744 | SAMPLE ID=1745 | SAMPLE ID=1746 | SAMPLE ID=1747 | SAMPLE ID=1748 | SAMPLE ID=1752 | SAMPLE ID=1757 | SAMPLE ID=1758 | SAMPLE ID=1759 | SAMPLE ID=1760 | SAMPLE ID=1761 | SAMPLE ID=1805 | SAMPLE ID=1807 | SAMPLE ID=1809 | SAMPLE ID=1817 | SAMPLE ID=1837 | SAMPLE ID=1840 | SAMPLE ID=1841 | SAMPLE ID=1844 | SAMPLE ID=1851 | SAMPLE ID=1855 | SAMPLE ID=1861 | SAMPLE ID=1875 | SAMPLE ID=1877 | SAMPLE ID=1878 | SAMPLE ID=1881 | SAMPLE ID=1882 | SAMPLE ID=1883 | SAMPLE ID=1886 | SAMPLE ID=1888 | SAMPLE ID=1890 | SAMPLE ID=1895 | SAMPLE ID=1909 | SAMPLE ID=1913 | SAMPLE ID=1919 | SAMPLE ID=1924 | SAMPLE ID=1926 | SAMPLE ID=1929 | SAMPLE ID=1937 | SAMPLE ID=1989 | SAMPLE ID=2032 | SAMPLE ID=not specified | STRAIN=GFAP (G)/tv-a wt | STRAIN=N/tva; Ink4a-Arf-/-; Ptenfl/fl | STRAIN=Nestin (N)/tv-a | STRAIN=Nestin (N)/tv-a wt | STRAIN=not specified | TUMOR GRADE=G2 | TUMOR GRADE=G3 | TUMOR GRADE=GBM | TUMOR GRADE=NA | TUMOR GRADE=ND | TUMOR GRADE=not specified | TUMOR LATENCY DAYS=107 | TUMOR LATENCY DAYS=116 days old | TUMOR LATENCY DAYS=125 | TUMOR LATENCY DAYS=129 | TUMOR LATENCY DAYS=134 days old | TUMOR LATENCY DAYS=145 | TUMOR LATENCY DAYS=149 | TUMOR LATENCY DAYS=150 days old | TUMOR LATENCY DAYS=154 | TUMOR LATENCY DAYS=156 | TUMOR LATENCY DAYS=164 | TUMOR LATENCY DAYS=176 days old | TUMOR LATENCY DAYS=193 | TUMOR LATENCY DAYS=194 days old | TUMOR LATENCY DAYS=196 | TUMOR LATENCY DAYS=197 | TUMOR LATENCY DAYS=202 | TUMOR LATENCY DAYS=208 | TUMOR LATENCY DAYS=222 | TUMOR LATENCY DAYS=234 | TUMOR LATENCY DAYS=254 | TUMOR LATENCY DAYS=257 | TUMOR LATENCY DAYS=266 | TUMOR LATENCY DAYS=268 | TUMOR LATENCY DAYS=307 | TUMOR LATENCY DAYS=336 | TUMOR LATENCY DAYS=338 | TUMOR LATENCY DAYS=34 | TUMOR LATENCY DAYS=343 days old | TUMOR LATENCY DAYS=39 | TUMOR LATENCY DAYS=40 | TUMOR LATENCY DAYS=43 | TUMOR LATENCY DAYS=44 | TUMOR LATENCY DAYS=46 | TUMOR LATENCY DAYS=47 | TUMOR LATENCY DAYS=48 | TUMOR LATENCY DAYS=49 | TUMOR LATENCY DAYS=50 | TUMOR LATENCY DAYS=51 | TUMOR LATENCY DAYS=52 | TUMOR LATENCY DAYS=53 days old | TUMOR LATENCY DAYS=56 | TUMOR LATENCY DAYS=57 | TUMOR LATENCY DAYS=60 | TUMOR LATENCY DAYS=63 | TUMOR LATENCY DAYS=65 | TUMOR LATENCY DAYS=69 | TUMOR LATENCY DAYS=70 | TUMOR LATENCY DAYS=71 | TUMOR LATENCY DAYS=82 | TUMOR LATENCY DAYS=not specified | VECTOR CONSTRUCTS=not specified | VECTOR CONSTRUCTS=pLKO.1-empty vector, SKI-RSI-249999, MSKCC | VECTOR CONSTRUCTS=pLKO.1-NF1shRNA (#2), SKI-RSI-192342, MSKCC | VECTOR CONSTRUCTS=pLKO.1-NF1shRNA (#5), SKI-RSI-192345, MSKCC","SUBCLONE ID=SC1 | SUBCLONE ID=SC10 | SUBCLONE ID=SC11 | SUBCLONE ID=SC12 | SUBCLONE ID=SC2 | SUBCLONE ID=SC3 | SUBCLONE ID=SC5 | SUBCLONE ID=SC6 | SUBCLONE ID=SC8 | SUBCLONE ID=SC9","SURVIVAL=intermediate OS | SURVIVAL=long-term OS | SURVIVAL=short-term OS","disease=glioma | disease=normal | tumor grading=GRADE II | tumor grading=GRADE III | tumor grading=GRADE IV | tumor grading=not applicable","BRAIN REGION=Infratentorial Midline (DIPG) | BRAIN REGION=not specified | BRAIN REGION=Supratentorial Midline (GBM) | BRAIN REGION=thalamus | MUTATION=H3F3A.G34R.V | MUTATION=H3F3A.K27M | MUTATION=HIST1H3B.K27M | MUTATION=HIST1H3C.K27M | MUTATION=IDH1 | MUTATION=WT","CELL TYPE=glioblastoma tumor-initiating cells (GBM TICs) | CELL TYPE=normal astrocytes | COMPOUND=ethanol | COMPOUND=H2O | COMPOUND=NAC | COMPOUND=tiron | COMPOUND=trolox | EXPOSURE TIME=48h | EXPOSURE TIME=6d","CELL LINE=HBMEC | CELL LINE=U87 | CELL LINE=U87-HBMEC","CELL LINE=U251 | CELL LINE=U343 | TRANSFECTION=control | TRANSFECTION=miR137","WHO GRADE=I | WHO GRADE=III | WHO GRADE=IV","CHIP ANTIBODY=anti-CHD4, Abcam, ab72418 | CHIP ANTIBODY=anti-ZFHX4,Abnova, H00079776-M11 | CHIP ANTIBODY=none","NA","CELL LINE BACKGROUND=Hs683 | CELL LINE BACKGROUND=LNZ308 | CELL LINE BACKGROUND=U87 | SAMPLE TYPE=TMZ-resistant subclone | SAMPLE TYPE=wild type cell line","CELL LINE=LN229 | CELL LINE=U178 | CELL LINE=U373 | CELL LINE=U373 DK | CELL LINE=U373 WT | CELL LINE=U373 WT + EGF | CELL LINE=U373 Δ | CELL LINE=U87 | CELL LINE=U87 WT + EGF | CELL LINE=U87 Δ | CELL LINE=U87DK | CELL LINE=U87WT | CELL TYPE=cell line overexpressing  dead kinase ΔEGFR | CELL TYPE=cell line overexpressing  ΔEGFR | CELL TYPE=cell line overexpressing wild type EGFR | CELL TYPE=cell line overexpressing wild type EGFR stimulated EGF for 1hr | CELL TYPE=cell linecell line","CELL TYPE=astrocytoma | CELL TYPE=Brain Cancer | CELL TYPE=Breast Cancer | CELL TYPE=Breast cancer stage IVa | CELL TYPE=Esophageal Cancer | CELL TYPE=glioblastoma multiforme | CELL TYPE=Healthy control | CELL TYPE=Healthy normal donor | CELL TYPE=Lung Cancer | CELL TYPE=Mixed Oligoastrocytoma | CELL TYPE=multiple myeloma | CELL TYPE=oligodendroglioma | CELL TYPE=Ovarian Cancer | CELL TYPE=pancreatic cancer | CELL TYPE=pancreatitis | CELL TYPE=recurrent Breast cancer | CELL TYPE=sarcoma | CELL TYPE=Valley Fever","CELL TYPE=astrocytoma | CELL TYPE=Breast Cancer | CELL TYPE=Breast cancer stage IVa | CELL TYPE=glioblastoma multiforme | CELL TYPE=Healthy normal donor | CELL TYPE=Lung Cancer | CELL TYPE=Mixed Oligoastrocytoma | CELL TYPE=multiple myeloma | CELL TYPE=oligodendroglioma | CELL TYPE=Ovarian Cancer | CELL TYPE=pancreatic cancer | CELL TYPE=pancreatitis | CELL TYPE=recurrent Breast cancer | CELL TYPE=sarcoma | CELL TYPE=Valley Fever","GENOTYPE=control | GENOTYPE=SET1 KD","DISEASE STATE=anaplastic astrocytoma | DISEASE STATE=anaplastic oligodendroglioma | DISEASE STATE=astrocytoma | DISEASE STATE=Glioblastoma | DISEASE STATE=oligodendroglioma | PATIENT AGE=17 | PATIENT AGE=18 | PATIENT AGE=19 | PATIENT AGE=20 | PATIENT AGE=21 | PATIENT AGE=23 | PATIENT AGE=25 | PATIENT AGE=27 | PATIENT AGE=28 | PATIENT AGE=29 | PATIENT AGE=30 | PATIENT AGE=31 | PATIENT AGE=32 | PATIENT AGE=33 | PATIENT AGE=34 | PATIENT AGE=35 | PATIENT AGE=36 | PATIENT AGE=37 | PATIENT AGE=38 | PATIENT AGE=39 | PATIENT AGE=40 | PATIENT AGE=41 | PATIENT AGE=42 | PATIENT AGE=43 | PATIENT AGE=44 | PATIENT AGE=45 | PATIENT AGE=46 | PATIENT AGE=48 | PATIENT AGE=49 | PATIENT AGE=50 | PATIENT AGE=51 | PATIENT AGE=52 | PATIENT AGE=53 | PATIENT AGE=57 | PATIENT AGE=58 | PATIENT AGE=59 | PATIENT AGE=60 | PATIENT AGE=61 | PATIENT AGE=62 | PATIENT AGE=63 | PATIENT AGE=66 | PATIENT AGE=70 | PATIENT AGE=not specified | PATIENT GENDER=1 | PATIENT GENDER=2 | PATIENT GENDER=female | PATIENT GENDER=male | PATIENT GENDER=not specified | TUMOR GRADE=WHO grade 2 | TUMOR GRADE=WHO grade 3 | TUMOR GRADE=WHO grade 4","PATIENT AGE=17 | PATIENT AGE=30 | PATIENT AGE=32 | PATIENT AGE=34 | PATIENT AGE=37 | PATIENT AGE=38 | PATIENT AGE=40 | PATIENT AGE=51 | PATIENT AGE=53 | PATIENT AGE=57 | PATIENT AGE=58 | PATIENT AGE=70 | PATIENT AGE=not specified | PATIENT GENDER=1 | PATIENT GENDER=2 | PATIENT GENDER=female | PATIENT GENDER=male | PATIENT GENDER=not specified","DISEASE STATE=anaplastic astrocytoma | DISEASE STATE=anaplastic oligodendroglioma | DISEASE STATE=astrocytoma | DISEASE STATE=Glioblastoma | DISEASE STATE=oligodendroglioma | PATIENT AGE=17 | PATIENT AGE=18 | PATIENT AGE=19 | PATIENT AGE=20 | PATIENT AGE=21 | PATIENT AGE=23 | PATIENT AGE=25 | PATIENT AGE=27 | PATIENT AGE=28 | PATIENT AGE=29 | PATIENT AGE=30 | PATIENT AGE=31 | PATIENT AGE=32 | PATIENT AGE=33 | PATIENT AGE=34 | PATIENT AGE=35 | PATIENT AGE=36 | PATIENT AGE=37 | PATIENT AGE=38 | PATIENT AGE=39 | PATIENT AGE=40 | PATIENT AGE=41 | PATIENT AGE=42 | PATIENT AGE=43 | PATIENT AGE=44 | PATIENT AGE=45 | PATIENT AGE=46 | PATIENT AGE=48 | PATIENT AGE=49 | PATIENT AGE=50 | PATIENT AGE=51 | PATIENT AGE=52 | PATIENT AGE=53 | PATIENT AGE=57 | PATIENT AGE=58 | PATIENT AGE=59 | PATIENT AGE=60 | PATIENT AGE=61 | PATIENT AGE=62 | PATIENT AGE=63 | PATIENT AGE=66 | PATIENT AGE=70 | PATIENT AGE=not specified | PATIENT GENDER=female | PATIENT GENDER=male | PATIENT GENDER=not specified | TUMOR GRADE=WHO grade 2 | TUMOR GRADE=WHO grade 3 | TUMOR GRADE=WHO grade 4","PHENOTYPE=CC214-2 resistant | PHENOTYPE=control","HOST=chick CAM (chorioallantoic membranne) | HOST=n/a | HOST=not specified | ORGANISM=Gallus gallus | ORGANISM=Homo sapiens | ORGANISM PART=CAM, at site of implantation | ORGANISM PART=CAM, distant to implantation | ORGANISM PART=CAM, pre tumour implantation | ORGANISM PART=not specified","CELL LINE=glioblastoma stem-like cell (GSC) line 12.1 | CELL LINE=glioblastoma stem-like cell (GSC) line 22","cell type=endothelial | cell type=fibroblast | cell type=glioblastoma | compound=Rad100 | compound=Unspecified | dose=1 micromolar | dose=Unspecified","age=17 | age=18 | age=19 | age=20 | age=21 | age=23 | age=25 | age=27 | age=28 | age=29 | age=30 | age=31 | age=32 | age=33 | age=34 | age=35 | age=36 | age=37 | age=38 | age=39 | age=40 | age=41 | age=42 | age=43 | age=44 | age=45 | age=46 | age=47 | age=48 | age=49 | age=50 | age=51 | age=52 | age=53 | age=54 | age=57 | age=58 | age=59 | age=60 | age=61 | age=62 | age=63 | age=66 | age=70 | clinical history=WHO grade 2 | clinical history=WHO grade 3 | clinical history=WHO grade 4 | disease=anaplastic astrocytoma | disease=anaplastic oligodendroglioma | disease=astrocytoma | disease=Glioblastoma | disease=oligodendroglioma | sex=female | sex=male","NA","CELL LINE=IstMes2 | CELL LINE=LNCAP | CELL LINE=MCF-7 | CELL TYPE=breast adenocarcinoma | CELL TYPE=mesothelioma | CELL TYPE=prostate adenocarcinoma | CULTURE TYPE=adherent | CULTURE TYPE=spheroid","TREATMENT=control empty vector transfection | TREATMENT=not specified | TREATMENT=WWOX transfection","ORGANISM PART=GBM | ORGANISM PART=normal brain","CELL TYPE=glioblastoma tumor cells | CELL TYPE=neural stem cells derived from fetal subventricular zone | M.CVIPI ACTIVITY=0U | M.CVIPI ACTIVITY=100U","disease=anaplastic astrocytoma | disease=anaplastic ependymoma | disease=astrocytoma | disease=gemistocytic astrocytoma | disease=glioblastoma | disease=haemangioblastoma | disease=meningioma | disease=metastatic adenocarcinoma | disease=metastatic large cell carcinoma | disease=pilocytic astrocytoma | tumor grading=not applicable | tumor grading=WHO grade I | tumor grading=WHO grade II | tumor grading=WHO grade III | tumor grading=WHO grade IV","AGE=25y | AGE=45y | AGE=48y | AGE=52y | AGE=56y | AGE=63y | DISEASE STATE=glioblastoma multiforme | DISEASE STATE=normal","GRADE=WHO GRADE 1 | GRADE=WHO GRADE 2 | GRADE=WHO GRADE 4","TRANSDUCTION=stably expressing non-target control shRNA | TRANSDUCTION=stably expressing shRNA against cyclophilin B","CELL LINE=GSC2 cells | CELL LINE=GSC8 cells | TRANSFECTION=pSuper-GFP-ID1-shRNA | TRANSFECTION=pSuper-GFP-Scramble-shRNA","TREATMENT=BKM 120 100 nM for 5 days | TREATMENT=DMSO | TREATMENT=LDE225 1 uM and BKM 120 100 nM for 5 days | TREATMENT=LDE225 at 1 uM for 5 days | TUMOR=hBT112 | TUMOR=hBT70","DISEASE STATE=Normal Lung Tissue sample | DISEASE STATE=SCLC Tumor sample","TREATMENT=DMSO | TREATMENT=SIO","1P19QLOH=0 | 1P19QLOH=LOH | 1P19QLOH=no loss | AGE=19 | AGE=20 | AGE=28 | AGE=31 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=37 | AGE=38 | AGE=39 | AGE=40 | AGE=41 | AGE=42 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=50 | AGE=51 | AGE=52 | AGE=53 | AGE=54 | AGE=55 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=65 | AGE=66 | AGE=67 | AGE=68 | CIMP=CIMP+ | CIMP=CIMP- | EGFR=0 | EGFR=AMP | EGFR=wt | IDH1=0 | IDH1=mut | IDH1=wt | IGS=0 | IGS=16 | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=0 | MGMT=meth | MGMT=unmeth | OR DIAGN=AOA | OR DIAGN=AOD | OS EVENT=alive | OS EVENT=deceased | OS YEARS=0.27 | OS YEARS=0.32 | OS YEARS=0.33 | OS YEARS=0.43 | OS YEARS=0.46 | OS YEARS=0.49 | OS YEARS=0.51 | OS YEARS=0.57 | OS YEARS=0.66 | OS YEARS=0.68 | OS YEARS=0.72 | OS YEARS=0.74 | OS YEARS=0.78 | OS YEARS=0.8 | OS YEARS=0.96 | OS YEARS=0.97 | OS YEARS=0.98 | OS YEARS=1.03 | OS YEARS=1.06 | OS YEARS=1.17 | OS YEARS=1.18 | OS YEARS=1.37 | OS YEARS=1.41 | OS YEARS=1.47 | OS YEARS=1.48 | OS YEARS=1.5 | OS YEARS=1.54 | OS YEARS=1.57 | OS YEARS=1.59 | OS YEARS=1.72 | OS YEARS=1.75 | OS YEARS=10.08 | OS YEARS=10.25 | OS YEARS=10.63 | OS YEARS=11.03 | OS YEARS=11.05 | OS YEARS=11.19 | OS YEARS=11.34 | OS YEARS=11.4 | OS YEARS=11.51 | OS YEARS=11.55 | OS YEARS=11.95 | OS YEARS=12.16 | OS YEARS=12.26 | OS YEARS=12.37 | OS YEARS=12.67 | OS YEARS=13.25 | OS YEARS=13.28 | OS YEARS=13.49 | OS YEARS=13.52 | OS YEARS=13.87 | OS YEARS=14.12 | OS YEARS=2.02 | OS YEARS=2.37 | OS YEARS=2.5 | OS YEARS=2.55 | OS YEARS=2.7 | OS YEARS=2.8 | OS YEARS=2.87 | OS YEARS=2.89 | OS YEARS=2.95 | OS YEARS=3.07 | OS YEARS=3.47 | OS YEARS=3.5 | OS YEARS=3.61 | OS YEARS=3.72 | OS YEARS=3.78 | OS YEARS=3.82 | OS YEARS=4.16 | OS YEARS=4.21 | OS YEARS=4.95 | OS YEARS=5.61 | OS YEARS=5.91 | OS YEARS=6.11 | OS YEARS=6.28 | OS YEARS=6.65 | OS YEARS=7.06 | OS YEARS=8.2 | OS YEARS=8.42 | OS YEARS=8.58 | OS YEARS=9.22 | OS YEARS=9.32 | OS YEARS=9.51 | OS YEARS=9.53 | OS YEARS=9.99 | PERF=0 | PERF=1 | PERF=2 | PFS EVENT=no prog | PFS EVENT=prog | PFS YEARS=0.04 | PFS YEARS=0.12 | PFS YEARS=0.17 | PFS YEARS=0.22 | PFS YEARS=0.24 | PFS YEARS=0.27 | PFS YEARS=0.28 | PFS YEARS=0.32 | PFS YEARS=0.36 | PFS YEARS=0.37 | PFS YEARS=0.39 | PFS YEARS=0.4 | PFS YEARS=0.41 | PFS YEARS=0.46 | PFS YEARS=0.47 | PFS YEARS=0.48 | PFS YEARS=0.51 | PFS YEARS=0.52 | PFS YEARS=0.59 | PFS YEARS=0.65 | PFS YEARS=0.7 | PFS YEARS=0.73 | PFS YEARS=0.77 | PFS YEARS=0.82 | PFS YEARS=0.94 | PFS YEARS=1.07 | PFS YEARS=1.11 | PFS YEARS=1.2 | PFS YEARS=1.22 | PFS YEARS=1.23 | PFS YEARS=1.28 | PFS YEARS=1.41 | PFS YEARS=1.43 | PFS YEARS=1.45 | PFS YEARS=1.47 | PFS YEARS=1.62 | PFS YEARS=1.7 | PFS YEARS=1.84 | PFS YEARS=1.86 | PFS YEARS=1.95 | PFS YEARS=10.25 | PFS YEARS=11.03 | PFS YEARS=11.19 | PFS YEARS=11.34 | PFS YEARS=11.4 | PFS YEARS=11.51 | PFS YEARS=11.55 | PFS YEARS=12.16 | PFS YEARS=12.26 | PFS YEARS=12.37 | PFS YEARS=12.67 | PFS YEARS=13.25 | PFS YEARS=13.28 | PFS YEARS=13.49 | PFS YEARS=13.52 | PFS YEARS=13.87 | PFS YEARS=14.12 | PFS YEARS=2.02 | PFS YEARS=2.21 | PFS YEARS=2.81 | PFS YEARS=2.82 | PFS YEARS=2.87 | PFS YEARS=3.35 | PFS YEARS=3.62 | PFS YEARS=4.08 | PFS YEARS=4.12 | PFS YEARS=4.16 | PFS YEARS=4.21 | PFS YEARS=4.75 | PFS YEARS=5.18 | PFS YEARS=5.36 | PFS YEARS=5.68 | PFS YEARS=5.85 | PFS YEARS=8.2 | PFS YEARS=9.32 | PFS YEARS=9.51 | PFS YEARS=9.99 | REV DIAGN=0 | REV DIAGN=AA/GBM | REV DIAGN=AOA | REV DIAGN=AOD | REV DIAGN=LGG | SEX=female | SEX=male | SEX=not specified | SURGERY=1 | SURGERY=2 | SURGERY=3 | TRT=RT | TRT=RT/PCV | TUM LOC=1 | TUM LOC=2 | TUM LOC=3 | TUM LOC=4 | TUM LOC=5 | TUM LOC=8 | TUM LOC=9","1P19QLOH=0 | 1P19QLOH=LOH | 1P19QLOH=no loss | AGE=20 | AGE=28 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=37 | AGE=39 | AGE=40 | AGE=42 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=49 | AGE=51 | AGE=52 | AGE=53 | AGE=54 | AGE=55 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=66 | AGE=67 | AGE=68 | CIMP=CIMP+ | CIMP=CIMP- | EGFR=0 | EGFR=AMP | EGFR=wt | IDH1=0 | IDH1=mut | IDH1=wt | IGS=0 | IGS=16 | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=0 | MGMT=meth | MGMT=unmeth | OR DIAGN=AOA | OR DIAGN=AOD | OS EVENT=alive | OS EVENT=deceased | OS YEARS=0.32 | OS YEARS=0.43 | OS YEARS=0.46 | OS YEARS=0.57 | OS YEARS=0.66 | OS YEARS=0.68 | OS YEARS=0.72 | OS YEARS=0.74 | OS YEARS=0.78 | OS YEARS=0.8 | OS YEARS=0.97 | OS YEARS=0.98 | OS YEARS=1.06 | OS YEARS=1.41 | OS YEARS=1.47 | OS YEARS=1.48 | OS YEARS=1.5 | OS YEARS=1.59 | OS YEARS=1.72 | OS YEARS=1.75 | OS YEARS=10.08 | OS YEARS=10.25 | OS YEARS=10.63 | OS YEARS=11.03 | OS YEARS=11.19 | OS YEARS=11.34 | OS YEARS=11.51 | OS YEARS=11.55 | OS YEARS=11.95 | OS YEARS=12.16 | OS YEARS=12.26 | OS YEARS=12.37 | OS YEARS=13.28 | OS YEARS=13.52 | OS YEARS=14.12 | OS YEARS=2.02 | OS YEARS=2.37 | OS YEARS=2.55 | OS YEARS=2.8 | OS YEARS=2.87 | OS YEARS=2.89 | OS YEARS=3.07 | OS YEARS=3.5 | OS YEARS=3.61 | OS YEARS=3.78 | OS YEARS=3.82 | OS YEARS=4.16 | OS YEARS=5.61 | OS YEARS=5.91 | OS YEARS=6.28 | OS YEARS=6.65 | OS YEARS=7.06 | OS YEARS=8.58 | OS YEARS=9.22 | OS YEARS=9.32 | OS YEARS=9.51 | OS YEARS=9.53 | OS YEARS=9.99 | PERF=0 | PERF=1 | PERF=2 | PFS EVENT=no prog | PFS EVENT=prog | PFS YEARS=0.17 | PFS YEARS=0.27 | PFS YEARS=0.28 | PFS YEARS=0.32 | PFS YEARS=0.36 | PFS YEARS=0.37 | PFS YEARS=0.39 | PFS YEARS=0.4 | PFS YEARS=0.46 | PFS YEARS=0.47 | PFS YEARS=0.48 | PFS YEARS=0.52 | PFS YEARS=0.59 | PFS YEARS=0.65 | PFS YEARS=0.73 | PFS YEARS=0.77 | PFS YEARS=0.94 | PFS YEARS=1.07 | PFS YEARS=1.11 | PFS YEARS=1.2 | PFS YEARS=1.22 | PFS YEARS=1.45 | PFS YEARS=1.47 | PFS YEARS=1.62 | PFS YEARS=1.7 | PFS YEARS=1.84 | PFS YEARS=1.86 | PFS YEARS=1.95 | PFS YEARS=10.25 | PFS YEARS=11.03 | PFS YEARS=11.19 | PFS YEARS=11.34 | PFS YEARS=11.51 | PFS YEARS=11.55 | PFS YEARS=12.16 | PFS YEARS=12.26 | PFS YEARS=12.37 | PFS YEARS=13.28 | PFS YEARS=13.52 | PFS YEARS=14.12 | PFS YEARS=2.02 | PFS YEARS=2.21 | PFS YEARS=2.81 | PFS YEARS=2.82 | PFS YEARS=2.87 | PFS YEARS=4.08 | PFS YEARS=4.16 | PFS YEARS=4.75 | PFS YEARS=5.18 | PFS YEARS=5.36 | PFS YEARS=5.68 | PFS YEARS=5.85 | PFS YEARS=9.32 | PFS YEARS=9.51 | PFS YEARS=9.99 | REV DIAGN=0 | REV DIAGN=AA/GBM | REV DIAGN=AOA | REV DIAGN=AOD | REV DIAGN=LGG | SEX=female | SEX=male | SURGERY=1 | SURGERY=2 | SURGERY=3 | TRT=RT | TRT=RT/PCV | TUM LOC=1 | TUM LOC=2 | TUM LOC=3 | TUM LOC=8 | TUM LOC=9","1P19QLOH=0 | 1P19QLOH=LOH | 1P19QLOH=no loss | AGE=19 | AGE=20 | AGE=31 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=38 | AGE=39 | AGE=41 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=50 | AGE=51 | AGE=53 | AGE=55 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=65 | AGE=66 | AGE=67 | AGE=68 | CIMP=CIMP+ | CIMP=CIMP- | EGFR=0 | EGFR=AMP | EGFR=wt | IDH1=0 | IDH1=mut | IDH1=wt | IGS=0 | IGS=16 | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=0 | MGMT=meth | MGMT=unmeth | OR DIAGN=AOA | OR DIAGN=AOD | OS EVENT=alive | OS EVENT=deceased | OS YEARS=0.27 | OS YEARS=0.32 | OS YEARS=0.33 | OS YEARS=0.46 | OS YEARS=0.49 | OS YEARS=0.51 | OS YEARS=0.78 | OS YEARS=0.8 | OS YEARS=0.96 | OS YEARS=0.98 | OS YEARS=1.03 | OS YEARS=1.17 | OS YEARS=1.18 | OS YEARS=1.37 | OS YEARS=1.41 | OS YEARS=1.48 | OS YEARS=1.5 | OS YEARS=1.54 | OS YEARS=1.57 | OS YEARS=1.59 | OS YEARS=10.08 | OS YEARS=10.25 | OS YEARS=11.05 | OS YEARS=11.19 | OS YEARS=11.34 | OS YEARS=11.4 | OS YEARS=11.51 | OS YEARS=11.95 | OS YEARS=12.16 | OS YEARS=12.37 | OS YEARS=12.67 | OS YEARS=13.25 | OS YEARS=13.49 | OS YEARS=13.52 | OS YEARS=13.87 | OS YEARS=2.37 | OS YEARS=2.5 | OS YEARS=2.55 | OS YEARS=2.7 | OS YEARS=2.8 | OS YEARS=2.95 | OS YEARS=3.47 | OS YEARS=3.61 | OS YEARS=3.72 | OS YEARS=3.78 | OS YEARS=4.16 | OS YEARS=4.21 | OS YEARS=4.95 | OS YEARS=5.61 | OS YEARS=5.91 | OS YEARS=6.11 | OS YEARS=7.06 | OS YEARS=8.2 | OS YEARS=8.42 | OS YEARS=9.32 | OS YEARS=9.51 | OS YEARS=9.53 | OS YEARS=9.99 | PERF=0 | PERF=1 | PERF=2 | PFS EVENT=no prog | PFS EVENT=prog | PFS YEARS=0.04 | PFS YEARS=0.12 | PFS YEARS=0.17 | PFS YEARS=0.22 | PFS YEARS=0.24 | PFS YEARS=0.27 | PFS YEARS=0.32 | PFS YEARS=0.37 | PFS YEARS=0.41 | PFS YEARS=0.46 | PFS YEARS=0.48 | PFS YEARS=0.51 | PFS YEARS=0.59 | PFS YEARS=0.7 | PFS YEARS=0.77 | PFS YEARS=0.82 | PFS YEARS=0.94 | PFS YEARS=1.07 | PFS YEARS=1.11 | PFS YEARS=1.23 | PFS YEARS=1.28 | PFS YEARS=1.41 | PFS YEARS=1.43 | PFS YEARS=1.62 | PFS YEARS=1.86 | PFS YEARS=10.25 | PFS YEARS=11.19 | PFS YEARS=11.34 | PFS YEARS=11.4 | PFS YEARS=11.51 | PFS YEARS=12.16 | PFS YEARS=12.37 | PFS YEARS=12.67 | PFS YEARS=13.25 | PFS YEARS=13.49 | PFS YEARS=13.52 | PFS YEARS=13.87 | PFS YEARS=2.02 | PFS YEARS=2.81 | PFS YEARS=2.87 | PFS YEARS=3.35 | PFS YEARS=3.62 | PFS YEARS=4.12 | PFS YEARS=4.16 | PFS YEARS=4.21 | PFS YEARS=4.75 | PFS YEARS=5.36 | PFS YEARS=5.68 | PFS YEARS=5.85 | PFS YEARS=8.2 | PFS YEARS=9.51 | PFS YEARS=9.99 | REV DIAGN=0 | REV DIAGN=AA/GBM | REV DIAGN=AOA | REV DIAGN=AOD | REV DIAGN=LGG | SEX=female | SEX=male | SURGERY=1 | SURGERY=2 | SURGERY=3 | TRT=RT | TRT=RT/PCV | TUM LOC=1 | TUM LOC=2 | TUM LOC=3 | TUM LOC=4 | TUM LOC=5 | TUM LOC=8 | TUM LOC=9","disease=Astrocytoma, Pilocytic | disease=ependymoma | disease=glioblastoma | disease=medulloblastoma | disease=normal","AGE=21 | AGE=38 | AGE=40 | AGE=43 | AGE=53 | AGE=not specified | CELL TYPE=differentiated cells | CELL TYPE=stem cells | CELL TYPE=tissue | GROWTH TYPE=adherent | GROWTH TYPE=neurospheres | GROWTH TYPE=not specified | ORGANISM PART=brain grey matter | ORGANISM PART=brain white matter | ORGANISM PART=Glioblastoma | ORGANISM PART=hippocampus | ORGANISM PART=subventricular zone | PASSAGE=0 | PASSAGE=1 | PASSAGE=2 | PASSAGE=3 | PASSAGE=4 | PASSAGE=5 | PASSAGE=9 | SEX=female | SEX=male | SEX=not specified","AGE=21 | AGE=43 | AGE=53 | AGE=not specified | GROWTH TYPE=adherent | GROWTH TYPE=neurospheres | ORGANISM PART=brain grey matter | ORGANISM PART=brain white matter | ORGANISM PART=Glioblastoma | ORGANISM PART=subventricular zone | PASSAGE=1 | PASSAGE=2 | PASSAGE=3 | PASSAGE=4 | PASSAGE=5","TREATMENT=IkappaB repressor | TREATMENT=TNFalpha challenged | TREATMENT=TNFalpha challenged + IkappaB repressor | TREATMENT=vector control","NA","CELL TYPE=cultured GSCs | CELL TYPE=Glioma Stem Cells isolated from glioblastoma | TREATMENT=IkappaB repressor | TREATMENT=not specified | TREATMENT=TNFalpha challenged | TREATMENT=TNFalpha challenged + IkappaB repressor | TREATMENT=vector control","AGE Y=46 | AGE Y=55 | AGE Y=56 | AGE Y=58 | AGE Y=59 | AGE Y=76 | AGE Y=not specified | SEX=female | SEX=male | TUMOR GRADE=IV | TUMOR GRADE=Not applicable | TUMOR GRADE=not specified","AGE Y=46 | AGE Y=55 | AGE Y=58 | AGE Y=59 | AGE Y=76 | AGE Y=not specified | SEX=female | SEX=male","AGE Y=46 | AGE Y=55 | AGE Y=56 | AGE Y=58 | AGE Y=59 | AGE Y=76 | SEX=female | SEX=male | TUMOR GRADE=IV | TUMOR GRADE=Not applicable","AGE=1 | AGE=10 | AGE=10 months | AGE=11 | AGE=12 | AGE=14 | AGE=15 | AGE=16 | AGE=2 | AGE=2 months | AGE=20 weeks | AGE=21 | AGE=22 | AGE=24 | AGE=24 weeks | AGE=25 | AGE=26 | AGE=26 weeks | AGE=27 | AGE=3 | AGE=32 weeks | AGE=33 weeks | AGE=37 weeks | AGE=38 weeks | AGE=4 | AGE=41 | AGE=6 | AGE=6 months | AGE=7 | AGE=7 months | AGE=8 | AGE=82 | AGE=9 | AGE=9 months | AGE=nd | GRADE=I | GRADE=II | GRADE=III | GRADE=IV | GRADE=ND | GRADE=not specified | ORGANISM PART=Adult control cerebellum | ORGANISM PART=Adult control frontal lobe | ORGANISM PART=anaplastic astrocytoma | ORGANISM PART=Atypical teratoid/rhabdoid tumour | ORGANISM PART=Choroid plexus papilloma | ORGANISM PART=Diffuse astrocytoma | ORGANISM PART=Ependymoma | ORGANISM PART=Foetal Cerebellum | ORGANISM PART=Foetal Frontal Lobe | ORGANISM PART=Glioblastoma | ORGANISM PART=medulloblastoma | ORGANISM PART=Pilocytic Astrocytoma | SEX=female | SEX=male","AGE=1 | AGE=10 | AGE=10 months | AGE=11 | AGE=12 | AGE=14 | AGE=15 | AGE=16 | AGE=2 | AGE=2 months | AGE=20 weeks | AGE=21 | AGE=22 | AGE=24 | AGE=24 weeks | AGE=25 | AGE=26 | AGE=26 weeks | AGE=27 | AGE=3 | AGE=32 weeks | AGE=33 weeks | AGE=37 weeks | AGE=38 weeks | AGE=4 | AGE=41 | AGE=6 | AGE=6 months | AGE=7 | AGE=7 months | AGE=8 | AGE=82 | AGE=9 | AGE=9 months | AGE=nd | GRADE=I | GRADE=II | GRADE=III | GRADE=IV | GRADE=ND | GRADE=not specified | ORGANISM PART=Adult control cerebellum | ORGANISM PART=Adult control frontal lobe | ORGANISM PART=anaplastic astrocytoma | ORGANISM PART=Atypical teratoid/rhabdoid tumour | ORGANISM PART=Choroid plexus papilloma | ORGANISM PART=Diffuse astrocytoma | ORGANISM PART=Ependymoma | ORGANISM PART=Foetal Cerebellum | ORGANISM PART=Foetal Frontal Lobe | ORGANISM PART=Glioblastoma | ORGANISM PART=medulloblastoma | ORGANISM PART=Pilocytic Astrocytoma | SEX=female | SEX=male","AGE=33 | AGE=35 | AGE=39 | AGE=44 | AGE=48 | AGE=50 | AGE=56 | AGE=60 | AGE=61 | AGE=64 | AGE=69 | AGE=71 | CELL TYPE=adult neural stem cells | CELL TYPE=glioma stem cells | ORIGIN=primary glioblastoma tissue | ORIGIN=subventricular zone, human brain tissue | SEX=female | SEX=male | TUMOUR STAGE=normal | TUMOUR STAGE=primary glioblastoma","ANTIBODY CATALOG NUMBER=Bethyl A300-793A | ANTIBODY CATALOG NUMBER=Bethyl A301-985A | ANTIBODY CATALOG NUMBER=Bethyl A301-985A-1 | ANTIBODY CATALOG NUMBER=None WCE | ANTIBODY CATALOG NUMBER=Santa Cruz SC-484 | ANTIBODY CATALOG NUMBER=Santa Cruz SC-6059 | ANTIBODY CATALOG NUMBER=Santa Cruz SC-899 | CELL TYPE=H2171 | CELL TYPE=MM1.S | CELL TYPE=plasma cell | CELL TYPE=U87 | CHIP ANTIBODY=Brd4 | CHIP ANTIBODY=Cdk9 | CHIP ANTIBODY=IRF4 | CHIP ANTIBODY=Med1/TRAP220 | CHIP ANTIBODY=None | CHIP ANTIBODY=RNA Pol II (Rpb1 N-terminus) | CONCENTRATION=150nM | CONCENTRATION=500nM | CONCENTRATION=50nM | CONCENTRATION=5nM | CONCENTRATION=5uM | CONCENTRATION=not specified | DRUG=DMSO | DRUG=JQ1 | DRUG=not specified","NA","cell line=786-0 | cell line=A375 | cell line=A549 | cell line=A549/Asc-1 | cell line=AS283 | cell line=AsPC-1 | cell line=CA46 | cell line=Caki-1 | cell line=CCRF-CEM | cell line=COLO 205 | cell line=COLO 829 | cell line=CP70 | cell line=EKVX | cell line=GTL-16 | cell line=HCC-2998 | cell line=HCT-116 | cell line=HCT-15 | cell line=HeLa-Luc | cell line=HL-60(TB) | cell line=HOP-62 | cell line=HOP-92 | cell line=HT-29 | cell line=HuH-7 | cell line=K-562 | cell line=KM12 | cell line=LOX IMVI | cell line=M14 | cell line=MALME-3M | cell line=MCF7 | cell line=MDA-MB-231T | cell line=MDA-MB-435 | cell line=MDA-N | cell line=MOLT-4 | cell line=NCI-H226 | cell line=NCI-H23 | cell line=NCI-H460 | cell line=NCI-H522 | cell line=OVCAR-3 | cell line=OVCAR-5 | cell line=PC-3 | cell line=PC-3/M | cell line=RXF 393 | cell line=SF-268 | cell line=SF-539 | cell line=SN12C | cell line=SR | cell line=SW-620 | cell line=U251 | cell line=UACC-62 | disease=acute lymphoblastic (T-ALL) leukemia | disease=acute lymphoblastic leukemia | disease=adenocarcinoma HER2/ERBB2 transfectant of MDA-MB-435 melanoma | disease=adenocarcinoma of colon | disease=adenocarcinoma of lung | disease=adenocarcinoma of prostate | disease=adenocarcinoma prostate PC-3 subline isolated from liver metastasis in mice | disease=adenocarcinoma, breast grown from mouse mammary fat pad | disease=AIDs related Burkitts lymphoma | disease=anaplastic astrocytoma | disease=breast adenocarcinoma | disease=carcinoma, renal cell | disease=cervical adenocarcinoma | disease=chronic myelogenous (blast crisis) leukemia | disease=colon carcinoma | disease=gastric adenocarcinoma | disease=glioblastoma | disease=hepatocellular carcinoma | disease=large cell lung carcinoma | disease=large cell undifferentiated lung | disease=lymphoblastic Burkitt's lymphoma | disease=malignant amelanocytic melanoma | disease=malignant melanoma | disease=melanoma | disease=metastatic malignant melanoma | disease=non-small cell lung carcinoma | disease=ovarian adenocarcinoma | disease=ovarian carcinoma | disease=pancreatic adenocarcinoma | disease=poorly differentiated B cell origin leukemia | disease=poorly differentiated hypernephroma | disease=promyelocytic leukemia | disease=renal adenocarcinoma | disease=renal carcinoma | disease=squamous cell lung carcinoma | passage=P0 | passage=P01 | passage=P04 | passage=P10","NA","INJECTED CELL LINE=NSC11 | INJECTED CELL LINE=NSC11R | INJECTED CELL LINE=U87 | INJECTED CELL LINE=U87R | TREATMENT=bevacizumab (Avastin) | TREATMENT=none","CELL SUBTYPE=monolayer | CELL SUBTYPE=Spheroid","CELL LINE=HepG2 | CELL LINE=K562 | TRANSFECTED WITH=scrambled siRNA (control) | TRANSFECTED WITH=siRNA against ADAR1 (ADAR knock down)","CELL LINE=HepG2 | CELL LINE=K562 | GENOTYPE=control | GENOTYPE=knock down ADAR expression (ADAR KD | TRANSFECTED WITH=scrambled siRNA (control) | TRANSFECTED WITH=siRNA against ADAR1 (ADARkd)","cell line=22Rv1 | cell line=23132/87 | cell line=253J | cell line=253J-BV | cell line=42-MG-BA | cell line=5637 | cell line=59M | cell line=639-V | cell line=647-V | cell line=697 | cell line=769-P | cell line=786-O | cell line=8-MG-BA | cell line=8305C | cell line=8505C | cell line=A-204 | cell line=A-253 | cell line=A-375 | cell line=A-498 | cell line=A-673 | cell line=A-704 | cell line=A101D | cell line=A172 | cell line=A2058 | cell line=A2780 | cell line=A3/KAW | cell line=A4/Fuk | cell line=A549 | cell line=ABC-1 | cell line=ACC-MESO-1 | cell line=ACHN | cell line=AGS | cell line=ALL-SIL | cell line=AM-38 | cell line=AML-193 | cell line=AMO-1 | cell line=AN3 CA | cell line=AsPC-1 | cell line=AU565 | cell line=B-CPAP | cell line=BC-3C | cell line=BCP-1 | cell line=BDCM | cell line=BEN | cell line=BFTC-905 | cell line=BFTC-909 | cell line=BHT-101 | cell line=BHY | cell line=BICR 16 | cell line=BICR 18 | cell line=BICR 22 | cell line=BICR 31 | cell line=BICR 56 | cell line=BICR 6 | cell line=BL-41 | cell line=BL-70 | cell line=BT-20 | cell line=BT-474 | cell line=BT-483 | cell line=BT-549 | cell line=BV-173 | cell line=BxPC-3 | cell line=C2BBe1 | cell line=C32 | cell line=CA46 | cell line=CADO-ES1 | cell line=Caki-1 | cell line=Caki-2 | cell line=CAL 27 | cell line=CAL-120 | cell line=CAL-12T | cell line=CAL-148 | cell line=CAL-29 | cell line=CAL-33 | cell line=CAL-51 | cell line=CAL-54 | cell line=CAL-62 | cell line=CAL-78 | cell line=CAL-85-1 | cell line=Calu-1 | cell line=Calu-3 | cell line=Calu-6 | cell line=CAMA-1 | cell line=Caov-3 | cell line=Caov-4 | cell line=Capan-1 | cell line=Capan-2 | cell line=CAS-1 | cell line=CCF-STTG1 | cell line=CCK-81 | cell line=CFPAC-1 | cell line=ChaGo-K-1 | cell line=CHP-126 | cell line=CHP-212 | cell line=CI-1 | cell line=CJM | cell line=CL-11 | cell line=CL-14 | cell line=CL-34 | cell line=CL-40 | cell line=CMK | cell line=CML-T1 | cell line=COLO 201 | cell line=COLO 668 | cell line=COLO 684 | cell line=COLO 741 | cell line=COLO 792 | cell line=COLO 829 | cell line=COLO-320 | cell line=COLO-678 | cell line=COLO-679 | cell line=COLO-680N | cell line=COLO-783 | cell line=COLO-800 | cell line=COR-L105 | cell line=COR-L23 | cell line=COR-L24 | cell line=COR-L279 | cell line=COR-L311 | cell line=COR-L47 | cell line=COR-L88 | cell line=COR-L95 | cell line=COV318 | cell line=COV362 | cell line=COV434 | cell line=COV644 | cell line=CW-2 | cell line=D283 Med | cell line=D341 Med | cell line=DAN-G | cell line=Daoy | cell line=Daudi | cell line=DB | cell line=DBTRG-05MG | cell line=DEL | cell line=Detroit 562 | cell line=DK-MG | cell line=DM-3 | cell line=DMS 114 | cell line=DMS 153 | cell line=DMS 273 | cell line=DMS 454 | cell line=DMS 53 | cell line=DMS 79 | cell line=DND-41 | cell line=DOHH-2 | cell line=DU 145 | cell line=DU4475 | cell line=DV-90 | cell line=EB1 | cell line=EBC-1 | cell line=EC-GI-10 | cell line=ECC10 | cell line=ECC12 | cell line=EFE-184 | cell line=EFM-19 | cell line=EFM-192A | cell line=EFO-21 | cell line=EFO-27 | cell line=EHEB | cell line=EJM | cell line=EKVX | cell line=EKVX-v1 | cell line=EM-2 | cell line=EN | cell line=EOL-1 | cell line=EPLC-272H | cell line=ES-2 | cell line=ESS-1 | cell line=F-36P | cell line=FaDu | cell line=FTC-133 | cell line=FTC-238 | cell line=FU-OV-1 | cell line=FU97 | cell line=G-292-clone-A141B1 | cell line=G-361 | cell line=G-401 | cell line=G-402 | cell line=GA-10 | cell line=GAMG | cell line=GB-1 | cell line=GCIY | cell line=GCT | cell line=GDM-1 | cell line=GI-1 | cell line=GMS-10 | cell line=GOS-3 | cell line=GP2d | cell line=GRANTA-519 | cell line=GSS | cell line=GSU | cell line=H4 | cell line=HARA | cell line=HCC-1171 | cell line=HCC-1195 | cell line=HCC-1359 | cell line=HCC-1438 | cell line=HCC-15 | cell line=HCC-1588 | cell line=HCC-1833 | cell line=HCC-2108 | cell line=HCC-2279 | cell line=HCC-33 | cell line=HCC-366 | cell line=HCC-44 | cell line=HCC-56 | cell line=HCC-78 | cell line=HCC-95 | cell line=HCC1143 | cell line=HCC1187 | cell line=HCC1395 | cell line=HCC1419 | cell line=HCC1428 | cell line=HCC1500 | cell line=HCC1569 | cell line=HCC1599 | cell line=HCC1806 | cell line=HCC1937 | cell line=HCC1954 | cell line=HCC202 | cell line=HCC2157 | cell line=HCC2218 | cell line=HCC2935 | cell line=HCC38 | cell line=HCC4006 | cell line=HCC70 | cell line=HCC827 | cell line=HCT 116 | cell line=HCT-15 | cell line=HD-MY-Z | cell line=HDQ-P1 | cell line=HEC-1-A | cell line=HEC-1-B | cell line=HEC-108 | cell line=HEC-151 | cell line=HEC-251 | cell line=HEC-265 | cell line=HEC-50B | cell line=HEC-59 | cell line=HEC-6 | cell line=HEL | cell line=HEL 92.1.7 | cell line=Hep 3B2.1-7 | cell line=Hep G2 | cell line=Hey-A8 | cell line=HGC-27 | cell line=HH | cell line=HL-60 | cell line=HLF | cell line=HLF-a | cell line=HMC-1-8 | cell line=HMCB | cell line=HOP-62 | cell line=HOP-62-v1 | cell line=HOP-92 | cell line=HOS | cell line=HPAC | cell line=HPAF-II | cell line=HPB-ALL | cell line=Hs 172.T | cell line=Hs 229.T | cell line=Hs 255.T | cell line=Hs 281.T | cell line=Hs 294T | cell line=Hs 343.T | cell line=Hs 578T | cell line=Hs 600.T | cell line=Hs 606.T | cell line=Hs 611.T | cell line=Hs 616.T | cell line=Hs 618.T | cell line=Hs 675.T | cell line=Hs 683 | cell line=Hs 688(A).T | cell line=Hs 695T | cell line=Hs 698.T | cell line=Hs 706.T | cell line=Hs 729 | cell line=Hs 737.T | cell line=Hs 739.T | cell line=Hs 742.T | cell line=Hs 746T | cell line=Hs 766T | cell line=Hs 819.T | cell line=Hs 821.T | cell line=Hs 822.T | cell line=Hs 834.T | cell line=Hs 839.T | cell line=Hs 840.T | cell line=Hs 852.T | cell line=Hs 863.T | cell line=Hs 870.T | cell line=Hs 888.T | cell line=Hs 895.T | cell line=Hs 934.T | cell line=Hs 936.T | cell line=Hs 939.T | cell line=Hs 940.T | cell line=Hs 944.T | cell line=HSC-2 | cell line=HSC-3 | cell line=HSC-4 | cell line=HT | cell line=HT-1080 | cell line=HT-1197 | cell line=HT-1376 | cell line=HT-144 | cell line=HT-29 | cell line=HT115 | cell line=HT55 | cell line=HuCCT1 | cell line=HuG1-N | cell line=huH-1 | cell line=HuH-6 | cell line=HuH-7 | cell line=HuNS1 | cell line=HUP-T3 | cell line=HUP-T4 | cell line=HuT 102 | cell line=HuT 78 | cell line=HuTu 80 | cell line=IA-LM | cell line=IGR-1 | cell line=IGR-37 | cell line=IGROV1 | cell line=IM95 | cell line=IMR-32 | cell line=IPC-298 | cell line=Ishikawa (Heraklio) 02 ER- | cell line=IST-MES1 | cell line=IST-MES2 | cell line=J82 | cell line=JeKo-1 | cell line=JHH-1 | cell line=JHH-2 | cell line=JHH-4 | cell line=JHH-5 | cell line=JHH-6 | cell line=JHH-7 | cell line=JHOC-5 | cell line=JHOM-1 | cell line=JHOM-2B | cell line=JHOS-2 | cell line=JHOS-4 | cell line=JHUEM-1 | cell line=JHUEM-2 | cell line=JHUEM-3 | cell line=JHUEM-7 | cell line=JIMT-1 | cell line=JJN-3 | cell line=JK-1 | cell line=JL-1 | cell line=JM1 | cell line=JMSU-1 | cell line=JURKAT | cell line=JURL-MK1 | cell line=JVM-2 | cell line=JVM-3 | cell line=K-562 | cell line=K029AX | cell line=KALS-1 | cell line=KARPAS-299 | cell line=KARPAS-422 | cell line=KARPAS-620 | cell line=KASUMI-1 | cell line=KASUMI-2 | cell line=Kasumi-6 | cell line=KATO III | cell line=KCL-22 | cell line=KE-37 | cell line=KE-39 | cell line=KE-97 | cell line=KELLY | cell line=KG-1 | cell line=KG-1-C | cell line=KHM-1B | cell line=Ki-JK | cell line=KLE | cell line=KM-H2 | cell line=KM12 | cell line=KMBC-2 | cell line=KMM-1 | cell line=KMRC-1 | cell line=KMRC-2 | cell line=KMRC-20 | cell line=KMRC-3 | cell line=KMS-11 | cell line=KMS-12-BM | cell line=KMS-20 | cell line=KMS-21BM | cell line=KMS-26 | cell line=KMS-27 | cell line=KMS-28BM | cell line=KMS-34 | cell line=KNS-42 | cell line=KNS-60 | cell line=KNS-62 | cell line=KNS-81 | cell line=KOPN-8 | cell line=KP-2 | cell line=KP-3 | cell line=KP-N-RT-BM-1 | cell line=KP-N-SI9s | cell line=KP-N-YN | cell line=KP4 | cell line=KPL-1 | cell line=KS-1 | cell line=KU-19-19 | cell line=KU812 | cell line=KURAMOCHI | cell line=KYM-1 | cell line=KYO-1 | cell line=KYSE-140 | cell line=KYSE-150 | cell line=KYSE-180 | cell line=KYSE-270 | cell line=KYSE-30 | cell line=KYSE-410 | cell line=KYSE-450 | cell line=KYSE-510 | cell line=KYSE-520 | cell line=KYSE-70 | cell line=L-1236 | cell line=L-363 | cell line=L-428 | cell line=L-540 | cell line=L3.3 | cell line=LAMA-84 | cell line=LC-1F | cell line=LCLC-103H | cell line=LCLC-97TM1 | cell line=Li-7 | cell line=LK-2 | cell line=LMSU | cell line=LN-18 | cell line=LN-229 | cell line=LNCaP clone FGC | cell line=LOU-NH91 | cell line=Loucy | cell line=LoVo | cell line=LOX IMVI | cell line=LP-1 | cell line=LS 180 | cell line=LS1034 | cell line=LS123 | cell line=LS411N | cell line=LS513 | cell line=LU65 | cell line=LU99 | cell line=LUDLU-1 | cell line=LXF-289 | cell line=M-07e | cell line=M059K | cell line=Malme-3M | cell line=MC116 | cell line=MCAS | cell line=MCF7 | cell line=MDA PCa 2b | cell line=MDA-MB-134-VI | cell line=MDA-MB-157 | cell line=MDA-MB-175-VII | cell line=MDA-MB-231 | cell line=MDA-MB-361 | cell line=MDA-MB-415 | cell line=MDA-MB-435S | cell line=MDA-MB-436 | cell line=MDA-MB-453 | cell line=MDA-MB-468 | cell line=MDST8 | cell line=ME-1 | cell line=MEC-1 | cell line=MEG-01 | cell line=MEL-HO | cell line=MEL-JUSO | cell line=MES-SA | cell line=MeWo | cell line=MFE-280 | cell line=MFE-296 | cell line=MFE-319 | cell line=MG-63 | cell line=MHH-CALL-2 | cell line=MHH-CALL-3 | cell line=MHH-CALL-4 | cell line=MHH-ES-1 | cell line=MHH-NB-11 | cell line=MIA PaCa-2 | cell line=Mino | cell line=MJ | cell line=MKN-45 | cell line=MKN1 | cell line=MKN7 | cell line=MKN74 | cell line=ML-1 | cell line=MM1-S | cell line=MOLM-13 | cell line=MOLM-16 | cell line=MOLM-6 | cell line=MOLP-2 | cell line=MOLP-8 | cell line=MOLT-13 | cell line=MOLT-16 | cell line=MOLT-3 | cell line=MONO-MAC-1 | cell line=MONO-MAC-6 | cell line=MOR/CPR | cell line=MPP 89 | cell line=MSTO-211H | cell line=MUTZ-3 | cell line=MUTZ-5 | cell line=MV-4-11 | cell line=NALM-1 | cell line=NALM-19 | cell line=NALM-6 | cell line=NAMALWA | cell line=NB-1 | cell line=NB-4 | cell line=NCC-StC-K140 | cell line=NCI-H1048 | cell line=NCI-H1092 | cell line=NCI-H1105 | cell line=NCI-H1155 | cell line=NCI-H1184 | cell line=NCI-H1299 | cell line=NCI-H1339 | cell line=NCI-H1341 | cell line=NCI-H1355 | cell line=NCI-H1385 | cell line=NCI-H1395 | cell line=NCI-H1435 | cell line=NCI-H1436 | cell line=NCI-H1437 | cell line=NCI-H146 | cell line=NCI-H1563 | cell line=NCI-H1568 | cell line=NCI-H1573 | cell line=NCI-H1581 | cell line=NCI-H1618 | cell line=NCI-H1623 | cell line=NCI-H1648 | cell line=NCI-H1650 | cell line=NCI-H1651 | cell line=NCI-H1666 | cell line=NCI-H1693 | cell line=NCI-H1694 | cell line=NCI-H1703 | cell line=NCI-H1734 | cell line=NCI-H1755 | cell line=NCI-H1781 | cell line=NCI-H1792 | cell line=NCI-H1793 | cell line=NCI-H1838 | cell line=NCI-H1869 | cell line=NCI-H1876 | cell line=NCI-H1915 | cell line=NCI-H1930 | cell line=NCI-H1944 | cell line=NCI-H196 | cell line=NCI-H1963 | cell line=NCI-H1975 | cell line=NCI-H2009 | cell line=NCI-H2023 | cell line=NCI-H2029 | cell line=NCI-H2030 | cell line=NCI-H2052 | cell line=NCI-H2066 | cell line=NCI-H2073 | cell line=NCI-H2081 | cell line=NCI-H2085 | cell line=NCI-H2087 | cell line=NCI-H209 | cell line=NCI-H2106 | cell line=NCI-H211 | cell line=NCI-H2110 | cell line=NCI-H2122 | cell line=NCI-H2126 | cell line=NCI-H2170 | cell line=NCI-H2171 | cell line=NCI-H2172 | cell line=NCI-H2196 | cell line=NCI-H2227 | cell line=NCI-H2228 | cell line=NCI-H226 | cell line=NCI-H2286 | cell line=NCI-H2291 | cell line=NCI-H23 | cell line=NCI-H2342 | cell line=NCI-H2347 | cell line=NCI-H2405 | cell line=NCI-H2444 | cell line=NCI-H2452 | cell line=NCI-H28 | cell line=NCI-H292 | cell line=NCI-H322 | cell line=NCI-H3255 | cell line=NCI-H358 | cell line=NCI-H441 | cell line=NCI-H446 | cell line=NCI-H460 | cell line=NCI-H508 | cell line=NCI-H510 | cell line=NCI-H520 | cell line=NCI-H522 | cell line=NCI-H524 | cell line=NCI-H526 | cell line=NCI-H596 | cell line=NCI-H647 | cell line=NCI-H650 | cell line=NCI-H660 | cell line=NCI-H661 | cell line=NCI-H684 | cell line=NCI-H69 | cell line=NCI-H716 | cell line=NCI-H727 | cell line=NCI-H747 | cell line=NCI-H810 | cell line=NCI-H82 | cell line=NCI-H838 | cell line=NCI-H841 | cell line=NCI-H854 | cell line=NCI-H889 | cell line=NCI-H929 | cell line=NCI-N87 | cell line=NCO2 | cell line=NH-6 | cell line=NMC-G1 | cell line=NOMO-1 | cell line=NU-DHL-1 | cell line=NU-DUL-1 | cell line=NUGC-2 | cell line=NUGC-3 | cell line=NUGC-4 | cell line=OAW28 | cell line=OAW42 | cell line=OC 314 | cell line=OCI-AML2 | cell line=OCI-AML3 | cell line=OCI-AML5 | cell line=OCI-LY-19 | cell line=OCI-M1 | cell line=OCUM-1 | cell line=OE19 | cell line=OE21 | cell line=OE33 | cell line=ONCO-DG-1 | cell line=ONS-76 | cell line=OPM-2 | cell line=OS-RC-2 | cell line=OUMS-23 | cell line=OV-90 | cell line=OV56 | cell line=OV7 | cell line=OVCAR-3 | cell line=OVCAR-4 | cell line=OVCAR-8 | cell line=OVISE | cell line=OVK18 | cell line=OVMANA | cell line=OVSAHO | cell line=OVTOKO | cell line=P12-ICHIKAWA | cell line=P31/FUJ | cell line=P3HR-1 | cell line=PA-TU-8902 | cell line=PA-TU-8988S | cell line=PA-TU-8988T | cell line=Panc 02.03 | cell line=Panc 02.13 | cell line=Panc 03.27 | cell line=Panc 04.03 | cell line=Panc 05.04 | cell line=Panc 08.13 | cell line=Panc 10.05 | cell line=PANC-1 | cell line=PC-14 | cell line=PC-3 | cell line=PE/CA-PJ15 | cell line=PE/CA-PJ34 (clone C12) | cell line=PE/CA-PJ41 (clone D2) | cell line=PE/CA-PJ49 | cell line=PEER | cell line=PF-382 | cell line=Pfeiffer | cell line=PK-1 | cell line=PK-45H | cell line=PK-59 | cell line=PL-21 | cell line=PLC/PRF/5 | cell line=PSN1 | cell line=QGP-1 | cell line=Raji | cell line=RCC10RGB | cell line=RCH-ACV | cell line=RCM-1 | cell line=RD | cell line=RD-ES | cell line=REC-1 | cell line=Reh | cell line=RERF-GC-1B | cell line=RERF-LC-Ad1 | cell line=RERF-LC-Ad2 | cell line=RERF-LC-AI | cell line=RERF-LC-KJ | cell line=RERF-LC-MS | cell line=RERF-LC-Sq1 | cell line=RH-18 | cell line=RH-30 | cell line=RH-41 | cell line=RI-1 | cell line=RKN | cell line=RKO | cell line=RL | cell line=RL95-2 | cell line=RMG-I | cell line=RMUG-S | cell line=RPMI 8226 | cell line=RPMI-7951 | cell line=RPMI-8402 | cell line=RS-5 | cell line=RS4;11 | cell line=RT-112 | cell line=RT4 | cell line=S-117 | cell line=Saos-2 | cell line=SBC-5 | cell line=SCaBER | cell line=SCC-15 | cell line=SCC-25 | cell line=SCC-4 | cell line=SCC-9 | cell line=SCLC-21H | cell line=SEM | cell line=Set-2 | cell line=SF-295 | cell line=SF126 | cell line=SF268 | cell line=SF539 | cell line=SH-10-TC | cell line=SH-4 | cell line=SHP-77 | cell line=SIG-M5 | cell line=SIMA | cell line=SJSA-1 | cell line=SK-BR-3 | cell line=SK-CO-1 | cell line=SK-ES-1 | cell line=SK-HEP-1 | cell line=SK-LMS-1 | cell line=SK-LU-1 | cell line=SK-MEL-1 | cell line=SK-MEL-24 | cell line=SK-MEL-28 | cell line=SK-MEL-3 | cell line=SK-MEL-30 | cell line=SK-MEL-31 | cell line=SK-MEL-5 | cell line=SK-MES-1 | cell line=SK-MM-2 | cell line=SK-N-AS | cell line=SK-N-BE(2) | cell line=SK-N-DZ | cell line=SK-N-FI | cell line=SK-N-MC | cell line=SK-OV-3 | cell line=SK-UT-1 | cell line=SKM-1 | cell line=SNB75 | cell line=SNG-M | cell line=SNU-1 | cell line=SNU-1033 | cell line=SNU-1040 | cell line=SNU-1041 | cell line=SNU-1066 | cell line=SNU-1076 | cell line=SNU-1077 | cell line=SNU-1079 | cell line=SNU-1105 | cell line=SNU-119 | cell line=SNU-1196 | cell line=SNU-1197 | cell line=SNU-1214 | cell line=SNU-1272 | cell line=SNU-16 | cell line=SNU-175 | cell line=SNU-182 | cell line=SNU-201 | cell line=SNU-213 | cell line=SNU-216 | cell line=SNU-245 | cell line=SNU-308 | cell line=SNU-324 | cell line=SNU-349 | cell line=SNU-387 | cell line=SNU-398 | cell line=SNU-407 | cell line=SNU-410 | cell line=SNU-423 | cell line=SNU-449 | cell line=SNU-466 | cell line=SNU-475 | cell line=SNU-478 | cell line=SNU-489 | cell line=SNU-5 | cell line=SNU-503 | cell line=SNU-520 | cell line=SNU-601 | cell line=SNU-61 | cell line=SNU-620 | cell line=SNU-626 | cell line=SNU-668 | cell line=SNU-685 | cell line=SNU-719 | cell line=SNU-738 | cell line=SNU-761 | cell line=SNU-8 | cell line=SNU-81 | cell line=SNU-840 | cell line=SNU-869 | cell line=SNU-878 | cell line=SNU-886 | cell line=SNU-899 | cell line=SNU-C1 | cell line=SNU-C2A | cell line=SNU-C4 | cell line=SNU-C5 | cell line=Sq-1 | cell line=SR-786 | cell line=ST486 | cell line=SU-DHL-1 | cell line=SU-DHL-10 | cell line=SU-DHL-4 | cell line=SU-DHL-5 | cell line=SU-DHL-6 | cell line=SU-DHL-8 | cell line=SU.86.86 | cell line=SUIT-2 | cell line=SUP-B15 | cell line=SUP-M2 | cell line=SUP-T1 | cell line=SUP-T11 | cell line=SW 1088 | cell line=SW 1271 | cell line=SW 1353 | cell line=SW 1573 | cell line=SW 1783 | cell line=SW 1990 | cell line=SW 780 | cell line=SW 900 | cell line=SW-1710 | cell line=SW1116 | cell line=SW1417 | cell line=SW1463 | cell line=SW403 | cell line=SW48 | cell line=SW480 | cell line=SW579 | cell line=SW620 | cell line=SW837 | cell line=SW948 | cell line=T-47D | cell line=T.T | cell line=T1-73 | cell line=T24 | cell line=T3M-10 | cell line=T3M-4 | cell line=T84 | cell line=T98G | cell line=TALL-1 | cell line=TC-71 | cell line=TCC-PAN2 | cell line=TCCSUP | cell line=TE 125.T | cell line=TE 159.T | cell line=TE 441.T | cell line=TE 617.T | cell line=TE-1 | cell line=TE-10 | cell line=TE-11 | cell line=TE-14 | cell line=TE-15 | cell line=TE-4 | cell line=TE-5 | cell line=TE-6 | cell line=TE-8 | cell line=TE-9 | cell line=TEN | cell line=TF-1 | cell line=TGBC11TKB | cell line=THP-1 | cell line=TM-31 | cell line=TO 175.T | cell line=Toledo | cell line=TOV-112D | cell line=TOV-21G | cell line=TT | cell line=TT2609-C02 | cell line=TUHR10TKB | cell line=TUHR14TKB | cell line=TUHR4TKB | cell line=TYK-nu | cell line=U-118 MG | cell line=U-2 OS | cell line=U-251 MG | cell line=U-87 MG | cell line=U-937 | cell line=U-BLC1 | cell line=U266B1 | cell line=UACC-257 | cell line=UACC-62 | cell line=UACC-812 | cell line=UACC-893 | cell line=UM-UC-1 | cell line=UM-UC-3 | cell line=UO-31 | cell line=VCaP | cell line=VM-CUB1 | cell line=VMRC-RCW | cell line=VMRC-RCZ | cell line=WM-115 | cell line=WM-266-4 | cell line=WM-793 | cell line=WM-88 | cell line=WM1799 | cell line=WM983B | cell line=WSU-DLCL2 | cell line=YAPC | cell line=YD-10B | cell line=YD-15 | cell line=YD-38 | cell line=YD-8 | cell line=YH-13 | cell line=YKG1 | cell line=ZR-75-1 | cell line=ZR-75-30 | disease=#N/A | disease=acute myeloid leukemia | disease=acute promyelocytic leukemia | disease=adenosquamous lung carcinoma | disease=adrenal gland neuroblastoma | disease=adult acute megakaryoblastic leukaemia | disease=adult acute monocytic leukemia | disease=adult acute myeloid leukemia | disease=adult B acute lymphoblastic leukemia | disease=adult T acute lymphoblastic leukemia | disease=alveolar rhabdomyosarcoma | disease=amelanotic melanoma | disease=ampulla of Vater adenocarcinoma | disease=anaplastic astrocytoma | disease=anaplastic large cell lymphoma | disease=Askin tumor | disease=astrocytoma | disease=B-cell acute lymphoblastic leukemia | disease=B-cell non-Hodgkins lymphoma | disease=B-cell prolymphocytic leukemia | disease=Barrett adenocarcinoma | disease=basaloid squamous cell carcinoma | disease=bladder carcinoma | disease=bladder squamous cell carcinoma | disease=bladder transitional cell carcinoma | disease=blast phase chronic myelogenous leukemia, BCR-ABL1 positive | disease=bone giant cell tumor | disease=breast adenocarcinoma | disease=breast carcinoma | disease=breast ductal adenocarcinoma | disease=bronchioloalveolar carcinoma | disease=bronchoalveolar adenocarcinoma | disease=bronchogenic carcinoma | disease=Burkitts lymphoma | disease=cecum adenocarcinoma | disease=childhood acute megakaryoblastic leukemia | disease=childhood acute monocytic leukemia | disease=childhood acute myeloid leukemia | disease=childhood acute myeloid leukemia with maturation | disease=childhood B acute lymphoblastic leukemia | disease=childhood T acute lymphoblastic leukemia | disease=childhood T lymphoblastic lymphoma | disease=cholangiocarcinoma | disease=chondrosarcoma | disease=chronic eosinophilic leukemia | disease=chronic lymphocytic leukemia | disease=chronic myelogenous leukemia | disease=clear cell renal carcinoma | disease=colon adenocarcinoma | disease=colon carcinoma | disease=colorectal carcinoma | disease=cutaneous melanoma | disease=cutaneous T-cell lymphoma | disease=desmoplastic medulloblastoma | disease=diffuse large B-cell lymphoma | disease=duodenal adenocarcinoma | disease=embryonal rhabdomyosarcoma | disease=endometrial adenosquamous carcinoma | disease=endometrial carcinoma | disease=endometrial endometrioid adenocarcinoma, variant with squamous differentiation | disease=endometrial stromal sarcoma | disease=endometrium adenocarcinoma | disease=Epstein-Barr virus-related Burkitt lymphoma | disease=erythroleukemia | disease=esophageal adenocarcinoma | disease=esophageal squamous cell carcinoma | disease=Ewing sarcoma | disease=fibrosarcoma | disease=follicular thyroid carcinoma | disease=gallbladder carcinoma | disease=gastric adenocarcinoma | disease=gastric adenosquamous carcinoma | disease=gastric carcinoma | disease=gastric small cell neuroendocrine carcinoma | disease=gastric tubular adenocarcinoma | disease=glioblastoma | disease=gliosarcoma | disease=head and neck squamous cell carcinoma | disease=hepatoblastoma | disease=hepatocellular carcinoma | disease=hereditary thyroid gland medullary carcinoma | disease=high grade ovarian serous adenocarcinoma | disease=hilar cholangiocarcinoma | disease=Hodgkins lymphoma | disease=hypopharyngeal squamous cell carcinoma | disease=intrahepatic cholangiocarcinoma | disease=invasive ductal carcinoma | disease=invasive lobular carcinoma | disease=large cell lung carcinoma | disease=laryngeal squamous cell carcinoma | disease=leiomyoma, epithelioid | disease=lung adenocarcinoma | disease=lung carcinoid tumor | disease=lung giant cell carcinoma | disease=malignant epithelioid mesothelioma | disease=malignant ovarian Brenner tumor | disease=Mantle cell lymphoma | disease=medulloblastoma | disease=melanoma | disease=mesothelioma | disease=mucinous gastric adenocarcinoma | disease=multiple endocrine neoplasia | disease=multiple myeloma | disease=mycosis fungoides | disease=myelodysplastic syndrome | disease=neuroblastoma | disease=non-small cell lung carcinoma | disease=oligodendroglioma | disease=oral squamous cell carcinoma | disease=osteosarcoma | disease=ovarian adenocarcinoma | disease=ovarian carcinoma | disease=ovarian clear cell adenocarcinoma | disease=ovarian cystadenocarcinoma | disease=ovarian endometrioid adenocarcinoma | disease=ovarian granulosa cell tumour | disease=ovarian leiomyosarcoma | disease=ovarian mucinous adenocarcinoma | disease=ovarian mucinous cystadenocarcinoma | disease=ovarian serous adenocarcinoma | disease=ovarian serous cystadenocarcinoma | disease=pancreatic adenocarcinoma | disease=pancreatic adenosquamous carcinoma | disease=pancreatic carcinoma | disease=pancreatic ductal adenocarcinoma | disease=pancreatic somatostatinoma | disease=papillary lung adenocarcinoma | disease=papillary renal cell carcinoma | disease=papillary thyroid carcinoma | disease=pharyngeal squamous cell carcinoma | disease=pleural mesothelioma | disease=primary effusion lymphoma | disease=prostate carcinoma | disease=pulmonary mucoepidermoid carcinoma | disease=rectal adenocarcinoma | disease=rectosigmoid adenocarcinoma | disease=renal cell adenocarcinoma | disease=renal cell carcinoma | disease=rhabdoid tumor of the kidney | disease=rhabdomyosarcoma | disease=salivary gland squamous cell carcinoma | disease=sarcomatoid mesothelioma | disease=signet ring cell gastric adenocarcinoma | disease=small cell lung carcinoma | disease=squamous cell breast carcinoma, acantholytic variant | disease=squamous cell lung carcinoma | disease=squamous papilloma | disease=stomach adenocarcinoma | disease=T-cell acute lymphoblastic leukemia | disease=thyroid gland sarcoma | disease=thyroid gland squamous cell carcinoma | disease=thyroid gland undifferentiated (anaplastic) carcinoma | disease=tongue squamous cell carcinoma | disease=transitional cell carcinoma of kidney | disease=unclassified pleomorphic sarcoma | disease=undifferentiated carcinoma | disease=ureter urothelial carcinoma | disease=uterine carcinosarcoma | disease=uterine leiomyosarcoma | disease=uterine sarcoma | disease=vulvar leiomyosarcoma","CELL LINE=human glioblastoma stem cells | CELL LINE=MGG23 | CELL LINE=MGG4 | CELL LINE=MGG6 | CELL LINE=MGG8 | CELL LINE=not specified | CELL LINE=NS | CELL TYPE=ES-derived neural stem cells | CELL TYPE=human glioblastoma serum-grown cells | CELL TYPE=human glioblastoma stem cells | CELL TYPE=MGG4 | CELL TYPE=MGG6 | CELL TYPE=MGG8 | CELL TYPE=not specified | CHIP-ANTIBODY=ASCL1 | CHIP-ANTIBODY=H3K27ac | CHIP-ANTIBODY=H3K27me3 | CHIP-ANTIBODY=H3K36me3 | CHIP-ANTIBODY=H3K4me1 | CHIP-ANTIBODY=H3K4me3 | CHIP-ANTIBODY=LEF1 | CHIP-ANTIBODY=None | CHIP-ANTIBODY=not specified | CHIP-ANTIBODY CAT. #=07-449 | CHIP-ANTIBODY CAT. #=07-473 | CHIP-ANTIBODY CAT. #=39133 | CHIP-ANTIBODY CAT. #=53293 | CHIP-ANTIBODY CAT. #=8895 | CHIP-ANTIBODY CAT. #=9050 | CHIP-ANTIBODY CAT. #=not specified | CHIP-ANTIBODY CAT. #=T091 | CHIP-ANTIBODY VENDOR=Abcam | CHIP-ANTIBODY VENDOR=Active motif | CHIP-ANTIBODY VENDOR=Epitomics | CHIP-ANTIBODY VENDOR=Millipore | CHIP-ANTIBODY VENDOR=not specified","CELL TYPE=MGG4 | CELL TYPE=MGG6 | CELL TYPE=MGG8","CELL LINE=MGG23 | CELL LINE=MGG4 | CELL LINE=MGG6 | CELL LINE=MGG8 | CELL LINE=not specified | CELL TYPE=ES-derived neural stem cells | CELL TYPE=human glioblastoma serum-grown cells | CELL TYPE=human glioblastoma stem cells | CHIP-ANTIBODY=ASCL1 | CHIP-ANTIBODY=H3K27ac | CHIP-ANTIBODY=H3K27me3 | CHIP-ANTIBODY=H3K36me3 | CHIP-ANTIBODY=H3K4me1 | CHIP-ANTIBODY=H3K4me3 | CHIP-ANTIBODY=LEF1 | CHIP-ANTIBODY=None | CHIP-ANTIBODY CAT. #=07-449 | CHIP-ANTIBODY CAT. #=07-473 | CHIP-ANTIBODY CAT. #=39133 | CHIP-ANTIBODY CAT. #=53293 | CHIP-ANTIBODY CAT. #=8895 | CHIP-ANTIBODY CAT. #=9050 | CHIP-ANTIBODY CAT. #=not specified | CHIP-ANTIBODY CAT. #=T091 | CHIP-ANTIBODY VENDOR=Abcam | CHIP-ANTIBODY VENDOR=Active motif | CHIP-ANTIBODY VENDOR=Epitomics | CHIP-ANTIBODY VENDOR=Millipore | CHIP-ANTIBODY VENDOR=not specified","CELL LINE=MGG23 | CELL LINE=MGG4 | CELL LINE=MGG6 | CELL LINE=MGG8 | CELL LINE=NS","CELL TYPE=Adult Neural Progenitor cells | CELL TYPE=Astrocytes | CELL TYPE=Foetal Neural Progenitor cells | CELL TYPE=Glioblastoma Multiforme stem like | CELL TYPE=human GBM-derived &amp;quot;stem-like&amp;quot; cells | CELL TYPE=mouse Glioma Initiating Cells | CELL TYPE=not specified | CELL TYPE=Sub ventricular-zone derived neural stem cells | CHIP ANTIBODY=anti-ATF3 | CHIP ANTIBODY=anti-BMI1 | CHIP ANTIBODY=none | CHIP ANTIBODY=not specified | GENETIC BACKGROUND=INK4a/Arf FVB | GENETIC BACKGROUND=INK4a/Arf FVB+EgfrVIII (retroviral) | GENETIC BACKGROUND=not specified | GENOTYPE=BMI1 dox-inducible | GENOTYPE=INK4A/ARF -/- | GENOTYPE=Ink4a/Arf -/-;BMI1 dox-inducible shRNA | GENOTYPE=Multiple genetic aberrations | GENOTYPE=Normal; diploid | GENOTYPE=not specified | ORGANISM=Homo sapiens | ORGANISM=Mus musculus | TREATMENT=BMI1 knockdown+BMP4(10ng/3hr) | TREATMENT=BMI1 knockdown+BMP4(10ng/6hr) | TREATMENT=BMI1 knockdown+BMP4(50ng/3hr) | TREATMENT=BMI1 knockdown+BMP4(50ng/6hr) | TREATMENT=BMI1 knockdown+BMP7+Arvanil+doxycycline | TREATMENT=BMI1 knockdown+FBS(1%/3hr) | TREATMENT=BMI1 knockdown+FBS(1%/6hr) | TREATMENT=BMI1 knockdown+FBS(10%/3hr) | TREATMENT=BMI1 knockdown+FBS(10%/6hr) | TREATMENT=Dox + Arvanil + BMP7 | TREATMENT=GFP knockdown+BMP4(10ng/3hr) | TREATMENT=GFP knockdown+BMP4(10ng/6hr) | TREATMENT=GFP knockdown+BMP4(50ng/3hr) | TREATMENT=GFP knockdown+BMP4(50ng/6hr) | TREATMENT=GFP knockdown+FBS(1%/3hr) | TREATMENT=GFP knockdown+FBS(1%/6hr) | TREATMENT=GFP knockdown+FBS(10%/3hr) | TREATMENT=GFP knockdown+FBS(10%/6hr) | TREATMENT=not specified","CELL TYPE=glial progenitor cell | CELL TYPE=microglia | CELL TYPE=Tumor | CELL TYPE=unsorted | ORGANISM PART=cortex | ORGANISM PART=Tumor | ORGANISM PART=white matter | PATHOLOGY=anaplastic astrocytoma | PATHOLOGY=anaplastic oligoastrocytoma | PATHOLOGY=anaplastic oligodendroglioma | PATHOLOGY=astrocytoma | PATHOLOGY=epilepsy | PATHOLOGY=ganglioglioma | PATHOLOGY=Glioblastoma | PATHOLOGY=glioblastoma, small cell | PATHOLOGY=gliosarcoma | PATHOLOGY=oligoastrocytoma | PATHOLOGY=oligodendroglioma | SORT POPULATION=A2B5+ | SORT POPULATION=A2B5- | SORT POPULATION=CD11b+ | SORT POPULATION=unsorted | TUMOR GRADE WHO=II | TUMOR GRADE WHO=III | TUMOR GRADE WHO=IV | TUMOR GRADE WHO=non-tumor","cell line=IN1472 | cell line=IN1760 | RNA interference=control | RNA interference=PDE1C siRNA","CELL LINE=KHOS | CELL LINE=T98G | CELL TYPE=Glioblastoma | CELL TYPE=osteosarcoma | OVEREXPRESSING=GFP | OVEREXPRESSING=miR190","ISOLATE=cells | ISOLATE=exosomes | TREATMENT=hypoxic (1% oxygen) | TREATMENT=normoxic (21% oxygen)","CellLine=Normal neural stem cell line CB660 | CellLine=Reprogrammed glioma iPS cell line iG26 | CellLine=Reprogrammed glioma iPS cell line iG7 | CellLine=Reprogrammed iPS cell line iCB660 | CellType=cancer iPS cell | CellType=neural stem cell | CellType=normal iPS cell | DiseaseState=glioblastoma multiforme | DiseaseState=normal","CellLine=Glioma neural stem cell line G7 | CellLine=Mesodermal cell line differentiated from iG7 | CellLine=Neural cell line differentiated from iG7 | CellLine=Normal neural stem cell line CB11130 | CellLine=Normal neural stem cell line CB11171 | CellLine=Normal neural stem cell line CB152 | CellLine=Normal neural stem cell line CB660 | CellLine=Reprogrammed glioma iPS cell line iG7 | CellType=cancer iPS cell | CellType=cancer stem cell | CellType=mesodermal cell | CellType=neural cell | CellType=neural stem cell | DiseaseState=glioblastoma multiforme | DiseaseState=normal | Sex=female | Sex=male | Sex=unknown sex","CellLine=Glioma neural stem cell line G26 | CellLine=Glioma neural stem cell line G7 | CellLine=Human ES cell line Edi-2 | CellLine=Mesodermal cell line differentiated from iG7 | CellLine=Normal neural stem cell line CB660 | CellLine=Reprogrammed glioma iPS cell line iG26 | CellLine=Reprogrammed glioma iPS cell line iG7 | CellLine=Reprogrammed iPS cell line iCB660 | CellType=cancer iPS cell | CellType=cancer stem cell | CellType=embryonic stem cell | CellType=mesodermal cell | CellType=neural stem cell | CellType=normal iPS cell | DiseaseState=glioblastoma multiforme | DiseaseState=normal","CellLine=Glioma neural stem cell line G26 | CellLine=Glioma neural stem cell line G7 | CellLine=Reprogrammed glioma iPS cell line iG26 | CellLine=Reprogrammed glioma iPS cell line iG7 | CellType=cancer iPS cell | CellType=cancer stem cell","CD133=NA | CD133=negative | CD133=positive | GROWTH PATTERN=Free floating | GROWTH PATTERN=Semi-adherent | HISTOLOGY=anaplastic oligoastrocytoma | HISTOLOGY=glioblastoma multiforme | INDIVIDUAL=NNI-1 | INDIVIDUAL=NNI-4 | INDIVIDUAL=NNI-8 | TREATMENT=DDC | TREATMENT=DPI | TREATMENT=NA","CELL LINE=G166 | CELL LINE=G179 | CELL LINE=GBM2 | CELL LINE=GBM7 | CELL LINE=GliNS2 | CELL LINE=not specified","CELL LINE=1 pool from 5 GBM biopsies | CELL LINE=CB660 from forebrain | CELL LINE=CB660SP form spinal cord | CELL LINE=G144 | CELL LINE=G166 | CELL LINE=GBM2","CELL TYPE=differentiated 4 days | CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient upon 4 days of differentiation | CELL TYPE=neurospheres | CELL TYPE=not specified | PATIENT=G48 | PATIENT=G52 | PATIENT=G59 | PATIENT=G63 | PATIENT=not specified","CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G52 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G59 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G63 patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of G97C patient upon 4 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient upon 14 days of differentiation | CELL TYPE=GBM neurospheres derived from a tumor sample of GN1C patient upon 4 days of differentiation | CELL TYPE=not specified","CELL TYPE=differentiated 4 days | CELL TYPE=neurospheres | PATIENT=G48 | PATIENT=G52 | PATIENT=G59 | PATIENT=G63","NA","NA","TIME=24 hpi first exp | TIME=24 hpi second exp | TIME=4 hpi first exp | TIME=4 hpi second exp | TIME=48 hpi first exp | TIME=48 hpi second exp","CLINICAL_INFORMATION=pool of different brain regions | CLINICAL_INFORMATION=subependimal zone | CLINICAL_INFORMATION=tumor margin | CLINICAL_INFORMATION=tumor mass | CLINICAL_INFORMATION=tumor subsample","CLINICAL_INFORMATION=post avastin recurrence | CLINICAL_INFORMATION=pre avastin","individual=42 | individual=49 | individual=50 | individual=52 | individual=54 | individual=55 | individual=56 | individual=57 | individual=58 | sampling site=blood | sampling site=subependimal zone | sampling site=tumor margin | sampling site=tumor mass","1P19Q LOH=LOH | 1P19Q LOH=no loss | 1P19Q LOH=not specified | AGE=18 | AGE=19 | AGE=20 | AGE=28 | AGE=31 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=37 | AGE=38 | AGE=39 | AGE=40 | AGE=41 | AGE=42 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=50 | AGE=51 | AGE=52 | AGE=53 | AGE=54 | AGE=55 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=62 | AGE=63 | AGE=64 | AGE=65 | AGE=66 | AGE=67 | AGE=68 | CIMP=CIMP+ | CIMP=CIMP- | CIMP=not specified | EGFR=AMP | EGFR=not specified | EGFR=wt | EVENT=alive | EVENT=deceased | EXPERIMENT=pt 1 | EXPERIMENT=pt 2 | EXPERIMENT=pt 3 | EXPERIMENT=pt 4 | EXPERIMENT=pt 5 | EXPERIMENT=pt 6 | IDHMUT=mut | IDHMUT=not specified | IDHMUT=wt | IGS=16 | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=meth | MGMT=not specified | MGMT=unmeth | ORIGINAL DIAGNOSIS=AOA | ORIGINAL DIAGNOSIS=AOD | REVIEW DIAGNOSIS=AOA | REVIEW DIAGNOSIS=AOD | REVIEW DIAGNOSIS=GBM/AA | REVIEW DIAGNOSIS=LGG | REVIEW DIAGNOSIS=not specified | SAMPLE=103 | SAMPLE=110 | SAMPLE=113 | SAMPLE=115 | SAMPLE=116 | SAMPLE=117 | SAMPLE=12 | SAMPLE=122 | SAMPLE=125 | SAMPLE=129 | SAMPLE=13 | SAMPLE=137 | SAMPLE=138 | SAMPLE=139 | SAMPLE=14 | SAMPLE=143 | SAMPLE=145 | SAMPLE=147 | SAMPLE=149 | SAMPLE=15 | SAMPLE=151 | SAMPLE=152 | SAMPLE=153 | SAMPLE=154 | SAMPLE=155 | SAMPLE=159 | SAMPLE=165 | SAMPLE=17 | SAMPLE=170 | SAMPLE=171 | SAMPLE=174 | SAMPLE=175 | SAMPLE=182 | SAMPLE=185 | SAMPLE=189 | SAMPLE=192 | SAMPLE=194 | SAMPLE=196 | SAMPLE=197 | SAMPLE=198 | SAMPLE=199 | SAMPLE=20 | SAMPLE=200 | SAMPLE=203 | SAMPLE=204 | SAMPLE=206 | SAMPLE=208 | SAMPLE=209 | SAMPLE=21 | SAMPLE=212 | SAMPLE=213 | SAMPLE=214 | SAMPLE=215 | SAMPLE=216 | SAMPLE=217 | SAMPLE=218 | SAMPLE=220 | SAMPLE=221 | SAMPLE=222 | SAMPLE=224 | SAMPLE=23 | SAMPLE=230 | SAMPLE=234 | SAMPLE=238 | SAMPLE=239 | SAMPLE=242 | SAMPLE=246 | SAMPLE=247 | SAMPLE=257 | SAMPLE=259 | SAMPLE=26 | SAMPLE=261 | SAMPLE=262 | SAMPLE=27 | SAMPLE=270 | SAMPLE=271 | SAMPLE=275 | SAMPLE=276 | SAMPLE=284 | SAMPLE=285 | SAMPLE=290 | SAMPLE=291 | SAMPLE=292 | SAMPLE=298 | SAMPLE=299 | SAMPLE=30 | SAMPLE=300 | SAMPLE=301 | SAMPLE=302 | SAMPLE=305 | SAMPLE=309 | SAMPLE=31 | SAMPLE=310 | SAMPLE=311 | SAMPLE=312 | SAMPLE=313 | SAMPLE=314 | SAMPLE=315 | SAMPLE=32 | SAMPLE=324 | SAMPLE=326 | SAMPLE=327 | SAMPLE=33 | SAMPLE=331 | SAMPLE=335 | SAMPLE=339 | SAMPLE=343 | SAMPLE=36 | SAMPLE=4 | SAMPLE=41 | SAMPLE=45 | SAMPLE=48 | SAMPLE=50 | SAMPLE=507 | SAMPLE=51 | SAMPLE=52 | SAMPLE=53 | SAMPLE=54 | SAMPLE=56 | SAMPLE=57 | SAMPLE=58 | SAMPLE=59 | SAMPLE=61 | SAMPLE=62 | SAMPLE=64 | SAMPLE=66 | SAMPLE=67 | SAMPLE=69 | SAMPLE=72 | SAMPLE=74 | SAMPLE=75 | SAMPLE=80 | SAMPLE=84 | SAMPLE=85 | SAMPLE=89 | SAMPLE=9 | SAMPLE=91 | SAMPLE=94 | SAMPLE=96 | SAMPLE=99 | SEX=female | SEX=male | SS Y=0.186301369863014 | SS Y=0.268493150684932 | SS Y=0.301369863013699 | SS Y=0.315068493150685 | SS Y=0.317808219178082 | SS Y=0.323287671232877 | SS Y=0.386301369863014 | SS Y=0.43013698630137 | SS Y=0.46027397260274 | SS Y=0.512328767123288 | SS Y=0.517808219178082 | SS Y=0.545205479452055 | SS Y=0.572602739726027 | SS Y=0.6 | SS Y=0.613698630136986 | SS Y=0.621917808219178 | SS Y=0.657534246575342 | SS Y=0.66027397260274 | SS Y=0.676712328767123 | SS Y=0.679452054794521 | SS Y=0.69041095890411 | SS Y=0.720547945205479 | SS Y=0.736986301369863 | SS Y=0.764383561643836 | SS Y=0.778082191780822 | SS Y=0.797260273972603 | SS Y=0.808219178082192 | SS Y=0.950684931506849 | SS Y=0.961643835616438 | SS Y=0.964383561643836 | SS Y=0.978082191780822 | SS Y=0.991780821917808 | SS Y=1.01643835616438 | SS Y=1.02191780821918 | SS Y=1.04657534246575 | SS Y=1.06027397260274 | SS Y=1.12328767123288 | SS Y=1.14794520547945 | SS Y=1.16986301369863 | SS Y=1.18082191780822 | SS Y=1.23561643835616 | SS Y=1.24657534246575 | SS Y=1.26301369863014 | SS Y=1.26849315068493 | SS Y=1.2958904109589 | SS Y=1.33424657534247 | SS Y=1.35342465753425 | SS Y=1.36986301369863 | SS Y=1.40547945205479 | SS Y=1.41917808219178 | SS Y=1.43287671232877 | SS Y=1.47945205479452 | SS Y=1.48767123287671 | SS Y=1.4958904109589 | SS Y=1.4986301369863 | SS Y=1.55616438356164 | SS Y=1.58356164383562 | SS Y=1.58904109589041 | SS Y=1.59178082191781 | SS Y=1.60547945205479 | SS Y=1.62739726027397 | SS Y=1.72054794520548 | SS Y=1.75068493150685 | SS Y=1.82465753424658 | SS Y=1.87671232876712 | SS Y=1.90684931506849 | SS Y=2.01369863013699 | SS Y=2.1041095890411 | SS Y=2.37260273972603 | SS Y=2.37534246575342 | SS Y=2.39178082191781 | SS Y=2.3972602739726 | SS Y=2.55068493150685 | SS Y=2.79452054794521 | SS Y=2.86849315068493 | SS Y=2.87671232876712 | SS Y=2.89315068493151 | SS Y=2.95068493150685 | SS Y=2.95616438356164 | SS Y=2.96986301369863 | SS Y=3.03835616438356 | SS Y=3.11506849315069 | SS Y=3.19178082191781 | SS Y=3.21917808219178 | SS Y=3.33424657534247 | SS Y=3.39452054794521 | SS Y=3.43013698630137 | SS Y=3.47123287671233 | SS Y=3.61369863013699 | SS Y=3.62739726027397 | SS Y=3.71780821917808 | SS Y=3.77534246575342 | SS Y=3.81095890410959 | SS Y=3.98082191780822 | SS Y=4.00821917808219 | SS Y=4.06301369863014 | SS Y=4.16164383561644 | SS Y=4.21643835616438 | SS Y=4.25205479452055 | SS Y=4.37260273972603 | SS Y=4.54520547945206 | SS Y=4.63013698630137 | SS Y=4.64383561643836 | SS Y=4.66301369863014 | SS Y=4.68219178082192 | SS Y=4.78904109589041 | SS Y=4.79452054794521 | SS Y=4.91780821917808 | SS Y=4.95068493150685 | SS Y=5.13698630136986 | SS Y=5.25479452054795 | SS Y=5.37534246575343 | SS Y=5.52054794520548 | SS Y=5.58082191780822 | SS Y=5.59178082191781 | SS Y=5.61095890410959 | SS Y=5.68767123287671 | SS Y=5.70958904109589 | SS Y=5.79452054794521 | SS Y=5.84657534246575 | SS Y=5.98356164383562 | SS Y=6.07123287671233 | SS Y=6.44383561643836 | SS Y=6.65205479452055 | SS Y=6.7041095890411 | SS Y=6.77808219178082 | SS Y=6.82191780821918 | SS Y=6.82465753424658 | SS Y=6.94246575342466 | SS Y=7.05753424657534 | SS Y=7.09315068493151 | SS Y=7.37260273972603 | SS Y=7.40547945205479 | SS Y=7.43835616438356 | SS Y=7.68767123287671 | SS Y=7.88219178082192 | TCGA CLASSIFICATION=C | TCGA CLASSIFICATION=M | TCGA CLASSIFICATION=N | TCGA CLASSIFICATION=not specified | TCGA CLASSIFICATION=P | TISSUE TYPE=FF | TISSUE TYPE=FFPE | TRT=RT | TRT=RT/PCV","AGE=18 | AGE=41 | AGE=47 | AGE=53 | AGE=66 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | ORIGINAL DIAGNOSIS=AOA | ORIGINAL DIAGNOSIS=AOD | REVIEW DIAGNOSIS=AOA | REVIEW DIAGNOSIS=AOD | REVIEW DIAGNOSIS=GBM/AA | SAMPLE=143 | SAMPLE=196 | SAMPLE=208 | SAMPLE=217 | SAMPLE=239 | SAMPLE=284 | SAMPLE=61 | SEX=female | SEX=male | SS Y=0.301369863013699 | SS Y=0.621917808219178 | SS Y=0.657534246575342 | SS Y=0.69041095890411 | SS Y=0.778082191780822 | SS Y=2.3972602739726 | SS Y=4.79452054794521 | TCGA CLASSIFICATION=C | TCGA CLASSIFICATION=M | TCGA CLASSIFICATION=N | TCGA CLASSIFICATION=P | TISSUE TYPE=FF | TISSUE TYPE=FFPE | TRT=RT | TRT=RT/PCV","1P19Q LOH=LOH | 1P19Q LOH=no loss | 1P19Q LOH=not specified | AGE=28 | AGE=31 | AGE=33 | AGE=35 | AGE=36 | AGE=38 | AGE=39 | AGE=40 | AGE=41 | AGE=43 | AGE=46 | AGE=48 | AGE=51 | AGE=52 | AGE=53 | AGE=57 | AGE=60 | AGE=62 | AGE=64 | AGE=65 | CIMP=CIMP+ | CIMP=CIMP- | CIMP=not specified | EGFR=AMP | EGFR=not specified | EGFR=wt | EVENT=alive | EVENT=deceased | IDHMUT=mut | IDHMUT=not specified | IDHMUT=wt | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=meth | MGMT=not specified | MGMT=unmeth | ORIGINAL DIAGNOSIS=AOA | ORIGINAL DIAGNOSIS=AOD | REVIEW DIAGNOSIS=AOA | REVIEW DIAGNOSIS=AOD | REVIEW DIAGNOSIS=GBM/AA | REVIEW DIAGNOSIS=LGG | REVIEW DIAGNOSIS=not specified | SAMPLE=113 | SAMPLE=117 | SAMPLE=125 | SAMPLE=13 | SAMPLE=147 | SAMPLE=17 | SAMPLE=182 | SAMPLE=242 | SAMPLE=259 | SAMPLE=262 | SAMPLE=27 | SAMPLE=275 | SAMPLE=290 | SAMPLE=30 | SAMPLE=301 | SAMPLE=305 | SAMPLE=31 | SAMPLE=32 | SAMPLE=326 | SAMPLE=33 | SAMPLE=41 | SAMPLE=48 | SAMPLE=50 | SAMPLE=54 | SAMPLE=57 | SAMPLE=58 | SAMPLE=66 | SAMPLE=84 | SEX=female | SEX=male | SS Y=0.323287671232877 | SS Y=0.517808219178082 | SS Y=0.613698630136986 | SS Y=0.964383561643836 | SS Y=0.991780821917808 | SS Y=1.01643835616438 | SS Y=1.12328767123288 | SS Y=1.24657534246575 | SS Y=1.36986301369863 | SS Y=1.48767123287671 | SS Y=1.55616438356164 | SS Y=2.79452054794521 | SS Y=2.86849315068493 | SS Y=2.95068493150685 | SS Y=2.96986301369863 | SS Y=3.11506849315069 | SS Y=3.19178082191781 | SS Y=3.33424657534247 | SS Y=3.43013698630137 | SS Y=4.00821917808219 | SS Y=4.21643835616438 | SS Y=4.68219178082192 | SS Y=4.91780821917808 | SS Y=4.95068493150685 | SS Y=6.77808219178082 | SS Y=6.94246575342466 | SS Y=7.40547945205479 | SS Y=7.43835616438356 | TCGA CLASSIFICATION=C | TCGA CLASSIFICATION=M | TCGA CLASSIFICATION=N | TCGA CLASSIFICATION=P | TRT=RT | TRT=RT/PCV","1P19Q LOH=LOH | 1P19Q LOH=no loss | 1P19Q LOH=not specified | AGE=20 | AGE=31 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=37 | AGE=38 | AGE=39 | AGE=40 | AGE=41 | AGE=42 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=50 | AGE=51 | AGE=52 | AGE=53 | AGE=54 | AGE=55 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=63 | AGE=64 | AGE=65 | AGE=66 | AGE=67 | AGE=68 | CIMP=CIMP+ | CIMP=CIMP- | CIMP=not specified | EGFR=AMP | EGFR=not specified | EGFR=wt | EVENT=alive | EVENT=deceased | IDHMUT=mut | IDHMUT=not specified | IDHMUT=wt | IGS=16 | IGS=17 | IGS=18 | IGS=22 | IGS=23 | IGS=9 | MGMT=meth | MGMT=not specified | MGMT=unmeth | ORIGINAL DIAGNOSIS=AOA | ORIGINAL DIAGNOSIS=AOD | REVIEW DIAGNOSIS=AOA | REVIEW DIAGNOSIS=AOD | REVIEW DIAGNOSIS=GBM/AA | REVIEW DIAGNOSIS=LGG | REVIEW DIAGNOSIS=not specified | SAMPLE=103 | SAMPLE=110 | SAMPLE=115 | SAMPLE=116 | SAMPLE=12 | SAMPLE=122 | SAMPLE=129 | SAMPLE=137 | SAMPLE=138 | SAMPLE=139 | SAMPLE=14 | SAMPLE=145 | SAMPLE=149 | SAMPLE=151 | SAMPLE=152 | SAMPLE=153 | SAMPLE=154 | SAMPLE=155 | SAMPLE=159 | SAMPLE=165 | SAMPLE=170 | SAMPLE=174 | SAMPLE=175 | SAMPLE=185 | SAMPLE=189 | SAMPLE=194 | SAMPLE=197 | SAMPLE=198 | SAMPLE=199 | SAMPLE=20 | SAMPLE=200 | SAMPLE=203 | SAMPLE=204 | SAMPLE=206 | SAMPLE=209 | SAMPLE=21 | SAMPLE=212 | SAMPLE=213 | SAMPLE=214 | SAMPLE=215 | SAMPLE=216 | SAMPLE=218 | SAMPLE=220 | SAMPLE=221 | SAMPLE=222 | SAMPLE=224 | SAMPLE=23 | SAMPLE=230 | SAMPLE=234 | SAMPLE=238 | SAMPLE=247 | SAMPLE=257 | SAMPLE=26 | SAMPLE=261 | SAMPLE=270 | SAMPLE=271 | SAMPLE=276 | SAMPLE=285 | SAMPLE=292 | SAMPLE=298 | SAMPLE=299 | SAMPLE=300 | SAMPLE=302 | SAMPLE=309 | SAMPLE=310 | SAMPLE=311 | SAMPLE=312 | SAMPLE=313 | SAMPLE=314 | SAMPLE=315 | SAMPLE=324 | SAMPLE=327 | SAMPLE=331 | SAMPLE=335 | SAMPLE=339 | SAMPLE=343 | SAMPLE=36 | SAMPLE=4 | SAMPLE=45 | SAMPLE=507 | SAMPLE=51 | SAMPLE=52 | SAMPLE=53 | SAMPLE=56 | SAMPLE=59 | SAMPLE=64 | SAMPLE=67 | SAMPLE=69 | SAMPLE=72 | SAMPLE=75 | SAMPLE=85 | SAMPLE=89 | SAMPLE=9 | SAMPLE=91 | SAMPLE=96 | SEX=female | SEX=male | SS Y=0.186301369863014 | SS Y=0.268493150684932 | SS Y=0.315068493150685 | SS Y=0.317808219178082 | SS Y=0.386301369863014 | SS Y=0.43013698630137 | SS Y=0.46027397260274 | SS Y=0.512328767123288 | SS Y=0.545205479452055 | SS Y=0.572602739726027 | SS Y=0.6 | SS Y=0.66027397260274 | SS Y=0.676712328767123 | SS Y=0.679452054794521 | SS Y=0.720547945205479 | SS Y=0.736986301369863 | SS Y=0.764383561643836 | SS Y=0.797260273972603 | SS Y=0.808219178082192 | SS Y=0.950684931506849 | SS Y=0.964383561643836 | SS Y=0.978082191780822 | SS Y=1.02191780821918 | SS Y=1.04657534246575 | SS Y=1.06027397260274 | SS Y=1.14794520547945 | SS Y=1.16986301369863 | SS Y=1.18082191780822 | SS Y=1.23561643835616 | SS Y=1.26301369863014 | SS Y=1.26849315068493 | SS Y=1.2958904109589 | SS Y=1.33424657534247 | SS Y=1.36986301369863 | SS Y=1.40547945205479 | SS Y=1.41917808219178 | SS Y=1.43287671232877 | SS Y=1.47945205479452 | SS Y=1.4958904109589 | SS Y=1.4986301369863 | SS Y=1.58356164383562 | SS Y=1.58904109589041 | SS Y=1.59178082191781 | SS Y=1.60547945205479 | SS Y=1.62739726027397 | SS Y=1.72054794520548 | SS Y=1.75068493150685 | SS Y=1.82465753424658 | SS Y=1.87671232876712 | SS Y=1.90684931506849 | SS Y=2.01369863013699 | SS Y=2.37534246575342 | SS Y=2.39178082191781 | SS Y=2.55068493150685 | SS Y=2.87671232876712 | SS Y=2.89315068493151 | SS Y=2.95616438356164 | SS Y=3.03835616438356 | SS Y=3.21917808219178 | SS Y=3.39452054794521 | SS Y=3.47123287671233 | SS Y=3.61369863013699 | SS Y=3.62739726027397 | SS Y=3.77534246575342 | SS Y=3.98082191780822 | SS Y=4.06301369863014 | SS Y=4.16164383561644 | SS Y=4.37260273972603 | SS Y=4.54520547945206 | SS Y=4.63013698630137 | SS Y=4.64383561643836 | SS Y=4.66301369863014 | SS Y=4.78904109589041 | SS Y=5.13698630136986 | SS Y=5.25479452054795 | SS Y=5.37534246575343 | SS Y=5.52054794520548 | SS Y=5.58082191780822 | SS Y=5.59178082191781 | SS Y=5.61095890410959 | SS Y=5.68767123287671 | SS Y=5.70958904109589 | SS Y=5.79452054794521 | SS Y=5.84657534246575 | SS Y=5.98356164383562 | SS Y=6.07123287671233 | SS Y=6.44383561643836 | SS Y=6.65205479452055 | SS Y=6.82191780821918 | SS Y=6.82465753424658 | SS Y=7.09315068493151 | SS Y=7.37260273972603 | SS Y=7.88219178082192 | TCGA CLASSIFICATION=C | TCGA CLASSIFICATION=M | TCGA CLASSIFICATION=not specified | TCGA CLASSIFICATION=P | TISSUE TYPE=FF | TISSUE TYPE=FFPE | TRT=RT | TRT=RT/PCV","NA","disease=atypical teratoid / rhabdoid tumor | disease=glioblastoma | disease=medulloblastoma | disease=medulloblastoma, large-cell | disease=normal | disease=normal cerebellum | disease=normal frontal | disease=primitive neuroectodermal tumor","AGE=22 | AGE=28 | AGE=29 | AGE=30 | AGE=31 | AGE=32 | AGE=36 | AGE=37 | AGE=39 | AGE=40 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=51 | AGE=53 | AGE=56 | AGE=57 | AGE=58 | AGE=58y | AGE=59 | AGE=60 | AGE=61 | AGE=62 | AGE=63 | AGE=64 | AGE=65 | AGE=67 | AGE=68 | AGE=69 | AGE=70 | AGE=71 | AGE=74 | AGE=76 | AGE=not specified | FOLLOW-UP LOSS=1 | FOLLOW-UP LOSS=2 | FOLLOW-UP LOSS=not specified | LOCATION OF LESION=Both Frontal | LOCATION OF LESION=Corpus Callosal | LOCATION OF LESION=Lt. Frontal | LOCATION OF LESION=Lt. Fronto-Parietal | LOCATION OF LESION=Lt. Fronto-Temporal | LOCATION OF LESION=Lt. Occipital | LOCATION OF LESION=Lt. Parietal | LOCATION OF LESION=Lt. Parieto-Occipital | LOCATION OF LESION=Lt. Temporal | LOCATION OF LESION=not specified | LOCATION OF LESION=Rt thalamus | LOCATION OF LESION=Rt. Frontal | LOCATION OF LESION=Rt. Fronto-Parietal | LOCATION OF LESION=Rt. Frontoparietal | LOCATION OF LESION=Rt. Parietal | LOCATION OF LESION=Rt. Parieto-Occipital | LOCATION OF LESION=Rt. sylvian | LOCATION OF LESION=Rt. Temporal | LOCATION OF LESION=Rt. Temporo-Parietal | OVERALL SURVIVAL WEEKS=102 | OVERALL SURVIVAL WEEKS=110 | OVERALL SURVIVAL WEEKS=12 | OVERALL SURVIVAL WEEKS=123 | OVERALL SURVIVAL WEEKS=13 | OVERALL SURVIVAL WEEKS=133 | OVERALL SURVIVAL WEEKS=144 | OVERALL SURVIVAL WEEKS=149 | OVERALL SURVIVAL WEEKS=157 | OVERALL SURVIVAL WEEKS=170 | OVERALL SURVIVAL WEEKS=184 | OVERALL SURVIVAL WEEKS=195 | OVERALL SURVIVAL WEEKS=214 | OVERALL SURVIVAL WEEKS=270 | OVERALL SURVIVAL WEEKS=28 | OVERALL SURVIVAL WEEKS=4 | OVERALL SURVIVAL WEEKS=40 | OVERALL SURVIVAL WEEKS=45 | OVERALL SURVIVAL WEEKS=48 | OVERALL SURVIVAL WEEKS=50 | OVERALL SURVIVAL WEEKS=53 | OVERALL SURVIVAL WEEKS=54 | OVERALL SURVIVAL WEEKS=60 | OVERALL SURVIVAL WEEKS=61 | OVERALL SURVIVAL WEEKS=63 | OVERALL SURVIVAL WEEKS=64 | OVERALL SURVIVAL WEEKS=65 | OVERALL SURVIVAL WEEKS=71 | OVERALL SURVIVAL WEEKS=73 | OVERALL SURVIVAL WEEKS=77 | OVERALL SURVIVAL WEEKS=80 | OVERALL SURVIVAL WEEKS=82 | OVERALL SURVIVAL WEEKS=87 | OVERALL SURVIVAL WEEKS=88 | OVERALL SURVIVAL WEEKS=89 | OVERALL SURVIVAL WEEKS=99 | OVERALL SURVIVAL WEEKS=NA | OVERALL SURVIVAL WEEKS=not specified | PATIENT=1 | PATIENT=10 | PATIENT=11 | PATIENT=12 | PATIENT=13 | PATIENT=14 | PATIENT=15 | PATIENT=16 | PATIENT=17 | PATIENT=18 | PATIENT=19 | PATIENT=2 | PATIENT=21 | PATIENT=23 | PATIENT=24 | PATIENT=26 | PATIENT=27 | PATIENT=28 | PATIENT=29 | PATIENT=3 | PATIENT=30 | PATIENT=31 | PATIENT=32 | PATIENT=33 | PATIENT=34 | PATIENT=35 | PATIENT=36 | PATIENT=38 | PATIENT=39 | PATIENT=4 | PATIENT=41 | PATIENT=42 | PATIENT=43 | PATIENT=44 | PATIENT=47 | PATIENT=49 | PATIENT=5 | PATIENT=50 | PATIENT=51 | PATIENT=52 | PATIENT=56 | PATIENT=58 | PATIENT=6 | PATIENT=7 | PATIENT=8 | PATIENT=9 | PATIENT=not specified | PROGRESSION-FREE SURVIVAL WEEKS=11 | PROGRESSION-FREE SURVIVAL WEEKS=119 | PROGRESSION-FREE SURVIVAL WEEKS=12 | PROGRESSION-FREE SURVIVAL WEEKS=120 | PROGRESSION-FREE SURVIVAL WEEKS=122 | PROGRESSION-FREE SURVIVAL WEEKS=13 | PROGRESSION-FREE SURVIVAL WEEKS=14 | PROGRESSION-FREE SURVIVAL WEEKS=17 | PROGRESSION-FREE SURVIVAL WEEKS=214 | PROGRESSION-FREE SURVIVAL WEEKS=24 | PROGRESSION-FREE SURVIVAL WEEKS=29 | PROGRESSION-FREE SURVIVAL WEEKS=30 | PROGRESSION-FREE SURVIVAL WEEKS=34 | PROGRESSION-FREE SURVIVAL WEEKS=36 | PROGRESSION-FREE SURVIVAL WEEKS=37 | PROGRESSION-FREE SURVIVAL WEEKS=38 | PROGRESSION-FREE SURVIVAL WEEKS=39 | PROGRESSION-FREE SURVIVAL WEEKS=4 | PROGRESSION-FREE SURVIVAL WEEKS=40 | PROGRESSION-FREE SURVIVAL WEEKS=41 | PROGRESSION-FREE SURVIVAL WEEKS=44 | PROGRESSION-FREE SURVIVAL WEEKS=45 | PROGRESSION-FREE SURVIVAL WEEKS=49 | PROGRESSION-FREE SURVIVAL WEEKS=50 | PROGRESSION-FREE SURVIVAL WEEKS=54 | PROGRESSION-FREE SURVIVAL WEEKS=56 | PROGRESSION-FREE SURVIVAL WEEKS=64 | PROGRESSION-FREE SURVIVAL WEEKS=67 | PROGRESSION-FREE SURVIVAL WEEKS=69 | PROGRESSION-FREE SURVIVAL WEEKS=71 | PROGRESSION-FREE SURVIVAL WEEKS=79 | PROGRESSION-FREE SURVIVAL WEEKS=8 | PROGRESSION-FREE SURVIVAL WEEKS=82 | PROGRESSION-FREE SURVIVAL WEEKS=84 | PROGRESSION-FREE SURVIVAL WEEKS=88 | PROGRESSION-FREE SURVIVAL WEEKS=NA | PROGRESSION-FREE SURVIVAL WEEKS=not specified | SEX=female | SEX=male | STAGE=GBM (IV) | STAGE=GS (IV) | STAGE=not specified | STAGE=R-GBM (IV)","AGE=22 | AGE=28 | AGE=29 | AGE=30 | AGE=31 | AGE=32 | AGE=36 | AGE=37 | AGE=39 | AGE=40 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=51 | AGE=53 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=62 | AGE=63 | AGE=64 | AGE=65 | AGE=67 | AGE=68 | AGE=69 | AGE=70 | AGE=71 | AGE=74 | AGE=76 | FOLLOW-UP LOSS=1 | FOLLOW-UP LOSS=2 | FOLLOW-UP LOSS=not specified | LOCATION OF LESION=Both Frontal | LOCATION OF LESION=Corpus Callosal | LOCATION OF LESION=Lt. Frontal | LOCATION OF LESION=Lt. Fronto-Parietal | LOCATION OF LESION=Lt. Fronto-Temporal | LOCATION OF LESION=Lt. Occipital | LOCATION OF LESION=Lt. Parietal | LOCATION OF LESION=Lt. Parieto-Occipital | LOCATION OF LESION=Lt. Temporal | LOCATION OF LESION=Rt thalamus | LOCATION OF LESION=Rt. Frontal | LOCATION OF LESION=Rt. Fronto-Parietal | LOCATION OF LESION=Rt. Frontoparietal | LOCATION OF LESION=Rt. Parietal | LOCATION OF LESION=Rt. Parieto-Occipital | LOCATION OF LESION=Rt. sylvian | LOCATION OF LESION=Rt. Temporal | LOCATION OF LESION=Rt. Temporo-Parietal | OVERALL SURVIVAL WEEKS=102 | OVERALL SURVIVAL WEEKS=110 | OVERALL SURVIVAL WEEKS=12 | OVERALL SURVIVAL WEEKS=123 | OVERALL SURVIVAL WEEKS=13 | OVERALL SURVIVAL WEEKS=133 | OVERALL SURVIVAL WEEKS=144 | OVERALL SURVIVAL WEEKS=149 | OVERALL SURVIVAL WEEKS=157 | OVERALL SURVIVAL WEEKS=170 | OVERALL SURVIVAL WEEKS=184 | OVERALL SURVIVAL WEEKS=195 | OVERALL SURVIVAL WEEKS=214 | OVERALL SURVIVAL WEEKS=270 | OVERALL SURVIVAL WEEKS=28 | OVERALL SURVIVAL WEEKS=4 | OVERALL SURVIVAL WEEKS=40 | OVERALL SURVIVAL WEEKS=45 | OVERALL SURVIVAL WEEKS=48 | OVERALL SURVIVAL WEEKS=50 | OVERALL SURVIVAL WEEKS=53 | OVERALL SURVIVAL WEEKS=54 | OVERALL SURVIVAL WEEKS=60 | OVERALL SURVIVAL WEEKS=61 | OVERALL SURVIVAL WEEKS=63 | OVERALL SURVIVAL WEEKS=64 | OVERALL SURVIVAL WEEKS=65 | OVERALL SURVIVAL WEEKS=71 | OVERALL SURVIVAL WEEKS=73 | OVERALL SURVIVAL WEEKS=77 | OVERALL SURVIVAL WEEKS=80 | OVERALL SURVIVAL WEEKS=82 | OVERALL SURVIVAL WEEKS=87 | OVERALL SURVIVAL WEEKS=88 | OVERALL SURVIVAL WEEKS=89 | OVERALL SURVIVAL WEEKS=99 | OVERALL SURVIVAL WEEKS=NA | PATIENT=1 | PATIENT=10 | PATIENT=11 | PATIENT=12 | PATIENT=13 | PATIENT=14 | PATIENT=15 | PATIENT=16 | PATIENT=17 | PATIENT=18 | PATIENT=19 | PATIENT=2 | PATIENT=21 | PATIENT=23 | PATIENT=24 | PATIENT=26 | PATIENT=27 | PATIENT=28 | PATIENT=29 | PATIENT=3 | PATIENT=30 | PATIENT=31 | PATIENT=32 | PATIENT=33 | PATIENT=34 | PATIENT=35 | PATIENT=36 | PATIENT=38 | PATIENT=39 | PATIENT=4 | PATIENT=41 | PATIENT=42 | PATIENT=43 | PATIENT=44 | PATIENT=47 | PATIENT=49 | PATIENT=5 | PATIENT=50 | PATIENT=51 | PATIENT=52 | PATIENT=56 | PATIENT=58 | PATIENT=6 | PATIENT=7 | PATIENT=8 | PATIENT=9 | PROGRESSION-FREE SURVIVAL WEEKS=11 | PROGRESSION-FREE SURVIVAL WEEKS=119 | PROGRESSION-FREE SURVIVAL WEEKS=12 | PROGRESSION-FREE SURVIVAL WEEKS=120 | PROGRESSION-FREE SURVIVAL WEEKS=122 | PROGRESSION-FREE SURVIVAL WEEKS=13 | PROGRESSION-FREE SURVIVAL WEEKS=14 | PROGRESSION-FREE SURVIVAL WEEKS=17 | PROGRESSION-FREE SURVIVAL WEEKS=214 | PROGRESSION-FREE SURVIVAL WEEKS=24 | PROGRESSION-FREE SURVIVAL WEEKS=29 | PROGRESSION-FREE SURVIVAL WEEKS=30 | PROGRESSION-FREE SURVIVAL WEEKS=34 | PROGRESSION-FREE SURVIVAL WEEKS=36 | PROGRESSION-FREE SURVIVAL WEEKS=37 | PROGRESSION-FREE SURVIVAL WEEKS=38 | PROGRESSION-FREE SURVIVAL WEEKS=39 | PROGRESSION-FREE SURVIVAL WEEKS=4 | PROGRESSION-FREE SURVIVAL WEEKS=40 | PROGRESSION-FREE SURVIVAL WEEKS=41 | PROGRESSION-FREE SURVIVAL WEEKS=44 | PROGRESSION-FREE SURVIVAL WEEKS=45 | PROGRESSION-FREE SURVIVAL WEEKS=49 | PROGRESSION-FREE SURVIVAL WEEKS=50 | PROGRESSION-FREE SURVIVAL WEEKS=54 | PROGRESSION-FREE SURVIVAL WEEKS=56 | PROGRESSION-FREE SURVIVAL WEEKS=64 | PROGRESSION-FREE SURVIVAL WEEKS=67 | PROGRESSION-FREE SURVIVAL WEEKS=69 | PROGRESSION-FREE SURVIVAL WEEKS=71 | PROGRESSION-FREE SURVIVAL WEEKS=79 | PROGRESSION-FREE SURVIVAL WEEKS=8 | PROGRESSION-FREE SURVIVAL WEEKS=82 | PROGRESSION-FREE SURVIVAL WEEKS=84 | PROGRESSION-FREE SURVIVAL WEEKS=88 | PROGRESSION-FREE SURVIVAL WEEKS=NA | SEX=female | SEX=male | STAGE=GBM (IV) | STAGE=GS (IV) | STAGE=R-GBM (IV)","SEX=female | SEX=male","OS AFTER BEVACIZUMAB/IRINOTECAN=1.4 months | OS AFTER BEVACIZUMAB/IRINOTECAN=11.8 months | OS AFTER BEVACIZUMAB/IRINOTECAN=12.8 months | OS AFTER BEVACIZUMAB/IRINOTECAN=14.3 months | OS AFTER BEVACIZUMAB/IRINOTECAN=15.2 months | OS AFTER BEVACIZUMAB/IRINOTECAN=15.7 months | OS AFTER BEVACIZUMAB/IRINOTECAN=16.5 months | OS AFTER BEVACIZUMAB/IRINOTECAN=17.3 months | OS AFTER BEVACIZUMAB/IRINOTECAN=18.9 months | OS AFTER BEVACIZUMAB/IRINOTECAN=26 months | OS AFTER BEVACIZUMAB/IRINOTECAN=3.3 months | OS AFTER BEVACIZUMAB/IRINOTECAN=4.1 months | OS AFTER BEVACIZUMAB/IRINOTECAN=5.5 months | OS AFTER BEVACIZUMAB/IRINOTECAN=5.9 months | OS AFTER BEVACIZUMAB/IRINOTECAN=6.1 months | OS AFTER BEVACIZUMAB/IRINOTECAN=6.4 months | OS AFTER BEVACIZUMAB/IRINOTECAN=6.6 months | OS AFTER BEVACIZUMAB/IRINOTECAN=7 months | OS AFTER BEVACIZUMAB/IRINOTECAN=7.7 months | OS AFTER BEVACIZUMAB/IRINOTECAN=7.8 months | OS AFTER BEVACIZUMAB/IRINOTECAN=8.3 months | OS AFTER BEVACIZUMAB/IRINOTECAN=8.6 months | OS AFTER BEVACIZUMAB/IRINOTECAN=8.8 months | OS AFTER BEVACIZUMAB/IRINOTECAN=9.6 months | OS SINCE DIAGNOSIS=12.6 months | OS SINCE DIAGNOSIS=13.4 months | OS SINCE DIAGNOSIS=13.9 months | OS SINCE DIAGNOSIS=14.6 months | OS SINCE DIAGNOSIS=14.7 months | OS SINCE DIAGNOSIS=16 months | OS SINCE DIAGNOSIS=17.6 months | OS SINCE DIAGNOSIS=18 months | OS SINCE DIAGNOSIS=18.3 months | OS SINCE DIAGNOSIS=19.3 months | OS SINCE DIAGNOSIS=19.4 months | OS SINCE DIAGNOSIS=20.6 months | OS SINCE DIAGNOSIS=21.7 months | OS SINCE DIAGNOSIS=23.1 months | OS SINCE DIAGNOSIS=24.8 months | OS SINCE DIAGNOSIS=25.3 months | OS SINCE DIAGNOSIS=25.5 months | OS SINCE DIAGNOSIS=28.5 months | OS SINCE DIAGNOSIS=32.1 months | OS SINCE DIAGNOSIS=33.8 months | OS SINCE DIAGNOSIS=36.4 months | OS SINCE DIAGNOSIS=40.8 months | OS SINCE DIAGNOSIS=43.4 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=0.9 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=1 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=1.9 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=10.6 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=10.7 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=12 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=18 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=2 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=2.2 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=2.4 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=3.9 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=4 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=4.1 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=6 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=6.1 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=7.9 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=8.3 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=9 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=9.4 months | PFS AFTER BEVACIZUMAB/IRINOTECAN=9.8 months | RESPONDER=patient has not shown a response to the treatment | RESPONDER=patient has shown a response to the treatment","CELL LINE=DBTRG | CELL LINE=U87 | TREATMENT=10 uM Y15 | TREATMENT=20 uM Temozolomide | TREATMENT=20 uM Temozolomide + 10 uM Y15 | TREATMENT=untreated","CELL TYPE=H2171 | CELL TYPE=MM1.S | CELL TYPE=U87 | CHIP ANTIBODY=Brd4 | CHIP ANTIBODY=Med1/TRAP220 | CHIP ANTIBODY=None | CHIP ANTIBODY=RNA Pol II (Rpb1 N-terminus) | CHIP ANTIBODY DETAILS=Bethyl A300-793A | CHIP ANTIBODY DETAILS=Bethyl A301-985A | CHIP ANTIBODY DETAILS=None | CHIP ANTIBODY DETAILS=Santa Cruz SC-899 | CONCENTRATION=0.05% | CONCENTRATION=500nM | CONCENTRATION=50nM | CONCENTRATION=5nM | CONCENTRATION=5uM | TREATMENT=DMSO | TREATMENT=JQ1","VARIATION=1.5 million copies of EGFRvIII receptor per cell | VARIATION=2 million copies of EGFRvIII receptor per cell | VARIATION=2.5 million copies of EGFRvIII receptor per cell | VARIATION=kinase dead EGFRvIII","VARIATION=1.5 million copies of EGFRvIII receptor per cell | VARIATION=2 million copies of EGFRvIII receptor per cell | VARIATION=2.5 million copies of EGFRvIII receptor per cell | VARIATION=kinase dead EGFRvIII","VARIATION=2 million copies of EGFRvIII receptor per cell | VARIATION=kinase dead EGFRvIII","ORGANISM PART=bladder carcinoma | ORGANISM PART=breast carcinoma | ORGANISM PART=Glioblastoma | ORGANISM PART=not specified | ORGANISM PART=ovarian small cell carcinoma | ORGANISM PART=pancreatic adenocarcinoma | SAMPLE TYPE=cell line | SAMPLE TYPE=commercial pooled reference | SAMPLE TYPE=formalin-fixed paraffin-embedded tissue | SAMPLE TYPE=fresh frozen tissue","CELL LINE=Invasive subline U87-2M1 derived from U87 | CELL LINE=U87 glioma cells | CELL LINE=U87-2M1 | CELL TYPE=Invasive subline derived from U87 glioma cells | CELL TYPE=Late passage cells | CELL TYPE=Passage 4 cells, maintained under hypoxia | TRANDUCED WITH=baculoviral control decoy vector | TRANDUCED WITH=baculoviral miR-10b decoy vector | TRANDUCED WITH=not specified","CELL LINE=U-251 MG | CELL LINE=U-251 MG human glioblastoma cell line | CHIP ANTIBODY=ETS1 | CHIP ANTIBODY=H3K4Me3 | CHIP ANTIBODY=H3K9Ac | CHIP ANTIBODY=not specified | CHIP ANTIBODY=p53 | CHIP ANTIBODY=RNA Pol II S2-P | CHIP ANTIBODY=RNA Pol II S5-P | CHIP ANTIBODY=SP1 | CHIP ANTIBODY VENDOR=Abcam | CHIP ANTIBODY VENDOR=ActiveMotif | CHIP ANTIBODY VENDOR=Millipore | CHIP ANTIBODY VENDOR=not specified | CHIP ANTIBODY VENDOR=Santa Cruz Biotechnology | CHIP ANTIBODY VENDOR=Upstate | TRANSFECTED WITH=control siRNA | TRANSFECTED WITH=not specified | TRANSFECTED WITH=p53-siRNA | TRANSFECTED WITH=scrambled control siRNA","NA","CHIP ANTIBODY=ETS1 | CHIP ANTIBODY=H3K4Me3 | CHIP ANTIBODY=H3K9Ac | CHIP ANTIBODY=not specified | CHIP ANTIBODY=p53 | CHIP ANTIBODY=RNA Pol II S2-P | CHIP ANTIBODY=RNA Pol II S5-P | CHIP ANTIBODY=SP1 | CHIP ANTIBODY VENDOR=Abcam | CHIP ANTIBODY VENDOR=ActiveMotif | CHIP ANTIBODY VENDOR=Millipore | CHIP ANTIBODY VENDOR=not specified | CHIP ANTIBODY VENDOR=Santa Cruz Biotechnology | CHIP ANTIBODY VENDOR=Upstate | TRANSFECTED WITH=control siRNA | TRANSFECTED WITH=not specified | TRANSFECTED WITH=p53-siRNA | TRANSFECTED WITH=scrambled control siRNA","CELL LINE=not specified | CELL LINE=SNB19 | CELL LINE=U251 | GENOTYPE=FGFR3-TACC3 negative | GENOTYPE=FGFR3-TACC3 positive | GENOTYPE=not specified | TREATMENT=empty vector | TREATMENT=FGFR3 wt | TREATMENT=FGFR3-TACC3 clone #2 | TREATMENT=FGFR3-TACC3 clone #5 | TREATMENT=FGFR3-TACC3 clone #8 | TREATMENT=FGFR3-TACC3 clones #2,5,and 8 mixture | TREATMENT=FGFR3-TACC3 fusion | TREATMENT=not specified | TREATMENT=TACC3 wt","cell line=SNB19 | cell line=U251 | treatment=empty vector | treatment=FGFR3 wt | treatment=FGFR3-TACC3 | treatment=FGFR3-TACC3 clones #2,5,and 8 mixture | treatment=FGFR3-TACC3 fusion | treatment=TACC3 wt","GENOTYPE=FGFR3-TACC3 negative | GENOTYPE=FGFR3-TACC3 positive | GENOTYPE=not specified","AGE AT DIAGNOSIS YEARS=10 | AGE AT DIAGNOSIS YEARS=11 | AGE AT DIAGNOSIS YEARS=12 | AGE AT DIAGNOSIS YEARS=13 | AGE AT DIAGNOSIS YEARS=14 | AGE AT DIAGNOSIS YEARS=15 | AGE AT DIAGNOSIS YEARS=16 | AGE AT DIAGNOSIS YEARS=17 | AGE AT DIAGNOSIS YEARS=18 | AGE AT DIAGNOSIS YEARS=19 | AGE AT DIAGNOSIS YEARS=2 | AGE AT DIAGNOSIS YEARS=20 | AGE AT DIAGNOSIS YEARS=21 | AGE AT DIAGNOSIS YEARS=22 | AGE AT DIAGNOSIS YEARS=23 | AGE AT DIAGNOSIS YEARS=24 | AGE AT DIAGNOSIS YEARS=25 | AGE AT DIAGNOSIS YEARS=26 | AGE AT DIAGNOSIS YEARS=31 | AGE AT DIAGNOSIS YEARS=32 | AGE AT DIAGNOSIS YEARS=33 | AGE AT DIAGNOSIS YEARS=34 | AGE AT DIAGNOSIS YEARS=36 | AGE AT DIAGNOSIS YEARS=38 | AGE AT DIAGNOSIS YEARS=39 | AGE AT DIAGNOSIS YEARS=4 | AGE AT DIAGNOSIS YEARS=40 | AGE AT DIAGNOSIS YEARS=41 | AGE AT DIAGNOSIS YEARS=42 | AGE AT DIAGNOSIS YEARS=43 | AGE AT DIAGNOSIS YEARS=44 | AGE AT DIAGNOSIS YEARS=45 | AGE AT DIAGNOSIS YEARS=46 | AGE AT DIAGNOSIS YEARS=47 | AGE AT DIAGNOSIS YEARS=48 | AGE AT DIAGNOSIS YEARS=49 | AGE AT DIAGNOSIS YEARS=5 | AGE AT DIAGNOSIS YEARS=50 | AGE AT DIAGNOSIS YEARS=51 | AGE AT DIAGNOSIS YEARS=52 | AGE AT DIAGNOSIS YEARS=53 | AGE AT DIAGNOSIS YEARS=54 | AGE AT DIAGNOSIS YEARS=55 | AGE AT DIAGNOSIS YEARS=57 | AGE AT DIAGNOSIS YEARS=6 | AGE AT DIAGNOSIS YEARS=66 | AGE AT DIAGNOSIS YEARS=68 | AGE AT DIAGNOSIS YEARS=69 | AGE AT DIAGNOSIS YEARS=7 | AGE AT DIAGNOSIS YEARS=71 | AGE AT DIAGNOSIS YEARS=72 | AGE AT DIAGNOSIS YEARS=75 | AGE AT DIAGNOSIS YEARS=8 | AGE AT DIAGNOSIS YEARS=9 | AGE AT DIAGNOSIS YEARS=not specified | BRAIN LOCATION=brain stem | BRAIN LOCATION=Cerebellar | BRAIN LOCATION=cerebellopontine angle | BRAIN LOCATION=DIPG | BRAIN LOCATION=frontal lobe | BRAIN LOCATION=frontal lobe, praecentral | BRAIN LOCATION=fronto-temporal | BRAIN LOCATION=gyrus cinguli | BRAIN LOCATION=NA | BRAIN LOCATION=occipital lobe | BRAIN LOCATION=parietal lobe | BRAIN LOCATION=temporal lobe | BRAIN LOCATION=thalamic | BRAIN LOCATION=ventricular | DEVELOPMENTAL STAGE=adult | DEVELOPMENTAL STAGE=fetus | DEVELOPMENTAL STAGE=not specified | DNA METHYLATION SUBGROUP=G34 | DNA METHYLATION SUBGROUP=IDH | DNA METHYLATION SUBGROUP=K27 | DNA METHYLATION SUBGROUP=mesenchymal | DNA METHYLATION SUBGROUP=not specified | DNA METHYLATION SUBGROUP=RTK I 'PDGFRA' | DNA METHYLATION SUBGROUP=RTK II 'classic' | H3F3A STATUS=G34R | H3F3A STATUS=G34V | H3F3A STATUS=K27M | H3F3A STATUS=not specified | H3F3A STATUS=WT | IDH1 STATUS=MUT | IDH1 STATUS=not specified | IDH1 STATUS=WT | ORGANISM PART=non-neoplastic brain | ORGANISM PART=primary glioblastoma | PMID 22286061=not specified | PMID 22286061=PGBM1 | PMID 22286061=PGBM11 | PMID 22286061=PGBM12 | PMID 22286061=PGBM13 | PMID 22286061=PGBM14 | PMID 22286061=PGBM15 | PMID 22286061=PGBM17 | PMID 22286061=PGBM18 | PMID 22286061=PGBM19 | PMID 22286061=PGBM2 | PMID 22286061=PGBM23 | PMID 22286061=PGBM24 | PMID 22286061=PGBM25 | PMID 22286061=PGBM26 | PMID 22286061=PGBM27 | PMID 22286061=PGBM29 | PMID 22286061=PGBM31 | PMID 22286061=PGBM32 | PMID 22286061=PGBM34 | PMID 22286061=PGBM39 | PMID 22286061=PGBM4 | PMID 22286061=PGBM43 | PMID 22286061=PGBM45 | PMID 22286061=PGBM46 | PMID 22286061=PGBM47 | PMID 22286061=PGBM48 | PMID 22286061=PGBM6 | PMID 22286061=PGBM8 | PMID 22286061=PGBM9 | SEX=female | SEX=male | SEX=not specified","AGE AT DIAGNOSIS YEARS=1 | AGE AT DIAGNOSIS YEARS=10 | AGE AT DIAGNOSIS YEARS=11 | AGE AT DIAGNOSIS YEARS=12 | AGE AT DIAGNOSIS YEARS=13 | AGE AT DIAGNOSIS YEARS=14 | AGE AT DIAGNOSIS YEARS=17 | AGE AT DIAGNOSIS YEARS=18 | AGE AT DIAGNOSIS YEARS=19 | AGE AT DIAGNOSIS YEARS=20 | AGE AT DIAGNOSIS YEARS=23 | AGE AT DIAGNOSIS YEARS=25 | AGE AT DIAGNOSIS YEARS=32 | AGE AT DIAGNOSIS YEARS=33 | AGE AT DIAGNOSIS YEARS=34 | AGE AT DIAGNOSIS YEARS=36 | AGE AT DIAGNOSIS YEARS=38 | AGE AT DIAGNOSIS YEARS=40 | AGE AT DIAGNOSIS YEARS=42 | AGE AT DIAGNOSIS YEARS=46 | AGE AT DIAGNOSIS YEARS=48 | AGE AT DIAGNOSIS YEARS=5 | AGE AT DIAGNOSIS YEARS=6 | AGE AT DIAGNOSIS YEARS=7 | AGE AT DIAGNOSIS YEARS=9 | AGE AT DIAGNOSIS YEARS=NA | AGE AT DIAGNOSIS YEARS=not specified | H3F3A STATUS=G34R | H3F3A STATUS=G34V | H3F3A STATUS=K27M | H3F3A STATUS=NA | H3F3A STATUS=WT | IDH1 STATUS=MUT | IDH1 STATUS=NA | IDH1 STATUS=WT | SEX=female | SEX=male | SUBGROUP=G34 | SUBGROUP=IDH | SUBGROUP=K27 | SUBGROUP=Mesenchymal | SUBGROUP=NA | SUBGROUP=RTK I | SUBGROUP=RTK II | TUMOR LOCATION=central region | TUMOR LOCATION=Cerebellar | TUMOR LOCATION=frontal lobe | TUMOR LOCATION=frontal/temporal | TUMOR LOCATION=hemispheric | TUMOR LOCATION=NA | TUMOR LOCATION=parietal lobe | TUMOR LOCATION=parieto-occipital | TUMOR LOCATION=pons | TUMOR LOCATION=temporal lobe | TUMOR LOCATION=temporo-parietal | TUMOR LOCATION=thalamic | TUMOR LOCATION=ventricular","AGE=18 | AGE=27 | AGE=49 | AGE=54 | AGE=57 | AGE=58 | AGE=59 | AGE=63 | AGE=66 | AGE=67 | AGE=73 | AGE=74 | AGE=76 | AGE=78 | EGFR STATUS=EGFR AMP | EGFR STATUS=EGFR WT | GLIOBLASTOMA SUBTYPE=Classical | GLIOBLASTOMA SUBTYPE=Mesenchymal | GLIOBLASTOMA SUBTYPE=Proneural | LOCALIZATION=F dx | LOCALIZATION=F sx | LOCALIZATION=FP dx | LOCALIZATION=FT dx | LOCALIZATION=FTP dx | LOCALIZATION=FTP sx | LOCALIZATION=P dx | LOCALIZATION=PO sx | LOCALIZATION=T dx | LOCALIZATION=T sx | LOCALIZATION=TPO sx | SEX=F | SEX=M","CELL LINE=A375 | CELL LINE=BS125-3 | CELL LINE=HuH7 | CELL LINE=THP-1 | CELL TYPE=acute monocytic leukemia | CELL TYPE=Glioblastoma | CELL TYPE=Hepatoma | CELL TYPE=melanoma","CLINICAL_INFORMATION=post avastin recurrence | CLINICAL_INFORMATION=pre avastin","DISEASESTATE=Giant Cell Glioblastoma | DISEASESTATE=glioblastoma multiforme | DISEASESTATE=normal","DISEASE_STATE=glioblastoma multiforme | DISEASE_STATE=normal","CELL LINE=IMR90 | CELL LINE=Primary culture | CELL TYPE=Glioblastoma | CELL TYPE=lung fiboblast cells","phenotype=control | phenotype=expressing O6-methylguanine methyltransferase","TIC CLASS=expansive | TIC CLASS=highly diffusive","TREATED WITH=doxycycline (0.5 µg/mL) for 24 hours | TREATED WITH=none (control)","TUMOR GRADE=II (diffuse low grade astrocytoma) | TUMOR GRADE=III (anaplastic astrocytoma) | TUMOR GRADE=IV (glioblastoma)","CELL LINE=HCT116 | CELL LINE=HOG | VARIATION=IDH1 R132H | VARIATION=IDH1 R132H plus | VARIATION=IDH1 wild-type | VARIATION=IDH1 wild-type plus","VARIATION=IDH1 R132H | VARIATION=wild-type","SIRNA=control | SIRNA=FOXM1","GRADE=III | GRADE=IV | HISTOLOGY=anaplastic oligoastrocytoma | HISTOLOGY=glioblastoma multiforme","Phenotype=Angiogenic | Phenotype=Invasive","CELL TYPE=Glioma stem-like cell | CELL TYPE=Serum-induced brain tumor cell","compound=0.1 micromolar AT13148 | compound=0.1 micromolar CCT128930 | compound=1xIC50 AT13148 | compound=1xIC50 CCT128930 | compound=3xIC50 AT13148 | compound=3xIC50 CCT128930 | compound=DMSO | compound=none","DISEASE STATE=normal | DISEASE STATE=primary glioblastoma multiform (brain tumor) | PATIENT AGE=12 | PATIENT AGE=17 | PATIENT AGE=21 | PATIENT AGE=22 | PATIENT AGE=24 | PATIENT AGE=28 | PATIENT AGE=30 | PATIENT AGE=32 | PATIENT AGE=33 | PATIENT AGE=34 | PATIENT AGE=35 | PATIENT AGE=36 | PATIENT AGE=37 | PATIENT AGE=38 | PATIENT AGE=39 | PATIENT AGE=40 | PATIENT AGE=41 | PATIENT AGE=42 | PATIENT AGE=43 | PATIENT AGE=44 | PATIENT AGE=45 | PATIENT AGE=46 | PATIENT AGE=47 | PATIENT AGE=48 | PATIENT AGE=49 | PATIENT AGE=51 | PATIENT AGE=52 | PATIENT AGE=53 | PATIENT AGE=54 | PATIENT AGE=55 | PATIENT AGE=56 | PATIENT AGE=57 | PATIENT AGE=59 | PATIENT AGE=60 | PATIENT AGE=61 | PATIENT AGE=62 | PATIENT AGE=63 | PATIENT AGE=65 | PATIENT AGE=68 | PATIENT AGE=70 | PATIENT AGE=not specified | PATIENT GENDER=female | PATIENT GENDER=male | PATIENT GENDER=not specified","PATIENT AGE=24 | PATIENT AGE=30 | PATIENT AGE=32 | PATIENT AGE=33 | PATIENT AGE=35 | PATIENT AGE=37 | PATIENT AGE=38 | PATIENT AGE=40 | PATIENT AGE=42 | PATIENT AGE=43 | PATIENT AGE=45 | PATIENT AGE=47 | PATIENT AGE=49 | PATIENT AGE=51 | PATIENT AGE=52 | PATIENT AGE=54 | PATIENT AGE=55 | PATIENT AGE=57 | PATIENT AGE=61 | PATIENT AGE=63 | PATIENT GENDER=female | PATIENT GENDER=male","AGE=46 | AGE=51 | AGE=55 | AGE=57 | AGE=58 | AGE=59 | AGE=61 | AGE=62 | AGE=65 | AGE=66 | AGE=69 | AGE=71.7 | AGE=99 | AGE=not specified | AGE=unknown | REFERENCE=Female Reference Genome | REFERENCE=not specified | REFERENCE=Reference RNA from pooled cellines | SEX=female | SEX=male | SEX=not specified | SEX=unknown | TREATMENT STATUS=2 cycles of TMZ adjuvant - 2/13/04 recurrent dz by biopsy - then 4 cycles of CCI-779 then BCNU then hospice | TREATMENT STATUS=not specified | TREATMENT STATUS=PREVIOUSLY_TREATED | TREATMENT STATUS=PRIOR_RADIATION_AND_CHEMO | TREATMENT STATUS=unknown | TREATMENT STATUS=UNTREATED","NA","AGE=46 | AGE=51 | AGE=55 | AGE=57 | AGE=58 | AGE=59 | AGE=61 | AGE=62 | AGE=65 | AGE=66 | AGE=69 | AGE=71.7 | AGE=99 | AGE=not specified | AGE=unknown | SEX=female | SEX=male | SEX=not specified | SEX=unknown | TREATMENT STATUS=2 cycles of TMZ adjuvant - 2/13/04 recurrent dz by biopsy - then 4 cycles of CCI-779 then BCNU then hospice | TREATMENT STATUS=not specified | TREATMENT STATUS=PREVIOUSLY_TREATED | TREATMENT STATUS=PRIOR_RADIATION_AND_CHEMO | TREATMENT STATUS=unknown | TREATMENT STATUS=UNTREATED","GRADE=1 | GRADE=2 | GRADE=3 | GRADE=4 | HISTOLOGICAL DIAGNOSIS=astrocytoma | HISTOLOGICAL DIAGNOSIS=glioblastoma | HISTOLOGICAL DIAGNOSIS=oligoastrocytoma | HISTOLOGICAL DIAGNOSIS=oligodendroglioma | HISTOLOGICAL DIAGNOSIS=pilocytic astrocytoma | SURVIVAL (YRS)=0.05 | SURVIVAL (YRS)=0.06 | SURVIVAL (YRS)=0.12 | SURVIVAL (YRS)=0.18 | SURVIVAL (YRS)=0.19 | SURVIVAL (YRS)=0.21 | SURVIVAL (YRS)=0.27 | SURVIVAL (YRS)=0.28 | SURVIVAL (YRS)=0.29 | SURVIVAL (YRS)=0.35 | SURVIVAL (YRS)=0.45 | SURVIVAL (YRS)=0.48 | SURVIVAL (YRS)=0.59 | SURVIVAL (YRS)=0.61 | SURVIVAL (YRS)=0.62 | SURVIVAL (YRS)=0.63 | SURVIVAL (YRS)=0.86 | SURVIVAL (YRS)=0.98 | SURVIVAL (YRS)=1.03 | SURVIVAL (YRS)=1.11 | SURVIVAL (YRS)=1.18 | SURVIVAL (YRS)=1.19 | SURVIVAL (YRS)=1.20 | SURVIVAL (YRS)=1.26 | SURVIVAL (YRS)=1.30 | SURVIVAL (YRS)=1.32 | SURVIVAL (YRS)=1.48 | SURVIVAL (YRS)=1.61 | SURVIVAL (YRS)=1.96 | SURVIVAL (YRS)=10.28 | SURVIVAL (YRS)=14.18 | SURVIVAL (YRS)=15.82 | SURVIVAL (YRS)=16.31 | SURVIVAL (YRS)=17.49 | SURVIVAL (YRS)=2.05 | SURVIVAL (YRS)=2.22 | SURVIVAL (YRS)=2.26 | SURVIVAL (YRS)=2.79 | SURVIVAL (YRS)=2.99 | SURVIVAL (YRS)=3.10 | SURVIVAL (YRS)=3.28 | SURVIVAL (YRS)=3.30 | SURVIVAL (YRS)=3.32 | SURVIVAL (YRS)=3.76 | SURVIVAL (YRS)=4.79 | SURVIVAL (YRS)=5.02 | SURVIVAL (YRS)=5.56 | SURVIVAL (YRS)=6.27 | SURVIVAL (YRS)=6.31 | SURVIVAL (YRS)=6.39 | SURVIVAL (YRS)=7.52 | SURVIVAL (YRS)=9.79 | SURVIVAL (YRS)=9.82","RNAi=siRNA BCAT | RNAi=siRNA EVI1 | RNAi=siRNA EVI3 | RNAi=siRNA RLUC","260/230=0.16 | 260/230=0.45 | 260/230=0.72 | 260/230=0.75 | 260/230=1.07 | 260/230=1.13 | 260/230=1.18 | 260/230=1.26 | 260/230=1.31 | 260/230=1.37 | 260/230=1.41 | 260/230=1.42 | 260/230=1.43 | 260/230=1.46 | 260/230=1.48 | 260/230=1.5 | 260/230=1.53 | 260/230=1.56 | 260/230=1.63 | 260/230=1.65 | 260/230=1.68 | 260/230=1.69 | 260/230=1.71 | 260/230=1.73 | 260/230=1.74 | 260/230=1.79 | 260/230=1.82 | 260/230=1.83 | 260/230=1.87 | 260/230=1.89 | 260/230=1.9 | 260/230=1.91 | 260/230=1.94 | 260/230=1.95 | 260/230=1.96 | 260/230=1.99 | 260/230=2.01 | 260/230=2.03 | 260/230=2.06 | 260/280=1.76 | 260/280=1.8 | 260/280=1.85 | 260/280=1.9 | 260/280=1.94 | 260/280=1.95 | 260/280=1.96 | 260/280=1.97 | 260/280=1.98 | 260/280=1.99 | 260/280=2 | 260/280=2.01 | 260/280=2.02 | 260/280=2.03 | 260/280=2.04 | 260/280=2.05 | RNA INTEGRITY SCORE=1 | RNA INTEGRITY SCORE=2.1 | RNA INTEGRITY SCORE=2.2 | RNA INTEGRITY SCORE=2.5 | RNA INTEGRITY SCORE=3.2 | RNA INTEGRITY SCORE=3.4 | RNA INTEGRITY SCORE=3.7 | RNA INTEGRITY SCORE=4.3 | RNA INTEGRITY SCORE=4.7 | RNA INTEGRITY SCORE=5 | RNA INTEGRITY SCORE=5.1 | RNA INTEGRITY SCORE=6.3 | RNA INTEGRITY SCORE=6.5 | RNA INTEGRITY SCORE=6.6 | RNA INTEGRITY SCORE=6.7 | RNA INTEGRITY SCORE=6.9 | RNA INTEGRITY SCORE=7 | RNA INTEGRITY SCORE=7.2 | RNA INTEGRITY SCORE=7.3 | RNA INTEGRITY SCORE=7.4 | RNA INTEGRITY SCORE=7.5 | RNA INTEGRITY SCORE=7.6 | RNA INTEGRITY SCORE=7.7 | RNA INTEGRITY SCORE=7.9 | RNA INTEGRITY SCORE=8.2 | RNA INTEGRITY SCORE=8.4 | RNA INTEGRITY SCORE=8.6 | RNA INTEGRITY SCORE=8.7 | RNA INTEGRITY SCORE=8.8 | RNA INTEGRITY SCORE=9 | RNA INTEGRITY SCORE=9.2 | RNA INTEGRITY SCORE=9.3 | RNA INTEGRITY SCORE=9.4 | RNA INTEGRITY SCORE=9.5 | RNA INTEGRITY SCORE=9.6 | RNA INTEGRITY SCORE=9.7 | RNA INTEGRITY SCORE=9.8 | RNA YIELD UG=0.731 | RNA YIELD UG=0.7394 | RNA YIELD UG=0.9732 | RNA YIELD UG=1.056 | RNA YIELD UG=1.0661 | RNA YIELD UG=1.0913 | RNA YIELD UG=1.2194 | RNA YIELD UG=1.2691 | RNA YIELD UG=1.4095 | RNA YIELD UG=1.5761 | RNA YIELD UG=1.5917 | RNA YIELD UG=1.7496 | RNA YIELD UG=1.8134 | RNA YIELD UG=1.83 | RNA YIELD UG=1.8559 | RNA YIELD UG=1.9896 | RNA YIELD UG=11.1742 | RNA YIELD UG=13.4738 | RNA YIELD UG=15.5484 | RNA YIELD UG=19.6855 | RNA YIELD UG=2.0582 | RNA YIELD UG=2.4137 | RNA YIELD UG=2.4612 | RNA YIELD UG=2.5181 | RNA YIELD UG=2.562 | RNA YIELD UG=2.6155 | RNA YIELD UG=2.6683 | RNA YIELD UG=2.9554 | RNA YIELD UG=3.0622 | RNA YIELD UG=3.2894 | RNA YIELD UG=3.5674 | RNA YIELD UG=3.5878 | RNA YIELD UG=3.9977 | RNA YIELD UG=4.1818 | RNA YIELD UG=4.2996 | RNA YIELD UG=4.4124 | RNA YIELD UG=4.5456 | RNA YIELD UG=4.7592 | RNA YIELD UG=5.4394 | RNA YIELD UG=5.4953 | RNA YIELD UG=5.5188 | RNA YIELD UG=5.7014 | RNA YIELD UG=6.2928 | RNA YIELD UG=7.8026 | RNA YIELD UG=7.8672 | RNA YIELD UG=7.8842 | RNA YIELD UG=8.6494 | RNA YIELD UG=9.8837 | SAMPLE ID=2_27602_L | SAMPLE ID=2_27686_H | SAMPLE ID=2_27698_L | SAMPLE ID=2_27702_L | SAMPLE ID=2_27758_H | SAMPLE ID=2_27766_H | SAMPLE ID=2_27770_L | SAMPLE ID=2_27774_H | SAMPLE ID=3_27610_L | SAMPLE ID=3_27626_H | SAMPLE ID=3_27674_H | SAMPLE ID=3_27678_H | SAMPLE ID=3_27710_H | SAMPLE ID=3_27714_L | SAMPLE ID=3_27734_L | SAMPLE ID=3_27782_L | SAMPLE ID=4_27614_L | SAMPLE ID=4_27622_L | SAMPLE ID=4_27646_H | SAMPLE ID=4_27662_H | SAMPLE ID=4_27722_L | SAMPLE ID=4_27730_H | SAMPLE ID=4_27746_H | SAMPLE ID=4_27754_L | SAMPLE ID=5_27593_L | SAMPLE ID=5_27630_H | SAMPLE ID=5_27634_H | SAMPLE ID=5_27642_L | SAMPLE ID=5_27650_H | SAMPLE ID=5_27666_L | SAMPLE ID=5_27682_L | SAMPLE ID=5_27738_H | SAMPLE ID=6_27606_H | SAMPLE ID=6_27618_L | SAMPLE ID=6_27638_L | SAMPLE ID=6_27654_L | SAMPLE ID=6_27658_L | SAMPLE ID=6_27670_H | SAMPLE ID=6_27694_H | SAMPLE ID=6_27762_H | SAMPLE ID=7_27597_L | SAMPLE ID=7_27690_L | SAMPLE ID=7_27706_H | SAMPLE ID=7_27718_L | SAMPLE ID=7_27726_H | SAMPLE ID=7_27742_L | SAMPLE ID=7_27750_H | SAMPLE ID=7_27778_H | SEX 0-FEMALE 1-MALE=0 | SEX 0-FEMALE 1-MALE=1 | SEX 0-FEMALE 1-MALE=not specified | SEX 0-MALE 1-FEMALE=0 | SEX 0-MALE 1-FEMALE=1 | SEX 0-MALE 1-FEMALE=not specified | SMOKING STATUS 0-NON SMOKER, 1-FORMER SMOKER, 2-CURRENT SMOKER=0 | SMOKING STATUS 0-NON SMOKER, 1-FORMER SMOKER, 2-CURRENT SMOKER=1 | SMOKING STATUS 0-NON SMOKER, 1-FORMER SMOKER, 2-CURRENT SMOKER=2 | STRESS 0-LOW, 1-HIGH=0 | STRESS 0-LOW, 1-HIGH=1","2 GENOTYPE=IDH1mutant | 2 GENOTYPE=wildtype | CELL LINE=HCT116 | CELL LINE=HCT116 DNMT1;DNMT3 double knockout | CELL LINE=not specified","2 GENOTYPE=IDH1mutant | 2 GENOTYPE=IDH2mutant | 2 GENOTYPE=not specified | 2 GENOTYPE=wildtype | CELL LINE=HCT116 | CELL LINE=HCT116 DNMT1;DNMT3 double knockout | CELL LINE=not specified | DISEASE=cholangiocarcinoma | DISEASE=colorectal cancer | DISEASE=glioblastoma | DISEASE=not specified","AGE=44 | AGE=53 | AGE=55 | AGE=60 | AGE=63 | AGE=67 | GRADE=III | GRADE=IV | GROWTH PATTERN=Free floating | GROWTH PATTERN=Semi-adherent | HISTOLOGY=anaplastic oligoastrocytoma | HISTOLOGY=glioblastoma multiforme | PATIENT=1 | PATIENT=2 | PATIENT=3 | PATIENT=4 | PATIENT=5 | PATIENT=8 | SEX=female | SEX=male","phenotype=control | phenotype=expression of a dominant negative form of MAML1 | phenotype=overexpression of Deltex1","AGE AT DIAGNOSIS (YEARS)=0.167 | AGE AT DIAGNOSIS (YEARS)=0.21 | AGE AT DIAGNOSIS (YEARS)=0.25 | AGE AT DIAGNOSIS (YEARS)=10 | AGE AT DIAGNOSIS (YEARS)=12 | AGE AT DIAGNOSIS (YEARS)=13 | AGE AT DIAGNOSIS (YEARS)=16 | AGE AT DIAGNOSIS (YEARS)=3 | AGE AT DIAGNOSIS (YEARS)=38 | AGE AT DIAGNOSIS (YEARS)=4 | AGE AT DIAGNOSIS (YEARS)=46 | AGE AT DIAGNOSIS (YEARS)=5 | AGE AT DIAGNOSIS (YEARS)=50 | AGE AT DIAGNOSIS (YEARS)=7 | AGE AT DIAGNOSIS (YEARS)=71 | AGE AT DIAGNOSIS (YEARS)=73 | AGE AT DIAGNOSIS (YEARS)=8 | DISEASE STATE=adult GBM tumor | DISEASE STATE=congenital GBM tumor | DISEASE STATE=pediatric GBM tumor | SEX=F | SEX=M","TREATMENT=dimethyl sulfoxide (DMSO) for 24 hours at a concentration equivalent to ET-770 | TREATMENT=dimethyl sulfoxide (DMSO) for 24 hours at a concentration equivalent to ET-770-DR | TREATMENT=dimethyl sulfoxide (DMSO) for 24 hours at a concentration equivalent to RM | TREATMENT=ET-770 for 24 hours at a concentration of IC50 (4.83 nM) | TREATMENT=ET-770-DR for 24 hours at a concentration of IC50 (1.70 nM) | TREATMENT=RM for 24 hours at a concentration of IC50 (3.10 nM)","PAR-CLIP=HIF2a | PAR-CLIP=RBM4","AGE (Y)=16 | AGE (Y)=30 | AGE (Y)=34 | AGE (Y)=49 | AGE (Y)=58 | AGE (Y)=66 | AGE (Y)=67 | SAMPLE=glioma 1 | SAMPLE=glioma 2 | SAMPLE=glioma 3 | SAMPLE=glioma 4 | SAMPLE=glioma 5 | SAMPLE=glioma 6 | SAMPLE=glioma 7 | SEX=female | SEX=male | TUMOR GRADE=AA III | TUMOR GRADE=GB IV","NA","CELL TYPE=GBAM1 CD133+ | CELL TYPE=GBAM1 CD133- | CELL TYPE=NSC11 CD133+ | CELL TYPE=NSC11 CD133- | CULTURE CONDITION=control | CULTURE CONDITION=direct co-cultured | CULTURE CONDITION=indirect co-cultured","phenotype=control | phenotype=expressing Cyr61","NA","TREATMENT=72h post transfection with control oligonucleotide | TREATMENT=72h post transfection with hsa-miR-34a","HISTOLOGY=carcinoid-endocrine_tumour | HISTOLOGY=carcinoma | HISTOLOGY=chondrosarcoma | HISTOLOGY=Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | HISTOLOGY=fibrosarcoma | HISTOLOGY=giant_cell_tumour | HISTOLOGY=glioma | HISTOLOGY=haematopoietic_neoplasm | HISTOLOGY=leiomyosarcoma | HISTOLOGY=lymphoid neoplasm | HISTOLOGY=malignant_fibrous_histiocytoma-pleomorphic_sarcoma | HISTOLOGY=malignant_melanoma | HISTOLOGY=mesothelioma | HISTOLOGY=neuroblastoma | HISTOLOGY=osteosarcoma | HISTOLOGY=other | HISTOLOGY=primitive_neuroectodermal_tumour-medulloblastoma | HISTOLOGY=rhabdoid_tumour | HISTOLOGY=rhabdomyosarcoma | HISTOLOGY=sarcoma | HISTOLOGY=sex_cord-stromal_tumour | HISTOLOGY SUBTYPE1=acute_lymphoblastic_B_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_T_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_myeloid_leukaemia | HISTOLOGY SUBTYPE1=adenocarcinoma | HISTOLOGY SUBTYPE1=adult_T_cell_lymphoma-leukaemia | HISTOLOGY SUBTYPE1=alveolar | HISTOLOGY SUBTYPE1=anaplastic large cell lymphoma | HISTOLOGY SUBTYPE1=anaplastic_carcinoma | HISTOLOGY SUBTYPE1=astrocytoma | HISTOLOGY SUBTYPE1=astrocytoma_Grade_III | HISTOLOGY SUBTYPE1=astrocytoma_Grade_IV | HISTOLOGY SUBTYPE1=B_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=blast_phase_chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=Brenner_tumour | HISTOLOGY SUBTYPE1=bronchioloalveolar_adenocarcinoma | HISTOLOGY SUBTYPE1=Burkitt_lymphoma | HISTOLOGY SUBTYPE1=carcinosarcoma-malignant_mesodermal_mixed_tumour | HISTOLOGY SUBTYPE1=chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | HISTOLOGY SUBTYPE1=chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=clear_cell_carcinoma | HISTOLOGY SUBTYPE1=clear_cell_renal_cell_carcinoma | HISTOLOGY SUBTYPE1=dedifferentiated | HISTOLOGY SUBTYPE1=diffuse large B-cell lymphoma | HISTOLOGY SUBTYPE1=diffuse_adenocarcinoma | HISTOLOGY SUBTYPE1=ductal_carcinoma | HISTOLOGY SUBTYPE1=embryonal | HISTOLOGY SUBTYPE1=endometrioid carcinoma | HISTOLOGY SUBTYPE1=essential_thrombocythaemia | HISTOLOGY SUBTYPE1=follicular_carcinoma | HISTOLOGY SUBTYPE1=giant_cell_tumour | HISTOLOGY SUBTYPE1=gliosarcoma | HISTOLOGY SUBTYPE1=granulosa_cell_tumour | HISTOLOGY SUBTYPE1=hepatoblastoma | HISTOLOGY SUBTYPE1=hepatocellular carcinoma | HISTOLOGY SUBTYPE1=Hodgkin_lymphoma | HISTOLOGY SUBTYPE1=intestinal_adenocarcinoma | HISTOLOGY SUBTYPE1=large_cell_carcinoma | HISTOLOGY SUBTYPE1=mantle_cell_lymphoma | HISTOLOGY SUBTYPE1=medullary_carcinoma | HISTOLOGY SUBTYPE1=metaplasia | HISTOLOGY SUBTYPE1=metaplastic_carcinoma | HISTOLOGY SUBTYPE1=mixed_adenosquamous_carcinoma | HISTOLOGY SUBTYPE1=mixed_carcinoma | HISTOLOGY SUBTYPE1=mucinous carcinoma | HISTOLOGY SUBTYPE1=mucoepidermoid_carcinoma | HISTOLOGY SUBTYPE1=mycosis_fungoides-Sezary_syndrome | HISTOLOGY SUBTYPE1=non_small_cell_carcinoma | HISTOLOGY SUBTYPE1=not specified | HISTOLOGY SUBTYPE1=oligodendroglioma | HISTOLOGY SUBTYPE1=papillary_carcinoma | HISTOLOGY SUBTYPE1=papilloma | HISTOLOGY SUBTYPE1=peripheral_T_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=plasma_cell_myeloma | HISTOLOGY SUBTYPE1=renal cell carcinoma | HISTOLOGY SUBTYPE1=serous_carcinoma | HISTOLOGY SUBTYPE1=signet_ring_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_carcinoma | HISTOLOGY SUBTYPE1=squamous cell carcinoma | HISTOLOGY SUBTYPE1=T_cell_large_granular_lymphocytic_leukaemia | HISTOLOGY SUBTYPE1=transitional_cell_carcinoma | HISTOLOGY SUBTYPE1=tubular_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_carcinoma | PRIMARY SITE=autonomic_ganglia | PRIMARY SITE=biliary_tract | PRIMARY SITE=bone | PRIMARY SITE=breast | PRIMARY SITE=central nervous system | PRIMARY SITE=endometrium | PRIMARY SITE=haematopoietic_and_lymphoid_tissue | PRIMARY SITE=kidney | PRIMARY SITE=large intestine | PRIMARY SITE=liver | PRIMARY SITE=lung | PRIMARY SITE=oesophagus | PRIMARY SITE=ovary | PRIMARY SITE=pancreas | PRIMARY SITE=pleura | PRIMARY SITE=prostate | PRIMARY SITE=salivary gland | PRIMARY SITE=skin | PRIMARY SITE=small intestine | PRIMARY SITE=soft_tissue | PRIMARY SITE=stomach | PRIMARY SITE=thyroid | PRIMARY SITE=upper_aerodigestive_tract | PRIMARY SITE=urinary_tract","HISTOLOGY=carcinoid-endocrine_tumour | HISTOLOGY=carcinoma | HISTOLOGY=chondrosarcoma | HISTOLOGY=Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | HISTOLOGY=fibrosarcoma | HISTOLOGY=giant_cell_tumour | HISTOLOGY=glioma | HISTOLOGY=haematopoietic_neoplasm | HISTOLOGY=leiomyosarcoma | HISTOLOGY=lymphoid neoplasm | HISTOLOGY=malignant_fibrous_histiocytoma-pleomorphic_sarcoma | HISTOLOGY=malignant_melanoma | HISTOLOGY=mesothelioma | HISTOLOGY=neuroblastoma | HISTOLOGY=osteosarcoma | HISTOLOGY=other | HISTOLOGY=primitive_neuroectodermal_tumour-medulloblastoma | HISTOLOGY=rhabdoid_tumour | HISTOLOGY=rhabdomyosarcoma | HISTOLOGY=sarcoma | HISTOLOGY=sex_cord-stromal_tumour | HISTOLOGY SUBTYPE1=acute_lymphoblastic_B_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_T_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_myeloid_leukaemia | HISTOLOGY SUBTYPE1=adenocarcinoma | HISTOLOGY SUBTYPE1=adult_T_cell_lymphoma-leukaemia | HISTOLOGY SUBTYPE1=alveolar | HISTOLOGY SUBTYPE1=anaplastic large cell lymphoma | HISTOLOGY SUBTYPE1=anaplastic_carcinoma | HISTOLOGY SUBTYPE1=astrocytoma | HISTOLOGY SUBTYPE1=astrocytoma_Grade_III | HISTOLOGY SUBTYPE1=astrocytoma_Grade_IV | HISTOLOGY SUBTYPE1=B_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=blast_phase_chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=Brenner_tumour | HISTOLOGY SUBTYPE1=bronchioloalveolar_adenocarcinoma | HISTOLOGY SUBTYPE1=Burkitt_lymphoma | HISTOLOGY SUBTYPE1=carcinosarcoma-malignant_mesodermal_mixed_tumour | HISTOLOGY SUBTYPE1=chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | HISTOLOGY SUBTYPE1=chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=clear_cell_carcinoma | HISTOLOGY SUBTYPE1=clear_cell_renal_cell_carcinoma | HISTOLOGY SUBTYPE1=dedifferentiated | HISTOLOGY SUBTYPE1=diffuse large B-cell lymphoma | HISTOLOGY SUBTYPE1=diffuse_adenocarcinoma | HISTOLOGY SUBTYPE1=ductal_carcinoma | HISTOLOGY SUBTYPE1=embryonal | HISTOLOGY SUBTYPE1=endometrioid carcinoma | HISTOLOGY SUBTYPE1=essential_thrombocythaemia | HISTOLOGY SUBTYPE1=follicular_carcinoma | HISTOLOGY SUBTYPE1=giant_cell_tumour | HISTOLOGY SUBTYPE1=gliosarcoma | HISTOLOGY SUBTYPE1=granulosa_cell_tumour | HISTOLOGY SUBTYPE1=hepatoblastoma | HISTOLOGY SUBTYPE1=hepatocellular carcinoma | HISTOLOGY SUBTYPE1=Hodgkin_lymphoma | HISTOLOGY SUBTYPE1=intestinal_adenocarcinoma | HISTOLOGY SUBTYPE1=large_cell_carcinoma | HISTOLOGY SUBTYPE1=mantle_cell_lymphoma | HISTOLOGY SUBTYPE1=medullary_carcinoma | HISTOLOGY SUBTYPE1=metaplasia | HISTOLOGY SUBTYPE1=metaplastic_carcinoma | HISTOLOGY SUBTYPE1=mixed_adenosquamous_carcinoma | HISTOLOGY SUBTYPE1=mixed_carcinoma | HISTOLOGY SUBTYPE1=mucinous carcinoma | HISTOLOGY SUBTYPE1=mucoepidermoid_carcinoma | HISTOLOGY SUBTYPE1=mycosis_fungoides-Sezary_syndrome | HISTOLOGY SUBTYPE1=non_small_cell_carcinoma | HISTOLOGY SUBTYPE1=not specified | HISTOLOGY SUBTYPE1=oligodendroglioma | HISTOLOGY SUBTYPE1=papillary_carcinoma | HISTOLOGY SUBTYPE1=papilloma | HISTOLOGY SUBTYPE1=peripheral_T_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=plasma_cell_myeloma | HISTOLOGY SUBTYPE1=renal cell carcinoma | HISTOLOGY SUBTYPE1=serous_carcinoma | HISTOLOGY SUBTYPE1=signet_ring_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_carcinoma | HISTOLOGY SUBTYPE1=squamous cell carcinoma | HISTOLOGY SUBTYPE1=T_cell_large_granular_lymphocytic_leukaemia | HISTOLOGY SUBTYPE1=transitional_cell_carcinoma | HISTOLOGY SUBTYPE1=tubular_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_carcinoma | PRIMARY SITE=autonomic_ganglia | PRIMARY SITE=biliary_tract | PRIMARY SITE=bone | PRIMARY SITE=breast | PRIMARY SITE=central nervous system | PRIMARY SITE=endometrium | PRIMARY SITE=haematopoietic_and_lymphoid_tissue | PRIMARY SITE=kidney | PRIMARY SITE=large intestine | PRIMARY SITE=liver | PRIMARY SITE=lung | PRIMARY SITE=oesophagus | PRIMARY SITE=ovary | PRIMARY SITE=pancreas | PRIMARY SITE=pleura | PRIMARY SITE=prostate | PRIMARY SITE=salivary gland | PRIMARY SITE=skin | PRIMARY SITE=small intestine | PRIMARY SITE=soft_tissue | PRIMARY SITE=stomach | PRIMARY SITE=thyroid | PRIMARY SITE=upper_aerodigestive_tract | PRIMARY SITE=urinary_tract","HISTOLOGY=carcinoid-endocrine_tumour | HISTOLOGY=carcinoma | HISTOLOGY=chondrosarcoma | HISTOLOGY=Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | HISTOLOGY=fibrosarcoma | HISTOLOGY=giant_cell_tumour | HISTOLOGY=glioma | HISTOLOGY=haematopoietic_neoplasm | HISTOLOGY=leiomyosarcoma | HISTOLOGY=lymphoid neoplasm | HISTOLOGY=malignant_fibrous_histiocytoma-pleomorphic_sarcoma | HISTOLOGY=malignant_melanoma | HISTOLOGY=mesothelioma | HISTOLOGY=neuroblastoma | HISTOLOGY=osteosarcoma | HISTOLOGY=other | HISTOLOGY=primitive_neuroectodermal_tumour-medulloblastoma | HISTOLOGY=rhabdoid_tumour | HISTOLOGY=rhabdomyosarcoma | HISTOLOGY=sarcoma | HISTOLOGY=sex_cord-stromal_tumour | HISTOLOGY SUBTYPE1=acute_lymphoblastic_B_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_leukaemia | HISTOLOGY SUBTYPE1=acute_lymphoblastic_T_cell_leukaemia | HISTOLOGY SUBTYPE1=acute_myeloid_leukaemia | HISTOLOGY SUBTYPE1=adenocarcinoma | HISTOLOGY SUBTYPE1=adult_T_cell_lymphoma-leukaemia | HISTOLOGY SUBTYPE1=alveolar | HISTOLOGY SUBTYPE1=anaplastic large cell lymphoma | HISTOLOGY SUBTYPE1=anaplastic_carcinoma | HISTOLOGY SUBTYPE1=astrocytoma | HISTOLOGY SUBTYPE1=astrocytoma_Grade_III | HISTOLOGY SUBTYPE1=astrocytoma_Grade_IV | HISTOLOGY SUBTYPE1=B_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=blast_phase_chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=Brenner_tumour | HISTOLOGY SUBTYPE1=bronchioloalveolar_adenocarcinoma | HISTOLOGY SUBTYPE1=Burkitt_lymphoma | HISTOLOGY SUBTYPE1=carcinosarcoma-malignant_mesodermal_mixed_tumour | HISTOLOGY SUBTYPE1=chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | HISTOLOGY SUBTYPE1=chronic_myeloid_leukaemia | HISTOLOGY SUBTYPE1=clear_cell_carcinoma | HISTOLOGY SUBTYPE1=clear_cell_renal_cell_carcinoma | HISTOLOGY SUBTYPE1=dedifferentiated | HISTOLOGY SUBTYPE1=diffuse large B-cell lymphoma | HISTOLOGY SUBTYPE1=diffuse_adenocarcinoma | HISTOLOGY SUBTYPE1=ductal_carcinoma | HISTOLOGY SUBTYPE1=embryonal | HISTOLOGY SUBTYPE1=endometrioid carcinoma | HISTOLOGY SUBTYPE1=essential_thrombocythaemia | HISTOLOGY SUBTYPE1=follicular_carcinoma | HISTOLOGY SUBTYPE1=giant_cell_tumour | HISTOLOGY SUBTYPE1=gliosarcoma | HISTOLOGY SUBTYPE1=granulosa_cell_tumour | HISTOLOGY SUBTYPE1=hepatoblastoma | HISTOLOGY SUBTYPE1=hepatocellular carcinoma | HISTOLOGY SUBTYPE1=Hodgkin_lymphoma | HISTOLOGY SUBTYPE1=intestinal_adenocarcinoma | HISTOLOGY SUBTYPE1=large_cell_carcinoma | HISTOLOGY SUBTYPE1=mantle_cell_lymphoma | HISTOLOGY SUBTYPE1=medullary_carcinoma | HISTOLOGY SUBTYPE1=metaplasia | HISTOLOGY SUBTYPE1=metaplastic_carcinoma | HISTOLOGY SUBTYPE1=mixed_adenosquamous_carcinoma | HISTOLOGY SUBTYPE1=mixed_carcinoma | HISTOLOGY SUBTYPE1=mucinous carcinoma | HISTOLOGY SUBTYPE1=mucoepidermoid_carcinoma | HISTOLOGY SUBTYPE1=mycosis_fungoides-Sezary_syndrome | HISTOLOGY SUBTYPE1=non_small_cell_carcinoma | HISTOLOGY SUBTYPE1=not specified | HISTOLOGY SUBTYPE1=oligodendroglioma | HISTOLOGY SUBTYPE1=papillary_carcinoma | HISTOLOGY SUBTYPE1=papilloma | HISTOLOGY SUBTYPE1=peripheral_T_cell_lymphoma_unspecified | HISTOLOGY SUBTYPE1=plasma_cell_myeloma | HISTOLOGY SUBTYPE1=renal cell carcinoma | HISTOLOGY SUBTYPE1=serous_carcinoma | HISTOLOGY SUBTYPE1=signet_ring_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_adenocarcinoma | HISTOLOGY SUBTYPE1=small_cell_carcinoma | HISTOLOGY SUBTYPE1=squamous cell carcinoma | HISTOLOGY SUBTYPE1=T_cell_large_granular_lymphocytic_leukaemia | HISTOLOGY SUBTYPE1=transitional_cell_carcinoma | HISTOLOGY SUBTYPE1=tubular_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_adenocarcinoma | HISTOLOGY SUBTYPE1=undifferentiated_carcinoma | PRIMARY SITE=autonomic_ganglia | PRIMARY SITE=biliary_tract | PRIMARY SITE=bone | PRIMARY SITE=breast | PRIMARY SITE=central nervous system | PRIMARY SITE=endometrium | PRIMARY SITE=haematopoietic_and_lymphoid_tissue | PRIMARY SITE=kidney | PRIMARY SITE=large intestine | PRIMARY SITE=liver | PRIMARY SITE=lung | PRIMARY SITE=oesophagus | PRIMARY SITE=ovary | PRIMARY SITE=pancreas | PRIMARY SITE=pleura | PRIMARY SITE=prostate | PRIMARY SITE=salivary gland | PRIMARY SITE=skin | PRIMARY SITE=small intestine | PRIMARY SITE=soft_tissue | PRIMARY SITE=stomach | PRIMARY SITE=thyroid | PRIMARY SITE=upper_aerodigestive_tract | PRIMARY SITE=urinary_tract","phenotype=expressing parkin | phenotype=vector","AGE=10 | AGE=11 | AGE=12 | AGE=13 | AGE=14 | AGE=15 | AGE=16 | AGE=17 | AGE=2 | AGE=20 | AGE=5 | AGE=5.4 | AGE=6 | AGE=7 | AGE=7.3 | AGE=8 | AGE=9 | AGE=NA | SEX=F | SEX=M | SEX=NA | STATUS=G34R | STATUS=G34V | STATUS=K27M | STATUS=wt","Genotype=C124S-mutant PTEN | Genotype=G129E-mutant PTEN | Genotype=GFP | Genotype=untransfected | Genotype=wild-type PTEN | Genotype=Y138L-mutant PTEN","OXYGEN TENSION=Hypoxic (1%O2) | OXYGEN TENSION=Normoxic (20% O2)","CDKN2A METHYLATION=M | CDKN2A METHYLATION=NA | CDKN2A METHYLATION=not specified | CDKN2A METHYLATION=U | EGFR AMP=NA | EGFR AMP=No | EGFR AMP=not specified | EGFR AMP=Yes | IDH MUT STATUS=mut | IDH MUT STATUS=not specified | IDH MUT STATUS=wt | P-PRAS40 IHC=NA | P-PRAS40 IHC=not specified | P-PRAS40 IHC=Unspecified | PTEN DEL=NA | PTEN DEL=No | PTEN DEL=not specified | PTEN DEL=Yes | PTEN METHYLATION=M | PTEN METHYLATION=NA | PTEN METHYLATION=not specified | PTEN METHYLATION=U | SUBCLASS=EPL | SUBCLASS=NB | SUBCLASS=not specified | SUBCLASS=PG | TP53 SEQ=mut | TP53 SEQ=NA | TP53 SEQ=not specified | TP53 SEQ=wt | TUMOR TYPE=diffuse astrocytic glioma | TUMOR TYPE=normal brain | WHO GRADE=II | WHO GRADE=III | WHO GRADE=not specified","DISEASESTATE=Malignant glioma | DISEASESTATE=normal | GROWTHCONDITION=DMEM+10%FBS | GROWTHCONDITION=NBE | GROWTHCONDITION=Unspecified","CELL TYPE=Glioblastoma | CELL TYPE=Human embryonic | STAGE=-- | STAGE=grade IV","DISEASE STATE=Glioblastoma | DISEASE STATE=Malignant melanoma | RNA SOURCE=cell RNA from low passage cell culture | RNA SOURCE=exosomes/microvesicle RNA","DISEASE STATE=control | DISEASE STATE=Glioblastoma | TISSUE=blood | TISSUE=Brain tumor","COMPOUND=control | COMPOUND=MIFE | DOSE=0 nM | DOSE=1 nM | GENETICMODIFICATION=transfection | GENETICMODIFICATION=Unspecified | GENOTYPE=CD26+ | GENOTYPE=wild_type | OBSERVATION=CD26 transfection effect | OBSERVATION=DPP-4 overexpression | OBSERVATION=Mifepristone effect | OBSERVATION=wild_type","CELL_LINE=T98G | CELL_LINE=U251MG | CELL_LINE=U343MG-a | CELL_LINE=U87MG | CELL_LINE=U87Mg | CELL_TYPE=Glioblastoma | GENOTYPE=PTEN and p16 mutant | GENOTYPE=TP53, PTEN and p16 mutant","CELL LINE PASSAGE=40 | CELL LINE PASSAGE=7 | TYPE OF CULTIVATION PLATE=Boyden chamber bottom chamber (co-culture) | TYPE OF CULTIVATION PLATE=Boyden chamber bottom chamber (single culture) | TYPE OF CULTIVATION PLATE=Boyden chamber top chamber (co-culture) | TYPE OF CULTIVATION PLATE=Boyden chamber top chamber (single culture)","AGE=1 day old | AGE=1 week old | AGE=E15.5 | AGE=E17.5 | AGE=not specified | CELL LINE=Daudi (Burkitt's lymphoma) | CELL LINE=DLD-1 (colorectal adenocarcinoma) | CELL LINE=not specified | CELL TYPE=human differentiated kidney | CELL TYPE=mouse kidney blastemal cells | CELL TYPE=not specified | GENDER=female | GENDER=male | GENDER=not specified | ORGANISM=Homo sapiens | ORGANISM=Mus musculus | REFERENCE=not specified | REFERENCE=pool of 15 human cell lines | REFERENCE=pool of 15 human cell lines (Daudi (Burkitt's lymphoma) | REFERENCE=pool of human fetal kidneys (Clontech) | STAGE=III | STAGE=IV | STAGE=not specified | WILMS TUMOR SAMPLE=no-relapse | WILMS TUMOR SAMPLE=no-relapse tumor | WILMS TUMOR SAMPLE=not specified | WILMS TUMOR SAMPLE=relapse | WILMS TUMOR SAMPLE=relapse tumor","BATCH=1 | BATCH=10 | BATCH=2 | BATCH=3 | BATCH=4 | BATCH=5 | BATCH=6 | BATCH=7 | BATCH=8 | BATCH=9 | CELL LINE=08-499 | CELL LINE=08-698 | CELL LINE=08-714 | CELL LINE=ALPS 1459 | CELL LINE=ALPS 1462 | CELL LINE=ALPS 1514 | CELL LINE=D54OTR | CELL LINE=D54P | CELL LINE=D54TR | CELL LINE=H80OTR | CELL LINE=H80P | CELL LINE=H80TR | CELL LINE=MGRI-OTR | CELL LINE=MGRI-P | CELL LINE=not specified | CELL LINE=U138OTR | CELL LINE=U138P | CELL LINE=UW15OTR | CELL LINE=UW15P | DATE OF ARRAY=1 | DATE OF ARRAY=2 | DATE OF ARRAY=3 | LINE NUMBER=1 | LINE NUMBER=10 | LINE NUMBER=11 | LINE NUMBER=12 | LINE NUMBER=13 | LINE NUMBER=14 | LINE NUMBER=15 | LINE NUMBER=16 | LINE NUMBER=17 | LINE NUMBER=18 | LINE NUMBER=19 | LINE NUMBER=2 | LINE NUMBER=20 | LINE NUMBER=21 | LINE NUMBER=22 | LINE NUMBER=23 | LINE NUMBER=24 | LINE NUMBER=25 | LINE NUMBER=26 | LINE NUMBER=27 | LINE NUMBER=28 | LINE NUMBER=29 | LINE NUMBER=3 | LINE NUMBER=30 | LINE NUMBER=31 | LINE NUMBER=32 | LINE NUMBER=33 | LINE NUMBER=34 | LINE NUMBER=35 | LINE NUMBER=36 | LINE NUMBER=37 | LINE NUMBER=38 | LINE NUMBER=39 | LINE NUMBER=4 | LINE NUMBER=40 | LINE NUMBER=41 | LINE NUMBER=42 | LINE NUMBER=43 | LINE NUMBER=44 | LINE NUMBER=45 | LINE NUMBER=46 | LINE NUMBER=47 | LINE NUMBER=48 | LINE NUMBER=49 | LINE NUMBER=5 | LINE NUMBER=50 | LINE NUMBER=6 | LINE NUMBER=7 | LINE NUMBER=8 | LINE NUMBER=9 | LINE TYPE=Serum Cell Line | LINE TYPE=Stem Cell Line | LINE TYPE=Subcutaneous Xenograft | LINE TYPE=Subcutaneous Xenograft, Grown Intracranially | XENOGRAFT LINE=08-308 | XENOGRAFT LINE=08-308L | XENOGRAFT LINE=08-430 | XENOGRAFT LINE=08-445 | XENOGRAFT LINE=08-446 | XENOGRAFT LINE=08-499 | XENOGRAFT LINE=08-500 | XENOGRAFT LINE=08-537 | XENOGRAFT LINE=08-624 | XENOGRAFT LINE=08-695 | XENOGRAFT LINE=08-714 | XENOGRAFT LINE=212 | XENOGRAFT LINE=2159 | XENOGRAFT LINE=2224 | XENOGRAFT LINE=2322 | XENOGRAFT LINE=2339 | XENOGRAFT LINE=2360 | XENOGRAFT LINE=245 | XENOGRAFT LINE=245PR | XENOGRAFT LINE=263 | XENOGRAFT LINE=270 | XENOGRAFT LINE=317 | XENOGRAFT LINE=320 | XENOGRAFT LINE=43 | XENOGRAFT LINE=456 | XENOGRAFT LINE=475 | XENOGRAFT LINE=54 | XENOGRAFT LINE=645 | XENOGRAFT LINE=693 | XENOGRAFT LINE=717 | XENOGRAFT LINE=930 | XENOGRAFT LINE=not specified","DISEASE STATE=glioblastoma multiforme | DISEASE STATE=healthy","CELL LINE=A2780/CP | CELL LINE=BEL-7404 | CELL LINE=BEL-7404-CP20 | CELL LINE=C200 | CELL LINE=C30 | CELL LINE=CNS.SF.268 | CELL LINE=CNS.SF.295 | CELL LINE=CNS.SF.539 | CELL LINE=CNS.SNB.19 | CELL LINE=CNS.SNB.75 | CELL LINE=CNS.U251 | CELL LINE=CO.COLO205 | CELL LINE=CO.HCC.2998 | CELL LINE=CO.HCT.116 | CELL LINE=CO.HCT.15 | CELL LINE=CO.HT29 | CELL LINE=CO.KM12 | CELL LINE=CO.SW.620 | CELL LINE=CP70 | CELL LINE=HEL | CELL LINE=HOSE | CELL LINE=IGROV1 | CELL LINE=Kasumi 1 | CELL LINE=Kasumi-6 | CELL LINE=KB-3-1 | CELL LINE=KB-CP.5 | CELL LINE=KB-CP20 | CELL LINE=LC.A549 | CELL LINE=LC.EKVX | CELL LINE=LC.HOP.62 | CELL LINE=LC.HOP.92 | CELL LINE=LC.NCI.H226 | CELL LINE=LC.NCI.H23 | CELL LINE=LC.NCI.H322M | CELL LINE=LC.NCI.H460 | CELL LINE=LC.NCI.H522 | CELL LINE=LE.CCRF.CEM | CELL LINE=LE.HL.60 | CELL LINE=LE.K.562 | CELL LINE=LE.MOLT.4 | CELL LINE=LE.RPMI.8226 | CELL LINE=LE.SR | CELL LINE=MBO2 | CELL LINE=ME-1 | CELL LINE=ME.LOXIMVI | CELL LINE=ME.M14 | CELL LINE=ME.MALME.3M | CELL LINE=ME.MDA.MB.435 | CELL LINE=ME.SK.MEL.2 | CELL LINE=ME.SK.MEL.28 | CELL LINE=ME.SK.MEL.5 | CELL LINE=ME.UACC.257 | CELL LINE=ME.UACC.62 | CELL LINE=MO7e | CELL LINE=not specified | CELL LINE=OC2 | CELL LINE=OV.IGROV1 | CELL LINE=OV.NCI.ADR.RES | CELL LINE=OV.OVCAR.3 | CELL LINE=OV.OVCAR.4 | CELL LINE=OV.OVCAR.5 | CELL LINE=OV.OVCAR.8 | CELL LINE=OV.SK.OV.3 | CELL LINE=OVCAR-3 | CELL LINE=OVCAR4 | CELL LINE=OVCAR5 | CELL LINE=OVCAR8 | CELL LINE=OVCAR8-ADR | CELL LINE=PAT-7 | CELL LINE=PEO1 | CELL LINE=PEO4 | CELL LINE=PR.DU.145 | CELL LINE=PR.PC.3 | CELL LINE=RE.786O | CELL LINE=RE.A498 | CELL LINE=RE.ACHN | CELL LINE=RE.CAKI.1 | CELL LINE=RE.RXF.393 | CELL LINE=RE.SN12C | CELL LINE=RE.TK.10 | CELL LINE=RE.UO.31 | CELL LINE=SK-OV3 | CELL LINE=SKOV1 | CELL LINE=TF-1 | CELL LINE=U937 | CELL LINE=UPN251 | CELL LINE=UT-7 | CELL TYPE=acute myeloid leukemia cells | CELL TYPE=central nervous system cancer | CELL TYPE=colon cancer cells | CELL TYPE=leukemia | CELL TYPE=liver carcinoma | CELL TYPE=megakaryoblastic leukemia cells | CELL TYPE=melanoma cells | CELL TYPE=non-small cell lung cancer cells | CELL TYPE=not specified | CELL TYPE=ovarian cancer cells | CELL TYPE=prostate cancer cells | CELL TYPE=renal cancer cells | ORGANISM PART=blood | ORGANISM PART=breast | ORGANISM PART=colon cancer tumor | ORGANISM PART=glioblastoma tumor | ORGANISM PART=melanoma | ORGANISM PART=normal colon | ORGANISM PART=normal ovary | ORGANISM PART=not specified | PERCENTAGE OF TUMOR CELLS=100%, microdissected sample | PERCENTAGE OF TUMOR CELLS=&gt;75% | PERCENTAGE OF TUMOR CELLS=not specified | SAMPLE TYPE=Bulk sample | SAMPLE TYPE=CD133+ sorted cells | SAMPLE TYPE=CD133- sorted cells | SAMPLE TYPE=NCI-60 panel | SAMPLE TYPE=NCI-60 panel CD44+/CD24+ | SAMPLE TYPE=NCI-60 panel CD44+/CD24- | SAMPLE TYPE=not specified","CELL LINE=U178MG | CELL LINE=U87MG | PARENTAL CELL LINE=U178 | PARENTAL CELL LINE=U87 | TREATMENT=EGF | TREATMENT=none","BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA06990 | BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA07349 | BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA17102 | BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA17110 | BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA17733 | BIOSOURCEPROVIDER=Coriell; http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA17737 | BIOSOURCEPROVIDER=not specified | CELL LINE=1321N1 | CELL LINE=1A6 | CELL LINE=201T | CELL LINE=22Rv1 | CELL LINE=23132/87 | CELL LINE=273T | CELL LINE=639V | CELL LINE=647V | CELL LINE=769P | CELL LINE=A-375 | CELL LINE=A-427 | CELL LINE=A2058 | CELL LINE=A2780 | CELL LINE=A2780ADR | CELL LINE=A2780cis | CELL LINE=A373-C6 | CELL LINE=A375.S2 | CELL LINE=A431 | CELL LINE=A549 | CELL LINE=A673 | CELL LINE=ABC-1 | CELL LINE=AGS | CELL LINE=AN3CA | CELL LINE=ASH-3 | CELL LINE=AZ-521 | CELL LINE=BALL-1 | CELL LINE=BEAS-2B | CELL LINE=BEN | CELL LINE=BFTC-905 | CELL LINE=BICR 10 | CELL LINE=BICR 22 | CELL LINE=BICR 31 | CELL LINE=BICR 78 | CELL LINE=BPH-1 | CELL LINE=BT-20 | CELL LINE=BT-483 | CELL LINE=BT-549 | CELL LINE=Bu25 TK- | CELL LINE=C170 | CELL LINE=C32 | CELL LINE=C8166 | CELL LINE=Ca Ski | CELL LINE=Ca9-22 | CELL LINE=CAL-120 | CELL LINE=CAL-12T | CELL LINE=CAL-148 | CELL LINE=CAL-29 | CELL LINE=CAL-51 | CELL LINE=CAL-85-1 | CELL LINE=Calu-3 | CELL LINE=CAMA-1 | CELL LINE=CaR-1 | CELL LINE=CCD 1103 KIDTr | CELL LINE=CCD 1105 KIDTr | CELL LINE=CCK-81 | CELL LINE=ChaGo-K-1 | CELL LINE=CoCM-1 | CELL LINE=COLO 201 | CELL LINE=COLO 205 | CELL LINE=COLO 320DM | CELL LINE=COLO 684 | CELL LINE=COLO 685 | CELL LINE=COLO 741 | CELL LINE=COLO 792 | CELL LINE=COLO 853 | CELL LINE=COLO 857 | CELL LINE=COLO 858 | CELL LINE=COLO-680N | CELL LINE=COR-L 105 | CELL LINE=COR-L 23/CPR | CELL LINE=COR-L95 | CELL LINE=CORL23 | CELL LINE=CORL279 | CELL LINE=CORL88 | CELL LINE=D1.1 | CELL LINE=D341Med | CELL LINE=Detroit 562 | CELL LINE=DG-75 | CELL LINE=DMS 153 | CELL LINE=DMS 273 | CELL LINE=DMS 92 | CELL LINE=DOK | CELL LINE=EB1 | CELL LINE=EBC-1 | CELL LINE=EJ138 | CELL LINE=EJM | CELL LINE=Eos-HL-60 | CELL LINE=EPLC-272H | CELL LINE=FLYA13 | CELL LINE=fR2 | CELL LINE=FTC-133 | CELL LINE=FTC-238 | CELL LINE=Fu97 | CELL LINE=G-292 Clone A141B1 | CELL LINE=G-361 | CELL LINE=G-401 | CELL LINE=G-402 | CELL LINE=GA-10 | CELL LINE=GCT | CELL LINE=GOTO | CELL LINE=GP5d | CELL LINE=GRANTA-519 | CELL LINE=H-EMC-SS | CELL LINE=H3255 | CELL LINE=H33HJ-JA1 | CELL LINE=H69 | CELL LINE=H69AR | CELL LINE=H69V | CELL LINE=HARA | CELL LINE=HBE4-E6/E7 | CELL LINE=HCC-15 | CELL LINE=HCC-366 | CELL LINE=HCC-44 | CELL LINE=HCC-56 | CELL LINE=HCC-78 | CELL LINE=HCC-827 | CELL LINE=HCC1428 | CELL LINE=HCC202 | CELL LINE=HCC38 | CELL LINE=HCE7 | CELL LINE=HCT 116 | CELL LINE=HCT-8 | CELL LINE=HDQ-P1 | CELL LINE=HEC-1 | CELL LINE=HGC-27 | CELL LINE=HK-2 | CELL LINE=HLE | CELL LINE=HMCB | CELL LINE=HMVII | CELL LINE=HO-1-N-1 | CELL LINE=HO-1-u-1 | CELL LINE=HOS | CELL LINE=HPAFII | CELL LINE=HRT-18 | CELL LINE=Hs 228.T | CELL LINE=Hs 417.Lu | CELL LINE=Hs 573.T | CELL LINE=Hs 600.T | CELL LINE=Hs 633T | CELL LINE=Hs 707(A).T | CELL LINE=Hs 737.T | CELL LINE=Hs 738.St/Int | CELL LINE=Hs 746T | CELL LINE=Hs 751.T | CELL LINE=Hs 781.T | CELL LINE=Hs 834.T | CELL LINE=Hs 839.T | CELL LINE=Hs 852.T | CELL LINE=Hs 891.T | CELL LINE=Hs 894(E).Lu | CELL LINE=Hs 895.T | CELL LINE=Hs 908.T | CELL LINE=Hs 936.T | CELL LINE=HSC-2 | CELL LINE=HSC-3 | CELL LINE=HSC-4 | CELL LINE=HT 1080 | CELL LINE=HT 1376 | CELL LINE=HT 728.T | CELL LINE=HT-1197 | CELL LINE=HT-29 | CELL LINE=HT115 | CELL LINE=HT55 | CELL LINE=HuCCT1 | CELL LINE=huH-1 | CELL LINE=HuH-7 | CELL LINE=HUP-T3 | CELL LINE=HuPT4 | CELL LINE=IHH-4 | CELL LINE=IM-95 | CELL LINE=IMR-90 | CELL LINE=Ishikawa | CELL LINE=Ishikawa (Heraklio) 02 ER- | CELL LINE=J.γ1 | CELL LINE=J82 | CELL LINE=JAR | CELL LINE=JHH-1 | CELL LINE=JHH-2 | CELL LINE=JHH-4 | CELL LINE=JHH-6 | CELL LINE=JIMT-1 | CELL LINE=JSC-1 | CELL LINE=Jurkat, Clone E6-1 | CELL LINE=K562/ADM | CELL LINE=KATO III | CELL LINE=KG-1-C | CELL LINE=KHM-3S | CELL LINE=KHOS-240S | CELL LINE=KHOS-312H | CELL LINE=KHOS/NP | CELL LINE=KMH-2 | CELL LINE=KMRC-1 | CELL LINE=KMRC-2 | CELL LINE=KMRC-20 | CELL LINE=KMS-12-PE | CELL LINE=KO52 | CELL LINE=KON | CELL LINE=KOSC-2 cl3-43 | CELL LINE=KP-1N | CELL LINE=KP-3 | CELL LINE=KP-4 | CELL LINE=KY821 | CELL LINE=KYM-1 | CELL LINE=KYSE-140 | CELL LINE=KYSE-150 | CELL LINE=KYSE-180 | CELL LINE=KYSE-220 | CELL LINE=KYSE-270 | CELL LINE=KYSE-30 | CELL LINE=KYSE-410 | CELL LINE=KYSE-450 | CELL LINE=KYSE-50 | CELL LINE=KYSE-510 | CELL LINE=KYSE-520 | CELL LINE=KYSE-70 | CELL LINE=LC-1 sq | CELL LINE=LC4-1 | CELL LINE=LCLC-103H | CELL LINE=LI90 | CELL LINE=LK-2 | CELL LINE=LNCaP clone FGC | CELL LINE=LOU-NH91 | CELL LINE=LS 123 | CELL LINE=LS174T | CELL LINE=LS180 | CELL LINE=Lu-134-B | CELL LINE=LU65 | CELL LINE=LU65A | CELL LINE=LU65B | CELL LINE=LU99A | CELL LINE=LUDLU-1 | CELL LINE=MB 157 | CELL LINE=MCAS | CELL LINE=MCF7 | CELL LINE=MDA-MB-361 | CELL LINE=MDST8 | CELL LINE=ME-180 | CELL LINE=MES-SA | CELL LINE=MES-SA/Dx-5 | CELL LINE=MEWO | CELL LINE=MG-63 | CELL LINE=MKN1 | CELL LINE=MKN45 | CELL LINE=MKN7 | CELL LINE=MKN74 | CELL LINE=MLMA | CELL LINE=MOG-G-CCM | CELL LINE=MOG-G-UVW | CELL LINE=MOLT-4F | CELL LINE=MRC-9 | CELL LINE=MRK-nu-1 | CELL LINE=MS-1-L | CELL LINE=MSTO-211H | CELL LINE=MY | CELL LINE=NA06990 | CELL LINE=NA07349 | CELL LINE=NA17102 | CELL LINE=NA17110 | CELL LINE=NA17733 | CELL LINE=NA17737 | CELL LINE=NB(TU)1-10 | CELL LINE=NB69 | CELL LINE=NCI-H1048 | CELL LINE=NCI-H1155 | CELL LINE=NCI-H1299 | CELL LINE=NCI-H1417 | CELL LINE=NCI-H1435 | CELL LINE=NCI-H1437 | CELL LINE=NCI-H1522 | CELL LINE=NCI-H1563 | CELL LINE=NCI-H1568 | CELL LINE=NCI-H1573 | CELL LINE=NCI-H1581 | CELL LINE=NCI-H1623 | CELL LINE=NCI-H1650 | CELL LINE=NCI-H1651 | CELL LINE=NCI-H1666 | CELL LINE=NCI-H1693 | CELL LINE=NCI-H1703 | CELL LINE=NCI-H1734 | CELL LINE=NCI-H1755 | CELL LINE=NCI-H1781 | CELL LINE=NCI-H1792 | CELL LINE=NCI-H1793 | CELL LINE=NCI-H1915 | CELL LINE=NCI-H1944 | CELL LINE=NCI-H196 | CELL LINE=NCI-H2009 | CELL LINE=NCI-H2023 | CELL LINE=NCI-H2081 | CELL LINE=NCI-H2085 | CELL LINE=NCI-H2122 | CELL LINE=NCI-H2135 | CELL LINE=NCI-H2170 | CELL LINE=NCI-H2171 | CELL LINE=NCI-H2172 | CELL LINE=NCI-H2196 | CELL LINE=NCI-H2228 | CELL LINE=NCI-H2286 | CELL LINE=NCI-H23 | CELL LINE=NCI-H2330 | CELL LINE=NCI-H2342 | CELL LINE=NCI-H2347 | CELL LINE=NCI-H2452 | CELL LINE=NCI-H322 | CELL LINE=NCI-H358 | CELL LINE=NCI-H441 | CELL LINE=NCI-H460 | CELL LINE=NCI-H522 | CELL LINE=NCI-H647 | CELL LINE=NCI-H650 | CELL LINE=NCI-H661 | CELL LINE=NCI-H711 | CELL LINE=NCI-H727 | CELL LINE=NCI-H810 | CELL LINE=NCI-H82 | CELL LINE=NCI-H838 | CELL LINE=NCI-H841 | CELL LINE=NCI-H889 | CELL LINE=NCI-N87 | CELL LINE=NEC8 | CELL LINE=NL20-TA | CELL LINE=NOMO-1/ADM | CELL LINE=Nthy-ori 3-1 | CELL LINE=NUGC-3 | CELL LINE=NUGC-4 | CELL LINE=NY | CELL LINE=OAW28 | CELL LINE=OAW42 | CELL LINE=OCUG-1 | CELL LINE=OCUM-1 | CELL LINE=OE19 | CELL LINE=OE21 | CELL LINE=OE33 | CELL LINE=OSC-20 | CELL LINE=OUMS-23 | CELL LINE=OUS-11 | CELL LINE=OVISE | CELL LINE=OVMIU | CELL LINE=OVTOKO | CELL LINE=P116 | CELL LINE=P30/OHK | CELL LINE=P31/FUJ | CELL LINE=P32/ISH | CELL LINE=PA-TU-8988T | CELL LINE=Panc 08.13 | CELL LINE=PC-14 | CELL LINE=PC-3 [JPC-3] | CELL LINE=PC-9 | CELL LINE=PCI-4B | CELL LINE=PE/CA-PJ15 | CELL LINE=PLC/PRF/5 | CELL LINE=PNT1A | CELL LINE=PNT2 | CELL LINE=PWR-1E | CELL LINE=QGP-1 | CELL LINE=RCM-1 | CELL LINE=RERF-GC-1B | CELL LINE=RERF-LC-Ad2 | CELL LINE=RERF-LC-KJ | CELL LINE=RERF-LC-MA | CELL LINE=RERF-LC-MS | CELL LINE=RERF-LC-Sq1 | CELL LINE=RKN | CELL LINE=RMG-I | CELL LINE=RO82-W-1 | CELL LINE=RPMI-7951 | CELL LINE=RT112/84 | CELL LINE=RT4 | CELL LINE=RWPE-1 | CELL LINE=RWPE-2 | CELL LINE=RWPE2-W99 | CELL LINE=Saos-2 | CELL LINE=SAS | CELL LINE=SAT | CELL LINE=SBC-2 | CELL LINE=SBC-3 | CELL LINE=SBC-5 | CELL LINE=SCC-3 | CELL LINE=SCC-4 | CELL LINE=SCH | CELL LINE=Sci-1 | CELL LINE=SK-BR-3 | CELL LINE=SK-CO-1 | CELL LINE=SK-ES-1 | CELL LINE=SK-LU-1 | CELL LINE=SK-MEL-1 | CELL LINE=SK-MEL-3 | CELL LINE=SK-MES | CELL LINE=SK-N-BE(2) | CELL LINE=SK-N-FI | CELL LINE=SK-NEP-1 | CELL LINE=SK-OV-3 | CELL LINE=SKG-IIIb | CELL LINE=SKN | CELL LINE=SKN-3 | CELL LINE=SLVL | CELL LINE=SNG-M | CELL LINE=SNU-1 | CELL LINE=SNU-16 | CELL LINE=SNU-398 | CELL LINE=SNU-5 | CELL LINE=SR | CELL LINE=STC 1 | CELL LINE=SUIT-2 | CELL LINE=SVts-8 | CELL LINE=SW 1116 | CELL LINE=SW 13 | CELL LINE=SW 1417 | CELL LINE=SW 1463 | CELL LINE=SW 156 | CELL LINE=SW 1573 | CELL LINE=SW 48 | CELL LINE=SW 780 | CELL LINE=SW 900 | CELL LINE=SW-1710 | CELL LINE=SW837 | CELL LINE=T.T | CELL LINE=T.Tn | CELL LINE=T1-73 | CELL LINE=T47D | CELL LINE=T84 | CELL LINE=TASK1 | CELL LINE=TCCSUP | CELL LINE=TCO-1 | CELL LINE=TE7 | CELL LINE=TK | CELL LINE=U-2 OS | CELL LINE=U266B1 | CELL LINE=U373 MG | CELL LINE=UE6E7T-2 | CELL LINE=UMC-11 | CELL LINE=VM-CUB1 | CELL LINE=VMRC-LCD | CELL LINE=VMRC-LCP | CELL LINE=VMRC-RCW | CELL LINE=VMRC-RCZ | CELL LINE=WI 38 | CELL LINE=WI-26 VA4 | CELL LINE=WIDR | CELL LINE=WIL2 NS | CELL LINE=WILCL | CELL LINE=WM 266-4 | CELL LINE=WM-115 | CELL LINE=WPE1-NA22 | CELL LINE=WPE1-NB11 | CELL LINE=WPE1-NB14 | CELL LINE=WPE1-NB26 | CELL LINE=YKG-1 | CELL LINE=YMB-1","GENOTYPE/VARIATION=p53 R175H mutant | GENOTYPE/VARIATION=p53-null","disease=control | disease=glioblastoma","ORGANISM PART=Peripheral brain tissue | ORGANISM PART=Tumor brain tissue","IDH1 STATUS=MUT | IDH1 STATUS=WT | RESTRICTION ENZYME=HpaII | RESTRICTION ENZYME=MspI | TUMOR TYPE=Anaplastic | TUMOR TYPE=Glioblastoma | TUMOR TYPE=Lowgrade","RNA interference=control shRNA | RNA interference=shRNA22","ANTIBODY=cMYC | ANTIBODY=CTCF | ANTIBODY=INPUT | ANTIBODY=Pol2 | ANTIBODY VENDER, CAT#, LOT#=Covance, MMS-126R, 14941801 | ANTIBODY VENDER, CAT#, LOT#=Covance, MMS-126R,14941801 | ANTIBODY VENDER, CAT#, LOT#=Millipore, 07-729, DAM1564576 | ANTIBODY VENDER, CAT#, LOT#=not specified | ANTIBODY VENDER, CAT#, LOT#=Santa Cruz, sc-764X, C1309 | ANTIBODY VENDER, CAT#, LOT#=Santa Cruz, sc-764X, K1810 | CELL LINE=FB0167P | CELL LINE=FB8470 | CELL LINE=H54 | CELL LINE=MCF7 | CELL TYPE=breast adenocarcinoma cells | CELL TYPE=Glioblastoma | CELL TYPE=Normal child fibroblasts | CELL TYPE=Progeria fibroblast","ANTIBODY=cMYC | ANTIBODY=CTCF | ANTIBODY=INPUT | ANTIBODY=not specified | ANTIBODY=Pol2 | ANTIBODY=rabbit polyclonal antibody | ANTIBODY (VENDER, CAT#, LOT#)=Covance, MMS-126R, 14941801 | ANTIBODY (VENDER, CAT#, LOT#)=Covance, MMS-126R,14941801 | ANTIBODY (VENDER, CAT#, LOT#)=Millipore, 07-729, DAM1564576 | ANTIBODY (VENDER, CAT#, LOT#)=not specified | ANTIBODY (VENDER, CAT#, LOT#)=Santa Cruz, sc-764X, C1309 | ANTIBODY (VENDER, CAT#, LOT#)=Santa Cruz, sc-764X, K1810 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA12878 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA12891 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA12892 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA19238 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA19239 | BIOSOURCEPROVIDER=Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&amp;q=NA19240 | BIOSOURCEPROVIDER=Corriell; http://ccr.coriell.org/Sections/Search/Sample_Detail.aspx?Ref=GM12878 | BIOSOURCEPROVIDER=not specified | CELL LINE=FB0167P | CELL LINE=FB8470 | CELL LINE=GM12878 | CELL LINE=H1 | CELL LINE=H1_ES | CELL LINE=H54 | CELL LINE=HeLa-S3 | CELL LINE=HepG2 | CELL LINE=HUVEC | CELL LINE=K562 | CELL LINE=MCF7 | CELL LINE=NHEK | CELL LINE=not specified | CELL TYPE=breast adenocarcinoma cells | CELL TYPE=cervical carcinoma | CELL TYPE=chronic myeloid leukemia | CELL TYPE=embryonic stem cells | CELL TYPE=glioblastoma | CELL TYPE=liver carcinoma cells | CELL TYPE=lymphoblastoid cells | CELL TYPE=Normal child fibroblasts | CELL TYPE=normal epidermal keratinocytes | CELL TYPE=not specified | CELL TYPE=Progeria fibroblast | CELL TYPE=umbilical vein endothelial cells | CHIP_ANTIBODY_CATALOG=07-729 | CHIP_ANTIBODY_CATALOG=MMS-126R | CHIP_ANTIBODY_CATALOG=not specified | CHIP_ANTIBODY_CATALOG=sc-764X | CHIP_ANTIBODY_LOT=C1309 | CHIP_ANTIBODY_LOT=DAM1421462 | CHIP_ANTIBODY_LOT=H107 | CHIP_ANTIBODY_LOT=not specified | CHIP_ANTIBODY_PROVIDER=Covance | CHIP_ANTIBODY_PROVIDER=Millipore | CHIP_ANTIBODY_PROVIDER=not specified | CHIP_ANTIBODY_PROVIDER=Santa Cruz | INDIVIDUAL=NA12878 | INDIVIDUAL=NA12891 | INDIVIDUAL=NA12892 | INDIVIDUAL=NA19238 | INDIVIDUAL=NA19239 | INDIVIDUAL=NA19240 | INDIVIDUAL=not specified","RNA interference=control | RNA interference=miR124 transfection | RNA interference=miR132 transfection | RNA interference=miR380 transfection | RNA interference=miR433 transfection | RNA interference=miR448 transfection","NA","ANTIBODY=ATF2_(SC-81188) | ANTIBODY=ATF3 | ANTIBODY=Bcl11a | ANTIBODY=BCL3 | ANTIBODY=CBX3_(SC-101004) | ANTIBODY=CEBPB_(SC-150) | ANTIBODY=CEBPD_(SC-636) | ANTIBODY=CREB1_(SC-240) | ANTIBODY=CTCF_(SC-5916) | ANTIBODY=CTCFL_(SC-98982) | ANTIBODY=E2F6 | ANTIBODY=Egr-1 | ANTIBODY=ELF1_(SC-631) | ANTIBODY=ERalpha_a | ANTIBODY=ETS1 | ANTIBODY=FOSL1_(SC-183) | ANTIBODY=FOSL2 | ANTIBODY=FOXA1_(SC-101058) | ANTIBODY=FOXA2_(SC-6554) | ANTIBODY=FOXM1_(SC-502) | ANTIBODY=FOXP2 | ANTIBODY=GABP | ANTIBODY=GATA3_(SC-268) | ANTIBODY=HDAC2_(SC-6296) | ANTIBODY=HEY1 | ANTIBODY=JunD | ANTIBODY=Max | ANTIBODY=MBD4_(SC-271530) | ANTIBODY=MEF2A | ANTIBODY=MTA3_(SC-81325) | ANTIBODY=MYBL2_(SC-81192) | ANTIBODY=NANOG_(SC-33759) | ANTIBODY=NFATC1_(SC-17834) | ANTIBODY=NFIC_(SC-81335) | ANTIBODY=not specified | ANTIBODY=NR2F2_(SC-271940) | ANTIBODY=NRSF | ANTIBODY=p300 | ANTIBODY=Pbx3 | ANTIBODY=PML_(SC-71910) | ANTIBODY=Pol2 | ANTIBODY=Pol2-4H8 | ANTIBODY=POU5F1_(SC-9081) | ANTIBODY=PU.1 | ANTIBODY=Rad21 | ANTIBODY=RevXlinkChromatin | ANTIBODY=RUNX3_(SC-101553) | ANTIBODY=RXRA | ANTIBODY=Sin3Ak-20 | ANTIBODY=SIX5 | ANTIBODY=SP1 | ANTIBODY=SP2_(SC-643) | ANTIBODY=SP4_(V-20) | ANTIBODY=srf | ANTIBODY=STAT5A_(SC-74442) | ANTIBODY=TAF1 | ANTIBODY=TAF7_(SC-101167) | ANTIBODY=TCF12 | ANTIBODY=TCF3_(SC-349) | ANTIBODY=TEAD4_(SC-101184) | ANTIBODY=THAP1_(SC-98174) | ANTIBODY=TRIM28_(SC-81411) | ANTIBODY=USF-1 | ANTIBODY=YY1 | ANTIBODY=YY1_(SC-281) | ANTIBODY=ZBTB33 | ANTIBODY=ZBTB7A_(SC-34508) | ANTIBODY=ZEB1_(SC-25388) | ANTIBODY ANTIBODYDESCRIPTION=Bcl-3(C-14) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of Bcl-3 of human origin. Recommended for detection of Bcl-3 of m, r and h origin by WB, IP, IF and ELISA. | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, 200 micrograms /ml. Epitope mapping at the N-terminus of Pax-5 of human origin. Recommended for detection of Pax-5 of human origin by WB, IP, IF and ELISA. Antibody Target: PAX5 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, 200 micrograms/ml. Epitope mapping at the C-terminus of Pax-5 of human origin. Recommended for detection of Pax-5 of m, r and h origin by WB, IP, IF, IHC(P) and ELISA. Antibody Target: PAX5 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the C-terminus of FOXA1 of human origin. Antibody Target: FOXA1 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the C-terminus of HDAC2 of human origin. Antibody Target: HDAC2 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the C-terminus of HNF4G of human origin. Antibody Target: HNF4G | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the C-terminus of IRF-4 of mouse origin. Antibody Target: IRF4 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the C-terminus of LRF of human origin. Antibody Target: ZBTB7A | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the N-terminus of CTCF of human origin. Antibody Target: CTCF | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping at the N-terminus of FOXA2 of human origin. Antibody Target: FOXA2 | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping near the C-terminus of MEF2C of human origin. Antibody Target: MEF2C | ANTIBODY ANTIBODYDESCRIPTION=Goat polyclonal IgG, epitope mapping near the C-terminus of THAP1 of human origin. Antibody Target: THAP1 | ANTIBODY ANTIBODYDESCRIPTION=HEB (A-20) Rabbit polyclonal IgG, 200 ?g/ml. Epitope mapping within the C-terminus of HEB of human origin. Antibody Target: TCF12 | ANTIBODY ANTIBODYDESCRIPTION=HRT1 (C-20) Goat polyclonal IgG, 200 ?g/ml. Epitope mapping near the C-terminus of HRT1 of human origin | ANTIBODY ANTIBODYDESCRIPTION=Kaiso (6F8) Mouse monoclonal IgG1. Raised against amino acids 1-504 representing full length Kaiso of human origin. Recommended for detection of Kaiso of m, r, h, canine and chicken origin by WB, IP, IF and ELISA. Antibody Target: ZBTB33 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal (p250). Antibody Target: TAF1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal [18B12DE6] to Ctip1. Raised against a cocktail of BCL11A fusion proteins. Reacts with human and mouse. Tested for ICC/IF, IHC-P, IP, WB. Antibody Target: BCL11A | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG raised against human recombinant GATA-3. Antibody Target: GATA3 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, N-terminal epitope corresponding to residues 37-51 of PML of human origin. Antibody Target: PML | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a recombinant protein corresponding to a region near the N-terminus of MTA3 of human origin. Antibody Target: MTA3 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a recombinant protein corresponding to an internal region of ATF2 of human origin. Antibody Target: ATF2 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a recombinant protein corresponding to an internal region of B-Myb of human origin. Antibody Target: MYBL2 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a recombinant protein corresponding to an internal region of NF-1 of human origin. Antibody Target: NFIC | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a recombinant protein corresponding to an internal region of TRIM28 of human origin. Antibody Target: TRIM28 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a synthetic peptide corresponding to a.a. 900-909 of BCLAF1 of human origin. Antibody Target: BCLAF1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against a.a. 1-300 mapping at the N-terminus of EBF of human origin. Antibody Target: EBF1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against amino acids 1-110 of NFATc1 of human origin. Antibody Target: NFATC1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against amino acids 191-300 of recombinant RUNX3 of human origin. Antibody Target: RUNX3 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against recombinant CBX3 of human origin. Antibody Target: CBX3 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against recombinant HNF-3a of human origin. Antibody Target: FOXA1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against recombinant protein TEF-3 (TEAD4) of human origin. Antibody Target: TEAD4 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, raised against recombinant TAF II p55 (TAF7) of human origin. Antibody Target: TAF7 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, recommended for the detection of Stat5a and Stat5b of human origin by WB, IP, IF and ELISA. Antibody Target: STAT5A | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, specific for an epitope mapping between a.a. 515-555 within an internal region of MBD4 of mouse origin. Antibody Target: MBD4 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG, specific for an epitope mapping between amino acids 13-44 at the N-terminus of NR2F2 of human origin. Antibody Target: NR2F2 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG. Antibody Target: GATA2 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal IgG1; raised against amino acids 254-327 mapping within the DNA binding and dimerization domain of human CREB-1. Antibody Target: CREB1 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal to RNA polymerase II CTD repeat YSPTSPS antibody (4H8) - ChIP Grade. Antibody Target: POL2 | ANTIBODY ANTIBODYDESCRIPTION=mouse monoclonal, clone 8WG16. Antibody Target: POL2 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal, GABPa(G-1), IgG1. Antibody Target: GABP | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal. Antibody Target: NRSF | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal. Dec-1(S-8) is an IgG2b antibody raised against recombinant DEC1 of human origin. Recommended for detection of DEC1 of mouse and human origin by WB, IP and ELISA. Antibody Target: BHLHE40 | ANTIBODY ANTIBODYDESCRIPTION=Mouse monoclonal. Raised against recombinant B-ATF of human origin. Recommended for detection of B-ATF of m, r and h origin by WB, IP and ELISA. Antibody Target: BATF | ANTIBODY ANTIBODYDESCRIPTION=not specified | ANTIBODY ANTIBODYDESCRIPTION=Oct-2(C-20) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of Oct-2 of human origin. Recommended for detection of Oct-2 of m, r and h origin by WB, IP, IF, IHC(P) and ELISA. Antibody Target: POU2F2 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit affinity purified polyclonal antibody. Epitope is the C-terminus of human estrogen receptor alpha (ESR1). Recommended for detection of estrogen receptor of m, r and h origin by WB, IP, IF, IHC(P) and ELISA. Antibody Target: ESR1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to a.a. 232-281 mapping at the C-terminus of E2F-6 of human origin. Antibody Target: E2F6 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to a.a. 295-465 mapping at the C-terminus of HNF4A of human origin. Antibody Target: HNF4A | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to a.a. 75-160 mapping within internal region of USF1 of human origin. Antibody Target: USF1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to amino acids 1-134 of Oct3/4 of human origin. Antibody Target: POU5F1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to amino acids 151-305 mapping at the C-terminus of Nanog of human origin. Antibody Target: NANOG | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to amino acids 39-140 mapping near the N-terminus of ZEB1 of human origin. Antibody Target: ZEB1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope corresponding to amino acids 91-210 mapping within an internal region of BORIS(CTCFL) of human origin. Antibody Target: CTCFL | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of ATF3 of human origin. Antibody Target: ATF3 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of CEBPB of rat origin. Antibody Target: CEBPB | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of CEBPD of human origin. Antibody Target: CEBPD | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of Elf-1 of human origin. Antibody Target: ELF1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of FOXM1 of human origin. Antibody Target: FOXM1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of Max of human origin. Antibody Target: Max | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of MEF-2 of human origin. Antibody Target: MEF2A | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of Sp4 of human origin. Antibody Target: SP4 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the C-terminus of YY1 of human origin. Antibody Target: YY1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping at the N-terminus of FOSL1 of human origin. Antibody Target: FOSL1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG, epitope mapping near the N-terminus of SP2 of human origin. Antibody Target: SP2 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal IgG. Antibody Target: ETS1 | ANTIBODY ANTIBODYDESCRIPTION=rabbit polyclonal IgG. Antibody Target: JunD | ANTIBODY ANTIBODYDESCRIPTION=Rabbit Polyclonal IgG. Antibody Target: PBX3 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit Polyclonal IgG. Antibody Target: PU1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal, EGR-1 (588). Antibody Target: EGR1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal, raised against C-terminal 127 amino acids of FOXP2 of human origin. Antibody Target: FOXP2 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal, Sin3A (k-20). Antibody Target: SIN3AK20 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal, USF-1 (C-20). Antibody Target: USF1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Antibody Target: CTCF | ANTIBODY ANTIBODYDESCRIPTION=Rabbit Polyclonal. Antibody Target: GR | ANTIBODY ANTIBODYDESCRIPTION=Rabbit Polyclonal. Antibody Target: P300 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Antibody Target: RAD21 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Antibody Target: SRF | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Antibody Target: YY1 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Bcl-3(C-14) is an affinity purified antibody raised against a peptide mapping at the C-terminus of Bcl-3 of human origin. Recommended for detection of Bcl-3 of mouse, rat and human origin by WB, IP, IF and ELISA. Antibody Target: BCL3 | ANTIBODY ANTIBODYDESCRIPTION=Rabbit polyclonal. Fra-2(Q-20) is an affinity purified raised against the N-terminus of Fra-2 of human origin. Recommended for detection of Fra-2 of m, r, h and chicken origin by WB, IP, IF, IHC(P) and ELISA. Antibody Target: FOSL2 | ANTIBODY ANTIBODYDESCRIPTION=RXRa(D-20) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the N-terminus of RXRalpha of human origin. Recommended for detection of RXRalpha of m, r and h origin by WB, IP, IF, IHC(P) and ELISA. Antibody Target: RXRA | ANTIBODY ANTIBODYDESCRIPTION=Six5 (K-20) Goat polyclonal IgG, 200?g/ml. Epitope mapping near the C-terminus of Six5 of human origin. Recommended for detection of Six5 of human origin by WB, IF and ELISA. Antibody Target: SIX5 | ANTIBODY ANTIBODYDESCRIPTION=Sp1(E-3) is a mouse monoclonal antibody raised against amino acids 121-345 mapping near the N-terminus of Sp1 ofhuman origin. Recommended for detection of Sp1 of m, r and h origin by WB, IP, IF and ELISA. Antibody Target: SP1 | ANTIBODY TARGETDESCRIPTION=Activating transcription factor 3. A bZIP transcription factor and member of the Ca2+/cAMP response element-binding (CREB) protein family. ATF3 is found to act both as an activator and repressor of transcription. | ANTIBODY TARGETDESCRIPTION=Binds to GT and GC boxes promoters elements. Probable transcriptional activator. | ANTIBODY TARGETDESCRIPTION=Co-repressor interacting with HDAC1, N-coR, SMRT, and MeCP2 | ANTIBODY TARGETDESCRIPTION=CTCF zinc finger transcription factor. A sequence specific DNA binding protein that functions as an insulator, blocking enhancer activity. It has also been suggested to block the spreading of chromatin structure in certain instances. | ANTIBODY TARGETDESCRIPTION=Early B-cell factor 1. Transcriptional activator which recognizes variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3' (By similarity). | ANTIBODY TARGETDESCRIPTION=EP300(c-20) | ANTIBODY TARGETDESCRIPTION=ETS transcriptions factors, such as ETS1, regulate numerous genes and are involved in stem cell development, cell senescence and death, and tumorigenesis | ANTIBODY TARGETDESCRIPTION=Glucocorticoid Receptor | ANTIBODY TARGETDESCRIPTION=Hepatocyte nuclear factor 4 gamma (HNF4G) also known as NR2A2 (nuclear receptor subfamily 2, group A, member 2) is a nuclear receptor that in humans is encoded by the HNF4G gene | ANTIBODY TARGETDESCRIPTION=KAISO is a transcriptional regulator that binds, via its zinc fingers, to DNA sequences containing methylated CGCG or to the consensus KAISO-binding site (KBS) TCCTGCNA | ANTIBODY TARGETDESCRIPTION=Neuron-restrictive silencer transcription factor | ANTIBODY TARGETDESCRIPTION=not specified | ANTIBODY TARGETDESCRIPTION=Pbx 3 (D-17) | ANTIBODY TARGETDESCRIPTION=Plays a key role in the instruction of early lymphoid progenitors to develop into B lineage by repressing T-cell instructive Notch signals (By similarity). | ANTIBODY TARGETDESCRIPTION=Plays a role in maintenance of the normal epithelial architecture through the repression of SNAI1 transcription in a histone deacetylase-dependent manner, and thus the regulation of E-cadherin levels. | ANTIBODY TARGETDESCRIPTION=PU.1 (H-135) | ANTIBODY TARGETDESCRIPTION=Recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication. | ANTIBODY TARGETDESCRIPTION=RNA Polymerase II | ANTIBODY TARGETDESCRIPTION=Serum response transcription factor | ANTIBODY TARGETDESCRIPTION=SP1 is a transcription factor that binds to GC box promoters elements and selectively activates mRNA synthesis from genes that contain functional recognition sites. It can interact with G/C-rich motifs from the serotonin receptor promoter. | ANTIBODY TARGETDESCRIPTION=Synthetic peptide (Human) conjugated to KLH - which represents a portion of human Rad21 encoded within exon 14 | ANTIBODY TARGETDESCRIPTION=TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa. Also designated TAF250. | ANTIBODY TARGETDESCRIPTION=The protein encoded by this gene is a DNA-binding transcription factor that activates many muscme-specific, growth factor-induced, and stress-induced genes. | ANTIBODY TARGETDESCRIPTION=The transcription factor GA-binding protein (GABP) is composed of two subunits, alpha and beta. Alpha binds to a specific DNA sequence. | ANTIBODY TARGETDESCRIPTION=This gene encodes a basic helix-loop-helix protein expressed in various tissues. Expression in the chondrocytes is responsive to the addition of Bt2cAMP. The encoded protein is believed to be involved in the control of cell differe | ANTIBODY TARGETDESCRIPTION=This gene encodes a member of the forkhead/winged-helix (FOX) family of transcription factors. Transcriptional repressor, involved in the development of speech | ANTIBODY TARGETDESCRIPTION=This gene encodes a transcriptional repressor that interacts with several members of the BCL2 family of proteins. Overexpression of this protein induces apoptosis, which can be suppressed by co-expression of BCL2 proteins (RefSeq). | ANTIBODY TARGETDESCRIPTION=This gene encodes the largest subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes | ANTIBODY TARGETDESCRIPTION=YIN YANG 1 transcription factor belongs to the GLI-Kruppel class of zinc finger proteins. | ANTIBODY VENDORID=(Made by Protein Expression Center: pec@caltech.edu) | ANTIBODY VENDORID=07-729 | ANTIBODY VENDORID=ab16046 | ANTIBODY VENDORID=ab19489 | ANTIBODY VENDORID=ab5408 | ANTIBODY VENDORID=ab992 | ANTIBODY VENDORID=MMS-126R | ANTIBODY VENDORID=not specified | ANTIBODY VENDORID=sc-1003 | ANTIBODY VENDORID=sc-100974 | ANTIBODY VENDORID=sc-101004 | ANTIBODY VENDORID=sc-101023 | ANTIBODY VENDORID=sc-101058 | ANTIBODY VENDORID=sc-101167 | ANTIBODY VENDORID=sc-101184 | ANTIBODY VENDORID=sc-101388 | ANTIBODY VENDORID=sc-101553 | ANTIBODY VENDORID=sc-110 | ANTIBODY VENDORID=sc-13268 | ANTIBODY VENDORID=sc-137065 | ANTIBODY VENDORID=sc-150 | ANTIBODY VENDORID=sc-16424 | ANTIBODY VENDORID=sc-1703 | ANTIBODY VENDORID=sc-17824 | ANTIBODY VENDORID=sc-17834 | ANTIBODY VENDORID=sc-183 | ANTIBODY VENDORID=sc-185 | ANTIBODY VENDORID=sc-188 | ANTIBODY VENDORID=sc-197 | ANTIBODY VENDORID=sc-1974 | ANTIBODY VENDORID=sc-1975 | ANTIBODY VENDORID=sc-22805 | ANTIBODY VENDORID=sc-22823 | ANTIBODY VENDORID=sc-229 | ANTIBODY VENDORID=sc-233 | ANTIBODY VENDORID=sc-23871 | ANTIBODY VENDORID=sc-240 | ANTIBODY VENDORID=sc-25388 | ANTIBODY VENDORID=sc-267 | ANTIBODY VENDORID=sc-268 | ANTIBODY VENDORID=sc-271530 | ANTIBODY VENDORID=sc-271940 | ANTIBODY VENDORID=sc-281 | ANTIBODY VENDORID=sc-28312 | ANTIBODY VENDORID=sc-313 | ANTIBODY VENDORID=sc-335 | ANTIBODY VENDORID=sc-33759 | ANTIBODY VENDORID=sc-34508 | ANTIBODY VENDORID=sc-349 | ANTIBODY VENDORID=sc-350 | ANTIBODY VENDORID=sc-357 | ANTIBODY VENDORID=sc-502 | ANTIBODY VENDORID=sc-543 | ANTIBODY VENDORID=sc-553 | ANTIBODY VENDORID=sc-55706 | ANTIBODY VENDORID=sc-585 | ANTIBODY VENDORID=sc-5916 | ANTIBODY VENDORID=sc-604 | ANTIBODY VENDORID=sc-6059 | ANTIBODY VENDORID=sc-6296 | ANTIBODY VENDORID=sc-631 | ANTIBODY VENDORID=sc-636 | ANTIBODY VENDORID=sc-643 | ANTIBODY VENDORID=sc-645 | ANTIBODY VENDORID=sc-6553 | ANTIBODY VENDORID=sc-6554 | ANTIBODY VENDORID=sc-6558 | ANTIBODY VENDORID=sc-71910 | ANTIBODY VENDORID=sc-735 | ANTIBODY VENDORID=sc-74 | ANTIBODY VENDORID=sc-74442 | ANTIBODY VENDORID=sc-81188 | ANTIBODY VENDORID=sc-81192 | ANTIBODY VENDORID=sc-81325 | ANTIBODY VENDORID=sc-81335 | ANTIBODY VENDORID=sc-81411 | ANTIBODY VENDORID=sc-891 | ANTIBODY VENDORID=sc-8983 | ANTIBODY VENDORID=sc-8987 | ANTIBODY VENDORID=sc-9081 | ANTIBODY VENDORID=sc-98174 | ANTIBODY VENDORID=sc-98982 | ANTIBODY VENDORID=sc-994 | ANTIBODY VENDORNAME=abcam | ANTIBODY VENDORNAME=Covance | ANTIBODY VENDORNAME=Dr. David Anderson at Caltech | ANTIBODY VENDORNAME=Millipore | ANTIBODY VENDORNAME=not specified | ANTIBODY VENDORNAME=Santa Cruz Biotech | ANTIBODY VENDORNAME=Santa Cruz Biotechnology | CELL=A549 | CELL=ECC-1 | CELL=GM12878 | CELL=H1-hESC | CELL=H1-neurons | CELL=HCT-116 | CELL=HepG2 | CELL=HL-60 | CELL=HUVEC | CELL=K562 | CELL=MCF-7 | CELL=not specified | CELL=PANC-1 | CELL=PFSK-1 | CELL=SK-N-MC | CELL=SK-N-SH | CELL=T-47D | CELL=U87 | CELL DESCRIPTION=B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus | CELL DESCRIPTION=B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed | CELL DESCRIPTION=cervical carcinoma | CELL DESCRIPTION=colorectal carcinoma (PMID: 7214343) | CELL DESCRIPTION=embryonic stem cell | CELL DESCRIPTION=epithelial cell line derived from a mammary ductal carcinoma. | CELL DESCRIPTION=epithelial cell line derived from an endometrium adenocarcinoma, fetal membranes were collected from women who underwent planned cesarean delivery at term, before labor and without rupture of membranes | CELL DESCRIPTION=glioblastoma, astrocytoma, (PMID: 4332744) | CELL DESCRIPTION=hepatocellular carcinoma | CELL DESCRIPTION=leukemia, &amp;quot;The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.&amp;quot; - ATCC | CELL DESCRIPTION=liver carcinoma | CELL DESCRIPTION=mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=neuroblastoma cell line, treatment: differentiated with retinoic acid, (Biedler, et al. Morphology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture. Cancer Research 33, 2643-2652, November 1973.) | CELL DESCRIPTION=neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. | CELL DESCRIPTION=neuroectodermal cell line derived from a cerebral brain tumor, (PMID: 1316433) | CELL DESCRIPTION=neurons derived from H1 embryonic stem cells, newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=not specified | CELL DESCRIPTION=promyelocytic leukemia cells, (PMID: 276884) | CELL DESCRIPTION=umbilical vein endothelial cell | CELL KARYOTYPE=cancer | CELL KARYOTYPE=normal | CELL KARYOTYPE=not specified | CELL KARYOTYPE=unknown | CELL LINEAGE=ectoderm | CELL LINEAGE=endoderm | CELL LINEAGE=inner cell mass | CELL LINEAGE=mesoderm | CELL LINEAGE=not specified | CELL SEX=female | CELL SEX=male | CELL SEX=not specified | CELL SEX=U | CONTROLID=SL102 | CONTROLID=SL103,SL414 | CONTROLID=SL108,SL410 | CONTROLID=SL1087,SL1035 | CONTROLID=SL1092,SL1034 | CONTROLID=SL1106 | CONTROLID=SL12050,SL12795 | CONTROLID=SL12050,SL12795,SL6019 | CONTROLID=SL1216,SL1490 | CONTROLID=SL12247,SL12246 | CONTROLID=SL12789,SL12049 | CONTROLID=SL12789,SL12049,SL6022 | CONTROLID=SL12791,SL13505 | CONTROLID=SL12791,SL16761,SL13505,SL16760 | CONTROLID=SL12792 | CONTROLID=SL12792,SL16759 | CONTROLID=SL12793 | CONTROLID=SL12793,SL11659 | CONTROLID=SL12793,SL6023,SL11659,SL9103 | CONTROLID=SL12796 | CONTROLID=SL12796,SL6018 | CONTROLID=SL13294 | CONTROLID=SL13320,SL16755 | CONTROLID=SL13321 | CONTROLID=SL13321,SL12790 | CONTROLID=SL13321,SL16753 | CONTROLID=SL13321,SL16753,SL12790 | CONTROLID=SL13504 | CONTROLID=SL13505 | CONTROLID=SL13506 | CONTROLID=SL1394 | CONTROLID=SL1394,SL1395 | CONTROLID=SL1394,SL3979 | CONTROLID=SL1394,SL516 | CONTROLID=SL1395,SL516 | CONTROLID=SL1396 | CONTROLID=SL1396,SL1397 | CONTROLID=SL1398 | CONTROLID=SL1400,SL1401 | CONTROLID=SL1400,SL1781 | CONTROLID=SL1490 | CONTROLID=SL150,SL16,SL412 | CONTROLID=SL150,SL412 | CONTROLID=SL16 | CONTROLID=SL1613 | CONTROLID=SL1613,SL1394 | CONTROLID=SL1613,SL1395 | CONTROLID=SL1613,SL2455 | CONTROLID=SL1668 | CONTROLID=SL1668,SL3898 | CONTROLID=SL16754,SL13506 | CONTROLID=SL16757,SL13504 | CONTROLID=SL16757,SL16756 | CONTROLID=SL16758,SL13504 | CONTROLID=SL16758,SL16757,SL13504,SL16756 | CONTROLID=SL16760,SL13505 | CONTROLID=SL16761,SL13505 | CONTROLID=SL16762 | CONTROLID=SL1714 | CONTROLID=SL1781 | CONTROLID=SL1781,SL593 | CONTROLID=SL1782 | CONTROLID=SL1783 | CONTROLID=SL1881 | CONTROLID=SL1882 | CONTROLID=SL2134 | CONTROLID=SL217,SL218 | CONTROLID=SL218 | CONTROLID=SL2338,SL3777 | CONTROLID=SL2339 | CONTROLID=SL2340 | CONTROLID=SL2455 | CONTROLID=SL247,SL305 | CONTROLID=SL2905 | CONTROLID=SL295,SL294 | CONTROLID=SL307 | CONTROLID=SL3077,SL3253,SL3978 | CONTROLID=SL3251,SL2665 | CONTROLID=SL335 | CONTROLID=SL3457 | CONTROLID=SL3774 | CONTROLID=SL3774,SL2134 | CONTROLID=SL3774,SL2134,SL3775 | CONTROLID=SL3774,SL3775 | CONTROLID=SL3776 | CONTROLID=SL3776,SL2340 | CONTROLID=SL3898 | CONTROLID=SL3976 | CONTROLID=SL3976,SL1781 | CONTROLID=SL3978 | CONTROLID=SL3979 | CONTROLID=SL3980,SL2455 | CONTROLID=SL4698,SL3900,SL3978 | CONTROLID=SL474 | CONTROLID=SL475 | CONTROLID=SL516 | CONTROLID=SL516,SL517 | CONTROLID=SL518 | CONTROLID=SL518,SL519 | CONTROLID=SL518,SL519,SL1396,SL1397 | CONTROLID=SL523,SL117 | CONTROLID=SL592 | CONTROLID=SL593 | CONTROLID=SL6018 | CONTROLID=SL6019 | CONTROLID=SL6021 | CONTROLID=SL6022 | CONTROLID=SL6023 | CONTROLID=SL6023,SL9103 | CONTROLID=SL678,SL1394,SL1395,SL516,SL517 | CONTROLID=SL678,SL516 | CONTROLID=SL678,SL517 | CONTROLID=SL817 | CONTROLID=SL818 | CONTROLID=SL819,SL1400,SL593,SL1401 | CONTROLID=SL819,SL593 | CONTROLID=SL879,SL878 | CONTROLID=SL969 | DATATYPE DESCRIPTION=ChIP-seq | DATATYPE DESCRIPTION=Chromatin IP Sequencing | LABEXPID=SL1012,SL1088 | LABEXPID=SL102 | LABEXPID=SL103,SL414 | LABEXPID=SL1049,SL1122 | LABEXPID=SL1054,SL984 | LABEXPID=SL1056,SL1194 | LABEXPID=SL1057 | LABEXPID=SL1062,SL805 | LABEXPID=SL108,SL410 | LABEXPID=SL1087,SL1035 | LABEXPID=SL10882,SL12417 | LABEXPID=SL1092,SL1034 | LABEXPID=SL1093,SL1011 | LABEXPID=SL1104,SL2387 | LABEXPID=SL1106 | LABEXPID=SL1107,SL632 | LABEXPID=SL1114,SL1320 | LABEXPID=SL1158,SL1315 | LABEXPID=SL116,SL522 | LABEXPID=SL1162,SL1317 | LABEXPID=SL1163,SL2346 | LABEXPID=SL11657,SL11656 | LABEXPID=SL1167,SL1060 | LABEXPID=SL1176,SL2085 | LABEXPID=SL1196 | LABEXPID=SL1197,SL1510 | LABEXPID=SL1200,SL1061 | LABEXPID=SL1204,SL1077 | LABEXPID=SL1205,SL1078 | LABEXPID=SL12050,SL12795,SL6019 | LABEXPID=SL1206,SL1079 | LABEXPID=SL1207,SL1080 | LABEXPID=SL1216,SL1490 | LABEXPID=SL1217,SL1491 | LABEXPID=SL1218,SL1492 | LABEXPID=SL12228,SL13065 | LABEXPID=SL12229,SL13066 | LABEXPID=SL12230,SL13067 | LABEXPID=SL12231,SL13068 | LABEXPID=SL12238,SL16733 | LABEXPID=SL12239,SL13072 | LABEXPID=SL12240,SL13073 | LABEXPID=SL12247,SL12246 | LABEXPID=SL12411,SL13302 | LABEXPID=SL12413,SL13303 | LABEXPID=SL12627,SL13752 | LABEXPID=SL12629,SL14712 | LABEXPID=SL12634,SL16300 | LABEXPID=SL12637,SL16299 | LABEXPID=SL12644,SL16316 | LABEXPID=SL1265,SL1063 | LABEXPID=SL1273,SL1512 | LABEXPID=SL12789,SL12049,SL6022 | LABEXPID=SL12791,SL16761,SL13505,SL16760 | LABEXPID=SL12792,SL16759 | LABEXPID=SL12793,SL6023,SL11659,SL9103 | LABEXPID=SL12796,SL6018 | LABEXPID=SL13069,SL12233 | LABEXPID=SL13070,SL12237 | LABEXPID=SL13074,SL12242 | LABEXPID=SL13075,SL12243 | LABEXPID=SL13076,SL12244 | LABEXPID=SL13084,SL14597 | LABEXPID=SL13085,SL14045 | LABEXPID=SL13086,SL14046 | LABEXPID=SL1313,SL1157 | LABEXPID=SL1314 | LABEXPID=SL1318,SL1166 | LABEXPID=SL1319,SL1159 | LABEXPID=SL13270,SL16305 | LABEXPID=SL13272,SL14583 | LABEXPID=SL13273,SL14584 | LABEXPID=SL13283,SL12399 | LABEXPID=SL13290,SL12405 | LABEXPID=SL13292,SL12422 | LABEXPID=SL13293,SL12420 | LABEXPID=SL13294 | LABEXPID=SL13298,SL14592 | LABEXPID=SL13299,SL14593 | LABEXPID=SL13304,SL12414 | LABEXPID=SL13310,SL16737 | LABEXPID=SL13317,SL11280 | LABEXPID=SL13320,SL16755 | LABEXPID=SL13321,SL16753,SL12790 | LABEXPID=SL13457,SL14682 | LABEXPID=SL13460,SL14684 | LABEXPID=SL13462,SL14686 | LABEXPID=SL13463,SL16333 | LABEXPID=SL13466,SL14690 | LABEXPID=SL13479,SL14702 | LABEXPID=SL13482,SL14692 | LABEXPID=SL13485,SL14695 | LABEXPID=SL13490,SL14697 | LABEXPID=SL13493,SL14704 | LABEXPID=SL13501,SL14710 | LABEXPID=SL13502,SL14711 | LABEXPID=SL1363,SL5604 | LABEXPID=SL13724,SL16336 | LABEXPID=SL13733,SL14719 | LABEXPID=SL13747,SL12632 | LABEXPID=SL13754,SL12638 | LABEXPID=SL1398 | LABEXPID=SL14,SL13 | LABEXPID=SL14041,SL13078 | LABEXPID=SL14042,SL13079 | LABEXPID=SL14048,SL14723 | LABEXPID=SL14054,SL16021 | LABEXPID=SL14056,SL16022 | LABEXPID=SL14057,SL16023 | LABEXPID=SL1425,SL1792 | LABEXPID=SL1430,SL1665 | LABEXPID=SL144,SL167 | LABEXPID=SL14572,SL16339 | LABEXPID=SL14575,SL16341 | LABEXPID=SL14581,SL13319 | LABEXPID=SL14585,SL13274 | LABEXPID=SL14586,SL13275 | LABEXPID=SL14589,SL13279 | LABEXPID=SL14590,SL13280 | LABEXPID=SL14591,SL13281 | LABEXPID=SL14594,SL13300 | LABEXPID=SL14596,SL13083 | LABEXPID=SL14600,SL13309 | LABEXPID=SL14602,SL16738 | LABEXPID=SL14603,SL13313 | LABEXPID=SL14681,SL16342 | LABEXPID=SL14683,SL13459 | LABEXPID=SL14689,SL13465 | LABEXPID=SL14694,SL13484 | LABEXPID=SL14698,SL13491 | LABEXPID=SL14705,SL13494 | LABEXPID=SL14708,SL13497 | LABEXPID=SL14716,SL13726 | LABEXPID=SL14721,SL13751 | LABEXPID=SL14725,SL14051 | LABEXPID=SL1475,SL2129 | LABEXPID=SL1481,SL2125 | LABEXPID=SL1483,SL1659 | LABEXPID=SL150,SL16,SL412 | LABEXPID=SL1508,SL1269 | LABEXPID=SL1509,SL2128 | LABEXPID=SL1519,SL1968 | LABEXPID=SL16025,SL14063 | LABEXPID=SL16026,SL13722 | LABEXPID=SL16042,SL13495 | LABEXPID=SL16043,SL13476 | LABEXPID=SL16044,SL13723 | LABEXPID=SL1613 | LABEXPID=SL16302,SL13276 | LABEXPID=SL16310,SL14560 | LABEXPID=SL16313,SL14570 | LABEXPID=SL16318,SL13301 | LABEXPID=SL16321,SL12633 | LABEXPID=SL16322,SL12628 | LABEXPID=SL16334,SL13483 | LABEXPID=SL16335,SL13492 | LABEXPID=SL16340,SL14574 | LABEXPID=SL1654,SL2127 | LABEXPID=SL1655,SL1507 | LABEXPID=SL1657,SL1967 | LABEXPID=SL1660,SL1518 | LABEXPID=SL1662,SL2131 | LABEXPID=SL1664,SL2133 | LABEXPID=SL1668 | LABEXPID=SL16741,SL12408 | LABEXPID=SL16754,SL13506 | LABEXPID=SL16758,SL16757,SL13504,SL16756 | LABEXPID=SL16762 | LABEXPID=SL16874,SL12234 | LABEXPID=SL1714 | LABEXPID=SL1782 | LABEXPID=SL1783 | LABEXPID=SL1787,SL2386 | LABEXPID=SL1794,SL3925 | LABEXPID=SL1877,SL1493 | LABEXPID=SL1881 | LABEXPID=SL1882 | LABEXPID=SL1885,SL1482 | LABEXPID=SL1962,SL3773 | LABEXPID=SL1963,SL5611 | LABEXPID=SL202,SL204 | LABEXPID=SL203,SL205 | LABEXPID=SL2080,SL1880 | LABEXPID=SL2081,SL1878 | LABEXPID=SL2082,SL1050 | LABEXPID=SL209,SL207 | LABEXPID=SL2124,SL1786 | LABEXPID=SL217,SL218 | LABEXPID=SL2194,SL1788 | LABEXPID=SL2195,SL3927 | LABEXPID=SL2196,SL3175 | LABEXPID=SL2202,SL3186 | LABEXPID=SL2203,SL2944 | LABEXPID=SL2250,SL1883 | LABEXPID=SL2253,SL3352 | LABEXPID=SL2265,SL3183 | LABEXPID=SL2338,SL3777 | LABEXPID=SL2339 | LABEXPID=SL2343,SL5609 | LABEXPID=SL2344,SL5042 | LABEXPID=SL2354,SL5041 | LABEXPID=SL2388,SL2130 | LABEXPID=SL244,SL306 | LABEXPID=SL245,SL334 | LABEXPID=SL246,SL304 | LABEXPID=SL247,SL305 | LABEXPID=SL2548,SL3453 | LABEXPID=SL2634,SL3014 | LABEXPID=SL2636,SL3013 | LABEXPID=SL2687,SL3068 | LABEXPID=SL2690,SL3065 | LABEXPID=SL2692,SL4211 | LABEXPID=SL274,SL273 | LABEXPID=SL275,SL276 | LABEXPID=SL2905 | LABEXPID=SL2914,SL2906 | LABEXPID=SL2915,SL2907 | LABEXPID=SL2918,SL2910 | LABEXPID=SL2919,SL2911 | LABEXPID=SL292,SL291 | LABEXPID=SL2940,SL2939 | LABEXPID=SL2941,SL2942 | LABEXPID=SL2945,SL3070 | LABEXPID=SL2946,SL3071 | LABEXPID=SL2947,SL3072 | LABEXPID=SL295,SL294 | LABEXPID=SL2950,SL3360 | LABEXPID=SL2951,SL3361 | LABEXPID=SL2952,SL3359 | LABEXPID=SL2957,SL3254 | LABEXPID=SL3015,SL2633 | LABEXPID=SL3062,SL2697 | LABEXPID=SL3066,SL2689 | LABEXPID=SL3067,SL2688 | LABEXPID=SL307 | LABEXPID=SL3073,SL2948 | LABEXPID=SL3075,SL5605 | LABEXPID=SL3077,SL3253 | LABEXPID=SL3164,SL3497 | LABEXPID=SL3166,SL3163 | LABEXPID=SL3176,SL3582 | LABEXPID=SL3177,SL3583 | LABEXPID=SL3178,SL3463 | LABEXPID=SL3182,SL2262 | LABEXPID=SL3187,SL2349 | LABEXPID=SL3189,SL3972 | LABEXPID=SL3250,SL2666 | LABEXPID=SL3251,SL2665 | LABEXPID=SL3272,SL3162 | LABEXPID=SL3273,SL3496 | LABEXPID=SL3275,SL3156 | LABEXPID=SL335 | LABEXPID=SL3356,SL2943 | LABEXPID=SL3447,SL2630 | LABEXPID=SL3454,SL3935 | LABEXPID=SL3457 | LABEXPID=SL3460,SL1059 | LABEXPID=SL349,SL348 | LABEXPID=SL3568,SL3274 | LABEXPID=SL3578,SL3827 | LABEXPID=SL3579,SL3828 | LABEXPID=SL358,SL359 | LABEXPID=SL3584,SL2132 | LABEXPID=SL3586,SL3179 | LABEXPID=SL3639,SL3640 | LABEXPID=SL3644,SL3154 | LABEXPID=SL3645,SL3986 | LABEXPID=SL3772,SL6969 | LABEXPID=SL3774,SL2134,SL3775 | LABEXPID=SL3776,SL2340 | LABEXPID=SL3819,SL3820 | LABEXPID=SL3821,SL3822 | LABEXPID=SL3830,SL3456 | LABEXPID=SL3897,SL1667 | LABEXPID=SL3898 | LABEXPID=SL3926,SL3184 | LABEXPID=SL3929,SL3987 | LABEXPID=SL3931,SL3728 | LABEXPID=SL3933,SL3934 | LABEXPID=SL3970,SL3646 | LABEXPID=SL3976,SL1781 | LABEXPID=SL3978 | LABEXPID=SL3979 | LABEXPID=SL3980,SL2455 | LABEXPID=SL3989 | LABEXPID=SL3990,SL3924 | LABEXPID=SL411,SL149 | LABEXPID=SL4209,SL4939 | LABEXPID=SL4437,SL5495 | LABEXPID=SL448,SL483 | LABEXPID=SL4500,SL3971 | LABEXPID=SL4698,SL3900 | LABEXPID=SL474 | LABEXPID=SL475 | LABEXPID=SL482 | LABEXPID=SL4940,SL4210 | LABEXPID=SL518,SL519,SL1396,SL1397 | LABEXPID=SL523,SL117 | LABEXPID=SL5358,SL5700 | LABEXPID=SL5360,SL5701 | LABEXPID=SL5497,SL5496 | LABEXPID=SL5607,SL3768 | LABEXPID=SL5610,SL2353 | LABEXPID=SL564,SL551 | LABEXPID=SL5699,SL5357 | LABEXPID=SL5895,SL5043 | LABEXPID=SL5896,SL5494 | LABEXPID=SL5897,SL5040 | LABEXPID=SL590,SL706 | LABEXPID=SL592 | LABEXPID=SL6005,SL5690 | LABEXPID=SL6006,SL5688 | LABEXPID=SL6016,SL6592 | LABEXPID=SL6021 | LABEXPID=SL611,SL610 | LABEXPID=SL612,SL963,SL649 | LABEXPID=SL615,SL647 | LABEXPID=SL633,SL480 | LABEXPID=SL635,SL629 | LABEXPID=SL636,SL582 | LABEXPID=SL637,SL583 | LABEXPID=SL6436,SL7113 | LABEXPID=SL6437,SL7115 | LABEXPID=SL6462,SL5612 | LABEXPID=SL6464,SL3973 | LABEXPID=SL648,SL851,SL614 | LABEXPID=SL6595,SL6015 | LABEXPID=SL6596,SL7109 | LABEXPID=SL6600,SL7108 | LABEXPID=SL672,SL631 | LABEXPID=SL673,SL1019 | LABEXPID=SL678,SL1394,SL1395,SL516,SL517 | LABEXPID=SL679,SL1322 | LABEXPID=SL6966,SL1103 | LABEXPID=SL705,SL646 | LABEXPID=SL7105,SL7568 | LABEXPID=SL7110,SL8075 | LABEXPID=SL7273,SL6010 | LABEXPID=SL7275,SL8401 | LABEXPID=SL7277,SL8400 | LABEXPID=SL7279,SL6593 | LABEXPID=SL7280,SL7830 | LABEXPID=SL7281,SL7831 | LABEXPID=SL7333,SL852 | LABEXPID=SL735,SL675 | LABEXPID=SL736,SL945 | LABEXPID=SL748,SL847 | LABEXPID=SL749,SL920 | LABEXPID=SL7551,SL7834 | LABEXPID=SL7554,SL7102 | LABEXPID=SL7561,SL7282 | LABEXPID=SL7564,SL7101 | LABEXPID=SL7836,SL8135 | LABEXPID=SL7841,SL7571 | LABEXPID=SL7894,SL8137 | LABEXPID=SL7897,SL8127 | LABEXPID=SL7899,SL8129 | LABEXPID=SL7904,SL8136 | LABEXPID=SL802,SL918 | LABEXPID=SL8076,SL7114 | LABEXPID=SL8077,SL7116 | LABEXPID=SL8083,SL8392 | LABEXPID=SL8128,SL7898 | LABEXPID=SL8132,SL7901 | LABEXPID=SL814,SL923 | LABEXPID=SL817 | LABEXPID=SL818 | LABEXPID=SL819,SL1400,SL593,SL1401 | LABEXPID=SL83,SL409 | LABEXPID=SL842,SL986 | LABEXPID=SL845 | LABEXPID=SL846,SL746 | LABEXPID=SL848,SL677 | LABEXPID=SL8577,SL8143 | LABEXPID=SL879,SL878 | LABEXPID=SL88,SL413 | LABEXPID=SL880,SL881 | LABEXPID=SL882,SL883 | LABEXPID=SL884,SL885 | LABEXPID=SL908,SL921 | LABEXPID=SL909,SL944 | LABEXPID=SL910,SL922 | LABEXPID=SL9116,SL8673 | LABEXPID=SL946,SL911 | LABEXPID=SL951,SL838 | LABEXPID=SL9542,SL8084 | LABEXPID=SL9545,SL8584 | LABEXPID=SL9547,SL8085 | LABEXPID=SL964,SL853 | LABEXPID=SL969 | LABEXPID=SL976,SL650 | LABEXPID=SL977,SL948 | LABEXPID=SL978,SL1053 | LABEXPID=SL979,SL1051 | LABEXPID=SL980,SL1052 | LABEXPID=SL981,SL1055 | LABEXPID=SL9830,SL8672 | LABEXPID=SL985,SL839 | LABEXPID=SL988,SL745 | LABVERSION=(Pol2 8WG16) | LABVERSION=1,2 | LABVERSION=2,5 | LABVERSION=3,4 | LABVERSION=4 | LABVERSION=5,6 | LABVERSION=8,5 | LABVERSION=8,6 | LABVERSION=8,7 | LABVERSION=Genestein 100nM treatment | LABVERSION=not specified | LABVERSION=PCR2x | LABVERSION=SL1054,SL984 | LABVERSION=SL116 | LABVERSION=SL1207,SL1080 | LABVERSION=SL275 | LABVERSION=SL523,SL117 | LABVERSION=SL588 | LABVERSION=SL590,SL706 | LABVERSION=SL611,SL610 | LABVERSION=SL615,SL647 | LABVERSION=SL631 | LABVERSION=SL632 | LABVERSION=SL635,SL629 | LABVERSION=SL636,SL582 | LABVERSION=SL637 | LABVERSION=SL646 | LABVERSION=SL648,SL614 | LABVERSION=SL649 | LABVERSION=SL673 | LABVERSION=SL748,SL847 | LABVERSION=SL749,SL920 | LABVERSION=SL802,SL918 | LABVERSION=SL817 | LABVERSION=SL819,SL593 | LABVERSION=SL846 | LABVERSION=SL848 | LABVERSION=SL908,SL921 | LABVERSION=SL910,SL922 | LABVERSION=SL977,SL948 | LABVERSION=SL981,SL1055 | PROTOCOL=PCR1x | PROTOCOL=PCR2x | PROTOCOL=v041610.1 | PROTOCOL=v041610.2 | PROTOCOL=v042211.1 | PROTOCOL DESCRIPTION=1-cycle of PCR (Myers) | PROTOCOL DESCRIPTION=2x10^7 cells, fragmentation by bioruptor, one 15-cycle round of PCR (Myers) | PROTOCOL DESCRIPTION=2x10^7 cells, fragmentation by probe-in sonicator, one 15-cycle round of PCR (Myers) | PROTOCOL DESCRIPTION=a 25-cycle round of PCR and an additional 15-cycle round of PCR after gel size selection (Myers) | PROTOCOL DESCRIPTION=Faster ChIP protocol &amp; AMpure XP size selection for ChIP-seq (Myers) | PROTOCOL DESCRIPTION=one 15-cycle round of PCR (Myers) | REPLICATE=1 | REPLICATE=1,2 | REPLICATE=1,3,2 | REPLICATE=1,3,2,4 | REPLICATE=1,3,2,5,4 | REPLICATE=1,3,4 | REPLICATE=2 | REPLICATE=3 | REPLICATE DESCRIPTION=not specified | REPLICATE DESCRIPTION=tier 1 | REPLICATE DESCRIPTION=tier 2 | SOFTWAREVERSION=1 | SOFTWAREVERSION=MACS | SOFTWAREVERSION=not specified | TREATMENT=BPA_100nM | TREATMENT=DEX_100nM | TREATMENT=DEX_500pM | TREATMENT=DEX_50nM | TREATMENT=DEX_5nM | TREATMENT=DMSO_0.02pct | TREATMENT=Estradiol_10nM | TREATMENT=EtOH_0.02pct | TREATMENT=Genistein_100nM | TREATMENT=None | TREATMENT DESCRIPTION=1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers) | TREATMENT DESCRIPTION=1 h with 0.02% Ethanol (Myers) | TREATMENT DESCRIPTION=1 h with 10 nM Estradiol (Myers) | TREATMENT DESCRIPTION=1 h with 100 nM Bisphenol A (Myers) | TREATMENT DESCRIPTION=1 h with 100 nM Dexamethasone (Myers) | TREATMENT DESCRIPTION=1 h with 100 nM Genistein (Myers) | TREATMENT DESCRIPTION=1 h with 5 nM Dexamethasone (Myers) | TREATMENT DESCRIPTION=1 h with 50 nM Dexamethasone (Myers) | TREATMENT DESCRIPTION=1 h with 500 pM Dexamethasone (Myers) | TREATMENT DESCRIPTION=No special treatment or protocol applies","AGE AT DIAGNOSIS (MONTHS)=0 | AGE AT DIAGNOSIS (MONTHS)=10 | AGE AT DIAGNOSIS (MONTHS)=11 | AGE AT DIAGNOSIS (MONTHS)=12 | AGE AT DIAGNOSIS (MONTHS)=16 | AGE AT DIAGNOSIS (MONTHS)=17 | AGE AT DIAGNOSIS (MONTHS)=19 | AGE AT DIAGNOSIS (MONTHS)=20 | AGE AT DIAGNOSIS (MONTHS)=22 | AGE AT DIAGNOSIS (MONTHS)=24 | AGE AT DIAGNOSIS (MONTHS)=30 | AGE AT DIAGNOSIS (MONTHS)=33 | AGE AT DIAGNOSIS (MONTHS)=38 | AGE AT DIAGNOSIS (MONTHS)=46 | AGE AT DIAGNOSIS (MONTHS)=5 | AGE AT DIAGNOSIS (MONTHS)=6 | AGE AT DIAGNOSIS (MONTHS)=7 | CHROMOSOME 22 MONOSOMY=no | CHROMOSOME 22 MONOSOMY=ring chromosome 22 | CHROMOSOME 22 MONOSOMY=unknown | CHROMOSOME 22 MONOSOMY=yes | GENDER=F | GENDER=M | OVERALL SURVIVAL (MONTHS)=1 | OVERALL SURVIVAL (MONTHS)=10 | OVERALL SURVIVAL (MONTHS)=101 | OVERALL SURVIVAL (MONTHS)=12 | OVERALL SURVIVAL (MONTHS)=16 | OVERALL SURVIVAL (MONTHS)=2 | OVERALL SURVIVAL (MONTHS)=31 | OVERALL SURVIVAL (MONTHS)=36 | OVERALL SURVIVAL (MONTHS)=4 | OVERALL SURVIVAL (MONTHS)=42 | OVERALL SURVIVAL (MONTHS)=6 | OVERALL SURVIVAL (MONTHS)=7 | OVERALL SURVIVAL (MONTHS)=Unknown | STATUS=Alive with recurrence | STATUS=Alive, no evidence of disease | STATUS=died of complications | STATUS=died of disease | STATUS=Lost to follow-up | TUMOR LOCATION=frontal lobe | TUMOR LOCATION=parietal / occipital lobes | TUMOR LOCATION=posterior fossa | TUMOR LOCATION=temporal","AGE=4 years | AGE=7.3 years | AGE=not specified | AGE AT DIAGNOSIS (YEARS)=10.2 | AGE AT DIAGNOSIS (YEARS)=10.9 | AGE AT DIAGNOSIS (YEARS)=11.8 | AGE AT DIAGNOSIS (YEARS)=12.3 | AGE AT DIAGNOSIS (YEARS)=12.5 | AGE AT DIAGNOSIS (YEARS)=13.2 | AGE AT DIAGNOSIS (YEARS)=13.7 | AGE AT DIAGNOSIS (YEARS)=14.9 | AGE AT DIAGNOSIS (YEARS)=15.7 | AGE AT DIAGNOSIS (YEARS)=3.6 | AGE AT DIAGNOSIS (YEARS)=3.7 | AGE AT DIAGNOSIS (YEARS)=4.3 | AGE AT DIAGNOSIS (YEARS)=5.2 | AGE AT DIAGNOSIS (YEARS)=5.3 | AGE AT DIAGNOSIS (YEARS)=5.5 | AGE AT DIAGNOSIS (YEARS)=5.6 | AGE AT DIAGNOSIS (YEARS)=5.7 | AGE AT DIAGNOSIS (YEARS)=5.9 | AGE AT DIAGNOSIS (YEARS)=6 | AGE AT DIAGNOSIS (YEARS)=6.1 | AGE AT DIAGNOSIS (YEARS)=7.9 | AGE AT DIAGNOSIS (YEARS)=8.9 | AGE AT DIAGNOSIS (YEARS)=9 | AGE AT DIAGNOSIS (YEARS)=NA | AGE AT DIAGNOSIS (YEARS)=not specified | AGE AT DIAGONOSIS (YEARS)=10.2 | AGE AT DIAGONOSIS (YEARS)=10.9 | AGE AT DIAGONOSIS (YEARS)=11.4 | AGE AT DIAGONOSIS (YEARS)=11.8 | AGE AT DIAGONOSIS (YEARS)=12.3 | AGE AT DIAGONOSIS (YEARS)=12.5 | AGE AT DIAGONOSIS (YEARS)=13.2 | AGE AT DIAGONOSIS (YEARS)=13.7 | AGE AT DIAGONOSIS (YEARS)=14.9 | AGE AT DIAGONOSIS (YEARS)=15.7 | AGE AT DIAGONOSIS (YEARS)=2 | AGE AT DIAGONOSIS (YEARS)=2.1 | AGE AT DIAGONOSIS (YEARS)=3 | AGE AT DIAGONOSIS (YEARS)=3.1 | AGE AT DIAGONOSIS (YEARS)=3.5 | AGE AT DIAGONOSIS (YEARS)=3.6 | AGE AT DIAGONOSIS (YEARS)=3.7 | AGE AT DIAGONOSIS (YEARS)=3.9 | AGE AT DIAGONOSIS (YEARS)=4.3 | AGE AT DIAGONOSIS (YEARS)=4.8 | AGE AT DIAGONOSIS (YEARS)=5.2 | AGE AT DIAGONOSIS (YEARS)=5.3 | AGE AT DIAGONOSIS (YEARS)=5.5 | AGE AT DIAGONOSIS (YEARS)=5.6 | AGE AT DIAGONOSIS (YEARS)=5.7 | AGE AT DIAGONOSIS (YEARS)=5.9 | AGE AT DIAGONOSIS (YEARS)=6 | AGE AT DIAGONOSIS (YEARS)=6.1 | AGE AT DIAGONOSIS (YEARS)=6.4 | AGE AT DIAGONOSIS (YEARS)=6.6 | AGE AT DIAGONOSIS (YEARS)=6.9 | AGE AT DIAGONOSIS (YEARS)=7.3 | AGE AT DIAGONOSIS (YEARS)=7.9 | AGE AT DIAGONOSIS (YEARS)=8.4 | AGE AT DIAGONOSIS (YEARS)=8.9 | AGE AT DIAGONOSIS (YEARS)=9 | AGE AT DIAGONOSIS (YEARS)=9.8 | AGE AT DIAGONOSIS (YEARS)=NA | AGE AT DIAGONOSIS (YEARS)=not specified | DISEASE=brainstem LGG | DISEASE=DIPG | DISEASE=Glioblastoma | DISEASE=normal | DISEASE=not specified | HISTOLOGY=anaplastic astrocytoma | HISTOLOGY=Diffuse astrocytoma | HISTOLOGY=Glioblastoma | HISTOLOGY=Low-grade astrocytoma | HISTOLOGY=ND | HISTOLOGY=not specified | HISTOLOGY=Pilocytic Astrocytoma | HISTOLOGY=Pilocytic astrocytoma | ORGANISM PART=LGG-brainstem | ORGANISM PART=normal-brainstem | ORGANISM PART=not specified | SAMPLE COLLECTION=not specified | SAMPLE COLLECTION=Postmortem | SAMPLE COLLECTION=Postmortem matched with pretreatment sample BSG022TD | SAMPLE COLLECTION=Postmortem matched with pretreatment sample BSG024TD | SAMPLE COLLECTION=Postmortem sample matched to pretreatment sample BSG024TD | SAMPLE COLLECTION=Pretreatment | SAMPLE COLLECTION=Pretreatment collected postmortem | SURVIVAL (YEARS)=0.03 | SURVIVAL (YEARS)=0.1 | SURVIVAL (YEARS)=0.39 | SURVIVAL (YEARS)=0.45 | SURVIVAL (YEARS)=0.53 | SURVIVAL (YEARS)=0.6 | SURVIVAL (YEARS)=0.62 | SURVIVAL (YEARS)=0.63 | SURVIVAL (YEARS)=0.66 | SURVIVAL (YEARS)=0.68 | SURVIVAL (YEARS)=0.69 | SURVIVAL (YEARS)=0.70 | SURVIVAL (YEARS)=0.76 | SURVIVAL (YEARS)=0.80 | SURVIVAL (YEARS)=0.85 | SURVIVAL (YEARS)=0.86 | SURVIVAL (YEARS)=0.92 | SURVIVAL (YEARS)=0.93 | SURVIVAL (YEARS)=1.06 | SURVIVAL (YEARS)=1.09 | SURVIVAL (YEARS)=1.14 | SURVIVAL (YEARS)=1.16 | SURVIVAL (YEARS)=1.2 | SURVIVAL (YEARS)=1.21 | SURVIVAL (YEARS)=1.22 | SURVIVAL (YEARS)=1.26 | SURVIVAL (YEARS)=1.28 | SURVIVAL (YEARS)=1.30 | SURVIVAL (YEARS)=1.31 | SURVIVAL (YEARS)=1.37 | SURVIVAL (YEARS)=1.57 | SURVIVAL (YEARS)=1.81 | SURVIVAL (YEARS)=12 | SURVIVAL (YEARS)=14.4 | SURVIVAL (YEARS)=2.00 | SURVIVAL (YEARS)=2.1 | SURVIVAL (YEARS)=2.78 | SURVIVAL (YEARS)=3.00 | SURVIVAL (YEARS)=4.3 | SURVIVAL (YEARS)=4.8 | SURVIVAL (YEARS)=7.8 | SURVIVAL (YEARS)=8.3 | SURVIVAL (YEARS)=NA | SURVIVAL (YEARS)=not specified","COMPOUND=Ly2109761 | COMPOUND=Unspecified | TREATMENT=compound | TREATMENT=compound+RT | TREATMENT=control | TREATMENT=RT | TREATMENT=solvent control","CELL LINE=273T | CELL LINE=9812 | CELL LINE=A427 | CELL LINE=A549 | CELL LINE=ABC1 | CELL LINE=ALAB | CELL LINE=ASPC-1 | CELL LINE=BEN | CELL LINE=BT-20 | CELL LINE=BT-474 | CELL LINE=BT-483 | CELL LINE=BT-549 | CELL LINE=BxPC-3 | CELL LINE=CACO2 | CELL LINE=CAL-120 | CELL LINE=CAL-12T | CELL LINE=CAL-148 | CELL LINE=CAL-51 | CELL LINE=CALU-1 | CELL LINE=CALU-3 | CELL LINE=CAMA-1 | CELL LINE=CAOV-1 | CELL LINE=CAOV-3 | CELL LINE=CAOV-4 | CELL LINE=CAPAN-1 | CELL LINE=Capan2 | CELL LINE=CDD14BR | CELL LINE=CFPAC-1 | CELL LINE=CHAGO-K-1 | CELL LINE=COLO206F | CELL LINE=COLO316 | CELL LINE=COLO320DM | CELL LINE=COLO320HSR | CELL LINE=COLO587 | CELL LINE=COLO677 | CELL LINE=COLO678 | CELL LINE=COLO824 | CELL LINE=CORL23 | CELL LINE=CPC-N | CELL LINE=CRL-2315 | CELL LINE=CRL-2326 | CELL LINE=CRL-2335 | CELL LINE=CRL-2336 | CELL LINE=DMS114 | CELL LINE=DU145 | CELL LINE=DU4475 | CELL LINE=DV90 | CELL LINE=E3GS2.4 | CELL LINE=EFM-19 | CELL LINE=EPLC-272H | CELL LINE=ES-2 | CELL LINE=EVSA-T | CELL LINE=H1155 | CELL LINE=H125 | CELL LINE=H1399 | CELL LINE=H1437 | CELL LINE=H1563 | CELL LINE=H1568 | CELL LINE=H1650 | CELL LINE=H1688 | CELL LINE=H1792 | CELL LINE=H196 | CELL LINE=H211 | CELL LINE=H2170 | CELL LINE=H2347 | CELL LINE=H345 | CELL LINE=H417 | CELL LINE=H441 | CELL LINE=H460 | CELL LINE=H510A | CELL LINE=H520 | CELL LINE=H647 | CELL LINE=H661 | CELL LINE=H69 | CELL LINE=H727 | CELL LINE=H838 | CELL LINE=H889 | CELL LINE=HCC-366 | CELL LINE=HCC1008 | CELL LINE=HCC1143 | CELL LINE=HCC1187 | CELL LINE=HCC1395 | CELL LINE=HCC15 | CELL LINE=HCC1500 | CELL LINE=HCC1569 | CELL LINE=HCC1599 | CELL LINE=HCC1937 | CELL LINE=HCC1954 | CELL LINE=HCC202 | CELL LINE=HCC2157 | CELL LINE=HCC2218 | CELL LINE=HCC38 | CELL LINE=HCC78 | CELL LINE=HCC827 | CELL LINE=HCT-116 | CELL LINE=HCT-15 | CELL LINE=HGC-25 | CELL LINE=HLC-1 | CELL LINE=HPAC | CELL LINE=HPAFII | CELL LINE=HS578T | CELL LINE=Hs700T | CELL LINE=Hs766T | CELL LINE=JIMT1 | CELL LINE=KPL-1 | CELL LINE=LC1sq | CELL LINE=LCLC-103H | CELL LINE=LCLC-97TMI | CELL LINE=LIM2045 | CELL LINE=LK2 | CELL LINE=LNCAP | CELL LINE=LOVO | CELL LINE=LS103A | CELL LINE=LS123 | CELL LINE=LS174T | CELL LINE=LS180 | CELL LINE=LXF-289 | CELL LINE=MB157 | CELL LINE=MCF-7 | CELL LINE=MDA-MB-134-VI | CELL LINE=MDA-MB-157 | CELL LINE=MDA-MB-175-VII | CELL LINE=MDA-MB-330 | CELL LINE=MDA-MB-361 | CELL LINE=MDA-MB-415 | CELL LINE=MDA-MB-435 | CELL LINE=MDA-MB-436 | CELL LINE=MDA-MB-453 | CELL LINE=MDA-MB-468 | CELL LINE=MFM-223 | CELL LINE=MIA Paca-2 | CELL LINE=MPanc-96 | CELL LINE=MT-3 | CELL LINE=NCI-157 | CELL LINE=NCI-322 | CELL LINE=NCI-522 | CELL LINE=NCI-H1299 | CELL LINE=NCI-H1395 | CELL LINE=NCI-H146 | CELL LINE=NCI-H1623 | CELL LINE=NCI-H1693 | CELL LINE=NCI-H1703 | CELL LINE=NCI-H1793 | CELL LINE=NCI-H1838 | CELL LINE=NCI-H187 | CELL LINE=NCI-H2023 | CELL LINE=NCI-H2030 | CELL LINE=NCI-H2085 | CELL LINE=NCI-H209 | CELL LINE=NCI-H2122 | CELL LINE=NCI-H2126 | CELL LINE=NCI-H292 | CELL LINE=NCI-H358 | CELL LINE=NCI-H446 | CELL LINE=NCI-H526 | CELL LINE=NCI-H596 | CELL LINE=NCI-H82 | CELL LINE=NCI-H820 | CELL LINE=NHBE | CELL LINE=not specified | CELL LINE=OV-90 | CELL LINE=OVCAR3 | CELL LINE=OVCAR4 | CELL LINE=OVCAR5 | CELL LINE=OVCAR8 | CELL LINE=PA-1 | CELL LINE=PANC-1 | CELL LINE=Panc03.27 | CELL LINE=Panc08.13 | CELL LINE=Panc10.05 | CELL LINE=PC3 | CELL LINE=PC9 | CELL LINE=R | CELL LINE=RERFLCKJ | CELL LINE=SCLC-21H | CELL LINE=SCLC-22H | CELL LINE=SK-BR-3 | CELL LINE=SK-LC-17 | CELL LINE=SK-LC-3 | CELL LINE=SK-MEL-022 | CELL LINE=SK-MEL-085 | CELL LINE=SK-MEL-100 | CELL LINE=SK-MEL-105 | CELL LINE=SK-MEL-11 | CELL LINE=SK-MEL-113 | CELL LINE=SK-MEL-118 | CELL LINE=SK-MEL-12 | CELL LINE=SK-MEL-130 | CELL LINE=SK-MEL-178 | CELL LINE=SK-MEL-187 | CELL LINE=SK-MEL-196 | CELL LINE=SK-MEL-199A | CELL LINE=SK-MEL-199S | CELL LINE=SK-MEL-200 | CELL LINE=SK-MEL-208 | CELL LINE=SK-MEL-217 | CELL LINE=SK-MEL-23 | CELL LINE=SK-MEL-238 | CELL LINE=SK-MEL-239 | CELL LINE=SK-MEL-27 | CELL LINE=SK-MEL109 | CELL LINE=SK-MES-1 | CELL LINE=SK-OV-3 | CELL LINE=SKLC-13 | CELL LINE=SKLU-1 | CELL LINE=SKMEL-1 | CELL LINE=SKMEL-103 | CELL LINE=SKMEL-173 | CELL LINE=SKMEL-19 | CELL LINE=SKMEL-24 | CELL LINE=SKMEL-28 | CELL LINE=SKMEL-29 | CELL LINE=SKMEL-30 | CELL LINE=STC1 | CELL LINE=SU.86.86 | CELL LINE=SW1116 | CELL LINE=SW1990 | CELL LINE=SW480 | CELL LINE=SW620 | CELL LINE=SW626 | CELL LINE=SW900 | CELL LINE=SW948 | CELL LINE=T47D | CELL LINE=TOV-112D | CELL LINE=TOV-21G | CELL LINE=UACC-812 | CELL LINE=UACC-893 | CELL LINE=UMC-11 | CELL LINE=V10M | CELL LINE=V394 | CELL LINE=V400 | CELL LINE=V410 | CELL LINE=V429 | CELL LINE=V456 | CELL LINE=V503 | CELL LINE=V531 | CELL LINE=V576 | CELL LINE=V9M | CELL LINE=VMRCLCD | CELL LINE=WI38VA13 | CELL LINE=WIDR | CELL LINE=ZR-75-1 | CELL LINE=ZR-75-30 | CELL TYPE=breast cancer cell line | CELL TYPE=Colon Cancer Cell Line | CELL TYPE=Glioblastoma Cell line | CELL TYPE=lung cancer cell line | CELL TYPE=Melanoma Cell line | CELL TYPE=not specified | CELL TYPE=ovarian cancer cell lines | CELL TYPE=Pancreas Cancer Cell Line | CELL TYPE=Primary Colon Cancer | CELL TYPE=Primary Glioblastoma | CELL TYPE=Primary Lung Cancer | CELL TYPE=Primary Melanoma | CELL TYPE=Primary Pancreas Cancer | CELL TYPE=Primary Prostate Cancer | CELL TYPE=Primay Ovarian Cancer | CELL TYPE=Prostate Cancer Cell Line","TREATMENT=DNA minor groove binding ligand | TREATMENT=DNA minor groove binding ligand and radiation | TREATMENT=none | TREATMENT=radiation","CASEID=IOIS1277 | CASEID=IOIS1504 | CASEID=IOIS3527 | CASEID=IOIS3581 | CASEID=IOIS3612 | CASEID=IOIS3990 | CASEID=IOIS4082 | CASEID=IOIS4104 | CASEID=IOIS4134 | CASEID=IOIS4208 | CASEID=IOIS4260 | CASEID=IOIS4284 | CASEID=IOIS4323 | CASEID=IOIS4372 | CASEID=IOIS4373 | CASEID=IOIS4414 | CASEID=IOIS4550 | CASEID=IOIS4598 | CASEID=IOIS4622 | CASEID=IOIS4714 | CASEID=IOIS4990 | CASEID=not specified | IDH1 STATUS=IDH1 mutant | IDH1 STATUS=IDH1 WT | IDH1 STATUS=not specified | PRBID=29114 | PRBID=29120 | PRBID=29122 | PRBID=29126 | PRBID=29127 | PRBID=29128 | PRBID=29130 | PRBID=29131 | PRBID=29139 | PRBID=29143 | PRBID=29149 | PRBID=29151 | PRBID=29152 | PRBID=29153 | PRBID=29158 | PRBID=29164 | PRBID=29171 | PRBID=29172 | PRBID=29173 | PRBID=29174 | PRBID=29647 | PRBID=not specified | SAMPLEID=not specified | SAMPLEID=SAM602533 | SAMPLEID=SAM602539 | SAMPLEID=SAM602541 | SAMPLEID=SAM602545 | SAMPLEID=SAM602546 | SAMPLEID=SAM602547 | SAMPLEID=SAM602588 | SAMPLEID=SAM602589 | SAMPLEID=SAM602725 | SAMPLEID=SAM602729 | SAMPLEID=SAM602735 | SAMPLEID=SAM602737 | SAMPLEID=SAM602738 | SAMPLEID=SAM602739 | SAMPLEID=SAM602744 | SAMPLEID=SAM602750 | SAMPLEID=SAM602757 | SAMPLEID=SAM602758 | SAMPLEID=SAM602759 | SAMPLEID=SAM602769 | SAMPLEID=SAM603295","GENOME/VARIATION=with DACH1 expression | GENOME/VARIATION=without DACH1 expression","AGE=32 yr | AGE=50 yr | AGE=63 yr | DISEASE STATE=ganglioglioma | DISEASE STATE=glioblastoma | DISEASE STATE=shwannoma | GENDER=female | GENDER=male | TISSUE=brain tumor | TISSUE=normal brain","GENDER=female | GENDER=male | TUMOR TYPE=Anaplastic neuroepithelial | TUMOR TYPE=anaplastic oligoastrocytoma | TUMOR TYPE=Cribriform nevroepithelial | TUMOR TYPE=Glioblastoma | TUMOR TYPE=medulloblastoma | TUMOR TYPE=neuroepithelial tumour | TUMOR TYPE=not specified | TUMOR TYPE=Pilocytic astrocytoma | TUMOR TYPE=Primitive Neuroectodermal Tumors of the Central Nervous System","CELL LINE=A-172 | CELL LINE=LN-405 | CELL TYPE=glioblastoma | CELL TYPE=glioblastoma-astrocytoma | GENDER=female | GENDER=male | PLASMID=none | PLASMID=not specified | PLASMID=pEYFP-C1 mock (BD Biosciences Clontech) | PLASMID=pEYFP-C1+HES6wt (Eun et al. 2008) | SIRNA=HES6 siRNA pool | SIRNA=Hs_HES6_1 siRNA | SIRNA=Hs_HES6_2 siRNA | SIRNA=Hs_HES6_3 siRNA | SIRNA=Negative Control siRNA | SIRNA=negative control siRNA | SIRNA=none | TRANSFECTION TIME=12 hrs | TRANSFECTION TIME=24 hrs | TRANSFECTION TIME=not specified","INTEGRATIVE ANALYSIS=DNA methylation data available | INTEGRATIVE ANALYSIS=gene expression data available | INTEGRATIVE ANALYSIS=not specified","CELL_LINE=DU145 | CELL_LINE=PC3 | CELL_LINE=U373 | CELL_LINE=U87 | CELL_TYPE=glioblastoma | CELL_TYPE=prostate carcinoma | DOSE=0 J / cm² | DOSE=0.5 J / cm² | DOSE=1 J / cm² | DOSE=1.5 J / cm² | DOSE=2 J / cm² | PHOTOSENSITIZER=5-ALA | PHOTOSENSITIZER=Photofrin | TIME=24 h | TIME=4 h","DISEASESTATE=Malignant glioma | DISEASESTATE=normal | GROWTHCONDITION=DMEM+10%FBS | GROWTHCONDITION=NBE | GROWTHCONDITION=Unspecified | INDIVIDUAL=1228 glioma-initiating cells expressing control-shRNA | INDIVIDUAL=1228 glioma-initiating cells expressing EZH2-shRNA | INDIVIDUAL=Commercial RNA mixture | INDIVIDUAL=glioma-initiating cells from the glioma patient #0316 | INDIVIDUAL=glioma-initiating cells from the glioma patient #1228 | INDIVIDUAL=neural stem cell line | INDIVIDUAL=Parental bulk tumor tissue from the glioma patient #0316 | INDIVIDUAL=Parental bulk tumor tissue from the glioma patient #1228 | INDIVIDUAL=Serum-induced brain tumor cells #0316 treated with DZNep | INDIVIDUAL=Serum-induced brain tumor cells #1228 treated with DZNep | INDIVIDUAL=Serum-induced brain tumor cells from the glioma patient #0316 | INDIVIDUAL=Serum-induced brain tumor cells from the glioma patient #1228 | TREATMENT=EXML-1 | TREATMENT=EXML-2 | TREATMENT=EXML-3 | TREATMENT=EXML-4","CELL=A549 | CELL=AG04449 | CELL=AG04450 | CELL=AG09309 | CELL=AG09319 | CELL=AG10803 | CELL=AoAF | CELL=BE2_C | CELL=BJ | CELL=bone_marrow_HS27a | CELL=bone_marrow_HS5 | CELL=bone_marrow_MSC | CELL=Caco-2 | CELL=CD20+_RO01778 | CELL=CD34+_Mobilized | CELL=CD4+_Naive_Wb11970640 | CELL=CD4+_Naive_Wb78495824 | CELL=CMK | CELL=GM04503 | CELL=GM04504 | CELL=GM06990 | CELL=GM12864 | CELL=GM12865 | CELL=GM12878 | CELL=H1-hESC | CELL=H7-hESC | CELL=HA-h | CELL=HA-sp | CELL=HAc | CELL=HAEpiC | CELL=HBMEC | CELL=HBVP | CELL=HBVSMC | CELL=HCF | CELL=HCFaa | CELL=HCM | CELL=HConF | CELL=HCPEpiC | CELL=HCT-116 | CELL=HEEpiC | CELL=HeLa-S3 | CELL=HepG2 | CELL=HFF | CELL=HFF-Myc | CELL=HGF | CELL=HIPEpiC | CELL=HL-60 | CELL=HMEC | CELL=HMF | CELL=HMVEC-dAd | CELL=HMVEC-dBl-Ad | CELL=HMVEC-dBl-Neo | CELL=HMVEC-dLy-Ad | CELL=HMVEC-dLy-Neo | CELL=HMVEC-dNeo | CELL=HMVEC-LBl | CELL=HMVEC-LLy | CELL=HNPCEpiC | CELL=HPAEC | CELL=HPAF | CELL=HPdLF | CELL=HPF | CELL=HRCEpiC | CELL=HRE | CELL=HRGEC | CELL=HRPEpiC | CELL=HSMM | CELL=HSMMtube | CELL=HUVEC | CELL=HVMF | CELL=Jurkat | CELL=K562 | CELL=LHCN-M2 | CELL=LNCAP | CELL=M059J | CELL=MCF-7 | CELL=Monocytes-CD14+ | CELL=Monocytes-CD14+_RO01746 | CELL=NB4 | CELL=NH-A | CELL=NHBE_RA | CELL=NHDF-Ad | CELL=NHDF-neo | CELL=NHEK | CELL=NHLF | CELL=NT2-D1 | CELL=PANC-1 | CELL=PrEC | CELL=RPMI-7951 | CELL=RPTEC | CELL=SAEC | CELL=SK-N-MC | CELL=SK-N-SH_RA | CELL=SKMC | CELL=T-47D | CELL=Th1 | CELL=Th17 | CELL=Th1_Wb33676984 | CELL=Th1_Wb54553204 | CELL=Th2 | CELL=Th2_Wb33676984 | CELL=Th2_Wb54553204 | CELL=Treg_Wb78495824 | CELL=Treg_Wb83319432 | CELL=WERI-Rb-1 | CELL=WI-38 | CELL DESCRIPTION=acute promyelocytic leukemia cell line. (PMID: 1995093) | CELL DESCRIPTION=adult dermal microvascular endothelial cells. | CELL DESCRIPTION=Adult human abdominal skin fibroblasts | CELL DESCRIPTION=Adult human gum tissue fibroblasts | CELL DESCRIPTION=Adult human toe fibroblast | CELL DESCRIPTION=Adult Normal Human Dermal Fibroblasts | CELL DESCRIPTION=adult twin pair fibroblasts, monozygotic twin of GM04503, 13% of the cells examined show random chromosome loss | CELL DESCRIPTION=adult twin pair fibroblasts, monozygotic twin of GM04504 | CELL DESCRIPTION=B cells, caucasian, draw number 1, newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=B-Lymphocyte, Lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1459, Treatment: Epstein-Barr Virus transformed | CELL DESCRIPTION=brain vascular pericytes | CELL DESCRIPTION=brain vascular smooth muscle cells. | CELL DESCRIPTION=bronchial epithelial cells with retinoic acid | CELL DESCRIPTION=CD4+ naive sorted cells, donor is Caucasian, male 26 year old, primary pheresis of single normal subject | CELL DESCRIPTION=CD4+ naive sorted cells, donor is Causasian, female 35 year old, primary pheresis of single normal subject | CELL DESCRIPTION=cervical carcinoma | CELL DESCRIPTION=colorectal adenocarcinoma. (PMID: 1939345) | CELL DESCRIPTION=colorectal carcinoma (PMID: 7214343) | CELL DESCRIPTION=Embryonic Lung Fibroblast Cells, hTERT immortalized, includes Raf1 construct | CELL DESCRIPTION=epithelial cell line &amp;quot;This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male.&amp;quot; - ATCC, derived from a lung carcinoma tissue. (PMID: 175022) | CELL DESCRIPTION=epithelial cell line derived from a mammary ductal carcinoma. | CELL DESCRIPTION=Fetal buttock/thigh fibroblast | CELL DESCRIPTION=Fetal lung fibroblast | CELL DESCRIPTION=hematopoietic progenitor cells- mobilized, from donor RO01679. | CELL DESCRIPTION=HS27a Human Marrow Stromal Cells are fibroblastoid cells immortalized with HPV16 E6/E7 genes as described in Roecklein and Torok-Storb, 1995 Blood 85:997-1005, insert DNA is LXSN-16 E6E7 packaged in PA31. | CELL DESCRIPTION=HS5 Human Marrow Stromal Cells are fibroblastoid cells immortalized with HPV16 E6/E7 genes as described in Roecklein and Torok-Storb, 1995 Blood 85:997-1005, insert DNA is LXSN-16 E6E7 packaged in PA31. | CELL DESCRIPTION=human acute megakaryocytic leukemia cells, &amp;quot;established from the peripheral blood of a 10-month-old boy with Down's syndrome and acute megakaryocytic leukemia (AML M7) at relapse in 1985&amp;quot; - DSMZ. (PMID: 3016165) | CELL DESCRIPTION=Human Amniotic Epithelial Cells | CELL DESCRIPTION=Human astrocytes spinal cord | CELL DESCRIPTION=Human Astrocytes-cerebellar | CELL DESCRIPTION=Human Astrocytes-hippocampal | CELL DESCRIPTION=Human Brain Microvascular Endothelial Cells | CELL DESCRIPTION=Human Cardiac Fibroblasts | CELL DESCRIPTION=Human Cardiac Fibroblasts-Adult Atrial | CELL DESCRIPTION=Human Cardiac Myocytes | CELL DESCRIPTION=Human Choroid Plexus Epithelial Cells | CELL DESCRIPTION=Human Conjunctival Fibroblast | CELL DESCRIPTION=Human Embryonic Stem Cells | CELL DESCRIPTION=Human Esophageal Epithelial Cells | CELL DESCRIPTION=Human Foreskin Fibroblast | CELL DESCRIPTION=Human Foreskin Fibroblast Cells Expressing Canine cMyc | CELL DESCRIPTION=Human Gingival Fibroblasts | CELL DESCRIPTION=Human Iris Pigment Epithelial Cells | CELL DESCRIPTION=human mammary epithelial cell | CELL DESCRIPTION=human mammary fibroblasts | CELL DESCRIPTION=Human neuroblastoma | CELL DESCRIPTION=Human Non-Pigment Ciliary Epithelial Cells | CELL DESCRIPTION=Human promyelocytic leukemia cells. (PMID: 276884) | CELL DESCRIPTION=Human Pulmonary Artery Fibroblasts | CELL DESCRIPTION=Human Pulmonary Fibroblasts isolated from lung tissue | CELL DESCRIPTION=Human Renal Cortical Epithelial cells (normal) | CELL DESCRIPTION=Human Renal Epithelial cells (normal) | CELL DESCRIPTION=Human Renal Glomerular Endothelial Cells | CELL DESCRIPTION=Human Retinal Pigment Epithelial Cells | CELL DESCRIPTION=Human Skeletal Muscle Cells | CELL DESCRIPTION=Human Skin Malignant Melanoma Cells, This is a hyperdiploid human cell line with the modal chromosome number of 49, occurring in 24% of cells. Polyploid cells occurred at 22%, which is high. | CELL DESCRIPTION=human umbilical vein endothelial cell | CELL DESCRIPTION=Human Villous Mesenchymal Fibroblast Cells | CELL DESCRIPTION=leukemia | CELL DESCRIPTION=liver carcinoma | CELL DESCRIPTION=lymphoblastoid | CELL DESCRIPTION=Lymphoblastoid, International HapMap Project, CEPH/Utah, Treatment: Epstein-Barr Virus transformed | CELL DESCRIPTION=malignant glioblastoma, glioma, lack DNA-dependent protein kinase activity, deficient in repair of DNA double strand breaks, the cells are negative for glial fibrillary acidic protein (GFAP), tumor specimen taken from a 33 year old | CELL DESCRIPTION=malignant pluripotent embryonal carcinoma (NTera-2), &amp;quot;The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.&amp;quot; - ATCC. (PMID: 6694356) | CELL DESCRIPTION=mammary gland, adenocarcinoma. (PMID: 4357757) | CELL DESCRIPTION=mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=Monocytes-CD14+ are CD14-positive cells from human leukapheresis product | CELL DESCRIPTION=Neonatal Human Dermal Fibroblasts | CELL DESCRIPTION=neuroblastoma cell line, treatment: differentiated with retinoic acid. (Biedler, et al. Morphology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture. Cancer Research 33, 2643-2652, November 1973.) | CELL DESCRIPTION=Normal Adult Human Blood Microvascular Endothelial Cells, Dermal-Derived | CELL DESCRIPTION=Normal Human Aortic Adventitial Fibroblast Cells | CELL DESCRIPTION=Normal Human Astrocytes | CELL DESCRIPTION=Normal Human Blood Microvascular Endothelial Cells, Lung-Derived | CELL DESCRIPTION=normal human epidermal keratinocyte | CELL DESCRIPTION=Normal Human Lung Fibroblasts | CELL DESCRIPTION=Normal Human Lymphatic Microvascular Endothelial Cells, Lung-Derived | CELL DESCRIPTION=Normal Human Periodontal Ligament Fibroblasts | CELL DESCRIPTION=Normal Human Skeletal Muscle Myoblasts | CELL DESCRIPTION=Normal Human Skeletal Muscle Myotubes | CELL DESCRIPTION=Normal Neonatal Human Blood Microvascular Endothelial Cells, Dermal-Derived | CELL DESCRIPTION=Normal Neonatal Human Lymphatic Microvascular Endothelial Cells, Dermal-Derived | CELL DESCRIPTION=Normal Neonatal Human Microvascular Endothelial Cells (single Donnor), Dermal-Derived | CELL DESCRIPTION=not specified | CELL DESCRIPTION=pancreatic carcinoma. (PMID: 1140870) | CELL DESCRIPTION=primary human Th1 T cells | CELL DESCRIPTION=Primary human Th2 T cells | CELL DESCRIPTION=primary Th1 T cells | CELL DESCRIPTION=primary Th2 T cells | CELL DESCRIPTION=prostate epithelial cell line | CELL DESCRIPTION=pulmonary artery endothelial cells. | CELL DESCRIPTION=Renal Proximal Tubule Epithelial Cells | CELL DESCRIPTION=retinoblastoma (PMID: 844036) | CELL DESCRIPTION=skeletal muscle myotubes differentiated from the HSMM cell line | CELL DESCRIPTION=Skin fibroblast &amp;quot;The line was established from skin taken from normal foreskin.&amp;quot; - ATCC.  (PMID: 9916803) | CELL DESCRIPTION=Small Airway Epithelial Cells | CELL DESCRIPTION=T helper cells expressing IL-17, primary pheresis of single normal subject | CELL DESCRIPTION=T lymphoblastoid derived from an acute T cell leukemia, &amp;quot;The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al., and was originally designated JM.&amp;quot; - ATCC. (PMID: 68013) | CELL DESCRIPTION=T regulatory cells in vivo isolation | CELL DESCRIPTION=T regulatory cells in vivo isolation, donor is Caucasian, male 28 year old, primary pheresis of single normal subject | CELL DESCRIPTION=Th1 cells in vivo isolation | CELL DESCRIPTION=Th1 cells in vivo isolation, donor is Caucasian, male 33 year old, primary pheresis of single normal subject | CELL DESCRIPTION=Th2 cells in vivo isolation, donor is Asian, female 26 year old, primary pheresis of single normal subject | CELL DESCRIPTION=Th2 cells in vivo isolation, donor is Caucasian, male 33 year old, primary pheresis of single normal subject | CELL DESCRIPTION=These cells are primary fibroblastoid cells obtained from human bone marrow of normal donors as described in Roecklein and Torok-Storb, 1995 Blood 85:997-1005. | CELL DESCRIPTION=undifferentiated embryonic stem cells | CELL DESCRIPTION=Undifferentiated human embryonic stem cells | CELL KARYOTYPE=cancer | CELL KARYOTYPE=normal | CELL KARYOTYPE=Normal (cMyc) | CELL KARYOTYPE=Normal (RAF) | CELL KARYOTYPE=normal donor is Asian, female 26 year old, primary pheresis of single normal subject | CELL KARYOTYPE=normal donor is Causasian, female 35 year old, primary pheresis of single normal subject | CELL KARYOTYPE=not specified | CELL KARYOTYPE=relatively normal | CELL KARYOTYPE=unknown | CELL LINEAGE=&amp;quot;The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.&amp;quot; - ATCC | CELL LINEAGE=Astrocytic | CELL LINEAGE=ectoderm | CELL LINEAGE=embryonic stem cell | CELL LINEAGE=endoderm | CELL LINEAGE=Endothelial | CELL LINEAGE=epithelial | CELL LINEAGE=fibroblast | CELL LINEAGE=inner cell mass | CELL LINEAGE=International HapMap Project - CEPH/Utah - European Caucasion; Epstein-Barr Virus | CELL LINEAGE=mesoderm | CELL LINEAGE=Monocytic | CELL LINEAGE=not specified | CELL SEX=B | CELL SEX=female | CELL SEX=male | CELL SEX=U | LABEXPID=DS11039 | LABEXPID=DS11814 | LABEXPID=DS11953 | LABEXPID=DS11959 | LABEXPID=DS11969 | LABEXPID=DS12088 | LABEXPID=DS12098 | LABEXPID=DS12147 | LABEXPID=DS12916 | LABEXPID=DS12952 | LABEXPID=DS12957 | LABEXPID=DS14108 | LABEXPID=DS14564 | LABEXPID=DS14575 | LABEXPID=DS14702 | LABEXPID=DS14732 | LABEXPID=DS14834 | LABEXPID=DS14845 | LABEXPID=DS14860 | LABEXPID=DS15241 | LABEXPID=DS15538 | LABEXPID=DS15665 | LABEXPID=DS15809 | LABEXPID=DS16597 | LABEXPID=DS16602 | LABEXPID=DS16814 | LABEXPID=DS17541 | LABEXPID=DS17589 | LABEXPID=DS17592 | LABEXPID=DS17593 | LABEXPID=DS17597 | LABEXPID=DS17603 | LABEXPID=DS18015 | LABEXPID=DS18018 | LABEXPID=DS18021 | LABEXPID=DS18025 | LABEXPID=DS18057 | LABEXPID=DS18065 | LABEXPID=DS18208 | LABEXPID=DS18267 | LABEXPID=DS18271 | LABEXPID=DS18637 | LABEXPID=DS18640 | LABEXPID=DS18973 | LABEXPID=DS18975 | LABEXPID=DS19790 | LABEXPID=DS19794 | LABEXPID=DS20485 | LABEXPID=DS20493 | LABEXPID=DS20497 | LABEXPID=DS20514 | LABEXPID=DS20518 | LABEXPID=DS20534 | LABEXPID=DS20548 | LABEXPID=DS20647 | LABEXPID=DS20904 | LABEXPID=DS20909 | LABEXPID=not specified | REPLICATE=1 | REPLICATE=2 | TREATMENT=DIFF_4d | TREATMENT=diffProtA_14d | TREATMENT=diffProtA_2d | TREATMENT=diffProtA_5d | TREATMENT=diffProtA_9d | TREATMENT=Estradiol_100nM_1hr | TREATMENT=Estradiol_ctrl_0hr | TREATMENT=None | TREATMENT=not specified | TREATMENT DESCRIPTION=1 h with 100 nM Estradiol, hormone treatment (Stam) | TREATMENT DESCRIPTION=Myocytes differentiated from myoblasts for 4 days. See specific cell protocol for treatment details. (Stam) | TREATMENT DESCRIPTION=No hormone control, zero timepoint, used to distinguish untreated sample in series (Stam) | TREATMENT DESCRIPTION=No special treatment or protocol applies | TREATMENT DESCRIPTION=not specified","CELL FRACTION=global cellular fraction | CELL FRACTION=RISC-immunoprecipitated | CELL LINE=human U-87 MG astrocytoma/glioblastoma cell line (ATCC, cat# HTB-14) | CELL LINE=primary human cerebral cortex astrocyte cell line (ScienCell Research Laboratories, cat#1800) | PASSAGE NUMBER=between 18 - 22 | PASSAGE NUMBER=between 4 - 6","KNOCKDOWN=control | KNOCKDOWN=HOXD9","CELL LINE=a172 | CELL LINE=fgg | CELL LINE=t98g | CELL LINE=u118 | CELL LINE=u87 | PHENOTYPE=Less aggressive tumor | PHENOTYPE=More aggressive tumor | PHENOTYPE=Normal Glial Cells","CELL LINE=10627 | CELL LINE=20913 | TREATMENT GROUP=control | TREATMENT GROUP=retinoic acid for 48h | TREATMENT GROUP=retinoic acid for 8h","GENOTYPE=not specified | GENOTYPE=Pten, p53 knockout | GENOTYPE=Pten, p53, Rb1 knockout | ORGANISM=Homo sapiens | ORGANISM=Mus musculus | ORGANISM PART=anterior cortex tumor | ORGANISM PART=basal ganglia tumor | ORGANISM PART=basal ganglia/midbrain tumor | ORGANISM PART=brain left hemisphere tumor | ORGANISM PART=brain right hemisphere tumor | ORGANISM PART=brain tumor | ORGANISM PART=cerebellum tumor | ORGANISM PART=corpus callosum tumor | ORGANISM PART=cortex tumor | ORGANISM PART=cranial nerve tumor | ORGANISM PART=diffuse tumor | ORGANISM PART=front lobe tumor | ORGANISM PART=frontal lobe tumor | ORGANISM PART=hypothalamus tumor | ORGANISM PART=left CN V tumor | ORGANISM PART=left cortex tumor | ORGANISM PART=left cranial nerve tumor | ORGANISM PART=left midbrain tumor | ORGANISM PART=left ventricle tumor | ORGANISM PART=LGG-brainstem | ORGANISM PART=normal | ORGANISM PART=normal-brainstem | ORGANISM PART=not specified | ORGANISM PART=Olf Bulb tumor | ORGANISM PART=olfactory bulb tumor | ORGANISM PART=right CN V tumor | ORGANISM PART=right cortex tumor | ORGANISM PART=right cranial nerve tumor | ORGANISM PART=right ventricle tumor | ORGANISM PART=spinal cord tumor | ORGANISM PART=ventricle tumor | SEX=female | SEX=male | SEX=not specified","AGE=13 | AGE=31 | AGE=33 | AGE=35 | AGE=37 | AGE=39 | AGE=40 | AGE=41 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=50 | AGE=52 | AGE=63 | AGE=64 | AGE=68 | AGE=69 | AGE=70 | AGE=not specified | CELL LINE=BS149 | CELL LINE=LN018 | CELL LINE=LN215 | CELL LINE=LN229 | CELL LINE=LN319 | CELL LINE=not specified | CELL TYPE=astrocytes | CELL TYPE=astrocytoma | CELL TYPE=glioblastoma | CELL TYPE=not specified | CELL TYPE=oligodendrioglioma | GENDER=female | GENDER=male | GENDER=not specified | TISSUE=brain | TISSUE=not specified | TISSUE=primary brain tumor | TISSUE=secondary brain tumor | TUMOR GRADE=AII | TUMOR GRADE=AIII | TUMOR GRADE=AIII/IV | TUMOR GRADE=IV | TUMOR GRADE=not specified | TUMOR GRADE=OA | TUMOR GRADE=OGII | TUMOR GRADE=OGIII","GENOTYPE/VARIATION=control | GENOTYPE/VARIATION=shTR1-mediated TRRAP knockdown | GENOTYPE/VARIATION=shTR2-mediated TRRAP knockdown","CELL=A549 | CELL=AG04449 | CELL=AG04450 | CELL=AG09309 | CELL=AG09319 | CELL=AG10803 | CELL=AoSMC | CELL=Astrocy | CELL=BC_Adrenal_Gland_H12803N | CELL=BC_Brain_H11058N | CELL=BC_Breast_02-03015 | CELL=BC_Kidney_01-11002 | CELL=BC_Left_Ventricle_N41 | CELL=BC_Leukocyte_UHN00204 | CELL=BC_Liver_01-11002 | CELL=BC_Lung_01-11002 | CELL=BC_Pancreas_H12817N | CELL=BC_Pericardium_H12529N | CELL=BC_Placenta_UHN00189 | CELL=BC_Skeletal_Muscle_01-11002 | CELL=BC_Skeletal_Muscle_H12817N | CELL=BC_Skin_01-11002 | CELL=BC_Stomach_01-11002 | CELL=BC_Testis_N30 | CELL=BC_Uterus_BN0765 | CELL=BE2_C | CELL=BJ | CELL=Caco-2 | CELL=CMK | CELL=ECC-1 | CELL=Fibrobl | CELL=GM06990 | CELL=GM12878 | CELL=GM12878-XiMat | CELL=GM12891 | CELL=GM12892 | CELL=GM19239 | CELL=GM19240 | CELL=H1-hESC | CELL=HAEpiC | CELL=HCF | CELL=HCM | CELL=HCPEpiC | CELL=HCT-116 | CELL=HEEpiC | CELL=HEK293 | CELL=HeLa-S3 | CELL=Hepatocytes | CELL=HepG2 | CELL=HIPEpiC | CELL=HL-60 | CELL=HMEC | CELL=HNPCEpiC | CELL=HPAEpiC | CELL=HRCEpiC | CELL=HRE | CELL=HRPEpiC | CELL=HSMM | CELL=HSMM_FSHD | CELL=HSMMtube | CELL=HSMMtube_FSHD | CELL=HTB-11 | CELL=HTR8svn | CELL=IMR90 | CELL=Jurkat | CELL=K562 | CELL=LNCAP | CELL=MCF-7 | CELL=MCF10A-Er-Src | CELL=Melano | CELL=Myometr | CELL=NB4 | CELL=NH-A | CELL=NHBE | CELL=NHDF-neo | CELL=NT2-D1 | CELL=Osteobl | CELL=ovcar-3 | CELL=PANC-1 | CELL=PanIslets | CELL=PFSK-1 | CELL=PrEC | CELL=ProgFib | CELL=RPTEC | CELL=SAEC | CELL=SK-N-MC | CELL=SK-N-SH_RA | CELL=SKMC | CELL=T-47D | CELL=U87 | CELL=UCH-1 | CELL DESCRIPTION=acute promyelocytic leukemia cell line | CELL DESCRIPTION=Adult human abdominal skin fibroblasts | CELL DESCRIPTION=Adult human gum tissue fibroblasts | CELL DESCRIPTION=Adult human toe fibroblast | CELL DESCRIPTION=aortic smooth muscle cell | CELL DESCRIPTION=B-lymphocyte | CELL DESCRIPTION=B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed | CELL DESCRIPTION=cervical carcinoma | CELL DESCRIPTION=chordoma cell line | CELL DESCRIPTION=colorectal adenocarcinoma. (PMID: 1939345) | CELL DESCRIPTION=Colorectal Carcinoma | CELL DESCRIPTION=Donor 01-11002; Age 83; Caucasian; DNA and RNA Extract | CELL DESCRIPTION=Donor 01-11002; Age 83; Caucasian; DNA Extract | CELL DESCRIPTION=Donor 02-03015; Age 21; Caucasian; DNA Extract | CELL DESCRIPTION=Donor BN0765; Age 44; Asian; DNA Extract | CELL DESCRIPTION=Donor H11058N; Age 66; Asian; DNA Extract | CELL DESCRIPTION=Donor H12529N; Age 70; Caucasian; DNA Extract | CELL DESCRIPTION=Donor H12803N; Age 88; Caucasian; DNA Extract | CELL DESCRIPTION=Donor H12817N; Age 71; Caucasian; DNA and RNA Extract | CELL DESCRIPTION=Donor N30; Age 41; Asian; DNA Extract | CELL DESCRIPTION=Donor N41; Age 26; Asian; DNA Extract | CELL DESCRIPTION=Donor UHN00189; Age 29; Native Indian; DNA Extract | CELL DESCRIPTION=Donor UHN00204; Age 54; Caucasian; DNA Extract | CELL DESCRIPTION=ECC-1 is a human epithelial cell line derived from an endometrium adenocarcinoma. | CELL DESCRIPTION=embryonic kidney | CELL DESCRIPTION=Fetal buttock/thigh fibroblast | CELL DESCRIPTION=Fetal lung fibroblast | CELL DESCRIPTION=hepatocellular carcinoma | CELL DESCRIPTION=HGPS (HGADFN167, progeria research foundation) | CELL DESCRIPTION=Human Acute Megakaryocytic Leukemia Cells | CELL DESCRIPTION=Human Amniotic Epithelial Cells | CELL DESCRIPTION=Human Cardiac Fibroblasts | CELL DESCRIPTION=Human Cardiac Myocytes | CELL DESCRIPTION=Human Choroid Plexus Epithelial Cells | CELL DESCRIPTION=Human Embryonic Stem Cells | CELL DESCRIPTION=Human Esophageal Epithelial Cells | CELL DESCRIPTION=human glioblastoma; astrocytoma | CELL DESCRIPTION=Human Iris Pigment Epithelial Cells | CELL DESCRIPTION=human mammary epithelial cell | CELL DESCRIPTION=Human neuroblastoma | CELL DESCRIPTION=Human Non-Pigment Ciliary Epithelial Cells | CELL DESCRIPTION=human pancreatic islets | CELL DESCRIPTION=Human Prostate Epithelial Cell line | CELL DESCRIPTION=Human Pulmonay Alevolar Epithelial Cells | CELL DESCRIPTION=Human Renal Cortical Epithelial cells (normal) | CELL DESCRIPTION=Human Renal Epithelial cells (normal) | CELL DESCRIPTION=Human Retinal Pigment Epithelial Cells | CELL DESCRIPTION=Human Skeletal Muscle Cells | CELL DESCRIPTION=leukemia | CELL DESCRIPTION=liver carcinoma | CELL DESCRIPTION=lymphoblastoid | CELL DESCRIPTION=malignant pluripotent embryonal carcinoma (Ntera2) | CELL DESCRIPTION=mammary gland, adenocarcinoma | CELL DESCRIPTION=mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=mammary gland, non-tumorigenic epithelial, inducible cell line | CELL DESCRIPTION=melanocytes | CELL DESCRIPTION=Myometrial cells | CELL DESCRIPTION=myotube from Facioscapulohumeral Muscular Dystrophy (FSHD) patient, muscle needle biopsies | CELL DESCRIPTION=Neonatal Human Dermal Fibroblasts | CELL DESCRIPTION=neuroblastoma cell line differentiated w/ retinoic acid | CELL DESCRIPTION=neuroectodermal cell line derived from a human cerebral brain tumor | CELL DESCRIPTION=neuroepithelioma cell line derived from a metastatic supra-orbital human brain tumor | CELL DESCRIPTION=Normal child fibroblast; donor sex: female | CELL DESCRIPTION=Normal Human Astrocytes | CELL DESCRIPTION=normal human bronchial epithelial cells | CELL DESCRIPTION=Normal Human Lung Fibroblasts | CELL DESCRIPTION=Normal human osteoblasts (NHOst) | CELL DESCRIPTION=Normal Human Skeletal Muscle Myoblasts | CELL DESCRIPTION=Normal Human Skeletal Muscle Myotubes | CELL DESCRIPTION=not specified | CELL DESCRIPTION=ovarian adenocarcinoma, &amp;quot;the NIH: OVCAR-3 line was established in 1982 by T.C. Hamilton, et al. from the malignant ascites of a patient with progressive adenocarcinoma of the ovary.&amp;quot; - ATCC. (PMID: 6604576) | CELL DESCRIPTION=pancreatic carcinoma | CELL DESCRIPTION=Primary Human Hepatocytes | CELL DESCRIPTION=primary myoblast from Facioscapulohumeral Muscular Dystrophy (FSHD) patients, muscle needle biopsies | CELL DESCRIPTION=promyelocytic leukemia cells, (PMID: 276884) | CELL DESCRIPTION=prostate adenocarcinoma | CELL DESCRIPTION=Renal Proximal Tubule Epithelial Cells | CELL DESCRIPTION=skin fibroblast | CELL DESCRIPTION=Small Airway Epithelial Cells | CELL DESCRIPTION=T lymphoblastoid cell line derived from an acute T cell leukemia | CELL DESCRIPTION=T-47D is a human epithelial cell line derived from an mammary ductal carcinoma. | CELL DESCRIPTION=Trophoblast (HTR-8/SVneo) cell line. A thin layer of ectoderm that forms the wall of many mammalian blastulas and functions in the nutrition and implantation of the embryo. | CELL KARYOTYPE=cancer | CELL KARYOTYPE=cancer, male | CELL KARYOTYPE=CEPH/UTAH PEDIGREE 1463, Epstein-Barr Virus, Female | CELL KARYOTYPE=CEPH/UTAH PEDIGREE 1463, Epstein-Barr Virus, Male | CELL KARYOTYPE=hyperdiploidï¿½femaleï¿½withï¿½aï¿½modalï¿½chromosomeï¿½numberï¿½ofï¿½47 | CELL KARYOTYPE=hypodiploidï¿½femaleï¿½withï¿½aï¿½modalï¿½chromosome numberï¿½of 44 in 48% of cellsï¿½andï¿½a 5.9% rateï¿½of higher ploidy | CELL KARYOTYPE=hypotriploid | CELL KARYOTYPE=normal | CELL KARYOTYPE=not specified | CELL KARYOTYPE=Progeria | CELL KARYOTYPE=relatively normal | CELL KARYOTYPE=stable and near-diploid | CELL KARYOTYPE=unknown | CELL KARYOTYPE=YORUBA, Epstein-Barr Virus, Female | CELL KARYOTYPE=YORUBA, Epstein-Barr Virus, Male | CELL LINEAGE=&amp;quot;SK-N-MC was isolated in September of l971 and was found to have moderate dopamine - beta - hydroxylase activity as well as formaldehyde induced fluorescence indicative of intracellular catecholamines.&amp;quot; - ATCC | CELL LINEAGE=&amp;quot;The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.&amp;quot; - ATCC | CELL LINEAGE=&amp;quot;The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al., and was originally designated JM.&amp;quot; - ATCC | CELL LINEAGE=&amp;quot;The line was established from skin taken from normal foreskin.&amp;quot; - ATCC | CELL LINEAGE=&amp;quot;The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.&amp;quot; - ATCC | CELL LINEAGE=adrenal glandadrenal gland | CELL LINEAGE=blastula | CELL LINEAGE=brain | CELL LINEAGE=Breast | CELL LINEAGE=derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) | CELL LINEAGE=ectoderm | CELL LINEAGE=embryonic stem cell | CELL LINEAGE=endoderm | CELL LINEAGE=epithelial | CELL LINEAGE=International HapMap Project - CEPH/Utah - European Caucasion; Epstein-Barr Virus | CELL LINEAGE=International HapMap Project - CEPH/Utah - European Caucasion; Epstein-Barr Virus;Cloned for maternal X inactivation | CELL LINEAGE=kidney | CELL LINEAGE=Left ventrible | CELL LINEAGE=liver | CELL LINEAGE=Liver perfused by enzymes to generate single cell suspension | CELL LINEAGE=lung | CELL LINEAGE=mesoderm | CELL LINEAGE=not specified | CELL LINEAGE=pancreas | CELL LINEAGE=pericardium | CELL LINEAGE=peripheral blood mononuclear cell | CELL LINEAGE=placenta | CELL LINEAGE=skeletal muscle | CELL LINEAGE=skin | CELL LINEAGE=stomach | CELL LINEAGE=testis | CELL LINEAGE=The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line. - ATCC | CELL LINEAGE=uterus | CELL SEX=B | CELL SEX=female | CELL SEX=male | CELL SEX=U | LABEXPID=not specified | LABEXPID=SL14361 | LABEXPID=SL14363 | LABEXPID=SL1814 | LABEXPID=SL1919 | LABEXPID=SL1920 | LABEXPID=SL3655 | LABEXPID=SL714,SL715 | LABEXPID=SL861,SL4743 | LABEXPID=SL862 | LABEXPID=SL901 | LABEXPID=SL902 | LABEXPID=SL904 | OBTAINEDBY=BioChain | OBTAINEDBY=Duke | OBTAINEDBY=HudsonAlpha | OBTAINEDBY=Stanford | OBTAINEDBY=UW | OBTAINEDBY=Uw | OBTAINEDBY DESCRIPTION=Crawford - Duke University | OBTAINEDBY DESCRIPTION=Myers - Hudson Alpha Institute for Biotechnology | OBTAINEDBY DESCRIPTION=not specified | OBTAINEDBY DESCRIPTION=Stamatoyannopoulous - University of Washington | REPLICATE=1 | REPLICATE=1,2 | REPLICATE=2 | REPLICATE=3 | REPLICATE=4 | REPLICATE=5 | TREATMENT=androgen | TREATMENT=CTCF_shRNA_knockdown | TREATMENT=DMSO_0.02pct_24hr | TREATMENT=DMSO_0.02pct_7d | TREATMENT=Estradiol_10nM_24hr | TREATMENT=None | TREATMENT=Randomized_shRNA_control | TREATMENT=TAM_1uM_36hr | TREATMENT DESCRIPTION=12hrs, 1nM Methyltrienolone (R1881) (Crawford) | TREATMENT DESCRIPTION=24,10nM Estradiol  (Myers) | TREATMENT DESCRIPTION=24h,0.02% DMSO (Myers) | TREATMENT DESCRIPTION=36h, 1uM tamoxifen (Myers) | TREATMENT DESCRIPTION=7 d with 0.02% Dimethyl sufloxide (DMSO) (Myers) | TREATMENT DESCRIPTION=No special treatment or protocol applies | TREATMENT DESCRIPTION=not specified","CELL TYPE=stem cells G48 | CELL TYPE=stem cells G52 | CELL TYPE=stem cells G63","NA","CELL_TYPE=endothelial cell line | CELL_TYPE=endothelial cells isolated from glioblastoma sample | CELL_TYPE=Glioblastoma stem cell line","cell line=A172 | cell line=DBTRG05MG | cell line=G111 | cell line=G112 | cell line=G118 | cell line=G120 | cell line=G121 | cell line=G122 | cell line=G124 | cell line=G130 | cell line=G140 | cell line=G141 | cell line=G142 | cell line=G22 | cell line=G28T | cell line=G44 | cell line=G59 | cell line=G61 | cell line=G63 | cell line=G84 | cell line=G96 | cell line=GS-1 | cell line=GS-10 | cell line=GS-11 | cell line=GS-12 | cell line=GS-2 | cell line=GS-2. | cell line=GS-3 | cell line=GS-3 clone 1 | cell line=GS-3 clone 2 | cell line=GS-3 clone 3 | cell line=GS-3 clone 4 | cell line=GS-4 | cell line=GS-5 | cell line=GS-6 | cell line=GS-7 | cell line=GS-7 clone 1 | cell line=GS-7 clone 2 | cell line=GS-7 clone 3 | cell line=GS-8 | cell line=GS-9 | cell line=HS683 | cell line=LN18 | cell line=LN229 | cell line=M059J | cell line=M059K | cell line=ML-4 | cell line=ML-5 | cell line=ML-8 | cell line=ML-9 | cell line=SF268 | cell line=SF539 | cell line=SW1783 | cell line=T98G | cell line=U118MG | cell line=U87MG | cell line=Unspecified | cell type=glioblastoma | cell type=glioblastoma (neurosphere) | cell type=glioblastoma stem-like | cell type=glioma","compound=LY2109761 | compound=none | dose=2 micromolar","NA","block=serie 1 | block=serie 2 | disease=control | disease=glioblastoma","CELL_LINE=786-0 | CELL_LINE=A498 | CELL_LINE=A549 | CELL_LINE=ACHN | CELL_LINE=BT-549 | CELL_LINE=CAKI-1 | CELL_LINE=CCRF-CEM | CELL_LINE=COLO 205 | CELL_LINE=DU-145 | CELL_LINE=EKVX | CELL_LINE=HCC2998 | CELL_LINE=HCT-116 | CELL_LINE=HCT-15 | CELL_LINE=HL-60(TB) | CELL_LINE=HOP-62 | CELL_LINE=HOP-92 | CELL_LINE=Hs-578-T | CELL_LINE=HT29 | CELL_LINE=IGROV-1 | CELL_LINE=K-562 | CELL_LINE=KM12 | CELL_LINE=LOXIMVI | CELL_LINE=M14 | CELL_LINE=Malme-3M | CELL_LINE=MCF7 | CELL_LINE=MDA-MB-231 | CELL_LINE=MDA-MB-435 | CELL_LINE=MDA-MB-468 | CELL_LINE=MOLT-4 | CELL_LINE=NCI-ADR-RES | CELL_LINE=NCI-H226 | CELL_LINE=NCI-H23 | CELL_LINE=NCI-H322M | CELL_LINE=NCI-H460 | CELL_LINE=NCI-H522 | CELL_LINE=OVCAR-3 | CELL_LINE=OVCAR-4 | CELL_LINE=OVCAR-5 | CELL_LINE=OVCAR-8 | CELL_LINE=PC-3 | CELL_LINE=RPMI-8226 | CELL_LINE=RXF 393 | CELL_LINE=SF-539 | CELL_LINE=SF268 | CELL_LINE=SF295 | CELL_LINE=SK-MEL-2 | CELL_LINE=SK-MEL-28 | CELL_LINE=SK-MEL-5 | CELL_LINE=SK-OV-3 | CELL_LINE=SN12C | CELL_LINE=SNB19 | CELL_LINE=SNB75 | CELL_LINE=SR | CELL_LINE=SW620 | CELL_LINE=T47D | CELL_LINE=TK10 | CELL_LINE=U251 | CELL_LINE=UACC-257 | CELL_LINE=UACC-62 | CELL_LINE=UO31","CHIP SEQ ANTIBODY=Normal IgG antibody | CHIP SEQ ANTIBODY=not specified | CHIP SEQ ANTIBODY=Sox2 antibody (Abcam cat#ab59776)","NA","CHIP SEQ ANTIBODY=Normal IgG antibody | CHIP SEQ ANTIBODY=Sox2 antibody (Abcam cat#ab59776)","Compound=control | Compound=PI103 | Dose=0 uM | Dose=1.4 uM | Time=0 h | Time=24 h","CellLine=KNS42 | CellLine=SF188 | Compound=control | Compound=NVP.AEW541 | Compound=PPP | Dose=0 uM | Dose=1.3 uM | Dose=2.5 uM | Dose=30.5 uM | Dose=32 uM | Time=0 h | Time=1 h | Time=24 h | Time=6 h","SAMPLE=NCH_1349 | SAMPLE=NCH_1355 | SAMPLE=NCH_1362 | SAMPLE=NCH_1367 | SAMPLE=NCH_1368 | SAMPLE=NCH_1374 | SAMPLE=NCH_1375 | SAMPLE=NCH_1376 | SAMPLE=NCH_1377 | SAMPLE=NCH_1379 | SAMPLE=NCH_1380 | SAMPLE=NCH_1381 | SAMPLE=NCH_1383 | SAMPLE=NCH_1384 | SAMPLE=NCH_1386 | SAMPLE=NCH_1390 | SAMPLE=NCH_1396 | SAMPLE=NCH_1397 | SAMPLE=NCH_1398 | SAMPLE=NCH_1399 | SAMPLE=NCH_1409 | SAMPLE=NCH_1410 | SAMPLE=NCH_1413 | SAMPLE=NCH_1419 | SAMPLE=NCH_1420 | SAMPLE=NCH_1428 | SAMPLE=NCH_1429 | SAMPLE=NCH_1432 | SAMPLE=NCH_1436 | SAMPLE=NCH_1437 | SAMPLE=NCH_1441 | SAMPLE=NCH_1443 | SAMPLE=NCH_1448 | SAMPLE=NCH_1457 | SAMPLE=NCH_1461 | SAMPLE=NCH_1474 | SAMPLE=NCH_1477 | SAMPLE=NCH_m_100 | SAMPLE=NCH_m_110 | SAMPLE=NCH_m_112 | SAMPLE=NCH_m_113 | SAMPLE=NCH_m_114 | SAMPLE=NCH_m_115 | SAMPLE=NCH_m_116 | SAMPLE=NCH_m_117 | SAMPLE=NCH_m_118 | SAMPLE=NCH_m_119 | SAMPLE=NCH_m_120 | SAMPLE=NCH_m_121 | SAMPLE=NCH_m_122 | SAMPLE=NCH_m_123 | SAMPLE=NCH_m_77 | SAMPLE=NCH_m_78 | SAMPLE=NCH_m_79 | SAMPLE=NCH_m_80 | SAMPLE=NCH_m_81 | SAMPLE=NCH_m_82 | SAMPLE=NCH_m_83 | SAMPLE=NCH_m_84 | SAMPLE=NCH_m_85 | SAMPLE=NCH_m_86 | SAMPLE=NCH_m_87 | SAMPLE=NCH_m_88 | SAMPLE=NCH_m_89 | SAMPLE=NCH_m_90 | SAMPLE=NCH_m_91 | SAMPLE=NCH_m_92 | SAMPLE=NCH_m_93 | SAMPLE=NCH_m_94 | SAMPLE=NCH_m_95 | SAMPLE=NCH_m_96 | SAMPLE=NCH_m_97 | SAMPLE=NCH_m_98 | SAMPLE=NCH_m_99 | TISSUE=brain | TISSUE=gliomatosis cerebri","MENINGIOMA TYPE=anaplastic | MENINGIOMA TYPE=atypical | MENINGIOMA TYPE=not specified | MENINGIOMA TYPE=typical | SAMPLE=NCH_C_1 | SAMPLE=NCH_C_10 | SAMPLE=NCH_C_11 | SAMPLE=NCH_C_111 | SAMPLE=NCH_C_112 | SAMPLE=NCH_C_113 | SAMPLE=NCH_C_12 | SAMPLE=NCH_C_13 | SAMPLE=NCH_C_14 | SAMPLE=NCH_C_15 | SAMPLE=NCH_C_16 | SAMPLE=NCH_C_17 | SAMPLE=NCH_C_18 | SAMPLE=NCH_C_19 | SAMPLE=NCH_C_77 | SAMPLE=NCH_C_78 | SAMPLE=NCH_C_79 | SAMPLE=NCH_C_8 | SAMPLE=NCH_C_81 | SAMPLE=NCH_C_82 | SAMPLE=NCH_C_83 | SAMPLE=NCH_C_84 | SAMPLE=NCH_C_85 | SAMPLE=NCH_C_86 | SAMPLE=NCH_C_87 | SAMPLE=NCH_C_88 | SAMPLE=NCH_C_89 | SAMPLE=NCH_C_9 | SAMPLE=NCH_C_91 | SAMPLE=NCH_C_92 | SAMPLE=NCH_C_93 | SAMPLE=NCH_C_94 | SAMPLE=NCH_C_95 | SAMPLE=NCH_C_96 | SAMPLE=NCH_C_97 | SAMPLE=NCH_C_98 | SAMPLE=NCH_C_99 | SAMPLE=NCH_T_1 | SAMPLE=NCH_T_12 | SAMPLE=NCH_T_127 | SAMPLE=NCH_T_128 | SAMPLE=NCH_T_129 | SAMPLE=NCH_T_130 | SAMPLE=NCH_T_131 | SAMPLE=NCH_T_132 | SAMPLE=NCH_T_133 | SAMPLE=NCH_T_14 | SAMPLE=NCH_T_17 | SAMPLE=NCH_T_18 | SAMPLE=NCH_T_2 | SAMPLE=NCH_T_23 | SAMPLE=NCH_T_26 | SAMPLE=NCH_T_27 | SAMPLE=NCH_T_31 | SAMPLE=NCH_T_33 | SAMPLE=NCH_T_34 | SAMPLE=NCH_T_36 | SAMPLE=NCH_T_39 | SAMPLE=NCH_T_43 | SAMPLE=NCH_T_45 | SAMPLE=NCH_T_48 | SAMPLE=NCH_T_5 | SAMPLE=NCH_T_54 | SAMPLE=NCH_T_57 | SAMPLE=NCH_T_59 | SAMPLE=NCH_T_6 | SAMPLE=NCH_T_62 | SAMPLE=NCH_T_63 | SAMPLE=NCH_T_65 | SAMPLE=NCH_T_68 | SAMPLE=NCH_T_69 | SAMPLE=NCH_T_72 | SAMPLE=NCH_T_73 | SAMPLE=NCH_T_9 | SURVIVAL (YEARS)=10 | SURVIVAL (YEARS)=11 | SURVIVAL (YEARS)=12 | SURVIVAL (YEARS)=13 | SURVIVAL (YEARS)=14 | SURVIVAL (YEARS)=15 | SURVIVAL (YEARS)=3 | SURVIVAL (YEARS)=4 | SURVIVAL (YEARS)=5 | SURVIVAL (YEARS)=6 | SURVIVAL (YEARS)=7 | SURVIVAL (YEARS)=8 | SURVIVAL (YEARS)=9 | SURVIVAL (YEARS)=not specified | TISSUE=meningeal | TISSUE=meningioma | TUMOR LOCATION=convexity | TUMOR LOCATION=falx | TUMOR LOCATION=not specified | TUMOR LOCATION=olfactory groove | TUMOR LOCATION=optic nerve | TUMOR LOCATION=parasagittal | TUMOR LOCATION=posterior fossa | TUMOR LOCATION=sphenoid wing | TUMOR LOCATION=supresellar","CELL=A549 | CELL=AG10803 | CELL=AoAF | CELL=CD20+_RO01778 | CELL=CD4+_Naive_Wb11970640 | CELL=GM06990 | CELL=GM12865 | CELL=H7-hESC | CELL=HA-h | CELL=HA-sp | CELL=HAEpiC | CELL=HCF | CELL=HCFaa | CELL=HCM | CELL=HCPEpiC | CELL=HEEpiC | CELL=HepG2 | CELL=HFF | CELL=HGF | CELL=HIPEpiC | CELL=HMF | CELL=HMVEC-dBl-Ad | CELL=HMVEC-dBl-Neo | CELL=HMVEC-dLy-Neo | CELL=HMVEC-LBl | CELL=HMVEC-LLy | CELL=HPAF | CELL=HPdLF | CELL=HPF | CELL=HRCEpiC | CELL=HSMM | CELL=HUVEC | CELL=HVMF | CELL=K562 | CELL=LHCN-M2 | CELL=M059J | CELL=NB4 | CELL=NH-A | CELL=NHDF-Ad | CELL=NHDF-neo | CELL=NHLF | CELL=RPMI-7951 | CELL=SAEC | CELL=SK-N-SH_RA | CELL=SKMC | CELL=T-47D | CELL=Th1 | CELL=Th17 | CELL=Th1_Wb33676984 | CELL=Th2 | CELL=Th2_Wb54553204 | CELL=Treg_Wb78495824 | CELL DESCRIPTION=abdominal skin fibroblasts from apparently heathly 22 year old, &amp;quot;8% of the cells examined showing random chromosome loss, 2% showing random chromosome gain, and 2% showing 69,XYY&amp;quot; -Coriell | CELL DESCRIPTION=acute promyelocytic leukemia cell line. (PMID: 1995093) | CELL DESCRIPTION=adult blood microvascular endothelial cells, dermal-derived | CELL DESCRIPTION=adult dermal fibroblasts | CELL DESCRIPTION=amniotic epithelial cells | CELL DESCRIPTION=aortic adventitial fibroblast cells | CELL DESCRIPTION=astrocytes (also called Astrocy) | CELL DESCRIPTION=astrocytes spinal cord | CELL DESCRIPTION=astrocytes-hippocampal | CELL DESCRIPTION=B cells, caucasian, draw number 1, newly promoted to tier 2: not in 2011 analysis | CELL DESCRIPTION=B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1459, treatment: Epstein-Barr Virus transformed | CELL DESCRIPTION=blood microvascular endothelial cells, lung-derived | CELL DESCRIPTION=cardiac fibroblasts | CELL DESCRIPTION=cardiac fibroblasts- adult atrial | CELL DESCRIPTION=cardiac myocytes | CELL DESCRIPTION=CD4+ naive sorted cells, donor is Caucasian, male 26 year old, primary pheresis of single normal subject | CELL DESCRIPTION=choroid plexus epithelial cells | CELL DESCRIPTION=epithelial cell line derived from a mammary ductal carcinoma. | CELL DESCRIPTION=esophageal epithelial cells | CELL DESCRIPTION=foreskin fibroblast | CELL DESCRIPTION=gingival fibroblasts | CELL DESCRIPTION=Human Skin Malignant Melanoma Cells, This is a hyperdiploid human cell line with the modal chromosome number of 49, occurring in 24% of cells. Polyploid cells occurred at 22%, which is high. | CELL DESCRIPTION=iris pigment epithelial cells | CELL DESCRIPTION=leukemia | CELL DESCRIPTION=liver carcinoma | CELL DESCRIPTION=lung fibroblasts | CELL DESCRIPTION=lymphatic microvascular endothelial cells, lung-derived | CELL DESCRIPTION=lymphoblastoid (CEPH) | CELL DESCRIPTION=malignant glioblastoma, glioma, lack DNA-dependent protein kinase activity, deficient in repair of DNA double strand breaks, the cells are negative for glial fibrillary acidic protein (GFAP), tumor specimen taken from a 33 year old | CELL DESCRIPTION=mammary fibroblasts | CELL DESCRIPTION=neonatal blood microvascular endothelial cells, dermal-derived | CELL DESCRIPTION=neonatal dermal fibroblasts | CELL DESCRIPTION=neonatal lymphatic microvascular endothelial cells, dermal-derived | CELL DESCRIPTION=neuroblastoma cell line differentiated w/ retinoic acid | CELL DESCRIPTION=not specified | CELL DESCRIPTION=periodontal ligament fibroblasts | CELL DESCRIPTION=primary human Th1 T cells | CELL DESCRIPTION=primary Th2 T cells | CELL DESCRIPTION=pulmonary artery fibroblasts | CELL DESCRIPTION=pulmonary fibroblasts isolated from lung tissue | CELL DESCRIPTION=renal cortical epithelial cells | CELL DESCRIPTION=skeletal muscle cell | CELL DESCRIPTION=skeletal muscle myoblast | CELL DESCRIPTION=small airway epithelial cells | CELL DESCRIPTION=T helper cells expressing IL-17, primary pheresis of single normal subject | CELL DESCRIPTION=T regulatory cells in vivo isolation | CELL DESCRIPTION=Th1 cells in vivo isolation | CELL DESCRIPTION=Th2 cells in vivo isolation, donor is Caucasian, male 33 year old, primary pheresis of single normal subject | CELL DESCRIPTION=umbilical vein endothelial cell | CELL DESCRIPTION=undifferentiated embryonic stem cells | CELL DESCRIPTION=villous mesenchymal fibroblast cells | CELL KARYOTYPE=cancer | CELL KARYOTYPE=normal | CELL KARYOTYPE=normal donor is Asian, female 26 year old, primary pheresis of single normal subject | CELL KARYOTYPE=normal donor is Causasian, female 35 year old, primary pheresis of single normal subject | CELL KARYOTYPE=not specified | CELL KARYOTYPE=relatively normal | CELL LINEAGE=&amp;quot;SK-N-MC was isolated in September of l971 and was found to have moderate dopamine - beta - hydroxylase activity as well as formaldehyde induced fluorescence indicative of intracellular catecholamines.&amp;quot; - ATCC | CELL LINEAGE=&amp;quot;The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.&amp;quot; - ATCC | CELL LINEAGE=CEPH/Utah - European Caucasion; Epstein-Barr Virus | CELL LINEAGE=ectoderm | CELL LINEAGE=endoderm | CELL LINEAGE=inner cell mass | CELL LINEAGE=mesoderm | CELL LINEAGE=not specified | CELL SEX=B | CELL SEX=female | CELL SEX=male | CELL SEX=U | LABEXPID=DS10060 | LABEXPID=DS11039 | LABEXPID=DS11752 | LABEXPID=DS11923 | LABEXPID=DS12374 | LABEXPID=DS12436 | LABEXPID=DS12501 | LABEXPID=DS12543 | LABEXPID=DS12599 | LABEXPID=DS12684 | LABEXPID=DS12763 | LABEXPID=DS12829 | LABEXPID=DS13150 | LABEXPID=DS13185 | LABEXPID=DS13242 | LABEXPID=DS13372 | LABEXPID=DS13480 | LABEXPID=DS13981 | LABEXPID=DS14108 | LABEXPID=DS14289 | LABEXPID=DS14426 | LABEXPID=DS14702 | LABEXPID=DS14790 | LABEXPID=DS15115 | LABEXPID=DS15192 | LABEXPID=DS17597 | LABEXPID=DS17603 | LABEXPID=DS18015 | LABEXPID=DS18208 | LABEXPID=DS19794 | LABEXPID=DS20493 | LABEXPID=DS20534 | LABEXPID=DS20548 | LABEXPID=DS20909 | LABEXPID=not specified | LABVERSION=Bowtie 0.12.7 | LABVERSION=Hotspot-v5.2,lmax-v1.0,WindowDensity-bin20-win+/-75 | LABVERSION=lmax-v1.0 | LABVERSION=not specified | TREATMENT=DIFF_4d | TREATMENT=None | TREATMENT=not specified | TREATMENT DESCRIPTION=Myocytes differentiated from myoblasts for 4 days. See specific cell protocol for treatment details. (Stam) | TREATMENT DESCRIPTION=No special treatment or protocol applies | TREATMENT DESCRIPTION=not specified","AGENT=DMSO | AGENT=G-TPP","CELL LINE=not specified | CELL LINE=SHSY-5Y | CELL LINE=U251 | CELL TYPE=glioblastoma | CELL TYPE=neuroblastoma | CELL TYPE=not specified | DEVELOPMENTAL STAGE=13-week gestation stage | DEVELOPMENTAL STAGE=14-week gestation stage | DEVELOPMENTAL STAGE=20-week gestation stage | DEVELOPMENTAL STAGE=24-week gestation stage | DEVELOPMENTAL STAGE=mix from 4 different gestational stages (13w, 14w, 20w, 24w) | DEVELOPMENTAL STAGE=not specified | TISSUE=fetal brain | TISSUE=fetal heart | TISSUE=fetal liver | TISSUE=fetal lung | TISSUE=fetal spleen | TISSUE=not specified","HISTOLOGY=AS II | HISTOLOGY=AS III | HISTOLOGY=EP | HISTOLOGY=GBM | HISTOLOGY=GBM2 | HISTOLOGY=normal | HISTOLOGY=OA II | HISTOLOGY=OA III | HISTOLOGY=OD II | HISTOLOGY=PA | IDH1 MUTATION=NA | IDH1 MUTATION=No | IDH1 MUTATION=Yes | TISSUE=brain | TISSUE=brain tumor","CellLine=KNS42 | CellLine=Res186 | CellLine=Res259 | CellLine=SF188 | CellLine=UW479 | Compound=5-Aza-2-deoxycytidine | Compound=DMEM | Compound=no compound | Dose=0 uM | Dose=5 uM | Time=0 hours | Time=72 hours","GENDER (MALE/FEMALE)=F | GENDER (MALE/FEMALE)=M | GENDER (MALE/FEMALE)=not specified | PRIMARY/RECURRANCE=- | PRIMARY/RECURRANCE=1st rec | PRIMARY/RECURRANCE=not specified | PRIMARY/RECURRANCE=Post ALL | PRIMARY/RECURRANCE=Primary | TUMOUR DIAGNOSIS=AA | TUMOUR DIAGNOSIS=AO | TUMOUR DIAGNOSIS=GBM | TUMOUR DIAGNOSIS=LGA | TUMOUR DIAGNOSIS=not specified | TUMOUR LOCATION=DIPG (brainstem) | TUMOUR LOCATION=Infratentorial | TUMOUR LOCATION=not specified | TUMOUR LOCATION=Supratentorial","AGE=29 y | AGE=41 y | AGE=45 y | AGE=46 y | AGE=47 y | AGE=51 y | AGE=53 y | AGE=60 y | AGE=61 y | AGE=63 y | AGE=69 y | AGE=74 y | AGE=76 y | AGE=80 y | AGE=not specified | AGE=unknown | CELL TYPE=CD105+  cell from GBM tumor | CELL TYPE=CD105+ cell from GBM tumor | CELL TYPE=CD31+  cell from GBM tumor | CELL TYPE=CDCD144+  cell from GBM tumor | CELL TYPE=CDCD144+ expression cell from GBM tumor | CELL TYPE=CDCD144-  cell from GBM tumor | CELL TYPE=CDCD144- expression cell from GBM tumor | CELL TYPE=not specified | GENDER=female | GENDER=male | GENDER=not specified","AGE=29 y | AGE=41 y | AGE=46 y | AGE=47 y | AGE=51 y | AGE=53 y | AGE=60 y | AGE=63 y | AGE=69 y | AGE=74 y | AGE=76 y | AGE=unknown | GENDER=female | GENDER=male","AGE=45 y | AGE=61 y | AGE=80 y | AGE=not specified | CELL TYPE=CD105+  cell from GBM tumor | CELL TYPE=CD105+ cell from GBM tumor | CELL TYPE=CD31+  cell from GBM tumor | CELL TYPE=CDCD144+  cell from GBM tumor | CELL TYPE=CDCD144+ expression cell from GBM tumor | CELL TYPE=CDCD144-  cell from GBM tumor | CELL TYPE=CDCD144- expression cell from GBM tumor | CELL TYPE=not specified | GENDER=female | GENDER=male | GENDER=not specified","AGE=29 y | AGE=41 y | AGE=46 y | AGE=47 y | AGE=51 y | AGE=53 y | AGE=60 y | AGE=63 y | AGE=69 y | AGE=74 y | AGE=76 y | AGE=not specified | GENDER=female | GENDER=male | GENDER=not specified","AGE=41 y | AGE=43 y | CELL TYPE=CD133+ cell | CELL TYPE=CD133+, CD144+ cell | CELL TYPE=CD133-, CD144- cell | CELL TYPE=CD144+ cell | GENDER=female | GENDER=male","CELL LINE=BT20 | CELL LINE=BT474 | CELL LINE=BT483 | CELL LINE=BT549 | CELL LINE=HCC1428 | CELL LINE=HCC1806 | CELL LINE=HS578T | CELL LINE=MCF7 | CELL LINE=MDA-MB-157 | CELL LINE=MDA-MB-231 | CELL LINE=MDA-MB-361 | CELL LINE=not specified | CELL LINE=SKBR3 | CELL LINE=T47D | CELL LINE=ZR75","NA","AGENT=Demethyl fructiculin A (Sco-1) | AGENT=vehicle alone (DMSO) | TIME=24 hours | TIME=48 hours","AGE=30 | AGE=34 | AGE=36 | AGE=38 | AGE=43 | AGE=46 | AGE=51 | AGE=52 | AGE=54 | AGE=55 | AGE=60 | AGE=63 | AGE=65 | AGE=66 | AGE=67 | AGE=68 | AGE=69 | AGE=70 | AGE=72 | AGE=73 | AGE=74 | AGE=76 | GENDER=female | GENDER=male | TYPE=glioma grade III | TYPE=glioma grade IV | TYPE=glioma grade V","AGEATSAMPLING=10 | AGEATSAMPLING=26 | AGEATSAMPLING=27 | AGEATSAMPLING=28 | AGEATSAMPLING=29 | AGEATSAMPLING=31 | AGEATSAMPLING=34 | AGEATSAMPLING=35 | AGEATSAMPLING=36 | AGEATSAMPLING=37 | AGEATSAMPLING=38 | AGEATSAMPLING=40 | AGEATSAMPLING=41 | AGEATSAMPLING=42 | AGEATSAMPLING=43 | AGEATSAMPLING=44 | AGEATSAMPLING=46 | AGEATSAMPLING=47 | AGEATSAMPLING=49 | AGEATSAMPLING=50 | AGEATSAMPLING=51 | AGEATSAMPLING=52 | AGEATSAMPLING=53 | AGEATSAMPLING=54 | AGEATSAMPLING=55 | AGEATSAMPLING=56 | AGEATSAMPLING=57 | AGEATSAMPLING=58 | AGEATSAMPLING=59 | AGEATSAMPLING=60 | AGEATSAMPLING=61 | AGEATSAMPLING=62 | AGEATSAMPLING=63 | AGEATSAMPLING=64 | AGEATSAMPLING=65 | AGEATSAMPLING=66 | AGEATSAMPLING=67 | AGEATSAMPLING=68 | AGEATSAMPLING=69 | AGEATSAMPLING=70 | AGEATSAMPLING=71 | AGEATSAMPLING=72 | AGEATSAMPLING=73 | AGEATSAMPLING=74 | AGEATSAMPLING=75 | AGEATSAMPLING=77 | AGEATSAMPLING=78 | AGEATSAMPLING=79 | AGEATSAMPLING=80 | AGEATSAMPLING=82 | AGEATSAMPLING=NA | AGEATSAMPLING=not specified | CHEMOTHERAPY=NA | CHEMOTHERAPY=no | CHEMOTHERAPY=no data | CHEMOTHERAPY=not specified | CHEMOTHERAPY=yes | OVERALL.SURVIVAL..DAYS.=106 | OVERALL.SURVIVAL..DAYS.=1060 | OVERALL.SURVIVAL..DAYS.=109 | OVERALL.SURVIVAL..DAYS.=112 | OVERALL.SURVIVAL..DAYS.=1123 | OVERALL.SURVIVAL..DAYS.=1124 | OVERALL.SURVIVAL..DAYS.=1187 | OVERALL.SURVIVAL..DAYS.=1193 | OVERALL.SURVIVAL..DAYS.=132 | OVERALL.SURVIVAL..DAYS.=134 | OVERALL.SURVIVAL..DAYS.=1365 | OVERALL.SURVIVAL..DAYS.=1386 | OVERALL.SURVIVAL..DAYS.=145 | OVERALL.SURVIVAL..DAYS.=148 | OVERALL.SURVIVAL..DAYS.=1526 | OVERALL.SURVIVAL..DAYS.=154 | OVERALL.SURVIVAL..DAYS.=1611 | OVERALL.SURVIVAL..DAYS.=162 | OVERALL.SURVIVAL..DAYS.=1680 | OVERALL.SURVIVAL..DAYS.=172 | OVERALL.SURVIVAL..DAYS.=1731 | OVERALL.SURVIVAL..DAYS.=178 | OVERALL.SURVIVAL..DAYS.=18 | OVERALL.SURVIVAL..DAYS.=181 | OVERALL.SURVIVAL..DAYS.=184 | OVERALL.SURVIVAL..DAYS.=195 | OVERALL.SURVIVAL..DAYS.=198 | OVERALL.SURVIVAL..DAYS.=1997 | OVERALL.SURVIVAL..DAYS.=215 | OVERALL.SURVIVAL..DAYS.=217 | OVERALL.SURVIVAL..DAYS.=218 | OVERALL.SURVIVAL..DAYS.=2191 | OVERALL.SURVIVAL..DAYS.=223 | OVERALL.SURVIVAL..DAYS.=230 | OVERALL.SURVIVAL..DAYS.=234 | OVERALL.SURVIVAL..DAYS.=240 | OVERALL.SURVIVAL..DAYS.=244 | OVERALL.SURVIVAL..DAYS.=245 | OVERALL.SURVIVAL..DAYS.=246 | OVERALL.SURVIVAL..DAYS.=25 | OVERALL.SURVIVAL..DAYS.=254 | OVERALL.SURVIVAL..DAYS.=256 | OVERALL.SURVIVAL..DAYS.=257 | OVERALL.SURVIVAL..DAYS.=264 | OVERALL.SURVIVAL..DAYS.=265 | OVERALL.SURVIVAL..DAYS.=267 | OVERALL.SURVIVAL..DAYS.=274 | OVERALL.SURVIVAL..DAYS.=281 | OVERALL.SURVIVAL..DAYS.=29 | OVERALL.SURVIVAL..DAYS.=2924 | OVERALL.SURVIVAL..DAYS.=297 | OVERALL.SURVIVAL..DAYS.=32 | OVERALL.SURVIVAL..DAYS.=3220 | OVERALL.SURVIVAL..DAYS.=34 | OVERALL.SURVIVAL..DAYS.=342 | OVERALL.SURVIVAL..DAYS.=352 | OVERALL.SURVIVAL..DAYS.=353 | OVERALL.SURVIVAL..DAYS.=3570 | OVERALL.SURVIVAL..DAYS.=371 | OVERALL.SURVIVAL..DAYS.=375 | OVERALL.SURVIVAL..DAYS.=380 | OVERALL.SURVIVAL..DAYS.=386 | OVERALL.SURVIVAL..DAYS.=400 | OVERALL.SURVIVAL..DAYS.=406 | OVERALL.SURVIVAL..DAYS.=409 | OVERALL.SURVIVAL..DAYS.=410 | OVERALL.SURVIVAL..DAYS.=413 | OVERALL.SURVIVAL..DAYS.=415 | OVERALL.SURVIVAL..DAYS.=417 | OVERALL.SURVIVAL..DAYS.=434 | OVERALL.SURVIVAL..DAYS.=444 | OVERALL.SURVIVAL..DAYS.=458 | OVERALL.SURVIVAL..DAYS.=462 | OVERALL.SURVIVAL..DAYS.=474 | OVERALL.SURVIVAL..DAYS.=484 | OVERALL.SURVIVAL..DAYS.=49 | OVERALL.SURVIVAL..DAYS.=496 | OVERALL.SURVIVAL..DAYS.=503 | OVERALL.SURVIVAL..DAYS.=51 | OVERALL.SURVIVAL..DAYS.=558 | OVERALL.SURVIVAL..DAYS.=559 | OVERALL.SURVIVAL..DAYS.=562 | OVERALL.SURVIVAL..DAYS.=564 | OVERALL.SURVIVAL..DAYS.=58 | OVERALL.SURVIVAL..DAYS.=646 | OVERALL.SURVIVAL..DAYS.=659 | OVERALL.SURVIVAL..DAYS.=661 | OVERALL.SURVIVAL..DAYS.=668 | OVERALL.SURVIVAL..DAYS.=675 | OVERALL.SURVIVAL..DAYS.=693 | OVERALL.SURVIVAL..DAYS.=702 | OVERALL.SURVIVAL..DAYS.=78 | OVERALL.SURVIVAL..DAYS.=792 | OVERALL.SURVIVAL..DAYS.=877 | OVERALL.SURVIVAL..DAYS.=879 | OVERALL.SURVIVAL..DAYS.=994 | OVERALL.SURVIVAL..DAYS.=NA | OVERALL.SURVIVAL..DAYS.=not specified | RADIATION.THERAPY=NA | RADIATION.THERAPY=no | RADIATION.THERAPY=no data | RADIATION.THERAPY=not specified | RADIATION.THERAPY=yes | SAMPLE_TYPE=control | SAMPLE_TYPE=not specified | SAMPLE_TYPE=sample | SEX=F | SEX=M | SEX=not specified | SEX=Pooled | SEX=unknown | TUMOR_ENTITY_SUBTYPE=AAIII | TUMOR_ENTITY_SUBTYPE=AII | TUMOR_ENTITY_SUBTYPE=NA | TUMOR_ENTITY_SUBTYPE=normal-brain | TUMOR_ENTITY_SUBTYPE=not specified | TUMOR_ENTITY_SUBTYPE=pGBIV | TUMOR_ENTITY_SUBTYPE=RZ-GBIV | TUMOR_ENTITY_SUBTYPE=sGBIV","phenotype=control | phenotype=expression of dominant negative transgene of IRE1alpha","15 meta-groups=blood neoplasm cell line | 15 meta-groups=blood non neoplastic disease | 15 meta-groups=breast cancer | 15 meta-groups=germ cell neoplasm | 15 meta-groups=leukemia | 15 meta-groups=nervous system neoplasm | 15 meta-groups=non breast carcinoma | 15 meta-groups=non leukemic blood neoplasm | 15 meta-groups=non neoplastic cell line | 15 meta-groups=normal blood | 15 meta-groups=normal solid tissue | 15 meta-groups=other neoplasm | 15 meta-groups=sarcoma | 15 meta-groups=solid tissue neoplasm cell line | 15 meta-groups=solid tissue non neoplastic disease | 369 groups=293t-tva | 369 groups=600MPE breast cancer | 369 groups=a498 renal cell carcinoma | 369 groups=A549 lung adenocarcinoma | 369 groups=A673 Ewing tumor | 369 groups=ABC-1 lung adenocarcinoma | 369 groups=acute lymphoblastic leukemia | 369 groups=acute megakaryoblastic leukaemia | 369 groups=acute monoblastic and monocytic leukemia | 369 groups=acute myeloid leukemia | 369 groups=acute myelomonocytic leukemia | 369 groups=acute promyelocytic leukemia | 369 groups=acute quadriplegic myopathy | 369 groups=adipose tissue normal | 369 groups=adipose tissue polycystic ovarian syndrome | 369 groups=adipose-derived adult stem cells | 369 groups=adipose-derived adult stem cells cultured | 369 groups=airway epithelial cell | 369 groups=airway epithelial cell cystic fibrosis | 369 groups=alveolar rhabdomyosarcoma | 369 groups=AMO-1 myeloma | 369 groups=amygdala | 369 groups=AU565 breast carcinoma | 369 groups=B cell | 369 groups=B-cell lymphoma | 369 groups=B-cell lymphoma cell line | 369 groups=BeWo choriocarcinoma | 369 groups=bladder | 369 groups=bladder cancer | 369 groups=bladder mucosa | 369 groups=blood | 369 groups=blood transplant rejection | 369 groups=bone | 369 groups=bone hyperparathyroidis | 369 groups=brain | 369 groups=brain bipolar disorder | 369 groups=brain tumor | 369 groups=breast cancer | 369 groups=bronchial epithelia | 369 groups=bronchoalveolar lavage cell | 369 groups=bronchoalveolar lavage cell transplant rejection | 369 groups=BT20 breast cancer | 369 groups=BT474 breast cancer | 369 groups=BT483 breast cancer | 369 groups=BT549 breast cancer | 369 groups=C2C12 mouse muscle myoblast | 369 groups=caco2 colon adenocarcinoma | 369 groups=caki-1 renal cell carcinoma | 369 groups=CAL27 head neck squamous cell carcinoma | 369 groups=Calu-1 lung epidermoid carcinoma | 369 groups=Calu-3 lung adenocarcinoma | 369 groups=Calu-6 lung anaplastic carcinoma | 369 groups=CAMA1 breast cancer | 369 groups=caudate nucleus | 369 groups=caudate nucleus Huntingtons | 369 groups=CCL-153 fetal pulmonary fibroblast | 369 groups=ccrf-cem T-ALL | 369 groups=CD138+ plasma cell | 369 groups=CD138+ plasma cell monoclonal gammopathy | 369 groups=CD138+ plasma cell myeloma | 369 groups=CD33+ cells | 369 groups=CD34+ blood cell | 369 groups=CD34+ blood cell thymus | 369 groups=cerebellum | 369 groups=cerebellum Huntingtons | 369 groups=chondroblastoma | 369 groups=chondromyxoid fibroma | 369 groups=chondrosarcoma | 369 groups=chordoma | 369 groups=chronic myeloid leukemia | 369 groups=cirrhosis | 369 groups=CMK megakaryoblastic | 369 groups=colo205 colorectal adenocarcinoma | 369 groups=colon mucosa bowel disease | 369 groups=colorectal cancer | 369 groups=conjunctiva | 369 groups=connective tissue fibroblast | 369 groups=coronary artery smooth muscle cell | 369 groups=dedifferentiated chondrosarcoma | 369 groups=dendritic cell | 369 groups=DU 145 prostate carcinoma | 369 groups=ea.hy926 cell imortalized endothelial | 369 groups=EBC-1 lung squamous cell carcinoma | 369 groups=EKVX lung non small cell carcinoma | 369 groups=embryonal rhabdomyosarcoma | 369 groups=embryonic lung fibroblast | 369 groups=embryonic skin fibroblast | 369 groups=embryonic stem cell | 369 groups=endothelial cell | 369 groups=epidermis | 369 groups=epidermis dermatitis | 369 groups=erythrocyte | 369 groups=esophageal adenocarcinoma | 369 groups=esophagus Barretts | 369 groups=esophagus epithelium | 369 groups=EW24 Ewing sarcoma cell line | 369 groups=ewings sarcoma | 369 groups=fetal lung | 369 groups=fetal lung fibroblast | 369 groups=fibroblast Cockayne syndrome | 369 groups=fibromatosis | 369 groups=FM9514 human embryonic myoblast | 369 groups=FR4 multiple myeloma | 369 groups=frontal cortex | 369 groups=frontal cortex Huntingtons | 369 groups=ganglioneuroblastoma | 369 groups=ganglioneuroma | 369 groups=germ cell tumor | 369 groups=gingiva cell periodontitis | 369 groups=glioblastoma | 369 groups=glioblastoma cell line | 369 groups=granulocyte | 369 groups=H1 mesenchymal precursor | 369 groups=H9 mesenchymal precursor | 369 groups=HBL 100 breast cancer | 369 groups=HCC lung adenocarcinoma | 369 groups=HCC-2998 colon cancer | 369 groups=HCC1007 breast cancer | 369 groups=HCC1171 lung non small cell lung carcinoma | 369 groups=HCC1187 breast cancer | 369 groups=HCC1195 lung adenocarcinoma | 369 groups=HCC1359 lung large cell carcinoma | 369 groups=HCC1428 breast cancer | 369 groups=HCC15 lung squamous cell carcinoma | 369 groups=HCC1500 breast cancer | 369 groups=HCC1937 breast cancer | 369 groups=HCC2157 breast cancer | 369 groups=HCC2185 breast cancer | 369 groups=HCC227 lung adenocarcinoma | 369 groups=HCC2935 lung non-small cell lung cancer line | 369 groups=HCC3153 breast cancer | 369 groups=HCC366 non-small cell lung carcinoma | 369 groups=HCC38 breast cancer | 369 groups=HCC44 non-small cell lung carcinoma | 369 groups=HCC515 lung adenocarcinoma | 369 groups=HCC70 breast cancer | 369 groups=HCC78 lung non-small cell carcinoma | 369 groups=HCC827 lung adenocarcinoma | 369 groups=HCC95 lung non-small cell carcinoma | 369 groups=HCT-15 colorectal adenocarcinoma | 369 groups=HCT116 colorectal carcinoma | 369 groups=head and neck squamous cell carcinoma | 369 groups=heart | 369 groups=heart disease | 369 groups=HEK293 embryonic kidney | 369 groups=HEK293T embryonic kidney | 369 groups=HeLa cervical adenocarcinoma | 369 groups=HeLa cervical adenocarcinoma transfected | 369 groups=hematopoietic stem cell | 369 groups=Hep-2 larynx sqamous cell carcinoma | 369 groups=hepatocellular carcinoma | 369 groups=hI60 promyelocytic leukemia | 369 groups=hippocampus CA1 | 369 groups=hippocampus CA1 Alzheimers | 369 groups=HMEC S1 | 369 groups=HMEC184 breast cancer | 369 groups=HMT3522S1 breast cancer | 369 groups=HMT3522S1 breast epithelium | 369 groups=HOP 92 non-small cell lung carcinoma | 369 groups=HOP-62 lung adenocarcinoma | 369 groups=HS578T breast cancer cell line | 369 groups=ht-29 colorectal adenocarcinoma | 369 groups=human bronchial epithelial cell line | 369 groups=hypopharynx | 369 groups=hypothalamus | 369 groups=I-6 embryonic stem cell | 369 groups=IB3-1 adenovirus transformed bronchial epithelia | 369 groups=IGROV1 ovarian cancer | 369 groups=JEG3 placental choriocarcinoma | 369 groups=Jurkat T lymphocyte | 369 groups=k562 myelogenous leukaemia | 369 groups=Kaposi sarcoma | 369 groups=KELLY neuroblastoma | 369 groups=keratinocyte | 369 groups=kidney | 369 groups=kidney carcinoma | 369 groups=kidney epithelium | 369 groups=KM12 colon cancer | 369 groups=KM4 multiple myeloma | 369 groups=KS Y-1 Kaposis sarcoma AIDS associated | 369 groups=KS-IMM  Kaposis sarcoma non AIDS associated | 369 groups=LC-1F lung squamous cell | 369 groups=LC1/SQ lung squamous cell | 369 groups=LC2/AD non-small cell lung adenocarcinoma | 369 groups=leiomyosarcoma | 369 groups=leukocyte | 369 groups=leukocyte multiple organ failure | 369 groups=ligament cell periodontitis | 369 groups=lipoma | 369 groups=liposarcoma | 369 groups=liver | 369 groups=LK-2 lung squamous cell | 369 groups=LNCaP prostate cancer | 369 groups=LOXIMVI malignant amelanotic melanoma | 369 groups=Lu130 lung small cell cancer | 369 groups=LU134 lung small cell cancer | 369 groups=LU139 lung small cell cancer | 369 groups=LU165 lung small cell cancer | 369 groups=Lu65 lung non-small cell adenocarcinoma | 369 groups=lung | 369 groups=lung cancer | 369 groups=lung emphysema | 369 groups=lymph node | 369 groups=lymphocyte | 369 groups=lymphocyte asthma | 369 groups=M14 malignant melanoma | 369 groups=M70e hematopoietic | 369 groups=macrophage | 369 groups=malignant peripheral nerve sheath tumor | 369 groups=MALME-3M malignant melanoma | 369 groups=mcf-7aro breast epithelial adenocarcinoma | 369 groups=MCF10A breast epithelial fibrocystic disease | 369 groups=MCF10A-myc breast epithelial fibrocystic disease | 369 groups=MCF12A breast epithelial+M824 | 369 groups=MCF7 breast epithelial adenocarcinoma | 369 groups=MDA-MB-134VI breast cancer | 369 groups=MDA-MB-175VII breast cancer | 369 groups=MDA-MB-231 breast cancer | 369 groups=MDA-MB-361 breast cancer | 369 groups=MDA-MB-415 breast cancer | 369 groups=MDA-MB-435 melanoma | 369 groups=MDA-MB-436 breast cancer | 369 groups=MDA-MB-453 breast cancer | 369 groups=MDA468 breast cancer | 369 groups=mesangial cell | 369 groups=mesenchymal stem cell | 369 groups=microvascular endothelial | 369 groups=MOLT4 T cell acute lymphoblastic leukemia | 369 groups=monocyte | 369 groups=monocyte familial hypercholesterolemia | 369 groups=monocyte multiple organ failure | 369 groups=mononuclear cell | 369 groups=mononuclear cell infection | 369 groups=monophasic synovial sarcoma | 369 groups=MRC5 fetal fibroblast | 369 groups=MS-1 lung small cell lung cancer | 369 groups=multiple myeloma | 369 groups=multipotent adult progenitor cell | 369 groups=myelogenous leukemia | 369 groups=myometrium | 369 groups=myxoid liposarcoma | 369 groups=NC-NC lymphoblastoid B cell | 369 groups=NCI-ADR-RES ovarian cancer | 369 groups=NCI-H226 lung squamous cell carcinoma | 369 groups=NCI-H322M lung small cell bronchioalveolar carcinoma | 369 groups=NCI-H460 lung large cell carcinoma | 369 groups=NCI-H522 lung adenocarcinoma | 369 groups=NCI-H929 myeloma | 369 groups=NCU-MM1 multiple myeloma | 369 groups=neuroblastoma | 369 groups=neurofibroma | 369 groups=oral squamous cell carcinoma | 369 groups=oropharynx | 369 groups=osteosarcoma | 369 groups=ovarian tumor | 369 groups=ovary | 369 groups=OVCAR-3 ovarian cancer | 369 groups=OVCAR-4 ovarian cancer | 369 groups=OVCAR-5 ovarian cancer | 369 groups=OVCAR-8 ovarian cancer | 369 groups=PC-1 lung squamous cell cancer | 369 groups=pc-10 lung sqamous cell cancer | 369 groups=pc3 prostate cancer | 369 groups=pc6 lung small cell cancer | 369 groups=pc7 lung non-small cell adenocarcinoma | 369 groups=PC9 lung non-small cell adenocarcinoma | 369 groups=placenta basal plate | 369 groups=plasma cell | 369 groups=plasma-cell leukemia | 369 groups=preadipocytes | 369 groups=precursor T lymphoblastic leukemia | 369 groups=prefrontal cortex | 369 groups=primary fibroblast | 369 groups=primary intervertebral disc | 369 groups=progeria syndrome fibroblast | 369 groups=prostate cancer | 369 groups=prostate gland | 369 groups=pterygium | 369 groups=QG-56 lung squamous cell cancer | 369 groups=regenerating cell periodontitis | 369 groups=renal cell carcinoma | 369 groups=RERF-LC-AI lung sqamous cell cancer | 369 groups=RERF-LC-KJ lung non-small cell adenocarcinoma | 369 groups=RERF-LC-MS lung non-small cell adenocarcinoma | 369 groups=RJ2.2.5 Burkitts lymphoma | 369 groups=RKO colon carcinoma | 369 groups=rpmi-8226 myeloma | 369 groups=RXF-393 renal cell carcinoma | 369 groups=sarcoma | 369 groups=SBC-5 lung small cell cancer | 369 groups=SBC3 lung small cell cancer | 369 groups=schwannoma | 369 groups=SF-268 glioblastoma | 369 groups=SF-539 glioma | 369 groups=sk-mel-28 melanoma | 369 groups=SK-N-AS neuroblastoma | 369 groups=SK-N-MC neuroblastoma | 369 groups=SK-N-SH neuroblastoma cell | 369 groups=SKBR3 breast adenocarcinoma | 369 groups=skeletal muscle | 369 groups=skeletal muscle diseased | 369 groups=skeletal muscle muscular dystrophy | 369 groups=Skgt4 esophageal cancer | 369 groups=skin | 369 groups=skin basal cell UV treated | 369 groups=SKMC fetal skeletal muscle myoblast | 369 groups=skmel5 melanoma | 369 groups=SKMM1 multiple myeloma | 369 groups=small intestine | 369 groups=smooth muscle | 369 groups=SN12C renal cell carcinoma | 369 groups=SNB-19 glioblastoma | 369 groups=SNB-75 astrocytoma | 369 groups=spindle cell tumor | 369 groups=SQ-5 lung sqamous cell cancer | 369 groups=squamous cell carcinoma of the oral cavity | 369 groups=SR lymphoma | 369 groups=ssMCF7 breast cancer | 369 groups=Su-dhl1 anaplastic large cell lymphoma | 369 groups=SUM1315MO2 breast cancer | 369 groups=SUM149PT breast cancer | 369 groups=SUM159PT breast cancer | 369 groups=SUM185PE breast cancer | 369 groups=SUM190PT breast cancer | 369 groups=SUM225CWN breast cancer | 369 groups=SUM44PE breast cancer | 369 groups=SUM52PE breast cancer | 369 groups=SW480 colon cancer primary tumor derived | 369 groups=T cell | 369 groups=T cell diseased | 369 groups=T47D breast ductal carcinoma | 369 groups=te85 osteosarcoma | 369 groups=TERV | 369 groups=testis | 369 groups=theca | 369 groups=theca polycystic ovarian syndrome | 369 groups=thymocyte | 369 groups=thyrocyte | 369 groups=thyroid adenocarcinoma | 369 groups=thyroid gland | 369 groups=TK-10 | 369 groups=tonsil | 369 groups=trabecular meshwork cell | 369 groups=ts anaplastic large cell lymphoma | 369 groups=u-20s osteosarcoma | 369 groups=U251 glioblastoma | 369 groups=U937 lymphoma | 369 groups=UACC-257 melanoma | 369 groups=UACC-62 melanoma | 369 groups=UACC812 breast cancer | 369 groups=umbilical vein endothelial cell | 369 groups=universal reference | 369 groups=unknown gliobastoma | 369 groups=unknown lung adenocarcinoma | 369 groups=unknown lung cancer | 369 groups=unknown lung cell carcinoma | 369 groups=unknown lung large cell carcinoma | 369 groups=unknown lung mesothelioma | 369 groups=unknown lung neuroendocrine | 369 groups=unknown lung non small cell cancer | 369 groups=unknown lung small cell cancer | 369 groups=unknown lung squamous cell carcinoma | 369 groups=unknown small cell lung cancer | 369 groups=UO-31 renal cell carcinoma | 369 groups=uterine tumor | 369 groups=WI38 fetal fibroblast | 369 groups=ZR751 breast cancer | 369 groups=ZR7530 breast cancer | 369 groups=ZR75B breast cancer | 4 groups from blood to incompletely diff=blood | 4 groups from blood to incompletely diff=connective | 4 groups from blood to incompletely diff=incompletely differentiated | 4 groups from blood to incompletely diff=the rest | 4 meta-groups=cell line | 4 meta-groups=disease | 4 meta-groups=neoplasm | 4 meta-groups=normal | 6 meta-groups=brain | 6 meta-groups=cell line | 6 meta-groups=hematopoietic system | 6 meta-groups=incompletely differentiated | 6 meta-groups=muscle | 6 meta-groups=solid tissue | 6 meta-groups=Unspecified | 96 groups=A549 lung adenocarcinoma | 96 groups=acute lymphoblastic leukemia | 96 groups=acute myeloid leukemia | 96 groups=acute promyelocytic leukemia | 96 groups=B cell | 96 groups=B-cell lymphoma | 96 groups=bladder cancer | 96 groups=blood | 96 groups=brain | 96 groups=brain bipolar disorder | 96 groups=brain tumor | 96 groups=breast cancer | 96 groups=bronchial epithelia | 96 groups=bronchoalveolar lavage cell | 96 groups=BT474 breast cancer | 96 groups=caco2 colon adenocarcinoma | 96 groups=Calu-3 lung adenocarcinoma | 96 groups=caudate nucleus | 96 groups=caudate nucleus Huntingtons | 96 groups=CD138+ plasma cell myeloma | 96 groups=cerebellum | 96 groups=cerebellum Huntingtons | 96 groups=chronic myeloid leukemia | 96 groups=colorectal cancer | 96 groups=embryonal rhabdomyosarcoma | 96 groups=embryonic lung fibroblast | 96 groups=embryonic skin fibroblast | 96 groups=epidermis dermatitis | 96 groups=ewings sarcoma | 96 groups=fetal lung fibroblast | 96 groups=FM9514 human embryonic myoblast | 96 groups=frontal cortex | 96 groups=frontal cortex Huntingtons | 96 groups=germ cell tumor | 96 groups=heart | 96 groups=heart disease | 96 groups=HEK293 embryonic kidney | 96 groups=HeLa cervical adenocarcinoma | 96 groups=HeLa cervical adenocarcinoma transfected | 96 groups=hematopoietic stem cell | 96 groups=Hep-2 larynx sqamous cell carcinoma | 96 groups=hepatocellular carcinoma | 96 groups=hI60 promyelocytic leukemia | 96 groups=ht-29 colorectal adenocarcinoma | 96 groups=hypothalamus | 96 groups=IB3-1 adenovirus transformed bronchial epithelia | 96 groups=INCaP prostate cancer | 96 groups=k562 myelogenous leukaemia | 96 groups=Kaposi sarcoma | 96 groups=kidney | 96 groups=leukocyte | 96 groups=lung cancer | 96 groups=lymph node | 96 groups=lymphocyte | 96 groups=macrophage | 96 groups=mcf-7aro breast epithelial adenocarcinoma | 96 groups=MCF7 breast epithelial adenocarcinoma | 96 groups=MDA-MB-231 breast cancer | 96 groups=MDA468 breast cancer | 96 groups=mesenchymal stem cell | 96 groups=MOLT4 T cell acute lymphoblastic leukemia | 96 groups=monocyte | 96 groups=mononuclear cell | 96 groups=mononuclear cell infection | 96 groups=myelogenous leukemia | 96 groups=myometrium | 96 groups=neuroblastoma | 96 groups=oral squamous cell carcinoma | 96 groups=ovarian tumor | 96 groups=pc3 prostate cancer | 96 groups=placenta basal plate | 96 groups=preadipocytes | 96 groups=precursor T lymphoblastic leukemia | 96 groups=primary intervertebral disc | 96 groups=prostate cancer | 96 groups=prostate gland | 96 groups=renal cell carcinoma | 96 groups=RKO colon carcinoma | 96 groups=skeletal muscle | 96 groups=skeletal muscle diseased | 96 groups=skeletal muscle muscular dystrophy | 96 groups=skmel5 melanoma | 96 groups=smooth muscle | 96 groups=ssMCF7 breast cancer | 96 groups=T cell | 96 groups=T cell diseased | 96 groups=T47D breast ductal carcinoma | 96 groups=thymocyte | 96 groups=thyroid adenocarcinoma | 96 groups=tonsil | 96 groups=ts anaplastic large cell lymphoma | 96 groups=umbilical vein endothelial cell | 96 groups=universal reference | 96 groups=unknown lung adenocarcinoma | 96 groups=unknown lung small cell cancer | 96 groups=Unspecified | 96 groups=uterine tumor | Blood-NonBlood meta-groups=blood | Blood-NonBlood meta-groups=non blood","AGE=11 | AGE=19 | AGE=22 | AGE=24 | AGE=31 | AGE=34 | AGE=36 | AGE=4 | AGE=42 | AGE=43 | AGE=44 | AGE=47 | AGE=49 | AGE=51 | AGE=52 | AGE=53 | AGE=54 | AGE=58 | AGE=60 | AGE=61 | AGE=62 | AGE=64 | AGE=67 | AGE=69 | AGE=70 | AGE=72 | AGE=74 | AGE=75 | AGE=NA | CELL LINE=BR:BT-549 | CELL LINE=BR:HS578T | CELL LINE=BR:MCF7 | CELL LINE=BR:MDB-MB-231 | CELL LINE=BR:T47D | CELL LINE=CNS:SF-268 | CELL LINE=CNS:SF-295 | CELL LINE=CNS:SF-539 | CELL LINE=CNS:SNB-19 | CELL LINE=CNS:SNB-75 | CELL LINE=CNS:U251 | CELL LINE=CO:COLO205 | CELL LINE=CO:HCC-2998 | CELL LINE=CO:HCT-116 | CELL LINE=CO:HCT-15 | CELL LINE=CO:HT29 | CELL LINE=CO:KM12 | CELL LINE=CO:SW-620 | CELL LINE=LC:A549-ATCC | CELL LINE=LC:EKVX | CELL LINE=LC:HOP-62 | CELL LINE=LC:HOP-92 | CELL LINE=LC:NCI-226 | CELL LINE=LC:NCI-H23 | CELL LINE=LC:NCI-H322M | CELL LINE=LC:NCI-H460 | CELL LINE=LC:NCI-H522 | CELL LINE=LE:CCRF-CEM | CELL LINE=LE:HL-60 | CELL LINE=LE:K-562 | CELL LINE=LE:MOLT-4 | CELL LINE=LE:RPMI-8226 | CELL LINE=LE:SR | CELL LINE=ME:LOXIMVI | CELL LINE=ME:M14 | CELL LINE=ME:MALME-3M | CELL LINE=ME:MDA-MB-435 d | CELL LINE=ME:MDA-N d | CELL LINE=ME:SK-MEL-2 | CELL LINE=ME:SK-MEL-28 | CELL LINE=ME:SK-MEL-5 | CELL LINE=ME:UACC-257 | CELL LINE=ME:UACC-62 | CELL LINE=OV:IGROV1 | CELL LINE=OV:NCI/ADR-RES | CELL LINE=OV:OVCAR-3 | CELL LINE=OV:OVCAR-4 | CELL LINE=OV:OVCAR-5 | CELL LINE=OV:OVCAR-8 | CELL LINE=OV:SKOV3 | CELL LINE=PR:DU-145 DTP | CELL LINE=PR:PC-3 | CELL LINE=RE:786-0 | CELL LINE=RE:A498 | CELL LINE=RE:ACHN | CELL LINE=RE:CAKI-1 | CELL LINE=RE:RXF-393 | CELL LINE=RE:SN12C | CELL LINE=RE:TK-10 | CELL LINE=RE:UO-31 | HISTOLOGY=adenocarcinoma | HISTOLOGY=Adenocarcinoma p/md | HISTOLOGY=Adenocarcinoma- mammary gland; breast; metastatic site: pleural effusion | HISTOLOGY=Adenocarcinoma-mammary gland; breast; epithelial; metastatic site: pleural effusion | HISTOLOGY=Adenocarcinoma-md | HISTOLOGY=Adenocarcinoma-p/md | HISTOLOGY=Adenocarcinoma-ud | HISTOLOGY=adenocarcinoma-ud | HISTOLOGY=Adenocarcinoma-vpd | HISTOLOGY=Adenocarcinoma-wd | HISTOLOGY=Adenocarcinome-pd | HISTOLOGY=Adenocarinoma | HISTOLOGY=ALL | HISTOLOGY=ALL (cells were taken when patient was in relapse) | HISTOLOGY=astrocytoma | HISTOLOGY=carcinoma | HISTOLOGY=Carcinoma-ud | HISTOLOGY=carcinoma-vpd | HISTOLOGY=Carcinosarcoma-mammary gland; breast | HISTOLOGY=Clear cell carcinoma | HISTOLOGY=CML | HISTOLOGY=Cystoadenocarcinoma-pd | HISTOLOGY=Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion | HISTOLOGY=Glial cell neoplasm | HISTOLOGY=Glioblastoma, ud | HISTOLOGY=Glioblastoma,ud | HISTOLOGY=hypernephroma-pd | HISTOLOGY=infiltrating ductal carcinoma | HISTOLOGY=Large Cell Carcinoma-ud | HISTOLOGY=Large cell-ud | HISTOLOGY=lymphoma | HISTOLOGY=Malignant amelanotic melanoma | HISTOLOGY=Malignant melanotic melanoma | HISTOLOGY=Melanotic melanoma | HISTOLOGY=Myeloma | HISTOLOGY=Papillary infiltrating ductal carcinoma-mammary gland; breast | HISTOLOGY=Pro myelocytic leukemia | HISTOLOGY=prostate | HISTOLOGY=prostate adenocarcinoma | HISTOLOGY=Renal cell carcinoma-p/md | HISTOLOGY=Renal cell carcinoma-pd | HISTOLOGY=Renal cell carcinoma-vpd | HISTOLOGY=Renal Spindle cell carcinoma | HISTOLOGY=Small cell Bronchioalveolar Carcinoma | HISTOLOGY=Squamous cell carcinoma-vpd | METASTATIC SITE=bone | METASTATIC SITE=brain | METASTATIC SITE=not specified | SEX=F | SEX=M | SEX=NA | TISSUE-OF-ORIGIN=Breast | TISSUE-OF-ORIGIN=CNS | TISSUE-OF-ORIGIN=colon | TISSUE-OF-ORIGIN=leukemia | TISSUE-OF-ORIGIN=melanoma | TISSUE-OF-ORIGIN=Non-Small Cell Lung | TISSUE-OF-ORIGIN=Ovarian | TISSUE-OF-ORIGIN=prostate | TISSUE-OF-ORIGIN=Renal","NA","CELL LINE=A549 | CELL LINE=Aspc1 | CELL LINE=BJ1 | CELL LINE=BxPC3 | CELL LINE=Hop62 | CELL LINE=MCF-7 | CELL LINE=MDA-MB-231 | CELL LINE=MEC | CELL LINE=MiaPaCa | CELL LINE=MRC5 | CELL LINE=MRC9 | CELL LINE=NCI-H23 | CELL LINE=not specified | CELL LINE=PANC1 | CELL LINE=SF126 | CELL LINE=SF295 | CELL LINE=SF539 | CELL LINE=T47D | CELL LINE=U251 | CELL LINE=U87 | CELL TYPE=Adenocarcinoma | CELL TYPE=Adenocarcinoma- mammary gland; breast | CELL TYPE=Adenocarcinoma-mammary gland; breast; epithelial | CELL TYPE=Adenocarcinoma-p/md;Non-Small Cell Lung | CELL TYPE=Adenocarcinoma-ud; Non-Small Cell Lung | CELL TYPE=Epithelioid carcinoma | CELL TYPE=Fibroblast | CELL TYPE=Glial cell neoplasm; brain/CNS | CELL TYPE=Glioblastoma, ud; brain/CNS | CELL TYPE=Glioblastoma,ud; brain/CNS | CELL TYPE=Glioblastoma; astrocytoma; brain/CNS | CELL TYPE=Glioblastoma; brain/CNS | CELL TYPE=infiltrating ductal carcinoma | CELL TYPE=Mammary epithelial | CELL TYPE=not specified | CELL TYPE=Pancreatic carcinoma | DISEASE STATE=Brain cancer | DISEASE STATE=Breast cancer | DISEASE STATE=Non-Small Cell Lung cancer | DISEASE STATE=not specified | DISEASE STATE=Pancreatic cancer | TISSUE=brain | TISSUE=breast | TISSUE=foreskin | TISSUE=lung | TISSUE=not specified | TISSUE=pancreas","clinical treatment=no response to chemiotherapy | clinical treatment=no response to radiotherapy | clinical treatment=response to chemiotherapy | clinical treatment=response to radiotherapy","Age=10 months | Age=104 months | Age=108 months | Age=116 months | Age=118 months | Age=119 months | Age=120 months | Age=124 months | Age=132 months | Age=135 months | Age=138 months | Age=146 months | Age=149 months | Age=150 months | Age=160 months | Age=165 months | Age=167 months | Age=168 months | Age=172 months | Age=174 months | Age=180 months | Age=183 months | Age=185 months | Age=190 months | Age=197 months | Age=202 months | Age=204 months | Age=229 months | Age=238 months | Age=240 months | Age=242 months | Age=253 months | Age=257 months | Age=273 months | Age=278 months | Age=35 months | Age=46 months | Age=49 months | Age=5 months | Age=58 months | Age=6 months | Age=60 months | Age=64 months | Age=68 months | Age=76 months | Age=79 months | Age=96 months | Age(months)=pool | DiseaseState=anaplastic astrocytoma | DiseaseState=anaplastic oligodendroglioma | DiseaseState=diffuse intrinsic pontine glioma | DiseaseState=glioblastoma | DiseaseState=Gliosarcoma | DiseaseState=normal | DiseaseState=oligoastrocytoma","response to chemotherapy=does not respond to chemotherapy | response to chemotherapy=not applicable | response to chemotherapy=respond to chemotherapy | response to radiotherapy=does not respond to radiotherapy | response to radiotherapy=not applicable | response to radiotherapy=respond to radiotherapy","NA","NA","NA","CELL LINE=MJ_LS1034 | CELL LINE=MJ_T196 | CELL LINE=MJ_T202 | CELL LINE=not specified | TEST=Colon tumor ZZ_00702A | TEST=Colon tumor ZZ_03393A | TEST=Colon tumor ZZ_03465A | TEST=Colon tumor ZZ_03544A | TEST=Colon tumor ZZ_04222V | TEST=Colon tumor ZZ_04388A | TEST=Colon tumor ZZ_04449A | TEST=Colon tumor ZZ_04494A | TEST=Colon tumor ZZ_04549A | TEST=Colon tumor ZZ_04800A | TEST=Colon tumor ZZ_05025A | TEST=Colon tumor ZZ_05334A | TEST=Colon tumor ZZ_05629A | TEST=Colon tumor ZZ_05708A | TEST=Colon tumor ZZ_05786A | TEST=Colon tumor ZZ_05839A | TEST=Colon tumor ZZ_05885A | TEST=Colon tumor ZZ_06265A | TEST=Colon tumor ZZ_06314A | TEST=Colon tumor ZZ_06432V | TEST=Colon tumor ZZ_06682V | TEST=Colon tumor ZZ_07061A | TEST=Colon tumor ZZ_07145A | TEST=Colon tumor ZZ_08018A | TEST=Colon tumor ZZ_09185A | TEST=Colon tumor ZZ_09297A | TEST=Colon tumor ZZ_09509A | TEST=Colon tumor ZZ_09728A | TEST=Colon tumor ZZ_10078t | TEST=Colon tumor ZZ_10194A | TEST=Colon tumor ZZ_10258V | TEST=Colon tumor ZZ_10264A | TEST=Colon tumor ZZ_10512A | TEST=Colon tumor ZZ_11053A | TEST=Colon tumor ZZ_12051V | TEST=Colon tumor ZZ_14938V | TEST=Colon tumor ZZ_3531T | TEST=Colon tumor ZZ_3657t | TEST=Colon tumor ZZ_3862t | TEST=Colon tumor ZZ_6220t | TEST=Colon tumor ZZ_7925t | TEST=Colon tumor ZZ_80649U | TEST=Colon tumor ZZ_8152t | TEST=Colon tumor ZZ_9394t | TEST=Colon tumor ZZ_9420t | TEST=Colon tumor ZZ_A1423U | TEST=Colon tumor ZZ_A1516 | TEST=Colon tumor ZZ_A1644A | TEST=Colon tumor ZZ_A1716A | TEST=Colon tumor ZZ_A2434A | TEST=Colon tumor ZZ_A2561 | TEST=Colon tumor ZZ_A2715A | TEST=Colon tumor ZZ_A3203U | TEST=Colon tumor ZZ_A3536A | TEST=Colon tumor ZZ_A3622U | TEST=Colon tumor ZZ_A3684U | TEST=Colon tumor ZZ_A4396U | TEST=Colon tumor ZZ_A4674U | TEST=Colon tumor ZZ_A4779A | TEST=Colon tumor ZZ_A5320A | TEST=Colon tumor ZZ_A5790A | TEST=Colon tumor ZZ_A5960U | TEST=Colon tumor ZZ_A6141A | TEST=Colon tumor ZZ_C0081A | TEST=Colon tumor ZZ_C0085A | TEST=Colon tumor ZZ_C0097A | TEST=Colon tumor ZZ_C0104A | TEST=Colon tumor ZZ_C0126A | TEST=Colon tumor ZZ_C70t | TEST=Colon tumor ZZ_C80T | TEST=Colon tumor ZZ_TB004A | TEST=Colon tumor ZZ_TB012A | TEST=Colon tumor ZZ_TB017A | TEST=Colon tumor ZZ_TB018 | TEST=Colon tumor ZZ_TB019A | TEST=Colon tumor ZZ_TB020A | TEST=Colon tumor ZZ_TB030A | TEST=Colon tumor ZZ_TB031A | TEST=Colon tumor ZZ_TB034 | TEST=Colon tumor ZZ_TB035A | TEST=Colon tumor ZZ_TB036A | TEST=Colon tumor ZZ_TB049A | TEST=Colon tumor ZZ_TB050A | TEST=Colon tumor ZZ_TB054A | TEST=Colon tumor ZZ_TB061A | TEST=Colon tumor ZZ_TB063A | TEST=Colon tumor ZZ_TB071A | TEST=Colon tumor ZZ_TB074A | TEST=Colon tumor ZZ_TB079A | TEST=Colon tumor ZZ_TB101A | TEST=Colon tumor ZZ_TB115A | TEST=Colon tumor ZZ_TB120A | TEST=Colon tumor ZZ_TB134A | TEST=Colon tumor ZZ_TB154A | TEST=Colon tumor ZZ_TB276A | TEST=not specified","AGE=0.42 years old | AGE=1 month years | AGE=1 month years old | AGE=1 years | AGE=1 years old | AGE=1.2 years | AGE=1.2 years old | AGE=1.6 years | AGE=1.6 years old | AGE=10 years | AGE=10 years old | AGE=10.2 years old | AGE=10.7 years | AGE=10.7 years old | AGE=10.9 years | AGE=10.9 years old | AGE=11 years old | AGE=11.25 years | AGE=11.25 years old | AGE=11.5 years old | AGE=12 years | AGE=12 years old | AGE=12.3 years old | AGE=12.75 years old | AGE=13.1 years | AGE=13.1 years old | AGE=13.2 years old | AGE=13.5 years | AGE=13.5 years old | AGE=13.8 years | AGE=13.8 years old | AGE=14 years | AGE=14 years old | AGE=14.08 years | AGE=14.08 years old | AGE=14.1 years old | AGE=14.3 years | AGE=14.3 years old | AGE=14.4 years old | AGE=14.8 years | AGE=14.8 years old | AGE=16.5 years | AGE=16.5 years old | AGE=16.7 years | AGE=16.7 years old | AGE=17.8 years | AGE=17.8 years old | AGE=19 years | AGE=19 years old | AGE=19.8 years | AGE=19.8 years old | AGE=2 years | AGE=2 years old | AGE=2.3 years old | AGE=2.75 years | AGE=2.75 years old | AGE=2.9 years old | AGE=20 years old | AGE=22.7 years | AGE=22.7 years old | AGE=23 years | AGE=23 years old | AGE=3 years | AGE=3 years old | AGE=3.3 years old | AGE=3.6 years | AGE=3.6 years old | AGE=3.8 years | AGE=3.8 years old | AGE=4 years | AGE=4 years old | AGE=4.2 years old | AGE=4.3 years old | AGE=4.7 years | AGE=4.7 years old | AGE=4.8 years old | AGE=5 days old | AGE=5 years | AGE=5 years old | AGE=5.6 years old | AGE=5.8 years | AGE=5.8 years old | AGE=6 years | AGE=6 years old | AGE=6.2 years | AGE=6.2 years old | AGE=6.3 years | AGE=6.3 years old | AGE=6.5 years old | AGE=7 years | AGE=7 years old | AGE=7.3 years | AGE=7.3 years old | AGE=7.5 years | AGE=7.5 years old | AGE=7.7 years old | AGE=8 years | AGE=8 years old | AGE=8.1 years old | AGE=8.5 years old | AGE=8.9 years | AGE=8.9 years old | AGE=9 years | AGE=9 years old | AGE=9.2 years | AGE=9.2 years old | AGE=9.7 years | AGE=9.7 years old | AGE=9.9 years | AGE=9.9 years old | DISEASE=anaplastic astrocytoma | DISEASE=anaplastic oligodendroglioma | DISEASE=Anaplastic PXA | DISEASE=Glioblastoma | DISEASE=Glioblastoma variant | OTHER=Diffuse pontine glioma | OTHER=not specified | OTHER=Post-ALL | OTHER=Post-Ependymoma | OTHER=Post-Germinoma | OTHER=Post-medulloblastoma","NA","CELL LINE=U87L4 | CELL LINE=U87MG | CELL LINE=U87R4","CELL TYPE=glioblastoma | CELL TYPE=normal human brain | CELL TYPE=U87MG cell line","NA","NA","CELL TYPE=glioblastoma | CELL TYPE=normal reference","CELL TYPE=glioblastoma | CELL TYPE=normal reference","CELL TYPE=glioblastoma | CELL TYPE=normal reference","TISSUE=glioblastoma tissue | TISSUE=normal brain","AGE AT DIAGNOSIS=11.72 | AGE AT DIAGNOSIS=14.38 | AGE AT DIAGNOSIS=15.02 | AGE AT DIAGNOSIS=15.67 | AGE AT DIAGNOSIS=17.55 | AGE AT DIAGNOSIS=22.28 | AGE AT DIAGNOSIS=22.52 | AGE AT DIAGNOSIS=23.02 | AGE AT DIAGNOSIS=23.33 | AGE AT DIAGNOSIS=23.72 | AGE AT DIAGNOSIS=23.88 | AGE AT DIAGNOSIS=24.42 | AGE AT DIAGNOSIS=26.17 | AGE AT DIAGNOSIS=26.66 | AGE AT DIAGNOSIS=28.55 | AGE AT DIAGNOSIS=28.69 | AGE AT DIAGNOSIS=29.55 | AGE AT DIAGNOSIS=30.33 | AGE AT DIAGNOSIS=30.43 | AGE AT DIAGNOSIS=30.69 | AGE AT DIAGNOSIS=31.53 | AGE AT DIAGNOSIS=31.56 | AGE AT DIAGNOSIS=31.72 | AGE AT DIAGNOSIS=31.77 | AGE AT DIAGNOSIS=32.14 | AGE AT DIAGNOSIS=32.15 | AGE AT DIAGNOSIS=32.35 | AGE AT DIAGNOSIS=32.36 | AGE AT DIAGNOSIS=32.50 | AGE AT DIAGNOSIS=32.59 | AGE AT DIAGNOSIS=32.92 | AGE AT DIAGNOSIS=32.98 | AGE AT DIAGNOSIS=33.09 | AGE AT DIAGNOSIS=33.12 | AGE AT DIAGNOSIS=33.20 | AGE AT DIAGNOSIS=33.25 | AGE AT DIAGNOSIS=33.26 | AGE AT DIAGNOSIS=33.48 | AGE AT DIAGNOSIS=33.74 | AGE AT DIAGNOSIS=33.83 | AGE AT DIAGNOSIS=33.88 | AGE AT DIAGNOSIS=33.89 | AGE AT DIAGNOSIS=34.71 | AGE AT DIAGNOSIS=34.78 | AGE AT DIAGNOSIS=34.84 | AGE AT DIAGNOSIS=34.93 | AGE AT DIAGNOSIS=35.23 | AGE AT DIAGNOSIS=35.67 | AGE AT DIAGNOSIS=35.70 | AGE AT DIAGNOSIS=35.92 | AGE AT DIAGNOSIS=36.27 | AGE AT DIAGNOSIS=36.50 | AGE AT DIAGNOSIS=36.61 | AGE AT DIAGNOSIS=36.66 | AGE AT DIAGNOSIS=37.02 | AGE AT DIAGNOSIS=37.08 | AGE AT DIAGNOSIS=37.11 | AGE AT DIAGNOSIS=37.12 | AGE AT DIAGNOSIS=37.18 | AGE AT DIAGNOSIS=37.25 | AGE AT DIAGNOSIS=37.44 | AGE AT DIAGNOSIS=37.55 | AGE AT DIAGNOSIS=37.60 | AGE AT DIAGNOSIS=37.61 | AGE AT DIAGNOSIS=37.84 | AGE AT DIAGNOSIS=37.98 | AGE AT DIAGNOSIS=38.05 | AGE AT DIAGNOSIS=38.07 | AGE AT DIAGNOSIS=38.11 | AGE AT DIAGNOSIS=38.37 | AGE AT DIAGNOSIS=38.40 | AGE AT DIAGNOSIS=38.42 | AGE AT DIAGNOSIS=38.53 | AGE AT DIAGNOSIS=38.58 | AGE AT DIAGNOSIS=39.36 | AGE AT DIAGNOSIS=39.92 | AGE AT DIAGNOSIS=39.99 | AGE AT DIAGNOSIS=40.06 | AGE AT DIAGNOSIS=40.58 | AGE AT DIAGNOSIS=40.74 | AGE AT DIAGNOSIS=41.09 | AGE AT DIAGNOSIS=41.39 | AGE AT DIAGNOSIS=41.77 | AGE AT DIAGNOSIS=41.93 | AGE AT DIAGNOSIS=41.98 | AGE AT DIAGNOSIS=42.56 | AGE AT DIAGNOSIS=42.67 | AGE AT DIAGNOSIS=42.70 | AGE AT DIAGNOSIS=42.98 | AGE AT DIAGNOSIS=43.00 | AGE AT DIAGNOSIS=43.11 | AGE AT DIAGNOSIS=43.21 | AGE AT DIAGNOSIS=43.26 | AGE AT DIAGNOSIS=43.57 | AGE AT DIAGNOSIS=43.64 | AGE AT DIAGNOSIS=43.85 | AGE AT DIAGNOSIS=43.89 | AGE AT DIAGNOSIS=43.90 | AGE AT DIAGNOSIS=43.93 | AGE AT DIAGNOSIS=44.09 | AGE AT DIAGNOSIS=44.15 | AGE AT DIAGNOSIS=44.41 | AGE AT DIAGNOSIS=44.57 | AGE AT DIAGNOSIS=44.74 | AGE AT DIAGNOSIS=45.39 | AGE AT DIAGNOSIS=45.50 | AGE AT DIAGNOSIS=45.63 | AGE AT DIAGNOSIS=45.71 | AGE AT DIAGNOSIS=46.04 | AGE AT DIAGNOSIS=46.15 | AGE AT DIAGNOSIS=46.47 | AGE AT DIAGNOSIS=46.51 | AGE AT DIAGNOSIS=46.52 | AGE AT DIAGNOSIS=46.61 | AGE AT DIAGNOSIS=46.83 | AGE AT DIAGNOSIS=46.86 | AGE AT DIAGNOSIS=47.29 | AGE AT DIAGNOSIS=47.40 | AGE AT DIAGNOSIS=47.74 | AGE AT DIAGNOSIS=47.93 | AGE AT DIAGNOSIS=48.03 | AGE AT DIAGNOSIS=48.04 | AGE AT DIAGNOSIS=48.10 | AGE AT DIAGNOSIS=48.35 | AGE AT DIAGNOSIS=48.60 | AGE AT DIAGNOSIS=48.84 | AGE AT DIAGNOSIS=49.14 | AGE AT DIAGNOSIS=49.64 | AGE AT DIAGNOSIS=49.83 | AGE AT DIAGNOSIS=49.94 | AGE AT DIAGNOSIS=50.23 | AGE AT DIAGNOSIS=50.34 | AGE AT DIAGNOSIS=50.83 | AGE AT DIAGNOSIS=51.17 | AGE AT DIAGNOSIS=51.40 | AGE AT DIAGNOSIS=51.44 | AGE AT DIAGNOSIS=51.62 | AGE AT DIAGNOSIS=51.63 | AGE AT DIAGNOSIS=51.64 | AGE AT DIAGNOSIS=51.85 | AGE AT DIAGNOSIS=51.92 | AGE AT DIAGNOSIS=52.06 | AGE AT DIAGNOSIS=52.07 | AGE AT DIAGNOSIS=52.20 | AGE AT DIAGNOSIS=52.50 | AGE AT DIAGNOSIS=52.52 | AGE AT DIAGNOSIS=52.69 | AGE AT DIAGNOSIS=52.88 | AGE AT DIAGNOSIS=52.98 | AGE AT DIAGNOSIS=53.26 | AGE AT DIAGNOSIS=53.30 | AGE AT DIAGNOSIS=53.65 | AGE AT DIAGNOSIS=53.85 | AGE AT DIAGNOSIS=54.00 | AGE AT DIAGNOSIS=54.06 | AGE AT DIAGNOSIS=54.12 | AGE AT DIAGNOSIS=54.18 | AGE AT DIAGNOSIS=54.35 | AGE AT DIAGNOSIS=54.37 | AGE AT DIAGNOSIS=54.59 | AGE AT DIAGNOSIS=54.60 | AGE AT DIAGNOSIS=54.72 | AGE AT DIAGNOSIS=54.94 | AGE AT DIAGNOSIS=54.98 | AGE AT DIAGNOSIS=55.20 | AGE AT DIAGNOSIS=55.39 | AGE AT DIAGNOSIS=55.42 | AGE AT DIAGNOSIS=55.49 | AGE AT DIAGNOSIS=55.52 | AGE AT DIAGNOSIS=55.55 | AGE AT DIAGNOSIS=55.71 | AGE AT DIAGNOSIS=55.98 | AGE AT DIAGNOSIS=56.15 | AGE AT DIAGNOSIS=56.41 | AGE AT DIAGNOSIS=56.42 | AGE AT DIAGNOSIS=56.62 | AGE AT DIAGNOSIS=56.64 | AGE AT DIAGNOSIS=56.85 | AGE AT DIAGNOSIS=57.01 | AGE AT DIAGNOSIS=57.22 | AGE AT DIAGNOSIS=57.25 | AGE AT DIAGNOSIS=57.58 | AGE AT DIAGNOSIS=57.64 | AGE AT DIAGNOSIS=57.68 | AGE AT DIAGNOSIS=57.70 | AGE AT DIAGNOSIS=58.23 | AGE AT DIAGNOSIS=58.58 | AGE AT DIAGNOSIS=58.71 | AGE AT DIAGNOSIS=58.78 | AGE AT DIAGNOSIS=59.03 | AGE AT DIAGNOSIS=59.35 | AGE AT DIAGNOSIS=59.56 | AGE AT DIAGNOSIS=60.28 | AGE AT DIAGNOSIS=60.33 | AGE AT DIAGNOSIS=60.36 | AGE AT DIAGNOSIS=60.39 | AGE AT DIAGNOSIS=60.46 | AGE AT DIAGNOSIS=60.78 | AGE AT DIAGNOSIS=61.10 | AGE AT DIAGNOSIS=61.28 | AGE AT DIAGNOSIS=61.31 | AGE AT DIAGNOSIS=61.33 | AGE AT DIAGNOSIS=61.74 | AGE AT DIAGNOSIS=62.11 | AGE AT DIAGNOSIS=62.20 | AGE AT DIAGNOSIS=62.28 | AGE AT DIAGNOSIS=62.36 | AGE AT DIAGNOSIS=62.46 | AGE AT DIAGNOSIS=62.96 | AGE AT DIAGNOSIS=63.08 | AGE AT DIAGNOSIS=63.10 | AGE AT DIAGNOSIS=63.30 | AGE AT DIAGNOSIS=63.33 | AGE AT DIAGNOSIS=63.61 | AGE AT DIAGNOSIS=63.73 | AGE AT DIAGNOSIS=64.01 | AGE AT DIAGNOSIS=64.26 | AGE AT DIAGNOSIS=64.28 | AGE AT DIAGNOSIS=64.29 | AGE AT DIAGNOSIS=64.61 | AGE AT DIAGNOSIS=64.97 | AGE AT DIAGNOSIS=65.35 | AGE AT DIAGNOSIS=65.52 | AGE AT DIAGNOSIS=65.53 | AGE AT DIAGNOSIS=65.59 | AGE AT DIAGNOSIS=66.39 | AGE AT DIAGNOSIS=66.80 | AGE AT DIAGNOSIS=66.86 | AGE AT DIAGNOSIS=67.01 | AGE AT DIAGNOSIS=67.03 | AGE AT DIAGNOSIS=67.10 | AGE AT DIAGNOSIS=67.11 | AGE AT DIAGNOSIS=67.13 | AGE AT DIAGNOSIS=67.48 | AGE AT DIAGNOSIS=67.60 | AGE AT DIAGNOSIS=68.04 | AGE AT DIAGNOSIS=68.18 | AGE AT DIAGNOSIS=68.46 | AGE AT DIAGNOSIS=69.38 | AGE AT DIAGNOSIS=69.88 | AGE AT DIAGNOSIS=69.89 | AGE AT DIAGNOSIS=69.95 | AGE AT DIAGNOSIS=70.07 | AGE AT DIAGNOSIS=70.23 | AGE AT DIAGNOSIS=70.28 | AGE AT DIAGNOSIS=70.30 | AGE AT DIAGNOSIS=70.51 | AGE AT DIAGNOSIS=70.67 | AGE AT DIAGNOSIS=70.98 | AGE AT DIAGNOSIS=71.02 | AGE AT DIAGNOSIS=71.09 | AGE AT DIAGNOSIS=71.11 | AGE AT DIAGNOSIS=72.22 | AGE AT DIAGNOSIS=73.11 | AGE AT DIAGNOSIS=73.19 | AGE AT DIAGNOSIS=73.64 | AGE AT DIAGNOSIS=73.65 | AGE AT DIAGNOSIS=74.56 | AGE AT DIAGNOSIS=75.13 | AGE AT DIAGNOSIS=77.31 | AGE AT DIAGNOSIS=78.08 | AGE AT DIAGNOSIS=78.12 | AGE AT DIAGNOSIS=78.52 | AGE AT DIAGNOSIS=78.82 | AGE AT DIAGNOSIS=79.06 | AGE AT DIAGNOSIS=79.19 | AGE AT DIAGNOSIS=80.65 | AGE AT DIAGNOSIS=81.18 | AGE AT DIAGNOSIS=not specified | GENDER=female | GENDER=male | GENDER=not specified | HISTOLOGY=A (grade II) | HISTOLOGY=A (grade III) | HISTOLOGY=control | HISTOLOGY=GBM (grade IV) | HISTOLOGY=OA (grade II) | HISTOLOGY=OA (grade III) | HISTOLOGY=OD (grade II) | HISTOLOGY=OD (grade III) | HISTOLOGY=PA (grade I)","CELL TYPE=12454_Neurosphere Cultures | CELL TYPE=12474_CD133 Pos_Neg_Sorted_Populations | CELL TYPE=15394_In vivo passaged | CELL TYPE=not specified | SAMPLE ID=24326 | SAMPLE ID=26460 | SAMPLE ID=31041 | SAMPLE ID=31A6 | SAMPLE ID=40152 | SAMPLE ID=40A6 | SAMPLE ID=6969-NSP | SAMPLE ID=7063 neg c14 | SAMPLE ID=7063 neg c16 | SAMPLE ID=7063 neg c18 | SAMPLE ID=7063 pos c3 | SAMPLE ID=7063 pos c4 | SAMPLE ID=7063 pos c7 | SAMPLE ID=7063c16m18 | SAMPLE ID=7063c16m18m87 | SAMPLE ID=7063c16m18m88 | SAMPLE ID=7063c18m13 | SAMPLE ID=7063c3m21 | SAMPLE ID=7063c3m21m65 | SAMPLE ID=7063c3m21m66 | SAMPLE ID=7063c4m9 | SAMPLE ID=7063c7m6 | SAMPLE ID=7063NC18m13m90 | SAMPLE ID=7063NC18m13m91 | SAMPLE ID=7081C10siCtrl | SAMPLE ID=7095c20c19m79 | SAMPLE ID=7095c20c20m82 | SAMPLE ID=7095C20C20siCtrl | SAMPLE ID=7095c20c21m86 | SAMPLE ID=7095c20m77 | SAMPLE ID=7095NC20-NC14m121 | SAMPLE ID=7095NC20-NC15m125 | SAMPLE ID=7095NC20-NC17m142 | SAMPLE ID=7095NC20-NC18m107 | SAMPLE ID=7095NC20-NC20m114 | SAMPLE ID=7095NC20-NC21m132 | SAMPLE ID=7095NC20-NC23m137 | SAMPLE ID=7095NC20-NC24m112 | SAMPLE ID=7095NC20-PC10m119 | SAMPLE ID=7095NC20-PC11m139 | SAMPLE ID=7095NC20-PC1m131 | SAMPLE ID=7095NC20-PC2m141 | SAMPLE ID=7095NC20-PC4m134 | SAMPLE ID=7095NC20-PC5m129 | SAMPLE ID=7095NC20-PC6m109 | SAMPLE ID=7095NC20-PC7m105 | SAMPLE ID=7095NC20-PC8m126 | SAMPLE ID=7095NC20-PC9m123 | SAMPLE ID=7095NC29-NC22m116 | SAMPLE ID=7101-NSP | SAMPLE ID=7113 neg c13 | SAMPLE ID=7113 neg c15 | SAMPLE ID=7113 neg c20 | SAMPLE ID=7113 pos c5 | SAMPLE ID=7113 pos c7 | SAMPLE ID=7113 pos c9 | SAMPLE ID=7113C13m24 | SAMPLE ID=7113C20m32 | SAMPLE ID=7113c5m25 | SAMPLE ID=7113c7m36 | SAMPLE ID=7179-NSP | SAMPLE ID=7186 nsp psg35 | SAMPLE ID=7192-NSP | SAMPLE ID=7194 NC16 unsorted | SAMPLE ID=7194 NC19 unsorted | SAMPLE ID=7194 NC20 unsorted | SAMPLE ID=7194C16m59 | SAMPLE ID=7194C16m60 | SAMPLE ID=7194c19m54 | SAMPLE ID=7194C7siCtrl | SAMPLE ID=7194C8m61 | SAMPLE ID=7194C8m62 | SAMPLE ID=7194PC7m57 | SAMPLE ID=71I | SAMPLE ID=7201C14siCtrl | SAMPLE ID=7202-NSP | SAMPLE ID=7225 nsp psg33 | SAMPLE ID=7227-NSP | SAMPLE ID=7259 nsp psg30 | SAMPLE ID=7276-NSP | SAMPLE ID=75A10 | SAMPLE ID=9957 | SAMPLE ID=FPC42 | SAMPLE ID=FPC43 | SAMPLE ID=FPC44 | SAMPLE ID=FPC47 | SAMPLE ID=FPC48 | SAMPLE ID=FPC49 | SAMPLE ID=FPC82 | SAMPLE ID=FPC85 | SAMPLE ID=FPC88 | SAMPLE ID=FPC90 | SAMPLE ID=FPC95 | SAMPLE ID=not specified | SAMPLE ID=SF6969 | SAMPLE ID=SF6977 | SAMPLE ID=SF7029 | SAMPLE ID=SF7030 | SAMPLE ID=SF7034 | SAMPLE ID=SF7048 | SAMPLE ID=SF7054 | SAMPLE ID=SF7059 | SAMPLE ID=SF7063 | SAMPLE ID=SF7081 | SAMPLE ID=SF7082 | SAMPLE ID=SF7093 | SAMPLE ID=SF7095 | SAMPLE ID=SF7101 | SAMPLE ID=SF7113 | SAMPLE ID=SF7179 | SAMPLE ID=SF7179-2 | SAMPLE ID=SF7180 | SAMPLE ID=SF7186 | SAMPLE ID=SF7192 | SAMPLE ID=SF7194 | SAMPLE ID=SF7201 | SAMPLE ID=SF7223 | SAMPLE ID=SF7225-2 | SAMPLE ID=SF7227 | SAMPLE ID=SF7228 | SAMPLE ID=SF7259 | SAMPLE ID=SF7276 | SAMPLE ID=SF7284 | SOURCE=MD Anderson | SOURCE=not specified | SOURCE=UCSF | VARIATION=not specified | VARIATION=p53 exon 4-8 mutation status: HETSUB. 273R&gt;L | VARIATION=p53 exon 4-8 mutation status: HETSUB.216V&gt;A | VARIATION=p53 exon 4-8 mutation status: HETSUB.220Y&gt;H | VARIATION=p53 exon 4-8 mutation status: HETSUB.266G&gt;R, HETSUB.267R&gt;W | VARIATION=p53 exon 4-8 mutation status: HETSUB.283R&gt;C | VARIATION=p53 exon 4-8 mutation status: HOMSUB.220Y&gt;C | VARIATION=p53 exon 4-8 mutation status: HOMSUB.282R&gt;W | VARIATION=p53 exon 4-8 mutation status: ND | VARIATION=p53 exon 4-8 mutation status: wt","DISEASE STATE=colorectal cancer stage 1 | DISEASE STATE=colorectal cancer stage I | DISEASE STATE=colorectal cancer stage II | DISEASE STATE=healthy | DISEASE STATE=normal | DISEASE STATE=not specified | TISSUE=blood | TISSUE=colorectal cancer | TISSUE=colorectal mucosa (same patient as ch1) | TISSUE=comprised of 10 cell lines for human giving broad gene coverage | TISSUE=normal colon mucosa obtained from the same patient as Channel 1 | TISSUE=tumor","NA","BIOSOURCEPROVIDER=GBM TIC cells were provided from Dr. A. Daga (IST, Genova, Italy) | BIOSOURCEPROVIDER=GBM TIC cells were provided from Dr. A. Daga (IST, Genova, Italy).","ANTIBODY=CBP | ANTIBODY=p300 | TIME AFTER STIMULATION=T0 (minutes) | TIME AFTER STIMULATION=T30 (minutes)","NA","CELL TYPE=glioblastoma | CELL TYPE=non-neoplastic | CLASS=normal | CLASS=WHO IV","CELL TYPE=glioblastoma | CELL TYPE=non-neoplastic | CELL TYPE=normal reference | CLASS=normal | CLASS=not specified | CLASS=WHO IV | GENDER=female | GENDER=male | GENDER=not specified","CELL TYPE=glioblastoma | CELL TYPE=normal reference","CELL TYPE=glioblastoma | CELL TYPE=normal reference | GENDER=female | GENDER=male | GENDER=not specified","CELL TYPE=glioblastoma | CELL TYPE=non-neoplastic | CLASS=normal | CLASS=WHO IV","TIME=0 d | TIME=3 d","AGE=10 | AGE=18 | AGE=28 | AGE=32 | AGE=34 | AGE=45 | AGE=54 | AGE=62 | AGE=64 | AGE=65 | AGE=68 | AGE=69 | AGE=72 | AGE=73 | AGE=78 | AGE=8 | AGE=80 | GRADE=not specified | GRADE=WHO grade Ⅰ | GRADE=WHO grade Ⅱ | GRADE=WHO grade Ⅲ | GRADE=WHO grade Ⅳ | SEX=F | SEX=M | TISSUE=anaplastic astrocytomas | TISSUE=Apilocytic astrocytoma, juvenile pilocytic astrocytoma, or cystic cerebellar astrocytoma | TISSUE=diffusely infiltrating astrocytic gliomas | TISSUE=Glioblastoma multiforme (GBM glioblastomas) | TISSUE=pooled normal brain tissue","NA","NA","AGE=13 years | AGE=16 years | AGE=24 years | AGE=3 years | AGE=4 years | AGE=44 years | AGE=50 years | AGE=53 years | AGE=60 years | AGE=8 years | CELLLINE=A172 | CELLLINE=KNS42 | CELLLINE=LN229 | CELLLINE=Res186 | CELLLINE=Res259 | CELLLINE=SF188 | CELLLINE=SF268 | CELLLINE=U118MG | CELLLINE=U87MG | CELLLINE=UW479 | DISEASESTATE=anaplastic astrocytoma | DISEASESTATE=diffusely infiltrating astrocytoma | DISEASESTATE=glioblastoma | DISEASESTATE=pilocytic astrocytoma | MATERIALTYPE=genomic_DNA | MATERIALTYPE=total_RNA | SEX=female | SEX=male","histology=control | histology=glioblastoma surrounding tissue | histology=glioblastoma tumor mass","DISEASESTATE=high grade glioblastoma | DISEASESTATE=high grade glioblastoma/gliosarcoma | DISEASESTATE=high grade gliosarcoma | DISEASESTATE=low grade anaplastic mixed glioma | DISEASESTATE=low grade oligodendroglioma","clinical history=first occurrence of tumor | clinical history=second occurrence of tumor | treatment=before treatment | treatment=dendritic cell vaccination | treatment=none","AGE=-- | AGE=25 | AGE=29 | AGE=32 | AGE=33 | AGE=34 | AGE=35 | AGE=36 | AGE=37 | AGE=38 | AGE=39 | AGE=40 | AGE=41 | AGE=42 | AGE=43 | AGE=44 | AGE=45 | AGE=46 | AGE=47 | AGE=48 | AGE=49 | AGE=50 | AGE=51 | AGE=52 | AGE=53 | AGE=55 | AGE=56 | AGE=57 | AGE=58 | AGE=59 | AGE=60 | AGE=61 | AGE=62 | AGE=63 | AGE=64 | AGE=65 | AGE=67 | AGE=68 | AGE=69 | AGE=70 | AGE=71 | AGE=72 | AGE=74 | AGE=75 | AGE=76 | AGE=77 | AGE=78 | AGE=79 | AGE=80 | AGE=82 | AGE=83 | AGE=84 | AGE=85 | AGE=86 | AGE=88 | AGE=not specified | BIOSOURCEPROVIDER=Charles Perou - UNC | BIOSOURCEPROVIDER=Mattew Ewend - UNC | BIOSOURCEPROVIDER=not specified | BIOSOURCEPROVIDER=Phil Bernard - Utah | BIOSOURCEPROVIDER=Strategene | BIOSOURCEPROVIDER=University of Chicago | DSCORES UNC337=-0.001378024 | DSCORES UNC337=-0.00217497 | DSCORES UNC337=-0.002873519 | DSCORES UNC337=-0.003811602 | DSCORES UNC337=-0.005894239 | DSCORES UNC337=-0.008820645 | DSCORES UNC337=-0.011542429 | DSCORES UNC337=-0.017456137 | DSCORES UNC337=-0.018129797 | DSCORES UNC337=-0.018193361 | DSCORES UNC337=-0.018873674 | DSCORES UNC337=-0.020824807 | DSCORES UNC337=-0.021718075 | DSCORES UNC337=-0.024572099 | DSCORES UNC337=-0.027772254 | DSCORES UNC337=-0.030324076 | DSCORES UNC337=-0.043220129 | DSCORES UNC337=-0.046578966 | DSCORES UNC337=-0.058322786 | DSCORES UNC337=-0.060366166 | DSCORES UNC337=-0.070927848 | DSCORES UNC337=-0.070995094 | DSCORES UNC337=-0.072230313 | DSCORES UNC337=-0.074100939 | DSCORES UNC337=-0.076956332 | DSCORES UNC337=-0.077427995 | DSCORES UNC337=-0.078075617 | DSCORES UNC337=-0.079277566 | DSCORES UNC337=-0.085534984 | DSCORES UNC337=-0.087492828 | DSCORES UNC337=-0.088074412 | DSCORES UNC337=-0.089245371 | DSCORES UNC337=-0.089467593 | DSCORES UNC337=-0.093314279 | DSCORES UNC337=-0.100059139 | DSCORES UNC337=-0.100214475 | DSCORES UNC337=-0.101088481 | DSCORES UNC337=-0.103120394 | DSCORES UNC337=-0.103352612 | DSCORES UNC337=-0.10398546 | DSCORES UNC337=-0.106251522 | DSCORES UNC337=-0.111452396 | DSCORES UNC337=-0.111825553 | DSCORES UNC337=-0.11487527 | DSCORES UNC337=-0.116155055 | DSCORES UNC337=-0.121555187 | DSCORES UNC337=-0.12512537 | DSCORES UNC337=-0.130368753 | DSCORES UNC337=-0.131055212 | DSCORES UNC337=-0.133012108 | DSCORES UNC337=-0.136748482 | DSCORES UNC337=-0.139728878 | DSCORES UNC337=-0.139970175 | DSCORES UNC337=-0.141073782 | DSCORES UNC337=-0.141183574 | DSCORES UNC337=-0.141196613 | DSCORES UNC337=-0.142482868 | DSCORES UNC337=-0.142681898 | DSCORES UNC337=-0.148836373 | DSCORES UNC337=-0.149187027 | DSCORES UNC337=-0.152624184 | DSCORES UNC337=-0.15275454 | DSCORES UNC337=-0.154199146 | DSCORES UNC337=-0.15499191 | DSCORES UNC337=-0.156379224 | DSCORES UNC337=-0.15923879 | DSCORES UNC337=-0.162222572 | DSCORES UNC337=-0.163597374 | DSCORES UNC337=-0.164353074 | DSCORES UNC337=-0.164728928 | DSCORES UNC337=-0.165466578 | DSCORES UNC337=-0.167149954 | DSCORES UNC337=-0.167184068 | DSCORES UNC337=-0.168717694 | DSCORES UNC337=-0.173309474 | DSCORES UNC337=-0.175019598 | DSCORES UNC337=-0.177821487 | DSCORES UNC337=-0.178244007 | DSCORES UNC337=-0.180655739 | DSCORES UNC337=-0.18480251 | DSCORES UNC337=-0.185911723 | DSCORES UNC337=-0.187392348 | DSCORES UNC337=-0.190093652 | DSCORES UNC337=-0.19453827 | DSCORES UNC337=-0.195556923 | DSCORES UNC337=-0.196194014 | DSCORES UNC337=-0.199466614 | DSCORES UNC337=-0.202063014 | DSCORES UNC337=-0.209007067 | DSCORES UNC337=-0.22418812 | DSCORES UNC337=-0.228123879 | DSCORES UNC337=-0.231023479 | DSCORES UNC337=-0.240188822 | DSCORES UNC337=-0.246967902 | DSCORES UNC337=-0.256040048 | DSCORES UNC337=-0.257101319 | DSCORES UNC337=-0.273592059 | DSCORES UNC337=0.000893689 | DSCORES UNC337=0.002466891 | DSCORES UNC337=0.002575898 | DSCORES UNC337=0.010829822 | DSCORES UNC337=0.012214554 | DSCORES UNC337=0.012227346 | DSCORES UNC337=0.016442362 | DSCORES UNC337=0.01718866 | DSCORES UNC337=0.021242022 | DSCORES UNC337=0.026924514 | DSCORES UNC337=0.028346589 | DSCORES UNC337=0.032427906 | DSCORES UNC337=0.035391403 | DSCORES UNC337=0.035865658 | DSCORES UNC337=0.036467632 | DSCORES UNC337=0.03807137 | DSCORES UNC337=0.040847836 | DSCORES UNC337=0.041379815 | DSCORES UNC337=0.045092888 | DSCORES UNC337=0.04989688 | DSCORES UNC337=0.05058388 | DSCORES UNC337=0.051503271 | DSCORES UNC337=0.055650828 | DSCORES UNC337=0.057844738 | DSCORES UNC337=0.05944229 | DSCORES UNC337=0.060468909 | DSCORES UNC337=0.06164142 | DSCORES UNC337=0.064431265 | DSCORES UNC337=0.068485715 | DSCORES UNC337=0.072543507 | DSCORES UNC337=0.076477925 | DSCORES UNC337=0.08086126 | DSCORES UNC337=0.084330757 | DSCORES UNC337=0.084596849 | DSCORES UNC337=0.085928653 | DSCORES UNC337=0.085930885 | DSCORES UNC337=0.087448903 | DSCORES UNC337=0.087786604 | DSCORES UNC337=0.089735024 | DSCORES UNC337=0.090605833 | DSCORES UNC337=0.091804097 | DSCORES UNC337=0.091992306 | DSCORES UNC337=0.096288498 | DSCORES UNC337=0.098357355 | DSCORES UNC337=0.099093004 | DSCORES UNC337=0.10431567 | DSCORES UNC337=0.104755066 | DSCORES UNC337=0.106901872 | DSCORES UNC337=0.108317434 | DSCORES UNC337=0.111592233 | DSCORES UNC337=0.112330611 | DSCORES UNC337=0.112666502 | DSCORES UNC337=0.11318318 | DSCORES UNC337=0.113688427 | DSCORES UNC337=0.114004379 | DSCORES UNC337=0.116023254 | DSCORES UNC337=0.120566521 | DSCORES UNC337=0.123575485 | DSCORES UNC337=0.124895261 | DSCORES UNC337=0.125716285 | DSCORES UNC337=0.130689938 | DSCORES UNC337=0.133365316 | DSCORES UNC337=0.133924899 | DSCORES UNC337=0.137394974 | DSCORES UNC337=0.141588937 | DSCORES UNC337=0.142178555 | DSCORES UNC337=0.148812671 | DSCORES UNC337=0.153505376 | DSCORES UNC337=0.153756391 | DSCORES UNC337=0.1567948 | DSCORES UNC337=0.165300669 | DSCORES UNC337=0.168800794 | DSCORES UNC337=0.168827946 | DSCORES UNC337=0.180559749 | DSCORES UNC337=0.182816726 | DSCORES UNC337=0.185046936 | DSCORES UNC337=0.185552911 | DSCORES UNC337=0.186692997 | DSCORES UNC337=0.189882962 | DSCORES UNC337=0.203598567 | DSCORES UNC337=0.205320044 | DSCORES UNC337=0.211011596 | DSCORES UNC337=0.214928388 | DSCORES UNC337=0.215012506 | DSCORES UNC337=0.215817398 | DSCORES UNC337=0.218022401 | DSCORES UNC337=0.232044838 | DSCORES UNC337=0.238798882 | DSCORES UNC337=0.241027684 | DSCORES UNC337=0.247607477 | DSCORES UNC337=0.296830543 | DSCORES UNC337=not specified | ER  (1=POSITIVE; 0=NEGATIVE)=-- | ER  (1=POSITIVE; 0=NEGATIVE)=0 | ER  (1=POSITIVE; 0=NEGATIVE)=1 | ER  (1=POSITIVE; 0=NEGATIVE)=not specified | GRADE=-- | GRADE=1 | GRADE=2 | GRADE=3 | GRADE=not specified | HER2 CLINICAL STATUS IHC/FISH (1=POSITIVE; 0=NEGATIVE)=-- | HER2 CLINICAL STATUS IHC/FISH (1=POSITIVE; 0=NEGATIVE)=0 | HER2 CLINICAL STATUS IHC/FISH (1=POSITIVE; 0=NEGATIVE)=1 | HER2 CLINICAL STATUS IHC/FISH (1=POSITIVE; 0=NEGATIVE)=not specified | NODE STATUS (1=POSITIVE=1 OR MORE NODES+; 0=NEGATIVE)=-- | NODE STATUS (1=POSITIVE=1 OR MORE NODES+; 0=NEGATIVE)=0 | NODE STATUS (1=POSITIVE=1 OR MORE NODES+; 0=NEGATIVE)=1 | NODE STATUS (1=POSITIVE=1 OR MORE NODES+; 0=NEGATIVE)=not specified | OVERALL SURVIVAL EVENT (0=ALIVE, 1=DOD OR DOC)=-- | OVERALL SURVIVAL EVENT (0=ALIVE, 1=DOD OR DOC)=0 | OVERALL SURVIVAL EVENT (0=ALIVE, 1=DOD OR DOC)=1 | OVERALL SURVIVAL EVENT (0=ALIVE, 1=DOD OR DOC)=not specified | OVERALL SUVIVAL MONTHS=-- | OVERALL SUVIVAL MONTHS=1 | OVERALL SUVIVAL MONTHS=10 | OVERALL SUVIVAL MONTHS=101 | OVERALL SUVIVAL MONTHS=106 | OVERALL SUVIVAL MONTHS=11 | OVERALL SUVIVAL MONTHS=118 | OVERALL SUVIVAL MONTHS=12 | OVERALL SUVIVAL MONTHS=13 | OVERALL SUVIVAL MONTHS=14 | OVERALL SUVIVAL MONTHS=15 | OVERALL SUVIVAL MONTHS=16 | OVERALL SUVIVAL MONTHS=17 | OVERALL SUVIVAL MONTHS=18 | OVERALL SUVIVAL MONTHS=19 | OVERALL SUVIVAL MONTHS=2 | OVERALL SUVIVAL MONTHS=20 | OVERALL SUVIVAL MONTHS=21 | OVERALL SUVIVAL MONTHS=22 | OVERALL SUVIVAL MONTHS=23 | OVERALL SUVIVAL MONTHS=24 | OVERALL SUVIVAL MONTHS=25 | OVERALL SUVIVAL MONTHS=26 | OVERALL SUVIVAL MONTHS=27 | OVERALL SUVIVAL MONTHS=28 | OVERALL SUVIVAL MONTHS=29 | OVERALL SUVIVAL MONTHS=3 | OVERALL SUVIVAL MONTHS=30 | OVERALL SUVIVAL MONTHS=31 | OVERALL SUVIVAL MONTHS=32 | OVERALL SUVIVAL MONTHS=33 | OVERALL SUVIVAL MONTHS=35 | OVERALL SUVIVAL MONTHS=36 | OVERALL SUVIVAL MONTHS=37 | OVERALL SUVIVAL MONTHS=39 | OVERALL SUVIVAL MONTHS=4 | OVERALL SUVIVAL MONTHS=41 | OVERALL SUVIVAL MONTHS=42 | OVERALL SUVIVAL MONTHS=43 | OVERALL SUVIVAL MONTHS=44 | OVERALL SUVIVAL MONTHS=47 | OVERALL SUVIVAL MONTHS=48 | OVERALL SUVIVAL MONTHS=5 | OVERALL SUVIVAL MONTHS=51 | OVERALL SUVIVAL MONTHS=53 | OVERALL SUVIVAL MONTHS=54 | OVERALL SUVIVAL MONTHS=57 | OVERALL SUVIVAL MONTHS=60 | OVERALL SUVIVAL MONTHS=62 | OVERALL SUVIVAL MONTHS=64 | OVERALL SUVIVAL MONTHS=65 | OVERALL SUVIVAL MONTHS=68 | OVERALL SUVIVAL MONTHS=7 | OVERALL SUVIVAL MONTHS=72 | OVERALL SUVIVAL MONTHS=74 | OVERALL SUVIVAL MONTHS=76 | OVERALL SUVIVAL MONTHS=8 | OVERALL SUVIVAL MONTHS=81 | OVERALL SUVIVAL MONTHS=9 | OVERALL SUVIVAL MONTHS=94 | OVERALL SUVIVAL MONTHS=96 | OVERALL SUVIVAL MONTHS=not specified | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=Basal | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=Claudin | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=Her2 | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=LumA | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=LumB | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=Normal | PAM50 PREDICTIONS PLUS CLAUDIN-LOW CLASSIFICATION (CELL LINE PREDICTOR)=not specified | PGR  (1=POSITIVE; 0=NEGATIVE)=-- | PGR  (1=POSITIVE; 0=NEGATIVE)=0 | PGR  (1=POSITIVE; 0=NEGATIVE)=1 | PGR  (1=POSITIVE; 0=NEGATIVE)=not specified | RFS EVENT (0=NO RELAPSE, 1=RELAPSED AT ANY SITE OR DIED OF DISEASE)=-- | RFS EVENT (0=NO RELAPSE, 1=RELAPSED AT ANY SITE OR DIED OF DISEASE)=0 | RFS EVENT (0=NO RELAPSE, 1=RELAPSED AT ANY SITE OR DIED OF DISEASE)=1 | RFS EVENT (0=NO RELAPSE, 1=RELAPSED AT ANY SITE OR DIED OF DISEASE)=not specified | RFS MONTHS=-- | RFS MONTHS=1 | RFS MONTHS=10 | RFS MONTHS=106 | RFS MONTHS=11 | RFS MONTHS=118 | RFS MONTHS=12 | RFS MONTHS=13 | RFS MONTHS=14 | RFS MONTHS=15 | RFS MONTHS=16 | RFS MONTHS=17 | RFS MONTHS=18 | RFS MONTHS=19 | RFS MONTHS=2 | RFS MONTHS=20 | RFS MONTHS=21 | RFS MONTHS=22 | RFS MONTHS=23 | RFS MONTHS=24 | RFS MONTHS=25 | RFS MONTHS=26 | RFS MONTHS=27 | RFS MONTHS=28 | RFS MONTHS=29 | RFS MONTHS=3 | RFS MONTHS=30 | RFS MONTHS=31 | RFS MONTHS=32 | RFS MONTHS=33 | RFS MONTHS=35 | RFS MONTHS=36 | RFS MONTHS=37 | RFS MONTHS=39 | RFS MONTHS=4 | RFS MONTHS=41 | RFS MONTHS=42 | RFS MONTHS=43 | RFS MONTHS=44 | RFS MONTHS=48 | RFS MONTHS=5 | RFS MONTHS=51 | RFS MONTHS=53 | RFS MONTHS=54 | RFS MONTHS=57 | RFS MONTHS=6 | RFS MONTHS=62 | RFS MONTHS=65 | RFS MONTHS=68 | RFS MONTHS=7 | RFS MONTHS=76 | RFS MONTHS=8 | RFS MONTHS=81 | RFS MONTHS=9 | RFS MONTHS=96 | RFS MONTHS=not specified | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=-- | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=1 | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=2 | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=3 | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=4 | SIZE (1= &lt;=2CM; 2= &gt;2CM TO &lt;=5CM; 3=&gt;5CM; 4=ANY SIZE WITH DIRECT EXTENSION TO CHEST WALL OR SKIN)=not specified","TISSUE TYPE=Glioblastoma multiforme (GBM) xenograft tumor tissue | TISSUE TYPE=Gliotic brain tissue | TUMOR GRADE=Grade-IV tumor | TUMOR GRADE=Non-tumor brain","AGE=10 | AGE=41 | AGE=44 | AGE=55 | AGE=56 | AGE=61 | AGE=64 | AGE=65 | AGE=69 | AGE=71 | AGE=73 | GENDER=F | GENDER=M","disease=astrocytoma | disease=glioblastoma multiforme | disease=mixed | disease=normal | disease=oligodendroglioma | disease=unclassified | disease=unknown","CellLine=ATCC:CRL-1544 | CellLine=ATCC:CRL-1690 | CellLine=ATCC:HTB-130 | CellLine=ATCC:HTB-92 | DiseaseStage=angiogenic tumor | DiseaseStage=dormant tumor","NA","compound=DMSO | compound=enzastaurin | time=10 hour | time=18 hour | time=4 hour","CELL_LINE=N/A | CELL_LINE=n/a | CELL_LINE=T98G | CELL_LINE=U118 | CELL_LINE=U138 | CELL_LINE=U343 | CELL_LINE=U373 | CELL_LINE=U87 | CELL_TYPE=neutrophil | CELL_TYPE=tumor cell | DISEASE_STATE=Glioblastoma | DISEASE_STATE=normal | INDIVIDUAL=C10 | INDIVIDUAL=C11 | INDIVIDUAL=C12 | INDIVIDUAL=C13 | INDIVIDUAL=C14 | INDIVIDUAL=C15 | INDIVIDUAL=C18 | INDIVIDUAL=C19 | INDIVIDUAL=C20 | INDIVIDUAL=C21 | INDIVIDUAL=C22 | INDIVIDUAL=C3 | INDIVIDUAL=C4 | INDIVIDUAL=C5 | INDIVIDUAL=C6 | INDIVIDUAL=C7 | INDIVIDUAL=C8 | INDIVIDUAL=C9 | INDIVIDUAL=D1 | INDIVIDUAL=D10 | INDIVIDUAL=D11 | INDIVIDUAL=D12 | INDIVIDUAL=D13 | INDIVIDUAL=D14 | INDIVIDUAL=D15 | INDIVIDUAL=D2 | INDIVIDUAL=D3 | INDIVIDUAL=D4 | INDIVIDUAL=D5 | INDIVIDUAL=D6 | INDIVIDUAL=D7 | INDIVIDUAL=D8 | INDIVIDUAL=D9 | INDIVIDUAL=GBM 1-CSC | INDIVIDUAL=GBM 12 | INDIVIDUAL=GBM 5 | INDIVIDUAL=GBM 7 | INDIVIDUAL=GBML10 | INDIVIDUAL=GBML2 | INDIVIDUAL=GBML3 | INDIVIDUAL=GBML4 | INDIVIDUAL=GBML5 | INDIVIDUAL=GBML6 | INDIVIDUAL=GBML7 | INDIVIDUAL=GBMS1 | INDIVIDUAL=GBMS10 | INDIVIDUAL=GBMS11 | INDIVIDUAL=GBMS2 | INDIVIDUAL=GBMS3 | INDIVIDUAL=GBMS4 | INDIVIDUAL=GBMS5 | INDIVIDUAL=GBMS6 | INDIVIDUAL=GBMS7 | INDIVIDUAL=GBMS8 | INDIVIDUAL=GBMS9 | INDIVIDUAL=n/a | MATERIAL TYPE=cell line | MATERIAL TYPE=explant | MATERIAL TYPE=frozen tissue","NA","DISEASE_STATE=Glioblastoma | DISEASE_STATE=reference | INDIVIDUAL=reference | INDIVIDUAL=tumor 1 | INDIVIDUAL=tumor 3 | INDIVIDUAL=tumor 4 | INDIVIDUAL=tumor 5 | INDIVIDUAL=tumor 6","BIOSOURCEPROVIDER=ATCC | BIOSOURCEPROVIDER=Lonza (Basel, Switzerland) | GROWTH MEDIUM=Astrocyte Basal Medium (ABM™) and the following growth supplements: rhEGF, 0.5 ml; Insulin, 1.25 ml; Ascorbic Acid, 0.5 ml; GA-1000, 0.5 ml, L-Glutamine, 5.0 ml; FBS, 15 ml. | GROWTH MEDIUM=Dulbecco's Modified Eagle Medium and the following growth supplements: Penicillin/streptomycin, 5.0 ml; L-Glutamine, 5.0 ml; FBS, 15 ml. | PASSAGE=4 | PASSAGE=50","DISEASE_STATE=glioblastoma | DISEASE_STATE=normal | PATIENT=patient 1 | PATIENT=patient 2","BIOSOURCEPROVIDER=ATCC | BIOSOURCEPROVIDER=DMSZ | BIOSOURCEPROVIDER=DSMZ | BIOSOURCEPROVIDER=ECACC | CELLLINE=1A2 | CELLLINE=22Rv1 | CELLLINE=5637 | CELLLINE=639V | CELLLINE=647V | CELLLINE=769P | CELLLINE=A101D | CELLLINE=A172 | CELLLINE=A204 | CELLLINE=A375 | CELLLINE=A427 | CELLLINE=A498 | CELLLINE=A673 | CELLLINE=A7 | CELLLINE=ACHN | CELLLINE=AGS | CELLLINE=AN3CA | CELLLINE=ARH77 | CELLLINE=AsPC1 | CELLLINE=BC1 | CELLLINE=BC2 | CELLLINE=BC3 | CELLLINE=BDCM | CELLLINE=BE2C | CELLLINE=BeWo | CELLLINE=BFTC905 | CELLLINE=BHT101 | CELLLINE=BM1604 | CELLLINE=BPH1 | CELLLINE=BT20 | CELLLINE=BT474 | CELLLINE=BV173 | CELLLINE=C32TG | CELLLINE=C33A | CELLLINE=C3A | CELLLINE=C4I | CELLLINE=C4II | CELLLINE=CA46 | CELLLINE=CaHPV10 | CELLLINE=Caki1 | CELLLINE=Caki2 | CELLLINE=CAL54 | CELLLINE=CAL62 | CELLLINE=Calu1 | CELLLINE=Calu3 | CELLLINE=Calu6 | CELLLINE=CaOv3 | CELLLINE=Caov4 | CELLLINE=Capan1 | CELLLINE=Capan2 | CELLLINE=CCFSTTG1 | CELLLINE=CCRFCEM | CELLLINE=CCRFSB | CELLLINE=CEMC1 | CELLLINE=CESS | CELLLINE=CGTHW1 | CELLLINE=CHL1 | CELLLINE=CHP212 | CELLLINE=CMLT1 | CELLLINE=COLO201 | CELLLINE=COLO320HSR | CELLLINE=COLO704 | CELLLINE=COLO829 | CELLLINE=CORL105 | CELLLINE=CORL23 | CELLLINE=CORL279 | CELLLINE=CORL88 | CELLLINE=CROAP2 | CELLLINE=CROAP5 | CELLLINE=D283Med | CELLLINE=D341Med | CELLLINE=Daudi | CELLLINE=DB | CELLLINE=DBTRG05MG | CELLLINE=Detroit562 | CELLLINE=DG75 | CELLLINE=DKMG | CELLLINE=DMS114 | CELLLINE=DMS153 | CELLLINE=DMS273 | CELLLINE=DMS53 | CELLLINE=DMS79 | CELLLINE=DOHH2 | CELLLINE=DoTc2 | CELLLINE=DU4475 | CELLLINE=EB1 | CELLLINE=EB2 | CELLLINE=EB3 | CELLLINE=EFM19 | CELLLINE=EM2 | CELLLINE=ES2 | CELLLINE=FaDu | CELLLINE=Farage | CELLLINE=G401 | CELLLINE=G402 | CELLLINE=GA10 | CELLLINE=GCT | CELLLINE=GDM1 | CELLLINE=H4 | CELLLINE=H69AR | CELLLINE=HCC1008 | CELLLINE=HCC1143 | CELLLINE=HCC1395 | CELLLINE=HCC1599 | CELLLINE=HCC1937 | CELLLINE=HCC1954 | CELLLINE=HCC2157 | CELLLINE=HCC2218 | CELLLINE=HCC38 | CELLLINE=HCC70 | CELLLINE=HCT15 | CELLLINE=HCT8 | CELLLINE=HDMYZ | CELLLINE=HEC1A | CELLLINE=HEC1B | CELLLINE=HEL9217 | CELLLINE=Hep3B | CELLLINE=HepG2 | CELLLINE=HH | CELLLINE=HL60 | CELLLINE=HL60MX1 | CELLLINE=HMCB | CELLLINE=HOS | CELLLINE=HPAC | CELLLINE=HPAFII | CELLLINE=HSSultan | CELLLINE=HT | CELLLINE=HT1080 | CELLLINE=HT1197 | CELLLINE=HT1376 | CELLLINE=HT3 | CELLLINE=HuNS1 | CELLLINE=HuPT4 | CELLLINE=HuT78 | CELLLINE=J82 | CELLLINE=JAR | CELLLINE=JEG3 | CELLLINE=Jiyoye | CELLLINE=JM1 | CELLLINE=JRT3T35 | CELLLINE=JVM3 | CELLLINE=K562 | CELLLINE=Kasumi2 | CELLLINE=KATOIII | CELLLINE=KG1 | CELLLINE=KHOS240S | CELLLINE=KLE | CELLLINE=KPL1 | CELLLINE=KU812 | CELLLINE=KYSE30 | CELLLINE=L428 | CELLLINE=LS1034 | CELLLINE=LS174T | CELLLINE=Malme3M | CELLLINE=MC116 | CELLLINE=MCCAR | CELLLINE=MCF7 | CELLLINE=MCIXC | CELLLINE=MDAMB175VII | CELLLINE=MDAMB453 | CELLLINE=MEC1 | CELLLINE=MEG01 | CELLLINE=MESSA | CELLLINE=MESSADX5 | CELLLINE=MESSAMX2 | CELLLINE=MG63 | CELLLINE=MHHPREB1 | CELLLINE=MIA Paca-2 | CELLLINE=MJ | CELLLINE=ML2 | CELLLINE=MOLT16 | CELLLINE=MOLT3 | CELLLINE=MOLT4 | CELLLINE=MT3 | CELLLINE=MV4II | CELLLINE=NALM1 | CELLLINE=NALM6 | CELLLINE=NAMALWA | CELLLINE=NC37 | CELLLINE=NCIH1048 | CELLLINE=NCIH1092 | CELLLINE=NCIH1155 | CELLLINE=NCIH1355 | CELLLINE=NCIH1395 | CELLLINE=NCIH1404 | CELLLINE=NCIH1436 | CELLLINE=NCIH1437 | CELLLINE=NCIH146 | CELLLINE=NCIH1573 | CELLLINE=NCIH1581 | CELLLINE=NCIH1618 | CELLLINE=NCIH1623 | CELLLINE=NCIH1650 | CELLLINE=NCIH1651 | CELLLINE=NCIH1666 | CELLLINE=NCIH1694 | CELLLINE=NCIH1703 | CELLLINE=NCIH1755 | CELLLINE=NCIH1770 | CELLLINE=NCIH1792 | CELLLINE=NCIH1793 | CELLLINE=NCIH1838 | CELLLINE=NCIH187 | CELLLINE=NCIH1930 | CELLLINE=NCIH1975 | CELLLINE=NCIH1993 | CELLLINE=NCIH2009 | CELLLINE=NCIH2030 | CELLLINE=NCIH2052 | CELLLINE=NCIH2081 | CELLLINE=NCIH2087 | CELLLINE=NCIH209 | CELLLINE=NCIH2107 | CELLLINE=NCIH2122 | CELLLINE=NCIH2126 | CELLLINE=NCIH2170 | CELLLINE=NCIH2171 | CELLLINE=NCIH2195 | CELLLINE=NCIH2228 | CELLLINE=NCIH226 | CELLLINE=NCIH23 | CELLLINE=NCIH2347 | CELLLINE=NCIH295R | CELLLINE=NCIH322 | CELLLINE=NCIH358 | CELLLINE=NCIH378 | CELLLINE=NCIH441 | CELLLINE=NCIH446 | CELLLINE=NCIH520 | CELLLINE=NCIH522 | CELLLINE=NCIH524 | CELLLINE=NCIH526 | CELLLINE=NCIH596 | CELLLINE=NCIH630 | CELLLINE=NCIH650 | CELLLINE=NCIH660 | CELLLINE=NCIH661 | CELLLINE=NCIH69 | CELLLINE=NCIH716 | CELLLINE=NCIH720 | CELLLINE=NCIH747 | CELLLINE=NCIH748 | CELLLINE=NCIH810 | CELLLINE=NCIH82 | CELLLINE=NCIH838 | CELLLINE=OE19 | CELLLINE=OE21 | CELLLINE=OE33 | CELLLINE=OV90 | CELLLINE=OVCAR3 | CELLLINE=P3HR1 | CELLLINE=Pfeiffer | CELLLINE=PLB985 | CELLLINE=Raji | CELLLINE=RCHACV | CELLLINE=RD | CELLLINE=RDES | CELLLINE=REC1 | CELLLINE=RKOE6 | CELLLINE=RL | CELLLINE=RL952 | CELLLINE=RPMI6666 | CELLLINE=RPMI8226 | CELLLINE=RWPE1 | CELLLINE=SCaBER | CELLLINE=SEM | CELLLINE=SH4 | CELLLINE=SHP77 | CELLLINE=SiHa | CELLLINE=SJRH30 | CELLLINE=SJSA1 | CELLLINE=SKLMS1 | CELLLINE=SKMEL1 | CELLLINE=SKMEL3 | CELLLINE=SKMES1 | CELLLINE=SKNAS | CELLLINE=SKNDZ | CELLLINE=SKNEP1 | CELLLINE=SKNFI | CELLLINE=SKO007 | CELLLINE=SKOV3 | CELLLINE=SKUT1 | CELLLINE=SNB19 | CELLLINE=SNU1 | CELLLINE=SNU16 | CELLLINE=SNU182 | CELLLINE=SNU387 | CELLLINE=SNU398 | CELLLINE=SNU423 | CELLLINE=SNU449 | CELLLINE=SNU475 | CELLLINE=SNU5 | CELLLINE=SR | CELLLINE=ST486 | CELLLINE=SUDHL10 | CELLLINE=SUDHL16 | CELLLINE=SUDHL5 | CELLLINE=SUDHL6 | CELLLINE=SW1088 | CELLLINE=SW1116 | CELLLINE=SW1353 | CELLLINE=SW1417 | CELLLINE=SW1463 | CELLLINE=SW1573 | CELLLINE=SW1783 | CELLLINE=SW1990 | CELLLINE=SW403 | CELLLINE=SW48 | CELLLINE=SW480 | CELLLINE=SW620 | CELLLINE=SW684 | CELLLINE=SW756 | CELLLINE=SW780 | CELLLINE=SW837 | CELLLINE=SW872 | CELLLINE=SW900 | CELLLINE=SW948 | CELLLINE=SW954 | CELLLINE=SW962 | CELLLINE=SW982 | CELLLINE=T84 | CELLLINE=TANOUE | CELLLINE=TE381T | CELLLINE=THP1 | CELLLINE=TO175T | CELLLINE=Toledo | CELLLINE=TT | CELLLINE=U138MG | CELLLINE=U266B1 | CELLLINE=UACC812 | CELLLINE=UACC893 | CELLLINE=UMUC3 | CELLLINE=WERIRb1 | CELLLINE=WI38 | CELLLINE=WIDR | CELLLINE=WM115 | CELLLINE=Y79 | CELLLINE=YPAC | CLINICALINFORMATION=ICDO: C06 | CLINICALINFORMATION=ICDO: C13 | CLINICALINFORMATION=ICDO: C15 | CLINICALINFORMATION=ICDO: C16 | CLINICALINFORMATION=ICDO: C18 | CLINICALINFORMATION=ICDO: C20 | CLINICALINFORMATION=ICDO: C22 | CLINICALINFORMATION=ICDO: C25 | CLINICALINFORMATION=ICDO: C34 | CLINICALINFORMATION=ICDO: C40 | CLINICALINFORMATION=ICDO: C42 | CLINICALINFORMATION=ICDO: C44 | CLINICALINFORMATION=ICDO: C48 | CLINICALINFORMATION=ICDO: C49 | CLINICALINFORMATION=ICDO: C50 | CLINICALINFORMATION=ICDO: C51 | CLINICALINFORMATION=ICDO: C53 | CLINICALINFORMATION=ICDO: C55 | CLINICALINFORMATION=ICDO: C56 | CLINICALINFORMATION=ICDO: C58 | CLINICALINFORMATION=ICDO: C61 | CLINICALINFORMATION=ICDO: C64 | CLINICALINFORMATION=ICDO: C67 | CLINICALINFORMATION=ICDO: C69 | CLINICALINFORMATION=ICDO: C71 | CLINICALINFORMATION=ICDO: C72 | CLINICALINFORMATION=ICDO: C73 | DISEASESTATE=Acute B Cell Lymphocytic Leukemia | DISEASESTATE=Acute Lymphoblastic Leukemia | DISEASESTATE=Acute Myeloid Leukemia | DISEASESTATE=Acute T Cell Lymphoblastic Leukemia | DISEASESTATE=Adenocarcinoma | DISEASESTATE=Amelanotic Skin Melanoma | DISEASESTATE=AML | DISEASESTATE=Anaplastic Carcinoma | DISEASESTATE=Astrocytoma | DISEASESTATE=B-Cell Neoplasm | DISEASESTATE=Blast Phase Chronic Myelogenous Leukemia | DISEASESTATE=Brain Glioblastoma | DISEASESTATE=Burkitt Lymphoma | DISEASESTATE=Carcinoma | DISEASESTATE=carcinoma | DISEASESTATE=carcinoma (NSCL) | DISEASESTATE=Choriocarcinoma | DISEASESTATE=Chronic Lymphocytic Leukemia | DISEASESTATE=Chronic Myelogenous Leukemia | DISEASESTATE=Clear Cell Adenocarcinoma | DISEASESTATE=Colon Carcinoma | DISEASESTATE=Cutaneous T Cell Lymphoma | DISEASESTATE=Erythroleukemia | DISEASESTATE=Esophageal Carcinoma | DISEASESTATE=Fibrosarcoma | DISEASESTATE=Glioblastoma | DISEASESTATE=glioma | DISEASESTATE=haematopoietic | DISEASESTATE=Hepatocellular Carcinoma | DISEASESTATE=Hodgkin Lymphoma | DISEASESTATE=hyperplasia | DISEASESTATE=Large B-cell lymphoma | DISEASESTATE=Large Cell Lung Carcinoma | DISEASESTATE=Leiomyoblastoma | DISEASESTATE=Leiomyosarcoma | DISEASESTATE=Liposarcoma | DISEASESTATE=Lung Adenocarcinoma | DISEASESTATE=Lung Atypical Carcinoid Tumor | DISEASESTATE=Lung Carcinoma | DISEASESTATE=Lymphoma | DISEASESTATE=Medulloblastoma | DISEASESTATE=Melanoma | DISEASESTATE=Mesothelioma | DISEASESTATE=Myeloid Leukemia | DISEASESTATE=Myeloma | DISEASESTATE=neuroblastoma | DISEASESTATE=Non-Hodgkin Lymphoma | DISEASESTATE=normal | DISEASESTATE=Osteosarcoma | DISEASESTATE=Ovarian Serous Adenocarcinoma | DISEASESTATE=Papillary Lung Adenocarcinoma | DISEASESTATE=Plasma Cell Myeloma | DISEASESTATE=Precursor B-Lymphoblastic Leukemia | DISEASESTATE=Retinoblastoma | DISEASESTATE=retinoblastoma | DISEASESTATE=Rhabdomyosarcoma | DISEASESTATE=rhabdomyosarcoma | DISEASESTATE=Sarcoma | DISEASESTATE=sarcoma | DISEASESTATE=Small Cell Carcinoma | DISEASESTATE=Small Cell carcinoma | DISEASESTATE=Small Cell Lung Carcinoma | DISEASESTATE=Squamous Cell Carcinoma | DISEASESTATE=Synovial Sarcoma | DISEASESTATE=T-Cell Acute Lymphoblastic Leukemia (TALL) | DISEASESTATE=T-Cell Lymphoma | DISEASESTATE=unavailable | DISEASESTATE=Uterine | DISEASESTATE=Wilms Tumor | DISEASESTATE=Wilms tumour | ORGANISMPART=bladder | ORGANISMPART=Bone | ORGANISMPART=Brain | ORGANISMPART=Central Nervous System | ORGANISMPART=Cervix Uteri | ORGANISMPART=Colon | ORGANISMPART=Connective and Soft Tissue | ORGANISMPART=Connective Tissue | ORGANISMPART=Esophagus | ORGANISMPART=Eye | ORGANISMPART=Hematopoietic and Lymphatic System | ORGANISMPART=kidney | ORGANISMPART=Liver | ORGANISMPART=lung | ORGANISMPART=mammary gland | ORGANISMPART=muscle | ORGANISMPART=Ovary | ORGANISMPART=Pancreas | ORGANISMPART=Pharynx | ORGANISMPART=Placenta | ORGANISMPART=prostate | ORGANISMPART=Rectum | ORGANISMPART=Sarcoma | ORGANISMPART=Skin | ORGANISMPART=Stomach | ORGANISMPART=Synovial Membrane | ORGANISMPART=Thyroid gland | ORGANISMPART=Uterus | ORGANISMPART=Vulva","NA","age=18 year | age=19 year | age=22 year | age=23 year | age=24 year | age=25 year | age=29 year | age=30 year | age=31 year | age=32 year | age=33 year | age=34 year | age=35 year | age=36 year | age=38 year | age=39 year | age=40 year | age=41 year | age=42 year | age=43 year | age=44 year | age=45 year | age=46 year | age=47 year | age=48 year | age=49 year | age=50 year | age=51 year | age=52 year | age=53 year | age=54 year | age=55 year | age=56 year | age=57 year | age=58 year | age=59 year | age=60 year | age=61 year | age=62 year | age=63 year | age=64 year | age=65 year | age=66 year | age=67 year | age=68 year | age=69 year | age=70 year | age=71 year | age=72 year | age=75 year | age=76 year | age=77 year | age=78 year | age=79 year | age=81 year | age=82 year | age=85 year | age=86 year | age=not available year | histology=mesenchymal | histology=proliferative | histology=proliferative mesenchymal | histology=proneural","compound=cilengitide | compound=none | time=0 hour | time=1 hour | time=8 hour","clinical information=none | clinical information=radiotherapy | clinical information=temozolomide and radiotherapy | disease=glioblastoma multiforme | disease=normal | disease=recurrent glioblastoma multiforme","BIOSOURCEPROVIDER=ATCC | BIOSOURCEPROVIDER=DMSZ | BIOSOURCEPROVIDER=DSMZ | BIOSOURCEPROVIDER=ECACC | CELLLINE=1A2 | CELLLINE=22Rv1 | CELLLINE=5637 | CELLLINE=639V | CELLLINE=647V | CELLLINE=769P | CELLLINE=A101D | CELLLINE=A172 | CELLLINE=A204 | CELLLINE=A375 | CELLLINE=A427 | CELLLINE=A498 | CELLLINE=A673 | CELLLINE=A7 | CELLLINE=ACHN | CELLLINE=AGS | CELLLINE=AN3CA | CELLLINE=ARH77 | CELLLINE=AsPC1 | CELLLINE=BC1 | CELLLINE=BC2 | CELLLINE=BC3 | CELLLINE=BDCM | CELLLINE=BE2C | CELLLINE=BeWo | CELLLINE=BFTC905 | CELLLINE=BHT101 | CELLLINE=BM1604 | CELLLINE=BT20 | CELLLINE=BT474 | CELLLINE=BV173 | CELLLINE=C32TG | CELLLINE=C33A | CELLLINE=C3A | CELLLINE=C4I | CELLLINE=C4II | CELLLINE=CA46 | CELLLINE=CaHPV10 | CELLLINE=Caki1 | CELLLINE=Caki2 | CELLLINE=CAL54 | CELLLINE=CAL62 | CELLLINE=Calu1 | CELLLINE=Calu6 | CELLLINE=CaOv3 | CELLLINE=Capan1 | CELLLINE=Capan2 | CELLLINE=CCFSTTG1 | CELLLINE=CCRFCEM | CELLLINE=CEMC1 | CELLLINE=CESS | CELLLINE=CGTHW1 | CELLLINE=ChaGoK1 | CELLLINE=CHL1 | CELLLINE=CHP212 | CELLLINE=CMLT1 | CELLLINE=COLO201 | CELLLINE=COLO320DM | CELLLINE=COLO320HSR | CELLLINE=COLO668 | CELLLINE=COLO704 | CELLLINE=COLO829 | CELLLINE=CORL105 | CELLLINE=CORL23 | CELLLINE=CORL279 | CELLLINE=CORL88 | CELLLINE=CROAP2 | CELLLINE=CROAP5 | CELLLINE=D283Med | CELLLINE=D341Med | CELLLINE=Daudi | CELLLINE=DB | CELLLINE=DBTRG05MG | CELLLINE=Detroit562 | CELLLINE=DG75 | CELLLINE=DKMG | CELLLINE=DMS114 | CELLLINE=DMS153 | CELLLINE=DMS273 | CELLLINE=DMS53 | CELLLINE=DMS79 | CELLLINE=DOHH2 | CELLLINE=DoTc2 | CELLLINE=DU4475 | CELLLINE=EB1 | CELLLINE=EB2 | CELLLINE=EB3 | CELLLINE=EFM19 | CELLLINE=EM2 | CELLLINE=ES2 | CELLLINE=FaDu | CELLLINE=G401 | CELLLINE=G402 | CELLLINE=GA10 | CELLLINE=GCT | CELLLINE=GDM1 | CELLLINE=H4 | CELLLINE=HCC1143 | CELLLINE=HCC1395 | CELLLINE=HCC1599 | CELLLINE=HCC1937 | CELLLINE=HCC1954 | CELLLINE=HCC2157 | CELLLINE=HCC2218 | CELLLINE=HCC38 | CELLLINE=HCT15 | CELLLINE=HCT8 | CELLLINE=HDMYZ | CELLLINE=HEC1A | CELLLINE=HEC1B | CELLLINE=HEL9217 | CELLLINE=Hep3B | CELLLINE=HepG2 | CELLLINE=HH | CELLLINE=HL60 | CELLLINE=HMCB | CELLLINE=HOS | CELLLINE=HPAC | CELLLINE=HPAFII | CELLLINE=HSSultan | CELLLINE=HT | CELLLINE=HT1080 | CELLLINE=HT1197 | CELLLINE=HT1376 | CELLLINE=HT3 | CELLLINE=HuNS1 | CELLLINE=HuPT4 | CELLLINE=HuT78 | CELLLINE=J82 | CELLLINE=JAR | CELLLINE=JEG3 | CELLLINE=Jiyoye | CELLLINE=JM1 | CELLLINE=JRT3T35 | CELLLINE=JVM3 | CELLLINE=K562 | CELLLINE=Kasumi2 | CELLLINE=KATOIII | CELLLINE=KG1 | CELLLINE=KHOS240S | CELLLINE=KLE | CELLLINE=KPL1 | CELLLINE=KU812 | CELLLINE=KYSE30 | CELLLINE=L428 | CELLLINE=LS1034 | CELLLINE=LS174T | CELLLINE=Malme3M | CELLLINE=MC116 | CELLLINE=MCCAR | CELLLINE=MCF7 | CELLLINE=MCIXC | CELLLINE=MDAMB175VII | CELLLINE=MDAMB453 | CELLLINE=MEC1 | CELLLINE=MEG01 | CELLLINE=MESSA | CELLLINE=MG63 | CELLLINE=MHHPREB1 | CELLLINE=MIA Paca-2 | CELLLINE=MJ | CELLLINE=ML2 | CELLLINE=MOLT16 | CELLLINE=MOLT4 | CELLLINE=MT3 | CELLLINE=MV4II | CELLLINE=NALM1 | CELLLINE=NALM6 | CELLLINE=NAMALWA | CELLLINE=NC37 | CELLLINE=NCIH1048 | CELLLINE=NCIH1092 | CELLLINE=NCIH1155 | CELLLINE=NCIH1355 | CELLLINE=NCIH1395 | CELLLINE=NCIH1436 | CELLLINE=NCIH1437 | CELLLINE=NCIH1563 | CELLLINE=NCIH1573 | CELLLINE=NCIH1581 | CELLLINE=NCIH1618 | CELLLINE=NCIH1623 | CELLLINE=NCIH1650 | CELLLINE=NCIH1651 | CELLLINE=NCIH1666 | CELLLINE=NCIH1694 | CELLLINE=NCIH1703 | CELLLINE=NCIH1770 | CELLLINE=NCIH1792 | CELLLINE=NCIH1793 | CELLLINE=NCIH1838 | CELLLINE=NCIH187 | CELLLINE=NCIH1930 | CELLLINE=NCIH1975 | CELLLINE=NCIH1993 | CELLLINE=NCIH2009 | CELLLINE=NCIH2030 | CELLLINE=NCIH2052 | CELLLINE=NCIH2081 | CELLLINE=NCIH2087 | CELLLINE=NCIH2107 | CELLLINE=NCIH2122 | CELLLINE=NCIH2126 | CELLLINE=NCIH2170 | CELLLINE=NCIH2171 | CELLLINE=NCIH2195 | CELLLINE=NCIH2228 | CELLLINE=NCIH226 | CELLLINE=NCIH23 | CELLLINE=NCIH2347 | CELLLINE=NCIH2405 | CELLLINE=NCIH295R | CELLLINE=NCIH322 | CELLLINE=NCIH358 | CELLLINE=NCIH441 | CELLLINE=NCIH446 | CELLLINE=NCIH508 | CELLLINE=NCIH522 | CELLLINE=NCIH524 | CELLLINE=NCIH630 | CELLLINE=NCIH650 | CELLLINE=NCIH661 | CELLLINE=NCIH69 | CELLLINE=NCIH716 | CELLLINE=NCIH720 | CELLLINE=NCIH747 | CELLLINE=NCIH748 | CELLLINE=NCIH810 | CELLLINE=NCIH82 | CELLLINE=NCIH838 | CELLLINE=OE19 | CELLLINE=OE21 | CELLLINE=OE33 | CELLLINE=OV90 | CELLLINE=P3HR1 | CELLLINE=PLB985 | CELLLINE=Raji | CELLLINE=RCHACV | CELLLINE=RD | CELLLINE=RDES | CELLLINE=REC1 | CELLLINE=RKOE6 | CELLLINE=RL | CELLLINE=RL952 | CELLLINE=RPMI6666 | CELLLINE=RPMI8226 | CELLLINE=RWPE1 | CELLLINE=SCaBER | CELLLINE=SEM | CELLLINE=SH4 | CELLLINE=SHP77 | CELLLINE=SiHa | CELLLINE=SJRH30 | CELLLINE=SJSA1 | CELLLINE=SKLMS1 | CELLLINE=SKMEL1 | CELLLINE=SKMEL3 | CELLLINE=SKMES1 | CELLLINE=SKNAS | CELLLINE=SKNDZ | CELLLINE=SKNEP1 | CELLLINE=SKNFI | CELLLINE=SKO007 | CELLLINE=SKOV3 | CELLLINE=SKUT1 | CELLLINE=SNB19 | CELLLINE=SNU1 | CELLLINE=SNU16 | CELLLINE=SNU182 | CELLLINE=SNU387 | CELLLINE=SNU398 | CELLLINE=SNU423 | CELLLINE=SNU449 | CELLLINE=SNU475 | CELLLINE=SNU5 | CELLLINE=SR | CELLLINE=ST486 | CELLLINE=SUDHL10 | CELLLINE=SUDHL16 | CELLLINE=SUDHL5 | CELLLINE=SUDHL6 | CELLLINE=SW1088 | CELLLINE=SW1116 | CELLLINE=SW1353 | CELLLINE=SW1417 | CELLLINE=SW1463 | CELLLINE=SW1573 | CELLLINE=SW1783 | CELLLINE=SW1990 | CELLLINE=SW403 | CELLLINE=SW48 | CELLLINE=SW480 | CELLLINE=SW620 | CELLLINE=SW684 | CELLLINE=SW756 | CELLLINE=SW780 | CELLLINE=SW837 | CELLLINE=SW872 | CELLLINE=SW900 | CELLLINE=SW948 | CELLLINE=SW954 | CELLLINE=SW962 | CELLLINE=SW982 | CELLLINE=T84 | CELLLINE=TANOUE | CELLLINE=THP1 | CELLLINE=Toledo | CELLLINE=TT | CELLLINE=U266B1 | CELLLINE=UACC812 | CELLLINE=UACC893 | CELLLINE=UMC11 | CELLLINE=UMUC3 | CELLLINE=WI38 | CELLLINE=Wi38 | CELLLINE=WIDR | CELLLINE=WM115 | CELLLINE=Y79 | CELLLINE=YPAC | CLINICALINFORMATION=ICDO: 06 | CLINICALINFORMATION=ICDO: 13 | CLINICALINFORMATION=ICDO: 15 | CLINICALINFORMATION=ICDO: 16 | CLINICALINFORMATION=ICDO: 18 | CLINICALINFORMATION=ICDO: 20 | CLINICALINFORMATION=ICDO: 22 | CLINICALINFORMATION=ICDO: 25 | CLINICALINFORMATION=ICDO: 34 | CLINICALINFORMATION=ICDO: 40 | CLINICALINFORMATION=ICDO: 42 | CLINICALINFORMATION=ICDO: 44 | CLINICALINFORMATION=ICDO: 48 | CLINICALINFORMATION=ICDO: 49 | CLINICALINFORMATION=ICDO: 50 | CLINICALINFORMATION=ICDO: 51 | CLINICALINFORMATION=ICDO: 53 | CLINICALINFORMATION=ICDO: 55 | CLINICALINFORMATION=ICDO: 56 | CLINICALINFORMATION=ICDO: 58 | CLINICALINFORMATION=ICDO: 61 | CLINICALINFORMATION=ICDO: 64 | CLINICALINFORMATION=ICDO: 67 | CLINICALINFORMATION=ICDO: 69 | CLINICALINFORMATION=ICDO: 71 | CLINICALINFORMATION=ICDO: 72 | CLINICALINFORMATION=ICDO: 73 | DISEASESTATE=Acute B Cell Lymphocytic Leukemia | DISEASESTATE=Acute Lymphoblastic Leukemia | DISEASESTATE=Acute Myeloid Leukemia | DISEASESTATE=Acute T Cell Lymphoblastic Leukemia | DISEASESTATE=Adenocarcinoma | DISEASESTATE=Amelanotic Skin Melanoma | DISEASESTATE=Anaplastic Carcinoma | DISEASESTATE=Astrocytoma | DISEASESTATE=B-Cell Neoplasm | DISEASESTATE=Blast Phase Chronic Myelogenous Leukemia | DISEASESTATE=Brain Glioblastoma | DISEASESTATE=Bronchogenic Carcinoma | DISEASESTATE=Burkitt Lymphoma | DISEASESTATE=Carcinoma | DISEASESTATE=Choriocarcinoma | DISEASESTATE=Chronic Lymphocytic Leukemia | DISEASESTATE=Chronic Myelogenous Leukemia | DISEASESTATE=Clear Cell Adenocarcinoma | DISEASESTATE=Colon Carcinoma | DISEASESTATE=Colorectal Adenocarcinoma | DISEASESTATE=Cutaneous T Cell Lymphoma | DISEASESTATE=Erythroleukemia | DISEASESTATE=Esophageal Carcinoma | DISEASESTATE=Fibrosarcoma | DISEASESTATE=Glioblastoma | DISEASESTATE=Hepatocellular Carcinoma | DISEASESTATE=Hodgkin Lymphoma | DISEASESTATE=Large Cell Lung Carcinoma | DISEASESTATE=Leiomyoblastoma | DISEASESTATE=Leiomyosarcoma | DISEASESTATE=Liposarcoma | DISEASESTATE=Lung Adenocarcinoma | DISEASESTATE=Lung Atypical Carcinoid Tumor | DISEASESTATE=Lung Carcinoma | DISEASESTATE=Lymphoma | DISEASESTATE=Medulloblastoma | DISEASESTATE=Melanoma | DISEASESTATE=Mesothelioma | DISEASESTATE=Myeloid Leukemia | DISEASESTATE=Myeloma | DISEASESTATE=Neuroblastoma | DISEASESTATE=Non-Hodgkin Lymphoma | DISEASESTATE=Normal | DISEASESTATE=Osteosarcoma | DISEASESTATE=Ovarian Serous Adenocarcinoma | DISEASESTATE=Papillary Lung Adenocarcinoma | DISEASESTATE=Plasma Cell Myeloma | DISEASESTATE=Precursor B-Lymphoblastic Leukemia | DISEASESTATE=Retinoblastoma | DISEASESTATE=Rhabdomyosarcoma | DISEASESTATE=Sarcoma | DISEASESTATE=Small Cell Carcinoma | DISEASESTATE=Small Cell Lung Carcinoma | DISEASESTATE=Squamous Cell Carcinoma | DISEASESTATE=Synovial Sarcoma | DISEASESTATE=T-Cell Lymphoma | DISEASESTATE=Wilms Tumor | DISEASESTATE=Wilms tumour | ORGANISMPART=Bladder | ORGANISMPART=Bone | ORGANISMPART=Brain | ORGANISMPART=Breast | ORGANISMPART=Central Nervous System | ORGANISMPART=Cervix Uteri | ORGANISMPART=Colon | ORGANISMPART=Connective Tissue | ORGANISMPART=Esophagus | ORGANISMPART=Eye | ORGANISMPART=Hematopoietic and Lymphatic System | ORGANISMPART=Kidney | ORGANISMPART=Liver | ORGANISMPART=Lung | ORGANISMPART=Muscle | ORGANISMPART=Ovary | ORGANISMPART=Pancreas | ORGANISMPART=Pharynx | ORGANISMPART=Placenta | ORGANISMPART=Prostate | ORGANISMPART=Rectum | ORGANISMPART=Sarcoma | ORGANISMPART=Skin | ORGANISMPART=Stomach | ORGANISMPART=Synovial Membrane | ORGANISMPART=Thyroid gland | ORGANISMPART=Thyroid gland | ORGANISMPART=Uterus | ORGANISMPART=Vulva","CellType=fibroblast | CellType=glioma cell | CellType=microvascular endothelial cell | Compound=mycophenolate | Compound=none | Dose=0 uM | Dose=1 uM | Time=0 h | Time=12 h | Time=6 h","NA","MATERIAL_TYPE=cell | MATERIAL_TYPE=organism_part","cell line=GS-1 | cell line=GS-2 | cell line=GS-3 | cell line=GS-4 | cell line=GS-5 | cell line=GS-6 | cell line=GS-7 | cell line=GS-8 | cell line=GS-9","growth condition=control | growth condition=deferoxamine | treatment=1 micromolar polyamide 1 | treatment=100 nanomolar echinomycin | treatment=HIF-1a siRNA | treatment=none","NA","NA","NA","CellType=glioblastoma | CellType=lung carcinoma | Compound=dichloroacetate | Compound=none","NA","NA","NA","NA","NA","NA","disease state=ClinicalHistory","NA","NA","NA","DiseaseState=anaplastic astrocytoma | DiseaseState=anaplastic mixed oligo-astrocytoma | DiseaseState=anaplastic oligodendroglioma | DiseaseState=glioblastoma | OrganismPart=left frontal lobe | OrganismPart=left frontal temporal lobe | OrganismPart=left parietal lobe | OrganismPart=left parietal Occipital | OrganismPart=left temporal lobe | OrganismPart=left temporal parietal | OrganismPart=right anterior temporal | OrganismPart=right cerebellum | OrganismPart=right frontal lobe | OrganismPart=right frontal parietal | OrganismPart=right frontal temporal | OrganismPart=right parietal lobe | OrganismPart=right parietal obe | OrganismPart=right parietal occipital | OrganismPart=right temporal lobe | OrganismPart=right temporal parietal | OrganismPart=thalamus","Compound=none | Compound=platelet-derived growth factor | Genotype=neo-resistant | Genotype=PDGF-A dominant-negative | Genotype=wild_type","CELLLINE=293 hek cells | CELLLINE=293t-tva | CELLLINE=a549 | CELLLINE=adenocarcinoma cell line | CELLLINE=ag10750, fibroblast cell line | CELLLINE=ag11498, fibroblast cell line | CELLLINE=ag11513, fibroblast cell line | CELLLINE=bewo cell line | CELLLINE=BM-MSC | CELLLINE=BT474 | CELLLINE=Caco-2 | CELLLINE=cancer cell line | CELLLINE=CCL-153 | CELLLINE=cell line | CELLLINE=CEM | CELLLINE=CMK | CELLLINE=cultured | CELLLINE=cultured  24 hours | CELLLINE=cultured polyclonal CD31- ADASCs | CELLLINE=ea.hy926 cell | CELLLINE=es cells | CELLLINE=freshly isolated (non-cultured (NC)) polyclonal CD31+ ADASCs | CELLLINE=freshly isolated (non-cultured (NC)) polyclonal CD31- ADASCs | CELLLINE=gingiva cells | CELLLINE=glioblastoma cell line | CELLLINE=gm00038c, fibroblast cell line | CELLLINE=gm00316b, fibroblast cell line | CELLLINE=gmo8398c, fibroblast cell line | CELLLINE=H1 | CELLLINE=H9 | CELLLINE=HEK293 | CELLLINE=hek293 cells | CELLLINE=hek293t cell line | CELLLINE=HeLa | CELLLINE=hela cells | CELLLINE=HeLa Tet-On | CELLLINE=hematopoietic cells, cultured 24 hours | CELLLINE=hematopoietic cells, cultured 4 days | CELLLINE=Hep-2 | CELLLINE=HES2 | CELLLINE=hl60 | CELLLINE=hl60 cell line | CELLLINE=hmec | CELLLINE=HSB2 | CELLLINE=ht-29 | CELLLINE=huvec | CELLLINE=I-6 ES | CELLLINE=ib3-1 | CELLLINE=imr-90 | CELLLINE=ITM | CELLLINE=ITM-E6E7 | CELLLINE=ITM-E6E7-ST | CELLLINE=ITM-ST | CELLLINE=itv cells | CELLLINE=jeg3 cell line | CELLLINE=Jurkat | CELLLINE=k562 | CELLLINE=KELLY | CELLLINE=KS Y-1 | CELLLINE=KS-IMM | CELLLINE=ligament cells | CELLLINE=m-o7e cell line | CELLLINE=mcf-7 | CELLLINE=mcf-7aro cells | CELLLINE=MCF10A | CELLLINE=mcf10a-myc cells | CELLLINE=mcf7 | CELLLINE=MDA-MB-231 | CELLLINE=mda-mb-231 | CELLLINE=MDA468 | CELLLINE=MOLT4 | CELLLINE=myoblasts cells, cultured | CELLLINE=NC-NC | CELLLINE=pc-3 | CELLLINE=pc3 | CELLLINE=primary cell line | CELLLINE=primary culture | CELLLINE=regenerating cells | CELLLINE=retinal sphere cells, cultured | CELLLINE=RJ2.2.5 | CELLLINE=RKO | CELLLINE=SK-N-AS | CELLLINE=SK-N-SH | CELLLINE=SKBR3 | CELLLINE=skgt4 cells | CELLLINE=skmc myoblast | CELLLINE=skmel5 | CELLLINE=ssmcf7 | CELLLINE=sw480 | CELLLINE=sw620 | CELLLINE=T47D | CELLLINE=te85 | CELLLINE=TERV | CELLLINE=TERV-AntiSenseB56 | CELLLINE=TERV-ST | CELLLINE=TERV-ST110 | CELLLINE=U937 | CELLLINE=Unspecified | CELLTYPE=721 B lymphoblasts | CELLTYPE=adipocyte | CELLTYPE=adipose-derived adult stem cells (ADASCs) | CELLTYPE=adrenal neuroblasts | CELLTYPE=aortic vascular smooth muscle cell | CELLTYPE=b cell | CELLTYPE=basal cell | CELLTYPE=BDCA4+ dentritic cells | CELLTYPE=blast cells | CELLTYPE=blasts | CELLTYPE=blasts, mononuclear cells | CELLTYPE=blood_vessel_endothelial_cell | CELLTYPE=bronchial epithelial cell | CELLTYPE=bronchial epithelial cells | CELLTYPE=bronchoalveolar lavage cells | CELLTYPE=cardiac myocytes | CELLTYPE=CD105+ endothelial | CELLTYPE=CD14+ monocytes | CELLTYPE=CD19+ B cells (neg. sel.) | CELLTYPE=CD3+CD4+CD8-CD45RA+CD62L+ na??ve T cells | CELLTYPE=CD33+ cells | CELLTYPE=CD33+ myeloid | CELLTYPE=CD34+ | CELLTYPE=CD34+ umbilical cord blood cells | CELLTYPE=CD34+CD1a+ thymocytes | CELLTYPE=CD34+CD1a- thymocytes | CELLTYPE=CD34+CD38- thymocytes | CELLTYPE=CD34+CD38-CD33-Rho(hi) cells | CELLTYPE=CD34+CD38-CD33-Rho(lo)c-kit+ cells | CELLTYPE=CD34+lin- | CELLTYPE=CD34lowCD3-CD4+CD8- intrathymic T progenitor cells | CELLTYPE=CD3highCD4+CD8- thymocytes | CELLTYPE=CD3intCD4+CD8+ thymocytes | CELLTYPE=CD4 lymphocytes | CELLTYPE=CD4+ T cells | CELLTYPE=CD4+CD25 high lymphocytes | CELLTYPE=CD4+CD25- lymphocytes | CELLTYPE=CD56+ NK cells | CELLTYPE=CD71+ early erythroid | CELLTYPE=CD8+ T cells | CELLTYPE=central memory 1 CD4 T cell | CELLTYPE=central memory CD4 T cell | CELLTYPE=CXCR5(-)ICOS(-/lo) CD4 T cell | CELLTYPE=CXCR5(hi)ICOS(hi) CD4 T cell | CELLTYPE=CXCR5(lo)ICOS(int) CD4 T cell | CELLTYPE=DP CD3+ thymocytes | CELLTYPE=DP CD3- thymocytes | CELLTYPE=effector memory CD4 T cell | CELLTYPE=embryonic_stem_cell | CELLTYPE=endothelial | CELLTYPE=endothelial cells | CELLTYPE=epithelial cell | CELLTYPE=epithelial_cell | CELLTYPE=fibroblast | CELLTYPE=fibroblasts | CELLTYPE=gingiva cells | CELLTYPE=hematopoietic stem cells | CELLTYPE=high_CD56_natural_killer_cell | CELLTYPE=human embryonic kidney cells | CELLTYPE=human lymphoblastoid cells | CELLTYPE=i-4 | CELLTYPE=immature-B cells | CELLTYPE=immortalized endothelial cell | CELLTYPE=ISP CD4+ thymocytes | CELLTYPE=KS cells | CELLTYPE=leukocyte, t cell, monocyte | CELLTYPE=leukocytes | CELLTYPE=ligament cells | CELLTYPE=low_CD56_natural_killer_cell | CELLTYPE=lymphoblast | CELLTYPE=lymphocyte | CELLTYPE=mesangial cells | CELLTYPE=mesenchymal precursor | CELLTYPE=mesenchymal stem cells | CELLTYPE=monocyte | CELLTYPE=monocyte-derived macrophages | CELLTYPE=monocytes | CELLTYPE=mononuclear cell | CELLTYPE=mononuclear cells, blasts | CELLTYPE=myoblasts | CELLTYPE=naive CD4 T cell | CELLTYPE=neuroblastoma cells | CELLTYPE=oesophageal cells | CELLTYPE=pbmcs | CELLTYPE=pre-B-I cells | CELLTYPE=pre-B-II large cells | CELLTYPE=pre-B-II small cells | CELLTYPE=primary aortic smooth muscle cell | CELLTYPE=primary blood vessel endothelial cell | CELLTYPE=primary bone marrow CD34+ stem cell | CELLTYPE=primary bone marrow CD34- mesenchymal stem cell | CELLTYPE=primary dermal fibroblast | CELLTYPE=primary embryonic fibroblasts | CELLTYPE=primary lymphatic endothelial cell | CELLTYPE=primary microvascular endothelial cell | CELLTYPE=primary uterine smooth muscle cell | CELLTYPE=pro-B-cells | CELLTYPE=progenitor cells, hematopoietic stem cells | CELLTYPE=pseudopalisading cells | CELLTYPE=regenerating cells | CELLTYPE=smooth muscle cells | CELLTYPE=SP CD4+ thymocytes | CELLTYPE=SP CD8+ thymocytes | CELLTYPE=squamous cell epithelium | CELLTYPE=stem cell | CELLTYPE=syncytiotrophoblast | CELLTYPE=syncytiotrophoblasts | CELLTYPE=T cell | CELLTYPE=t cells | CELLTYPE=T lymphocytes | CELLTYPE=T-cell line | CELLTYPE=testis - germ cell | CELLTYPE=testis - leydig cell | CELLTYPE=Th lymphocytes | CELLTYPE=theca | CELLTYPE=thymic stromal cells | CELLTYPE=thyrocytes | CELLTYPE=thyroid follicular epithelial cell | CELLTYPE=umbilical vein endothelial cells | CELLTYPE=unpurified thymus cells | CELLTYPE=Unspecified | CELLTYPE=white blood cells | DEVELOPMENTALSTAGE=adult | DEVELOPMENTALSTAGE=embryo | DEVELOPMENTALSTAGE=embryoid_bodies | DEVELOPMENTALSTAGE=embryonic | DEVELOPMENTALSTAGE=fetal | DEVELOPMENTALSTAGE=fetus | DEVELOPMENTALSTAGE=infant | DEVELOPMENTALSTAGE=newborn | DEVELOPMENTALSTAGE=Unspecified | DISEASESTAGE=adrenal gland metastasis | DISEASESTAGE=aggressive | DISEASESTAGE=dead | DISEASESTAGE=disease | DISEASESTAGE=early | DISEASESTAGE=grade 0 | DISEASESTAGE=grade 1 | DISEASESTAGE=grade 2 | DISEASESTAGE=grade 3 | DISEASESTAGE=grade 4 | DISEASESTAGE=lung metastasis | DISEASESTAGE=lymph node metastasis | DISEASESTAGE=metastasis | DISEASESTAGE=metastatic | DISEASESTAGE=post mortem | DISEASESTAGE=pre-LVAD | DISEASESTAGE=primary | DISEASESTAGE=Unspecified | DISEASESTATE=limb-girdle muscular dystrophy type 2I | DISEASESTATE=2h after infection with fasX-mutant Streptococcus pyogenes | DISEASESTATE=2h after infection with wildtype Streptococcus pyogenes | DISEASESTATE=4h after infection with fasX-mutant Streptococcus pyogenes | DISEASESTATE=4h after infection with wildtype Streptococcus pyogenes | DISEASESTATE=6h after infection with fasX-mutant Streptococcus pyogenes | DISEASESTATE=6h after infection with wildtype Streptococcus pyogenes | DISEASESTATE=8h after infection with fasX-mutant Streptococcus pyogenes | DISEASESTATE=8h after infection with wildtype Streptococcus pyogenes | DISEASESTATE=acute erythroid leukemia | DISEASESTATE=acute lymphoblastic leukemia | DISEASESTATE=acute lymphoblastic leukemia, chemotherapy response | DISEASESTATE=acute monoblastic/monocytic leukemia | DISEASESTATE=acute myeloid leukemia | DISEASESTATE=acute myelomonocytic leukemia | DISEASESTATE=acute promyelocytic leukemia | DISEASESTATE=acute promyelocytic leukemia, apl | DISEASESTATE=acute quadriplegic myopathy | DISEASESTATE=acute rejection | DISEASESTATE=adenocarcinoma | DISEASESTATE=adenovirus expressing GFP | DISEASESTATE=AIDS-KS, HIV+, nodular (late) stage | DISEASESTATE=AIDS-KS, KSHV- | DISEASESTATE=alveolar rhabdomyosarcoma | DISEASESTATE=alzheimer's disease | DISEASESTATE=aml | DISEASESTATE=amyotrophic lateral sclerosis | DISEASESTATE=atopic mild asthmatics | DISEASESTATE=atopic severe asthma | DISEASESTATE=atrial fibrillation | DISEASESTATE=B-cell acute lymphoblastic leukemia, B-ALL | DISEASESTATE=B-cell lymphoma | DISEASESTATE=B-cell lymphoma, dlbcl | DISEASESTATE=B-cell lymphoma, nhl | DISEASESTATE=barrett's esophagus | DISEASESTATE=becker muscular dystrophy | DISEASESTATE=bipolar disorder | DISEASESTATE=bladder tumor | DISEASESTATE=bone marrow relapse | DISEASESTATE=brain tumor | DISEASESTATE=brain tumor, glioblastoma | DISEASESTATE=breast cancer | DISEASESTATE=breast cancer cells, adenovirus expressing GFP | DISEASESTATE=breast cancer, inflammatory | DISEASESTATE=breast carcinoma | DISEASESTATE=breast tumor | DISEASESTATE=breast tumor, basal | DISEASESTATE=breast tumor, luminal | DISEASESTATE=breast tumor, normal like | DISEASESTATE=Burkitt's lymphoma | DISEASESTATE=calpainopathy | DISEASESTATE=carcinoma in situ | DISEASESTATE=carcinoma in situ, bladder tumor | DISEASESTATE=cardiomyopathy | DISEASESTATE=cardiomyopathy, calcifications | DISEASESTATE=cardiovascular disease, obesity | DISEASESTATE=chondroblastoma | DISEASESTATE=chondromyxoid fibroma | DISEASESTATE=chondrosarcoma | DISEASESTATE=chordoma | DISEASESTATE=chronic myelogenous leukemia | DISEASESTATE=chronic myelogenous leukemia K562 | DISEASESTATE=chronic myeloid leukemia | DISEASESTATE=Classic-KS, HIV-, nodular (late) stage | DISEASESTATE=cockayne syndrome | DISEASESTATE=cololrectal tumor | DISEASESTATE=colon adenocarcinoma | DISEASESTATE=colon cancer | DISEASESTATE=colon carcinoma | DISEASESTATE=colorectal adenocarcinoma | DISEASESTATE=colorectal cancer | DISEASESTATE=congestive heart failure | DISEASESTATE=control brain | DISEASESTATE=control sample without infection after 2h | DISEASESTATE=control sample without infection after 8h | DISEASESTATE=current smoker | DISEASESTATE=CVID | DISEASESTATE=cystic fibrosis | DISEASESTATE=Daudi Burkitt's lymphoma | DISEASESTATE=dedifferentiated chondrosarcoma | DISEASESTATE=dermatomyositis | DISEASESTATE=Down syndrome, acute megakaryoblastic leukaemia | DISEASESTATE=Down syndrome, non-leukaemic | DISEASESTATE=Down syndrome, transient myleoproliferative disorder | DISEASESTATE=duchenne muscular dystrophy | DISEASESTATE=dysferlinopathy | DISEASESTATE=ebv infection | DISEASESTATE=embryonal rhabdomyosarcoma | DISEASESTATE=Emery-Dreifuss muscular dystrophy | DISEASESTATE=emphysema | DISEASESTATE=Ewing's Sarcoma | DISEASESTATE=facioscapulohumeral muscular dystrophy | DISEASESTATE=fibromatosis | DISEASESTATE=follicular thyroid adenoma | DISEASESTATE=follicular thyroid carcinoma | DISEASESTATE=former smoker | DISEASESTATE=ganglioneuroblastoma | DISEASESTATE=ganglioneuroblastoma intermixed | DISEASESTATE=ganglioneuroma | DISEASESTATE=germ cell tumor | DISEASESTATE=glioblastoma | DISEASESTATE=grade 2, primary hnscc | DISEASESTATE=healthy | DISEASESTATE=hereditary spastic paraplegia | DISEASESTATE=high-stage neuroblastoma | DISEASESTATE=hlrcc | DISEASESTATE=Huntington's disease | DISEASESTATE=Huntington's Disease (HD) Pathological Grade 0 | DISEASESTATE=Huntington's Disease (HD) Pathological Grade 1 | DISEASESTATE=Huntington's Disease (HD) Pathological Grade 2 | DISEASESTATE=Huntington's Disease (HD) Pathological Grade 3 | DISEASESTATE=Huntington's Disease (HD) Pathological Grade 4 | DISEASESTATE=iatrogenic-KS, KSHV- | DISEASESTATE=inflammatory myopathy | DISEASESTATE=intracranial hemorrhage NOS | DISEASESTATE=irritable bowel syndrome | DISEASESTATE=Ischemia | DISEASESTATE=ischemic cardiomyopathy | DISEASESTATE=juvenile dermatomyositis | DISEASESTATE=KSHV infection, 14 days | DISEASESTATE=KSHV infection, 2 days | DISEASESTATE=KSHV infection, 7 days | DISEASESTATE=leiomyosarcoma | DISEASESTATE=lipoma | DISEASESTATE=low-stage neuroblastoma | DISEASESTATE=lung adenocarcinoma (NCI_Thesaurus C0152013) has DiseaseStaging Stage I | DISEASESTATE=lung adenocarcinoma (NCI_Thesaurus C0152013) has DiseaseStaging Stage II | DISEASESTATE=lung adenocarcinoma (NCI_Thesaurus C0152013) has DiseaseStaging Stage III | DISEASESTATE=lung adenocarcinoma (NCI_Thesaurus C0152013) has DiseaseStaging Stage IV | DISEASESTATE=lung cancer | DISEASESTATE=lung cancer, cytotoxicity | DISEASESTATE=lymphoblastic leukemia MOLT-4 | DISEASESTATE=lymphoma | DISEASESTATE=malignant peripheral nerve sheath tumor | DISEASESTATE=meningitis infected | DISEASESTATE=metabolic syndrome | DISEASESTATE=mitochondrial disorder | DISEASESTATE=monophasic synovial sarcoma | DISEASESTATE=myocardial infarction | DISEASESTATE=myositis | DISEASESTATE=myxoid liposarcoma | DISEASESTATE=neuroblastoma-differentiating | DISEASESTATE=neuroblastoma-poorly differentiated | DISEASESTATE=neuroblastoma-undifferentiated | DISEASESTATE=neurofibroma | DISEASESTATE=no tendon xanthomas | DISEASESTATE=non-atopic mild asthma | DISEASESTATE=nonischemic cardiomyopathy | DISEASESTATE=normal | DISEASESTATE=oral squamous cell carcinoma | DISEASESTATE=osteosarcoma | DISEASESTATE=pcos | DISEASESTATE=periodontitis | DISEASESTATE=pituitary adenoma, ACTH-secreting | DISEASESTATE=pituitary adenoma, GH-secreting | DISEASESTATE=pituitary adenoma, non-functioning | DISEASESTATE=pituitary adenoma, PRL-secreting | DISEASESTATE=polymyositis | DISEASESTATE=precursor T lymphoblastic leukemia | DISEASESTATE=primary hyperparathyroidism | DISEASESTATE=progeria syndrome | DISEASESTATE=promyelocytic leukemia | DISEASESTATE=promyelocytic leukemia HL-60 | DISEASESTATE=prostate cancer | DISEASESTATE=pterygium | DISEASESTATE=pulmonary disease, cystic fibrosis | DISEASESTATE=Raji Burkitt's lymphoma | DISEASESTATE=renal clear cell carcinoma | DISEASESTATE=response | DISEASESTATE=response, dominant negative | DISEASESTATE=sarcoma | DISEASESTATE=schwannoma | DISEASESTATE=seasonal allergy | DISEASESTATE=small cell cancer | DISEASESTATE=squamous cell cancer | DISEASESTATE=squamous cell carcinoma | DISEASESTATE=sudden death | DISEASESTATE=T cell acute lymphoblastic leukemia | DISEASESTATE=T-cell acute lymphoblastic leukemia, T-ALL | DISEASESTATE=T-cell lymphoblastic lymphoma, T-LL | DISEASESTATE=t3a, bladder tumor | DISEASESTATE=t3b, bladder tumor | DISEASESTATE=t4a, bladder tumor | DISEASESTATE=t4b | DISEASESTATE=t4b, bladder tumor | DISEASESTATE=tendon xanthomas | DISEASESTATE=trauma | DISEASESTATE=ulcerative colitis | DISEASESTATE=Unspecified | DISEASESTATE=uterated prostate cancer | DISEASESTATE=uterine fibroid | DISEASESTATE=UV treated | DISEASESTATE=well-differentiated liposarcoma | DISEASESTATE=XLA | ORGANISMPART=abdomen | ORGANISMPART=abdominal | ORGANISMPART=adipose tissue | ORGANISMPART=adipose tissue from abdomen | ORGANISMPART=adipose tissue from abdomen and thigh | ORGANISMPART=adrenal cortex, adrenal gland | ORGANISMPART=adrenal cortex, kidney | ORGANISMPART=adrenal gland | ORGANISMPART=amygdala | ORGANISMPART=amygdala, brain | ORGANISMPART=aorta | ORGANISMPART=appendix | ORGANISMPART=atrial myocardium | ORGANISMPART=atrioventricular node, heart | ORGANISMPART=beta cell islets, pancreas | ORGANISMPART=bladder | ORGANISMPART=bladder mucosa | ORGANISMPART=blood | ORGANISMPART=blood, cord blood | ORGANISMPART=bone | ORGANISMPART=bone marrow | ORGANISMPART=brachial_plexus | ORGANISMPART=brain | ORGANISMPART=brain caudate nucleus | ORGANISMPART=brain cerebellum | ORGANISMPART=brain, caudate nucleus | ORGANISMPART=brain, cerebellum | ORGANISMPART=brain, cerebellum peduncles | ORGANISMPART=brain, ciliary ganglion | ORGANISMPART=brain, cingulate cortex | ORGANISMPART=brain, dorsal root ganglion | ORGANISMPART=brain, frontal cortex, primary motor cortex, Brodmann's Area 4 | ORGANISMPART=brain, frontal cortex, superior frontal cortex, Brodmann's Area 9 | ORGANISMPART=brain, globus pallidus | ORGANISMPART=brain, medulla oblongata | ORGANISMPART=brain, occipital lobe | ORGANISMPART=brain, olfactory bulb | ORGANISMPART=brain, parietal lobe | ORGANISMPART=brain, prefrontal cortex | ORGANISMPART=brain, subthalamic nucleus | ORGANISMPART=brain, superior cervical ganglion | ORGANISMPART=brain, temporal lobe | ORGANISMPART=brain, trigeminal ganglion | ORGANISMPART=breast | ORGANISMPART=bronchial epithelia | ORGANISMPART=buccal | ORGANISMPART=cardiac ventricle | ORGANISMPART=caudate nucleus | ORGANISMPART=cerebellum | ORGANISMPART=chest_wall | ORGANISMPART=ciliary, eye | ORGANISMPART=colon | ORGANISMPART=colon mucosa | ORGANISMPART=conjunctiva | ORGANISMPART=connective tissue | ORGANISMPART=coronary artery | ORGANISMPART=corpus | ORGANISMPART=diaphragm | ORGANISMPART=distal_right_femur | ORGANISMPART=dura_mater, skin_of_scalp | ORGANISMPART=endothelium | ORGANISMPART=esophageal epithelium | ORGANISMPART=esophagus | ORGANISMPART=extracranial | ORGANISMPART=extraocular muscle | ORGANISMPART=fetal blood | ORGANISMPART=fetal brain | ORGANISMPART=fetal liver | ORGANISMPART=fetal lung | ORGANISMPART=fetal thyroid | ORGANISMPART=frontal cortex | ORGANISMPART=gingiva | ORGANISMPART=groin | ORGANISMPART=hair follicle bulge | ORGANISMPART=heart | ORGANISMPART=hippocampal CA1 tissue | ORGANISMPART=hippocampus | ORGANISMPART=human prostate | ORGANISMPART=human universal reference | ORGANISMPART=hypopharynx | ORGANISMPART=hypothalamus | ORGANISMPART=iliac_fossa | ORGANISMPART=kidney | ORGANISMPART=larynx | ORGANISMPART=left ventricle, heart | ORGANISMPART=left ventricular myocardium | ORGANISMPART=left_calf | ORGANISMPART=left_deltoid | ORGANISMPART=left_femur | ORGANISMPART=left_fibula | ORGANISMPART=left_foot | ORGANISMPART=left_forearm | ORGANISMPART=left_knee | ORGANISMPART=left_leg | ORGANISMPART=left_posterior_triangle_of_neck | ORGANISMPART=left_thigh | ORGANISMPART=left_tibia | ORGANISMPART=liver | ORGANISMPART=lower_back | ORGANISMPART=lung | ORGANISMPART=lung tissue | ORGANISMPART=lung transplant | ORGANISMPART=lymph node | ORGANISMPART=mammary gland | ORGANISMPART=mandible | ORGANISMPART=mediastinum | ORGANISMPART=multiple human tissues | ORGANISMPART=muscle | ORGANISMPART=myometrium | ORGANISMPART=nasal, epithelium | ORGANISMPART=oral | ORGANISMPART=oral, floor of mouth | ORGANISMPART=oral, floor of the mouth | ORGANISMPART=oral, mandible | ORGANISMPART=oral, maxilla | ORGANISMPART=oral, tongue | ORGANISMPART=oral, vestibule | ORGANISMPART=oropharynx | ORGANISMPART=ovary | ORGANISMPART=palatine tonsil | ORGANISMPART=pancreas | ORGANISMPART=peripheral blood | ORGANISMPART=peroneal_nerve | ORGANISMPART=pituitary | ORGANISMPART=pituitary gland | ORGANISMPART=placenta | ORGANISMPART=pleura | ORGANISMPART=pons | ORGANISMPART=prostate | ORGANISMPART=proximal_epiphysis_of_left_tibia | ORGANISMPART=proximal_epiphysis_of_right_fibula | ORGANISMPART=proximal_epiphysis_of_right_humerus | ORGANISMPART=quadriceps femoris muscle | ORGANISMPART=ray_of_foot | ORGANISMPART=rib_cage | ORGANISMPART=right_axilla | ORGANISMPART=right_buttock | ORGANISMPART=right_calf | ORGANISMPART=right_elbow | ORGANISMPART=right_femur | ORGANISMPART=right_forearm | ORGANISMPART=right_humerus | ORGANISMPART=right_knee | ORGANISMPART=right_latissimus_dorsi | ORGANISMPART=right_leg | ORGANISMPART=right_shoulder | ORGANISMPART=right_thigh | ORGANISMPART=right_tibia | ORGANISMPART=right_trapezius | ORGANISMPART=right_ulnar_nerve | ORGANISMPART=right_upper_arm | ORGANISMPART=sacrum | ORGANISMPART=salivary gland | ORGANISMPART=skeletal | ORGANISMPART=skeletal muscle | ORGANISMPART=skin | ORGANISMPART=small intestine | ORGANISMPART=smooth muscle | ORGANISMPART=spinal cord | ORGANISMPART=spine disc | ORGANISMPART=spine_of_scapula | ORGANISMPART=spleen | ORGANISMPART=stomach | ORGANISMPART=superior rectus extraocular muscle | ORGANISMPART=T2_vertebra | ORGANISMPART=T5_vertebra | ORGANISMPART=testi | ORGANISMPART=testis | ORGANISMPART=testis - interstitial | ORGANISMPART=testis - seminiferous tubule | ORGANISMPART=thalamus | ORGANISMPART=thymus | ORGANISMPART=thyroid | ORGANISMPART=thyroid gland | ORGANISMPART=tibia | ORGANISMPART=tongue | ORGANISMPART=tonsil | ORGANISMPART=trachea | ORGANISMPART=tumor | ORGANISMPART=umbilical cord blood | ORGANISMPART=umbilical vein | ORGANISMPART=umbilical veins, vessels | ORGANISMPART=Unspecified | ORGANISMPART=uterine tube | ORGANISMPART=uterus | ORGANISMPART=uterus corpus | ORGANISMPART=vastus lateralis | ORGANISMPART=white blood cells | ORGANISMPART=whole blood | ORGANISMPART=whole brain | ORGANISMPART=yolk sac","DiseaseState=glioma cell line | DiseaseState=high grade glioblastoma | DiseaseState=low grade glioblastoma","CellLine=R11 | CellLine=R18 | CellLine=R28 | CellLine=R43 | CellLine=R46 | CellLine=R8 | CellType=CD133+ | CellType=CD133- | Phenotype=adherent | Phenotype=neurosphere-like","CellLine=GLI56 glioblastoma cell line | CellLine=GLI60 glioblastoma cell line | CellLine=GLI72 glioblastoma cell line | Compound=5-aza-2'-deoxycytidine | Compound=none | Dose=5 micromolar | Dose=Unspecified","Compound=epidermal growth factor | Compound=sphingosine 1-phosphate","CellType=common tumor cell | CellType=pseudopalisading cell","DiseaseState=astrocytoma | DiseaseState=epilepsy | DiseaseState=glioblastoma | DiseaseState=oligodendroglioma | TumorGrading=grade II | TumorGrading=grade III | TumorGrading=grade IV | TumorGrading=Unspecified","DiseaseState=normal;glioma | TumorGrading=grade II | TumorGrading=grade III | TumorGrading=grade IV","disease state=giant cell glioblastoma | disease state=glioma | individual=cell culture 10 | individual=cell culture 11 | individual=cell culture 13 | individual=cell culture 15 | individual=cell culture 16 | individual=cell culture 18 | individual=cell culture 21 | individual=cell culture 30 | individual=cell culture 31 | individual=cell culture 34 | individual=cell culture 35 | individual=cell culture 38 | individual=cell culture 4 | individual=cell culture 43 | individual=cell culture 45 | individual=cell culture 5 | individual=cell culture 6 | individual=cell culture 7 | individual=cell culture 8 | individual=cell culture 9 | individual=reference pool | TumorGrading=2-3 | TumorGrading=2-4 | TumorGrading=3 | TumorGrading=3-4 | TumorGrading=4 | TumorGrading=reference pool","cell line=U373 | cell line=U87 | compound1=LY2109761 | compound1=none | compound2=none | compound2=TGFb | dose1=2 micromolar | dose1=Unspecified | dose2=100 picomolar | dose2=Unspecified","disease=astrocytoma | disease=glioblastoma | disease=normal","cell type=adherent cell | cell type=neurosphere cell","compound=camptothecin | compound=none | dose=0 uM | dose=0.2 uM | time=0 h | time=16 h | time=2 h | time=24 h | time=48 h | time=6 h | time=72 h","compound=camptothecin | compound=none | dose=0 uM | dose=1 uM | time=0 h | time=16 h | time=2 h | time=24 h | time=48 h | time=6 h | time=72 h","GBM=25A35 #6 | GBM=32A6 | GBM=34A33 | GBM=36A35 #9 | GBM=38K | GBM=40L | GBM=41A1 | GBM=41A31 | GBM=45A9 | GBM=46A15 | GBM=49A34 | GBM=4A10 | GBM=4A34 | GBM=52A28 | GBM=5A4 | GBM=61A31 | GBM=62A34 #7 | GBM=64A5 | GBM=69A29 | GBM=6A33 | GBM=6A35 #9 | GBM=70P | GBM=76A34 #7 | GBM=79A34 #6 | GBM=90A20 | GBM=96E | GBM=99A6 | GBM=not specified | HET=64A34 #5 | HET=69A34 #5 | HET=not specified | OAC=_1A24 | OAC=_36A8 | OAC=_92A2 | OAC=not specified | ODG=55D | ODG=80A25 | ODG=not specified","cell line=A-172 | cell line=A-549 | cell line=Becker | cell line=C32TG | cell line=Capan-1 | cell line=CaSki | cell line=HCC-1937 | cell line=HCT 116 | cell line=HeLaS3 | cell line=HFL-III | cell line=KNS-60 | cell line=KNS-89 | cell line=KS-1 | cell line=KYSE110 | cell line=KYSE1260 | cell line=KYSE140 | cell line=KYSE150 | cell line=KYSE180 | cell line=KYSE190 | cell line=KYSE200 | cell line=KYSE2400 | cell line=Marcus | cell line=MDA-MB-468 | cell line=ME-180 | cell line=NB1RGB | cell line=ONS-76 | cell line=SF126 | cell line=SK-MG-1 | cell line=SKG-I | cell line=SKG-II | cell line=T98G | cell line=U-251MG(KO) | irradiation dose=0 Gy | irradiation dose=2 Gy | time after irradiation=1 h | time after irradiation=3 h | time after irradiation=Unspecified","cell line=A-172 | cell line=A-549 | cell line=Becker | cell line=C32TG | cell line=HFL-III | cell line=KNS-60 | cell line=KNS-89 | cell line=KS-1 | cell line=Marcus | cell line=NB1RGB | cell line=ONS-76 | cell line=SF126 | cell line=SK-MG-1 | cell line=T98G | cell line=U-251MG(KO) | irradiation dose=0 Gy | irradiation dose=2 Gy | time after irradiation=1 h | time after irradiation=3 h","OrganismPart=blood | OrganismPart=central_nervous_system | OrganismPart=colon | OrganismPart=kidney | OrganismPart=lung | OrganismPart=mammary gland | OrganismPart=ovary | OrganismPart=prostate | OrganismPart=skin","NA","NA","DiseaseState=astrocytoma | DiseaseState=glioblastoma | DiseaseState=normal | DiseaseState=oligoastrocytoma | MaterialType=cell | MaterialType=organism_part"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>ID<\/th>\n      <th>Raw<\/th>\n      <th>Processed<\/th>\n      <th>ReleaseDate<\/th>\n      <th>PubmedID<\/th>\n      <th>Species<\/th>\n      <th>ExperimentDesign<\/th>\n      <th>ExperimentFactors<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}]}},"evals":[],"jsHooks":[]}</script>
<script type="application/htmlwidget-sizing" data-for="htmlwidget-f08fdf9aa10ee606c4ff">{"viewer":{"width":450,"height":350,"padding":15,"fill":true},"browser":{"width":960,"height":500,"padding":40,"fill":false}}</script>
</body>
</html>
